Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION
Document Type and Number:
WIPO Patent Application WO/2023/017152
Kind Code:
A1
Abstract:
The present invention relates to novel specific small molecule inhibitors that block KMT9 methyltransferase activity. In particular, the present invention is concerned with a compound of formula (I) wherein X1, X2, X3, X4, R1, R2, R3, R5, R6 and L are as defined herein. Further, the present invention is concerned with a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I). The present invention also relates to a compound of formula (I) and a pharmaceutical composition comprising a compound of formula (I) for use in medicine. Yet further, the present invention is concerned with a compound of formula (I) and a pharmaceutical composition comprising a compound of formula (I) for use as inhibitor of KMT9. Finally, the present invention is concerned with a compound of formula (I), wherein X1, X2, X3, X4, R1, R2, R3, R5, R6 and L are as defined herein, for use in the treatment of cancer selected from the group as defined herein.

Inventors:
SCHÜLE ROLAND (DE)
WANG SHENG (DE)
METZGER ERIC (FR)
JUNG MANFRED (DE)
KLEIN SEBASTIAN (CH)
Application Number:
PCT/EP2022/072677
Publication Date:
February 16, 2023
Filing Date:
August 12, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV FREIBURG ALBERT LUDWIGS (DE)
International Classes:
C07D487/04; A61K31/52; A61K31/7064; A61K31/7076; A61P35/00; C07H19/14; C07H19/167
Domestic Patent References:
WO2018085818A12018-05-11
WO2015200680A22015-12-30
WO2016135582A12016-09-01
WO2020058358A12020-03-26
WO2022081739A12022-04-21
WO2020033288A12020-02-13
Other References:
STRAHL, B.D.ALLIS, C.D., NATURE, vol. 203, 2000, pages 41 - 45
MORERA ET AL., CLINICAL EPIGENETICS, vol. 8, 2016, pages 57
METZGER ET AL., NAT. STRUCT. MOL. BIOL., vol. 26, no. 5, May 2019 (2019-05-01), pages 361
Attorney, Agent or Firm:
MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH (DE)
Download PDF:
Claims:
Claims

1. A compound of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof, wherein

X1 is CH2, or N;

X2 is CR4 or N;

X3 is CH or N;

X4 is CH, or N;

R1, R2 are independently of each other selected from H, halogen and OH;

R3 is H, or C1-C4alkyl;

R4 is H, CN, halogen, C1-C4alkyl, C2-C4-alkenyl, phenyl, or a 3- to 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents Rx;

R5 is H, Cq-C4-alkyl, C1-C4haloalkyl, or NRaRb; or

R4 and R5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents Rx;

R6 is H, halogen, C1-C4alkyl, NRaRb, or ORC; wherein

L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY, or a 5- or 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents RY; or a 7- to 10-membered aromatic carbobicyclyl or heterobicyclyl, wherein the aforementioned heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; or

(ii) is selected from wherein each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, or two substituents together form C(=O); wherein

Ra, Rb are independently of each other selected from H, C1-C4alkyl and phenyl;

Rc is H, C1-C4-alkyl, NRaRb, NRaRb- C1-C4alkyl, benzyl, or a 5- or 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized;

Rd is benzophenone-C1-C4-alkyl, phenoxybenzene- C1-C4alkyl, N-methyl-diphenylamine-Cr C4-alkyl, or diphenylsulfide- C1-C4alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C1-C4haloalkyl, and phenyl-Cr C4-alkyl, or a substituent according to the following formulae

Re is a 5- or 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents Rx;

R9 is H, C(=O)RC, phenyl-C1-C4-alkyl, benzophenone- C1-C4alkyl, phenoxybenzene- C1-C4alkyl, N-methyl-diphenylamine-C1-C4-alkyl, diphenylsulfide- C1-C4alkyl, or naphthalene- C1-C4 alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C1-C4haloalkyl, and phenyl- C1-C4alkyl, or a substituent according to the following formulae

Rh is C1-C4alkyl, or phenyl;

R' is C1-C4alkyl, or phenyl;

Rx is C1-C4alkyl, C(=O)RC, S(=O)2Rh, OR', or phenyl- C1-C4alkyl;

RY is halogen, NH2, OH, C1-C4alkyl, C1-C4haloalkyl, C2-C6-alkenyl, C1-C4alkoxy, C1-C4 haloalkoxy, cyclopropyl, cyclopropyl- C1-C4-alkyl, phenyl- C1-C4alkyl, two RY form =0, or a 4- to 6- membered saturated, partially or fully unsaturated or aromatic carbocyclyl, carbocyclyl- C1-C4 alkyl, heterocyclyl or heterocyclyl- C1-C4-alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from NH2, or two substituents form =0; and n is 1, 2, 3 or 4; with the proviso that if X2 is N or CR4, wherein R4 is H, then R5 is not H or NH2.

2. The compound according to claim 1, wherein Rx is Cq-C4-alkyl, C(=O)RC, or phenyl- C1-C4alkyl.

3. The compound according to claim 1 or 2, wherein

X1 is CH2;

X2 is CR4;

X3 is N; and

X4 is N; with the proviso that if X2 is CR4, wherein R4 is H, then R5 is not H or NH2.

4. The compound according to any one of claims 1 to 3, wherein R1, R2 are OH;

R3 is H;

R4 is H, halogen, C1-C4alkyl or a 5-membered fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents Rx;

R5 is H, or NRaRb; or

R4 and R5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents Rx;

R6 is H, or halogen; with the proviso that if X2 is CR4, wherein R4 is H, then R5 is not H or NH2.

5. The compound according to any one of claims 1 to 4, wherein

L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY, or a 5- or 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents RY.

6. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to any one of claims 1 to 5 and optionally a pharmaceutically acceptable carrier, diluent, or excipient.

7. A compound according to any one of claims 1 to 5 or the pharmaceutical composition according to claim 6 for use in medicine.

8. A compound according to any one of claims 1 to 5, or a pharmaceutical composition according to claim 6 for use in the treatment of cancer selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, colon cancer, glioblastoma, lung cancer, neuroblastoma, osteosarcoma, liposarcoma, colorectal cancer, rectal adenocarcinoma, mesothelioma, endometrium adenocarcinoma, leukemia, erythroleukemia, medulloblastoma, astrocytoma, Ewing sarcoma, myelodysplastic syndrome (MDS), diffuse large B-cell lymphoma, myelogenic leukemia, myeloid leukemia, acute monocytic leukemia, gallbladder carcinoma, cecum adenocarcinoma, gastric adenocarcinoma, stomach adenocarcinoma, renal cell carcinoma, bladder carcinoma, melanoma, cervical squamous cell carcinoma, pancreatic carcinoma, chondrosarcoma, duodenal adenocarcinoma, rhabdomyosarcoma, hepatocellular carcinoma and uterine adenocarcinoma.

9. The compound or pharmaceutical composition for use according to claim 8, wherein said cancer is selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, colon cancer, glioblastoma, lung cancer, neuroblastoma, colorectal cancer and bladder carcinoma.

10. A compound of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof, wherein

X1 is CH2, N or O;

X2 is CR4, or N;

X3 is CH, or N;

X4 is CH, or N;

R1, R2 are independently of each other selected from H, halogen and OH;

R3 is H, or C1-C4alkyl;

R4 is H, CN, halogen, C1-C4alkyl, C2-C4-alkenyl, phenyl, or a 3- to 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents Rx;

R5 is H, halogen, C1-C4alkyl, C1-C4haloalkyl, or NRaRb; or

R4 and R5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents Rx;

R6 is H, halogen, C1-C4alkyl, NRaRb, or ORC; wherein

L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, or heterocyclyl-C1-C4-alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY, or a 5- or 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents RY; or a 7- to 10-membered aromatic carbobicyclyl or heterobicyclyl, wherein the aforementioned heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; or

(ii) is selected from wherein each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, or two substituents together form C(=O);

RN is H, C1-C4-alkyl, C1-C4-haloalkyl, NRaRb, cyclopropyl- C1-C4alkyl, or a 5- or 6-membered saturated, partially or fully unsaturated or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents Rx; and wherein

Ra, Rb are independently of each other selected from H, C1-C4alkyl, and phenyl;

Rc is H, Cq-C4-alkyl, NRaRb, NRaRb- C1-C4alkyl, benzyl, or a 5- or 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized;

Rd is H, C(=O)RC, phenyl-C1-C4-alkyl, benzophenone- C1-C4alkyl, phenoxybenzene- C1-C4alkyl, N-methyl-diphenylamine-C1-C4-alkyl, diphenylsulfide- C1-C4alkyl, or naphthalene- C1-C4 alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C1-C4haloalkyl, and phenyl- C1-C4alkyl, or a substituent according to the following formulae

Re is C1-C4alkyl, C(=O)RC, or a 5- or 6-membered saturated heterocyclyl, or heterocyclyl-Cr C4-alkyl, wherein said heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents Rx;

Rf is H, or Cq-C4-alkyl; or

Re and Rf together with the nitrogen atom to which they are bonded form a 7- to 10-membered saturated spiro-heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S- atoms are independently oxidized or non-oxidized;

R9 is H, C(=O)RC, phenyl-C1-C4-alkyl, benzophenone- C1-C4alkyl, phenoxybenzene- C1-C4alkyl, N-methyl-diphenylamine-C1-C4-alkyl, diphenylsulfide- C1-C4-alkyl, or naphthalene- C1-C4 alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C1-C4haloalkyl, and phenyl- C1-C4alkyl, or a substituent according to the following formulae

Rh is Cq-C4-alkyl, or phenyl;

R' is Cq-C4-alkyl, or phenyl;

Rx is halogen, C1-C4alkyl, C(=O)RC, S(=O)2Rh, OR', or phenyl- C1-C4alkyl, or two Rx form =0;

RY is halogen, NH2, OH, C1-C4alkyl, C1-C4haloalkyl, C2-C6-alkenyl, C1-C4alkoxy, C1-C4 haloalkoxy, cyclopropyl, cyclopropyl- C1-C4-alkyl, phenyl- C1-C4alkyl, two RY form =0, or a 4- to 6- membered saturated, partially or fully unsaturated or aromatic carbocyclyl, carbocyclyl- C1-C4 alkyl, heterocyclyl or heterocyclyl- C1-C4alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from NH2, or two substituents form =0; and n is 1, 2, 3 or 4, for use in the treatment of prostate cancer.

11. The compound for use according to claim 10, wherein said prostate cancer is castration resistant prostate cancer.

12. The compound for use according to claim 10 or 11, wherein in said compound of formula (I) Rx is halogen, C1-C4alkyl, C(=O)RC, or phenyl-C1-C4-alkyl, or two Rx form =0.

13. The compound for use according to any one of claims 10 to 12, wherein in said compound of formula (I)

X1 is CH2, or O;

X2 is CR4;

X3 is N; and

X4 is N.

14. The compound for use according to any one of claims 10 to 13, wherein in said compound of formula (I)

R1, R2 are OH;

R3 is H; and

R6 is H, halogen, or Cq-C4-alkyl.

15. The compound for use according to any one of claims 10 to 14, wherein in said compound of formula (I)

R4 is H, halogen, Cq-C4-alkyl, C2-C4-alkenyl, phenyl, or a 3- to 6-membered fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S- atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents Rx;

R5 is H, Cq-C4-alkyl, or NRaRb; or

R4 and R5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents Rx.

16. The compound for use according to any one of claims 10 to 15, wherein in said compound of formula (I)

L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, or heterocyclyl-C1-C4-alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY, or a 5- or 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents RY; or (ii) is selected from wherein

RN is H, or a 5- or 6-membered saturated, partially or fully unsaturated or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents Rx; and wherein

Rd is H, phenyl-C1-C4-alkyl, benzophenone-C1-C4-alkyl, phenoxybenzene- C1-C4alkyl, or naphthalene-C1-C4-alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C1-C4haloalkyl, and phenyl- C1-C4 alkyl, or a substituent according to the following formulae

17. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I) as defined in any one of claims 10 to 16 and optionally a pharmaceutically acceptable carrier, diluent, or excipient for use in the treatment of castration resistant prostate cancer.

Description:
Specific small molecule inhibitors that block KMT9 methyltransferase activity and function

Field of the Invention

The present invention relates to novel specific small molecule inhibitors that block KMT9 methyltransferase activity. In particular, the present invention is concerned with a compound of formula (I) wherein X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , R 5 , R 6 and L are as defined herein. Further, the present invention is concerned with a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I). The present invention also relates to a compound of formula (I) and a pharmaceutical composition comprising a compound of formula (I) for use in medicine. Yet further, the present invention is concerned with a compound of formula (I) and a pharmaceutical composition comprising a compound of formula (I) for use as inhibitor of KMT9. Finally, the present invention is concerned with a compound of formula (I), wherein X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , R 5 , R 6 and L are as defined herein, for use in the treatment of cancer selected from the group as defined herein.

Background of the Invention

Posttranslational modifications of histones such as methylation regulate chromatin structure and gene expression, and dysregulation of these mostly reversible modifications has been shown to have a central role in cancer onset and cancer progression (Strahl, B.D. & Allis, C.D. Nature 203, 41-45, doi:10.1038/47412 (2000)).

Histone methyl transferases (HMT) possess high selectivity as regards the targeted histone lysine residue. Further, the pattern of methylation is specific for each HMT. There are two families of HMTs, namely the SET domain-containing HMTs (with the four subfamilies SET1 [a specific member here is EZH2], SET2, SUV39 and RIZ) and other HMTS, wherein e.g. DOTH does not contain a SET domain but is a member of the seven-beta-strand family of histone methyltransferases. Further details in this respect as well as information on the effect of HMT- inhibition and specific inhibitors can be found in the review by Morera eta/. Clinical Epigenetics, 8:57 (2016), doi: 10.1186/s13148-016-0223-4, 2016.

EZH2 and DOTH have in particular been studied over the last years when it comes to their role in cancer. EZH2 is the catalytic component of the polycomb repressive complex 2 (PRC2), which performs three successive methyl transfer reactions arriving at H3K27me3. DOTH is capable of catalyzing mono-, di-, and trimethylation of H3K79. While H3K79 is an activating mark when it comes to gene transcription, H3K27me3 is associated with gene silencing. The inhibition of DOTH is in particular implicated in the treatment of leukemias presenting a chromosomal translocation of the mixed-lineage leukemia (MLL) gene (chromosome 11q23), such as e.g., acute myeloid leukemias (AML), acute lymphoblastic leukemias (ALL) and the biphenotypic (mixed lineage) leukemias (MLL).

Recently, a further member of the seven-beta-strand family of histone methyltransferases was identified by Metzger etai, namely KMT9, a heterodimer comprised of KMT9alpha and KMT9beta (see Metzger et al., Nat. Struct. Mol. Biol., 2019 May, 26(5):361). KMT9 writes the methylation mark on lysine 12 of histone H4 and H4K12 methylation has been shown to be implicated in prostate tumor cell proliferation.

There is of course an ongoing need for novel compounds that inhibit HMTs, in particular members of the seven-beta-strand family, preferably KMT9 as recent member of this family.

Objects and Summary of the Invention

It is therefore an object of the present invention to provide compounds, which inhibit HMTs, preferably members of the seven-beta-strand family, more preferably KMT9.

It is another object of the present invention to provide compounds, which are suitable for use as a medicament. It is another object of the present invention to provide compounds, which are suitable for use in the treatment of cancer linked to the inhibition of KMT9. In particular, it is an object to provide compounds, which are suitable for the treatment of cancer selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, colon cancer, glioblastoma, lung cancer, neuroblastoma, osteosarcoma, liposarcoma, colorectal cancer, rectal adenocarcinoma, mesothelioma, endometrium adenocarcinoma, leukemia, erythroleukemia, medulloblastoma, astrocytoma, Ewing sarcoma, myelodysplastic syndrome (MDS), diffuse large B-cell lymphoma, myelogenic leukemia, myeloid leukemia, acute monocytic leukemia, gallbladder carcinoma, cecum adenocarcinoma, gastric adenocarcinoma, stomach adenocarcinoma, renal cell carcinoma, bladder carcinoma, melanoma, cervical squamous cell carcinoma, pancreatic carcinoma, chondrosarcoma, duodenal adenocarcinoma, rhabdomyosarcoma, hepatocellular carcinoma and uterine adenocarcinoma.

The above objects can be achieved by the compounds of formula (I) as defined herein as well as pharmaceutical compositions comprising the same, and by the medical uses thereof.

The inventors of the present invention inter alia surprisingly found that the compounds of formula (I) as defined herein inhibit HMTs, in particular members of the seven-beta-strand family, preferably KMT9. Accordingly, the compounds of formula (I) can be used as a medicament, in particular for the treatment of cancer selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, colon cancer, glioblastoma, lung cancer, neuroblastoma, osteosarcoma, liposarcoma, colorectal cancer, rectal adenocarcinoma, mesothelioma, endometrium adenocarcinoma, leukemia, erythroleukemia, medulloblastoma, astrocytoma, Ewing sarcoma, myelodysplastic syndrome (MDS), diffuse large B-cell lymphoma, myelogenic leukemia, myeloid leukemia, acute monocytic leukemia, gallbladder carcinoma, cecum adenocarcinoma, gastric adenocarcinoma, stomach adenocarcinoma, renal cell carcinoma, bladder carcinoma, melanoma, cervical squamous cell carcinoma, pancreatic carcinoma, chondrosarcoma, duodenal adenoca c o a, abdo yosarcoma, hepatocellular carcinoma and uterine adenocarcinoma. In a first aspect, the present invention therefore relates to a compound of formula (I) or a salt, stereoisomer, tautomer or N- wherein X 1 is CH 2 , N or O; X 2 is CR 4 or N; X 3 is CH or N; X 4 is CH, or N; R 1 , R 2 are independently of each other selected from H, halogen and OH; R 3 is H, or C 1 -C 4 -alkyl; R 4 is H, CN, halogen, C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, phenyl, or a 3- to 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R 5 is H, C 1 -C 4 -alkyl, or NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R 6 is H, halogen, C 1 -C 4 -alkyl, NR a R b , or OR c ; wherein L (i) is a 4- to 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, or (ii) is selected from each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, or two substituents together form C(=O); wherein R a , R b are independently of each other selected from H, C1-C4-alkyl and phenyl; R c is H, C 1 -C 4 -alkyl, NR a R b , NR a R b -C 1 -C 4 -alkyl, benzyl, or a 5- or 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized; R d is benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 - C4-alkyl, or diphenylsulfide-C1-C4-alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 - C 4 -alkyl, or a substituent according to the following formulae R e is a 5- or 6- , ng comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R g is H, C(=O)R c , phenyl-C 1 -C 4 -alkyl, benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 -C 4 -alkyl, diphenylsulfide-C 1 -C 4 -alkyl, or naphthalene-C 1 -C 4 - alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 -alkyl, or a substituent according to the following formulae R x is C 1 -C 4 -alky , , n is 1, 2, 3 or 4; with the proviso that if X 2 is N or CR 4 , wherein R 4 is H, then R 5 is not H or NH 2 .

In a preferred embodiment, the present invention relates to a compound of formula (I), wherein X 1 is CH 2 or O;

X 2 is CR 4 ;

X 3 is N; and

X 4 is N; with the proviso that if X 2 is CR 4 , wherein R 4 is H, then R 5 is not H or NH 2 .

In another preferred embodiment, the present invention refers to a compound of formula (I), wherein

R 1 , R 2 are OH;

R 3 is H;

R 4 is H, halogen, C 1 -C 4 -alkyl or a 5-membered aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized;

R 5 is NR a R b ; or

R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ;

R 6 is H; with the proviso that if X 2 is CR 4 , wherein R 4 is H, then R 5 is not NH 2 .

In another preferred embodiment, the present invention relates to a compound of formula (I), wherein

L (i) is a 4- to 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, or (ii) is selected from

In a further aspect, the present invention relates to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I) as defined herein and optionally a pharmaceutically acceptable carrier, diluent, or excipient.

In yet another aspect, the present invention relates to a compound of formula (I) as defined herein or a pharmaceutical composition comprising the same as defined herein for use in medicine.

In yet another aspect, the present invention relates to a compound of formula (I) as defined herein or a pharmaceutical composition comprising the same as defined herein for use in the treatment of cancer selected from t e g oup co sst g o prostate cancer, breast cancer, ovarian cancer, colon cancer, glioblastoma, lung cancer, neuroblastoma, osteosarcoma, liposarcoma, colorectal cancer, rectal adenocarcinoma, mesothelioma, endometrium adenocarcinoma, leukemia, erythroleukemia, medulloblastoma, astrocytoma, Ewing sarcoma, myelodysplastic syndrome (MDS), diffuse large B-cell lymphoma, myelogenic leukemia, myeloid leukemia, acute monocytic leukemia, gallbladder carcinoma, cecum adenocarcinoma, gastric adenocarcinoma, stomach adenocarcinoma, renal cell carcinoma, bladder carcinoma, melanoma, cervical squamous cell carcinoma, pancreatic carcinoma, chondrosarcoma, duodenal adenocarcinoma, rhabdomyosarcoma, hepatocellular carcinoma and uterine adenocarcinoma. In one embodiment, the compound of formula (I) as defined herein or the pharmaceutical composition comprising the same as defined herein is for use in the treatment of cancer selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, colon cancer, glioblastoma, lung cancer, neuroblastoma, colorectal cancer and bladder carcinoma. In a second aspect, the present invention relates to a compound of formula (I) or a salt, stereoisomer, tautomer or N- wherein X 1 is CH 2 , N or O; X 2 is CR 4 , or N; X 3 is CH, or N; X 4 is CH, or N; R 1 , R 2 are independently of each other selected from H, halogen and OH; R 3 is H, or C 1 -C 4 -alkyl; R 4 is H, CN, halogen, C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, phenyl, or a 3- to 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ; R 5 is H, halogen, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, or NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the afore e to ed g oups s dependently unsubstituted or substituted with one or more, same or different substituents R x ; R 6 is H, halogen, C 1 -C 4 -alkyl, NR a R b , or OR c ; wherein L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, or heterocyclyl-C 1 -C 4 -alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or a 5- or 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or a 7- to 10-membered aromatic carbobicyclyl or heterobicyclyl, wherein the aforementioned heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or (ii) is selected from each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, or two substituents together form C(=O); R N is H, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, NR a R b , cyclopropyl-C 1 -C 4 -alkyl, or a 5- or 6-membered saturated, partially or fully unsaturated or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and wherein R , R are independently of each ot e seected o , C 1 C 4 alkyl, and phenyl; R c is H, C 1 -C 4 -alkyl, NR a R b , NR a R b -C 1 -C 4 -alkyl, benzyl, or a 5- or 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized; R d is H, C(=O)R c , phenyl-C 1 -C 4 -alkyl, benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 -C 4 -alkyl, diphenylsulfide-C 1 -C 4 -alkyl, or naphthalene-C 1 -C 4 - alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 -alkyl, or a substituent according to the following formulae R e is C 1 -C 4 -alky , , , eterocyclyl-C 1 - C 4 -alkyl, wherein said heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R f is H, or C 1 -C 4 -alkyl; or R e and R f together with the nitrogen atom to which they are bonded form a 7- to 10-membered saturated spiro-heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S- atoms are independently oxidized or non-oxidized; R g is H, C(=O)R c , phenyl-C 1 -C 4 -alkyl, benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 -C 4 -alkyl, diphenylsulfide-C 1 -C 4 -alkyl, or naphthalene-C 1 -C 4 - alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 -alkyl, or a substituent according to the following formulae R h is C1-C4-alky , R i is C 1 -C 4 -alkyl, or phenyl; R x is halogen, C 1 -C 4 -alkyl, C(=O)R c , S(=O) 2 R h , OR i , or phenyl-C 1 -C 4 -alkyl, or two R x form =O; R Y is halogen, NH 2 , OH, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 2 -C 6 -alkenyl, C 1 -C 4 -alkoxy, C 1 -C 4 - haloalkoxy, cyclopropyl, cyclopropyl-C 1 -C 4 -alkyl, phenyl-C 1 -C 4 -alkyl, two R Y form =O, or a 4- to 6- membered saturated, partially or fully unsaturated or aromatic carbocyclyl, carbocyclyl-C 1 -C 4 - alkyl, heterocyclyl or heterocyclyl-C 1 C 4 a y, w e e t e aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from NH2, or two substituents form =O; and n is 1, 2, 3 or 4, for use in the treatment of prostate cancer. In one embodiment of the present invention of said use, said prostate cancer is castration resistant prostate cancer. In another embodiment of said use, in said compound of formula (I) R x is halogen, C 1 -C 4 -alkyl, C(=O)R c , or phenyl-C 1 -C 4 -alkyl, or two R x form =O. In another embodiment of said use, in said compound of formula (I) X 1 is CH 2 , or O; X 2 is CR 4 ; X 3 is N; and X 4 is N. In another embodiment of said use, in said compound of formula (I) R 1 , R 2 are OH; R 3 is H; and R 6 is H, halogen, or C 1 -C 4 -alkyl. In another embodiment of said use, in said compound of formula (I) R 4 is H, halogen, C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, phenyl, or a 3- to 6-membered fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S- atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ; R 5 is H, C 1 -C 4 -alkyl, or NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x . In another embodiment of said use, in said compound of formula (I) L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, or heterocyclyl-C 1 -C 4 -alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or a 5- or 6-membered aromatc ca bocycy, w e e t e aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or (ii) is selected from wherein R N is H, or a 5- or 6-membered saturated, partially or fully unsaturated or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and wherein R d is H, phenyl-C 1 -C 4 -alkyl, benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, or naphthalene-C 1 -C 4 -alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 - alkyl, or a substituent according to the following formulae In another aspec , on comprising a pharmaceutically effective amount of the compound of formula (I) as defined in the above second aspect and optionally a pharmaceutically acceptable carrier, diluent, or excipient for use in the treatment of castration resistant prostate cancer. In a third aspect, the present invention relates to a compound of formula (I) or a salt, stereoisomer, tautomer or N- wherein X 1 is CH 2 , or N; X 2 is CR 4 or N; X 3 is CH or N; X 4 is CH, or N; R 1 , R 2 are independently of each other selected from H, halogen and OH; R 3 is H, or C 1 -C 4 -alkyl; R 4 is H, CN, halogen, C1-C4-alkyl, C2-C4-alkenyl, phenyl, or a 3- to 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ; R 5 is H, C1-C4-alkyl, C1-C4-haloalkyl, or NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R 6 is H, halogen, C 1 -C 4 -alkyl, NR a R b , or OR c ; wherein L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or a 5- or 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or a 7- to 10-membered aromatic carbobicyclyl or heterobicyclyl, wherein the aforementioned heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or (ii) is selected from wherein each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, or two substituents together form C(=O); wherein R a , R b are independently of each other selected from H, C 1 -C 4 -alkyl and phenyl; R c is H, C 1 -C 4 -alkyl, NR a R b , NR a R b -C 1 -C 4 -alkyl, benzyl, or a 5- or 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized; R d is benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 - C 4 -alkyl, or diphenylsulfide-C 1 -C 4 -alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 - C 4 -alkyl, or a substituent according to the following formulae R e is a 5- or 6- , ng comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R g is H, C(=O)R c , phenyl-C 1 -C 4 -alkyl, benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 -C 4 -alkyl, diphenylsulfide-C 1 -C 4 -alkyl, or naphthalene-C 1 -C 4 - alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 -alkyl, or a substituent according to the following formulae R h is C1-C4-alky , R i is C 1 -C 4 -alkyl, or phenyl; R x is C 1 -C 4 -alkyl, C(=O)R c , S(=O) 2 R h , OR i , or phenyl-C 1 -C 4 -alkyl; R Y is halogen, NH 2 , OH, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 2 -C 6 -alkenyl, C 1 -C 4 -alkoxy, C 1 -C 4 - haloalkoxy, cyclopropyl, cyclopropyl-C 1 -C 4 -alkyl, phenyl-C 1 -C 4 -alkyl, two R Y form =O, or a 4- to 6- membered saturated, partially or fully unsaturated or aromatic carbocyclyl, carbocyclyl-C 1 -C 4 - alkyl, heterocyclyl or heterocyclyl-C1-C4-alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from NH 2 , or two substituents form =O; and n is 1, 2, 3 or 4; with the proviso that if X 2 is N or C , w e e s , t e R 5 is not H or NH 2 . In a preferred embodiment, the present invention relates to a compound of formula (I), wherein R x is C 1 -C 4 -alkyl, C(=O)R c , or phenyl-C 1 -C 4 -alkyl. In another preferred embodiment, the present invention relates to a compound of formula (I), wherein X 1 is CH 2 ; X 2 is CR 4 ; X 3 is N; and X 4 is N; with the proviso that if X 2 is CR 4 , wherein R 4 is H, then R 5 is not H or NH 2 . In another preferred embodiment, the present invention relates to a compound of formula (I), wherein R 1 , R 2 are OH; R 3 is H; R 4 is H, halogen, C 1 -C 4 -alkyl or a 5-membered fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ; R 5 is H, or NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R 6 is H, or halogen; with the proviso that if X 2 is CR 4 , wherein R 4 is H, then R 5 is not H or NH 2 . In another preferred embodiment, the present invention relates to a compound of formula (I), wherein L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or a 5- or 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y . In a further aspect, the present invention relates to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I) as defined above and optionally a pharmaceutically acceptable carrier, diluent, or excipient.

In yet another aspect, the present invention relates to a compound of formula (I) as defined above or a pharmaceutical composition comprising the same as defined above for use in medicine.

In yet another aspect, the present invention relates to a compound of formula (I) as defined above or a pharmaceutical composition comprising the same as defined above for use in the treatment of cancer selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, colon cancer, glioblastoma, lung cancer, neuroblastoma, osteosarcoma, liposarcoma, colorectal cancer, rectal adenocarcinoma, mesothelioma, endometrium adenocarcinoma, leukemia, erythroleukemia, medulloblastoma, astrocytoma, Ewing sarcoma, myelodysplastic syndrome (MDS), diffuse large B-cell lymphoma, myelogenic leukemia, myeloid leukemia, acute monocytic leukemia, gallbladder carcinoma, cecum adenocarcinoma, gastric adenocarcinoma, stomach adenocarcinoma, renal cell carcinoma, bladder carcinoma, melanoma, cervical squamous cell carcinoma, pancreatic carcinoma, chondrosarcoma, duodenal adenocarcinoma, rhabdomyosarcoma, hepatocellular carcinoma and uterine adenocarcinoma.

In one embodiment, the compound of formula (I) as defined above or the pharmaceutical composition comprising the same as defined above is for use in the treatment of cancer selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, colon cancer, glioblastoma, lung cancer, neuroblastoma, colorectal cancer and bladder carcinoma.

Detailed Description

In the following, preferred embodiments of the substituents of the compounds of formula (I) according to the first aspect of the present invention are described in further detail. It is to be understood that each preferred embodiment is relevant on its own as well as in combination with other preferred embodiments. Furthermore, it is to be understood that the preferences in each case also apply to the salts, stereoisomers, tautomers, and N-oxides of the compounds according to formula (I) of the invention.

As indicated above, in a first aspect the present invention relates to a compound of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof, wherein

X 1 is CH 2 , N or O;

X 2 is CR 4 or N; X 3 is CH or N; and X 4 is CH, or N. In a preferred embodiment, the present invention relates to a compound of formula (I) wherein the following substituent me for X 1 , X 2 , X 3 and X 4 : X 1 is CH 2 or O; X 2 is CR 4 ; X 3 is N; and X 4 is N. Thus, in a more preferred embodiment, the compound of formula (I) is a compound of formula (Ia) or formula (Ib) In connection with the ts it is to be understood that R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and L are as defined above with regard to the compound of formula (I) of the first aspect of the present invention. Furthermore, it is to be understood with regard to the above preferred and more preferred embodiments that if X 2 is N or CR 4 , wherein R 4 is H, then R 5 is not H or NH 2 , preferably it is to be understood that if X 2 is CR 4 , wherein R 4 is H, then R 5 is not H or NH 2 . In a preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib) the following substituent meanings with regard to R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are preferred: R 1 , R 2 are independently of each other selected from H, halogen and OH; R 3 is H, or C 1 -C 4 -alkyl; R 4 is H, CN, halogen, C1-C4-alkyl, C2-C4-alkenyl, phenyl, or a 3- to 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubsttuted o substtuted with one or more same or different substituents R x ; R 5 is H, C 1 -C 4 -alkyl, or NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and R 6 is H, halogen, C 1 -C 4 -alkyl, NR a R b , or OR c . In a more preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib) the following substituent meanings with regard to R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are preferred: R 1 , R 2 are independently of each other selected from halogen and OH; R 3 is H; R 4 is H, halogen, C 1 -C 4 -alkyl or a 5-membered aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized; R 5 is NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and R 6 is H. In another more preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib) the following substituent meanings with regard to R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are preferred: R 1 , R 2 are independently of each other selected from F and OH; R 3 is H; R 4 is H, halogen, C 1 -C 4 -alkyl or a 5-membered aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized; R 5 is NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and R 6 is H.

In a particularly preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (la) and (lb) the following substituent meanings with regard to R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are preferred: R 1 , R 2 are OH;

R 3 is H;

R 4 is H, halogen, C 1 -C 4 alkyl or a 5-membered aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized;

R 5 is NR a R b ; or

R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and R 6 is H. Thus, in an even more preferred embodiment of the present invention, the compound of formula (I), preferably the compound of formula (la) or (lb), is a compound according to formula (1.1a), or (1.1b) wherein R 4 is H, halogen, C 1 -C 4 alkyl or a 5-membered aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized;

R 5 is NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x . In connection with the above preferred embodiments it is to be understood that R a , R b , R x and L are as defined above with regard to the compounds of formula (I) of the first aspect of the present invention.

Preferably, R 4 and R 5 have the following substituent meanings with regard to the compounds of formula (I), preferably with regard to the compounds of formula (la) and (lb), and more preferably with regard to the compounds of formula (1.1a), and (1.1b):

R 4 is H, I, CH 3 or thiazolyl;

R 5 is NH 2 , or NHCH 3 , or

R 4 and R 5 together with the atoms to which they are bonded form a 7-membered partially unsaturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized.

In connection with the above preferred embodiments it is to be understood that if X 2 is CR 4 , wherein R 4 is H, then R 5 is not NH 2 . Furthermore, it is to be understood that L is as defined above with regard to the compounds of formula (I) of the first aspect of the present invention.

In a preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (la) and (lb), and more preferably with regard to the compounds of formula (1.1a) and (1.1b) the following substituent meanings with regard to L are preferred:

L (i) is a 4- to 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, or (ii) is selected from wherein each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, or two substituents together form C(=O).

In connection with the above definitions for L it is to be understood that the curled line in the structural formula indicates the connection to the remainder of the molecule.

Furthermore, in connection with regard to the group of L being (ii) it is to be understood that the group may be also present in the form of its salt. Preferably, the group of L being may be present in the form of the trifluoroacetic acid salt, preferably the 2, 2, 2- trifluoroacetic acid salt. Further, it is to be understood that R d , R e , R 9 and n are as defined above with regard to the compounds of formula (I) of the first aspect of the present invention or as defined further below. In a more preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib), and more preferably with regard to the compounds of formula (I.1a) and (I.1b) the following substituent meanings with regard to L are preferred: L (i) is a 4- to 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, or (ii) is selected from In connectio R d is benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 - C4-alkyl, or diphenylsulfide-C1-C4-alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 - C 4 -alkyl, or a substituent according to the following formulae R g is H, C(=O , , , ne-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 -C 4 -alkyl, diphenylsulfide-C 1 -C 4 -alkyl, or naphthalene-C 1 -C 4 - alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 -alkyl, or a substituent according to the following formulae preferably R d is benzophenone-C 1 -C 4 -alkyl, preferably benzophenone-C 2 -alkyl; and R g is phenyl-C 1 -C 4 -alkyl, preferably phenyl-C 2 -alkyl. Further, in connection with the above preferred embodiments it is to be understood that R d is phenoxybenzene-C 1 -C 4 -alkyl, preferably phenoxybenzene-C 2 -alkyl; and R g is phenyl-C 1 -C 4 -alkyl, preferably phenyl-C 2 -alkyl. Furthermore, in connection with regard to the group of L being (ii) , it is to be understood that the group may be also present in the form of its salt . re era ly, the group of L being may be present in the form of the trifluoroacetic acid salt, preferably the 2, 2, 2- trifluoroacetic acid salt.

Furthermore, in connection with the above preferred embodiments it is to be understood that n is 1, 2, 3 or 4.

Preferably, it is to be understood that n is 1, 2 or 3.

In connection with the above definitions for L, R d and R 9 it is to be understood that the curled line in the structural formula indicates the connection to the remainder of the molecule.

Thus, in a particularly preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (la) and (lb), and more preferably with regard to the compounds of formula (1.1a) and (1.1b) the following substituent meanings with regard to L are preferred:

L (i) is a 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, preferably

L (i) is piperidinyl; or

L (ii) is

In connection with re ood that the group may be also present in the form of its salt. Preferably, the group of L being may be present in the form of the trifluoroacetic acid salt, preferably the 2, 2, 2-trifluoroacetic acid salt.

Further, in connection with the above definitions for L it is to be understood that the curled line in the structural formula indicates the connection to the remainder of the molecule.

Thus, in another particularly preferred embodiment, the present invention relates to a compound of formula (1.1b) wherein

R 4 is CH 3 ;

R 5 is NHCH 3 ; and

• , .

L IS wherein is present in the form of the trifluoroacetic acid salt, preferably the 2, 2, 2-trifluoroacetic acid salt.

In another particularly preferred embodiment, the present invention relates to a compound of formula (1.1b) wherein

R 4 is H;

R 5 is NHCH 3 ; and

• H

L S 2 hk . •

I wherein is present in the form of the trifluoroacetic acid salt, preferably the 2, 2, 2-trifluoroacetic acid salt.

In another particularly preferred embodiment, the present invention relates to a compound of formula (1.1b) wherein

R 4 and R 5 together with the atoms to which they are bonded form a 7-membered partially unsaturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one nitrogen atom;

L i In another particularly preferred embodiment, the present invention relates to a compound of formula (1.1a)

In another particularly preferred embodiment, the present invention relates to a compound of formula (1.1a)

In another particularly preferred embodiment, the present invention relates to a compound of formula (1.1a) wherein

R 4 is H;

R 5 is NHCH 3 ; and

In another particularly preferred embodiment, the present invention relates to a compound of formula (1.1a)

In another particularly preferred embodiment, the present invention relates to a compound of formula (1.1a)

In another particularly preferred embodiment, the present invention relates to a compound of formula (1.1a) wherein

R 4 is thiazolyl;

R 5 is NH 2 ; and

L is piperidinyl.

Accordingly, in an even more particularly preferred embodiment of the present invention, the compound of formula (I) is selected from the group consisting of (1 R,2S,3 R, 5R)-3-(4- (methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(3-(pheneth ylamino)prop-1-yn-1- yl)cyclopentane-1,2-diol; (1R,2S,3R,5R)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(4- (phenethylamino)but-1-yn-1-yl)cyclopentane-1,2-diol; (1R,2S,3R,5R)-3-(4-(methylamino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-5-((E)-4-(phenethylamino)but-1 -en-1-yl)cyclopentane-1,2-diol; (1R,2S,3R,5R)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-((2-(3-((3- phenoxyphenethyl)amino)propyl)-1H-imidazol-1-yl)methyl)cyclo pentane-1,2-diol; (1R,2S,3R,5R)-3- (4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((E)-5-( phenethylamino)pent-1-en-1- yl)cyclopentane-1,2-diol; (2R,3S,4R,5R)-2-(aminomethyl)-5-(6,7,8,9-tetrahydro-2H-2,3,5 ,6- tetraazabenzo[cd]azulen-2-yl)tetrahydrofuran-3,4-diol; ((2R,3S,4R,5R)-3,4-dihydroxy-5-(4- (methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofura n-2-yl)methanaminium 2,2,2- trifluoroacetate; ((2R,3S,4R,5R)-3,4-dihydroxy-5-(5-methyl-4-(methylamino)-7H- pyrrolo[2,3- d]pyrimidin-7-yl)tetrahydrofuran-2-yl)methanaminium 2,2,2-trifluoroacetate; and (1R,2S,3R,5R)-3- (4-amino-5-(thiazol-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5 -(piperidin-4-yl)cyclopentane-1,2- diol.

In a second aspect, the present invention relates to a compound of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof, wherein

X 1 is CH 2 , N or O;

X 2 is CR 4 , or N;

X 3 is CH, or N;

X 4 is CH, or N; R 1 , R 2 are independently of each ot e seected o , aogen and OH; R 3 is H, or C 1 -C 4 -alkyl; R 4 is H, CN, halogen, C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, phenyl, or a 3- to 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ; R 5 is H, halogen, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, or NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R 6 is H, halogen, C 1 -C 4 -alkyl, NR a R b , or OR c ; wherein L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, or heterocyclyl-C 1 -C 4 -alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or a 5- or 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or a 7- to 10-membered aromatic carbobicyclyl or heterobicyclyl, wherein the aforementioned heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or (ii) is selected from wh each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, or two substituents together form C(=O); R N is H, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, NR a R b , cyclopropyl-C 1 -C 4 -alkyl, or a 5- or 6-membered saturated, partially or fully unsaturated or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and wherein R a , R b are independently of each other selected from H, C1-C4-alkyl, and phenyl; R c is H, C 1 -C 4 -alkyl, NR a R b , NR a R b -C 1 -C 4 -alkyl, benzyl, or a 5- or 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized; R d is H, C(=O)R c , phenyl-C 1 -C 4 -alkyl, benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C1-C4-alkyl, diphenylsulfide-C1-C4-alkyl, or naphthalene-C1-C4- alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 -alkyl, or a substituent according to the following formulae R e is C 1 -C 4 -alky , , , eterocyclyl-C 1 - C 4 -alkyl, wherein said heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R f is H, or C1-C4-alkyl; or R e and R f together with the nitrogen atom to which they are bonded form a 7- to 10-membered saturated spiro-heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S- atoms are independently oxidized or non-oxidized; R g is H, C(=O)R c , phenyl-C 1 -C 4 -a y, be op e o e C 1 C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 -C 4 -alkyl, diphenylsulfide-C 1 -C 4 -alkyl, or naphthalene-C 1 -C 4 - alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C1-C4-haloalkyl, and phenyl-C1-C4-alkyl, or a substituent according to the following formulae R h is C 1 -C 4 -alky , R i is C 1 -C 4 -alkyl, or phenyl; R x is halogen, C 1 -C 4 -alkyl, C(=O)R c , S(=O) 2 R h , OR i , or phenyl-C 1 -C 4 -alkyl, or two R x form =O; R Y is halogen, NH 2 , OH, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 2 -C 6 -alkenyl, C 1 -C 4 -alkoxy, C 1 -C 4 - haloalkoxy, cyclopropyl, cyclopropyl-C 1 -C 4 -alkyl, phenyl-C 1 -C 4 -alkyl, two R Y form =O, or a 4- to 6- membered saturated, partially or fully unsaturated or aromatic carbocyclyl, carbocyclyl-C 1 -C 4 - alkyl, heterocyclyl or heterocyclyl-C 1 -C 4 -alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from NH 2 , or two substituents form =O; and n is 1, 2, 3 or 4, for use in the treatment of prostate cancer. In a further embodiment of the second aspect, the present invention relates to a compound of formula (I) or a salt, stereoisomer, tautomer or N- wherein X 1 is CH 2 , N or O; X 2 is CR 4 , or N; X 3 is CH, or N; X 4 is CH, or N; R 1 , R 2 are independently of each other selected from H, halogen and OH; R 3 is H, or C 1 -C 4 -alkyl; R 4 is H, CN, halogen, C 1 -C 4 -alky, C 2 C 4 a e y, p e y, or a 3- to 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ; R 5 is H, halogen, C 1 -C 4 -alkyl, or NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R 6 is H, halogen, C 1 -C 4 -alkyl, NR a R b , or OR c ; wherein L (i) is a 4- to 6-membered saturated heterocyclyl, or heterocyclyl-C 1 -C 4 -alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, or (ii) is selected from each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, or two substituents together form C(=O); R N is H, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, NR a R b , cyclopropyl-C 1 -C 4 -alkyl, or a 5- or 6-membered saturated, partially or fully unsaturated or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubsttuted o substtuted with one or more, same or different substituents R x ; and wherein R a , R b are independently of each other selected from H, C 1 -C 4 -alkyl, and phenyl; R c is H, C1-C4-alkyl, NR a R b , NR a R b -C1-C4-alkyl, benzyl, or a 5- or 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized; R d is H, C(=O)R c , phenyl-C 1 -C 4 -alkyl, benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 -C 4 -alkyl, diphenylsulfide-C 1 -C 4 -alkyl, or naphthalene-C 1 -C 4 - alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 -alkyl, or a substituent according to the following formulae R e is C 1 -C 4 -alky , , , heterocyclyl-C 1 - C 4 -alkyl, wherein said heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R f is H, or C 1 -C 4 -alkyl; or R e and R f together with the nitrogen atom to which they are bonded form a 7- to 10-membered saturated spiro-heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S- atoms are independently oxidized or non-oxidized; R g is H, C(=O)R c , phenyl-C 1 -C 4 -alkyl, benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 -C 4 -alkyl, diphenylsulfide-C 1 -C 4 -alkyl, or naphthalene-C 1 -C 4 - alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 -alkyl, or a substituent according to the following formulae R x is halogen, , , , and n is 1, 2, 3 or 4, for use in the treatment of prostate cancer. In the following, preferred embodiments of the substituents of the compounds of formula (I) according to the second aspect of the present invention are described in further detail. It is to be understood that each preferred embodiment is relevant on its own as well as in combination with other preferred embodiments. Furthermore, it is to be understood that the preferences in each case also apply to the salts, stereoisomers, tautomers, and N-oxides of the compounds according to formula (I) of the invention. Further, it is to be understood that the following preferred embodiments of the substituents of the compounds of formula (I) relate to the compound of formula (I) for use in the treatment of prostate cancer.

As indicated above, in a second aspect the present invention relates to a compound of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof, wherein

X 1 is CH 2 , N or O;

X 2 is CR 4 , or N;

X 3 is CH, or N; and

X 4 is CH, or N.

In a preferred embodiment, the present invention relates to a compound of formula (I) wherein the following substituent meanings are preferred for X 1 , X 2 , X 3 and X 4 :

X 1 is CH 2 , or O;

X 2 is CR 4 ;

X 3 is N; and

X 4 is N.

Thus, in a more preferred embodiment, the compound of formula (I) is a compound of formula (la) or formula (lb) In connection with the ts it is to be understood that R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and L are as defined above with regard to the compound of formula (I) for use in the treatment of prostate cancer of the second aspect of the present invention. In a preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib) the following substituent meanings with regard to R 1 , R 2 , R 3 and R 6 are preferred: R 1 , R 2 are independently of each other selected from H, halogen and OH; R 3 is H, or C 1 -C 4 -alkyl; and R 6 is H, halogen, C 1 -C 4 -alkyl, NR a R b , or OR c . In another preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib) the following substituent meanings with regard to R 1 , R 2 , R 3 and R 6 are preferred: R 1 , R 2 are independently of each other selected from halogen and OH; R 3 is H; and R 6 is H, halogen, or C 1 -C 4 -alkyl. In another preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib) the following substituent meanings with regard to R 1 , R 2 , R 3 and R 6 are preferred: R 1 , R 2 are independently of each other selected from F, Cl, Br and OH; R 3 is H; and R 6 is H, halogen, or C 1 -C 4 -alkyl. In a particularly preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib) the following substituent meanings with regard to R 1 , R 2 , R 3 and R 6 are preferred: R 1 , R 2 are OH; R 3 is H; and R 6 is H, halogen, or C 1 -C 4 -alkyl. In another particularly preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib) the following substituent meanings with regard to R 1 , R 2 , R 3 and R 6 are preferred: R 1 , R 2 are OH; R 3 is H; and R 6 is H, Br, Cl, or C 1 -C 4 -alkyl. In another particularly preferred e bod e t o t e p esent invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib) the following substituent meanings with regard to R 1 , R 2 , R 3 and R 6 are preferred: R 1 , R 2 are OH; R 3 is H; and R 6 is H, Cl, or C 1 -C 4 -alkyl. In another particularly preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib) the following substituent meanings with regard to R 1 , R 2 , R 3 and R 6 are preferred: R 1 , R 2 are OH; R 3 is H; and R 6 is H, or C1-C4-alkyl. Thus, in a more particularly preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib) the following substituent meanings with regard to R 1 , R 2 , R 3 and R 6 are preferred: R 1 , R 2 are OH; R 3 is H; and R 6 is H. Thus, in another more particularly preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib) the following substituent meanings with regard to R 1 , R 2 , R 3 and R 6 are preferred: R 1 , R 2 are OH; R 3 is H; and R 6 is H, or Cl. In connection with the above preferred embodiments it is to be understood that R 4 , R 5 , R a , R b , R c and L are as defined above with regard to the compound of formula (I) for use in the treatment of prostate cancer of the second aspect of the present invention or as defined further below. Thus, in an even more preferred embodiment of the present invention, the compound of formula (I) is a compound according to formula (I.1a), (I.2a) or (I.1b) wherein R 4 , R (I) of the second aspect of the present invention or further below. In another more preferred embodiment of the present invention, the compound of formula (I) is a compound according to formula (I.1a) or (I.2a). In a preferred embodiment of the p ese t ve to wt regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib), and more preferably with regard to the compounds of formula (I.1a), (I.2a) and (I.1b) the following substituent meanings with regard to R 4 and R 5 are preferred: R 4 is H, CN, halogen, C1-C4-alkyl, C2-C4-alkenyl, phenyl, or a 3- to 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ; R 5 is H, halogen, C1-C4-haloalkyl, C1-C4-alkyl, or NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x . In another preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib), and more preferably with regard to the compounds of formula (I.1a), (I.2a) and (I.1b) the following substituent meanings with regard to R 4 and R 5 are preferred: R 4 is H, CN, halogen, C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, phenyl, or a 3- to 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ; R 5 is H, halogen, C 1 -C 4 -alkyl, or NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x . In a more preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib), and more preferably with regard to the compounds of formula (I.1a), (I.2a) and (I.1b) the following substituent meanings with regard to R 4 and R 5 are preferred: R 4 is H, halogen, C1-C4-alkyl, C2-C4-alkenyl, phenyl, or a 3- to 6-membered fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S- atoms are independently oxd ed o o o d ed, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ; R 5 is H, C 1 -C 4 -alkyl, or NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x . In a more preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib), and more preferably with regard to the compounds of formula (I.1a), (I.2a) and (I.1b) the following substituent meanings with regard to R 4 and R 5 are preferred: R 4 is H, halogen, C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, phenyl, or a 3- to 6-membered aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ; R 5 is H, C 1 -C 4 -alkyl, or NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x . In a particularly preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib), and more preferably with regard to the compounds of formula (I.1a), (I.2a) and (I.1b) the following substituent meanings with regard to R 4 and R 5 are preferred: R 4 is H, Br, C 1 -C 2 -alkyl, C 2 -C 3 -alkenyl, or a 5-membered fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ; and R 5 is H, or NR a R b . In connection with the above preferred embodiments it is to be understood that R a , R b and R x are as defined above with regard to the compounds of formula (I) of the second aspect of the present invention. Furthermore, in connection with t e above p e e ed e bodiments it is to be understood that R x is as defined above with regard to the compounds of formula (I) of the second aspect of the present invention, preferably R x is halogen, C 1 -C 4 -alkyl, C(=O)R c , or phenyl-C 1 -C 4 -alkyl, or two R x form =O. More preferably, in connection with the above preferred embodiments R x has the following preferred substituent meanings: R x is Cl, C 1 -C 2 -alkyl, or phenyl-C 1 -C 2 -alkyl, more preferably R x is Cl, C 1 -alkyl, or phenyl-C 1 -alkyl. Furthermore, in connection with the above preferred embodiments it is to be understood that R a and R b are as defined above with regard to the compounds of formula (I) of the second aspect of the present invention, preferably R a , R b are independently of each other selected from H, C 1 -C 4 -alkyl, and phenyl, more preferably R a , R b are independently of each other selected from H, and C 1 -alkyl. In a preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib), and more preferably with regard to the compounds of formula (I.1a), (I.2a) and (I.1b) the following substituent meanings with regard to L are preferred: L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, or heterocyclyl-C 1 -C 4 -alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or a 5- or 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or a 7- to 10-membered aromatic carbobicyclyl or heterobicyclyl, wherein the aforementioned heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or (ii) is selected from wh each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, or two substituents together form C(=O); R N is H, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, NR a R b , cyclopropyl-C 1 -C 4 -alkyl, or a 5- or 6-membered saturated, partially or fully unsaturated or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and wherein R a , R b are independently of each other selected from H, C1-C4-alkyl, and phenyl; R c is H, C 1 -C 4 -alkyl, NR a R b , NR a R b -C 1 -C 4 -alkyl, benzyl, or a 5- or 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized; R d is H, C(=O)R c , phenyl-C 1 -C 4 -alkyl, benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C1-C4-alkyl, diphenylsulfide-C1-C4-alkyl, or naphthalene-C1-C4- alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 -alkyl, or a substituent according to the following formulae R e is C 1 -C 4 -alky , , , eterocyclyl-C 1 - C 4 -alkyl, wherein said heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R f is H, or C1-C4-alkyl; or R e and R f together with the nitrogen atom to which they are bonded form a 7- to 10-membered saturated spiro-heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S- atoms are independently oxidized or non-oxidized; R g is H, C(=O)R c , phenyl-C 1 -C 4 -a y, be op e o e C 1 C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 -C 4 -alkyl, diphenylsulfide-C 1 -C 4 -alkyl, or naphthalene-C 1 -C 4 - alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C1-C4-haloalkyl, and phenyl-C1-C4-alkyl, or a substituent according to the following formulae R h is C 1 -C 4 -alky , R i is C 1 -C 4 -alkyl, or phenyl; R x is halogen, C 1 -C 4 -alkyl, C(=O)R c , S(=O) 2 R h , OR i , or phenyl-C 1 -C 4 -alkyl, or two R x form =O; R Y is halogen, NH 2 , OH, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 2 -C 6 -alkenyl, C 1 -C 4 -alkoxy, C 1 -C 4 - haloalkoxy, cyclopropyl, cyclopropyl-C 1 -C 4 -alkyl, phenyl-C 1 -C 4 -alkyl, two R Y form =O, or a 4- to 6- membered saturated, partially or fully unsaturated or aromatic carbocyclyl, carbocyclyl-C 1 -C 4 - alkyl, heterocyclyl or heterocyclyl-C 1 -C 4 -alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from NH 2 , or two substituents form =O. In another preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib), and more preferably with regard to the compounds of formula (I.1a), (I.2a) and (I.1b) the following substituent meanings with regard to L are preferred: L (i) is a 4- to 6-membered saturated heterocyclyl, or heterocyclyl-C 1 -C 4 -alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, or (ii) is selected from wherein each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, or two substituents together form C(=O); wherein R N is H, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, NR a R b , cyclopropyl-C 1 -C 4 -alkyl, or a 5- or 6-membered saturated, partially or fully unsaturated or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and wherein R a , R b are independently of each other selected from H, C 1 -C 4 -alkyl, and phenyl; R c is H, C 1 -C 4 -alkyl, NR a R b , NR a R b -C 1 -C 4 -alkyl, benzyl, or a 5- or 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized; R d is H, C(=O)R c , phenyl-C 1 -C 4 -alkyl, benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 -C 4 -alkyl, diphenylsulfide-C 1 -C 4 -alkyl, or naphthalene-C 1 -C 4 - alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 -alkyl, or a substituent according to the following formulae R e is C 1 -C 4 -alky , , , heterocyclyl-C 1 - C 4 -alkyl, wherein said heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R f is H, or C 1 -C 4 -alkyl; or R e and R f together with the nitrogen atom to which they are bonded form a 7- to 10-membered saturated spiro-heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S- atoms are independently oxidized or non-oxidized; R g is H, C(=O)R c , phenyl-C 1 -C 4 -alkyl, benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 -C 4 -alkyl, diphenylsulfide-C 1 -C 4 -alkyl, or naphthalene-C 1 -C 4 - alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from haoge , C 1 C 4 aoa y, and phenyl-C 1 -C 4 -alkyl, or a substituent according to the following formulae In connection wi that the curled line in the structur olecule. Furthermore, it is to be understood that R x is as defined above with regard to the compounds of formula (I) of the second aspect of the present invention. In a more preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib), and more preferably with regard to the compounds of formula (I.1a), (I.2a) and (I.1b) the following substituent meanings with regard to L are preferred: L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, or heterocyclyl-C 1 -C 4 -alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or a 5- or 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or (ii) is selected from wherein R N is H, or a 5- or 6-membered saturated, partially or fully unsaturated or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and wherein R d is H, phenyl-C1-C4-alkyl, benzophenone-C1-C4-alkyl, phenoxybenzene-C1-C4-alkyl, or naphthalene-C 1 -C 4 -alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 - alkyl, or a substituent according to the following formulae In an even more o the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib), and more preferably with regard to the compounds of formula (I.1a), (I.2a) and (I.1b) the following substituent meanings with regard to L are preferred: L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or a 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or (ii) is selected from wherein R N is H, or a 5- or 6-membered saturated, partially or fully unsaturated or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and wherein R d is H, phenyl-C 1 -C 4 -alkyl, benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, or naphthalene-C1-C4-alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 - alkyl, or a substituent according to the following formulae In another even gard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib), and more preferably with regard to the co pou ds o o ua (I.1a), (I.2a) and (I.1b) the following substituent meanings with regard to L are preferred: L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or a 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or (ii) is selected from wherein R N is H, or a 5- or 6-membered saturated, partially or fully unsaturated or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and wherein R d is phenyl-C 1 -C 2 -alkyl, phenoxybenzene-C 1 -C 2 -alkyl, or naphthalene-C 1 -C 2 -alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 -alkyl, or a substituent according to the following formulae In a particularly preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib), and more preferably with regard to the compounds of formula (I.1a), (I.2a) and (I.1b) the following substituent meanings with regard to L are preferred: L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforemento ed g oups s depe dently unsubstituted or substituted with one or more, same or different substituents R Y , or a 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or (ii) is selected from , wherein R N is H, or a 5- or 6-membered saturated, partially or fully unsaturated or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and wherein R d is phenyl-C 1 -C 2 -alkyl, phenoxybenzene-C 1 -C 2 -alkyl, or naphthalene-C 1 -C 2 -alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 -alkyl, or a substituent according to the following formulae In an even more ith regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib), and more preferably with regard to the compounds of formula (I.1a), (I.2a) and (I.1b) the following substituent meanings with regard to L are preferred: L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or a 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or (ii) is selected from , wherein R N is H; and wherein R d is phenyl-C 1 -C 2 -alkyl, phenoxybenzene-C 1 -C 2 -alkyl, or naphthalene-C 1 -C 2 -alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, and C 1 -C 4 -haloalkyl. In connection with the above preferred embodiments, it is to be understood that R x and R Y are as defined above with regard to the compounds of formula (I) of the second aspect of the present invention. Preferably, R x has the following substituent meanings with regard to the above preferred embodiments: R x is halogen, C 1 -C 4 -alkyl, C(=O)R c , or phenyl-C 1 -C 4 -alkyl, or two R x form =O. Furthermore, in connection with the above definitions for L and R d it is to be understood that the curled line in the structural formula indicates the connection to the remainder of the molecule. In another more preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (Ia) and (Ib), and more preferably with regard to the compounds of formula (I.1a), (I.2a) and (I.1b) the following substituent meanings with regard to L are preferred: L (i) is a 4- to 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, or (ii) is selected from In connection with the stood that R N is H, or a 5- or 6-membered saturated, partially or fully unsaturated or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R d is H, phenyl-C 1 -C 4 -alkyl, benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, or naphthalene-C 1 -C 4 -alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 - alkyl, or a substituent according to the following formulae In connection wit od that R x is as defined above with regard to the compounds of formula (I) of the second aspect of the present invention. Furthermore, in connection with the above preferred embodiments it is to be understood that R x is as defined above with regard to the compounds of formula (I) of the second aspect of the present invention, preferably R x is halogen, C1-C4-alkyl, C(=O)R c , or phenyl-C1-C4-alkyl, or two R x form =O. Furthermore, in connection with the above definitions for L and R d it is to be understood that the curled line in the structural formula indicates the connection to the remainder of the molecule. Furthermore, it is to be understood that n is 1, 2, 3 or 4, preferably n is 1, 2, or 3, more preferably n is 1 or 2. In the following, preferred embodiments of the substituents of the compounds of formula (I) according to the third aspect of the present invention are described in further detail. It is to be understood that each preferred embodiment is relevant on its own as well as in combination with other preferred embodiments. Furthermore, it is to be understood that the preferences in each case also apply to the salts, stereoisomers, tautomers, and N-oxides of the compounds according to formula (I) of the invention. As indicated above with regard to the objects and summary of the invention, in a third aspect the present invention relates to a compound of formula (I) or a salt, stereoisomer, tautomer or N wherein X 1 is CH 2 , or N; X 2 is CR 4 or N; X 3 is CH or N; X 4 is CH, or N. In a preferred embodiment, the present invention relates to a compound of formula (I) wherein the following substituent meanings are preferred for X 1 , X 2 , X 3 and X 4 :

X 1 is CH 2 ;

X 2 is CR 4 ;

X 3 is CH or N; and

X 4 is CH or N.

In a more preferred embodiment, the present invention relates to a compound of formula (I) wherein the following substituent meanings are preferred for X 1 , X 2 , X 3 and X 4 :

X 1 is CH 2 ;

X 2 is CR 4 ;

X 3 is N; and

X 4 is N.

Thus, in an even more preferred embodiment, the compound of formula (I) is a compound of formula (la)

In connection with the above preferred and more preferred embodiments it is to be understood that R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and L are as defined above with regard to the compounds of formula (I) of the third aspect of the present invention or as defined further below.

Furthermore, it is to be understood with regard to the above preferred and more preferred embodiments that if X 2 is N or CR 4 , wherein R 4 is H, then R 5 is not H or NH 2 , preferably it is to be understood that if X 2 is CR 4 , wherein R 4 is H, then R 5 is not H or NH 2 . In a preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (la) of the third aspect as defined above, the following substituent meanings with regard to R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are preferred:

R 1 , R 2 are independently of each other selected from H, halogen and OH;

R 3 is H, or C 1 -C 4 alkyl;

R 4 is H, CN, halogen, C 1 -C 4 alkyl, C 2 -C 4 -alkenyl, phenyl, or a 3- to 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ;

R 5 is H, Cq-C 4 -alkyl, C 1 -C 4 haloalkyl, or NR a R b ; or

R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and

R 6 is H, halogen, Cq-C 4 -alkyl, NR a R b , or OR C .

In a more preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (la) of the third aspect as defined above, the following substituent meanings with regard to R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are preferred:

R 1 , R 2 are OH;

R 3 is H;

R 4 is H, halogen, C 1 -C 4 alkyl or a 5-membered fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ;

R 5 is H, or NR a R b ; or

R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; and

R 6 is H, or halogen. In another more preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (la) of the third aspect as defined above, the following substituent meanings with regard to R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are preferred:

R 1 , R 2 are OH;

R 3 is H;

R 4 is H, Br, CH 3 , CH 2 CH 3 or a 5-membered fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ;

R 5 is H, or NR a R b ; or

R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ;

R 6 is H, or Cl.

In an even more preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (la) of the third aspect as defined above, the following substituent meanings with regard to R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are preferred:

R 1 , R 2 are OH;

R 3 is H;

R 4 is H, Br, CH 3 , CH 2 CH 3 or a 5-membered fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ;

R 5 is H, or NR a R b ; and

R 6 is H, or Cl.

In connection with the above preferred embodiments it is to be understood that R a , R b , R c , R x and L are as defined above with regard to the compounds of formula (I) of the third aspect of the present invention. In addition, it is to be understood that the remaining substituents such as X 1 , X 2 , X 3 , X 4 are as defined above with regard to the compound of formula (I) of the third aspect. Furthermore, in connection with the above preferred embodiments it is to be understood that if X 2 is N or CR 4 , wherein R 4 is H, then R 5 is not H or NH 2 , preferably it is to be understood that if X 2 is CR 4 , wherein R 4 is H, then R 5 is not H or NH 2 . Thus, in an even more preferred embodiment of the present invention, the compound of formula (I), preferably the compound of formula (la) of the third aspect, is a compound according to formula (1.1a), or (1.2a) wherein

R 4 is H, Br, CH 3 , CH 2 CH 3 or a 5-membered fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ; and

R 5 is H, or NR a R b .

In connection with the above more preferred embodiment it is to be understood that R a , R b , R x and L are as defined above with regard to the compounds of formula (I) of the third aspect of the present invention or as defined further below.

In a preferred embodiment of the present invention, R 4 and R 5 have the following substituent meanings with regard to the compounds of formula (I), preferably with regard to the compounds of formula (la) and more preferably with regard to the compounds of formula (1.1a), and (1.2a): R 4 is H, Br, CH 3 , CH 2 CH 3 or a 5-membered fully unsaturated or aromatic heterocyclyl selected from the following structural formulae wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ; and R 5 is H, or NR a R b .

In connection with the above structural formulae of R 4 it is to be understood that the curled line in the structural formulae indicates the connection to the remainder of the molecule.

Furthermore, in connection with the above preferred embodiments it is to be understood that if X 2 is N or CR 4 , wherein R 4 is H, then R 5 is not H or NH 2 , preferably it is to be understood that if X 2 is CR 4 , wherein R 4 is H, then R 5 is not H or NH 2 .

Further, in connection with the above preferred embodiments regarding the substituents R 4 and R 5 , it is to be understood that R x , R a and R b have the following preferred substituent meanings: R x is C 1 -C 4 alkyl, C(=O)R C , S(=O) 2 R h , OR', or phenyl-C 1 -C 4 -alkyl; and

R a , R b are independently of each other selected from H, C 1 -C 4 alkyl and phenyl.

Preferably, R x , R a and R b have the following preferred substituent meanings:

R x is C 1 -C 4 alkyl, C(=O)R C , or phenyl- C 1 -C 4 alkyl; and

R a , R b are independently of each other selected from H, C 1 -C 4 alkyl and phenyl.

More preferably, R x , R a and R b have the following preferred substituent meanings:

R x is CH 3 , CH 2 CH 3 , or phenyl-C 1 -C 2 -alkyl; and

R a , R b are independently of each other selected from H, CH 3 and CH 2 CH 3 .

Even more preferably, R x , R a and R b have the following preferred substituent meanings:

R x is CH 3 , CH 2 CH 3 , or phenyl-Q-alkyl; and

R a , R b are independently of each other selected from H, and CH 3 .

In connection with the above preferred embodiments it is to be understood that if X 2 is CR 4 , wherein R 4 is H, then R 5 is not H or NH 2 .

In a preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (la), and more preferably with regard to the compounds of formula (1.1a) and (1.2a) of the third aspect as defined above, the following substituent meanings with regard to L are preferred:

L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or a 5- or 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or a 7- to 10-membered aromatic carbobicyclyl or heterobicyclyl, wherein the aforementioned heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or

(ii) is selected from wherein each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, or two substituents together form C(=O). In connection with the above preferred embodiment, it is to be understood that R e , R d , R Y and n are as defined above with regard to the compounds of formula (I) of the third aspect or as defined further below.

Preferably, the substituents R d , R e as well as n have the following preferred meanings:

R d is benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C r

C 4 -alkyl, or diphenylsulfide- C 1 -C 4 alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 haloalkyl, and phenyl-C r C 4 -alkyl, or a substituent according to the following formulae

R e is a 5- or 6-membered saturated heterocyclyl, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; wherein

R x is Cq-C 4 -alkyl, C(=O)R C , S(=O) 2 R h , OR', or phenyl- C 1 -C 4 alkyl; and n is 1, 2, 3 or 4.

Preferably, R x has the following preferred substituent meanings with regard to the above preferred embodiments:

R x is Cq-C 4 -alkyl, C(=O)R C , or phenyl- C 1 -C 4 alkyl.

In a more preferred embodiment of the present invention with regard to the compounds of formula (I), preferably with regard to the compounds of formula (la), and more preferably with regard to the compounds of formula (1.1a) and (1.2a) of the third aspect as defined above, the following substituent meanings with regard to L are preferred:

L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or a 5- or 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y ; or a 7- to 10-membered aromatic carbobicyclyl or heterobicyclyl, wherein the aforementioned heterobicyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y .

More preferably, with regard to the compounds of formula (I), preferably with regard to the compounds of formula (la), and more preferably with regard to the compounds of formula (1.1a) and (1.2a) of the third aspect as defined above, the following substituent meanings with regard to L are preferred:

L (i) is a 4- to 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or a 5- or 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y .

In connection with the above preferred embodiments, it is to be understood that R Y are as defined above with regard to the compounds of formula (I) of the third aspect of the present invention or as defined further below.

Even more preferably, with regard to the compounds of formula (I), preferably with regard to the compounds of formula (la), and more preferably with regard to the compounds of formula (1.1a) and (1.2a) of the third aspect as defined above, the following substituent meanings with regard to L are preferred:

L (i) is a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or a 5- or 6-membered aromatic carbocyclyl, wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y .

In a particularly preferred embodiment, L has the following substituent meanings with regard to the compounds of formula (I), preferably with regard to the compounds of formula (la) and more preferably with regard to the compounds of formula (1.1a), and (1.2a) of the third aspect as defined above:

L (i) is a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, selected from the following structural formulae wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R Y , or

L is a 6-membered aromatic carbocyclyl and has the following structural formula wherein the aforementioned carbocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents R Y .

In one preferred embodiment of the present invention, L is a 5- or 6-membered saturated, partially or fully unsaturated or aromatic heterocyclyl wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, according to the following structural formulae wherein the heterocyclic ring is not further substituted.

In another preferred embodiment of the present invention, L is a 6-membered aromatic carbocyclyl and has the following structural formula wherein the carbocyclic ring is not further substituted.

In connection with the above structural formulae of L it is to be understood that the curled line in the structural formulae indicates the connection to the remainder of the molecule.

Furthermore, in connection with the above preferred embodiments regarding the substituent L, it is to be understood that R Y has the following preferred substituent meanings:

R Y is halogen, NH 2 , OH, C 1 -C 4 alkyl, C 1 -C 4 -haloalkyl, C 2 -C 6 -alkenyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, cyclopropyl, cyclopropyl- C 1 -C 4 -alkyl, phenyl- C 1 -C 4 alkyl, two R Y form =0, or a 4- to 6- membered saturated, partially or fully unsaturated or aromatic carbocyclyl, carbocyclyl- C 1 -C 4 alkyl, heterocyclyl or heterocyclyl- C 1 -C 4 -alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from NH 2 , or two substituents form =0.

Preferably, R Y has the following preferred substituent meanings with regard to L as defined above:

R Y is Cl, Br, OH, C 1 -C 3 -alkyl, C 1 -C 4 -haloalkyl, C 2 -C 4 -alkenyl, C r C 2 -alkoxy, cyclopropyl, cyclopropyl- C 1 -C 2 -alkyl, phenyl- C 1 -C 4 -alkyl, or a 4- to 6-membered saturated or fully unsaturated or aromatic carbocyclyl, carbocyclyl- C 1 -C 4 -alkyl, heterocyclyl or heterocyclyl- C 1 -C 4 -alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non- oxidized, and wherein each substtutabe ca bo t e a o ementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from NH 2 , or two substituents form =O. More preferably, R Y has the following preferred substituent meanings with regard to L as defined above: R Y is Cl, OH, C 1 -C 3 -alkyl, C 1 -alkoxy, cyclopropyl, cyclopropyl-C 1 -alkyl, C 2 -haloalkyl, phenyl-C 1 -C 2 - alkyl, C 3 -alkenyl, or a 4- to 6-membered saturated or fully unsaturated or aromatic carbocyclyl, carbocyclyl-C 1 -alkyl, heterocyclyl or heterocyclyl-C 1 -C 2 -alkyl, wherein the aforementioned heterocyclic rings comprise one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from NH2, or two substituents form =O. In a particularly preferred embodiment of the present invention, R Y has the following preferred substituent meanings with regard to L as defined above: R Y is CH 3 , CH(CH 3 ) 2 , cyclopropyl-C 1 -alkyl, phenyl-C 2 -alkyl, or a 4- to 6-membered saturated or aromatic carbocyclyl-C 1 -alkyl or heterocyclyl-C 1 -C 2 -alkyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from NH 2 , or two substituents form =O; more preferably R Y is CH 3 , CH(CH 3 ) 2 , cyclopropyl-C 1 -alkyl, phenyl-C 2 -alkyl, or a 4- to 6-membered saturated or aromatic carbocyclyl-C 1 -alkyl or heterocyclyl-C 1 -C 2 -alkyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized. In connection with the above embodiments regarding the substituent L it is to be understood that the remaining substituents of the compound of formula (I) such as X 1 , X 2 , X 3 and X 4 as well as R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined above with regard to the compounds of formula (I) of the third aspect. In a fourth aspect, the present invention relates to a compound of formula (I) or a salt, stereoisomer, tautomer or N- wherein X 1 is CH 2 , or N; X 2 is CR 4 or N; X 3 is CH or N; X 4 is CH, or N; R 1 , R 2 are independently of each other selected from H, halogen and OH; R 3 is H, or C 1 -C 4 -alkyl; R 4 is H, CN, halogen, C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, phenyl, or a 3- to 6-membered saturated, partially or fully unsaturated, or aromatic carbocyclyl, or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more same or different substituents R x ; R 5 is H, C 1 -C 4 -alkyl, or NR a R b ; or R 4 and R 5 together with the atoms to which they are bonded form a 7- to 10-membered partially or fully unsaturated carbocyclyl or heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R 6 is H, halogen, C 1 -C 4 -alkyl, NR a R b , or OR c ; wherein L (i) is a 4- to 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized, or (ii) is selected from wherein each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, or two substituents together form C(=O); wherein R a , R b are independently of each other selected from H, C 1 -C 4 -alkyl and phenyl; R c is H, C 1 -C 4 -alkyl, NR a R b , NR a R b -C 1 -C 4 -alkyl, benzyl, or a 5- or 6-membered saturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, and wherein said N- and/or S-atoms are independently oxidized or non-oxidized; R d is benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 - C 4 -alkyl, or diphenylsulfide-C 1 -C 4 -alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substtue ts seected o alogen, C 1 C 4 haloalkyl, and phenyl C 1 C 4 -alkyl, or a substituent according to the following formulae R e is a 5- or 6- , ng comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents R x ; R g is H, C(=O)R c , phenyl-C 1 -C 4 -alkyl, benzophenone-C 1 -C 4 -alkyl, phenoxybenzene-C 1 -C 4 -alkyl, N-methyl-diphenylamine-C 1 -C 4 -alkyl, diphenylsulfide-C 1 -C 4 -alkyl, or naphthalene-C 1 -C 4 - alkyl, wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents selected from halogen, C 1 -C 4 -haloalkyl, and phenyl-C 1 -C 4 -alkyl, or a substituent according to the following formulae R x is C 1 -C 4 -alky , , n is 1, 2, 3 or 4; with the proviso that if X 2 is N or CR 4 , wherein R 4 is H, then R 5 is not H or NH 2 . Preferred embodiments of the substituents of the compounds of formula (I) according to the fourth aspect of the present invention are described in further detail in the first aspect of the present invention. It is to be understood that each preferred embodiment is relevant on its own as well as in combination with other preferred embodiments. Furthermore, it is to be understood that the preferences in each case also apply to the salts, stereoisomers, tautomers, and N-oxides of the compounds according to formula (I) of the invention. Thus, the preferred embodiments of the substituents of the compounds of formula (I) according to the fourth aspect are covered by the first aspect of the present invention. Definitions The term “compound(s) of the present invention” is to be understood as equivalent to the term “compound(s) according to the invention”, and also covers a salt, stereoisomer, tautomer or N- oxide thereof. The compounds according to the invention may be amorphous or may exist in one or more different crystalline states (polymorphs), which may have different macroscopic properties such as stability or show different biological properties such as activities. The present invention relates to amorphous and crystalline forms of compounds of formula (I), mixtures of different crystalline states of the compounds of formula (I), as well as amorphous or crystalline salts thereof.

Salts of the compounds according to the invention are preferably pharmaceutically acceptable salts, such as those containing counterions present in drug products listed in the US FDA orange Book database. They can be formed in a customary manner, e.g., by reacting the compound with an acid of the anion in question, if the compounds according to the invention have a basic functionality, or by reacting acidic compounds according to the invention with a suitable base.

Suitable cationic counterions are in particular the ions of alkali metals, preferably lithium, sodium and potassium, of the alkaline earth metals, preferably calcium, magnesium and barium, and of the transition metals preferably manganese, copper, silver, zinc and iron, and also ammonium (NH 4 + ) and substituted ammonium in which one to four of the hydrogen atoms are replaced by C 1 -C 4 -alkyl, C 1 -C 4 -hydroxyalkyl, C 1 -C 4 alkoxy, C 1 -C 4 -alkoxy-C 1 -C 4 alkyl, hydroxy- C 1 -C 4 alkoxy- C 1 -C 4 alkyl, phenyl or benzyl. Examples of substituted ammonium ions comprise methylammonium, isopropylammonium, dimethylammonium, diisopropylammonium, trimethylammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, 2- hydroxy-ethylammonium, 2-(2-hydroxyethoxy)ethyl-ammonium, bis(2-hydroxyethyl)ammonium, benzyltrimethylammonium and benzyltriethylammonium, furthermore the cations of 1,4- piperazine, meglumine, benzathine and lysine.

Suitable anionic counterions are in particular chloride, bromide, hydrogensulfate, sulfate, dihydrogenphosphate, hydrogenphosphate, phosphate, nitrate, bicarbonate, carbonate, hexafluorosilicate, hexafluorophosphate, benzoate, and the anion of C 1 -C 4 alkanoic acids, preferably formate, acetate, propionate and butyrate, furthermore lactate, gluconate, and the anions of poly acids such as succinate, oxalate, maleate, fumarate, malate, tartrate and citrate, furthermore sulfonate anions such as besylate (benzenesulfonate), tosylate (p-toluenesulfonate), napsylate (naphthalene-2-sulfonate), mesylate (methanesulfonate), esylate (ethanesulfonate), and ethanedisulfonate. They can be formed by reacting compounds according to the invention that have a basic functionality with an acid of the corresponding anion.

Depending on the substitution pattern, the compounds according to the invention may have one or more centers of chirality, including axial chirality. The invention provides both, pure enantiomers or pure diastereomers, of the compounds according to the invention, and their mixtures, including racemic mixtures. Suitable compounds according to the invention also include all possible geometrical stereoisomers (cis/trans isomers or E/Z isomers) and mixtures thereof. E/Z-isomers may be present with respect to e.g., an alkene, carbon-nitrogen double bond or amide groups.

Tautomers may be formed, if a substituent is present at the compound of formula (I), which allows for the formation of tautomers such as keto-enol tautomers, imine-enamine tautomers, amide-imidic acid tautomers or the like.

The term "N-oxide" includes any compound of the present invention which has at least one tertiary nitrogen atom that is oxidized to a N-oxide moiety.

The term "substituted" as used herein, means that a hydrogen atom bonded to a designated atom is replaced with a specified substituent, provided that the substitution results in a stable or chemically feasible compound. Unless otherwise indicated, a substituted atom may have one or more substituents and each substituent is independently selected. The term "substitutable", when used in reference to a designated atom, means that attached to the atom is a hydrogen, which can be replaced with a suitable substituent.

When it is referred to certain atoms or moieties being substituted with "one or more" substituents, the term "one or more" is intended to cover at least one substituent, e.g. 1 to 10 substituents, preferably 1, 2, 3, 4 or 5 substituents, more preferably 1, 2, or 3 substituents, most preferably 1 or 2 substituents. When neither the term "unsubstituted" nor "substituted" is explicitly mentioned concerning a moiety, said moiety is to be considered as unsubstituted.

The organic moieties mentioned in the above definitions of the variables are - like the term halogen - collective terms for individual listings of the individual group members. The prefix C n - C m indicates in each case the possible number of carbon atoms in the group.

The term "halogen" denotes in each case fluorine, bromine, chlorine or iodine, in particular fluorine, chlorine, or bromine.

As used herein, the term "two substituents together form (=0)" or the term "two substituents together form C(=O)" is to be understood in a way that the substitutable designated atom to which two hydrogen atoms are attached is substituted by two substituents together forming (=0). In other words, if the designated atom is a carbon atom, from which two hydrogen atoms are substituted by forming a group (=0) this results in the following moiety

The term "alkyl" as used herein denotes in each case a straight-chain or branched alkyl group having usually from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, more preferably 1 to 3 or 1 or 2 carbon atoms. Examples of an alkyl group are methyl, ethyl, n-propyl, iso-propyl, n- butyl, 2-butyl, iso-butyl, tert-butyl, n-pentyl, 1- methyl butyl, 2-methylbutyl, 3 -methyl butyl, 2,2-di- methylpropyl, 1-ethylpropyl, n-hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2- methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethyl- butyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2- trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl, and 1-ethyl-2-methylpropyl.

The term "haloalkyl" as used herein denotes in each case a straight-chain or branched alkyl group having usually from 1 to 6 carbon atoms, frequently 1 to 4 carbon atoms, preferably 1 to 3 or 1 or 2 carbon atoms, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms. Preferred haloalkyl moieties are selected from C 1 -C 4 -haloalkyl, more preferably from C 1 -C 3 -haloalkyl or C 1 -C 2 -haloalkyl, in particular from C 1 -C 2 -fluoroalkyl such as fluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, and the like.

The term "alkoxy" as used herein denotes in each case a straight-chain or branched alkyl group which is bonded via an oxygen atom and has usually from 1 to 4 carbon atoms, preferably 1 to 2 carbon atoms, more preferably 1 carbon atom. Examples of an alkoxy group are methoxy, ethoxy, n-propoxy, iso-propoxy, n-butyloxy, 2-butyloxy, iso-butyloxy, tert.-butyloxy, and the like.

The term "haloalkoxy" as used herein denotes in each case a straight-chain or branched alkoxy group having from 1 to 4 carbon atoms, preferably 1 to 2 carbon atoms, more preferably 1 carbon atom, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms, in particular fluorine atoms. Preferred haloalkoxy moieties include -haloalkoxy, in particular C 1 -fluoroalkoxy, such as trifluoromethoxy and the like.

The term "alkenyl" as used herein denotes in each case an unsaturated hydrocarbon group having usually 2 to 6, preferably 2 to 4 carbon atoms comprising at least one carbon-carbon double bond in any position, e.g. vinyl (ethenyl), allyl (2-propen-1-yl), 1-propen-1-yl, 2-propen-2- yl, methallyl (2-methylprop-2-en-1-yl), 2-buten-1-yl, 3-buten-1-yl, 2-penten-1-yl, 3-penten-1-yl, 4- penten-1-yl, 1-methylbut-2-en-1-yl, 2-ethylprop-2-en-1-yl and the like. If geometric isomers are possible with regard to the double bond, the present invention relates to both, the E- and Z- isomers. The bonding of vinyl is exemplified below:

The term "cycloalkyl" as used herein denotes in each case a monocyclic cycloaliphatic radical having usually from 3 to 10 or from 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl or cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term "carbocyclic" or "carbocyclyl" includes, unless otherwise indicated, in general a 3- to 9- membered, preferably a 4- to 8-membered or a 3- to 6-membered or a 5- to 7-membered, more preferably a 5- or 6-membered monocyclic ring comprising 3 to 9, preferably 4 to 8 or 3 to 6 or 5 to 7, more preferably 5 or 6 carbon atoms. The carbocycle may be saturated, partially or fully unsaturated, or aromatic, wherein saturated means that only single bonds are present, and partially or fully unsaturated means that one or more double bonds may be present in suitable positions, while the Huckel rule for aromaticity is not fulfilled, whereas aromatic means that the Huckel (4n + 2) rule is fulfilled. The term "carbocycle" or "carbocyclyl", unless otherwise indicated, may therefore cover inter alia cycloalkyl, cycloalkenyl, as well as phenyl. Preferably, the term "carbocycle" covers cycloalkyl and cycloalkenyl groups, for example cyclopropane, cyclobutane, cyclopentane and cyclohexane rings.

The term "heterocyclic" or "heterocyclyl" includes, unless otherwise indicated, in general a 3- to 9-membered, preferably a 4- to 8-membered or 5- to 7-membered, more preferably 5- or 6- membered, in particular 6-membered monocyclic ring. The heterocycle may be saturated, partially or fully unsaturated, or aromatic, wherein saturated means that only single bonds are present, and partially or fully unsaturated means that one or more double bonds may be present in suitable positions, while the Huckel rule for aromaticity is not fulfilled, whereas aromatic means that the Huckel (4n + 2) rule is fulfilled. The heterocycle typically comprises one or more, e.g. 1, 2, 3, or 4, preferably 1, 2, or 3 heteroatoms selected from N, O and S as ring members, where S- atoms as ring members may be present as S, SO or SO 2 . The remaining ring members are carbon atoms. In a preferred embodiment, the heterocycle is an aromatic heterocycle, preferably a 5- or 6-membered aromatic heterocycle comprising one or more, e.g. 1, 2, 3, or 4, preferably 1, 2, or 3 heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO 2 . Examples of 5- or 6-membered aromatic heterocycles include pyridyl (also referred to as pyridinyl), i.e. 2-, 3-, or 4-pyridyl, pyrimidinyl, i.e. 2-, 4- or 5-pyrimidinyl, pyrazinyl, pyridazinyl, i.e. 3- or 4-pyridazinyl, thienyl, i.e. 2- or 3-thienyl, furyl, i.e. 2-or 3-furyl, pyrrolyl, i.e. 2- or 3-pyrrolyl, oxazolyl, i.e. 2-, 3- or 5-oxazolyl, isoxazolyl, i.e. 3-, 4- or 5-isoxazolyl, thiazolyl, i.e. 2-, 3- or 5-thiazolyl, isothiazolyl, i.e. 3-, 4- or 5-isothiazolyl, pyrazolyl, i.e. 1-, 3-, 4- or 5-pyrazolyl, i.e. 1-, 2-, 4- or 5-imidazolyl, oxadiazolyl, e.g. 2- or 5-[1,3,4]oxadiazolyl, 4- or 5-(1,2,3- oxadiazol)yl, 3- or 5-(1,2,4-oxadiazol)yl, 2- or 5-(1,3,4-thiadiazol)yl, thiadiazolyl, e.g. 2- or 5-(1,3,4- thiadiazol)yl, 4- or 5-(1,2,3-thiadiazol)yl, 3- or 5-(1,2,4-thiadiazol)yl, triazolyl, e.g. 1H-, 2H- or 3H-1,2,3-triazol-4-yl, 2H-triazol-3-yl, 1H-, 2H-, or 4H-1,2,4-triazolyl and tetrazolyl, i.e. 1H- or 2H-tetrazolyl. "Hetaryls" or "heteroaryls" are covered by the term "heterocycles". The saturated or partially or fully unsaturated heterocycles usually comprise 1, 2, 3, 4 or 5, preferably 1, 2 or 3 heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO 2 . The skilled person is aware that S, SO or SO 2 is to be understood as follows: s /

Further, a skilled person is aware that resonance structures of the oxidized forms may be possible. Saturated heterocycles include, unless otherwise indicated, in general 3- to 9- membered, preferably 4- to 8-membered or 5- to 7-membered, more preferably 5- or 6- membered monocyclic rings comprising 3 to 9, preferably 4 to 8 or 5 to 7, more preferably 5 or 6 atoms comprising at least one heteroatom, such as pyrrolidine, tetrahydrothiophene, tetra hydrofuran, piperidine, tetrahydropyran, dioxane, morpholine or piperazine.

As used herein the term "carbobicyclic" or "carbobicyclyl" includes in general 6 to 14- membered, preferably 7- to 12-membered or 7- to 10-membered bicyclic rings comprising 6 to 14, preferably 7 to 12 or 7 to 10 carbon atoms. The carbobicycle may be saturated, partially or fully unsaturated, or aromatic, wherein saturated means that only single bonds are present, and partially or fully unsaturated means that one or more double bonds may be present in suitable positions, while the Huckel rule for aromaticity is not fulfilled, whereas aromatic means that the Huckel (4n + 2) rule is fulfilled. Preferably, the term "aromatic" in connection with the carbobicyclic ring means that both rings of the bicyclic moiety are aromatic, so that, e.g., 8 TT electrons are present in case of a 10-membered aromatic carbobicyclic ring.The term "carbobicyclic" or "carbobicyclyl", unless otherwise indicated, may therefore cover inter alia bicycloalkyl, bicycloalkenyl, as well as bicyclic aromatic groups, for example bicyclohexane (decalin), bicycloheptane (such as norbornane), bicyclooctane (such as bicyclo[2.2.2]octane, bicyclo[3.2.1]octane or bicyclo[4.2.0]octane), bicyclononane (such as bicyclo[3.3.1]nonane or bicyclo[4.3.0]nonane ), bicyclodecane (such as bicyclo[4.4.0]decane), bicycloundecane (such as bicyclo[3.3.3]undecane), norbornene, naphthalene and the like. Preferably, the carbobicycle is a fused carbobicycle, which is preferably aromatic, for example naphthalene.

The term "heterobicyclic" or "heterobicyclyl" includes, unless otherwise indicated, in general 6 to 14-membered, preferably 7- to 12-membered or 7- to 10-membered bicyclic rings. The heterobicycle may be saturated, partially or fully unsaturated, or aromatic, wherein saturated means that only single bonds are present, and partially or fully unsaturated means that one or more double bonds may be present in suitable positions, while the Huckel rule for aromaticity is not fulfilled, whereas aromatic means that the Huckel (4n + 2) rule is fulfilled. In principal, for being "aromatic", it is sufficient if one of the two rings of the bicyclic moieties is aromatic, while the other is non-aromatic. However, it is preferred in connection with the term "aromatic" that both rings of the bicyclic moiety are aromatic, so that, e.g., 8 TT electrons are present in case of a 9- or 10-membered aromatic heterobicyclic ring. The heterobicycle typically comprises one or more, e.g. 1, 2, 3, or 4, preferably 1, 2, or 3 heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO 2 . The remaining ring members are carbon atoms. Examples of heterobicycles include benzofuranyl, benzothienyl, indolyl, indazolyl, benzimidazolyl, benzoxathiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzoxazinyl, quinolinyl, isoquinolinyl, purinyl, or quinuclidine and the like. Preferred heterobicycles according to the invention are aromatic heterobicycles.

As used herein, the terms "carbocyclylalkyl", "heterocyclylalkyl", and "cyclopropylalkyl" as well as the terms "NRR-alkyl", "phenyl-alkyl, benzophenone-alkyl, phenoxybenzene-alkyl, N-methyl- diphenylamine-alkyl, diphenylsulfide-Calkyl, or naphthalene-alkyl" and the like refer to the corresponding groups, which are bonded to the remainder of the molecule via an alkyl, preferably via a C 1 -C 4 -alkyl group. Examples include but are not limited to benzyl (i.e. phenylmethyl), cyclohexylmethyl, pyridinylmethyl, and piperidinomethyl.

As used herein the term "spiro-heterocyclyl" refers to a polycyclic heterocyclyl having usually from 7 to 10 atoms. The atoms may be carbon or heteroatoms, wherein the spiro-heterocycle comprises at least one heteroatom, preferably 1 to 3 heteroatoms, more preferably 1 or 2 heteroatoms. The remaining atoms of the spiro-heterocycle are carbon atoms. The polycycle is preferably a bicycle, preferably a heterobicycle having usually from 7 to 10 atoms. The cycles of the polycycle, preferably the two cycles of the heterobicycle are attached to each other over one atom only, which is referred to as the "spiro-atom", wherein said spiro-atom may be a carbon or heteroatom. The cycles of the polycyclic ring may be the same or different.

As used in the specification and the claims, the singular forms of "a" and "an" also include the corresponding plurals unless the context clearly dictates otherwise. The same applies for plural forms used herein, which also include the singular forms unless the context clearly dictates otherwise.

The terms "about" and "approximately" in the context of the present invention denotes an interval of accuracy that a person skilled in the art will understand to still ensure the technical effect of the feature in question. The term typically indicates a deviation from the indicated numerical value of ±10% and preferably ±5%.

It needs to be understood that the term "comprising" is not limiting. For the purposes of the present invention, the term "consisting of" is considered to be a preferred embodiment of the term "comprising of". If hereinafter a group is defined to comprise at least a certain number of embodiments, this is also meant to encompass a group, which preferably consists of these embodiments only.

The term "pharmaceutically acceptable excipient" as used herein refers to compounds commonly comprised in pharmaceutical compositions, which are known to the skilled person. Examples of suitable excipients are exemplary listed below. Typically, a pharmaceutically acceptable excipient can be defined as being pharmaceutically inactive.

The term "treatment" is to be understood as also including the option of "prophylaxis". Thus, whenever reference is made herein to a "treatment" or "treating", this is to be understood as "treatment and/or prophylaxis" or "treating and/or preventing".

The term "seven-beta-strand family of histone methyltransferases" refers to the respective family of enzymes. Presently, this family comprises DOTH and KMT9. The term "KTM9" means the heterodimer composed of KMT9 alpha and KMT9beta. The term "KMT9alpha" as used herein refers to the protein "N-6 adenine-specific DNA methyltransferase 1" [Homo sapiens (human)], with the underlying Gene ID: 29104 (updated on 11-Sep-2019, database: https://www.ncbi.nlm.nih.gov/gene). "N6AMT1" or "KMT9alpha" is the corresponding gene. Other names for KMT9alpha are C21orf127, Hemk2, Mtq2, N6amt1, PrmC or PRED28. The sequence of the KMT9alpha protein (isoform 1 [Homo sapiens]) is depicted in SEQ ID NO: 1. The term "KMT9beta" as used herein refers to the protein "tRNA methyltransferase subunit11-2" [Homo sapiens (human)] with the underlying Gene ID: 51504 (updated on 11-Sep-2019, database: https://www.ncbi.nlm.nih.gov/gene). "TRMT112" or "KMT9beta" is the corresponding gene. The sequence of the KMT9beta protein (isoform 2 [Homo sapiens]) is depicted in SEQ ID NO: 2.

Description of pharmaceutical compositions according to the present invention

A pharmaceutical composition according to the present invention may be formulated for oral, buccal, nasal, rectal, topical, transdermal, or parenteral application. Preferred non-parenteral routes include mucosal (e.g., oral, vaginal, nasal, cervical, etc.) routes, of which the oral application may be preferred. Preferred parenteral routes include but, are not limited to, one or more of subcutaneous, intravenous, intra-muscular, intraarterial, intradermal, intrathecal, and epidural administrations. Preferred administration is by subcutaneous, intratumoral or peritumoral routes. Particularly preferred is intratumoral administration. The compound according to formula (I) should be applied in pharmaceutically effective amounts, for example in the amounts as set out herein below.

A pharmaceutical composition of the present invention may also be designated as formulation or dosage form. A compound of formula (I) may also be designated in the following as (pharmaceutically) active agent, active ingredient, or active compound.

Pharmaceutical compositions may be solid or liquid dosage forms or may have an intermediate, e.g. gel-like character depending inter alia on the route of administration.

In general, the inventive dosage forms can comprise various pharmaceutically acceptable excipients, which will be selected depending on which functionality is to be achieved for the dosage form. A "pharmaceutically acceptable excipient" in the meaning of the present invention can be any substance used for the preparation of pharmaceutical dosage forms, including coating materials, film-forming materials, fillers, disintegrating agents, release-modifying materials, carrier materials, diluents, binding agents, and other adjuvants. Typical pharmaceutically acceptable excipients include substances like sucrose, mannitol, sorbitol, starch and starch derivatives, lactose, and lubricating agents such as magnesium stearate, d i si nteg rants, and buffering agents.

The term "carrier" denotes pharmaceutically acceptable organic or inorganic carrier substances with which the active ingredient is combined to facilitate the application. Suitable pharmaceutically acceptable carriers include, for instance, water, aqueous salt solutions, alcohols, oils, preferably vegetable oils, propylene glycol, polyoxyethelene sorbitans, polyethylenepolypropylene block co-polymers such as poloxamer 188 or poloxamer 407, polyethylene glycols such as polyethylene glycol 200, 300, 400, 600, etc., gelatin, lactose, amylose, magnesium stearate, surfactants, perfume oil, fatty acid monoglycerides, diglycerides and triglycerides, polyoxyethylated medium or long chain fatty acids such as ricinoleic acid, and polyoxyethylated fatty acid mono-, di-, and triglycerides such as capric or caprilic acids, petroethral fatty acid esters, hydroxymethyl celluloses such as hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxypropyl acetate succinate, polyvinylpyrrolidone, crosspovidone, and the like.

The pharmaceutical compositions can be sterile and, if desired, mixed with auxiliary agents, like lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavoring and/or aromatic substances and the like which do not deleteriously react with the active compound.

If liquid dosage forms are considered for the present invention, these can include pharmaceutically acceptable emulsions, solutions, suspensions, and syrups containing inert diluents commonly used in the art such as water. These dosage forms may contain e.g. microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer and sweeteners/flavoring agents.

For parenteral application, particularly suitable vehicles consist of solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants. Pharmaceutical formulations for parenteral administration are particularly preferred and include aqueous solutions of the compounds of formula (I) in water-soluble form. Additionally, suspensions of the compounds of formula (I) may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.

In one preferred embodiment, dosage forms are injectable preparations of a compound of formula (I). Thus, sterile injectable aqueous or oleaginous suspensions can for example be formulated according to the known art using suitable dispersing agents, wetting agents and/or suspending agents. A sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent. Among the acceptable vehicles and solvents that can be used are water and isotonic sodium chloride solution. Sterile oils are also conventionally used as solvent or suspending medium. Preferred applications for injectable preparations comprising the compounds of the present invention are intravenous, intratumoral and peritumoral administration.

Suppositories for rectal administration of a compound of formula (I) can be prepared by e.g. mixing the compound with a suitable non-irritating excipient such as cocoa butter, synthetic triglycerides and polyethylene glycols which are solid at room temperature but liquid at rectal temperature such that they will melt in the rectum and release the compound according to formula (I) from said suppositories.

For administration by inhalation, the compounds according to the present invention may be conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch. In one preferred embodiment the pharmaceutical composition is an oral dosage form. Oral dosage forms may be liquid or solid and include e.g. tablets, troches, pills, capsules, powders, effervescent formulations, dragees, and granules. Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. The oral dosage forms may be formulated to ensure an immediate release of the compound of formula (I) or a sustained release of the compound of formula (I).

A solid dosage form may comprise a film coating. For example, the inventive dosage form may be in the form of a so-called film tablet. A capsule of the invention may be a two-piece hard gelatin capsule, a two-piece hydroxypropylmethylcellulose capsule, a two-piece capsule made of vegetable or plant-based cellulose or a two-piece capsule made of polysaccharide.

The dosage form according to the invention may be formulated for topical application. Suitable pharmaceutical application forms for such an application may be a topical nasal spray, sublingual administration forms and controlled and/or sustained release skin patches. For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

The compositions may conveniently be presented in unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy. The methods can include the step of bringing the compounds into association with a carrier, which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the compounds into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product. Liquid dose units are vials or ampoules. Solid dose units are tablets, capsules and suppositories.

As regards human patients, the compound of formula (I) may be administered to a patient in an amount of about 0.001 mg to about 5000 mg per day, preferably of about 0.01 mg to about 1000 mg per day, more preferably of about 0.05 mg to about 250 mg per day, which is the effective amount. The phrase "effective amount" means an amount of compound that, when administered to a mammal in need (i.e. a patient in need) of such treatment, is sufficient to treat or prevent a particular disease or condition.

In one embodiment, the pharmaceutical composition may contain the compound of formula (I) in the form of a prodrug. A prodrug is generally any compound, which is converted under physiological conditions or by solvolysis to a more potent compound. A prodrug may be inactive or only slightly active prior to administration but may be converted to an active compound of the invention in vivo.

It is to be understood that the use of either a prodrug or a compound that has shown to have strong in vitro inhibitory capacity depends on the pharmaceutical composition and the route of administration that is used. If a pharmaceutical composition is used that includes a delivery system of an active agent into an intact cell, one would be inclined to use a compound with a strong in vitro inhibitory capacity, while rather a compound assumed to be a prodrug would be used if the pharmaceutical formulation rather delivers the compound to the cell membrane of an intact cell.

In one embodiment, the present invention relates to a pharmaceutical composition comprising a compound according to formula (I) as defined above with regard to the second aspect of the present invention and optionally a pharmaceutically acceptable carrier, diluent, or escipient as defined above for use in the treatment of castration resistant prostate cancer.

Indications for which the compounds of the present invention may be used

The compounds according to the present invention, in particular the compounds of formula (I) according to the first, third and fourth aspect of the present invention or the pharmaceutical composition comprising the same are suitable for use in medicine. In particular, the compounds according to formula (I) of the first, third and fourth aspect of the present invention are suitable for use in the treatment of cancer.

In one embodiment, the compound of formula (I) according to the first, third and fourth aspect of the present invention or a pharmaceutical composition comprising the same is for use in the treatment of cancer selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, colon cancer, glioblastoma, lung cancer, neuroblastoma, osteosarcoma, liposarcoma, colorectal cancer, rectal adenocarcinoma, mesothelioma, endometrium adenocarcinoma, leukemia, erythroleukemia, medulloblastoma, astrocytoma, Ewing sarcoma, myelodysplastic syndrome (MDS), diffuse large B-cell lymphoma, myelogenic leukemia, myeloid leukemia, acute monocytic leukemia, gallbladder carcinoma, cecum adenocarcinoma, gastric adenocarcinoma, stomach adenocarcinoma, renal cell carcinoma, bladder carcinoma, melanoma, cervical squamous cell carcinoma, pancreatic carcinoma, chondrosarcoma, duodenal adenocarcinoma, rhabdomyosarcoma, hepatocellular carcinoma and uterine adenocarcinoma.

In a preferred embodiment of the present invention, the cancer is selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, colon cancer, glioblastoma, lung cancer, neuroblastoma, colorectal cancer and bladder carcinoma.

In a particularly preferred embodiment of the present invention, the compound of formula (I) according to the first, third and fourth aspect of the present invention or a pharmaceutical composition comprising the same is for use in the treatment of prostate cancer, preferably castration resistant prostate cancer.

With regard to the above embodiments it is noted that the prostate cancer may be hormonedependent prostate cancer or castration-resistant prostate cancer, wherein the castration resistant prostate cancer may be further resistant to enzalutamide. Preferably, the prostate cancer as mentioned above is castration resistant prostate cancer.

Furthermore, in connection with the above embodiments it is to be understood that the lung cancer may be non-small cell lung cancer or small cell lung cancer.

In another embodiment of the present invention the compounds according to the present invention, in particular the compounds of formula (I) according to the second aspect of the present invention are for use in the treatment of prostate cancer. In a particularly preferred embodiment of the present invention, said prostate cancer is a castration resistant prostate cancer. In this connection it is to be understood that the castration resistant prostate cancer may be further resistant to enzalutamide.

The present invention is further illustrated by the following examples.

Examples

1. Synthesis of compounds

List of abbreviations

Ac acetyl

ACN acetonitrile

AcOH acetic acid

AcOEt ethyl acetate

BINAP (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl)

C18 C18 stationary phase column

DEAD diethyl azodicarboxylate

DIAD diisopropyl azodicarboxylate

DIEA /VA/-diisopropylethylamine

DCE dichloromethane

DCM dichloromethane

DMAP 4-dimethylaminopyridine

DMF /VA/-dimethylformamide

DMP Dess-Martin periodinane

DMSO dimethyl sulfoxide dba dibenzylideneacetone dppf / (diphenylphosphino)ferrocen dtbpf 1,1'-Z?/5(di-te/'f-butylphosphino)ferrocene dr diastereomeric ratio

ES electrospray ionization

EtOH ethanol

FA formic acid h hours

HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyri dinium

3-oxide hexafluorophosphate

HPLC high performance liquid chromatography

LCMS liquid chromatography-mass spectrometry

M Molar m-CPBA meta-chloroperoxybenzoic acid MeOH methanol

MH: megahertz min minutes mL milli t es mM millimole MTBE methyl tert-butyl ether Ms mesylate MSA methanesulfonic acid NBS N-bromosuccinimide NIS N-iodosuccinimide NMR nuclear magnetic resonance NMP N-methyl-2-pyrrolidone PCy 3 tricyclohexylphosphine Prep-HPLC preparative-scale high performance liquid chromatography Prep-TLC preparative thin layer chromatography P(t-Bu) 3 -PdCl-2nd G (chloro[(tri-tert-butylphosphine)-2-(2-aminobiphenyl)] palladium(II)) SEM trimethylsilylethoxymethyl THF tetrahydrofuran T R retention time Ts toluenesulfonyl TsOH p-toluenesulfonic acid SFC supercritical fluid chromatography TEA or Et 3 N triethylamine TFA trifluoroacetic acid UV ultraviolet PE petroleum ether EtOAC ethylacetate DIPEA diisopropylethylamine EDCl 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide NaBH4 sodium borohydride STAB sodium trisacetoxyborohydride NH 4 Cl ammonium chloride DMP Dess-Martin-periodinane Due to the respective synthetic procedure, the compounds according to the following examples may be provided as the corresponding salt thereof, such as e.g., a trifluoroacetate salt. Materials & Methods All reactions were carried out in glassware under inert (nitrogen) atmosphere. All used chemicals and reagents were purchased from commercial sources and were used without further purification. Solvents were freshly purified by distillation/drying over molecular sieves following the instructions from the Purification Book. Particularly mentioned anhydrous/dry solvents were purchased from Acros organics. Reactions were monitored by thin-layer chromatography (TLC) performed with Merck alumina plates coated with silica gel 60 F254, silica gel 60 RP-18 F254s or silica gel 60 NH 2 F 254 S (layer thickness: 0.2 mm) and analyzed under UV light (254 nm and 365 nm) or revealed using KMnO 4 , Bromocresol green, ninhydrin, phosphomolybdic acid or 2,4- dinitrophenylhydrazine (2,4-DNPH) as staining agent. The composition of the mobile phase was adjusted to the compound properties. Yields were not optimized. Flash column chromatography was performed on a Biotage® Isolera Prime/One purification system using 40-60 pm prepacked silica gel columns from Biotage®, HP-spherical 50 pm pre-packed silica gel columns from Interchim (Jumbo Pack), Star Silica D 60 pm, Star KP amino D 50 pm or Star Silica HC D 20 pm pre-packed silica gel columns from Biotage®. NMR spectroscopy and mass spectrometry were used for product identification. NMR spectra were acquired on a BRUKER Avance 400 spectrometer (400 MHz and 100.6 MHz for 1 H and 13 C respectively), at a temperature of 303 K unless specified using DMSO-c/ 6 as solvent. Chemical shifts (5) are reported in ppm, multiplicity abbreviations are as follows: bs = broad singlet, s = singlet, d = doublet, dd = doublet of doublets, dt = doublet of triplets, t = triplet, td = triplet of doublets, q = quartet, m = multiplet, coupling constant (7) are expressed in Hz. The 1 H assignment resulted from COSY experiments. Mass spectra were recorded on an Advion expression CMS using an ASAP® (Atmospheric Solids Analysis Probe; aka APCI: Atmospheric Pressure Chemical Ionization) as ion source, on a Thermo Scientific Exactive mass spectrometer using electrospray ionization (ESI) as ion source or HR-MS were obtained on a THERMO SCIENTIFIC Advantage. HPLC analysis was performed to determine the purity of all final compounds on an Agilent Technologies 1260 Infinity II system using diode array detector (DAD) UV detection at either 230, 248, 254, 260 & 280 nm or at 210 & 260 nm. 2 methods were used:

Method A: Phenomenex Kinetex® 5 .m XB-C18 100 A 250 x 4.6 mm column and eluent A was H 2 O containing 0.05 % trifluoracetic acid (TFA) and eluent B was CH 3 CN containing 0.05 % TFA. Linear gradient conditions were as follows: 0-4 min: 90:10 (A/B); 4-29 min: 90:0->100 (A/B); 29- 31 min: 0:100; (A/B); 31-31.5 min: 90:10 (A/B); 31.5-40 min: 90:10 (A/B) with a flowrate of 1.00 mL.min -1 .

Method A XBridge: XBridge® Shield RP18 5 .m XB-C18 100 A 150 x 4.6 mm column and eluent A was H 2 O containing 0.05 % trifluoracetic acid (TFA) and eluent B was CH 3 CN containing 0.05 % TFA. Linear gradient conditions were as follows: 0-4 min: 90:10 (A/B); 4-19 min: 90:0->100 (A/B); 19-21 min: 0:100; (A/B); 21-31.5 min: 90:10 (A/B); 31.5-25 min: 90:10 (A/B) with a flowrate of 1.00 mL.min -1 .

Method B: Phenomenex Kinetex® 5 .m XB-C18 100 A 250 x 4.6 mm column and eluent A was H 2 O containing 0.05 % trifluoracetic acid (TFA) and eluent B was CH 3 CN containing 0.05 % TFA. Linear gradient conditions were as follows: 0-1 min: 100:0 (A/B); 1-9 min: 60:40 (A/B); 9-11 min: 5:95; (A/B); 11-13 min: 5:95 (A/B); 13-14 min: 100:0 (A/B); 14-16 min: 100:0 (A/B) with a flowrate of 0.95 mL.min -1 .

Method B XBridge: XBridge® Shield RP18 5 .m XB-C18 100 A 150 x 4.6 mm column and eluent A was H 2 O containing 0.05 % trifluoracetic acid (TFA) and eluent B was CH 3 CN containing 0.05 % TFA. Linear gradient conditions were as follows: 0-1 min: 100:0 (A/B); 1-9 min: 60:40 (A/B); 9- 11 min: 5:95; (A/B); 11-13 min: 5:95 (A/B); 13-14 min: 100:0 (A/B); 14-16 min: 100:0 (A/B) with a flowrate of 0.95 mL.min -1 .

HPLC purification methods: Method C: Prep-HPLC was performed at conditions: (Flash: Welchrom C18, 150 x 20 mm); Wavelength 220 nm; Mobile phase: A MeCN (0.1% TFA); B water (0.1% TFA); Flow rate: 25 mL /min; Injection volume: 2 mL; Run time: 30 min; Equilibration: 5 min.

Method D: Phenomenex Kinetex® 5u XB-C18 100 A 250 x 21.2 mm column and eluent A was H 2 O containing 0.05 % trifluoracetic acid (TFA) and eluent B was CH 3 CN containing 0.05 % TFA. Linear gradient conditions were as follows: 0-4 min: 90:10 (A/B); 4-29 min: 90:0->100 (A/B); 29- 31 min: 0:100; (A/B); 31-31.5 min: 90:10 (A/B); 31.5-40 min: 90:10 (A/B) with a flowrate of 22.00 mL.min -1 .

Method E: Phenomenex Kinetex® 5u XB-C18 100 A 250 x 21.2 mm column and eluent A was H 2 O containing 0.05 % trifluoracetic acid (TFA) and eluent B was CH 3 CN containing 0.05 % TFA. Linear gradient conditions were as follows: 0-1 min: 100:0 (A/B); 1-9 min: 100:0->60:40 (A/B); 9- 11 min: 60:40^5:95; (A/B); 11-13 min: 5:95 (A/B); 13-14 min: 5:95^100:0 (A/B); 14-20 min: 100:0 (A/B) with a flowrate of 20.20 mL.min -1 .

Method F: Chiral HPLC: column: chiralpak IC, 250 mm x 4.6 mm, 5 urn; mobile phase: hexane/ethanol/diethylamine = 70:30:0.3; Flow rate: 1.0 mL/min; Wavelength: 230 nm; T = 30 °C.

Method G: XBridge® Prep Shield RP 18 5 pm OBD TM 19 x 150 mm column and eluent A was H 2 O containing 0.05% TFA and eluent B was CH 3 CN containing 0.05% TFA. Linear gradient conditions were as follows: 0 - 4 min: 90:10 (A/B); 4 - 19 min: 90:10 0:100 (A/B); 19 - 21 min:

0:100 (A/B); 21 - 21.5 min: 0:100 90:10 (A/B); 21.5 - 25 min: 90:10 (A/B) with a flowrate of

1.00 mL/min (procedure B).

General procedures for final compounds

Reductive amination general procedure A: An aldehyde 3, 7, 32, 42, and 49 (1.00 eq.) was dissolved in dry MeOH (0.10 M based on the aldehyde). Then a solution of amine 138, 144, and 150 (1.00 eq.) in dry MeOH (0.10 M based on amine) was added and stirred at ambient temperature for 72 h. The solution was cooled down to 0 °C in an ice-bath before NaBH 4 (1.5 eq.) was added portion wise. The ice-bath was removed, and the solution was stirred for 6 h at ambient temperature. Afterwards, water was added, and the aqueous phase was extracted 3 times with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified over silica eluting with CH 2 CI 2 /MeOH (mostly 0-10%) to afford the secondary amine 286, 288, 290, 308, 310, 320 and 322 as yellowish foams to colorless foams.

Reductive amination general procedure B: For the secondary amines: A solution of aldehyde 13, 19, and 40 (1.20 eq.) and amine 150 (1.00 eq.) in MeOH (0.02 M based on 150) was stirred at room temperature for 20 min. NaBH 3 CN (3.00 eq.) and AcOH (0.10 eq.) was added. The solution was stirred at room temperature for 4 hrs. The resulting mixture was diluted with EtOAc, washed with H 2 O. The organic phase was dried over Na 2 SO 4 and concentrated. The crude was purified by prep-HPLC using method C with varying buffer system (mentioned in the compound description) to give the pure compounds 361, 363, and 365 For the tertiary amines: To the reaction mixture was directly added either acetaldehyde, acetone, cyclopropanecarbalydehyde (1.20 eq.) and the mixture was stirred at room temperature for 12 hrs. The target was found by LC-MS. The reaction solution was quenched with several drops of water and concentrated to dryness. The residue was purified by prep-HPLC using method C with varying buffer system (mentioned in the compound description) to give the pure compounds 369, 371, and 373.

Acylation/urea synthesis general procedure C: To an ice-cooled solution of Fmoc-protected amine 111 (1.00 eq.) in a mixture of CH 2 CI 2 and Et 3 N (0.03 M based on 111) was added the corresponding isocyanate or the acylchloride (1.00 eq.). The resulted solution was stirred for 24 h at ambient temperature. The reaction mixture was concentrated over vacuum to complete dryness. The obtained residue was purified by flash chromatography eluting CH 2 CI 2 /MeOH (mostly 0-15%) to afford the penultimate products 312 and 314 yellowish foam.

Reductive amination general procedure D: To a solution of aldehyde 3, 27, 29, 30, 42, 59, 60, 63, 66, and 67 (1.10 eq.) in dry DCE (0.02 M based on aldeyhde) was added a solution of amine 127, 150, 156, 164, 167, 172, and 175 (0.02 M based on amine) under nitrogen atmosphere. The solution was stirred for 30 min at ambient temperature. Then, NaBH(OAc) 3 (1.50 eq.) was added portion wise under nitrogen. The resulted mixture was tired for 24 h at ambient temperature. HPLC analytics showed complete consumption of the amine. At this point, the reaction was quenched by addition of 1 M 2 CO 3 solution to reach pH 8-9. Then, CH 2 CI 2 was added, and the organic layer was separated. The aqueous phase was further extracted with CH 2 CI 2 (2 times). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The crude product was purified over silica CH 2 CI 2 /MeOH (mostly 0-7%) to afford the product 310, 316, 318, 327, 329, 331, 333, 335, 337, 339, 341, 343, 378 and 380 as colorless foam.

Peptidic coupling general procedure E: The acid 133 (1.20 eq.) was suspended in DMF (0.20 M based on amine). The suspension was cooled down with an ice-bath before EDCI (1.50 eq.) was portion wise added. The mixture was stirred for 10 min at 0 °C and then allowed to warm up to rt. Then, a solution of amine 69, 71, 91, 98, 102, 103, 107, and 109 in CH 2 CI 2 (0.2 M based on amine), DIPEA, and DMAP were added. The mixture was stirred overnight at ambient temperature. Then, the organic solvent was evaporated by rotatory evaporation. The obtained residue was subjected to silica gel column chromatography eluting with CH 2 CI 2 /MeOH (mostly 0-5%) to afford the penultimate amides 296, 298, 300, 302, 304, 306, 324, 683 and 687 as yellowish foams.

Peptidic coupling general procedure F: A solution of acid 135 (1.00 eq), amine tert-butyl 3- (aminomethyl)piperidine-l-carboxylate, tert-butyl 2-(aminomethyl)piperidine-1-carboxylate 1- Boc-4-(aminomethyl)piperidine, 75, 77, 78, 79, 80, and 98 (2.00 eq.) and DIPEA (3.00 eq.) in DMF (0.10 M based on acid) was stirred at r. t. for 10 min. HATU (1.50 eq.) was then added, and the reaction mixture was stirred at r. t. overnight. The reaction solution was directly purified by prep- HPLC (TFA or NH 4 OAC buffer) to give the desired compounds 345, 347, 349, 351, 352, 353, 354, 355, and 356 as white foams (TFA salt or free base).

CuAAC general procedure G: The alkyne 181 and 182 (1.00 eq.), THPTA (0.20 eq.), and CuBr (0.20 eq.) in a tBuOH/H2O (2:1; 0.01 M based on alkyne). Then, 1-azido-2-methoxyethane (1.10 eq.) was added to the reaction mixture at ambient temperature. The mixture was stirred for 24 h at rt. The organic solvent was evaporated and the aqueous phase was extracted with CH 2 CI 2 . The combine organic layers were washed with brine, dried, and concentrated. The obtained residue was purified over silica (CH 2 CI 2 /MeOH; mostly 0-10%) to afford the pure products 292 and 294 as colorless solid.

Rh-catalyzed 1,4-addition general procedure H: To a heat-dried three-necked round bottom flask equipped with a stirring bar and air condenser was charged with (3a/?,6aA)-2,2-dimethyl-3a,6a- dihydro-47/-cyclopenta[<7|[1,3]dioxol-4-one (1.00 eq.), [Cp*RhCI 2 ] 2 (0.01 eq.), KOH (0.2 eq.), and a corresponding aryl or alkenyl pinacol ester (1.50 eq.) under nitrogen atmosphere, Then, 1,4- dioxane (0.20 M) was added and the resulted mixture was degassed. Degassed water was then added, and the mixture was placed into a pre-heated heating plate (50 °C). The reaction mixture was heated to 80 °C and stirred for 3 to 7 h upon cpmplete consumption of the carbasugar mimic. TLC was used for monitoring the reaction progress. Then, the reaction was cooled down to ambient temperature and was diluted with water. The aqueous phase was extracted three times with EtOAc and the combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained crude product was purified by flash chromatography to obtain the desired products 213, 214, 215, 216, 217, 218, 219, 220, 221,

222, 223, 224.

Ketone reduction general procedure I: Compounds 213, 214, 215, 216, 217, 218, 219, 220, 221, 222,

223, 224 (1.00 eq.) were dissolved in anhydrous MeOH (0.20 M) and cooled down to 0 °C. Then, NaBH 4 (1.50 eq.) was added portion wise. The reaction mixture was stirred for 1 h at 0 °C (until the bubbling stopped). Upon full conversion indicated by TLC, Cold water was added. The aqueous phase was extracted five times with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The obtained residue was purified with silica gel chromatography to afford the pure products 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239. 240.

Nucleophilic substitution general procedure J: The alcohol 227 & 228 (1.00 eq.) was dissolved in dry CH 2 CI 2 (0.10 M). Then, dry pyridine (3.00 eq.) was added and cooled down to 0 °C. To the cooled solution Tf 2 O (2.00 eq.) was added dropwise. The reaction mixture was stirred for 1 h at 0 °C. Then, the reaction mixture was quenched with cold water and extracted with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate and concentrated to complete dryness. Nucleobase (1.20 eq.) was dissolved in dry DMF (0.08 M) and cooled down to 0 °C before NaH (2.00 eq.) was added portion wise. The resulted mixture was stirred for 15 min at ambient temperature before a corresponding triflate solution (1.00 eq.) in DMF was added dropwise. The mixture was stirred for 17 h at ambient temperature. Then, water was added carefully, and the resulted mixture was extracted with EtOAc. The combined organic layers were washed extensively with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude products were purified over silica to afford the target compounds 244, 245, 246.

Mitsunobu type glycosylation general procedure K: To a cooled solution of compounds 229, 230, 231, 232, 233 (1.00 eq.) in dry THF was added PPh 3 (2.00 eq.) followed by dropwise addition of DIAD (1.80 eq.) under nitrogen atmosphere. The resulted mixture was stirred for 30 min at 0 °C. Then, corresponding nucleobase (1.40 eq.) was added at 0 °C. The reaction mixture was stirred for 17 h at ambient temperature. After 17 h, the reaction was diluted with saturated bicarbonate solution and extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by flash chromatography to afford the target compounds 247, 248, 249, 250, 251, 252, 253.

Mitsunobu type glycosylation general procedure L: A heat dried three-necked round bottom flask equipped with stirring bar, thermometer, and air condenser was charged with alcohol 192, 197, 234, 235, 236 (1.50 eq.) under nitrogen atmosphere. Then, dry toluene (0.50 M) was added and cooled down to 0 °C. To the solution PPh 3 (2.00 eq.) and nucleobase (1.00 eq.) was added and cooled down to 0 °C. To the cooled solution a solution of DBAD (1.10 M, 2.00 eq.) in dry toluene was added dropwise under nitrogen atmosphere. The mixture was stirred 10 min at 0 °C before heated to 60 °C for 17 h. The resulting mixture was allowed to cool to room temperature and was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography to afford the title compounds 193, 254, 255, 256, 257, 259.

Aromatic substitution general procedure M: A pressure flask was charged with compound 193, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256 (1.00 eq.). Then, a 2:1 mixture of ammonia/ 1,4-dioxane () was added, and the resulted mixture was heated to 100 °C and stirred upon full consumption. After 24 h, the reaction was allowed to cool down to rt and concentrated to complete dryness. The crude products were purified over silica gel chromatography to afford the target compounds 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276.

Deprotection general procedure N: A solution of 358, 361, 363, 365, 369, 371, and 373 (0.01 M) in DCM/TFA (1:1) was stirred at room temperature for 16 hrs. The mixture was concentrated to dryness and the residue was purified by prep-HPLC to afford the products 357, 360, 362, 364, 366, 367, 368, 370, 372, 374, and 375 as white foam.

Deprotection general procedure O: Secondary amines 316, 318, 333, 335, 337, 339, 341, 343, 378, 380, and 382were dissolved (0.02 M) in pure TEA and stirred at 50 °C for 24 h. The solvent was evaporated by rotatory evaporation at 45 °C. The crude products were purified by preparative HPLC according to method C to afford the desired products 317, 319, 334, 336, 338, 340, 342, 344, 379, and 381 as colorless foams (2 TEA).

Deprotection general procedure P: A solution of amides 345 & 347 were dissolved (0.02 M) in MeOH/HCI (1:1) and were stirred at r. t. for 1 hr, followed by concentration to afford the desired compounds 346, 348 and 350 as a white solid (TEA salt or free base).

Deprotection general procedure Q: Secondary amines and amides 194, 258, 259, 264, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281 283, 284, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 320, 322, 324, 327, 329, 331, and 376 were dissolved (0.02 M) in freshly prepared TFA/H 2 O (4:1) solution and stirred at rt mostly for 7 h. The solvent was evaporated by rotatory evaporation at 45 °C to give the desired products 287, 289, 291, 293, 295 297, 299, 301, 303, 305, 307, 311, 313, 315, 321, 323, 325, 328, 330, 332, 377, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 684, 686, and 688 as white foams (no, 1 or 2 TFA salts).

Aldehyde sidechains

Preparation of tert- butyl (4-(benzyioxy)benzyi)(3-oxopropyi)carbamate 3-((4-(benzyloxy)benzyl)amino)propan-1-ol (1):

To a mixture of 4-benzyloxybenzaldeyhde (1.00 g, 4.66 mmol) in dry MeOH (4.50 mL) was added dropwise as solution of of 3-aminopropanol (0.39 mL, 4.99 mmol) in dry MeOH (4.50 mL). The solution was stirred overnight at ambient temperature. Then, the reaction mixture was cooled down to 0 °C. Afterwards, NaBH 4 (0.29 g, 7.46 mmol) was added portion wise. After complete conversion the reaction was concentrated under reduced pressure. The obtained residue was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over sodu su ate, a d co ce t ated. The crude product was purified by flash chromatography (CH 2 Cl 2 /MeOH; 0-10%) to afford the product as colorless oil (0.95 g; 75%). tert-butyl (4-(benzyloxy)benzyl)(3-hydroxypropyl)carbamate (2): d 1 (0.94 g, 3.43 mmol) in CH 2 Cl 2 (20.80 mL), Et 3 N (0.72 mL, 5.14 mmol) was added. Then, the solution was cooled down in an ice-bath. Afterwards, di-tert- butyl dicarbonate (0.88 mL, 3.77 mmol) was added dropwise to the cooled solution. The reaction mixture was stirred magnetically at rt until complete conversion was monitored by TLC (cyclohexane/EtOAc; 50%). After 4 h, the reaction was diluted with saturated bicarbonate solution and extracted with CH 2 Cl 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained crude product was purified by flash chromatography (cyclohexane/EtOAc; 10-80%) which afforded the desired product (1.21 g, 95%). tert-butyl (4-(benzyloxy)benzyl)(3-oxopropyl)carbamate (3): loride (0.41 mL, 4.84 mmol) in dry DCM (10.70 mL), DMSO (0.46 mL, 6.45 mmol) was added dropwise at -78 °C. After stirring for 20 min at -78 °C, a solution of compound 3 in dry DCM (10.70 mL) was added slowly. The solution was stirred at -78 °C for 30 min. Then, triethylamine (2.27 mL, 16.12 mmol) was added slowly and stirred for further 10 min. Afterwards, the reaction mixture was allowed to warm up to rt. The solution was poured onto brine and stirred for 10 min. The organic layer was separated, and the aqueous layer was extracted two times with DCM. The combined organic layers were dried over sodium sulfate and concentrated under vacuum. The obtained residue was purified over silica (cyclohexane, EtOAc, 10-100%) to afford the product (1.05 g, 88%). Preparation of tert-butyl (naphthalen-2-ylmethyl)(3-oxopropyl)carbamate 3-((naphthalen-2-ylmethyl)amino)propan-1-ol (4): phtaldehyde (1.00 g, 6.34 mmol) in dry MeOH (6.30 mL) was added dropwise as solution of of 3-aminopropanol (0.49 mL, 6.34 mmol) in dry MeOH (6.30 mL). The solution was stirred overnight at ambient temperature. Then, the reaction mixture was cooled down to 0 °C. Afterwards, NaBH 4 (0.36 g, 9.51 mmol) )was added portion wise. After complete conversion the reaction was concentrated under reduced pressure. The obtained residue was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The crude product was purified by flash chromatography (CH 2 Cl 2 /MeOH; 0-10%) to afford the product 4 as colorless oil (1.02 g; 74%). tert-butyl (3-hydroxypropyl)(naphthalen-2-ylmethyl)carbamate (5): To a solution of compound 5 (1.00 g, .60 o) C 2 C 2 (27.90 mL), Et 3 N (0.97 mL, 6.90 mmol) was added. Then, the solution was cooled down in an ice-bath. Afterwards, di-tert- butyl dicarbonate (1.18 mL, 5.06 mmol) was added dropwise to the cooled solution. The reaction mixture was stirred magnetically at rt until complete conversion was monitored by TLC (cyclohexane/EtOAc; 50%). After 4 h, the reaction was diluted with saturated bicarbonate solution and extracted with CH 2 Cl 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained crude product was purified by flash chromatography (cyclohexane/EtOAc; 10-80%) which afforded the desired product 6 (1.08 g, 75%). tert-butyl (naphthalen-2-ylmethyl)(3-oxopropyl)carbamate (7): alyl chloride (0.44 mL, 5.09 mmol) in dry DCM (11.30 mL), DMSO (0.49 mL, 6.79 mmol) was added dropwise at -78 °C. After stirring for 20 min at -78 °C, a solution of compound 7 in dry DCM (11.30 mL) was added slowly. The solution was stirred at -78 °C for 30 min. Then, triethylamine (2.40 mL, 16.98 mmol) was added slowly and stirred for further 10 min. Afterwards, the reaction mixture was allowed to warm up to rt. The solution was poured onto brine and stirred for 10 min. The organic layer was separated, and the aqueous layer was extracted two times with DCM. The combined organic layers were dried over sodium sulfate and concentrated under vacuum. The obtained residue was purified over silica (cyclohexane, EtOAc, 10-100%) to afford the product (0.66 g, 62%). Preparation of tert-butyl (3-oxopropyl)(3-(phenylthio)phenethyl)carbamate 2-(3-(phenylthio)phenyl)-1,3-dioxolane (8): 3-bromophenyl)-1,3-dioxolane (3 g, 13 mmol) in tetrahydrofuran (50 mL) cooled at -78° C was treated with tert-butyllithium (26 mmol in pentane), followed by phenydisulphide (3.14 g, 25 mmol) in THF (40 mL). Once the additions were complete the reaction was stirred at -78° C for one hour and then allowed to warm to room temperature. After one hour at room temperature the reaction was quenched by the addition of water (150 ml). The mixture was concentrated in vacuo and the residue extracted into ether (25 mL x5). The combined extracts were dried (MgSO 4 ) and evaporated in vacuo. The mixture was purified by flash chromatography (eluding with 10% ethyl acetate/ petrol) to afford 8 as a color oil (2.5 g, yield: 77%). 3-(phenylthio)benzaldehyde (9): .5 g, 9.7mmol) was dissolved in a mixture solution of ethanol (15 mL), water (15 mL), tetrahydrofuran (15 mL) and sulfuric acid (2 mL), and the solution was stirred for 2.5 hours under reflux. The reaction solution was cooled to 0°C, an aqueous solution of saturated sodium bicarbonate was added thereto. The solution was extracted with ethyl acetate (25 mL x3). The organic layer was washed with brine and dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 20: 1), and the title compound 9 (2 g, 9.3 mmol, 96%) was obtained as a colorless oil. MS Calc.: 214.0; MS Found: 215.0 [M + H] + .

2-(3-(phenylthio)phenyl)acetaldehyde (10):

( aMeth s oxxyrme^thyl°)triphenylphosphonium chloride (12.8 g, 37.4 mmol, 4.0 eq) was suspended in dry THF (0.2 M) and cooled to 0°C under an argon atmosphere. A solution of potassium tert- butoxide in THF (4.2 g, 37.4 mmol, 4.0 eq) was added slowly to the suspension and allowed to stir for 45 minutes at 0 °C. The desired aryl aldehyde 9 (2 g, 9.3 mmol) was added dropwise and the solution was allowed to stir at room temperature for one hour. The reaction was quenched with saturated NH 4 CI (100 mL) and extracted with EtOAc (100 mL x3). The organic phase was dried over MgSO 4 , filtered, and concentrated to yield an oil. The oil was then dissolved in a 5:2 THF:5 N HC1 solution (0.2 M) and refluxed for one hour. The solution was cooled to room temperature, quenched with saturated NaHCO 3 and extracted with EtOAc (100 mL x3). The organic layer was dried with MgSO 4 , filtered, and concentrated to yield an oil which was purified via silica gel column chromatography eluting with 30:1 PE:EtOAc. and the title compound 10 (0.6 g, yield: 28%) was obtained as a colorless oil. MS Calc.: 228.1; MS Found: 229.1 [M + H] + .

3-((3-(phenylthio)phenethyl)amino)propan-1-ol (11):

To a solution of compound 10 (600 mg, 2.63 mmol) and in MeOH (10 mL) was added compound 3-aminopropan-1-ol (790 mg, 10.5 mmol)), and the mixture was stirred at room temperature for 0.1 h. Then NaBH 4 (390 mg, 10.5 mmol) was added and the mixture was stirred at room temperature for an additional hour. The reaction was quenched with water and concentrated to dryness. The residue was directly purified by flash (ACN:H 2 O=5-95%) to afford compound 11 as an oil (2.5 g, 77%). MS Calc.: 287.1; MS Found: 288.1 [M + H] + fe/t- butyl (3-hydroxypropyl)(3-(phenylthio)phenethyl)carbamate (12):

To a solution of compound 11 (650 mg, 2.26 mmol) in DCM (20 mL) was added TEA (686 mg, 6.8 mmol)) and Boc 2 O (739 mg, 3.4 mmol). The mixture was stirred room temperature for 2 hrs Solvent was removed and the residue was purified by flash chromatography (25% EA in PE) to give compound 12 (650 mg, yield: 74.3%) as a yellow oil. MS Calc.: 387.2; MS Found: 288.2 [M- 100+H] + . fe/t- butyl (3-oxopropyl)(3-(phenylthio)phenethyl)carbamate (13):

To a mixture of compound 12 (650 mg, 1.68 mmol) in DCM (20 mL) was added Dess-Martin Periodinane (1.39 g, 3.36mmol) at room temperature. After addition the mixture was then stirred for 6 hrs. A mixture of sat. NaHCO 3 (50 mL) and sat. Na 2 S 2 O 3 (50 mL) was added into the reaction mixture, which was stirred for 5 min and stood. The organic phase was separated, washed with brine (50 mL), dried and concentrated to provide a crude compound 13 (600 mg, yield: 92.3%), which could be used in the next step. MS Calc.: 385.2; MS Found: 386.2 [M + H] + .

Preparationof tert-butyl (3 -oxopropyl)(4-phenethylphenethyl)carbamate

(E)-2-(4-styrylphenyl)ethan-1-ol (14):

A suspension of (E)-4,4,5,5-tetramethyl-2-styryl-1,3,2-dioxaborolane (1.0 g, 4.3 mmol), 2-(4- bromophenyl)ethan-1-ol (960 mg, 4.8 mmol), K 2 CO 3 (1.2 g, 8.6 mmol), Pd(dppf)CI 2 (157 mg, 0.22 mmol) in dioxane (20 mL) and H 2 O (2 ml) was stirred at 90 °C for 16 hrs under nitrogen atmosphere. The reaction mixture was filtered and the organic phase was concentrated. The crude was purified by flash (A: H 2 O; B: MeCN) to give 14 (900 mg, yield: 92%) as a white solid. MS Calc.: 224.1; MS Found: 225.0 [M + H + ], 207.0 [M-OH],

2-(4-phenethylphenyl)ethan-1-ol (15):

To a solution of 14 (900 mg, 4 mmol) in MeOH (20 mL) was added wet 10% Pd/C (50 mg), and the suspension was stirred at room temperature for 16 hrs. The suspension was filtered and the filtrate was concentrated to give 15 (800 mg, yield: 89%) as a white solid. MS Calc.: 226.1; MS Found: 209.0 [M-OH],

2-(4-phenethylphenyl)acetaldehyde (16):

To a solution of 15 (400 mg, 1.8 mmol) in DCM (10 mL) was added Dess-Martin periodinane (1.1 g, 2.6 mmol) and the solution was stirred at room temperature for 4 hrs. The reaction solution was diluted with DCM (20 mL) and washed with H 2 O (20 mL), aq. NaSO 3 (20 ml), aq. NaHCO 3 (20 ml). The organic phase was dried over Na 2 SO 4 and concentrated to give 16 (400 mg, crude) as a brown oil.

3-((4-phenethylphenethyl)amino)propan-1-ol (17):

H

A solution of 16 (400 mg, 1.8 mmol), 3-aminopropanol (402 mg, 5.4 mmol) in MeOH (5 mL) was stirred at room temperature for 20 min. NaBH 3 CN (234 mg, 3.6 mmol) and AcOH (2 drops) was added, the solution was stirred at room temperature for 4 hrs. The resulting mixture was diluted with EA (100 mL), washed with H 2 O (100 mL x3) dried over Na 2 SO 4 . The solution was concentrated to give 17 (400 mg, crude) as a brown oil. MS Calc.: 283.2; MS Found: 284.1 [M + H + ], fe/t- butyl (3-hydroxypropyl)(4-phenethylphenethyl)carbamate (18):

To a solution of 17 (400 mg crude), TEA (545 mg, 5.4 mmol) in DCM (10 mL) was added Boc 2 O (785 mg, 3.6 mmol). The solution was stirred at room temperature for 16 hrs. The resulting mixture was concentrated and the c ude was pu ed by ash (A: H 2 O; B: MeCN) to give 18 (150 mg, three-step yield: 22%) as a clear oil. MS Calc.: 383.2; MS Found: 284.1 [M+H + -Boc]. tert-butyl (3-oxopropyl)(4-phenethylphenethyl)carbamate (19): g, 0.39 mmol) in DCM (10 mL), was added Dess-Martin periodinane (249 mg, 0.59 mmol) and the solution was stirred at room temperature for 4 hrs. The reaction mixture was diluted with DCM (20 mL) and washed with H 2 O (20 mL), aq. NaSO 3 (20 ml), aq. NaHCO 3 (20 ml). The organic phase was dried over Na 2 SO 4 and concentrated to give 19 (100 mg, crude) as a brown oil. Preparation of tert-butyl (2-(naphthalen-2-yl)ethyl)(3-oxopropyl)carbamate N-(3-hydroxypropyl)-2-(naphthalen-2-yl)acetamide (20): phthalen-2-yl)acetic acid (3 g, 16.1 mmol), 3-aminopropanol (1.8 g, 24.2 mmol), DIPEA (6.2 g, 48.3 mmol), HATU (9.18 g,24.2 mmol) in DMF (30 mL) was stirred at room temperature for 2 hrs. The resulting solution was concentrated to dryness and the residue was diluted with EtOAc (100 mL) and washed with water (50 mL x3). Then the organic phase was dried over Na 2 SO 4 and concentrated. The residue was purified by reverse phase flash (MeCN/H 2 O) to afford 20 (3.5 g, yield: 90%) as a yellow oil. MS Calc.: 243.1; MS Found: 244.1 [M+H] + . 3-((2-(naphthalen-2-yl)ethyl)amino)propan-1-ol (21): ound 20 (3.5 g, 14.4 mmol) in THF (50 mL) was added BH 3. DMS (2.9 mL, 28.8 mmol) dropwise. Then the mixture was stirred at 65 °C for 4 hrs. The mixture was quenched by adding MeOH and then concentrated. The residue was purified by reverse phase flash (MeCN/H 2 O) to afford 21 (2 g, yield: 60.4%) as a yellow oil. MS Calc.: 229.1; MS Found: 230.1 [M+H] + . tert-butyl (3-hydroxypropyl)(2-(naphthalen-2-yl)ethyl)carbamate (22): ound 22 (2 g, 8.7 mmol) in DCM (30 mL) was added TEA (2.64 g, 26.1 mmol)) and Boc 2 O (2.84 g, 13 mmol). The mixture was stirred at room temperature for 2 hrs. Solvent was removed and the residue was purified by flash chromatography (25% EA in PE) to give compound 23 (2.5 g, yield: 87.3%) as a yellow oil. MS Calc.: 329.1; MS Found: 230.1 [M- 100+H] + tert-butyl (2-(naphthalen-2-yl)ethyl)(3-oxopropyl)carbamate (24): To a mixture of compound 23 (2.5 g, 7.6 mmol) and in DCM (50 mL) was added Dess-Martin periodinane (6.3 g, 15.2 mmol) at room temperature. After addition the mixture was then stirred for 6 hrs at room temperature. A mixture of sat. NaHCO 3 (50 mL) and sat. Na 2 S 2 O 3 (50 mL) was added into the reaction mixture, which was further stirred for 5 min and stood. The organic phase was separated, washed with brine (50 mL) and dried over Na 2 SO 4 . The solution was concentrated to provide a crude compound 24 (2.5 g, quantitative yield), which could be used in the next step. MS Calc.: 327.2; MS Found: 328.1 [M + H] + .

Preparation of tert- butyl (3-oxopropyi)(4-phenoxybenzyi)carbamate 3-((4-phenoxybenzyl)amino)propan-1-ol (25)

4-Phenoxybenzaldehyde (0.51 g, 2.55 mmol, 1.03 equiv.) was dissolved in 37 ml dry MeOH under N 2 atmosphere. Then, 3-aminopropan-1-ol (0.19 ml, 0.187 g, 2.48 mmol, 1.0 equiv) was added dropwise at room temperature and the resulted mixture was stirred overnight. After 19 h stirring, the reaction mixture was cooled down to 0°C and NaBH 4 (0.144 g, 3.81 mmol, 1.53 equiv.) was added portionwise. After the reaction was stirred at RT for 5 h, the solvent was removed under reduced pressure. Water was added and was extracted with EtOAc (3x), the combined organic phases were washed with brine (lx) and dried over Na 2 SO 4 . After filtration, the solvent was removed under vacuum and the residue was purified by flash chromatography eluting CH 2 CI 2 /MeOH (0.4% to 8%) to afford the product as a yellowish oil. Yield: 0.43 g, 67 %). C 16 H 19 NO 2 (257.33 g/mol). APCI: calc. For C 16 H 19 NO 2 [M + H] + : 257.14 found: 257.9. 1 H NMR (400 MHz, DMSO-aL) 5 7.42 - 7.26 (m, 4H, oH, /77-H'), 7.14 - 7.05 (m, 1H, / H'), 7.04 - 6.89 (m, 4H, /77-H, OH'), 3.64 (s, 2H, Ar-CH 2 -N), 3.45 (t, J = 6.3 Hz, 2H, H1'), 3.39 (bs, 1H, NH), 2.56-2.44 (m, 2H, H3'), 1.57 (p, J = 12 Hz, 2H, H2'). tert-butyl (3-hydroxypropyl)(4-phenoxybenzyl)carbamate (26)

Compound 25 (0.43 g, 1.66 mmol, 1.0 equiv.) was dissolved in 10 ml dry DCM. Then triethylamine (0.35 ml, 0.26 g, 2.52 mmol, 1.52 equiv.) was added and the reaction was cooled down to 0 °C. After that, Boc 2 O (0.43 ml, 0.41 g, 1.87 mmol, 1.13 equiv.) was dropwise added to the mixture. The reaction was stirred at room temperature for 3 h (monitored by TLC; DCM/MeOH 9:1). After that, the reaction mixture was filtered over cotton and silica, washed with EtOAC and the solvents were evaporated. The residue was purified by flash chromatography eluting Cyclohexane/EtOAc (5%-50%) to afford the product as a transparent oil (yield: 0.529 g, 89 %). 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 7.41-7.34 (m, 2H, /77-H'), 7.24-7.21 (m, 2H, oH), 7.14-7.05 (m, 1H, / H'), 7.01-6.97 (m, 4H, o- H', /77-H), 4.41 (t, J = 5.1 Hz, 1H, OH), 4.34 (bs, 2H, Ar-CH 2 -N), 3.36 (td, J = 6.3 Hz, 4,9 Hz, 2H, H1'), 3.15 (bs, 2H, H3'), 1.66-1.53 (m, 2H, H2'), 1.47-1.26 (m, 9H, t-Bu, Boc) tert-butyl (3-oxopropyl)(4-phenoxybenzyl)carbamate (27)

Under N 2 atmosphere, solution of oxalyl-chloride (89 uL, 0.13 g, 1.05 mmol, 1.50 equiv.) in 1.4 ml dry DCM was cooled down to -78 °C. Then solution of DMSO (0.1 ml, 0.11 g, 1.41 mmol, 2.01 equiv.) in 0.6 ml dry DCM was added. t was st ed o 0 min at -78 °C. Then, solution of 26 (0.25 g, 0.70 mmol, 1.0 equiv.) in 1 ml dry DCM was added dropwise at -78°C. After the reaction mixture was stirred at -78 °C for 1 h, triethylamine (0.49 ml, 0.36 g, 3.53 mmol, 5.05 eqiv.) was slowly added and was stirred at -78 °C for 20 min. Then the reaction was allowed to warm up to room temperature and 5 % citric acid (aq.) solution was added. The mixture was extracted with DCM (3x), the combined organic phases were washed with saturated NaHCO 3 (aq.) solution (1x) and dried over Na 2 SO 4 . After filtration, the solvent was removed under vacuum and the residue was purified by flash chromatography eluting Cyclohexane/EtOAc (2% to 50%) to afford the product as an oil (yield: 0.106 g, 43%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.64 (t, J = 1.8 Hz, 1H, CHO), 7.43-7.37 (m, 2H, m-H´), 7.31-7.20 (m, 2H, o-H), 7.14-7.05 (m, 1H, p-H´), 7.01-6.97 (m, 4H, o- H´, m-H), 4.36 (s, 2H, Ar-CH 2 -N), 3.39 (bs, 2H, H3´), 2.62 (td, J = 6.7 Hz, 1.9 Hz, 2H, H2´), 1.50- 1.32 (m, 10H, t-Bu, Boc). Preparation of 2-(2,4-difluorophenyl)acetaldehyde 2-(2,4-difluorophenyl)ethan-1-ol (28) f LiAlH 4 (2.3 ml, 2.30 mmol, 2.0 equiv.) was charged into a previously N 2 flushed round bottom flask and it was cooled to 0 °C. Then solution of 2-(2,4-difluorophenyl)acetic acid (0.203 g, 1.18 mmol, 1.0 equiv.) in 4.4 ml dry THF was added dropwise over 4 min to the LiAlH 4 solution at 0 °C. The reaction was stirred at ambient temperature for 6.5 h. Then the reaction mixture was cooled down to 0 °C and 0.1 ml H 2 O was added carefully during stirring and it was stirred for 50 min. After that, 0.1 ml 15 w/w% NaOH (aq.) solution and 0.2 ml H 2 O was added and stirred overnight. On the next morning (after 11 h stirring), the reaction mixture was filtered through celite and washed with THF. Then the filtrate was concentrated under vacuum. The residue was purified by flash chromatography eluting cyclohexane/ethylacetate (1%-25%) to afford the product (0.095 g, 52%) as a yellow oil. R f = 0.16 (cyclohexane/EtOAc 8:2). 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.34 (q, J = 6.9 Hz, 1H,), 7.14 (m, 1H,), 6.99 (tdd, J = 8.6, 2.6, 0.9 Hz, 1H,), 4.71 (t, J = 5.3 Hz, 1H, OH), 3.55 (td, J = 6.9, 5.5 Hz, 2H, CH 2 -OH), 2.71 (t, J = 6.9 Hz, 2H, Ph-CH 2 ). 2-(2,4-difluorophenyl)acetaldehyde (29) sion of Dess-Martin periodinane (0.277 mg, 0.65 mmol, 1.2 equiv.) in anhydrous CH 2 Cl 2 (5 ml) was added dropwise a solution of 28 (0.086 mg, 0.54 mmol, 1 equiv.) in anhydrous CH 2 Cl 2 (1.7 ml) at 0 °C. The resulted reaction mixture was stirred at room temperature for 18.7 h. Then the reaction was quenched with 1.7 M Na 2 S 2 O 3 (aq.) solution (5.4 ml) and stirred for 15 min. The two layers were separated and the aqueous layer was extracted with CH 2 Cl 2 (2x), then the combined organic layers were washed with 5% NaHCO 3 (aq.) solution (1x) and with brine (1x), and dried over Na2SO4. After filtration, the solvent was removed under vacuum and the residue was purified by flash chromatography eluting Cyclohexane/EtOAc (2%-12%) to afford the product (0.020 g, 23%) as a clear liquid. Preparation of 2-(4-(trifluoromethyl)phenyl)acetaldehyde 2-(4-(trifluoromethyl)phenyl)acetaldehyde (30) eriodinane (0.54 g, 1.25 mmol, 1.2 equiv.) was suspended in 13 ml dry CH2CL2 and it was cooled down to 0 °C. Then 0.16 ml 2-(4-(trifluoromethyl)phenyl)ethan-1-ol (0.20 g, 1.04 mmol, 1 equiv.) was added dropwise to the suspension. The mixture was stirred at room temperature for 15.5 h, then 1 M Na 2 S 2 O 3 (aq.) solution was added and the phases were separated. The water phase was extracted with CH2CL2 (2x), the combined organic phases were washed with 5% NaHCO 3 (aq.) solution (2x) and with brine (1x), dried over Na 2 SO 4 , filtered and the solvent was evaporated. The residue was purified by flash chromatography eluting Cyclohexane/EtOAc (2%-15%) to afford the product as a yellow liquid (0.095 mg, 48%). Rf= 0.4 (Cyclohexane/EtOAc 8:2). 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.73 (t, J = 1.5 Hz, 1H, -CHO), 7.72 (d, J = 8.1 Hz, 2H, m-H), 7.48 (d, J = 8.1 Hz, 2H, o-H,), 3.95 (s, 2H, -CH 2 ) Preapration of tert-butyl (3-oxopropyl)(3-phenoxyphenethyl)carbamate 3-((3-phenoxyphenethyl)amino)propan-1-ol (31) d 2-(3-phenoxyphenyl)acetaldehyde (2 g, 9.4 mmol) in MeOH (20 mL) was added 3-aminopropan-1-ol (1.41 g, 18.8 mmol)), and the mixture was stirred at room temperature for 1 hr. Then NaBH3CN (2.87 g, 47 mmol) was added and the mixture was stirred overnight. Solvent was removed and the residue was purified by flash chromatography (30% EA in PE) to give compound 31 (1 g, yield: 39.2%) as a yellow oil. MS Calc.: 271.2; MS Found: 272.2 [M+H] + . tert-butyl (3-hydroxypropyl)(3-phenoxyphenethyl)carbamate (32) d 31 (1 g, 3.7 mmol) in DCM (20 mL) was added TEA (1.1g, 11.1 mmol) and (Boc) 2 O (1.2 g, 5.5 mmol). The mixture was stirred at room temperature for 2 hrs. Solvent was removed and the residue was purified by flash chromatography (25% EA in PE) to give compound 32 (1.3 g, yield: 94.7%) as a yellow oil. MS Calc.: 371.2; MS Found: 272.1 [M-100+H] + . tert-butyl (3-oxopropyl)(3-phenoxyphenethyl)carbamate (33) nd 32 (1.3 g, 3.5 mmol) in DCM (20 mL) was added Dess-Martin periodinane (2.9 g, 7 mmol), and the mixture was at room temperature stirred for 1 hr. A mixture of sat. NaHCO 3 (20 mL) and sat. Na 2 S 2 O 3 (20 mL) was added into the reaction mixture, which was stirred for 5 min and separated. The organic phase was washed with brine (10 mL), dried over Na 2 SO 4 and concentrated to provide a crude compound 33 (1 g, yield: 77%), which was used for the next step without further purification. MS Calc.: 369.2; MS Found: 370.2 [M+H] + . Preparationof tert-butyl (4-(4-chlorophenoxy)-3-fluorophenethyl)(3-oxopropyl)carbamat e 2-fluoro-4-(2-hydroxyethyl) phenol (34):

To a heat dried three-necked round bottom flask equipped with a thermometer and a dropping funnel, NaBH 4 (2.65 g, 70.00 mmol)) was added in dry THF (60.00 mL). To this mixture, Me 2 SO 4 (6.64 mL, 70.00 mmol) was slowly added at 0 °C and stirred for 1 h at 0 °C. Then, the mixture was allowed to warm up to rt and stirred for 3 h. Afterwards, a solution of 2-(3-fluoro-4- hydroxyphenyl) acetic acid (5.95 g, 35.00 mmol) and B(OMe) 3 (7.91 mL, 70.00 mmol) in dry THF (10 mL) were added slowly added at rt while cooling the flask with an ice-bath. The mixture was stirred overnight at rt. TLC (100% EtOAc) monitored the formation of a new spot. The mixture was cooled down in an ice-bath and stirred vigorously while water was carefully added. Then, the organic solvent was evaporated under reduced pressure. The aqueous phase was extracted three times with EtOAc. The combined organic layers were washed three times with saturated sodium bicarbonate solution and three times with brine. The separated organic layer was dried over sodium sulfate and concentrated under reduced pressure. 1 H NMR (400 MHz, DMSO-c/ 6 ) <59.53 (s, Ar-OH 1H), 6.98 (dd, 7 = 12.7, 1.8 Hz, 1H, Ar-H), 6.89 - 6.77 (m, 2H- Ar-H), 4.61 (t, 7 = 5.1 Hz, 1H, OH), 3.55 (td, 7 = 7.0, 5.1 Hz, 2H, CH 2 ), 2.61 (t, 7 = 7.0 Hz, 2H, CH 2 ). APCI-MS(+): m/z 157.0

In a heat- dried three-necked round bottom flask, 4-Chlorophenylboronic acid (3.05 g, 19.50 mmol) and 34 (1.0 g, 6.50 mmol) were added in dry C 2 H 2 CI 2 (40.60 mL). Afterwards, dry pyridine (1.51 mL, 19.50 mmol), anhydrous copper acetate (1.77 g, 9.75 mmol), and 4 A molecular sieves (1.12 g) were added to the mixture. The reaction mixture was stirred for 48 h at rt. The mixture was filtered over celite and the cake was rinsed several times with CH 2 CI 2 . The filtrate was concentrated under vacuum to complete dryness. The obtained residue was purified over silica (cyclohexane/EtOAc; 10-80%) to afford the pure product (0.93 g, 54%). 1 H NMR (400 MHz, DMSO-tA) <57.46 - 7.37 (m, 2H, H 2,6), 7.28 (dd, 7= 12.1, 1.9 Hz, 1H, 6'H), 7.15 (t, 7 = 8.3 Hz, 1H, 2'H), 7.10 (dd, 7 = 8.5, 1.9 Hz, 1H, 5'H), 6.99 - 6.94 (m, 2H, 2,6 H), 4.69 (t, 7 = 5.2 Hz, 1H, OH), 3.64 (td, 7 = 6.8, 5.2 Hz, 2H, CH 2 ), 2.75 (t, 7 = 6.8 Hz, 2H, CH 2 ). APCI-MS(+): m/z 265.1/268.1 [M + H] + .

The compound 35 (1.28 g, 4.80 mmol) was dissolved in dry CH 2 CI 2 (24.00 mL). Then, TsCI (0.92 g, 4.80 mmol) was added. Afterwards, dry pyridine (1.16 mL, 14.34 mmol) and DMAP (0.06 g, 0.48 mmol) were added 0 °C. The solution was stirred at rt overnight. TLC (cyclohexane/EtOAc; 20%) monitored no full conversion. In addition, dry pyridine (0.58 mL, 7.20 mmol) was added and stirred at rt till complete conversion. After 6 h, the mixture was diluted with saturated bicarbonate solution and extracted three times with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude was purified by flash chromatography (cyclohexane/EtOAc; 0-80%) to afford the product as a colorless oil (1.33 g, 75%). 1 H NMR (400 MHz, DMSO-tA) <57.73 - 7.68 (m, 2H, otosyl), 7.48 - 7.38 (m, 4H, /77-tosyl, H3/5), 7.19 (dd, 7= 12.0, 2.0 Hz, 1H, H5'), 7.10 (t, 7 = 8.4 Hz, 1H, H2'), 7.02 (dd, 7 = 8.3, 1.3 Hz, 1H, H6´), 7.02 – 6.93 (m, , /6), . 8 (t, J 6.3 Hz, 2H, CH 2 ), 2.92 (t, J = 6.3 Hz, 2H, CH 2 ), 2.41 (s, 3H, CH 3 ). APCI-MS(+): m/z 420.0/422.1 [M+H] + . 3-((tert-butyldiphenylsilyl)oxy)propan-1-amine (37): solved in dry CH 2 Cl 2 (91.00 mL) and cooled down in an ice-bath. Then, TBDPS-Cl (4.73 mL, 18.19 mmol) was added dropwise at 0 °C. Afterwards, triethylamine (3.78 mL, 27.29 mmol) was added. The solution was allowed to warm up to rt and the reaction was stirred magnetically at rt overnight. The reaction mixture was diluted with saturated bicarbonate solution and extracted with CH2Cl2. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated over vacuum. The obtained crude was purified over silica (CH 2 Cl 2 /MeOH; 0-20%) to afford the pure product as a colorless oil (3.42 g, 60%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.67 – 7.58 (m, 4H, o-Ar-H), 7.52 – 7.39 (m, 6H, m,p-Ar-H), 3.71 (t, J = 6.3 Hz, 2H, CH 2 , H3), 2.64 (t, J = 6.8 Hz, 2H, CH 2 , H1), 1.61 (p, J 3.76 mmol) in dry DMF (6.25 mL) at rt. Then, CsCO 3 (1.77 g, 5.01 mmol) was added and the suspension was heated to 80 °C and stirred at this temperature for 5 h. TLC (cyclohexane/EtOAc; 50%) monitored full consumption of 35. Then, the reaction was allowed to cool down to rt and was diluted with saturated bicarbonate solution. The aqueous phase was extracted three times with EtOAc. Afterwards, the combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by flash chromatography (cyclohexane/EtOAc; 0-60%) to afford the pure product. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.64 – 7.60 (m, 2H, Ar-H), 7.51 – 7.35 (m, 8H, Ar-H, H3/5), 7.26 (dd, J = 12.0, 1.9 Hz, 1H, H5´), 7.15 – 7.08 (m, 1H, H2´), 7.06 (dd, J = 8.4, 1.8 Hz, 1H, H6´), 7.00 – 6.91 (m, 2H, H2/6), 3.71 (t, J = 6.3 Hz, 2H, CH 2 , H5´´), 2.77 – 2.66 (m, 4H, CH 2 , H1´´/H2´´), 2.63 (t, J = 6.8 Hz, 2H, CH 2 , H3´´), 1.67 (p, J = 6.5 Hz, 2H, CH 2 , H4´´), 1.00 (s, 9H, CH 3 , t-butyl). APCI-MS(+): m/z 561.8/563.8 [M+H] + . added dropwise. Then, the solution was stirred magnetically at rt for 5 h. TLC (CH 2 Cl 2 /MeOH; 10%) indicated full conversion. After 5h, the organic solvent was evaporated under vacuum and the obtained residue was purified over silica (CH 2 Cl 2 /MeOH; 0-10%) to afford the desired product (0.23 g, 60%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.44 – 7.39 (m, 2H, H2/6), 7.29 (dd, J = 12.1, 1.9 Hz, 1H, H5´), 7.15 (t, J = 8.3 Hz, 1H, H2´), 7.09 (dd, J = 8.2, 1.8 Hz, 1H, H6´), 6.99 – 6.95 (m, 2H, H3/5), 3.45 (t, J = 6.3 Hz, 2H, CH2, H5´´), 2.82 – 2.68 (m, 4H, CH2, H1´´/2´´), 2.61 (t, J = 6.9 Hz, 2H, CH2, H3´´), 1.56 (p, J = 6.6 Hz, 2H, CH 2 , H4´´). APCI-MS(+): m/z 324.0/326.0 [M+H] + .

Triethylamine (0.14 mL, 1.02 mmol) was added to a solution of 39 (0.22 g, 0.68 mmol) in dry CH 2 CI 2 (3.40 mL). The solution was cooled down to 0 °C in an ice-bath. Afterwards, di-tert-butyl dicarbonate (0.17 mL, 0.75 mmol) was added portion wise. Then, the reaction mixture was allowed to warm up to rt and stirred for 5 h till complete conversion was monitored by TLC (cyclohexane/EtOAc; 50%). The mixture was diluted with saturated sodium bicarbonate solution and the organic phase was separated. The aqueous phase was extracted three times with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated over vacuum. The crude was purified by flash chromatography (cyclohexane/EtOAc; 10-80%) to afford a white solid (0.26 g, 89%). 1 H NMR (400 MHz, DMSO-5 6 ) 57.44 - 7.38 (m, 2H, H2/6), 7.26 (dd, 7 = 11.9, 2.0 Hz, 1H, H5'), 7.17 (t, 7 = 8.5 Hz, 1H, H2'), 7.06 (d, 7 = 8.3 Hz, 2H, H6'), 6.99 - 6.94 (m, 2H, H3/5), 4.43 (t, 7 = 5.0 Hz, 1H, OH), 3.42 - 3.35 (m, 4H, CH 2 , H2"/5"), 3.21 - 3.10 (m, 2H, CH 2 , H3"), 2.79 (t, 7 = 7.2 Hz, 2H, CH 2 , H1"), 1.60 (p, 7 = 6.5 Hz, 2H, CH 2 , H4"), 1.35 (s, 9H, CH 3 , t-butyl). APCI-MS(+): m/z 32A2/12 2 [M + H ] + without Boc- group.

To a solution of 40 (0.06 g, 0.14 mmol) in dry DMSO (0.70 mL), triethylamine (0.04 mL, 0.28 mmol) was added at rt. Then, a solution of sulfur trioxide pyridine complex (0.05 g, 0.28 mmol) in dry DMSO (0.70 mL) was added while vigorously stirring. TLC (cyclohexane/EtOAc; 50%) monitored conversion. After 1 h, the solution was quenched with water at 0 °C and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude was purified over silica (cyclohexane/EtOAc; 10-60%) to afford the product (0.06 g, 100%) as a yellowish resin. 1 H NMR (400 MHz, DMSO-5 6 ) 59.66 (s, 1H, R-CHO), 7.45 - 7.37 (m, 2H, H2/6), 7.27 (dd, J = 12.0, 1.8 Hz, 1H, H5), 7.17 (t, J = 8.5 Hz, 1H, H2), 7.07 (dd, 7 = 8.0, 1.3 Hz, 1H, H6), 3.45 - 3.36 (m, 4H, CH 2 , H2"/3"), 2.78 (t, J = 12 Hz, 2H, CH 2 , H1"), 2.63 (td, J = 6.6, 1.7 Hz, 2H, CH 2 , H4"), 1.33 (s, 9H, CH 3 , t-butyl). APCI-MS(+): m/z 322.1/324.1 [M + H] + without Boc-group. To a solution of 2-phenylacetaldehyde (0.60 g, 5.00 mmol) in dry MeOH (10 mL) was added 3- aminopropan-1-ol (0.38 g, 5.00 mmol) dropwise at rt. The reaction mixture was stirred overnight at rt. TLC monitored complete conversion. The reaction was then cooled down in an ice-bath. Then, NaBH 4 (0.28 g, 7.50 mmol) was added portion wise to the solution. After the bubbling hat stopped, the solvent was evaporated under vacuum. The obtained residue was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained crude was purified by flash chromatography (EtOAc 100%, then DCM/MeOH; 0-20%) to afford the product 42 (0.82 g, 92%). 1 H NMR (400 MHz, DMSO-5 6 ) 57.31 - 7.25 (m, 1H), 7.23 - 7.15 (m, 2H), 3.44 (t, 7 = 6.3 Hz, 1H), 2.70 (dt, 7 = 4.4, 2.4 Hz, 3H), 2.58 (t, 7 = 6.8 Hz, 1H), 1.54 (p, 7 = 6.6 Hz, 1H).

To a solution of 42 (0.59 g, 3.29 mmol) in dry DCM (16.5 mL), triethylamine (0.68 mL, 4.94 mmol). Then, the solution was cooled down in an ice-bath and stirred at this temperature for 10 min. Afterwards, di-tert-butyl dicarbonate (0.83 mL, 3.62 mmol) was added portionwise to the cooled solution. The reaction mixture was allowed to warm up to rt and stirred magnetically at this temperature until TLC (cyclohexane/EtOAc; 50% and DCM/MeOH: 20%) monitored complete conversion. After the reaction was completed, the mixture was filtrated over silica and washed with EtOAc. The filtrate was then concentrated under reduced pressure. Step 2: To a solution of oxalyl chloride (0.42 mL, 4.94 mmol) in dry DCM (14.0 mL), DMSO (0.70 mL, 9.87 mmol) was added dropwise at -78 °C. After stirring for 20 min at -78 °C, a solution of the boc-protected amine in dry DCM (2.5 mL) was added slowly. The solution was stirred at -78 °C for 30 min. Then, triethylamine (2.05 mL, 14.81 mmol) was added slowly and stirred for further 10 min. Afterwards, the reaction mixture was allowed to warm up to rt. The solution was poured onto brine and stirred for 10 min. The organic layer was separated, and the aqueous layer was extracted two times with DCM. The combined organic layers were dried over sodium sulfate and concentrated under vacuum. The obtained residue was purified over silica (cyclohexane, EtOAc, 0-35%) to afford the product 43 (0.58 g, 64%). 1 H NMR (400 MHz, DMSO-5 6 ) 5 9.65 (t, 7 = 1.8 Hz, 1H, CHO), 7.34 - 7.24 (m, 2H, o'), 7.24 - 7.14 (m, 3H, m', p'), 3.44 - 3.37 (m, 2H, CH 2 , H2'), 3.37 - 3.31 (m, 2H, CH 2 , H3'), 2.79 - 2.71 (m, 2H, CH 2 , H4'), 2.61 (td, 7 = 6.7, 1.9 Hz, 2H, CH 2 , H1'), 1.45 - 1.25 (m,

A heat-dried three-necked round bottom flask was charged with Pd 2 (dba) 3 (0.20 g, 0.22 mmol) and cyclohexyl-JohnPhos (0.09 g, 0.26 mmol) under inert atmosphere. Then, dry degassed THE (55.10 mL) was added. To this stirred suspension were added 2-(3-bromophenyl)ethan-1-ol (1.50 g, 11.02 mmol), methylaniline (1.82 g, 13.22 mmol), and a 1M solution of LiN(TMS) 2 (4.10 g, 24.24 mmol) in THE. The resulted mixture was degassed and heated to 65 °C. After 18 h, the mixture was cooled down to rt before diluted with saturated bicarbonate solution. The aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified over silica (cyclohexane/EtOAc; 0-30%) to afford the desired compound as an orange resin (0.95 g, 38%). 1 H NMR (400 MHz, DMSO-5 6 ) 57.27 - 7.21 (m, 2H, H3, H4), 7.16 (t, 7= 7.8 Hz, 1H, H5'), 6.98 - 6.93 (m, 2H, H2, H6), 6.92 - 6.87 (m, 1H, H4), 6.87 - 6.85 (m, 1H, H2'), 6.84 - 6.78 (m, 2H, H4', H6'), 4.60 (t, 7 = 5.3 Hz, 1H, OH), 3.56 (td, 7 = 7.1, 5.3 Hz, 2H, CH 2 , H1" ), 3.23 (s, 3H, CH 3 , N-Me), 2.64 (t, 7 = 7.1 Hz, 2H, , CH 2 , H2").

The alcohol 44 (0.95 g, 4.14 mmol) and TsCI (0.80 g, 4.14 mmol) were dissolved in CH 2 CI 2 (20.70 mL). Then, pyridine (1.52 mL, 18.62 mmol) and DMAP (0.05 g, 0.41 mmol) were added at 0 °C. The resulted mixture was stirred overnight at rt. Then, the reaction mixture was diluted with sat. bicarbonate solution and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated over vacuum. The obtained crude was purified by flash chromatography (cyclohexane/EtOAc; 0-60%) to afford the product as colorless oil (0.80 g, 51%). 1 H NMR (400 MHz, DMSO-<7 6 ) 57.71 - 7.64 (m, 2H, /77-tosyl), 7.47 - 7.38 (m, 2H, otosyl), 7.32 - 7.22 (m, 2H, H3, H5), 7.16 (t, 7 = 7.8 Hz, 1H, H5'), 7.01 - 6.90 (m, 3H, H2, H4, H6), 6.84 (ddd, 7 = 8.1, 2.3, 0.8 Hz, 1H, H4), 6.82 - 6.76 (m, 1H, H2'), 6.76 - 6.71 (m, 1H, H6'), 4.20 (t, 7 = 6.4 Hz, 2H, CH 2 , H1"), 3.22 (s, 3H, CH 3 , N-Me), 2.82 (t, 7 = 6.4 2.40 (s, 3H, CH 3 , tosyl-Me). ethylsilyl)oxy)propan- 1-amine (46):

To a solution of 3-aminopropanol (2.00 g, 26.63 mmol) in CH 2 CI 2 (100.00 mL), Et 3 N (4.10 mL, 29.29 mmol) was added. Followed by the addition of a solution of TBSCI (4.05 g, 26.63 mmol) in CH 2 CI 2 (33.10 mL). over 5 min. The reaction mixture was stirred magnetically overnight at ambient temperature. Then, the reaction was diluted with saturated bicarbonate solution and the organic layer was separated. The aqueous phase was extracted with CH 2 CI 2 . The combine organic layers were washed with brine, and dried over sodium sulfate. The crude product was purified over silica to afford the product as colorless liquid (4.35 g, 84%). 1 H NMR (400 MHz, DMSO-5 6 ) 53.60 (t, 7 = 6.3 Hz, 2H, CH 2 , H3), 2.56 (t, 7 = 6.8 Hz, 2H, CH 2 , H1), 1.50 (p, 7 = 6.5 Hz, 2H, CH 2 , H2), 0.83 (s

A solution of compound 45 (0.57 g, 1.49 mmol) in dry DMF (3.70 mL) was added a solution of amine 46 (0.43 g, 2.23 mmol) in dry DMF (3.70 mL). Then, CsCO 3 (1.06 g, 2.98 mmol) was added and the suspension was heated to 80 °C and stirred at this temperature for 6 h. The reaction was allowed to cool down to rt. Then, the organic solvent was removed, and the obtained residue was diluted with saturated bicarbonate solution. The aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The crude product was purified over silica (cyclohexane/EtOAc; 0-70-100%) to afford the product (0.25 g, 43%). 1 H NMR (400 MHz, DMSO-5 6 ) 57.28 - 7.21 (m, 2H, H3, H5), 7.17 (t, 7 = 7.7 Hz, 1H, H5'), 6.99 - 6.94 (m, 2H, H2, H6), 6.90 (tt, 7 = 7.5, 1.1 Hz, 1H, H4), 6.86 - 6.83 (m, 1H, H2'), 6.82 (ddd, 7 = 8.1, 2.4, 1.0 Hz, 1H, H4'), 6.80 - 6.77 (m, 1H, H6'), 3.60 (t, 7 = 6.3 Hz, 2H, CH 2 , H1"), 3.23 (s, 3H, CH 3 , N-Me), 2.70 - 2.64 (m, 2H, CH 2 , H4"), 2.64 - 2.57 (m, 2H, CH 2 , H5"), 2.57 - 2.51 (m, 2H, CH 2 , H3"), 1.55 (p, 7 = 6.6 Hz, 2H, CH 2 , H2"), 0.84 (s, 9H, CH 3 , f-butyl), 0.00 (s,

Compound 47 (0.23 g, 0.57 mmol) was dissolved in THF (2.80 mL). Then, TBAF (0.31 mL,

1.13 mmol) was added dropwise. The reaction mixture was stirred overnight at ambient temperature. TLC (CH 2 CI 2 /MeOH; 10%) indicated complete conversion. Then, the reaction mixture was concentrated under reduced pressure. The obtained residue was purified over silica (CH 2 CI 2 /MeOH; 0-20%) to give the desired product 48 (0.14 g, 87%). 1 H NMR (400 MHz, DMSO- d 6 ) 51.30 - 7.23 (m, 2H, H3, H5), 7.19 (t, 7 = 7.8 Hz, 1H, H5'), 7.01 - 6.96 (m, 2H, H2, H6), 6.92 (tt, 7 = 7.5, 1.1 Hz, 1H, H4), 6.88 - 6.85 (m, 1H, H2'), 6.87 - 6.82 (m, 1H, H4'), 6.82 - 6.79 (m, 1H, H6'), 3.44 (t, 7 = 6.3 Hz, 2H, CH 2 , H1"), 3.25 (s, 3H, CH 3 , N-Me), 2.75 - 2.68 (m, 2H, CH 2 , 4"), 2.67 - 2.62 (m, 2H, CH 2 , H5"), 2.59 (t, 7 = 6.9 Hz, 2H, CH 2 , H3"), 1.54 (p, 7 = 6.6 Hz, 2H, CH 2 , H2").

To a solution of compound 48 (0.13 g, 0.47 mmol) in CH 2 CI 2 (2.30 mL), Et 3 N (0.10 mL,

0.70 mmol) was added. Then, the solution was cooled down in an ice-bath. Afterwards, di-tert- butyl dicarbonate (0.12 mL, 0.51 mmol) was added dropwise to the cooled solution. The reaction mixture was stirred magnetically at rt until complete conversion was monitored by TLC (cyclohexane/EtOAc; 50%). After 5 h, the reaction was diluted with saturated bicarbonate solution and extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained crude product was purified by flash chromatography (cyclohexane/EtOAc; 10-80%) which afforded the desired product (0.15 g, 85%). 1 H NMR (400 MHz, DMSO-t/ 6 ) 57.27(m, 2H, H3, H5), 7.20 (dd, 7 = 8.4, 7.5 Hz, 1H, H5'), 7.02 - 6.95 (m, 2H, H2, H6), 6.93 (t, 7= 7.2 Hz, 1H, H4), 6.88 - 6.81 (m, 2H. H2', H4'), 6.81 - 6.75 (m, 1H, H6'), 4.41 (t, 7 = 4.8 Hz, 1H, OH), 3.37 (q, 7 = 6.4 Hz, 2H, CH 2 , 1"), 3.34 - 3.28 (m, 2H, CH 2 , H4"), 3.25 (s, 3H, CH 3 , N-Me), 3.18 - 3.08 (m, 2H, CH 2 , H3"), 2.73 - 2.65 (m, 2H, CH 2 , H5"), 1.58 (p, 7 = 6.4 Hz, 2H, CH 2 , H2"), 1.42 - 1.26 (m, 9H, CH 3 , f-butyl).

To a solution of alcohol 49 (0.09 g, 0.23 mmol) in dry DMSO (1.20 mL) was added Et 3 N

(0.07 mL, 0.47 mmol) at rt. The solution was vigorously stirred while a solution of SO 3 pyridine complex (0.08 g, 0.47 mmol) in dry DMSO (1.10 mL) was dropwise added. TLC (cyclohexane/EtOAc; 33%) indicated the formation of a new spot. After 1 h, the solution was quenched with water at 0 °C and extracted with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate and concentrated over vacuum. The crude product was purified over silica (cyclohexane/EtOAc; 10-60%) to afford the product as yellowish oil (0.05 g, 60%). 1 H NMR (400 MHz, DMSO-af) <59.64 (s, 1H, -CHO, H1"), 7.30 - 7.24 (m, 2H, H3, H5), 7.21 (dd, 7 = 8.3, 7.6 Hz, 1H, H5'), 6.99 (d, 7 = 7.7 Hz, 2H, H2, H6), 6.93 (t, 7 = 7.3 Hz, 1H, H4), 6.89 - 6.81 (m, 2H, H2', H4'), 6.82 - 6.75 (m, 1H, H6'), 3.43 - 3.35 (m, 2H, CH 2 , H3"), 3.34 - 3.28 (m, 2H, CH 2 , H4"), 3.25 (s, 3H, CH 3 , N-Me), 2.72 - 2.65 (m, 2H, CH 2 , H5"), 2.59 (td, 7 = 6.7, 1.8 Hz, 2H, CH 2 , H2"), 1.41 - 1.27 (m, 9H, CH 3 , Abutyl).

3-Amino-propanol (1.24 mL, 1.22 mmol) was dissolved in CH 2 CI 2 (33.50 mL) and then cooled down in an ice-bath. To this cooled solution a solution of FmocCI (3.50 g, 13.39 mmol) in CH 2 CI 2 (33.50 mL) was added dropwise. The reaction mixture was allowed to warm up to rt and stirred at this temperature overnight. Then, the mixture was diluted with sat. bicarbonate solution. The organic phase was separated, and the aqueous phase was extracted three times with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified over silica (cyclohexane/EtOAc; 0- 100%) to afford the product as white solid (2.74 g, 69%). 1 H NMR (400 MHz, DMSO-c/ 6 ) <57.90 (dd, 7 = 0.8 Hz, 1H, H5, Fmoc), 7.88 (dd, 7 = 1.2, 0.7 Hz, 1H, H4, Fmoc), 7.86 (dd, 7 = 0.8 Hz, 1H, H1, Fmoc), 7.84 (dd, 7 = 0.8 Hz, 1H, H8, Fmoc), 7.42 (td, 7 = 7.4, 1.2 Hz, 2H, H2/7, Fmoc), 7.35 (td, 7 = 7.4, 1.2 Hz, 2H, H3/6, Fmoc), 6.62 (t, 7 = 4.8 Hz, 1H, NH), 6.29 (s, 2H, CH 2 , Fmoc), 3.40 (t, 7 = 6.3 Hz, 2H, CH 2 , H1), 2.98 (q, 7 = 6.5 Hz, 2H, CH 2 , H3), 1.53 (p, 7 = 6.5 Hz, 2H, CH 2 , H2).

The alcohol 51 (0.93 g, 3.08 mmol) was dissolved in CH 2 CI 2 (15.40 mL) and cooled down to 0 °C in an ice-bath. Then, DMP (1.45 g, 3.39 mmol) was added, and the resulted mixture was stirred for 10 min at 0 °C. The reaction mixture was allowed to warm up to rt and stirred magnetically for 4 h. TLC () indicated that the reaction was terminated. Then, the reaction was quenched with saturated bicarbonate solution and stirred for 10 min at ambient temperature. The organic layer was separated, and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified by flash chromatography () to afford the pure product was white solid (0.78 g, 86%). 1 H NMR (400 MHz, DMSO-t/ 6 ) <59.62 (t, 7 = 1.6 Hz, 1H, H3, -CHO), 7.91 - 7.87 (m, 2H, H4/5, Fmoc), 7.67 (d, 7 = 7.3 Hz, 2H, H1/8, Fmoc), 7.44 - 7.39 (m, 2H, H2/7, Fmoc), 7.37 (t, 7 = 5.7 Hz, 1H, NH), 7.33 (td, 7 = 7.4, 1.1 Hz, 2H, H3/6, Fmoc), 4.29 (s, 2H, CH 2 , Fmoc), 3.27 (q, 7 = 6.4 Hz, 2H, CH 2 , H1), 2.56 (td, 7 = 6.5, 1.5 Hz, 2H, CH 2 , H2).

Preparation of tert-butyl (4-ethynyiphenethyi)(3-oxopropyi)carbamate N-(4-bromophenethyl)-3-((tert-butyldimethylsilyl)oxy)propan- 1-amine {53y.

4-Bromophenyl-acetaldehyde (0.72 g, 3.58 mmol) was dissolved in dry MeOH (8.95 mL). Then, a solution of compound x (0.69 g, 3.58 mmol) in dry MeOH (8.95 mL) was added portion wise ade rt. The resulted mixture was stirred for 72 h at ambient temperature. The solution was cooled down to 0 °C before NaBH 4 (0.21 g, 5.37 mmol) was added portion wise. The solution was stirred for 6 h at rt. Then, water was added. The aqueous phase was extracted with EtOAc. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The obtained residue was purified over silica (cyclohexane/EtOAc; 20-100%) to afford the desired product as yellowish resin (0.36 g, 27%). 1 H NMR (400 MHz, DMSO-<5 6 ) <57.49 - 7.42 (m, 2H, /77-Ar), 7.21 - 7.14 (m, 2H, oAr), 3.65 - 3.57 (m, 4H, CH 2 , H3', H4'), 2.72 - 2.61 (m, 2H, CH 2 , H5'), 2.57 - 2.52 (m, 2H, CH 2 , H1'), 1.62 - 1.51 (m, 2H, CH 2 , H2'), 0.85 - 0.83 (m, 9H, CH 3 , t- butyl, OTBS), 0.01 - -0.01 (m, 6H, CH 3 , Me, OTBS).

To a solution of 53 (0.36 g, 0.97 mmol) in CH 2 CI 2 (4.80 mL), Et 3 N (0.20 mL, 1.45 mmol) was added. Then, the solution was cooled down in an ice-bath before di-tert-butyl decarbonate (0.25 mL, 1.07 mmol) was added portion wise. The reaction mixture was allowed to warm up to rt and stirred magnetically at this temperature until TLC (cyclohexane/EtOAc; 50%) monitored complete conversion. After 3 h, the reaction was diluted with sat. bicarbonate solution and extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated over vacuum. The obtained residue was purified over silica (cyclohexane/EtOAc; 10-80%) to afford the product as yellowish resin (0.36 g, 79%). 1 H NMR (400 MHz, DMSO-<5 6 ) <57.56 - 7.41 (m, 2H, /77-Ar), 7.19 - 7.08 (m, 2H, oAr), 3.58 - 3.47 (m, 2H, CH 2 , HT), 3.32 - 3.27 (m, 2H, CH 2 , H4'), 3.20 - 3.05 (m, 2H, CH 2 , H3'), 2.77 - 2.66 (m, 2H, CH 2 , H5'), 1.65 - 1.54 (m, 2H, CH 2 , H2'), 1.39 - 1.28 (m, 9H, CH 3 , Abutyl, NBoc), 0.85 - 0.81 (m, 9H, CH 3 , t- butyl, OTBS), 0.01 - -0.03 (m, 6H, CH 3 , Me, OTBS).

A heat-dried two-necked round bottom flash was equipped with a stirring bar and charged with Na 2 PdCI 4 (7.00 mg, 0.02 mmol), Cui (13.00 mg, 0.07 mmol), and PlntB (7.00 mg, 0.02 mmol) under nitrogen atmosphere. Afterwards, a solution of compound 54 in TEMEDA (3.50 mL) was added under nitrogen atmosphere. Then, the mixture was degassed before TMS-acetylene (0.22 mL, 1.47 mmol) was added. The reaction mixture was degassed and then heated to 80 °C. The mixture was stirred overnight at 80 °C. After 17 h, the reaction mixture was cooled down to ambient temperature. Then, water was added, and the mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium suflate, and concentrated under vacuum. The obtained residue was purified over silica (cyclohexane/EtOAc; 0-100%) to afford the product as colorless oil (0.25 g, 75%). 1 H NMR (400 MHz, DMSO-c/ 6 ) <57.25 - 7.11 (m, 2H, /77-Ar), 7.02 - 6.92 (m, 2H, oAr), 3.31 (t, 7 = 6.1 Hz, 2H, CH 2 , H1'), 3.13 - 3.06 (m, 2H, CH 2 , H4'), 2.89 - 2.81 (m, 2H, CH 2 , H3'), 2.58 - 2.51 (m, 2H, CH 2 , H5'), 1.42 - 1.32 (m, 2H, CH 2 , H2'), 1.22 - 1.09 (m, 9H, CH 3 , Abutyl, NBoc), 0.64 - 0.60 (m, 9H, CH 3 , Abutyl, OTBS), 0.01 - -0.01 (m, 9H, CH 3 , CH 3 , TMS), -0.21 - -0.23 (m, 6H, CH 3 , Me, OTBS).

Compound 55 (0.25 g, 0.51 mmol) was dissolved in THE (5.10 mL). Then, a 1 M TBAF (0.21 mL, 0.76 mmol) solution in THE (0.55 mL) was added portion wise. The reaction mixture was stirred at ambient temperature for 4 h. TLC (CH 2 CI 2 /MeOH, 5%) indicated full conversion. The reaction mixture was diluted with CH 2 CI 2 and water. The organic layer was separated, and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate and concentrated over vacuum. The obtained residue was purified over silica (CH 2 CI 2 /MeOH, 0- 5%) to afford the desired product as colorless oil (0.14 g, 93%). 1 H NMR (400 MHz, DMSO-c/ 6 ) <5 7.48 - 7.36 (m, 2H, /77-Ar), 7.24 - 7.17 (m, 2H, oAr), 4.44 - 4.35 (m, 2H, OH, alkyne), 3.39 - 3.30 (m, 2H, CH 2 , H1'), 3.22 - 3.07 (m, 2H, CH 2 , H3', H4'), 2.76 (t, 7 = 7.4 Hz, 2H, CH 2 , H5'), 1.58 (p, 7 = 6.4 Hz, 2H, CH 2 , H2'), 1.40 - 1.28 (m, 9H, CH 3 , Abutyl, NBoc).

The alcohol 56 (0.06 g, 0.20 mmol) was dissolved in dry DMSO (2.00 mL). To this solution was added Et 3 N (0.06 mL, 0.40 mmol). Then, a solution of sulfur trioxide pyridine complex in dry DMSO (2.00 mL) were added slowly to the vigorously stirred solution. After 2 h, the solution was quenched with water at 0 °C and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by FC (cyclohexane/EtOAc; 10-60%) to afford the product as yellowish oil (0.04 g, 69%). 1 H NMR (400 MHz, DMSO-t/ 6 ) <59.66 - 9.63 (m, 1H, CHO), 7.50 - 7.37 (m, 2H, /77-Ar), 7.27 - 7.18 (m, 2H, oAr), 4.39 (s, 1H, CH, alkyne), 3.44 - 3.32 (m, 2H, CH 2 , H2', H3'), 2.77 (t, 7 = 7.3 Hz, 2H, CH 2 , H4'), 2.65 - 2.58 (m, 2H, CH 2 , H1'), 1.40 - 1.27 (m, 9H, CH 3 , Abutyl, NBoc).

Synthesis of tert-butyl (2-fluorophenethyl)(3-oxopropyl)carbamate 2-(2-fluorophenyl)acetaldehyde (58):

1.34 mL (10 mmol; 1.0 eq) of 2-fluorophenethyl alcohol were dissolved in 50 mL of DCM. At 0 °C, 5090 mg (12 mmol; 1.2 eq) of dess-martin-periodinane were added in portions. The reaction solution was continuously stirred for 2.5 h while warming to RT. Then, 40 mL of a 1 m Na 2 S 2 O 3 solution were added to the reaction mixture and stirred for an additional 15 min. After addition of another 100 mL of DCM, the organic phase was washed with 80 mL each of a 5% NaHCO 3 solution and a saturated NaCI solution. The organic phase was dried over MgSO 4 , filtered, and the solvent was removed under reduced pressure. Column chromatography on silica gel (cyclohexane/EtOAc 100:0% to 90:10%) gave 663 mg (4.80 mmol; 48%) of the title compound in the form of a colorless oil. 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 9.72-9.69 (m, 1H), 7.38-7.33 (m, 1H), 7.32-7.29 (m, 1H), 7.23-7.19 (m, 1H), 7.19-7.16 (m, 1H), 3.88-3.84 (m, 2H) ppm. 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 7.32-7.28 (m, 1H), 7.26- 7.21 (m, 2H), 7.14-7.09 (m, 2H), 3.43 (t, 3 7 = 6.3 Hz, 2H), 2.76-2.67 (m, 4H), 2.58 (t, 3 7 = 6.8 Hz, 2H), 1.57-1.50 (m, 2H) ppm.

3-((2-fluorophenethyl)amino)propan-1-ol (59):

663 mg (4.80 mmol; 1.0 eq) of 2-(2-fluorophenyl)acetaldehyde were dissolved in 20 mL of methanol and 0.37 mL (4.80 mmol; 1.0 eq) of 3-amino-1-propanol were added. The reaction solution was stirred at RT for 16 h under N 2 atmosphere. Finally, at 0 °C, 12. mg (7.20 mmol;

1.5 eq) NaBH 4 were added. After another 2 h of stirring, during which the solution warmed to RT, it was quenched with 50 mL of a saturated NaCI solution. Extraction was performed with EtOAc (3x 60 mL). The combined organic phases were dried over MgSO 4 , filtered, and the solvent was removed under reduced pressure. After purification by column chromatography on silica gel (DCM/MeOH 100:0% to 80:20%), 300 mg (1.52 mmol; 32%) of the title compound was obtained in the form of a colorless oil. fe/t- butyl (2-fluorophenethyl)(3-hydroxypropyl)carbamate (60):

300 mg (1.52 mmol; 1.0 eq) 3-((2-fluorophenethyl)amino)propan-1-ol were dissolved in 30 mL DCM and 0.32 mL Et 3 N (2.28 mmol; 1.5 eq) and 365 mg (1.67 mmol; 1.1 eq) Boc 2 O were added at 0 °C. The solution was warmed to RT and stirred for 16 h. The solvent was then removed and the resulting residue adsorbed on silica gel. Column chromatography (cyclohexane/EtOAc 100:0% to 50:50%) gave 411 mg (1.38 mmol; 91%) of the title compound in the form of a colorless oil. 1 H- NMR: (400 MHz, DMSO-d 6 ) 5 = 7.30-7.21 (m, 2H), 7.18-7.09 (m, 2H), 4.41 (t, 3 7 = 5.1 Hz, 1H), 3.41- 3.34 (m, 4H), 3.22-3.03 (m, 2H), 2.79 (t, 3 7 = 7.1 Hz), 1.63-1.54 (m, 2H), 1.35 and 1.28 (s, 9H) ppm. fe/t- butyl (2-fluorophenethyl)(3-oxopropyl)carbamate (61):

411 mg (1.38 mmol; 1.0 eq) te/f-butyl (2-fluorophenethyl)(3-hydroxypropyl)carbamate were dissolved in 5 mL DMSO, to which were added 0.38 mL (2.76 mmol; 2.0 eq) Et 3 N. Then, 439 mg (2.76 mmol; 2.0 eq) of pyridine sulfur trioxide were added to the reaction solution in portions. Stirring was continued for 2 h at RT before the reaction was stopped with addition of 20 mL dist. H 2 O. After extraction with DCM (3x 60 mL), the combined organic phases were dried over MgSO 4 and filtered. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (cyclohexane/EtOAc 100:0% to 70:30%). 282 mg (0.95 mmol; 69%) of the title compound was obtained as a colorless oil. 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 9.64 (t, 3 7 = 1.8 Hz), 7.31-7.21 (m, 2H), 7.18-7.09 (m, 2H), 3.49-3.30 (m, 4H), 2.79 (t, 3 7 = 7.0 Hz, 2H), 2.61 (td, 3 7 = 6.6, 1.5 Hz), 1.35 and 1.25 (s, 9H) ppm.

Synthesis of tert-butyl (4-fluorophenethyl)(3-oxopropyl)carbamate 2-(4-fluorophenyl)acetaldehyde (62):

1.35 mL (10.78 mmol; 1.0 eq) of 4-fluorophenethyl alcohol were dissolved in 50 mL of DCM. At 0 °C, 5480 mg (12.92 mmol; 1.2 eq) of dess-martin-periodinane were added in portions. The reaction solution was continuously stirred for 2 h while warming to RT. Then, 40 mL of a 1 M Na 2 S 2 O 3 solution were added to the reaction mixture and stirred for an additional 15 min. After addition of another 100 mL of DCM, the organic phase was washed with 80 mL each of a 5% NaHCO 3 solution and a saturated NaCI solution. The organic phase was dried over MgSO 4 , filtered, and the solvent was removed under reduced pressure. Column chromatography on silica gel (cyclohexane/EtOAc 100:0% to 90:10%) gave 1140 mg (8.24 mmol; 76%) of the title compound in the form of a colorless oil.

3-((4-fluorophenethyl)amino)propan-1-ol (63):

1140 mg (8.24 mmol; 1.0 eq) of 2-(4-fluorophenyl)acetaldehyde were dissolved in 50 mL of methanol and 0.63 mL of 3-amino-1-propanol (8.24 mmol; 1.0 eq) were added. The reaction solution was stirred at RT for 14 h under N 2 atmosphere. Finally, at 0 °C, 467 mg (12.36 mmol;

1.5 eq) NaBH 4 were added. After another 3.5 h of stirring, during which the solution warmed to RT, it was quenched with 80 mL of a saturated NaCI solution. Extraction was performed with EtOAc (3x 90 mL). The combined organic phases were dried over MgSO 4 , filtered, and the solvent was removed under reduced pressure. After purification by column chromatography on silica gel (DCM/MeOH 100:0% to 80:20%), 490 mg (2.48 mmol; 30%) of the title compound was obtained in the form of a pale yellow oil. fe/t- butyl (4-fluorophenethyl)(3-hydroxypropyl)carbamate (64): 490 mg (2.48 mmol; 1.0 eq) 3-((4-fluorophenethyl)amino)propan-1-ol were dissolved in 30 mL DCM and 0.50 mL Et 3 N (3.60 mmol; 1.5 eq) and 595 mg (2.73 mmol; 1.1 eq) Boc 2 O were added at 0 °C. The solution was warmed to RT and stirred for 14 h. The solvent was then removed and the resulting residue adsorbed on silica gel. Column chromatography (cyclohexane/EtOAc 100:0% to 50:50%) gave 640 mg (2.15 mmol; 87%) of the title compound in the form of a colorless oil. fe/t- butyl (4-fluorophenethyl)(3-oxopropyl)carbamate (65):

640 mg (2.15 mmol; 1.0 eq) terf-butyl (4-fluorophenethyl)(3-hydroxypropyl)carbamate were dissolved in 7 mL DMSO, to which were added 0.60 mL (4.30 mmol; 2.0 eq) Et 3 N. Then, 684 mg (4.30 mmol; 2.0 eq) of pyridine sulfur trioxide were added to the reaction solution in portions. Stirring was continued for 2 h at RT before the reaction was stopped with addition of 20 mL dist. H 2 O. After extraction with DCM (3x 60 mL), the combined organic phases were dried over MgSO 4 and filtered. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (cyclohexane/EtOAc 100:0% to 40:60%). 437 mg (1.48 mmol; 62%) of the title compound was obtained as a colorless oil.

Synthesis of tert-butyl (4-fluorobenzyl)(3-oxopropyl)carbamate 3-((4-fluorobenzyl)amino)propan-1-ol (66):

2482 mg (20.00 mmol; 1.0 eq) of 4-fluorobenzaldehyde were dissolved in 30 mL of methanol and 1.53 mL (20.00 mmol; 1.0 eq) of 3-amino-1-propanol were added. The reaction solution was stirred at RT for 20 h under N 2 atmosphere. Finally, at 0 °C, 1135 mg (30.00 mmol; 1.5 eq) NaBH 4 were added. After another 2 h of stirring, during which the solution warmed to RT, it was quenched with 50 mL of a saturated NaCI solution. Extraction was performed with EtOAc (3x 60 mL). The combined organic phases were dried over MgSO 4 , filtered, and the solvent was removed under reduced pressure. After purification by column chromatography on silica gel (DCM/MeOH 100:0% to 80:20%), 2163 mg (11.80 mmol; 59%) of the title compound was obtained in the form of a colorless oil. fe/t- butyl (4-fluorobenzyl)(3-hydroxypropyl)carbamate (67):

2163 mg (11.80 mmol; 1.0 eq) 3-((4-fluorobenzyl)amino)propan-1-ol were dissolved in 100 mL DCM and 2.47 mL Et 3 N (17.70 mmol; 1.5 eq) and 2832 mg (12.98 mmol; 1.1 eq) Boc 2 O were added at 0 °C. The solution was warmed to RT and stirred for 13.5 h. The solvent was then removed and the resulting residue adsorbed on silica gel. Column chromatography (cyclohexane/EtOAc 100:0% to 50:50%) gave 3087 mg (10.89 mmol; 92%) of the title compound in the form of a colorless oil. fe/t- butyl (4-fluorobenzyl)(3-oxopropyl)carbamate (68): 850 mg (3.00 mmol; 1.0 eq) 3-((4 uo obe y)a o)p opan-1-ol were dissolved in 5 mL DMSO, to which was added 0.83 mL (6.00 mmol; 2.0 eq) Et 3 N. Then, 955 mg (6.00 mmol; 2.0 eq) of pyridine sulfur trioxide were added to the reaction solution in portions. Stirring was continued for 3.4 h at RT before the reaction was stopped with addition of 20 mL dist. H 2 O. After extraction with DCM (5x 60 mL), the combined organic phases were dried over MgSO4 and filtered. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (cyclohexane/EtOAc 100:0% to 40:60%). 614 mg (2.18 mmol; 73%) of the title compound was obtained as a colorless oil. Synthesis of 2-(3-fluorophenyl)acetaldehyde 2-(3-fluorophenyl)acetaldehyde (69): solution of 3-fluorophenetyl alcohol (1.00 g, 7.06 mmol) in DCM (35.30 mL) DMP (3.33 g, 7.77 mmol) was added. After 10 min, the mixture was allowed to warm up to rt and stirred for 3 h. The mixture was quenched with saturated bicarbonate solution and stirred for 10 min. The organic layer was separate. The aqueous phase was extracted with DCM. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The crude product was purified over silica (cyclohexane/EtOAc; 0-10%) to afford the pure product as colorless oil (0.36 g, 37%). Synthesis of tert-butyl (3-oxopropyl)(4-(trifluoromethyl)phenethyl)carbamate 3-((4-(trifluoromethyl)phenethyl)amino)propan-1-ol (70): eq) of 2-(4-(trifluoromethyl)phenyl)acetaldehyde were dissolved in 20 mL of Dichloromethane and 2515 mg (5.93 mmol; 1.20 eq) of Dess-Martin-periodinane were added in portions at 0 °C. The reaction solution was continuously stirred for 6 h while warming to RT. Afterwards the solvent was removed under reduced pressure and the crude was adsorbed on silica. Column chromatography (Cyclohexane/EtOAc 100:0% to 80:20%) yielded to 440 mg (2.34 mmol; 24%) of the corresponding aldehyde, which was used for further reaction without characterization. Therefore, the aldehyde was dissolved in 20 mL of MeOH and 176 mg (2.34 mmol; 1.00 eq referred to the Aldehyde) of Aminopropanol were added. The reaction mixture was stirred over night at RT and then 133 mg (3.51 mmol; 1.50 eq) of NaBH 4 were added at 0 °C. The reaction was warmed to RT. After 3 h the solvent was removed under reduced pressure. Column chromatography resulted in 260 mg (1.05 mmol; 30%) of the title compound in form of a colorless oil. 1 H-NMR: (400 MHz, DMSO-d 6 ) δ = 7.70-7.60 (m, 2H), 7.49- 7.41 (m, 2H), 3.44 (t, J = 6.3 Hz, 1H), 2.85-2.76 (m, 4H), 2.63 (t, J = 6.9 Hz, 2H), 1.59-1.53 (m, 2H) ppm; signal of two Protons overlayed by the H 2 O-peak. APCI-MS(+) m/z for C 12 H 16 F 3 NO: calc.: 247.26; found: 248.2. tert-butyl (3-hydroxypropyl)(4-(trifluoromethyl)phenethyl)carbamate (71): 00 eq) 3-((4-(trifluoromethyl)phenethyl)amino)propan-1-ol were dissolved in 30 mL of DCM. At 0 °C 0.22 mL (1.58 mmol; 1.50 eq) of Et 3 N and 253 mg (1.16 mmol; 1.10 eq) of Boc 2 O were added. The solution was warmed to RT and stirred for 20 h. The solvent was then removed and the resulting residue was adso bed o s ca gel. Column chromatography (Cyclohexane/EtOAc 100:0% to 50:50%) gave 340 mg (0.98 mmol; 78%) of the title compound in the form of a colorless oil. TLC: R f = 0.50 (Cyclohexane/EtOAc 1:1). 1 H-NMR: (400 MHz, DMSO-d 6 ) δ = 7.70-7.60 (m, 2H), 7.46-7.38 (m, 2H), 4.41 (t, J = 5.0 Hz, 1H), 3.40- 3.35 (m, 4H), 3.24-3.11 (m, 2H), 2.85 (t, J = 7.2 Hz, 2H), 1.63-1.56 (m, 2H), 1.35 and 1.26 (s, 9H) ppm. tert-butyl (3-oxopropyl)(4-(trifluoromethyl)phenethyl)carbamate (72): 1.00 eq) of tert-butyl (3-hydroxypropyl)(4- (trifluoromethyl)phenethyl)carbamate were dissolved in 7 mL of DMSO. 0.27 mL (1.96 mmol; 2.00 eq) of Et3N and 312 mg (1.96 mmol; 2.00 eq) of pyridine sulfur trioxide were added to the. Stirring was continued for 3 h at RT before the reaction was stopped with addition of 20 mL dist. H 2 O. Extraction with DCM (3x 60 mL) followed. The combined organic phases were dried over MgSO 4 and filtered. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (Cyclohexane/EtOAc 100:0% to 40:60%). 235 mg (0.68 mmol; 69%) of the title compound were obtained as a colorless oil. TLC: Rf = 0.71 (Cyclohexane/EtOAc 1:1). 1 H-NMR: (400 MHz, DMSO-d6) δ = 9.65 (s, 1H), 7.69-7.58 (m, 2H), 7.49-7.36 (m, 2H), 3.46-3.36 (m, 4H), 2.84 (t, J = 7.2 Hz, 2H), 2.65-2.58 (m, 2H), 1.35 and 1.26 (s, 9H) ppm. Synthesis of tert-butyl (2,4-difluorophenethyl)(3-oxopropyl)carbamate 1400 mg (8.97 mmol; 1.0 eq) of 2-(2,4-difluorophenyl)acetaldehyde were dissolved in 20 mL of methanol and 0.37 mL (4.80 mmol; 1.0 eq) of 3-amino-1-propanol were added. The reaction solution was stirred at RT overnight under N 2 atmosphere. Finally, at 0 °C, 512 mg (13.45 mmol; 1.5 eq) of NaBH 4 were added. After another 2 h of stirring, during which the solution was warmed to RT, it was quenched with 50 mL of a saturated NaCl solution. Extraction was performed with EtOAc (3x 60 mL). The combined organic phases were dried over MgSO 4 , filtered, and the solvent was removed under reduced pressure. After purification by column chromatography on silica gel (DCM/MeOH 100:0% to 90:10%), 738 mg (3.74 mmol; 42%) of the title compound were obtained in the form of a colorless oil. TLC: R f = 0.09 (DCM/MeOH 10:1). 1 H-NMR: (400 MHz, DMSO-d 6 ) δ = 7.37-7.31 (m, 1H), 7.17-7.12 (m, 1H), 7.02-6.97 (m, 1H), 3.43 (t, J = 6.3 Hz, 2H), 2.72- 2.66 (m, 4H), 2.56 (t, J = 6.8 Hz, 2H), 1.56-1.49 (m, 2H) ppm; signal of one Proton overlayed by the H 2 O-peak. tert-butyl (2,4-difluorophenethyl)(3-hydroxypropyl)carbamate (74): 1.0 eq) of 3-((2,4-difluorophenethyl)amino)propan-1-ol were dissolved in 30 mL of DCM and 0.49 mL (3.57 mmol; 1.5 eq) of Et 3 N and 571 mg (2.62 mmol; 1.1 eq) of Boc 2 O were added at 0 °C. The solution was warmed to RT and stirred overnight. The solvent was then removed and the resulting residue adsorbed on silica gel. Column chromatography (Cyclohexane/EtOAc 95:5% to 50:50%) gave 642 mg (2.04 mmol; 86%) of the title compound in the form of a coo ess o . N : ( 00 MHz, DMSO-d 6 ) δ = 7.33-7.26 (m, 1H), 7.23-7.13 (m, 1H), 7.06-6.97 (m, 1H), 4.42 (t, J = 5.1 Hz, 1H), 3.39-3.31 (m, 4H), 3.21-3.05 (m, 2H), 2.76 (t, J = 7.0 Hz, 2H), 1.61-1.54 (m, 2H), 1.34 and 1.27 (s, 9H) ppm. tert-butyl (2,4-difluorophenethyl)(3-oxopropyl)carbamate (75): l; 1.0 eq) of tert-butyl (2,4-difluorophenethyl)(3-hydroxypropyl)carbamate were dissolved in 7 mL of DMSO, to which were added 0.88 mL (6.36 mmol; 2.0 eq) of Et 3 N. Then, 1012 mg (6.36 mmol; 2.0 eq) of pyridine sulfur trioxide were added to the reaction solution, which was stirred for another 3 h at RT. After extraction with DCM (3x 60 mL), the combined organic phases were dried over MgSO 4 and filtered. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (Cyclohexane/EtOAc 100:0% to 40:60%). 554 mg (1.79 mmol; 56%) of the title compound were obtained in form of a colorless oil. TLC: R f = 0.33 (Cyclohexane/EtOAc 3:1). 1 H-NMR: (400 MHz, DMSO-d 6 ) δ = 9.64 (t, J = 1.8 , ), 7.34-7.28 (m, 1H), 7.23-7.11 (m, 1H), 7.08-6.97 (m, 1H), 3.44-3.34 (m, 4H), 2.77 (t, J = 6.9 Hz, 2H), 2.61 (td, J = 6.7, 1.9 Hz, 2H), 1.33 and 1.25 (s, 9H) ppm. Amine sidechains Preparation of 1-phenethylpiperidin-4-amine tert-butyl (1-phenethylpiperidin-4-yl)carbamate (76): lacetaldeyde (0.50 g, 4.12 mmol) in dry MeOH (4.10 mL) was added dropwise as solution of of tert-butyl piperidin-4-ylcarbamate (0.83 mL, 4.12 mmol) in dry MeOH (4.10 mL). The solution was stirred overnight at ambient temperature. Then, the reaction mixture was cooled down to 0 °C. Afterwards, NaBH 4 (0.24 g, 6.18 mmol) )was added portion wise. After complete conversion the reaction was concentrated under reduced pressure. The obtained residue was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The crude product was purified by flash chromatography (CH 2 Cl 2 /MeOH; 0-10%) to afford the product as colorless oil (0.31 g; 24%). 1-phenethylpiperidin-4-amine (77): .30 g, 0.98 mmol) was dissolved in dry CH2Cl2 (5.90 mL). Then, a 6M HCl solution in iPrOH (4.00 mL) was added stirred for 3 h at rt. The solution was evaporated, and the obtained residue was diluted with 10% NaOH solution. The aqueous phase was extracted with EtOAc. The combined organic layers were dried over sodium sulfate and concentrated under vacuum to afford the pure product (0.17 g, 84%). Preparation of tert-butyl (3-aminopropyl)(2-(naphthalen-2-yl)ethyl)carbamate tert-butyl (3-azidopropyl)(2-(naphthalen-2-yl)ethyl)carbamate (70h): f tert-butyl (3-hydroxypropyl)(2-(naphthalen-2-yl)ethyl)carbamate (0.30 g, 0.90 mmol) in CH 2 Cl 2 (4.50 mL) Et 3 N (0.19 mL; 1.35 mmol) and MsCl (0.09 mL, 1.08 mmol) were added at 0 °C under nitrogen atmosphere. After 1 h stirring at rt, the reaction was diluted with brine. The organic layer was separated, and the aqueous phase was extracted with CH 2 Cl 2 . The combined organic layers were dried over sodium sulfate and concentrated over vacuum to complete dryness. The mesylated product was dissolved in dry DMF (4.50 mL). To this solution NaN 3 (0.18 g, 2.71 mmol) was added and heated to 60 °C. After 5 h, TLC (cyclohexane/EtOAc; 50%) monitored full consumption. Then, the organic solvent was removed under reduced pressure. Water was added and the aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated over vacuum. The obtained residue was purified over silica (cyclohexane/EtOAc; 0-50%) to afford the pure product (0.15, 45%). tert-butyl (3-aminopropyl)(2-(naphthalen-2-yl)ethyl)carbamate (71h): .14 g, 0.39 mmol) in EtOH (3.90 mL) palladium on activated charcoal moistened with water (0.08 g, 0.04 mmol) was added under nitrogen atmosphere at rt. Then, the reaction mixture was purged with hydrogen and stirred for 2 h at rt. The reaction progress was monitored by TLC (CH 2 Cl 2 /MeOH; 1%). Then, the reaction mixture was purged with nitrogen and the catalyst was filtered off. The filtrate was concentrated under reduced pressure and the obtained crude product was purified over silica (CH 2 Cl 2 /MeOH; 0-10%) to afford the product as colorless oil (0.12 g, 95%). Preparation of N1-(4-(4-chlorophenoxy)-3-fluorophenethyl)propane-1,3-diamin e 4-(4-chlorophenoxy)-3-fluorobenzaldehyde (78): ,4-difluorobenzaldehyde (1.4 g, 10 mmol), 4-chlorophenol (1.3 g, 10 mmol), K2CO3 (2.8 g, 20 mmol) in DMF (15 mL) was stirred at 100 o C for 2 hrs. The mixture was diluted with EA (200 mL) and washed with H 2 O (100 mL x2). The organic layer was dried over Na 2 SO 4 and concentrated. The crude was purified by silica gel column (PE/EA =10/1) to give 4-(4- chlorophenoxy)-3-fluorobenzaldehyde (2.0 g, 80% yield) as a brown oil. MS Calc.: 250.0; MS Found: 251.2 [M+H] + . (E)-1-(4-chlorophenoxy)-2-fluoro-4-(2-methoxyvinyl)benzene (79): oxymethyl)triphenylphosphonium chloride (2.7 g, 8 mmol) in THF (20 mL) was added t-BuOK (900 mg, 8mmol) at 0 o C, and the solution was stirred at r. t. for 20 min. 4-(4- chlorophenoxy)-3-fluorobenzaldehyde (3, 500 mg, 2 mmol) was added and the solution was reacted for 1 hr. The reaction solution was diluted with EA (100 mL) and filtered. The filtrate was concentrated. The crude was purified by silica gel column (PE/EA = 20/1) to give (E)-1-(4- chlorophenoxy)-2-fluoro-4-(2-methoxyvinyl)benzene (200 mg, Y: 36%) as a brown oil. MS Calc.: 278.1; MS Found: 279.2 [M + H] + .

2-(4-(4-chlorophenoxy)-3-fluorophenyl)acetaldehyde (80):

To a solution of (E)-1-(4-chlorophenoxy)-2-fluoro-4-(2-methoxyvinyl)benzene (200 mg, 0.82 mmol) in THE (5 mL) was added con. HCI (3 mL), and the solution was stirred at 70 °C for 1 hr. The reaction solution was diluted with EA (100 mL) and washed with H 2 O (100 mL x2). The organic phase was dried over Na 2 SO 4 and concentrated to give 2-(4-(4-chlorophenoxy)-3- fluorophenyl)acetaldehyde (200 mg, crude) as a brown oil.

/VI-(4-(4-chlorophenoxy)-3-fluorophenethyl)propane-1, 3-diamine (81): F

A solution of 2-(4-(4-chlorophenoxy)-3-fluorophenyl)acetaldehyde (200 mg, 0.82 mmol) and propane-1, 3-diamine (607 mg, 8.2 mmol) in MeOH (5 mL) was stirred at r. t. for 20 min. Then NaBH 4 (47 mg, 1.2 mmol) was added at 0°C, and the solution was stirred at r. t. for 1 hr. The reaction solution was diluted with EA (100 mL) and washed with H 2 O (100 mL x3). The organic phase was dried over Na 2 SO 4 and concentrated to give N1-(4-(4-chlorophenoxy)-3- fluorophenethyl)propane-1, 3-diamine (250 mg, crude) as a brown oil. MS Calc.: 322.0; MS Found: 323.3 [M + H] + .

Preparation ofN1-methyl-N3-(3-phenoxyphenethyl)propane- 1,3 -diamine fe/t- butyl methyl(3-((3-phenoxyphenethyl)amino)propyl)carbamate (82):

To a solution of tert-butyl (3-aminopropyl)(methyl)carbamate (376 mg; 2 mmol) in MeOH (5 mL) at 0 °C was added 2-(3-phenoxyphenyl)acetaldehyde (106 mg; 0.5 mmol) in small portions. After the addition, sodium borohydride (19 mg, 0.5 mmol) was added slowly in small portions at 0 °C. The reaction was allowed to warm to room temperature overnight with stirring. The reaction was quenched with little water and concentrated to dryness. The crude was purified by reverse phase flash (MeCN/H 2 O) to afford tert-butyl methyl(3-((3- phenoxyphenethyl)amino)propyl)carbamate (100 mg, 74% yield) as a yellow oil. MS Calc.: 385.2; MS Found: 386.2 [M + H] + .

/VI-methyl-A3-(3-phenoxyphenethyl)propane-1, 3-diamine (83):

A solution of tert-butyl methyl(3-((3-phenoxyphenethyl)amino)propyl)carbamate (300 mg) in

MeOH/HCI (5 mL) was stirred at r. t. for 2 hrs, followed by concentration to afford N1-methyl-N3- (3-phenoxyphenethyl)propane-1, 3-diamine (crude) as a yellow oil.

Preparation of N1-(4-(4-chiorophenoxy)-3-fiuorobenzyi)propane-1, 3-diamine

/VI-(4-(4-chlorophenoxy)-3-fluorobenzyl)propane-1, 3-diamine (84):

A solution of 4-(4-chlorophenoxy)-3-fluorobenzaldehyde (500 mg, 2 mmol), 1,3- diaminopropane (740 mg, 10 mmol) in MeOH (5 mL) was stirred at r. t. for 20 min. Then NaBH 4 (114 mg, 3 mmol) was added at 0°C, and the solution was stirred at r. t. for 1 h r. The reaction mixture was diluted with EA (100 mL). The organic phase was washed with H 2 O (100 mL x3), dried over Na 2 SO 4 and concentrated to give N1-(4-(4-chlorophenoxy)-3-fluorobenzyl)propane-1,3- diamine (200 mg, crude) as a brown oil. MS Calc.: 308.1; MS Found: 309.3 [M + H] + .

Preparation of N1-(3-phenoxybenzyi)propane- 1,3 -diamine /VI-(3-phenoxybenzyl)propane-1,3-diamine (85):

To a solution of 1,3-diaminopropane (150 mg; 2 mmol) in MeOH (5 mL) at 0 °C was added 3- (phenoxy)benzaldehyde (100 mg; 0.5 mmol) in small portions. After the addition, sodium borohydride (19 mg, 0.5 mmol) was added slowly in small portions at 0 °C. The reaction was allowed to warm to room temperature overnight with stirring. The reaction was quenched with little water and concentrated to dryness. The crude was purified by reverse phase flash (MeCN/H 2 O) to afford N1-(3-phenoxybenzyl)propane-1,3-diamine (100 mg, 77% yield) as a yellow oil. MS Calc.: 256.2; MS Found: 257.3 [M + H] + .

Preaparation of N1-(3-phenoxybenzyl)ethane- 1,2-diamine /VI-(3-phenoxybenzyl)ethane-1,2-diamine (86):

To a solution of ethane-1,2-diamine (120 mg, 2 mmol) (150 mg, 2 mmol) in MeOH (5 mL) at 0 °C was added 3-(phenoxy)benzaldehyde (100 mg, 0.5 mmol) in small portions. After the addition, sodium borohydride (19 mg, 0.5 mmol) was added slowly in small portions at 0 °C. The reaction was allowed to warm to room temperature overnight with stirring. The reaction was quenched with little water and concentrated to dryness. The crude was purified by reverse phase flash (MeCN/H 2 O) to afford N1-(3-phenoxyphenethyl)ethane-1,2-diamine (100 mg, 78% yield) as a yellow oil. MS Calc.: 256.2; MS Found: 257.3 [M + H] + .

Preparation of2,2-difluoro-N1-(2-(naphthalen-2-yl)ethyl)propane-1,3-diam ine 2,2-difluoromalonamide (87):

A mixture of diethyl 2,2-difluoromalonate (5.0 g, 25.5 mmol) in ammonia solution in methanol (100mL) was stirred at room temperature for 16 hrs. The reaction mixture was concentrated to afford 2,2-difluoromalonamide (3.5g, yield: 99%) as a white solid.

2,2-difluoropropane-1,3-diamine (88):

To a solution of 87 (3.5 g, 25.5 mmol) in THF (50 mL) was added BH 3 in THF (12.7mL, 127mmol, 10N) at 0 °C. The resulting mixture was refluxed overnight. After cooling to 0 °C, the reaction was quenched with MeOH (20 mL) and concentrated. Then a solution of HCI in MeOH was added, and the mixture was stirred at room temperature for 30 min. The solid was filtered out and dried under vacuum to afford 2, 2-difluoropropane-1,3-diamine (2.1g, yield: 75%) as a colorless oil.

2-(naphthalen-2-yl)acetaldehyde (89):

To a solution of 2-(naphthalen-2-yl)ethan-1-ol (200 mg, 1.16mmol) in DCM (10mL) was added Dess-Martin periodinane (0.74 g, 1.75 mmol) and the solution was stirred at room temperature for 2 hrs. The reaction solution was diluted with DCM (20 mL) and washed with H 2 O (10 mL), aq. Na 2 SO 3 (10 ml), and aq. NaHCO 3 (10 ml). The organic phase was dried over Na 2 SO 4 and concentrated to give 89 (70 mg, yield: 35%) as a brown oil.

2,2-difluoro-/VI-(2-(naphthalen-2-yl)ethyl)propane-1,3-di amine (90):

A solution of 89 (70 mg, 0.41 mmol) and 88 (68 mg, 0.62 mmol) in MeOH (3 mL) was stirred at room temperature for 20 min. NaBH 3 CN (102 mg, 1.65 mmol) and AcOH (2 drops) was added, the solution was stirred at room temperature for 16 hrs. The resulting mixture was concentrated. The residue was purified via flash with the solvent of ACN in H 2 O. The collected fraction was concentrated. This afforded the desired product 90 (50mg, yield: 46%) as a white solid. MS Calc.: 264.1; MS Found: 265.0 [M + H + ],

In a heat- dried three-necked round bottom flask, Phenylboronic acid (3.97 g, 32.57 mmol) and 2-(4-Hydroxyphenyl)ethanol (1.50 g, 10.86 mmol) were added in dry C 2 H 2 CI 2 (67.90 mL). Afterwards, dry pyridine (2.52 mL, 32.57 mmol), anhydrous copper acetate (2.96 g, 16.28 mmol), and 4 A molecular sieves (1.87 g) were added to the mixture. The reaction mixture was stirred for 48 h at rt. The mixture was filtered off and the cake was rinsed several times with CH 2 CI 2 . The filtrate was concentrated under vacuum to complete dryness. The obtained residue was purified over silica (cyclohexane/EtOAc; 10-80%) to afford the pure product (0.0.85 g, 37%). 1 H NMR (400 MHz, DMSO-tA) <57.43 - 7.33 (m, 2H, H3/5), 7.26 - 7.21 (m, 2H, H3'/5'), 7.15 - 7.09 (m, 1H, H4), 7.00 - 6.95 (m, 2H. H2/6), 6.95 - 6.91 (m, 2H, H2'/6'), 4.65 (t, J = 52 Hz, 1H, OH), 3.60 (td, 7 = 7.0, 5.2 Hz, 2H, CH 2 , 1"), 2.71 (t, 7 = 7.0 Hz, 2H, CH 2 , 2").

The compound 91 (1.06 g, 4.97 mmol) was dissolved in dry CH 2 CI 2 (24.80 mL). Then, TsCI (0.95 g, 4.97 mmol) was added. Afterwards, dry pyridine (1.20 mL, 14.90 mmol) and DMAP (0.06 g, 0.50 mmol) were added 0 °C. The solution was stirred at rt overnight. The mixture was diluted with saturated bicarbonate solution and extracted three times with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude was purified by flash chromatography (cyclohexane/EtOAc; 0-80%) to afford the product as a colorless solid (1.06 g, 58%). 1 H NMR (400 MHz, DMSO-c/ 6 ) <57.74 - 7.65 (m, 2H, otosyl), 7.45 - 7.40 (m, 2H, /77-tosyl), 7.40 - 7.36 (m, 2H, H3/5), 7.20 - 7.10 (m, 3H, H4/375'), 7.02 - 6.94 (m, 2H, H2/6), 6.93 - 6.84 (m, 2H, H2'/6'), 4.22 (t, 7 = 6.5 Hz, 2H, CH 2 , 1"), 2.87 (t, 7 = 6.5 Hz, 2H, CH 2 , 2"), 2.40 (s, 3H, CH 3 ).

A solution of 92 (0.63 g, 1.71 mmol) in dry DMF (4.25 mL) was added to a solution of 3-((te/f- butyldiphenylsilyl)oxy)propan-1-amine (0.80 g, 2.57 mmol) in dry DMF (4.25 mL) at rt. Then, 2CO 3 (0.47 g, 3.42 mmol) was added and the suspension was heated to 80 °C and stirred at this temperature overnight. TLC (cyclohexane/EtOAc; 50%) monitored full consumption of 92. Then, the reaction was allowed to cool down to rt and was diluted with saturated bicarbonate solution. The aqueous phase was extracted three times with EtOAc. Afterwards, the combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by flash chromatography (cyclohexane/EtOAc; 0- 60%) to afford the pure product (0.34 g, 43%). 1 H NMR (400 MHz, DMSO-5 6 ) 57.66 - 7.58 (m, 4H, Ar-H), 7.49 - 7.40 (m, 6H, Ar-H), 7.40 - 7.34 (m, 2H, H3/5), 7.24 - 7.17 (m, 2H, H3'/5'), 7.16 - 7.07 (m, 1H, H4), 6.99 - 6.95 (m, 2H, H2/6), 6.92 - 6.89 (m, 2H, H2'/6'), 3.71 (t, 7 = 6.3 Hz, 2H, CH 2 , H1"), 2.72 - 2.60 (m, 6H, H3"/475"), 1.67 (h, 7 = 6.5 Hz, 2H, CH 2 , H2"), 0.99 (s, 9H, CH 3 , t-butyl).

To a solution of 93 (0.33 g, 0.65 mmol) in dry THE (3.20 mL), TBAF (0.36 mL, 1.30 mmol) was added dropwise. Then, the solution was stirred magnetically at rt for 5 h. TLC (CH 2 CI 2 /MeOH; 10%) indicated after this 5 h full conversion. The organic solvent was evaporated under vacuum and the obtained residue was purified over silica (CH 2 CI 2 /MeOH; 0-20%) to afford the desired product (0.13 g, 71%). 1 H NMR (400 MHz, DMSO-5 6 ) 5 7.42 - 7.34 (m, 2H, m"), 7.26 - 7.20 (m, 2H, m'), 7.17 - 7.07 (m, 1H, p"), 7.01 - 6.90 (m, 4H, o', o"), 3.45 (t, 7 = 6.3 Hz, 2H, CH 2 , H1'), 2.78 - 2.66 (m, 4H, CH 2 , H4', H5'), 2.63 (t, 7 = 6.9 Hz, 2H, CH 2 , H3'), 1.56 (p, 7 = 6.6 Hz, 2H, CH 2 , H2').

Triethylamine (0.12 mL, 0.83 mmol) was added to a solution of 94 (0.15 g, 0.55 mmol) in dry CH 2 CI 2 (2.80 mL). The solution was cooled down to 0 °C in an ice-bath. Afterwards, di-tert-butyl dicarbonate (0.14 mL, 0.61 mmol) was added portion wise. Then, the reaction mixture was allowed to warm up to rt and stirred for 5 h till complete conversion was monitored by TLC (cyclohexane/EtOAc; 80%). The mixture was diluted with saturated sodium bicarbonate solution and the organic phase was separated. The aqueous phase was extracted three times with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated over vacuum. The crude was purified by flash chromatography (cyclohexane/EtOAc; 0-80%) to afford a colorless oil (0.18 g, 88%). 1 H NMR (400 MHz, DMSO-c/ 6 ) 5 7.42 - 7.34 (m, 2H, m"), 7.21 (d, 7 = 8.0 Hz, 2H, m'), 7.15 - 7.09 (m, 1H, p"), 7.01 - 6.91 (m, 4H, o', o "), 4.42 (t, 7 = 5.2 Hz, 1H, OH), 3.42 - 3.30 (m, 4H, CH 2 , H1', H4'), 3.21 - 3.11 (m, 2H, CH 2 , H3'), 2.75 (t, 7 = 7.4 Hz, 2H, CH 2 , H5'), 1.60 (p, 7 = 6.5 Hz, 2H, CH 2 , H2'), 1.36 (s, 9H, CH 3 , ZBu).

Compound 95 (0.09 g, 0.24 mmol) was dissolved in dry 1,4-dioxane (1.20 mL) and cooled down to 0 °C. To the cooled solution DPPA (0.10 mL, 0.48 mmol) was added followed by DBU (0.11 mL, 0.72 mmol). The reaction mixture was stirred for 17 h at rt. Then, NaN 3 (0.08 g, 1.2 mmol) and 15- crown-5 (0.05 mL, 0.24 mmol) were added to the suspension and heated to 110 °C. After 6 h, the organic solvent was removed under vacuum and then water was added. The aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. 1 H NMR (400 MHz, DMSO-c/ 6 ) 5 7.41 - 7.34 (m, 2H, m"), 7.22 (d, 7 = 8.0 Hz, 2H, m'), 7.15 - 7.09 (m, 1H, p'), 7.01 - 6.92 (m, 4H, o', o"), 3.38 - 3.27 (m, 4H, CH 2 , H3', H4'), 3.22 - 3.14 (m, 2H, CH 2 , H1'), 2.75 (t, 7 = 7.4 Hz, 2H, CH 2 , H5'), 1.70 (p, 7 = 6.8 Hz, 2H, CH 2 , H2'), 1.44 - 1.31 (m, 9H CH 3 , ZBu).

To a solution of 96 (0.07 g, 0.18 mmol) in EtOH (1.70 mL) palladium on activated charcoal moistened with water (0.04 g, 0.02 mmol) was added under nitrogen atmosphere at rt. Then, the reaction mixture was purged with hydrogen and stirred for 2 h at rt. The reaction progress was monitored by TLC (cyclohexane/EtOAc; 20%). Then, the reaction mixture was purged with nitrogen and the catalyst was filtered off. The filtrate was concentrated under reduced pressure and the obtained crude product was purified over silica (CH 2 CI 2 /MeOH; 0-20%) to afford the product as colorless oil (0.05 g, 69%). 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 7.42 - 7.34 (m, 2H, m"), 7.25 - 7.18 (m, 2H, m'), 7.15 - 7.09 (m, 1H, p"), 7.00 - 6.91 (m, 4H, o', o"), 3.39 - 3.28 (m, 2H, CH 2 , H4'), 3.22 - 3.12 (m, 2H, CH 2 , H3'), 2.75 (t, 7 = 7.4 Hz, 2H, CH 2 , H5'), 2.54 - 2.52 (m, 2H, H1'), 1.53 (p, 7 = 6.9 Hz, 2H, CH 2 , H2'), 1.41 - 1.32 (m, 9H CH 3 , ZBu).

In a heat- dried three-necked round bottom flask, Phenylboronic acid (3.97 g, 32.57 mmol) and 2-(3-Hydroxyphenyl)ethanol (1.50 g, 10.86 mmol) were added in dry C 2 H 2 CI 2 (67.90 mL). Afterwards, dry pyridine (2.52 mL, 32.57 mmol), anhydrous copper acetate (2.96 g, 16.28 mmol), and 4 A molecular sieves (1.87 g) were added to the mixture. The reaction mixture was stirred for 48 h at rt. The mixture was filtered off and the cake was rinsed several times with CH 2 CI 2 . The filtrate was concentrated under vacuum to complete dryness. The obtained residue was purified over silica (cyclohexane/EtOAc; 10-80%) to afford the pure product (0.58 g, 25%) as a yellowish oil. 1 H NMR (400 MHz, DMSO-5 6 ) 57.42 - 7.36 (m, 2H, H3/5), 7.33 - 7.23 (m, 1H, H5'), 7.18 - 7.09 (m, 1H, H4), 7.05 - 6.96 (m, 3H, H2/6/6'), 6.90 - 6.88 (m, 1H, H2'), 6.81 (ddd, 7 = 8.1, 2.5, 1.0 Hz, 1H, H4'), 4.64 (t, 7 = 5.2 Hz, 1H, OH), 3.60 (td, 7 = 7.0, 5.2 Hz, 2H, CH 2 , 1"), 2.71 (t, 7 = 6.9 Hz, 2H, CH 2 ,

The compound 98 (0.55 g, 2.57 mmol) was dissolved in dry CH 2 CI 2 (12.80 mL). Then, TsCI (0.49 g, 2.57 mmol) was added. Afterwards, dry pyridine (0.62 mL, 7.70 mmol) and DMAP (0.03 g, 0.26 mmol) were added at 0 °C. The solution was stirred at rt overnight. TLC (cyclochexane/EtOAc, 20%) monitored no complete conversion. At this point further dry pyridine (0.31 mL, 3.85 mmol) was added and stirred magnetically for 8 h at rt. Then, the mixture was diluted with saturated bicarbonate solution and extracted three times with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude was purified by flash chromatography (cyclohexane/EtOAc; 0-60%) to afford the product as a colorless oil (0.66 g, 70%). 1 H NMR (400 MHz, DMSO-5 6 ) 57.69 - 7.65 (m, 2H, o-tosyl), 7.45 - 7.40 (m, 2H, /77-tosyl), 7.40 - 7.36 (m, 2H, H3/5), 7.32 - 7.23 (m, 1H, H5'), 7.19 - 7.10 (m, 1H, H4), 6.99 - 6.96 (m, 2H, H2/6), 6.98 - 6.91 (m, 1H, H4'), 6.87 - 6.81 (m, 2H, H2'/6'), 4.23 (t, 7 = 6.3 Hz, 2H, CH 2 , 1"), 2.88 (t, 7 = 6.3 Hz, 2H, CH 2 , H2"), 2.41 (s, 3H, CH 3 ).

A solution of 99 (0.62 g, 1.69 mmol) in dry DMF (4.20 mL) was added to a solution of 3-((tert- butyldiphenylsilyl)oxy)propan-1-amine (0.79 g, 2.53 mmol) in dry DMF (4.20 mL) at rt. Then, 2CO 3 (0.47 g, 3.38 mmol) was added and the suspension was heated to 80 °C and stirred at this temperature overnight. TLC (cyclohexane/EtOAc; 50%) monitored full consumption of 99. Then, the reaction was allowed to cool down to rt and was diluted with saturated bicarbonate solution. The aqueous phase was extracted three times with EtOAc. Afterwards, the combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by flash chromatography (cyclohexane/EtOAc; 0- 60%) to afford the pure product (0.29 g, 34%). 1 H NMR (400 MHz, DMSO-5 6 ) 57.66 - 7.57 (m, 4H, Ar-H), 7.49 - 7.38 (m, 6H, Ar-H), 7.42 - 7.33 (m, 2H, H3/5), 7.32 - 7.23 (m, 1H, H5'), 7.17 - 7.08 (m, 1H. H4), 7.04 - 6.94 (m, 3H, H2/4'/6), 6.88 - 6.77 (m, 2H, H2'/6'), 3.70 (t, 7 = 6.3 Hz, 2H, CH 2 , 1"), 2.73 - 2.60 (m, 4H, CH 2 , 4"/5"), 2.60 (t, 7= 6.8 Hz, 2H, CH 2 , 3"), 1.64 (p, 7 = 6.5 Hz, 2H, CH 2 , H2"), 0.99 (s, 9H, CH 3 , t-butyl).

3-((3-phenoxyphenethyl)amino)propan-1-ol '\Q'\ .

To a solution of 100 (0.30 g, 0.59 mmol) in dry THF (2.90 mL), TBAF (0.32 mL, 1.18 mmol) was added dropwise. Then, the solution was stirred magnetically at rt for 5 h. TLC (CH 2 CI 2 /MeOH; 10%) indicated after this 5 h full conversion. The organic solvent was evaporated under vacuum and the obtained residue was purified over silica (CH 2 CI 2 /MeOH; 0-20%) to afford the desired product (0.13 g, 75%). 1 H NMR (400 MHz, DMSO-5 6 ) 57.41 - 7.35 (m, 2H, H3/H5), 7.28 (t, 7 = 7.8 Hz, 1H, H5'), 7.17 - 7.08 (m, 1H, H4), 7.02 - 6.97 (m, 3H, H2/6/4'), 6.88 - 6.85 (m, 1H, H2'), 6.81 (ddd, 7 = 8.1, 2.5, 0.9 Hz, 1H, H6'), 3.42 (t, 7 = 6.3 Hz, 2H, CH 2 , 1"), 2.76 - 2.64 (m, 4H, CH 2 , H4 H5"), 2.58 (t, 7 = 6.9 Hz, 2H, CH 2 , H3"), 1.53 (p, 7 = 6.6 Hz, 2H, CH 2 , H2"). ' tert-butyl (3-hydroxypropyl)(3-phenoxyphenethyl)carbamate (102):

Triethylamine (0.11 mL, 0.77 mmol) was added to a solution of 101 (0.14 g, 0.52 mmol) in dry CH 2 CI 2 (2.60 mL). The solution was cooled down to 0 °C in an ice-bath. Afterwards, di-tert-butyl dicarbonate (0.13 mL, 0.57 mmol) was added portion wise. Then, the reaction mixture was allowed to warm up to rt and stirred for 5 h till complete conversion was monitored by TLC (cyclohexane/EtOAc; 50%). The mixture was diluted with saturated sodium bicarbonate solution and the organic phase was separated. The aqueous phase was extracted three times with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated over vacuum. The crude was purified by flash chromatography (cyclohexane/EtOAc; 0-80%) to afford a colorless oil (0.15 g, 73%). 1 H NMR (400 MHz, DMSO-5 6 ) 57.42 - 7.36 (m, 2H, H3,5), 7.31 (t, 7 = 7.9 Hz, 1H, H5'), 7.14 (t, 7 = 7.3 Hz, 1H, H4), 7.03 - 6.94 (m, 3H, H3,5,4'), 6.85 (d, 7 = 7.5 Hz, 2H, H2',6'), 4.42 (t, 7 = 4.8 Hz, 1H, OH), 3.40 - 3.29 (m, 4H, CH 2 , H1",4"), 3.19 - 3.05 (m, 2H, CH 2 , H3"), 2.74 (t, 7 = 7.3 Hz, 2H, CH 2 , H5"), 1.58 (p, 7= 6.6 Hz, 2H, CH 2 , H2"), 1.38 - 1.28 (m, 9H, CH 3 , Abutyl).

To a stirred solution of 102 (0.14 g, 0.37 mmol) in CH 2 CI 2 (1.90 mL) Et 3 N (0.08 mL; 0.56 mmol) and MsCI (0.04 mL, 0.45 mmol) were added at 0 °C under nitrogen atmosphere. After 1 h stirring at rt, the reaction was diluted with brine. The organic layer was separated, and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate and concentrated over vacuum to complete dryness. The mesylated product was dissolved in dry DMF (1.90 mL). To this solution NaN 3 (0.07 g, 1.12 mmol) was added and heated to 60 °C. After 5 h, TLC (cyclohexane/EtOAc; 50%) monitored full consumption. Then, the organic solvent was removed under reduced pressure. Water was added and the aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated over vacuum. The obtained residue was purified over silica (cyclohexane/EtOAc; 0- 30%). 1 H NMR (400 MHz, DMSO-5 6 ) <57.42 - 7.36 (m, 2H, H3/5), 7.31 (dd, 7 = 8.4, 7.6 Hz, 1H, H5'), 7.18 - 7.10 (m, 1H, H4), 7.03 - 6.95 (m, 3H, H2,6,4'), 6.88 - 6.83 (m, 2H, H2',6'), 3.37 - 3.27 (m, 4H, CH 2 , H1",4"), 3.21 - 3.06 (m, 2H, CH2, H3"), 2.75 (t, 7 = 7.2 Hz, 2H, CH 2 , H5"), 1.67 (p, 7 = 6.7 Hz, 2H, CH 2 , H2"), 1.43 - 1.27 (m, 9H, CH 3 , f-butyl). fe/t- butyl (3-aminopropyl)(3-phenoxyphenethyl)carbamate (104):

Compound 103 (0.09 g, 0.23 mmol) was dissolved in EtOH (2.30 mL). This solution was degassed and stirred at rt under nitrogen. Afterwards, palladium on activated charcoal moistened with water (0.05 g, 0.02 mmol) was added and the resulted suspension was degassed purged with nitrogen. Then, the mixture was set under hydrogen atmosphere with a storage vessel and stirred at rt for 2 h. TLC (cyclohexane/EtOAc; 20%) showed full consumption of 103. Thus, the mixture was purged with nitrogen and filtered off. The filter cake was rinsed with EtOH and CH 2 CI 2 . The filtrate was concentrated under reduced pressure. The crude product was purified by flash chromatography (CH 2 CI 2 /MeOH; 0-20%) to afford the product as colorless oil (0.05 g, 59%). 1 H NMR (400 MHz, DMSO-5 6 ) 57.42 - 7.36 (m, 2H, H3,5), 7.34 - 7.28 (m, 1H, H5'), 7.14 (t, 7 = 7.4 Hz, 1H, H4), 7.03 - 6.95 (m, 3H, H2,6,4'), 6.90 - 6.80 (m, 2H, H2',6'), 3.35 - 3.28 (m, 2H, CH 2 , H4"), 3.19 - 3.05 (m, 2H, CH 2 , H1"), 2.78 - 2.71 (m, 2H, CH 2 , H5"), 2.49 - 2.45 (m, 2H, CH 2 , H3"), 1.50 (p, 7 = 6.9 Hz, 2H, CH 2 , H2"), 1.41 - 1.26 (m, 9H, CH 3 , Abutyl).

To a solution of 2-phenylacetaldehyde (0.60 g, 5.00 mmol) in dry MeOH (10 mL) was added 3- aminopropan-1-ol (0.38 g, 5.00 mmol) dropwise at rt. The reaction mixture was stirred overnight at rt. TLC monitored complete conversion. The reaction was then cooled down in an ice-bath. Then, NaBH 4 (0.28 g, 7.50 mmol) was added portion wise to the solution. After the bubbling hat stopped, the solvent was evaporated under vacuum. The obtained residue was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained crude was purified by flash chromatography (EtOAc 100%, then DCM/MeOH; 0-20%) to afford the product (0.82 g, 92%). 1 H NMR (400 MHz, DMSO-5 6 ) 57.31 - 7.25 (m, 1H), 7.23 - 7.15 (m, 2H), 3.44 (t, 7 = 6.3 Hz, 1H), 2.70 (dt, 7 = 4.4, 2.4 Hz, 3H), 2.58 (t, 7 = 6.8 Hz, 1H), 1.54 (p, 7 = 6.6 Hz, 1H).

Compound 105 (0.46 g, 2.57 mmol) in CH 2 CI 2 (12.80 mL) Et 3 N (0.53 mL, 3.85 mmol) was added. Then, the solution was cooled down in an ice-bath. Afterwards, boc anhydride (0.65 mL, 2.82 mmol) was added portionwise to the cooled solution. The reaction mixture was allowed to warm up to rt and stirred magnetically at this temp until complete conversion. TLC was used to monitor the progress (cyclohexane/EtOAc; 50%) & (DCM/MeOH; 20%). After 3 h, the solution was diltued with sat. bicarbonate solution and extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified over silica (cyclohexane/EtOAc; 20-100%) to afford the product (0.60 g, 83%). 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 7.33 - 7.26 (m, 2H, H3, H5), 7.24 - 7.16 (m, 3H, H2, H4, H6), 4.43 (t, 7 = 5.0 Hz, 1H, OH), 3.41 - 3.30 (m, 4H, CH 2 , H4', H5'), 3.21 - 3.09 (m, 2H, CH 2 , H1'), 2.75 (t, 2H, CH 2 , H3'), 1.60 (p, 7 = 6.4 Hz, 2H, CH 2 , H2'), 1.46 - 1.27 (m, 9H, CH 3 , Abutyl).

To a stirred solution of 106 (0.10 g, 0.35 mmol) in CH 2 CI 2 (1.80 mL) Et 3 N (0.07 mL; 0.53 mmol) and MsCI (0.03 mL, 0.05 mmol) were added at 0 °C under nitrogen atmosphere. After 1 h stirring at rt, the reaction was diluted with brine. The organic layer was separated, and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate and concentrated over vacuum to complete dryness. The mesylated product was dissolved in dry DMF (1.80 mL). To this solution NaN 3 (0.07 g, 1.06 mmol) was added and heated to 60 °C. After 5 h, TLC (cyclohexane/EtOAc; 50%) monitored full consumption. Then, the organic solvent was removed under reduced pressure. Water was added and the aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated over vacuum. The obtained residue was purified over silica (cyclohexane/EtOAc; 0- 30%) to afford a colorless oil. 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 7.36 - 7.26 (m, 2H, o'), 7.25 - 7.17 (m, 3H, m', p'), 3.34 - 3.27 (m, 2H, CH 2 , H3', H4'), 3.22 - 3.11 (m, 2H, CH 2 , H1'), 2.81 - 2.70 (m, 2H, CH 2 , H5'), 1.69 (p, 7 = 6.7z Hz, 2H, CH 2 , H2'), 1.43 - 1.29 (m, 9H, CH 3 , ZBu).

To a solution of 107 (0.11 g, 0.36 mmol) in EtOH (3.60 mL) palladium on activated charcoal moistened with water (0.08 g, 0.04 mmol) was added under nitrogen atmosphere at rt. Then, the reaction mixture was purged with hydrogen and stirred for 2 h at rt. The reaction progress was monitored by TLC (cyclohexane/EtOAc; 20%). Then, the reaction mixture was purged with nitrogen and the catalyst was filtered off. The filtrate was concentrated under reduced pressure and the obtained crude product was purified over silica (CH 2 CI 2 /MeOH; 0-10%) to afford the product as colorless oil (0.05 g, 69%). 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 7.34 - 7.25 (m, 2H, o'), 7.25 - 7.17 (m, 3H, m', p'), 3.43 - 3.26 (m, 2H, CH 2 , H4'), 3.21 - 3.09 (m, 2H, CH 2 , H3'), 2.81 - 2.71 (m, 2H, CH 2 , H5'), 1.60 - 1.47 (m, 2H, CH 2 , H2'), 1.42 - 1.28 (m, 9H, CH 3 , ZBu). A solution of phenylacetylchloride (2.00 g, 14.48 mmol) in dry CH2CI2 was added over 2 h to a solution of 3-propanmediamine (12.18 mL, 144.75 mmol) and triethylamine (4.05 mL, 28.95 mmol) in dry CH 2 CI 2 at ambient temperature. The mixture was stirred for 24 h at rt. The organic solvent was removed under vacuum and the residue was taken up with CH 2 CI 2 and brine. The organic layer was separated, and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate, and concentrated. The obtained resdidue was purified over NH-coated silica (DCM/MeOH; 0-10%) to afford the compound as a colorless oil (0.20 g, 7%). NMR according to literature data.

A solution of propionyl chloride (0.50 g, 5.40 mmol) in dry CH 2 CI 2 was added to a solution of terf-butyl (3-aminopropyl)carbamate (1.14 mL, 6.49 mmol) and triethylamine (1.13 mL, 8.11 mmol) in dry CH 2 CI 2 at ambient temperature. The mixture was stirred for 24 h at rt. The organic solvent was removed under vacuum and the residue was taken up with CH 2 CI 2 and brine. The organic layer was separated, and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate, and concentrated. The crude product was purified over silica () to afford the desired product was a colorless oil (0.42 g, 34%). 1 H NMR (400 MHz, DMSO- d 6 ) 5132 (t, 7 = 5.0 Hz, 1H, NH), 6.78 (t, 7 = 5.5 Hz, 1H, NH), 3.01 (q, 7= 6.8 Hz, 2H, CH 2 , H3), 2.91 (q, 7 = 6.7 Hz, 2H, CH 2 , H • ), 2.05 (q, 7 = 7.6 Hz, 2H, CH 2 , H2'), 1.48 (p, 7 = 6.9 Hz, 2H, CH 2 , H2), 1.38 (s, 9H, CH 3 . Abutyl), 0.98 (t, 7 = 7.6 Hz, 3H, CH 3 , Hp).

Compound 110 (0.37 g, 1.59 mmol) was dissolved in CH 2 CI 2 (6.40 mL). Then, TFA (1.60 mL) was added, and the solution was stirred at ambient temperature for 3 h. TLC (CH 2 CI 2 /MeOH; 10%) monitored full conversion. Then, the solution was concentrated to complete dryness which afforded the product as colorless oil (0.39 g, quant.; 1 TFA salt). 1 H NMR (400 MHz, DMSO-c/ 6 ) 5 7.94 (t, 7 = 5.4 Hz, 1H, NH), 7.72 (bs, 3H, NH 3 + ), 3.10 (q, 7 = 6.7 Hz, 2H, CH 2 , H3), 2.83 - 2.72 (m, 2H, CH 2 , H1), 2.09 (q, 7 = 7.6 Hz, 2H, CH 2 , H • ), 1.66 (p, 7 = 14.2, 6.8 Hz, 2H, CH 2 , H2), 1.00 (t, 7 = 7.6 Hz, 3H, CH 3 , HP).

To a cooled solution of tert-butyl 3-aminopropylcarbamate (0.74 g, 4.20 mmol) in dry CH 2 CI 2 (21.0 mL) phenylisocyanate (0.50 g, 4.20 mmol) was added and stirred overnight at rt. Then, the solvents were removed by rotatory evaporation. The obtained residue was purified over silica (cyclohexane/EtOAc; 20-80%) to afford the product as white solid (79%). 1 H NMR (400 MHz, DMSO-aL) <58.49 (s, 1H, NH), 7.38 (dt, 7 = 8.8, 1.6 Hz, 2H, H3, H5), 7.25 - 7.18 (m, 2H, H2, H6), 6.93 - 6.83 (m, 1H, H4), 6.84 (t, 7 = 5.9 Hz, 1H, NH), 6.13 (t, 7 = 5.7 Hz, 1H, NH), 3.07 (q, 7 = 6.6 Hz, 2H, CH 2 , H3), 2.96 (q, 7 = 6.6 Hz, 2H, CH 2 , H1), 1.51 (p, 7 = 6.7, 6.1 Hz, 2H, CH 2 , H2), 1.39 (s, 9H, CH 3 , Abutyl). H H

Compound 106h (0.91 g, 3.11 mmol) was dissolved in CH 2 CI 2 (12.40 mL). Then, TFA (3.10 mL) was added and the mixture was stirred at rt for 3 h. TLC (CH 2 CI 2 MeOH; 10%) showed complete conversion. The reaction mixture was concentrated to complete dryness over vacuum which afforded the desired compound as colorless solid (0.61 g, quant.; 1 TFA salt). 1 H NMR (400 MHz, DMSO-A) <58.69 (s, 1H, NH), 7.72 (s, 3H, NH 3 + ), 7.42 - 7.37 (m, 2H, H3, H5), 7.25 - 7.19 (m, 2H, H2, H6), 6.90 (tt, J = 7.5, 1.2 Hz, 1H, H4), 6.47 (s, 1H, NH), 3.16 (t, J = 6.3 Hz, 2H, CH 2 , H3), 2.89 - 2.76 (m, 2H, CH 2 , H1), 1.71 (p, J = 6.7 Hz, 2H, CH 2 , H2).

Preparation of 1-(3-aminopropyl)-3 -ethylurea tert-buty/ (3-(3-ethylureido)propyl)carbamate (108h) :

To a cooled solution of tert-butyl 3-aminopropylcarbamate (1.24 g, 7.03 mmol) in dry CH 2 CI 2 (35.20 mL) ethylisocyanate (0.50 g, 7.03 mmol) was added and stirred overnight at rt. Then, the solvents were removed by rotatory evaporation. The obtained residue was purified over silica (cyclohexane/EtOAc; 20-80%) to afford the product as white solid (34%). 1 H NMR (400 MHz, DMSO-<5 6 ) < 6.79 (t, J = 5.7 Hz, 1H, NH), 5.84 - 5.74 (m, 2H, NH), 3.03 - 2.93 (m, 4H, CH 2 , H1', H3), 2.90 (q, J = 6.8 Hz, 2H, CH 2 , H1), 1.48 - 1.41 (m, 2H, CH 2 , H2), 1.38 (s, 9H, CH 3 , Abutyl), 0.97 (t, J = 12 Hz, 3H, CH 3 , H2').

To a solution of compound 108h (1.05 g, 4.30 mmol) in CH 2 CI 2 (17.20 mL) was added TFA (4.30 mL) and stirred magnetically at rt for 3 h. After this time the solvents were removed under vacuum which afforded the compound as a colorless oil (1.20 g, quant.; 1 TFA salt). 1 H NMR (400 MHz, DMSO-<5 6 ) <57.74 (s, 3H, NH 3 + ), 3.06 (t, J = 6.5 Hz, 2H, CH 2 , H3), 3.01 (q, J = 12 Hz, 2H, CH 2 , H1'), 2.76 (h, J = 5.9 Hz, 2H, CH 2 , H1), 1.63 (p, J = 6.8 Hz, 2H, CH 2 , H2), 0.99 (t, J = 12 Hz, 3H, CH 3 , H2').

Nucleosides building blocks

Preparation of tert-butyl (3-aminopropy/)(((3aR,4R, 6R, 6aR)-6-(6-((tert-butoxycarbonyl)amino)-

9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]diox ol-4-yl)methyl)carbamate tert-butyl (9-((3aR f 4R f 6R, 6aR)-6-(((3-((((9H-fluoren-9-yl)meth- oxy)carbonyl)amino)propyl)amino)methyl)-2,2-dimethyltetrahyd rofuro[3,4-d][1,3]dioxol-4-yl)-9H- purin-6-y!)carbamate (112):

To a solution of aldehyde 51 (0.71 g, 2.37 mmol) in dry DCE (10.75 mL) was added drop wise as solution of 138 (0.88 g, 2.15 mmol) in dry DCE (10.75 mL). The solution was stirred 2 h at ambient temperature and then STAB (0.69 g, 3.23 mmol) was added portion wise over 30 min at ambient temperature. The mixture was stirred for 48 h and then quenched with an aqueous 1 m K 2 CO 3 solution to reach pH ~8. The organic layer was separated, and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated over vacuum. The obtained residue was purified over silica (CH 2 CI 2 /MeOH; 0-10%) to afford the product as white foam (0.60 g, 41%). 1 H NMR (400 MHz, DMSO-c/ 6 ) <58.66 (s, 1H, H2, adenine), 8.63 (s, 1H, H8, adenine), 7.90 (dd, 7 = 0.8 Hz, 1H, H5, Fmoc), 7.88 (dd, 7 = 1.2, 0.7 Hz, 1H, H4, Fmoc), 7.86 (dd, 7 = 0.8 Hz, 1H, H8, Fmoc), 7.87 - 7.81 (m, 1H, H1, Fmoc), 7.42 (td, 7 = 7.4, 1.2 Hz, 2H, H2/7, Fmoc), 7.35 (td, 7 = 7.4, 1.2 Hz, 2H, H3/6, Fmoc), 6.29 (s, 2H, CH 2 , Fmoc), 6.19 (d, 7z= 2.6 Hz, 1H, HT), 5.49 (dd, 7 = 6.1, 2.6 Hz, 1H, H2'), 4.99 (dd, 7 = 6.1, 2.3 Hz, 1H, H3'), 4.28 - 4.20 (m, 1H, H4'), 2.97 - 2.79 (m, 2H, CH 2 , H3"), 2.74 - 2.58 (m, 2H, CH 2 , H5')„ 2.49 - 2.43 (m, 2H, CH 2 , H1"), 1.55 (s, 3H, CH 3 , acetonide), 1.48 (s, 9H, CH 3 , Abutyl), 1.48 - 1.45 (m, 2H, CH 2 , H2"), 1.33 (s, 3H, CH 3 , acetonide). tert-butyl (3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propyl)(((3aR, 4R, 6R, 6aR)-6-(6-((tert- butoxycarbonyl)amino)-9H-purin-9-yl)-2,2-dimethyltetrahydrof uro[3,4-d][1,3]dioxol-4- yl)methyl)carbamate (113):

To cooled a solution of compound 112 (0.59 g, 0.85 mmol) in dry CH 2 CI 2 (8.50 mL), di-tert-butyl decarbonate (0.22 mL, 0.94 mmol) was added. The reaction solution was stirred overnight at ambient temperature. After 17 h, reaction mixture was diluted with sodium bicarbonate solution. The organic layer was separated, and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The obtained residue was purified by flash chromatography (CH 2 CI 2 /MeOH; 0-7%) to afford the product as white foam (0.55 g, 82%). 1 H NMR (400 MHz, DMSO-t/ 6 ) 510.18 (s, 1H, NHBoc), 8.64 (s, 1H, H2, adenine), 8.63 (s, 1H, H8, adenine), 7.89 (d, 7 = 7.4 Hz, 2H, H4/5, Fmoc), 7.67 (d, 7 = 7.2 Hz, 2H, H1/8, Fmoc), 7.41 (t, 7 = 7.4 Hz, 2H, H3/6, Fmoc), 7.32 (t, 7 = 7.4 Hz, 2H, H2/7, Fmoc), 7.19 (t, 7 = 5.3 Hz, 1H, NH), 6.28 (s, 1H, H1'), 5.56 - 5.47 (m, 1H, H2'), 5.08 - 4.98 (m, 1H, H3'), 4.32 (dd, 7 = 6.5, 2.3 Hz, 1H, H4'), 4.32 - 4.22 (m, 2H, CH 2 , Fmoc), 3.58 - 3.47 (m, 1H, CH 2 , H5'), 3.32 - 3.19 (m, 1H, CH 2 , H5'), 3.16 - 3.02 (m, 2H, CH 2 , H1"), 2.93 - 2.75 (m, 2H, CH 2 , H3"), 1.54 (s, 3H, CH 3 , acetonide), 1.47 (s, 11H, CH 2 , CH 3 , H2", Abutyl), 1.34 (s, 9H, CH 3 , Abutyl), 1.33 (s, 3H, CH 3 , acetonide). tert-butyl (3-aminopropyl)(((3aR,4R, 6R, 6aR)-6-(6-((tert-butoxycarbonyl)amino)-9H-purin-9-yl)- 2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)car bamate ^'\4y. Nucleoside 113 (0.54 g, 0.79 mmo) was dssoved a 0% piperidine solution in CH 2 Cl 2 (7.80 mL). The reaction mixture was stirred for 24h at ambient temperature. After 24 h, the mixture was diluted with water. The organic phase was separated, and the aqueous phase was extracted with CH 2 Cl 2 . The combined organic layers were dried over sodium sulfate and concentrated to complete dryness. The crude product was purified over silica (CH2Cl2/MeOH; 0- 20%) to afford the pure product as colorless solid (0.44 g, 100%). Preparation of N1-(((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyrr olo[2,3- d]pyrimidin-7-yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl )methyl)-2,2-difluoro-N3-(2- (naphthalen-2-yl)ethyl)propane-1,3-diamine N1-(((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methyl)-2,2-difluoro-N3-(2-(na phthalen-2-yl)ethyl)propane-1,3- diamine (115): naphthalen-2-yl)ethyl)propane-1,3-diamine (25 mg, 0.09 mmol), (3aR,4S,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl) -2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxole-4-carbaldehyde (30 mg, 0.09 mmol) in MeOH (3 mL) was stirred at room temperature for 20 min. NaBH 3 CN (22 mg, 0.35 mmol) and AcOH (2 drops) was added. The solution was stirred at room temperature for 16 hrs. The resulting mixture was concentrated. The residue was purified via flash with the solvent of ACN in H 2 O. The collected fraction was concentrated. This afforded the desired product 8 (30 mg, yield: 57%) as a white solid. MS Calc.: 569.2; MS Found: 570.0 [M+H + ]. N 1 -(((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H- pyrrolo[2,3-d]pyrimidin-7- yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)-2,2-d ifluoro-N3-(2-(naphthalen-2- yl)ethyl)propane-1,3-diamine (116): ol) in methylamine in MeOH (5mL) was stirred at room temperature for 16 hrs. The reaction solution was diluted with water (30mL), extracted with EA (15mL x3). The combined organic layer was dried with Na 2 SO 4 , filtered and concentrated. This afforded the crude desired product 116 (30 mg) as colorless oil. The crude product was used for next step without further purification. Preparation of tert-butyl ((E)-5-((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino )-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4-yl)pent-4- en-1-yl)(phenethyl)carbamate 3-((tert-butoxycarbonyl)(phenethyl)amino)propyl methanesulfonate (117): butyl (3-hydroxypropyl)(phenethyl)carbamate (1.0 g, 3.4 mmol), TEA (1.2 g, 10.2 mmol) in DCM (20 mL) was added MsCl (534 mg, 5.1 mmol) at 0 o C, and the solution was stirred at room temperature for 2 hrs. The reaction solution was diluted with DCM (100 mL). The organic phase was washed with H 2 O (100 mL), dried over Na 2 SO 4 and concentrated to dryness. The crude was purified by flash (A: H2O; B: MeCN) to give 117 (1.2 g, crude) as a clear oil. MS Calc.: 371.2; MS Found: 316.0 [M+H + -56]. tert-butyl (3-iodopropyl)(phenethyl)carbamate (118): (1.2 g, 3.4 mmol) and NaI (1.0 g, 6.8 mmol) in acetone (20 mL) was stirred at 40 o C for 2 hrs. The reaction solution was concentrated and the crude was purified by flash (A: H2O; B: MeCN) to give 118 (600 mg, two step yield: 48%) as a clear oil. MS Calcd.: 403.1; MS Found: 347.8 [M+H + -56]. (4-((tert-butoxycarbonyl)(phenethyl)amino)butyl)triphenylpho sphonium iodide (119): 300 mg, 0.74 mmol) and PPh 3 (215 mg, 0.82 mmol) in toluene (10 mL) was stirred at 110 o C for 24 hrs. The reaction mixture was hold still at room temperature for 2 hrs. The supernatant was removed and the remaining was concentrated to give 119 (300 mg, yield: 75%) as a white solid. MS Calcd.: 538.3; MS Found: 538.1 [M + ]. ((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-py rrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methanol (120): R,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2, 2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methanol (100 mg, 0.31 mmol), 1-(4- methoxyphenyl)-N-methylmethanamine (94 mg, 0.62 mmol) and TEA (94 mg, 0.93 mmol) in DMF (5 mL) was stirred at 70 o C for 24 hrs. The crude was purified by flash (A: H2O; B: MeCN) to give 120 (100 mg, yield: 73%) as a clear oil. MS Calc.: 438.2; MS Found: 439.0 [M+H + ]. (3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-pyr rolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carbaldehy de (121) 120 (100 mg, 0.23 mmol) in DCM (10 mL) was added Dess-Martin periodinane (134 mg, 0.34 mmol) and the solution was stirred at room temperature for 4 hrs. The reaction solution was diluted with DCM (20 mL). The organic phase was washed with H 2 O (20 mL), aq. NaSO 3 (20 ml), aq. NaHCO 3 (20 ml) and dried over Na 2 SO 4 . The solution was concentrated to give 121 (100 mg, crude) as a brown oil. tert-butyl ((E)-5-((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino )-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)pent-4-en-1- yl)(phenethyl)carbamate (122): 7 mmol) in THF (5 ml), was added n-BuLi (0.15 ml, 0.37 mmol) at -78 o C. and then was added 121 (100 mg, 0.23 mmol), the solution was stirred at room temperature for 2 hrs. The crude was purified by prep-HPLC (A : H2O, TFA; B: MeCN) to give 122 (7 mg) as a white solid. MS Calcd.: 695.4; MS Found: 696.1 [M+H + ]. Preparation of 7-((3aS,4R,6R,6aR)-2,2-dimethyl-6-((3-(((2-(naphthalen-2- yl)ethyl)amino)methyl)azetidin-1-yl)methyl)tetrahydro-4H-cyc lopenta[d][1,3]dioxol-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-4-amine tert-butyl 3-((2-(naphthalen-2-yl)acetamido)methyl)azetidine-1-carboxyl ate (123): phthalen-2-yl)acetamide (300 mg, 1.61 mmol), tert-butyl 3- (aminomethyl)azetidine-1-carboxylate (300 mg, 1.61 mmol), HATU (735 mg, 1.94 mmol), TEA (325 mg, 3.22 mmol) in DMF (10 mL) was stirred at room temperature for 16 hrs under nitrogen atmosphere. The reaction mixture was diluted with EA (100 mL), washed with H2O (50 mL x3) and dried over Na 2 SO 4. The solution was concentrated and the crude was purified by flash (A: H 2 O; B: MeCN) to give 123 (495 mg, yield: 87%) as a white solid. MS Calcd.: 354.1; MS Found: 355.0 [M+H + ]. tert-butyl 3-(((2-(naphthalen-2-yl)ethyl)amino)methyl)azetidine-1-carbo xylate (124): 25 mg, 1.2 mmol) in DCM (14 mL) was added DIBAL-H (6 mL, 6.0 mmol, 1M in THF) at -78 o C, and the solution was stirred at room temperature for 16 hrs. The reaction was quenched with 10 mL of aq.NaHCO 3 . The resulting solid was filtered. The filtrate was concentrated and the crude was purified by flash (A: H 2 O, 0.1% TFA; B: MeCN) to give 124 (134 mg, yield: 33%) as a clear oil. MS Calcd.: 340.2; MS Found: 341.0 [M+H + ]. tert-butyl 3-((2,2,2-trifluoro-N-(2-(naphthalen-2-yl)ethyl)acetamido)me thyl)azetidine-1- carboxylate (125): 34 mg, 0.394 mmol), TEA (119 mg, 1.182 mmol) in DCM (10 mL) was added TFAA (124 mg, 0.591 mmol) and the solution was stirred at room temperature for 1 hr. The resulting mixture was concentrated and the crude was purified by flash (A: H 2 O, 0.1% TFA; B: MeCN) to give 125 (78 mg, yield: 45%) as a clear oil. MS Calcd.: 436.2; MS Found: 437.0 [M+H + ]. N-(azetidin-3-ylmethyl)-2,2,2-trifluoro-N-(2-(naphthalen-2-y l)ethyl)acetamide (126): 78 mg, 0.179 mmol) in DCM (1.5 mL) was added TFA (1.5 mL), and the solution was stirred at room temperature for 1 hr. The mixture was concentrated to give 126 (80 mg, crude) as a clear oil. MS Calcd.: 336.1; MS Found: 337.0 [M+H + ]. N-((1-(((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-2,2-dimethyltetrahydro- 4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)azetidin-3-yl)methyl )-2,2,2-trifluoro-N-(2-(naphthalen-2- yl)ethyl)acetamide (127): mmol) and (3aR,4S,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxole-4-carbaldehyde (90 mg, 0.28 mmol) in MeOH (15 mL) was stirred at room temperature for 30 min. NaBH 3 CN (88 mg, 0.54 mmol) and AcOH (1 drop) was added. The solution was stirred at room temperature for 16 hrs. The reaction mixture was purified by flash (A: H 2 O; B: MeCN) after low temperature decompression and concentration to give 127 (104 mg, yield: 90%) as a clear oil. MS Calcd.: 641.2; MS Found: 642.0 [M+H + ]. 7-((3aS,4R,6R,6aR)-2,2-dimethyl-6-((3-(((2-(naphthalen-2-yl) ethyl)amino)methyl)azetidin-1- yl)methyl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)-N-met hyl-7H-pyrrolo[2,3-d]pyrimidin-4- amine (128): mmol) in MeNH 2 (6 mL) was stirred at 60 0 C for 30 min. The resulting mixture was diluted with EA (50 mL), washed with H 2 O (20 mL x2). The organic phase was dried over Na 2 SO 4 and concentrated to give 128 (71 mg, yield: 81%) as a clear oil. MS Calcd.: 540.3; MS Found: 541.1 [M+H + ]. Synthesis of tert-butyl (7-((3aS,4R,6R,6aR)-6-(((3-((tert- butoxycarbonyl)(phenethyl)amino)propyl)(2,2,2-trifluoroethyl )amino)methyl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)-7H-pyrr olo[2,3-d]pyrimidin-4- yl)(methyl)carbamate tert-butyl (7-((3aS,4R,6R,6aR)-2,2-dimethyl-6-(((2,2,2-trifluoroethyl)a mino)methyl)tetrahydro- 4H-cyclopenta[d][1,3]dioxol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin -4-yl)(methyl)carbamate (129): phere, tert-butyl (7-((3aS,4R,6R,6aR)-6-(aminomethyl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)-7H-pyrr olo[2,3-d]pyrimidin-4-yl)(methyl) carbamate (0.103 g, 0.25 mmol, 1.0 equiv.) was dissolved in 2 ml dry THF. Then, triethylamine (67 μl, 0.049 g, mmol, 1.9 equiv.) was added, followed by addition of 2,2,2-trifluoroethyl trifluoromethanesulfonate (69 μl, 0.11 g, 0.48 mmol, 1.9 equiv.). The reaction was then stirred overnight at room temperature. After 17.5 h, the solvent was evaporated and water was added. The mixture was extracted with DCM (3x), dried over Na 2 SO 4 and after filtration and evaporation the residue was purified by flash chromatography eluting Cyclohexane/EtOAc (5% to 57%) to afford the product as a white foam (yield: 0.082 g, 0.16 mmol, 66%). 1 H NMR (400 MHz, DMSO- d 6 ) δ 8.63 (s, 1H, H2), 7.75 (d, J = 3.7 Hz, 1H, H8), 6.45 (d, J = 3.7 Hz, 1H, H7), 5.09 (dt, J = 12.7, 6.4 Hz, 1H, H1´), 4.94-4.88 (m, , 1H, H2´), 4.50 (dd, J = 7.3, 4.9 Hz, 1H, H3´), 3.35 (s, 3H, -NH-CH 3 ), 3.27 (qd, J = 10.3, 6.7 Hz, 2H), 2.86-2.77 (m, 1H, H5´A), 2.76-2.69 (m, 1H, H5´ B ), 2.49 – 2.39 (m, 1H, -NH- ), 2.35-2.18 (m, 2H, H4´, H6´ A ), 2.07-1.96 (m, 1H, H6´ B ), 1.49 (s, 3H, CH 3 , acetonide), 1.45 (s, 9H, t- Bu, Boc), 1.20 (s, 3H, CH 3, acetonide). C 23 H 32 F 3 N 5 O 4 (499.54 g/mol). APCI: calcd. For C 23 H 32 F 3 N 5 O 4 [M+H] + : 499.24, found: 499.7/399.7. Preparation of tert-butyl 2-(3-((tert-butoxycarbonyl)(3-phenoxyphenethyl)amino)propyl) -2- (((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyrrolo [2,3-d]pyrimidin-7-yl)tetrahydro- 4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)-1-methylhydrazine-1 -carboxylate tert-butyl 1-(3-((tert-butoxycarbonyl)(3-phenoxyphenethyl)amino)propyl) -2-methylhydrazine-1- carboxylate (130) t-butyl (3-oxopropyl)(3-phenoxyphenethyl)carbamate (200 mg, 0.54 mmol) and tert-butyl 1-methylhydrazinecarboxylate (157 mg, 1.08 mmol) in MeOH (3 mL) was stirred at room temperature for 1 hr. Then NaBH 3 CN (170 mg, 2.7 mmol) was added. The resulting mixture was stirred for additional 1 hr and purified by flash chromatography (50% EA in PE) to give compound 130 (100 mg, yield: 37%) as a yellow solid. MS Calc.: 499.3; MS Found: 500.3 [M+H] + . (3aR,4S,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyrrolo[2 ,3-d]pyrimidin-7-yl)tetrahydro- 4H-cyclopenta[d][1,3]dioxole-4-carbaldehyde (131) of ((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyrrolo[ 2,3-d]pyrimidin- 7-yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methanol (100 mg, 0.23 mmol) in DCM (10 mL) was added Dess-Martin periodinane (134 mg, 0.34 mmol) and the solution was stirred at room temperature for 4 hrs. The reaction solution was diluted with DCM (20 mL). The organic phase was washed with H 2 O (20 mL), aq. NaSO 3 ( 0 ), aq. Na CO 3 (20 ml) and dried over Na 2 SO 4 . The solution was concentrated to give 131 (100 mg, crude) as a brown oil. tert-butyl 2-(3-((tert-butoxycarbonyl)(3-phenoxyphenethyl)amino)propyl) -2-(((3aR,4R,6R,6aS)- 2,2-dimethyl-6-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7 -yl)tetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methyl)-1-methylhydrazine-1-ca rboxylate (132) , 0.2 mmol) and 131 (63.5 mg, 0.2 mmol) in MeOH (3 mL) was stirred at room temperature for 1 hr. Then NaBH 3 CN (120 mg, 2.0 mmol) was added. The resulting mixture was stirred for additional 1 h and purified by prep-HPLC (TFA buffer) to give compound 132 (40 mg, yield: 25%) as a white solid. Synthesis of tert-butyl (3-((((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyr rolo[2,3- d]pyrimidin-7-yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl )methyl)(ethyl)amino)propyl)(2- (naphthalen-2-yl)ethyl)carbamate tert-butyl (3-((((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyr rolo[2,3-d]pyrimidin-7- yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)amino) propyl)(2-(naphthalen-2- yl)ethyl)carbamate (133) mmol) and HOAc (0.1 mL)in MeOH (2 mL) was added compound N1-(2-(naphthalen-2-yl)ethyl)propane-1,3-diamine (65 mg, 0.2 mmol)), and the mixture was stirred at room temperature for 0.1 h. Then NaBH 3 CN (99 mg, 1.6 mmol) was added and the mixture was stirred at room temperature for 1 hr. The mixture was used for next step. MS Calc.: 628.4; MS Found: 629.2 [M+H] + tert-butyl (3-((((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyr rolo[2,3-d]pyrimidin-7- yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)(ethyl )amino)propyl)(2-(naphthalen-2- yl)ethyl)carbamate (134) added acetaldehyde (0.2 mL), and the mixture was stirred at room temperature for 2 hrs. The compound was found by LC-MS. The reaction was quenched with water (0.5 mL). The solution was concentrated to dryness and the residue was purified by prep-HPLC (NH 4 OAc buffer) to give compound 134 (30 mg, two-step yield: 28.5%) as an off- white solid. MS Calc.:656.4; MS Found: 657.4 [M+H] + . Synthesis of (3aS,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrah ydrofuro[3,4- d][1,3]dioxole-4-carboxylic acid (3aS,4S,6R,6aR)-6-(6-amino-9H-pu 9 y) , d et ytetrahydrofuro[3,4-d][1,3]dioxole-4- (0.21 g, 1.35 mmol) were added to a 100 mL flask. Then, this solid mixture was dissolved in a 1:1 mixture of MeCN/H 2 O (33.80 mL) and stirred magnetically at rt for 4 h. During this time a precipitate was formed which was filtered off. The filter cake was rinsed with additional MeCN and dried to complete dryness which afforded the pure product as white solid (1.85 g, 85%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.82 (s, 1H, COOH), 8.25 (s, 1H, H2), 8.09 (s, 1H, H8), 7.30 (s, 2H, N6-NH 2 ), 6.34 (s, 1H, H1´), 5.55 (dd, J = 6.0, 2.0 Hz, 1H, H3´), 5.47 (d, J = 6.0 Hz, 1H, H2´), 4.70 (d, J = 1.9 Hz, 1H, H4´), 1.53 (s, 3H, CH 3 , acetonide), 1.36 (s, 3H, CH 3 , acetonide). Synthesis of (3aR,4S,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl) -2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carboxylic acid (3aR,4S,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl) -2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxole-4-carboxylic acid (136): f ((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methanol (2.85 g, 8.8 mmol) in DCM (130 mL) was added Dess-Martin periodinane (9.7 g, 23 mmol) at 0 °C under N 2 . The mixture was stirred at room temperature for 24 h. The reaction was quenched with saturated NaHCO 3 solution (65 mL) and stirred for around 15 min. The organic layer was separated, dried over Na 2 SO 4 and concentrated in vacuum to afford a crude product, which was purified by reverse phase flash (MeCN/H 2 O)(330mg,11% yield) to afford compound 136 as a white solid. MS Calc.: 337.1; MS Found: 338.3 [M+H] + . (3aR,4S,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyrrolo[2 ,3-d]pyrimidin-7-yl)tetrahydro- 4H-cyclopenta[d][1,3]dioxole-4-carboxylic acid (137): of compound 136 (330 mg, 1.0 mmol) in MeOH (5 mL) was added CH 3 NH 2 /C 2 H 5 OH (5 mL), the reaction mixture was stirred at r. t. for 0.5 hr, followed by concentration. The residue was acidified with HCl (6M) and purified by reverse phase flash (MeCN/H 2 O) to afford compound 137 (200 mg, 68% yield) as a white solid. MS Calc.: 292.1; MS Found: 293.1 [M+H] + ..

In an oven-dried three-necked round bottom flask 2',3'-O-lsopropylideneadenosine (4.00 g, 12.89 mmol) was suspended in hexamethyldisilazane (5.47 mL, 25.77 mmol) under nitrogen, Then, DMAP (0.40 g, 3.22 mmol) was added followed by addition of TMSOTf (0.05 mL, 0.26 mmol) at rt. The suspension was heated to 75 °C and stirred for 2 h at this temperature. Afterwards, the mixture was concentrated to complete dryness. The obtained residue was dissolved in dry THF (43.00 mL) and cooled down in an ice-bath. To this cooled solution di-t- butyl decarbonate (8.36 mL, 38.66 mmol) was added portion wise. The mixture was stirred overnight at ambient temperature. The solution was concentrated under reduced pressure. The obtained residue was re-dissolved in EtOH (43.00 mL) and then treated with a 33% MeNH 2 solution in EtOH (5.28 mL, 4.00 eq). The solution was heated to 50 °C and stirred for 48 h at this temperature. Then, the reaction mixture was concentrated under reduced pressure. The residue was diluted with water and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate and concentrated to an oil. The crude product was purified over silica (cyclohexane/EtOAc; 0-100%) to afford a colorless foam (3.88 g, 74%). Analytical data according to literature data.

To a stirred solution of compound 138 (1.75 g, 4.30 mmol) in CH 2 CI 2 (21.50 mL) triethylamine (0.90 mL, 6.44 mmol) and MsCI (0.40 mL, 5.15 mmol) were added at 0 °C under nitrogen atmosphere. After 30 min stirring at rt, the solution was diluted with brine. The organic layer was separated, and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate, filtered, and concentrated to complete dryness. The crude product was redissolved in DMF and sodium azide (0.85 g, 12.87 mmol) was added. The suspension was heated to 60 °C and stirred for 5 h. Then, the organic solvent was evaporated. Water was added to the obtained residue and the aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The crude product was purified by flash chromatography (cyclohexane/EtOAc; 0-80%) to afford the product as colorless foam (1.27 g, 69%). Analytical data according to literature data.

Compound 139 (125 g, 2.86 mmol) was dissolved in a mixture of EtOH and MeOH (2:1, 38.60 mL). The solution was degassed and stirred at rt under nitrogen. Then, palladium on activated charcoal moistened with water (0.61 g, 0.29 mmol) was added and the mixture was again degassed. Afterwards, the reaction mixture was purged with H2 from a storage vessel and stirred overnight at ambient temperature. Then the suspension was purged with nitrogen and filtered off over Celite. The filter cake was rinsed with EtOH and CH 2 CI 2 .The filtrate was concentrated under reduced pressure and the obtained residue was purified over silica () which afforded the product as colorless foam (0.90 g, 85%). Analytical data according to literature data.

In a heat-dried three-necked round bottom flask was added the nucleobase (2.89 g, 10.34 mmol) in dry MeCN (51.70 mL) under nitrogen. Then, BSA (2.81 mL, 11.38 mmol) was added to the stirred suspension. The suspension was stirred for 10 minutes. During this time the reaction became a homogenous solution. Then, the sugar (5.80 g, 11.38 mmol) was added, and the reaction mixture was heated to 85 °C for 2 h. After this the reaction was cooled down to rt before diluted with EtOAc (100 mL). The organic phase was washed with saturated bicarbonate solution (1x100 mL) and with brine (1x100 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified over silica (cyclohexane/EtOAc; 0-40%) to afford the product as yellowish foam. (5.24 g, 64%). 1 H NMR (400 MHz, DMSO-of) 58.60 (s, 1H, H2), 8.30 (s, 1H, H5), 8.01 - 7.83 (m, 6H, o-Ar, Bz), 7.71 - 7.60 (m, 3H, -Ar, Bz), 7.55 - 7.40 (m, 6H, /77-Ar, Bz), 6.71 (d, J = 5.0 Hz, 1H, H1'), 6.29 (dd, J = 6.1, 5.1 Hz, 1H, H2'), 6.14 (t, J= 5.8 Hz, 1H, H3'), 4.87 (q, J = 5.0 Hz, 1H, H4'), 4.83 - 4.64 (m, 2H, H5').

The nucleoside 141 (7.08 g, 9.68 mmol) was dissolved in 1,4-dioxane (96.90 mL) and 33%

MeNH 2 solution in EtOH (96.90 mL) in a sealed flask under nitrogen. The solution was heated to 60 °C overnight. Then, the reaction was allowed to cool down to rt before concentrated under reduced pressure. The obtained oil was purified by flash chromatography (CH^l MeOH; 0-20%) which afford the product as slightly yellowish foam (3.02 g, 77%). 1 H NMR (400 MHz, DMSO-c/ 6 ) 8 8.19 (s, 1H, H2), 7.66 (s, 1H, H6), 6.44 (q, 7 = 4.6 Hz, 1H, NH), 6.03 (d, 7 = 6.3 Hz, 1H, H1'), 5.31 (d, 7 = 6.5 Hz, 1H, 2'OH), 5.16 (t, 7 = 5.6 Hz, 1H, 5'OH), 5.12 (d, 7 = 4.8 Hz, 1H, 3'OH), 4.38 - 4.32 (m, 1H, H2'), 4.06 (td, 7 = 4.8, 3.2 Hz, 1H, H3'), 3.88 (q, 7 = 3.7 Hz, 1H, H4'), 3.57 (m, 2H, H5'), 3.02 (d, 7 = 4.7 Hz, 3H, CH 3 , NMe).

Compound 142 (3.00 g, 7.31 mmol) was dissolved in dry DMF (36.60 mL) under nitrogen. Then, Et 3 N (2.05 mL, 14.62 mmol) was added under nitrogen before palladium on activated charcoal moistened with water (1.56 g, 0.73 mmol) was added. The reaction mixture was purged with hydrogen from a storage vessel and was magnetically stirred overnight. At this point TLC (CH 2 CI 2 /MeOH; 10%) indicated full conversion of the starting. Then, the reaction mixture was purged with nitrogen followed by filtration over Celite. The filter cake was rinsed with EtOH and the filtrate was concentrated over vacuum. The dehalogenated compound (2.05 g, 7.24 mmol) was suspended in acetone (36.60 mL). To the stirred suspension triethoxymethane (6.09 mL, 36.19 mmol) and p-TsOH (6.95 g, 36.19 mmol) were added sequentially at rt. The suspension became a clear yellow solution and was stirred overnight at rt. Then, the mixture was quenched by 5% aqueous sodium bicarbonate solution. The organic solvent was removed under reduced pressure. The aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated over vacuum. The obtained residue was purified by flash chromatography (CH 2 CI 2 /MeOH; 0-5%) which afforded the product as a colorless foam (2.24 g, 97%). 1 H NMR (400 MHz, DMSO-t/ 6 ) <58.16 (s, 1H, H2), 7.61 - 7.54 (m, 1H, NH), 7.35 (d, 7 = 3.6 Hz, 1H, H6), 6.60 (d, 7 = 3.5 Hz, 1H, H5), 6.16 (d, 7 = 3.6 Hz, 1H, H1'), 5.23 (t, 7 = 5.6 Hz, 1H, 5'OH), 5.15 (dd, 7 = 6.2, 3.7 Hz, 1H, H2'), 4.90 (dd, 7 = 6.3, 2.8 Hz, 1H, H3'), 4.15 - 4.09 (m, 1H, H4'), 3.60 - 3.48 (m, 7 = 5.2 Hz, 2H, H5'), 2.95 (d, 7 = 4.5 Hz, 3H, CH 3 , NMe), 1.54 (s, 3H, CH 3 , acetonide), 1.31 (s, 3H, CH 3 , acetonide).

Compound 143 (2.23 g, 6.88 mmol) was dissolved in dry 1,4-dioxane (34.40 mL) and then cooled down in an ice-bath. Afterwards, DPPA (2.99 mL, 13.75 mmol) and DBU (3.11 mL, 20.63 mmol) were added to the cooled solution and stirred for 24 h at rt. Then, 15-crown-5 (1.44 mL, 6.88 mmol) and NaN 3 (2.26 g, 34.38 mmol) were added, and the suspension was heated to 110 °C. After 6 h, the reaction mixture was allowe to cool down to rt and then the organic solvent was evaporated. The obtained oil was diluted with water and the aqueous phase was extracted three times with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified over silica (cyclohexane/EtOAc; 0-100%) to obtain the desired product as colorless foam (1.06 g, 45%). 1 H NMR (400 MHz, DMSO-t/ 6 ) <58.18 (s, 1H, H2), 7.58 (q, 7 = 4.0 Hz, 1H, NH), 7.34 (d, 7 = 3.7 Hz, 1H, H6), 6.62 (d, 7 = 3.6 Hz, 1H, H5), 6.23 (d, 7 = 3.2 Hz, 1H, H1'), 5.31 (dd, 7 = 6.4, 3.2 Hz, 1H, H2'), 4.93 (dd, 7 = 6.4, 3.4 Hz, 1H, H3'), 4.21 (td, 7 = 5.6, 3.4 Hz, 1H, H4'), 3.57 - 3.54 (m, 2H, H5'), 2.95 (d, 7 = 4.6 Hz, 3H, CH 3 , NMe), 1.54 (s, 3H, CH 3 , acetonide), 1.32 (s, 3H, CH 3 , acetonide).

Compound 144 (1.04 g, 2.99 mmol) was dissolved in dry THE (13.00 mL). The solution was cooled down before NaH (60% in mineral oil, 1.79 g, 44.81 mmol) was added portion wise. The suspension was stirred for 45 min at rt before cooling down to 0 °C. To the cooled suspension, di-tert butyl dicarbonate (4.16 mL, 17.92 mmol) was added dropwise. After 3 days TLC (CH 2 CI 2 /MeOH; 5%) indicated poor conversion. At this point dry DMF (3.00 mL) was added, and the mixture was stirred for 6 h at rt. TLC (CH 2 CI 2 /MeOH; 5%) indicated almost full conversion. Then, the reaction mixture was cooled down in an ice-bath and then carefully quenched with dropwise addition of water. The aqueous phase was extracted with CH2CI2. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified over silica (cyclohexane/EtOAc; 0-100%) which afforded the product as colorless foam (0.82 g, 62%). 1 H NMR (400 MHz, DMSO-c/ 6 ) <58.67 (s, 1H, H2), 7.76 (d, 7 = 3.8 Hz, 1H, H6), 6.50 (d, 7 = 3.8 Hz, 1H, H5), 6.37 (d, 7 = 3.2 Hz, 1H, H1'), 5.36 (dd, 7 = 6.4, 3.2 Hz, 1H, H2'), 4.97 (dd, 7 = 6.4, 3.4 Hz, 1H, H3'), 4.30 - 4.24 (m, 1H, H4'), 3.63 - 3.51 (m, 2H, H5'), 3.36 (s, 3H, CH 3 . N-Me), 1.56 (s, 3H, CH 3 , acetonide), 1.44 (s, 9H, CH 3 , Abutyl), 1.33 (s, 3H, CH 3 , acetonide). tert-butyl (7-((3aR,4R,6R,6aR)-6-(aminomethyl)-2,2-dimethyltetrahydrofu ro[3,4-d][1,3]dioxol-4- yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)carbamate (146):

The azide 145 (0.81 g, 1.81 mmol) was dissolved in a 4:1 EtOH/MeOH mixture (18.00 mL) under nitrogen. Then, palladium on activated charcoal moistened with water (0.38 g, 0.18 mmol) was added at rt. Then, the mixture was purged with H 2 from a storage vessel and stirred overnight at rt. TLC (CH 2 CI 2 /MeOH; 5%) monitored full consumption of the SM. Then, the mixture was purged with nitrogen and filtered over Celite. The filter cake was rinsed with EtOH and the filtrate was concentrated under reduced pressure. The crude product was purified over silica (CH 2 CI 2 /MeOH; 0-5%) which afforded the product as colorless foam (0.47 g, 63%). 1 H NMR (400 MHz, DMSO-<7 6 ) <58.66 (s, 1H, H2), 7.78 (d, 7= 3.8 Hz, 1H, H6), 6.48 (d, 7 = 3.7 Hz, 1H, H5), 6.29 (d, 7 = 3.7 Hz, 1H, H1'), 5.29 (dd, 7 = 6.4, 3.7 Hz, 1H, H2'), 4.96 (dd, 7 = 6.4, 3.1 Hz, 1H, H3'), 4.09 - 4.03 (m, 1H, H4'), 3.37 (s, 3H, CH 3 , N-Me), 2.73 (dd, 7 = 5.6, 3.9 Hz, 2H, H5'), 1.56 (s, 3H, CH 3 , acetonide), 1.45 (s, 9H, CH 3 , f-butyl), 1.33 (s, 3H, CH 3 , acetonide).

Preparation oftert-butyl(7-((3aS,4R,6R,6aR)-6-(aminomethyl)-2,2-dimethyl tetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)(methyl)carbamate

(1R,2S,3R,5R)-3-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-5-(hydroxymethyl)cyclopentane-1,2- diol (147): ci

The 3-amino-5-(hydroxymethyl)cyclopentane-1,2-diol (5.00 g, 26.96 mmol) was dissolved in EtOH (234.40 mL). To this solution, 4,6-dichloropyrimidin-5-acetaldehyde (5.15 g, 26.96 mmol) and triethylamine (12.52 mL, 53.91 mmol) were added at ambient temperature. The reaction mixture was heated to 90 °C and stirred magnetically overnight. After 18 h, the volatiles were evaporated under reduces pressure and the obtained residue was purified over silica (CH 2 CI 2 /MeOH; 0-10%) which afforded the product as yellowish solid (6.96 g, 91%). 1 H NMR (400 MHz, DMSO-<7 6 ) < 8.63 (s, 1H, H2), 7.91 (d, 7 = 3.7 Hz, 1H, H6), 6.70 (d, 7 = 3.6 Hz, 1H, H5), 5.05 (dt, 7 = 10.4, 8.6 Hz, 1H, H1'), 4.87 (d, 7= 6.7 Hz, 1H, 2'OH), 4.76 (t, 7 = 5.2 Hz, 1H, 5'OH), 4.70 (d, 7 = 4.2 Hz, 1H, 3'OH), 4.24 (ddd, 7 = 9.2, 6.6, 5.3 Hz, 1H, H2'), 3.84 (dq, 7= 4.9, 3.0 Hz, 1H, H3'), 3.55 - 3.43 (m, 2H, CH 2 , H5'), 2.23 (dt, 7 = 12.8, 8.7 Hz, 1H, CH 2 , cyclopentane), 2.11 - 2.01 (m, 1H, H4'), 1.61 (ddd, 7 = 12.9, 10.5, 7.9 Hz, 1H, CH 2 , cyclopentane).

((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methanol (148): ci

To a suspension of compound 147 (4.21 g, 14.67 mmol) in acetone (391.30 mL), triethoxymethane (12.33 mL, 73.37 mmol) and pTsOH (14.10 g, 73.37 mmol) were added. The suspension became a clear solution and was stirred at ambient temperature for 20 h. Then, the reaction mixture was quenched with 5% aqueous sodium bicarbonate solution. The organic solvent was removed under reduced pressure. The aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The obtained residue was purified over silica (CH 2 CI 2 /MeOH; 0-5%) to afford the product as yellowish foam (4.90 g, 62%). 1 H NMR (400 MHz, DMSO-t/ 6 ) <58.66 (s, 1H, H2), 7.97 (d, 7 = 3.7 Hz, 1H, H6), 6.73 (d, 7 = 3.7 Hz, 1H, H5), 5.10 (dt, 7 = 13.0, 6.5 Hz, 1H, H1'), 4.92 (t, 7 = 6.8 Hz, 1H, H2'), 4.82 (t, 7 = 5.3 Hz, 1H, 5'OH), 4.55 (dd, 7 = 7.2, 4.3 Hz, 1H, H3'), 3.53 (td, 7 = 5.4, 1.3 Hz, 2H, CH 2 , H5'), 2.31 - 2.20 (m, 1H, H4', CH 2 , cyclopentane), 2.14 - 2.09 (m, 1H, CH 2 , cyclopentane), 1.49 (s, 3H, CH 3 , acetonide), 1.23 (s, 3H, CH 3 , acetonide). ((3aR,4R,6R,6aS)-2,2-dimethyl-6 ( ( et ya o) 7 pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydro- 4H-cyclopenta[d][1,3]dioxol-4-yl)methanol (149): 8 (2.93 g, 8.96 mmol) was dissolved in n-BuOH (22.40 mL). Then, a 33% MeNH 2 solution in EtOH (22.40 mL) was added. The mixture was stirred under microwave irradiation at 120 °C (100 W, 100 psi) for 25 min The volatiles were removed in vacuo and the resulting residue was purified over silica (CH 2 Cl 2 /MeOH; 0-10%) to afford the product as greyish foam (2.25 g, 79%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.14 (s, 1H, H2), 7.46 (q, J = 4.3 Hz, 1H, NH), 7.30 (d, J = 3.5 Hz, 1H, H6), 6.56 (d, J = 3.5 Hz, 1H, H5), 4.93 (dt, J = 11.7, 6.3 Hz, 1H, H1´), 4.90 – 4.85 (m, 1H, H2´), 4.77 (t, J = 5.4 Hz, 1H, 5´OH), 4.52 (dd, J = 7.0, 4.5 Hz, 1H, H3´), 3.50 (td, J = 5.4, 2.0 Hz, 2H, CH 2 , H5´), 2.96 (d, J = 4.7 Hz, 3H, CH 3 , NMe), 2.23 – 2.13 (m, 2H, H4´, CH 2 , cyclopentane), 2.08 – 1.99 (m, 1H, CH 2 , cyclopentane), 1.47 (s, 3H, CH 3 , acetonide), 1.22 (s, 3H, CH 3 , acetonide). 7-((3aS,4R,6R,6aR)-6-(azidomethyl)-2,2-dimethyltetrahydro-4H -cyclopenta[d][1,3]dioxol-4-yl)- N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (150): 1.30 g, 4.04 mmol) was dissolved in dry 1,4 dioxane (16.20 mL). The solution was cooled down to 0 °C. Then, DPPA (1.76 mL, 8.09 mmol) and DBU (1.83 mL, 12.13 mmol) were added to the cooled solution. The reaction mixture was stirred magnetically overnight at rt. TLC monitored full consumption of the SM. Then, NaN 3 (1.33 g, 20.21 mmol) and 15-crown-5 (0.84 mL, 4.04 mmol) were added, and the mixture was heated to 110 °C. At this temperature, the mixture was stirred for 6 h. After this time, the mixture was allowed to cool down to rt and the organic solvent was evaporated under vacuum. Afterwards, water was added, and the aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dired over sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified over silica (cyclohexane /EtOAc; 20-80%) afford the product as yellowish foam (0.61 g, 44%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.15 (s, 1H, H2), 7.48 (q, J = 4.5 Hz, 1H, NH), 7.30 (d, J = 3.6 Hz, 1H, H6), 6.57 (d, J = 3.5 Hz, 1H, H5), 4.96 (dt, J = 11.7, 6.3 Hz, 1H, H1´), 4.95 – 4.86 (m, 1H, H2´), 4.52 (dd, J = 7.1, 5.4 Hz, 1H, H3´), 3.58 – 3.45 (m, 2H, CH 2 , H5´), 2.96 (d, J = 4.7 Hz, 3H, CH 3 , NMe), 2.36 – 2.21 (m, 2H, H4´, CH 2 , cyclopentane), 2.12 – 2.01 (m, 1H, CH 2 , cyclopentane), 1.48 (s, 3H, CH 3 , acetonide), 1.23 (s, 3H, CH 3 , acetonide). tert-butyl (7-((3aS,4R,6R,6aR)-6-(azidomethyl)-2,2-dimethyltetrahydro-4 H- cyclopenta[d][1,3]dioxol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)(methyl)carbamate (151):

The azido-nucleoside 150 (0.60 g, 1.73 mmol) was dissolved in dry THF (7.50 mL) and cooled down in an ice-bath. To this cooled solution, NaH (60% in mineral oil, 0.14 g, 3.46 mmol) was added portion wise. The mixture was allowed to warm up rt and stirred for 30 min before the mixture was cooled down again to 0 °C. Then, di-tert-butyl decarbonate (0.40 mL, 1.73 mmol) was added portion wise at 0 °C. The mixture was stirred magnetically at rt for 6 h. TLC indicated slow conversion. At this point, the mixture was cooled down and 8 eq. NaH was added. The reaction mixture was stirred for 30 min at rt before the mixture was again cooled down to 0 °C. Then, 3 eq. di-tert-butyl decarbonate was added and the mixture was stirred for 72 h at rt. At this point, TLC monitored still SM. Therefore, the mixture was cooled down and 5 eq NaH was added and the mixture was stirred at rt for 30 min. Then, the mixture was cooled down again and 2 eq. di-tert-butyl decarbonate were added. The reaction mixture was stirred for further 48 h at ambient temperature. After this time almost all SM was converted. Then, the mixture was cooled down and quenched carefully with water (highly exothermic reaction). Then, the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under vacuum. The crude product was purified by flash chromatography (CH 2 CI 2 /MeOH, 0-10%) to afford the product as greyish foam (0.57 g, 74%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.62 (s, 1H, H2), 7.72 (d, 7 = 3.7 Hz, 1H, H6, 6.45 (d, 7 = 3.7 Hz, 1H, H5), 5.12 (dt, 7 = 12.1, 6.4 Hz, 1H, H1'), 4.92 (dd, 7 = 7.2, 6.2 Hz, 1H, H2'), 4.53 (dd, 7 = 7.3, 5.2 Hz, 1H, H3'), 3.53 (ddt, 7 = 19.4, 12.4, 6.6 Hz, 2H, CH 2 , H5'), 3.34 (s, 3H, CH 3 , NMe), 2.40 - 2.26 (m, 2H, H4', CH 2 , cyclopentane), 2.16 - 2.06 (m, 1H, CH 2 , cyclopentane), 1.49 (s, 3H, CH 3 , acetonide), 1.44 (s, 9H, CH 3 , Abutyl), 1.23 (s, 3H, CH 3 , acetonide).

7-((3aS,4R,6R,6aR)-6-(azidomethyl)-2,2-dimethyltetrahydro -4H-cyclopenta[d][1,3]dioxol-4-yl)- N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (152):

Compound 151 (0.56 g, 1.25 mmol) was dissolved in a mixture of EtOAc/MeOH (4.20 mL, 1:1) under nitrogen atmosphere. Then, the solution was degassed before palladium on activated charcoal moistened with water (0.10 g, 0.13 mmol) was added. The suspension was degassed and purged with H 2 from a storage vessel. The reaction mixture was stirred for 17 h at ambient temperature. Then, the mixture was purged with nitrogen and filtered over celite. The filter cake was rinsed with MeOH and the filtrate was concentrated under reduced pressure. The obtained residue was purified over silica (CH 2 CI 2 /MeOH, 0-20%) for afford the desired product as greyish foam (0.25 g, 48%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.63 (s, 1H, H2), 7.76 (d, 7= 3.7 Hz, 1H, H6), 6.45 (d, 7= 3.7 Hz, 1H, H5), 5.09 (dt, 7 = 12.1, 6.7 Hz, 1H, H1'), 4.91 - 4.86 (m, 1H, H2'), 4.51 (dd, 7 = 7.2, 4.9 Hz, 1H, H3'), 3.35 (s, 3H, CH 3 , NMe), 2.78 - 2.62 (m, 2H, CH 2 , H5'), 2.31 - 2.23 (m, 1H, CH 2 , cyclopentane), 2.19 - 2.08 (m, 1H, H4'), 2.08 - 1.99 (m, 1H, CH 2 , cyclopentane), 1.48 (s, 3H, CH 3 , acetonide), 1.45 (s, 9H, CH 3 , f-butyl), 1.23 (s, 3H, CH 3 , acetonide).

Preparation of tert-butyl (7-((3aR,4R, 6R, 6aR)-6-(aminomethyl)-2,2-dimethyltetrahydrofuro[3,4- d][1,3]dioxol-4-yl)-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl )(methyl)carbamate

(2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(4-chloro-5-methyl -7H-pyirolo[2,3-d]pyrimidin-7- yl)tetrahydrofuran-3,4-diyl dibenzoate (153):

In a heat-dried three-necked round bottom flask was added 4-chloro-5-methyl-7/7-pyrrolo[2,3- d\ pyrimidine (2.32 g, 13.85 mmol) in dry MeCN (69.20 mL) under nitrogen. Then, BSA (3.76 mL, 15.23 mmol) was added to the stirred suspension. The suspension was stirred for 10 minutes. During this time the reaction became a homogenous solution. Then, the 1-O-Acetyl-2,3,5-tri-O- benzoyl-p-D-ribofuranose (7.76 g, 15.23 mmol) was added and the reaction mixture was heated to 85 °C for 5 h. After this the reaction was cooled down to rt before diluted with EtOAc (100 mL). The organic phase was washed with saturated bicarbonate solution (1x100 mL) and with brine (1x100 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified over silica (cyclohexane/EtOAc; 0-40%) to afford the product as yellowish foam. (2.60 g, 31%). 1 H NMR (400 MHz, DMSO-aL) <58.52 (s, 1H, H2), 8.03 - 7.89 (m, 6H, o-Ar, Bz), 7.73 (s, 1H, H6), 7.70 - 7.58 (m, 3H, p-Ar, Bz), 7.57 - 7.45 (m, 6H, /77-Ar, Bz), 6.68 (d, J = 52 Hz, 1H, H1'), 6.29 (t, 7 = 6.0 Hz, 1H, H2'), 6.11 (t, 7 = 5.6 Hz, 1H, H3'), 4.84 (q, 7 = 3.6, 3.0 Hz, 1H, H4'), 4.79 (dd, 7 = 12.0, 3.5 Hz, 1H, H5'), 4.64 (dd, 7 = 12.0, 4.6 Hz, 1H, H6'), 2.34 (s, 3H, CH 3 , Me).

(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(5-methyl-4-(methylamin o)-7H-pyrrolo[2,3-d]pyrimidin-7- yl)tetrahydrofuran-3,4-diol (154):

The nucleoside 153 (4.18 g, 6.76 mmol) was dissolved in 1,4-dioxane (33.80 mL) and 33% MeNH 2 solution in EtOH (33.80 mL) in a sealed flask under nitrogen. The solution was heated to 60 °C overnight. Then, the reaction was allowed to cool down to rt before concentrated under reduced pressure. The obtained oil was purified by flash chromatography (CH 2 CI 2 /MeOH; 0-20%) which afforded the product as slightly yellowish foam (1.69 g, 85%). 1 H NMR (400 MHz, DMSO- d 6 ) <58.11 (s, 1H, H2), 7.08 (s, 1H, H6), 6.56 (q, 7 = 4.2 Hz, 1H, NH), 5.98 (d, 7 = 6.4 Hz, 1H, H1'), 4.35 (t, 7 = 5.7 Hz, 1H, H2'), 4.06 (dd, 7= 5.0, 3.2 Hz, 1H, H3'), 3.86 (q, 7 = 3.7 Hz, 1H, H4'), 3.55 (ddd, 7 = 34.8, 11.7, 3.6 Hz, 1H, H5'), 2.95 (d, 7 = 4.6 Hz, 3H, CH 3 , N-Me), 2.36 (s, 3H, CH 3 , Me).

((3aR,4R,6R,6aR)-2,2-dimethyl-6-(5-methyl-4-(methylamino) -7H-pyrrolo[2,3-d]pyrimidin-7- yl)tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol (155):

Compound 154 (1.68 g, 5.65 mmol) was suspended in acetone (28.30 mL). To the stirred suspension triethoxymethane (4.76 mL, 28.27 mmol) and p-TsOH (5.43 g, 28.27 mmol) were added sequentially at rt. The suspension became a clear yellow solution and was stirred overnight at rt. Then, the mixture was quenched with 5% aqueous sodium bicarbonate solution. The organic solvent was removed under reduced pressure. The aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated over vacuum. The obtained residue was purified by flash chromatography (CH 2 CI 2 /MeOH; 0-5%) which afforded the product as a colorless foam (1.38 g, 73%). 1 H NMR (400 MHz, DMSO-aL) <58.12 (s, 1H, H2), 7.09 (d, 7 = 1.1 Hz, 1H, H6), 6.60 (q, 7 = 4.4 Hz, 1H, NH), 6.13 (d, 7 = 3.7 Hz, 1H, HT), 5.17 (t, 7 = 5.6 Hz, 1H, OH), 5.09 (dd, 7 = 6.3, 3.7 Hz, 1H, H2'), 4.87 (dd, 7 = 6.4, 3.0 Hz, 1H, H3'), 4.07 (td, 7 = 4.7, 3.2 Hz, 1H, H4'), 3.58 - 3.45 (m, 2H, CH 2 , H5'), 2.94 (d, 7= 4.6 Hz, 3H, CH 3 , NMe), 2.35 (d, 7 = 1.0 Hz, 3H, CH 3 ), 1.53 (s, 3H, CH 3 , acetonide), 1.30 (s, 3H, CH 3 , acetonide).

7-((3aR,4R ; 6R,6aR)-6-(azidomethyl)-2,2-dimethyltetrahydrofuro[3,4 -d][1,3]dioxol-4-yl)-N ; 5- dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (156):

Compound 155 (1.37 g, 4.05 mmol) was dissolved in dry 1,4-dioxane (20.30 mL) and then cooled down in an ice-bath. Afterwards, DPPA (1.76 mL, 8.11 mmol) and DBU (1.83 mL, 12.16 mmol) were added to the cooled solution and stirred for 24 h at rt. Then, 15-crown-5 (0.85 mL, 4.05 mmol) and NaN 3 (1.33 g, 20.27 mmol) were added and the suspension was heated to 110 °C. After 7 h, the reaction mixture was allowed to cool down to rt and then the organic solvent was evaporated. The obtained oil was diluted with water and the aqueous phase was extracted three times with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified over silica () to obtain the desired product as colorless foam (0.71 g, 49%). 1 H NMR (400 MHz, DMSO-c/ 6 ) <5 8.15 (s, 1H, H2), 7.12 - 7.07 (m, 1H, H6), 6.62 (q, 7 = 4.3 Hz, 1H, NH), 6.20 (d, 7= 3.2 Hz, 1H, H1'), 5.25 (dd, 7 = 6.4, 3.2 Hz, 1H, H2'), 4.91 (dd, 7 = 6.4, 3.5 Hz, 1H, H3'), 4.22 - 4.15 (m, 1H, H4'), 3.61 - 3.49 (m, 2H, CH 2 , H5'), 2.95 (d, 7 = 4.6 Hz, 3H, CH 3 , NMe), 2.39 - 2.34 (m, 3H, CH 3 ), 1.53 (s, 3H, CH 3 , acetonide), 1.32 (s, 3H, CH 3 , acetonide). tert-butyl (7-((3aR,4R,6R,6aR)-6-(azidomethyl)-2,2-dimethyltetrahydrofu ro[3,4-d][1,3]dioxol-4- yl)-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)carbama te (157):

Compound 156 (0.69 g, 1.91 mmol) was dissolved in dry THF (9.60 mL) under nitrogen atmosphere. To the solution, triethylamine (0.40 mL, 2.89 mmol) and DMAP (0.12 g, 0.96 mmol) were added at rt. Then, the solution was cooled down in an ice-bath before di-tert butyl dicarbonate (0.67 mL, 2.87 mmol) was added portion wise. The reaction mixture was stirred overnight at ambient temperature. TLC (cyclohexane/EtOAc; 60%) indicated almost complete conversion. After 18 h the reaction mixture was diluted with saturated sodium bicarbonate solution and extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified by flash chromatography (cyclohexane/EtOAc; 0-80%) to afford the product as greyish foam (0.66 g, 75%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.69 (s, 1H, 1H, H2), 7.60 - 7.57 (m, 1H, H6), 6.34 (d, 7 = 3.2 Hz, 1H, HT), 5.32 (dd, 7 = 6.4, 3.2 Hz, 1H, H2'), 4.96 (dd, 7 = 6.4, 3.5 Hz, 1H, H3'), 4.26 (dt, 7 = 6.3, 4.5 Hz, 1H, H4'), 3.64 - 3.51 (m, 2H, CH 2 , H5'), 3.26 (s, 3H, CH 3 , NMe), 2.24 (d, 7= 1.0 Hz, 3H, CH 3 ), 1.56 (s, 3H, CH 3 , acetonide), 1.38 (s, 9H, CH 3 , Abutyl), 1.34 (s, 3H, CH 3 , acetonide). tert-butyl (7-((3aR,4R,6R,6aR)-6-(aminomethyl)-2,2-dimethyltetrahydrofu ro[3,4-d][1,3]dioxol-4- yl)-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)carbama te (158):

The azido nucleoside 157 (0.65 g, 1.40 mmol) was dissolved in EtOH (14.00 mL) under nitrogen atmosphere. The solution was degassed and then palladium on activated charcoal moistened with water (0.30 g, 0.14 mmol) was added under nitrogen. The reaction mixture was purged with hydrogen from a storage vessel (1 atm) and stirred at ambient temperature overnight. TLC (CH 2 CI 2 /MeOH; 10%) indicated full conversion. Then, the mixture was purged with nitrogen and filtered over Celite. The filter cake was rinsed with EtOH and CH 2 CI 2 . The filtrated was concentrated under reduced pressure. The obtained residue was purified over silica (CH 2 CI 2 /MeOH; 20%) to afford the product as greyish foam (0.53 g, 87%). 1 H NMR (400 MHz, DMSO-<7 6 ) 58.67 (s, 1H, H2), 7.60 (d, 7 = 1.1 Hz, 1H, H6), 6.27 (d, 7 = 3.7 Hz, 1H, H1'), 5.23 (dd, 7 = 6.5, 3.7 Hz, 1H, H2'), 4.94 (dd, 7 = 6.5, 3.2 Hz, 1H, H3'), 4.04 (td, 7 = 5.6, 3.2 Hz, 1H, H4'), 3.26 (s, 3H, CH 3 , N-Me), 2.72 (dd, 7 = 5.6, 3.9 Hz, 2H H5'), 2.24 (d, 7= 1.1 Hz, 3H, CH 3 , 7'Me), 1.57 (bs, 2H, NH 2 ), 1.55 (s, 3H, CH 3 , acetonide), 1.39 (s, 9H, CH 3 , Abutyl), 1.33 (s, 3H, CH 3 , acetonide).

7-((3aS,4R,6R,6aR)-6-(aminomethyl)-2,2-dimethyltetrahydro -4H-cyclopenta[d][1,3]dioxol-4-yl)- 5-bromo-N-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ami ne

(1R,2S,3R,5R)-3-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-5-(hydroxymethyl)cyclopentane-1,2- diol (159):

The 3-amino-5-(hydroxymethyl)cyclopentane-1,2-diol (5.00 g, 26.96 mmol) was dissolved in EtOH (234.40 mL). To this solution, 4,6-dichloropyrimidin-5-acetaldehyde (5.15 g, 26.96 mmol) and triethylamine (12.52 mL, 53.91 mmol) were added at ambient temperature. The reaction mixture was heated to 90 °C and stirred magnetically overnight. After 18 h, the volatiles were evaporated under reduces pressure and the obtained residue was purified over silica (CH 2 CI 2 /MeOH; 0-10%) which afforded the product as yellowish solid (6.96 g, 91%). 1 H NMR (400 MHz, DMSO-af) <58.63 (s, 1H, H2), 7.91 (d, 7 = 3.7 Hz, 1H, H6), 6.70 (d, 7 = 3.6 Hz, 1H, H5), 5.05 (dt, 7 = 10.4, 8.6 Hz, 1H, H1'), 4.87 (d, 7= 6.7 Hz, 1H, 2'OH), 4.76 (t, 7 = 5.2 Hz, 1H, 5'OH), 4.70 (d, 7 = 4.2 Hz, 1H, 3'OH), 4.24 (ddd, 7 = 9.2, 6.6, 5.3 Hz, 1H, H2'), 3.84 (dq, 7= 4.9, 3.0 Hz, 1H, H3'), 3.55 - 3.43 (m, 2H, CH 2 , H5'), 2.23 (dt, 7 = 12.8, 8.7 Hz, 1H, CH 2 , cyclopentane), 2.11 - 2.01 (m, 1H, H4'), 1.61 (ddd, 7 = 12.9, 10.5, 7.9 Hz, 1H, CH 2 , cyclopentane).

((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methanol (160):

To a suspension of compound 159 (4.21 g, 14.67 mmol) in acetone (391.30 mL), triethoxymethane (12.33 mL, 73.37 mmol) and pTsOH (14.10 g, 73.37 mmol) were added. The suspension became a clear solution and was stirred at ambient temperature for 20 h. Then, the reaction mixture was quenched with 5% aqueous sodium bicarbonate solution. The organic solvent was removed under reduced pressure. The aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The obtained residue was purified over silica (CH 2 CI 2 /MeOH; 0-5%) to afford the product as yellowish foam (4.90 g, 62%). 1 H NMR (400 MHz, DMSO-t/ 6 ) <58.66 (s, 1H, H2), 7.97 (d, 7 = 3.7 Hz, 1H, H6), 6.73 (d, 7 = 3.7 Hz, 1H, H5), 5.10 (dt, 7 = 13.0, 6.5 Hz, 1H, H1'), 4.92 (t, 7 = 6.8 Hz, 1H, H2'), 4.82 (t, 7 = 5.3 Hz, 1H, 5'OH), 4.55 (dd, 7 = 7.2, 4.3 Hz, 1H, H3'), 3.53 (td, 7 = 5.4, 1.3 Hz, 2H, CH 2 , H5'), 2.31 - 2.20 (m, 1H, H4', CH 2 , cyclopentane), 2.14 - 2.09 (m, 1H, CH 2 , cyclopentane), 1.49 (s, 3H, CH 3 , acetonide), 1.23 (s, 3H, CH 3 , acetonide).

7-((3aS,4R,6R,6aR)-6-(((tert-butyldimethylsilyl)oxy)methy l)-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-4-chloro-7H-pyrrolo[2,3-d]pyr imidine (161):

TBSCI (2.15 g, 14.15 mmol) was added to a solution of compound 160 (3.86 g, 11.79 mmol) and imidazole (1.95 g, 28.29 mmol) in CH 2 CI 2 (58.90 mL). The reaction mixture was stirred magnetically at ambient temperature overnight. After 18 h, the mixture was quenched with saturated bicarbonate solution and extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified by FC (cyclohexane/EtOAc; 0-100%) to afford the product as yellowish oil (4.79 g, 93%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.63 (s, 1H, H2), 7.92 (d, 7 = 3.7 Hz, 1H, H6), 6.73 (d, 7 = 3.7 Hz, 1H, H5), 5.12 - 5.04 (m, 1H, H1'), 4.96 - 4.91 (m, 1H, H2'), 4.56 - 4.49 (m, 1H, H3'), 3.76 - 3.63 (m, 2H, CH 2 , H5'), 2.31 - 2.21 (m, 2H, CH 2 , cyclopentane & H4'), 2.21 - 2.12 (m, 1H, CH 2 , cyclopentane), 1.48 (s, 3H, CH 3 , acetonide), 1.21 (s, 3H, CH 3 , acetonide), 0.88 (s, 9H, CH 3 , t- butyl, OTBS), 0.06 - 0.05 (m, 6H, CH 3 , Me, OTBS).

5-bromo-7-((3aS,4R ; 6R,6aR)-6-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-d imethyltetrahydro- 4H-cyclopenta[d][1,3]dioxol-4-yl)-4-chloro-7H-pyrrolo[2,3-d] pyrimidine (162):

A solution of NBS (2.04 g, 11.32 mmol) in DMF (20.00 mL) was added dropwise onto a solution of compound 161 (4.77 g, 10.78 mmol) in DMF (33.90 mL). The reaction mixture was stirred at 35 °C for 30 min. The mixture was allowed to cool down to rt and then water was added. The mixture was extracted with EtOAc. The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. The obtained residue was purified over silica (cyclohexane/EtOAc; 0-100%) to afford the product as yellowish solid (4.67 g, 84%). 1 H NMR (400 MHz, DMSO-aL) 58.67 (s, 1H, H2), 8.21 (s, 1H, H6), 5.10 (dt, 7 = 12.5, 6.3 Hz, 1H, H1'), 4.92 (dd, 7 = 7.1, 5.9 Hz, 1H, H2'), 4.50 (dd, 7 = 7.1, 4.5 Hz, 1H, H3'), 3.74 - 3.62 (m, 2H, CH 2 , H5'), 2.32 - 2.22 (m, 2H, CH 2 , cyclopentane & H4'), 2.18 - 2.07 (m, 1H, CH 2 , cyclopentane), 1.47 (s, 3H, CH 3 , acetonide), 1.21 (s, 3H, CH 3 , acetonide), 0.88 (s, 9H, CH 3 , Abutyl, OTBS), 0.05 (s, 6H, CH 3 , Me, OTBS).

5-bromo-7-((3aS,4R ; 6R,6aR)-6-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-d imethyltetrahydro- 4H-cyclopenta[d][1,3]dioxol-4-yl)-N-(4-methoxybenzyl)-7H-pyr rolo[2,3-d]pyrimidin-4-amine

To a solution of compound 162 (4.65 g, 8.91 mmol) in 1,4-dioxane (44.50 mL), Et 3 N (1.88 mL, 13.36 mmol) was added. Then, 4-methoxybenzylamine (1.41 mL, 10.69 mmol) was added portion wise and the resulted mixture was stirred at 80 °C over 2 d. The mixture was allowed to cool down to rt. Then, the organic solvent was evaporated in vacuo. To the obtained residue saturated bicarbonate solution was added and then extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated in vacuo. The crude product was purified by FC (cyclohexane/EtOAc; 0-50%) to afford the desired product as yellowish solid (4.32 g, 79%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.15 (s, 1H, H2), 7.61 (s, 1H, H6), 7.31 - 7.25 (m, 2H, o-benzyl), 6.98 (t, 7 = 6.1 Hz, 1H, NH), 6.90 - 6.83 (m, 2H, /77-benzyl), 4.96 (dt, 7 = 11.6, 6.2 Hz, 1H, H1'), 4.88 (dd, 7 = 7.1, 5.9 Hz, 1H, H2'), 4.69 (d, 7 = 6.1 Hz, 2H, CH 2 , PMB), 4.47 (dd, 7 = 7.0, 4.6 Hz, 1H, H3'), 3.71 (s, 3H, CH 3 , OMe), 3.70 - 3.60 (m, 2H, CH 2 , H5'), 2.29 - 2.14 (m, 2H, CH 2 , cyclopentane & H4'), 2.10 - 2.01 (m, 1H, CH 2 , cyclopentane), 1.45 (s, 3H, CH 3 , acetonide), 1.20 (s, 3H, CH 3 , acetonide), 0.87 (s, 9H, CH 3 , f-butyl, OTBS), 0.05 (s, 6H, CH 3 , Me, OTBS).

((3aR,4R,6R,6aS)-6-(5-bromo-4-((4-methoxybenzyl)amino)-7H -pyirolo[2,3-d]pyrimidin-7-yl)- 2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)meth anol (164):

Compound 163 (2.35 g, 3.77 mmol) was dissolved in dry THF (18.80 mL). Then, a 1 M TBAF (1.42 mL, 5.65 mmol) solution in THF (4.23 mL) was added dropwise. The reaction mixture was stirred at ambient temperature for 4 h. Then, the mixture was diluted with water and extracted with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The crude product was purified over silica (cyclohexane/EtOAc; 0-100%) to afford the product as yellowish foam (1.50 g, 79%). 1 H NMR (400 MHz, DMSO-t/ 6 ) <58.17 (s, 1H, H2), 7.65 (s, 1H, H6), 7.31 - 7.26 (m, 2H, obenzyl), 6.97 (t, 7 = 6.0 Hz, 1H, NH), 6.90 - 6.84 (m, 2H- /77-benzyl), 4.96 (dt, 7 = 12.6, 6.4 Hz, 1H, H1'), 4.85 (t, 7 = 6.7 Hz, 1H, H2'), 4.76 (t, 7 = 5.3 Hz, 1H, 5'OH), 4.69 (d, 7 = 6.1 Hz, 2H, CH 2 , PMB), 4.49 (dd, 7 = 7.2, 4.4 Hz, 1H, H3'), 3.71 (s, 3H, CH 3 . OMe), 3.52 - 3.45 (m, 2H, CH 2 , H5'), 2.22 - 2.13 (m, CH 2 , cyclopentane & H4'), 2.02 - 1.96 (m, 1H, CH 2 , cyclopentane), 1.45 (s, 3H, CH 3 , acetonide), 1.21 (s, 3H, CH 3 , acetonide).

2-(((3aR / 4R,6R,6aS)-6-(5-bromo-4-((4-methoxybenzyl)amino)-7H-py rrolo[2,3-d]pyrimidin-7-yl)- 2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)meth yl)isoindoline-1, 3-dione (165):

To a solution of the alcohol 164 (1.52 g, 2.99 mmol) in dry THF (29.90 mL), phthalimide (0.58 g, 3.89 mmol), PPh 3 (1.03 g, 3.89 mmol), and DEAD (0.62 mL, 3.89 mmol) were added in this order. The solution was stirred overnight at ambient temperature. The reaction mixture was diluted with water and was extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated in vacuo. The crude product was purified by FC (cyclohexane/EtOAc; 0-100%) to afford the product as colorless foam (1.33 g, 70%). 1 H NMR (400 MHz, DMSO-aL) <58.12 (s, 1H, H2), 7.90 - 7.87 (m, 2H, H5/6, phthalimide), 7.85 - 7.82 (m, 2H, H4/7, phthalimide), 7.71 (s, 1H, H6), 7.29 - 7.25 (m, 2H, o-benzyl), 6.97 (t, 7 = 6.0 Hz, 1H, NH), 6.89 - 6.84 (m, 2H, /77-benzyl), 5.02 - 4.93 (m, 1H, H1'), 4.82 (dd, 7 = 7.4, 5.3 Hz, 1H, H2'), 4.69 (d, 7 = 6.1 Hz, 2H, CH 2 , PMB), 4.59 - 4.53 (m, 1H, H3'), 3.85 - 3.65 (m, 2H, CH 2 , H5'), 3.71 (s, 3H, CH 3 , OMe), 2.47 - 2.40 (m, 1H, H4'), 2.25 (dt, 7 = 13.0, 6.7 Hz, 1H, CH 2 , cyclopentane), 2.14 - 2.02 (m, 1H, CH 2 , cyclopentane), 1.38 (s, 3H, CH 3 , acetonide), 1.14 (s, 3H, CH 3 , acetonide).

7-((3aS,4R,6R,6aR)-6-(aminomethyl)-2,2-dimethyltetrahydro -4H-cyclopenta[d][1,3]dioxol-4-yl)- 5-bromo-N-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ami ne (166):

Hydrazine monohydrate (1.62 mL, 33.06 mmol) was added to a suspension of compound 165 (1.32 g, 2.07 mmol) in EtOH (51.70 mL) and stirred at reflux for 1 h. After 10 min the suspension became a clear solution. After 20 min, a precipitation is formed. The reaction mixture was cooled down to 0 °C in an ice-bath. The suspension was filtered, and the filter cake was washed with EtOH. The filtrate was evaporated in vacuo and the obtained residue was purified by FC (CH 2 CI 2 /MeOH, 0-10%) to afford the product as colorless foam (0.79 g, 76%). 1 H NMR (400 MHz, DMSO-aL) <58.17 (s, 1H, H2), 7.67 (s, 1H, H6), 7.31 - 7.26 (m, 2H, o-benzyl), 6.97 (t, J = 6.0 Hz, 1H, NH), 6.90 - 6.84 (m, 2H, /77-benzyl), 4.96 (dt, J = 11.7, 6.6 Hz, 1H, H1'), 4.85 - 4.80 (m, 1H, H2'), 4.69 (d, J= 6.1 Hz, 2H, CH 2 , PMB), 4.45 (dd, J = 72, 5.0 Hz, 1H, H3'), 3.71 (s, 3H, CH 3 , OMe), 2.74 - 2.57 (m, 2H, CH 2 , H5'), 2.21 (dt, 7 = 12.2, 6.6 Hz, CH 2 , cyclopentane), 2.14 - 2.01 (m, 1H, H4'), 2.00 - 1.92 (m, 1H, CH 2 , cyclopentane), 1.45 (s, 3H, CH 3 , acetonide), 1.21 (s, 3H, CH 3 , acetonide).

Synthesis of 7-((3as,4r r 6r, 6ar)-6-(aminomethyi)-2, 2-dimethyitetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-N-(4-methoxybenzyl)-5-phenyl- 7H-pyrrolo[2,3-d] pyrimidin-4- amine

7-((3as,4r,6r,6ar)-6-(((7e/t-butyldimethylsilyl)oxy)methy l)-2,2-dimethyltetrahydro-4Z/- cyclopenta[d][1,3]dioxol-4-yl)-4-chloro-5-phenyl-7Z/-pyrrolo [2,3-d]pyrimidine (167):

1228 mg of 162 (2.38 mmol; 1.0 eq) were dissolved in 25 mL degassed H 2 O and 25 mL dioxane. 319 mg (2.62 mmol; 1.1 eq) phenylboronic acid, 1010 mg (4.76 mmol; 2.0 eq) < 3 PO 4 and 156 mg (0.24 mmol; 0.1 eq) Pd(dtbpf)CI 2 were added. The reaction solution was heated at 80 °C for 15 h under N 2 atmosphere. The dioxan was removed under reduced pressure and the residue obtained was mixed with 60 mL EtOAc and extracted 3 times. After column chromatography on silica gel (cyclohexane/EtOAc 100:0% to 70:30%), 490 mg (0.95 mmol; 40%) of the title compound was obtained as a colorless oil.

7-((3as,4r,6r,6ar)-6-(((7e/t-butyldimethylsilyl)oxy)methy l)-2,2-dimethyltetrahydro-4Z/- cyclopenta[d][1,3]dioxol-4-yl)-/V-(4-methoxybenzyl)-5-phenyl -7H-pyrrolo[2, 3-d] pyrimidin-4-

490 mg of 167 (0.95 mmol; 1.0 eq) 7-((3as,4r,6r,6ar)-6-(((te/'f-butyldimethylsilyl)oxy)methyl) -2,2- dimethyltetrahydro-4A L cyclopenta[d][1,3]dioxol-4-yl)-4-chloro-5-phenyl-7A L pyrrolo[2,3- d]pyrimidine were dissolved in 15 mL dioxane and mixed with 0.20 mL (1.43 mmol; 1.5 eq) Et 3 N. To this were added 0.15 mL (1.14 mmol; 1.2 eq) of 4-methoxybenzylamine, and the reaction solution was heated at reflux for 72 h. Then the solvent was removed under reduced pressure. After purification by column chromatography on silica gel (cyclohexane/EtOAc 100:0% to 70:30%), 370 mg (0.60 mmol; 63%) of the title compound was obtained as a colorless foam.

((3aR,4R,6r,6as)-6-(4-((4-methoxybenzyl)amino)-5-phenyl-7 Z/-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4Z/-cyclopenta[d][1,3]dioxol-4-yl)methano l (169):

370 mg of 168 (0.60 mmol; 1.0 eq) 7-((3as,4r,6r,6ar)-6-(((terAbutyldimethylsilyl)oxy)methyl)-2 ,2- dimethyltetrahydro-4//-cyclopenta[d][1,3]dioxol-4-yl)-A/-(4- methoxybenzyl)-5-phenyl-7H- pyrrolo[2,3-d]pyrimidin-4-amine were dissolved in 12 mL THE and reacted with 0.90 mL (0.90 mmol; 1.5 eq) of a 1 m solution of TBAF in THF. After 18 h, the reaction was stopped by addition of 20 mL dist. H 2 O and extracted with DCM (3x 60 mL). The combined organic phases were dried over MgSO 4 , filtered, and the solvent was removed under reduced pressure. Column chromatography on silica gel (cyclohexane/EtOAc 100:0% to 50:50%) gave 275 mg (0.55 mmol; 92%) of the title compound in the form of a colorless foam.

7-((3as,4r,6r,6ar)-6-(aminomethyl)-2,2-dimethyltetrahydro -4Z/-cyclopenta[d][1,3]dioxol-4-yl)-/V- (4-methoxybenzyl)-5-phenyl-7Z/-pyrrolo[2,3-d] pyrimidin-4-amine (170):

275 mg of 169 (0.55 mmol; 1.0 eq) ((3aR,4R,6r,6as)-6-(4-((4-methoxybenzyl)amino)-5-phenyl- 77/-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4A , -cyclopenta[d][1,3]dioxol-4- yl)methanol were dissolved in 10 mL THF. There were first added 105 mg (0.72 mmol; 1.3 eq) phthalimide, then 188 mg (0.72 mmol; 1.3 eq) PPh 3 and finally 0.31 mL (0.72 mmol; 1.3 eq) of a 40% solution of azodicarboxylic acid diethyl ester in toluene. The reaction solution was stirred at RT for 16 h and afterwards adsorbed on silica gel. The residue was roughly cleaned by column chromatography (cyclohexane/EtOAc 100:0% to 50:50%) and then after drying used without further purification. The residue was therefore dissolved in 25 mL EtOH. 0.43 mL (8.80 mmol;

16 eq) hydrazine hydrate were added and the resulting solution was heated under refluxation for 3 h. The reaction mixture was cooled to 0 °C. The resulting precipitate was filtered off and the residue was washed with 80 mL EtOH. Column chromatography on silica gel (DCM/MeOH 100:0% to 90:10%) gave 275 mg (0.55 mmol; quantitative over 2 steps; crude) of the title compound in the form of a colorless foam.

Synthesis of 7-((3as,4r r 6r, 6ar)-6-(aminomethy/)-2, 2-dimethy/tetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-5-iodo-N-(4-methoxybenzyl)-7H -pyrrolo[2,3-d]pyrimidin-4-amine 7-((3as,4R,6R,6ar)-6-(((tert-butyldimethylsilyl)oxy)methyl)- 2,2-dimethyltetrahydro-4//- cyclopenta[d][1,3]dioxol-4-yl)-4-chloro-5-iodo-7//-pyrrolo[2 ,3-d]pyrimidine (171): l)oxy)methyl)-2,2-dimethyltetrahydro- 4//-cyclopenta[</|[1,3]dioxol-4-yl)-4-chloro-7//-pyrrolo[ 2,3-</|pyrimidine (3.08 mmol; 1.0 eq) were dissolved in 20 mL DMF and 762 mg (3.39 mmol; 1.1 eq) of /V-iodosuccinimide were added. The reaction solution was heated to 60 °C for 15 h. The solvent was removed under reduced pressure and the resulting residue was taken up in 120 mL EtOAc. The organic phase was washed with a saturated NaCI solution, dried over MgSO 4 , filtered, and adsorbed on silica gel. Column chromatography (cyclohexane/EtOAc 100:0% to 90:10%) gave 1200 mg (2.13 mmol; 69%) of the title compound in the form of a colorless foam.

7-((3as,4r,6r,6ar)-6-(((fe/7-butyldimethylsilyl)oxy)methy l)-2,2-dimethyltetrahydro-4Z7- cyclopenta[d][1,3]dioxol-4-yl)-5-iodo-/V-(4-methoxybenzyl)-7 H-pyrrolo[2,3-d]pyrimidin-4-amine

1200 mg of 171 (2.13 mmol; 1.0 eq) were dissolved in 25 mL dioxane and mixed with 0.44 mL (3.19 mmol; 1.5 eq) Et 3 N. To this were added 0.33 mL (2.55 mmol; 1.2 eq) of 4- methoxybenzylamine, and the reaction solution was heated at reflux for 48 h. Then the solvent was removed under reduced pressure. After purification by column chromatography on silica gel (cyclohexane/EtOAc 100:0% to 60:40%), 1090 mg (1.64 mmol; 77%) of the title compound was obtained as a colorless foam.

((3aR,4R,6r,6as)-6-(5-iodo-4-((4-methoxybenzyl)amino)-7Z/ -pyrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4Z/-cyclopenta[d][1,3]dioxol-4-yl)methano l (173):

1090 mg of 172 (1.64 mmol; 1.0 eq) were dissolved in 15 mL THE and reacted with 2.46 mL (2.46 mmol; 1.5 eq) of a 1 m solution of TBAF in THF. After 16 h, the reaction was stopped by addition of 30 mL dist. H 2 O and extracted with DCM (3x 80 mL). The combined organic phases were dried over MgSO 4 , filtered, and the solvent was removed under reduced pressure. Column chromatography on silica gel (cyclohexane/EtOAc 100:0% to 20:80%) gave 854 mg (1.55 mmol; 95%) of the title compound in the form of a colorless foam.

7-((3as,4r,6r,6ar)-6-(aminomethyl)-2,2-dimethyltetrahydro -4//-cyclopenta[d][1,3]dioxol-4-yl)-5- iodo-N-(4-methoxybenzyl)-7//-pyrrolo[2,3-d]pyrimidin-4-amine (174):

854 mg of 173 (1.55 mmol; 1.0 eq) were dissolved in 20 mL THF. There were first added 296 mg (2.02 mmol; 1.3 eq) phthalimide, then 529 mg (2.02 mmol; 1.3 eq) PPh 3 and finally 0.79 mL (2.02 mmol; 1.3 eq) of a 40% solution of azodicarboxylic acid diethyl ester in toluene. The reaction solution was stirred at RT for 18 h and afterwards adsorbed on silica gel. The residue was roughly cleaned by column chromatography (cyclohexane/EtOAc 100:0% to 50:50%) and then after drying used without further purification. The residue was therefore dissolved in 40 mL EtOH. 1.20 mL (24.80 mmol; 16 eq) hydrazine hydrate were added and the resulting solution was heated under refluxation for 2 h. The reaction mixture was cooled to 0 °C. The resulting precipitate was filtered off and the residue was washed with 80 mL EtOH. Column chromatography on silica gel (DCM/MeOH 100:0% to 80:10%) gave 600 mg (1.09 mmol; 70% over 2 steps) of the title compound in the form of a colorless foam.

Preparation of tert-butyl (3-aminopropyi)(((3aR f 4R, 6R, 6aS)-6-(5-bromo-4-((4- methoxybenzyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-di methyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methyl)carbamate

(9Z/-fluoren-9-yl)methyl (3-((((3a/?,4/?,6/?,6a5)-6-(5-bromo-4-((4-methoxybenzyl)amin o)-7Z7- pyrrolo[2,3-</|pyrimidin-7-yl)-2,2-dimethyltetrahydro-4// -cyclopenta[</|[1,3]dioxol-4- yl)methyl)amino)propyl)carbamate (175): NHPMB P j* '"O bp-

To a solution of compound 166 (0.77 g, 1.52 mmol) in dry DCE (7.50 mL) was added a solution of 52 (0.50 g, 1.70 mmol) in dry DCE (7.50 mL) under nitrogen. The solution was stirred for 30 min at ambient temperature. Then, STAB (0.49 g, 2.28 mmol) was added portion wise over 30 min under nitrogen. The mixture was stirred for 48 h at rt. Then, 1 m K2CO3 solution was added to reach pH 8-9. Then, DCM was added, and the organic layer was separated. The water phase was extracted 2 times with DCM. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under rotatory evaporation. The crude product was purified over silica (DCM/MeOH; 0-10%) to afford the product as colorless foam (0.50 g, 42%). fe/t- butyl (3-((((9//-fluoren-9-yl)methoxy)carbonyl)amino)propyl)(((3a/ ?,4/?,6/?,6a5)-6-(5-bromo- 4-((4-methoxybenzyl)amino)-7//-pyrrolo[2,3-d|pyrimidin-7-yl) -2,2-dimethyltetrahydro-4//- cyclopenta[o][1,3]dioxol-4-yl)methyl)carbamate (176):

To cooled a solution of compound 175 (0.49 g, 0.63 mmol) in dry CH 2 CI 2 (6.30 mL), di-tert-butyl decarbonate (0.16 mL, 0.69 mmol) was added. The reaction solution was stirred overnight at ambient temperature. After 17 h, reaction mixture was diluted with sodium bicarbonate solution. The organic layer was separated, and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The obtained residue was purified by flash chromatography (CH 2 CI 2 /MeOH; 0-10%) to afford the title product as colorless foam (0.49 g, 89%). fe/t- butyl (3-aminopropyl)(((3a/?,4/?,6/?,6a5)-6-(5-bromo-4-((4-methoxy benzyl)amino)-7//- pyrrolo[2,3-o]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4//-cyc lopenta[</|[1,3]dioxol-4- yl)methyl)carbamate (177):

Br NHPMB

Nucleoside 176 (0.48 g, 0.55 mmol) was dissolved in a 10% piperidine solution in CH 2 CI 2 (11.00 mL). The reaction mixture was stirred for 24h at ambient temperature. After 24 h, the mixture was diluted with water. The organic phase was separated, and the aqueous phase was extracted with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate and concentrated to complete dryness. The crude product was purified over silica (CH 2 CI 2 /MeOH; 0- 20%) to afford the pure product 177 as colorless solid (0.29 g, 79%). tert-butyl (3-(1-(((3aR,4R, 6R, 6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimi din- 7-yl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methyl)-1H -imidazol-2-yl)propyl)(3- phenoxyphenethy/)carbamate

Synthesis of 4,4-diethoxy-N-(3-phenoxyphenethyl)butan-1-amine (178):

A solution of 2-(3-phenoxyphenyl)acetaldehyde (400 mg, 1.9 mmol), 4,4-diethoxybutan-1- amine (911 mg, 5.7 mmol) in MeOH (3 mL) was stirred at room temperature for 30 min. Then NaBH 4 (72 mg, 1.9 mmol) was added to the solution. The solution was stirred at room temperature for 16 hrs. The reaction was quenched with water (2 mL) and diluted with EA (20 mL). The organic phase was washed with H 2 O (10 mL x3), dried over Na 2 SO 4 and concentrated to dryness. The residue was purified by silica gel flash chromatography (DCM: MeOH = 20:1) to give compound 178 (400 mg, yield: 80%) as colorless oil. 1 H NMR (400 MHz, CD 3 CI): 5 = 7.38 ( t, J - 7.6 Hz, 2H ) , 7.28 ( t, 7 = 7.6 Hz, 1H ) , 7.13 ( t, 7 = 7.2 Hz, 1H ) , 7.00-6.98 (m, 3 H), 6.87 (s, 1H), 6.80 (dd, 7 = 8.0, 2.0 Hz, 1H), 4.42 (t, 7 = 5.2 Hz, 1H), 3.56-3.49 (m, 2H), 3.43-3.36 (m, 2H), 2.72- 2.66 (m, 4H), 2.51-2.48 (m, 2H), 1.52-1.36 (m, 4H), 1.09 ( t, 7 = 7.2 Hz, 6H ) . benzyl (4,4-diethoxybutyl)(3-phenoxyphenethyl)carbamate (179):

To a solution of 4,4-diethoxy-N-(3-phenoxyphenethyl)butan-1-amine 178 (200 mg, 0.7 mmol) in THF/H 2 O (5/1 mL) was added benzyl chloroformate (256 mg, 1.5 mmol) and < 2 CO 3 (207 mg, 1.5 mmol), then the solution was stirred at room temperature overnight. The solution was partitioned between water (10 mL) and EA (20 mL). The organic phase was washed with H 2 O (10 mL x3), dried over Na 2 SO 4 and concentrated to dryness. The residue was purified by silica gel flash chromatography (PE: EA = 10:1) to give compound 177 (230 mg, yield: 63%) as colorless oil. benzyl (3-oxopropyl)(3-phenoxyphenethyl)carbamate (180):

To a solution of 179 (230 mg, 0.47 mmol) in THF (5 mL) was added aq HCI (2 mL, 2 M) and the solution was stirred at room temperature for 2 hrs. The reaction solution was partitioned between aq. NH4CI (20 mL) EA (20 mL). The organic phase was washed with H 2 O (10 mL x3), dried over Na 2 SO 4 and concentrated to dryness. The residue was purified by silica gel flash chromatography (PE: EA = 4:1) to give compound 180 (160 mg, yield: 82%) as colorless oil. 1 H NMR (400 MHz, CD 3 CI): 5 = 9.68 (d, J = 45.2 Hz, 1H), 7.37-6.79 (m, 14 H), 5.12-5.10 (m, 2H), 3.44 (s, 2H), 3.23-3.18 (m, 2H), 2.85-2.78 (m, 2H), 2.44-2.35 (m, 2H), 1.83-1.77 (m, 2H), 2.62 (t, J = 8.4 Hz, 2H), 1.33-1.28 (m, 3H). benzyl (3-(1-(((3aR / 4R,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyrrolo[ 2,3-d]pyrimidin-7- yl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methyl)-1H-i midazol-2-yl)propyl)(3- phenoxyphenethyl)carbamate (181):

To a solution of 180 (100 mg, 0.2 mmol), 131 (76 mg, 0.2 mmol) and ammonium acetate (18 mg, 0.2 mmol) in MeOH (5 mL) was added glyoxal (30 mg, 0.2 mmol) and the solution was stirred at 35 °C overnight. The crude was purified by reverse phase flash (MeCN/H 2 O) to afford 181 (30 mg, yield: 17%) as a white solid. MS Calc.: 755.3; MS Found: 756.1 [M + H + ], tert-butyl (3-(1-(((3aR / 4R,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyrrolo[ 2,3-d]pyrimidin- 7-yl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methyl)-1H -imidazol-2-yl)propyl)(3- phenoxyphenethyl)carbamate (182):

To a solution of 181 (10 mg, 0.01 mmol) in EA (3 mL) was added Pd/C (10 mg) and Boc 2 O (5 mg, 0.02 mmol). The suspension was stirred at room temperature under H 2 for 16 hrs. The suspension is filtered and concentrated for the use of next step. MS Calcd.: 721.4; MS Found: 722.4 [M + H + ],

Preparation oftert-butyi (((3aR,4R, 6R, 6aR)-6-(6-((tert-butoxycarbonyl)amino)-9H-purin-9-yl)~ 2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)(3- ((4-(prop-2-yn-1- yloxy)benzyl)amino)propyl)carbamate fe/t- butyl (((3a/?,4/?,6/?,6aA)-6-(6-((7e/t-butoxycarbonyl)amino)-9Z/-p urin-9-yl)-2,2- dimethyltetrahydrofuro[3,4-a][1,3]dioxol-4-yl)methyl)(3-((4- (prop-2-yn-1- yloxy)benzyl)amino)propyl)carbamate (183):

4-(prop-2-yn-1-yloxy)benzaldehyde (0.06 g, 0.35 mmol) was dissolved in dry DCE under nitrogen. Then, a solution of compound te/f-butyl (3-aminopropyl)(((3a/?,4/?,6/?,6aA)-6-(6-((te/f- butoxycarbonyl)amino)-97/-purin-9-yl)-2,2-dimethyltetrahydro furo[3,4-<7|[1,3]dioxol-4- yl)methyl)carbamate (0.18 g, 0.31 mmol) was added. The solution was stirred for 30 min at rt. STAB (0.10 g, 0.47 mmol) was then added portion wise over 30 min. The mixture was stirred for 48 h at rt. 1M K 2 CO 3 solution was added to reach pH 8-9. DCM was added and separated. The aqueous phase was extracted with DCM. The combined organic layers were dried over sodium sulfate, and concentrated. The crude product was purified by FC (CH 2 CI 2 /MeOH; 0-10%) to afford the product as white foam (0.14 g, 64%).

Preparation of tert-butyl (3-((((3aR,4R, 6R, 6aR)-6-(6-((tert-butoxycarbonyi)amino)-9H-purin-9- yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl )amino)propyl)(4- ethynylphenethyl)carbamate fe/t- butyl (3-((((3a/?,4/?,6/?,6a/^-6-(6-((7e/7-butoxycarbonyl)amino)-9 Z/-purin-9-yl)-2,2- dimethyltetrahydrofuro[3,4-a][1,3]dioxol-4-yl)methyl)amino)p ropyl)(4- ethynyl phe nethyl)ca rba mate (184) :

NHBoc

Compound terf-butyl (4-ethynylphenethyl)(3-oxopropyl)carbamate (0.08 g, 0.26 mmol) was dissolved in dry DCE under nitrogen. Then, a solution of terf-butyl (9-((3a/?,4/?,6/?,6aA)-6- (aminomethyl)-2,2-dimethyltetrahydrofuro[3,4-<7ni,3]dioxo l-4-yl)-97/-purin-6-yl)carbamate (0.11 g, 0.26 mmol) was added under nitrogen. The solution was stirred for 30 min at rt. STAB (0.08 g, 0.38 mmol) was then added portion wise over 30 min. The mixture was stirred for 48 h at rt. 1M < 2 CO 3 solution was added to reach pH 8-9. DCM was added and separated. The aqueous phase was extracted with DCM. The combined organic layers were dried over sodium sulfate, and concentrated. The crude product was purified by FC (CH 2 CI 2 /MeOH; 0-10%) to afford the product as white foam (0.08 g, 42%).

Preparation of 7-((3aS,4R, 6R, 6aR)-6-(aminomethyi)-2,2-dimethyitetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-5-ethyl-N-(4-methoxybenzyl)-7 H-pyrrolo[2,3-d]pyrimidin-4-amine 7-((3aS,4/?,6/?,6a/^-6-(((7e/7-butyldimethylsilyl)oxy)methyl )-2,2-dimethyltetrahydro-4Z/- cyclopenta[o][1,3]dioxol-4-yl)-/V-(4-methoxybenzyl)-5-vinyl- 7Z/-pyrrolo[2,3-a]pyrimidin-4-amine

1300 mg (2.10 mmol; 1.00 eq) of 5-bromo-7-((3as,4r,6r,6ar)-6-(((te/'A butyldimethylsilyl)oxy)methyl)-2,2-dimethyltetrahydro-47/-cy clopenta[d][1,3]dioxol-4-yl)-A/-(4- methoxybenzyl)-77/-pyrrolo[2,3-d]pyrimidin-4-amine were dissolved in 15 mL of Dioxane and 15 mL of dist. H 2 O. 0.40 mL (2.31 mmol; 1.10 eq) of Vinylboronicpinacolester, 890 mg (4.20 mmol; 2.00 eq) of K 3 PO 4 and 137 mg (0.210 mol; 0.10 eq) of Pd(dtbpf) were added under N 2 - atmosphere. The resulting reaction mixture was heated to 80 °C for 14 h. Extraction with EtOAc (5x 50 mL) followed. The combined organic phases were dried over MgSO 4 , filtered and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (Cyclohexane/EtOAc 100:0% to 50:50%). 400 mg (0.71 mmol; 34%) of the title compound were received in form of a white solid. TLC: Rf = 0.33 (Cyclohexane/EtOAc 1:1). 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 8.10 (s, 1H), 7.61 (s, 1H), 7.28-7.24 (m, 2H), 7.20 (d, J = 10.9 Hz, 1H), 7.16 (d, J = 11.0 Hz, 1H), 7.11 (t, J = 6.1 Hz, 1H), 6.87-6.83 (m, 2H), 5.55 (dd, J = 17.2, 1.7 Hz, 1H), 5.13 (dd, 7 = 10.8, 1.7 Hz, 1H), 4.99-4.95 (m, 1H), 4.94-4.89 (m, 1H), 4.66 (d, J = 6.1 Hz, 2H), 4.52-4.48 (m, 1H), 3.70 (s, 3H), 3.68-3.63 (m, 2H), 2.27-2.16 (m, 2H), 2.12-2.03 (m, 1H), 1.46 (s, 3H), 1.21 (s, 3H), 0.88 (s, 9H), 0.05 (s, 6H) ppm. APCI-MS(+) m/z for C 3 iH 44 N 4 O 4 Si: calc.: 564.80; found: 565.7 and 566.7.

7-((3aS,4/?,6/?,6a/^-6-(((7e/7-butyldimethylsilyl)oxy)met hyl)-2,2-dimethyltetrahydro-4Z/- cyclopenta[o][1,3]dioxol-4-yl)-5-ethyl-/V-(4-methoxybenzyl)- 7//-pyrrolo[2,3-a]pyrimidin-4-amine

400 mg (0.71 mmol; 1.00 eq) of 7-((3as,4r,6r,6ar)-6-(((te/'f-butyldimethylsilyl)oxy)methyl) -2,2- dimethyltetrahydro-4//-cyclopenta[d][1,3]dioxol-4-yl)-A/-(4- methoxybenzyl)-5-vinyl-7/7- pyrrolo[2,3-d]pyrimidin-4-amine were dissolved in 40 mL of Methanol. Catalytic amounts of Pd/C were added and the reaction mixture was flushed by H2-gas with continuous stirring. The catalyst was filtered off over celite and the filtrate was purified by column chormatography on silica gel (Cyclohexane/EtOAc 100:0% to 60:40%). 400 mg (0.71 mmol; quantitative) of the title compound were isolated in form of a colorless foam. TLC: Rf = 0.48 (Cyclohexane/EtOAc 1:1). 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 8.05 (s, 1H), 7.30-7.22 (m, 2H), 7.03 (s, 1H), 6.89 (t, J = 6.3 Hz, 1H), 6.87- 6.82 (m, 2H), 4.96-4.89 (m, 1H), 4.87-4.83 (m, 1H), 4.65 (d, J = 6.1 Hz, 2H), 4.51-4.47 (m, 1H), 3.70 (s, 3H), 3.68-3.63 (m, 2H), 2.86-2.80 (m, 2H), 2.26-2.12 (m, 2H), 2.12-2.01 (m, 1H), 1.45 (s, 3H), 1.23 (t, J = 7.4 Hz, 3H), 1.20 (s, 3H), 0.88 (s, 9H), 0.05 (s, 6H) ppm. APCI-MS(+) m/z for C 31 H 46 N 4 O 4 Si: calc.: 566.82; found: 567.6 and 568.7.

((3a/?,4/?,6/?,6a5)-6-(5-ethyl-4-((4-methoxybenzyl)amino) -7//-pyrrolo[2,3-a]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4//-cyclopenta[d|[1,3]dioxol-4-yl)methano l (187):

660 mg (1.16 mmol; 1.00 eq) of 7-((3as,4r,6r,6ar)-6-(((te/'f-butyldimethylsilyl)oxy)methyl) -2,2- dimethyltetrahydro-4//-cyclopenta[d][1,3]dioxol-4-yl)-5-ethy l-A/-(4-methoxybenzyl)-7/7- pyrrolo[2,3-d]pyrimidin-4-amine were dissolved in 10 mL of THE. 1.80 mL of a 1 m solution of TBAF in THE (1.74 mmol; 1.50 eq) were added and the reaction mixture was stirred at RT overnight. The solvent was removed under reduced pressure and the remaining residue was purified by flash chromatography eluting with Cyclohexane/EtOAc (100%/0% to 50%/50%).

300 mg (0.66 mmol; 57% of the title compound were isolated in form of a white solid. 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 8.06 (s, 1H), 7.30-7.25 (m, 2H), 7.08 (s, 1H), 6.89 (t, J = 6.0 Hz, 1H), 6.86- 6.83 (m, 2H), 4.95-4.88 (m, 1H), 4.85-4.81 (m, 1H), 4.72 (t, 7 = 5.3 Hz, 1H), 4.65 (d, 7 = 5.9 Hz, 2H),

4.51-4.48 (m, 1H), 3.70 (s, 3H), 3.54-3.44 (m, 2H), 2.83 (q, 7 = 7.3 Hz, 2H), 2.22-2.09 (m, 2H), 2.03-

1.94 (m, 1H), 1.45 (s, 3H), 1.23 (t, 7 = 7.4 Hz, 3H), 1.21 (s, 3H) ppm. APCI-MS(+) m/z for C 2 5H3 2 N 4 O 4 : calc.: 452.56; found 453.4 and 454.4.

2-(((3ar ; 4r,6r,6as)-6-(5-ethyl-4-((4-methoxybenzyl)amino)-7//-p yrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4//-cyclopenta[d][1,3]dioxol-4-yl)methyl) isoindoline-1, 3-dione (188) and 7- ((3ar,4r,6r,6as)-6-(aminomethyl)-2,2-dimethyltetrahydro-4//- cyclopenta[d][1,3]dioxol-4-yl)-5- ethyl-/V-(4-methoxybenzyl)-7//-pyrrolo[2,3-d]pyrimidin-4-ami ne (189): u

300 mg (0.66 mmol; 1.0 eq) of ((3aR,4R,6R,6as)-6-(5-ethyl-4-((4-methoxybenzyl)amino)-7/7- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4//-cyc lopenta[d][1,3]dioxol-4-yl)methanol were dissolved in 20 mL of THF. 226 mg (0.86 mmol; 1.3 eq) of PPh 3 , 127 mg (0.86 mmol; 1.3 eq) of phthalimide and finally 0.38 mL (0.86 mmol; 1.3 eq) of a 40% solution of azodicarboxylic acid diethyl ester in toluene were added The reaction solution was stirred at RT overnight and afterwards adsorbed on silica gel. The residue was purified by column chromatography (Cyclohexane/EtOAc 95:5% to 0:100%) and directly used for further reaction. Therefore, the intermediate (320 mg; 0.55 mmol; 1.0 eq) was dissolved in 40 mL of EtOH and 0.43 mL (8.80 mmol; 16 eq) hydrazine hydrate were added. The resulting solution was heated under refluxation for 2 h. The reaction mixture was then cooled to 0 °C and the formed precipitate was filtered off. The residue was washed with EtOH. Final column chromatography on silica gel (DCM/MeOH 100:0% to 80:20%) gave 200 mg (0.44 mmol; 66% over 2 steps) of the title compound in the form of a colorless foam. TLC: Rf = 0.08 (DCM/MeOH 10:1). 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 8.06 (s, 1H), 7.30-7.23 (m, 2H), 7.11 (s, 1H), 6.89 (t, 7 = 6.0 Hz, 1H), 6.87-6.81 (m, 2H), 4.94-4.88 (m, 1H), 4.84-4.81 (m, 1H), 4.65 (d, 7 = 5.7 Hz, 2H), 4.49-4.45 (m, 1H), 3.70 (s, 3H), 2.83 (q, 7 = 7.2 Hz, 2H), 2.78-2.61 (m, 2H), 2.24-2.04 (m, 2H), 1.98-1.90 (m, 1H), 1.45 (s, 3H), 1.23 (t, 7 = 7.3 Hz, 3H), 1.21 (s, 3H) ppm. APCI-MS(+) m/z for C33H35N5O5: calc.: 581.67; found 582.4 and 583.4. APCI-MS(+) m/z for C 25 H33N 5 O3: calc.: 451.57; found 452.5 and 453.5.

Constrained left hand side nucleoside series fe/t- butyl 4-((3a/?,4/?,6a/t)-2,2-dimethyl-6-oxotetrahydro-4A/-cyclopen ta[d|[1,3]dioxol-4-yl)-3,6- d i hyd ropyrid i ne-1 (2 H)-ca rboxylate (190) :

To a heat-dried three-necked round bottom flask equipped with a stirring bar and air condenser was charged with (3a/?,6aA)-2,2-dimethyl-3a,6a-dihydro-4//-cyclopenta[</|[ 1,3]dioxol-4-one (0.80 g, 4.93 mmol), [Cp*RhCI 2 ]2 (0.25 g, 0.49 mmol), KOH (0.06 g, 0.99 mmol), and te/7-butyl 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyr idine-1(2A)-carboxylate (2.36 g, 7.39 mmol) under nitrogen atmosphere, Then, 1,4-dioxane (32.90 mL) was added and the resulted mixture was degassed. Degassed water (1.00 mL) was then added, and the mixture was placed into a pre-heated heating plate (50 °C). The reaction mixture was heated to 80 °C and stirred for 4 h upon complete consumption of the starting material. TLC (cyclohexane/EtOAc; 30%) was used for monitoring the reaction progress. Then, the reaction was cooled down to ambient temperature and was diluted with water. The aqueous phase was extracted three times with EtOAc and the combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained crude product was purified by flash chromatography (cyclohexane/EtOAc; 0-20%) to obtain the desired product as colorless oil (1.40 g, 84%). R f = 0.37 (petrol ether /EtOAc; 30%). 1 H NMR (400 MHz, Chloroform-o) 5 5.31 -

5.20 (m, 1H, -NCH 2 C//-), 4.57 (d, 7 = 5.5 Hz, 1H, H2'), 4.17 (d, 7 = 5.5 Hz, 1H, H1'), 3.82 - 3.77 (m, 2H, -NC// 2 CH-), 3.48 - 3.39 (m, 2H, -NC// 2 CH 2 -), 2.86 (d, 7 = 9.4 Hz, 1H, H3'), 2.83 - 2.75 (m, 1H, H4'), 2.28 - 2.21 (m, 1H, H4'), 2.20 - 1.94 (m, 2H, -NCH 2 C// 2 -), 1.40 (s, 9H, -NCO 2 C(C// 3 ) 3 ), 1.39 (s, 3H, CH 3 , acetonide), 1.28 (s, 3H, CH 3 , acetonide). APCI: calc, for C 18 H 28 NO5 [M + H] + : 338.19, found:

238.20 [M + H, Boc cleaved]*. fe/'A butyl 4-((3a/?,4/?,6S,6a5)-6-hydroxy-2,2-dimethyltetrahydro-4//-cy clopenta[d|[1,3]dioxol-4- yl)-3,6-dihydropyridine-1(2A)-carboxylate (191):

Compound 190 (2.71 g, 6.43 mmol) was dissolved in anhydrous MeOH (32.20 mL) and cooled down to 0 °C. Then, NaBH 4 (0.37 g, 9.65 mmol) was added portion wise. The reaction mixture was stirred for 1 h at 0 °C (until the bubbling stopped). Upon full conversion indicated by TLC (cyclohexane/EtOAc; 40%), cold water was added. The aqueous phase was extracted five times with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The obtained residue was purified with silica gel chromatography (cyclohexane/EtOAc; 0-40%) to afford the pure product as colorless resin (1.68 g, 77%). 1 H NMR (400 MHz, DMSO-of) 5 5.34 (s, 1H, -NCH 2 C//-), 4.44 - 4.40 (m, 1H, H3'), 4.38 - 4.33 (m, 2H, H2', - CHOA), 3.90 (ddd, 7 = 11.0, 9.1, 5.5 Hz, 1H, H1'), 3.78 (s, 2H, -NC// 2 CH-), 3.46 - 3.34 (m, 2H, - NC// 2 CH 2 -), 2.45 - 2.39 (m, 1H, H4'), 2.07 - 1.98 (m, 2H, -NCH 2 C// 2 -), 1.82 (dt, 7 = 12.5, 8.2 Hz, 1H, H5'), 1.69 (dt, 7 = 12.5, 5.0 Hz, 1H. H5'), 1.41 (s, 12H, -NCO 2 C(CH 3 ) 3 , C// 3 , acetonide), 1.25 (s, 3H, CH 3 , acetonide). APCI: calc, for C 18 H 30 NO 5 [M + H] + : 340.20, found: 239.90 [M + H, Boc cleaved]*, fe/t- butyl 4-((3a/?,4/?,6S,6a5)-6-hydroxy-2,2-dimethyltetrahydro-4//-cy clopenta[</|[1,3]dioxol-4- yl)piperidine-1-carboxylate (192):

Compound 191 (1.65 g, 4.81 mmol) was dissolved in MeOH (24.10 mL) under nitrogen atmosphere. Then, palladium on activated charcoal moistened with water (0.51 g, 10 mol%) was added and the mixture was degassed. The reaction mixture was then purged with hydrogen (balloon) and stirred upon complete consumption. After 17 h, the reaction mixture was set under nitrogen atmosphere and was filtered over celite. The filter cake was rinsed with MeOH and the filtrate was concentrated under reduced pressure. The obtained crude product was purified over silica gel chromatography (cyclohexane/EtOAc; 0-40%) to afford the title product as colorless resin (2.20 g, 72%). R f = 0.45 (petrol ether /EtOAc; 50%). 1 H NMR (400 MHz, Chloroform-o) 5

4.40 (dd, 7 = 7.1, 5.0 Hz, 1H, H2'), 4.29 (dd, 7 = 7.1, 3.6 Hz, 1H, H3'), 4.09 - 3.99 (m, 2H, - N(CM 2 ) 2 (CH 2 ) 2 -), 3.99 - 3.94 (m, 1H, H1'), 2.67 - 2.52 (m, 2H, -N(CM 2 ) 2 (CH 2 ) 2 -), 2.47 (s, 1H, -CHOA), 2.01 - 1.86 (m, 2H, H4', H5'), 1.77 - 1.68 (m, 1H, -N(CH 2 ) 2 (CM 2 ) 2 -), 1.58 - 1.46 (m, 3H, N(CH 2 ) 2 (CM 2 ) 2 , H5'), 1.45 (s, 3H, CM, acetonide), 1.38 (s, 9H, -NCO 2 C(CH 3 ) 3 ), 1.29 (s, 3H, CM, acetonide), 1.20 - 1.01 (m, 2H, , -N(CH 2 ) 2 (CM 2 ) 2 CM-). APCI: calc, for C 18 H 32 NO 5 [M + H] + : 342.22, found: 242.00 [M + H, Boc cleaved]*. fe/A butyl 4-((3a/?,4/?,6/?,6a5)-6-(4-chloro-7M-pyrrolo[2,3-d|pyrimidin -7-yl)-2,2- dimethyltetrahydro-4M-cyclopenta[d|[1,3]dioxol-4-yl)piperidi ne-1-carboxylate (193):

Following the general procedure B for Mitsunobu-type glycosylation, compound x was obtained starting from 4-chloro-7M-pyrrolo[2,3-t/|pyrimidine (0.32 g, 2.03 mmol), compound 192 (0.50 g, 1.45 mmol), PPh 3 (0.77 g, 2.90 mmol), and DIAD (0.53 mL, 2.61 mmol) in dry THF (0.15 M, 9.70 mL) after column chromatography on silica (petrol ether/THF; 0-20%) as white foam (336 mg, 49%). APCI: calc, for C^H^CIN^ [M + H] + : 476.22, found: 476.9/478.9 [M + H] + . fe/A butyl 4-((3a/?,4/?,6/?,6a5)-6-(4-amino-7M-pyrrolo[2,3-d|pyrimidin- 7-yl)-2,2- dimethyltetrahydro-4M-cyclopenta[d|[1,3]dioxol-4-yl)piperidi ne-1-carboxylate (194):

Following the general procedure for aromatic substitution, compound x was obtained starting from compound 193 (0.12 g, 0.25 mmol) in a mixture of 1,4-dioxane and ammonia (0.10 M, 2.40 mL, 1:2) after column chromatography on silica (n-heptane/EtOAc; 0-80%) as white foam (177 mg, 94%). APCI: calc, for C 24 H 36 N 5 O4 [M + H] + : 458.27, found: 458.1 [M + H] + . fe/A butyl 5-((3a/?,4/?,6a/i)-2,2-dimethyl-6-oxotetrahydro-4M-cyclopent a[d|[1,3]dioxol-4-yl)-3,6- d i hyd ropyrid i ne-1 (2 H)-ca rboxylate (195):

To a heat-dried three-necked round bottom flask equipped with a stirring bar and air condenser was charged with (3a/?,6aA)-2,2-dimethyl-3a,6a-dihydro-4M-cyclopenta[</|[1 ,3]dioxol-4-one (1.00 g, 6.16 mmol), [Cp*RhCI 2 ] 2 (0.31 g, 0.62 mmol), KOH (0.07 g, 1.23 mmol), and te/f-butyl 5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyr idine-1(2M“Carboxylate (2.95 g, 9.24 mmol) under nitrogen atmosphere, Then, 1,4-dioxane (41.10 mL) was added and the resulted mixture was degassed. Degassed water (1.20 mL) was then added, and the mixture was placed into a pre-heated heating plate (50 °C). The reaction mixture was heated to 80 °C and stirred for 4 h upon copmplete consumption of the starting material. TLC (cyclohexane/EtOAc; 30%) was used for monitoring the reaction progress. Then, the reaction was cooled down to ambient temperature and was diluted with water. The aqueous phase was extracted three times with EtOAc and the combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained crude product was purified by flash chromatography (cyclohexane/EtOAc; 0-20%) to obtain the desired product as colorless oil (1.72 g, 83%). APCI: calc, for C 18 H 28 NO 5 [M + H] + : 338.19, found: 238.20 [M + H, Boc cleaved]-. fe/t- butyl 5-((3a/?,4/?,6S,6a5)-6-hydroxy-2,2-dimethyltetrahydro-4//-cy clopenta[</|[1,3]dioxol-4- yl)-3,6-dihydropyridine-1(2A)-carboxylate (196):

Compound 195 (3.92 g, 11.51 mmol) was dissolved in anhydrous MeOH (57.60 mL) and cooled down to 0 °C. Then, NaBH 4 (0.66 g, 17.27 mmol) was added portion wise. The reaction mixture was stirred for 1 h at 0 °C (until the bubbling stopped). Upon full conversion indicated by TLC (cyclohexane/EtOAc; 40%), cold water was added. The aqueous phase was extracted five times with CH 2 CI 2 . The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The obtained residue was purified with silica gel chromatography (cyclohexane/EtOAc; 0-40%) to afford the pure product as colorless resin (3.54 g, 91%). fe/t- butyl 3-((3a/?,4/?,6S,6a5)-6-hydroxy-2,2-dimethyltetrahydro-4//-cy clopenta[</|[1,3]dioxol-4- yl)piperidine-1-carboxylate (197):

Compound 196 (0.02 g, 0.05 mmol) was dissolved in MeOH () under nitrogen atmosphere. Then, palladium on activated charcoal moistened with water (0.01 g, 10 mol%) was added and the mixture was degassed. The reaction mixture was then purged with hydrogen (balloon) and stirred upon complete consumption. After 17 h, the reaction mixture was set under nitrogen atmosphere and was filtered over celite. The filter cake was rinsed with MeOH and the filtrate was concentrated under reduced pressure. The obtained crude product was purified over silica gel chromatography (cyclohexane/EtOAc; 0-50%) to afford the title product as colorless resin (). APCI: calc, for C 18 H 32 NO 5 [M + H] + : 342.22, found: 4-iodo-7//-pyrrolo[2,3-</|pyrimidine (198):

A mixture of 4-chloro-7//-pyrrolo[2,3-</|pyrimidine (3.00 g, 19.34 mmol) and hydroiodic acid (57%, 4.34 g, 19.34 mmol) was stirred at room temperature overnight. The resulted solid was filtered off, and suspended with water. The suspension was cooled down to 0 °C and the pH was subsequently adjusted to 8 by adding aqueous ammonia solution. The solid was filtered off, washed with cold water and dried to complete dryness to afford the title product as beige solid (4191 mg, 8

7//-pyrrolo Compound 198 (2.00 g, 8.08 mmol) was dissolved in MeOH (40.40 mL) under nitrogen atmosphere. Then, Et 3 N (1.71 mL, 12.12 mmol) was added, and the resulted solution was degassed. Palladium on activated charcoal moistened with water (1.72 g, 0.81 mmol) was added and the mixture was degassed. Afterwards the reaction mixture was purged with hydrogen (ballon) and stirred at ambient temperature overnight. After 17 h, the reaction mixture was purged with nitrogen and filtered over celite. The filtrate was concentrated under reduced pressure. The obtained residue was purified over silica (cyclohexane/EtOAc; 0-100%) to afford the pure product (853 mg, 89%).

5-iodo-7//-pyrrolo[2,3-</|pyrimidine (200):

I to H ™

Compound 199 (0.84 g, 7.00 mmol) and NIS (1.67 g, 7.35 mmol) was stirred in dry MeCN (11.70 mL under nitrogen atmosphere. The solution was concentrated to complete dryness and the obtained crude product was purified by flash chromatography (cyclohexane/EtOAc; 0-100%) to afford the title product (1.44 g, 84%).

4-iodo-7-((2-(trimethylsilyl)ethoxy)methyl)-7//-pyrrolo[2 ,3-d|pyrimidine (201):

4-iodo-7//-pyrrolo[2,3-</|pyrimidine (2.16 g, 7.52 mmol) was dissolved in dry DMF (25.10 mL) and cooled down to 0 °C. The solution was treated portion wise with sodium hydride (60% in mineral oil, 0.33 g, 8.27 mmol) and stirred for 15 min. Then, a solution of SEMCI (1.41 mL, 7.89 mmol) in DMF was added and the mixture was stirred for 1 h. The mixture was partitioned between EtOAc and water. The organic layer was separated and the aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified by flash chromatography (cyclohexane/EtOAc; 0-30%) to afford the title product as white soid (2.36 g, 84%). ethyl 2,2-difluoro-2-(7-((2-(trimethylsilyl)ethoxy)methyl)-7//-pyr rolo[2,3-</|pyrimidin-4-yl)acetate

Compound 201 (2.00 g, 5.28 mmol) was added to a heat dried three-necked round bottom flask under nitrogen atmosphere. Then, Cui (1.22 g, 6.33 mmol), CsF (1.13 g, 7.39 mmol), and dry DMSO (17.60 mL) was added. The resulted mixture was degassed and at last TMSCF 2 CO 2 Et (2.07 mL, 10.55 mmol) was added. The reaction mixture was stirred at 70 °C for 18 h. Then, the reaction mixture was allowed to cool down to rt and then diluted with water and EtOAc. The organic layer was separated, and the aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The obtained residue was purified over silica (cyclohexane/EtOAc; 0-20%) to afford the title product (867 mg, 44%).

4-(difluoromethyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7 //-pyrrolo[2,3-o]pyrimidine (203):

To a solution of compound 202 (0.85 g, 2.27 mmol) in MeOH (2.30 mL) was added a 2 M sodium carbonate solution (4.53 mL, 9.06 mmol) and stirred at ambient temperature for 2 h. The reaction mixture was concentrated, and the obtained residue was taken up in water and the pH was adjusted to 4 with a 1 M HCI solution. The aqueous phase extracted with EtOAc.. The combined organic layers were dried over sodium sulfate and concentrated to complete dryness. The obtained residue was redissolved in DMF (26.30 mL). Then, KF (0.80 g, 13.59 mmol) was added and the resulted mixture was heated to 140 °C for 1 h. The mixture was allowed to cool down to rt and extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The crude product was purified over silica gel chromatography (650 mg, 96%).

4-(difluoromethyl)-7Z/-pyrrolo[2,3-o]pyrimidine (204): co

H IN

To a solution of compound 203 (0.64 g, 2.11 mmol) in CH 2 CI 2 (5.20 mL) was added TFA (5.20 mL). The reaction mixture was stirred at room temperature for 4h and then concentrated to complete dryness. The obtained residue was dissolved in MeOH (10.50 mL) and then ammonia solution (2.19 mL, 29.32 mmol) and ethylenediamine (0.07 mL, 1.06 mmol) were added. The reaction mixture was stirred for 2 h and concentrated. The obtained residue was diluted with water and pH was adjusted to 8. The aqueous phase was extracted with CH2CI2. The combined organic layers were dried over sodium sulfate and concentrated to obtain the title product (261 mg, 73%). fe/t- butyl 2-((3a/?,4/?,6a/^-2,2-dimethyl-6-oxotetrahydro-4Z/-cyclopent a[<7][1,3]dioxol-4- yl)pyrrolidine-1-carboxylate (205):

A heat-dried vial was charged with (-)-(3aR,6aR)-3a,6a-Dihydro-2,2-dimethyl-4H-cyclopenta-1,3- dioxol-4-one (0.20 g, 1.23 mmol), Boc-Pro-OH (0.80 g, 3.70 mmol), and anhydrous CsF (0.57 g, 3.70 mmol) under nitrogen atmosphere. Then, dry DMSO (12.30 mL, 0.10 M) was added followed by addition of 3 mol% (I r[d F(CF 3 )ppy] 2 (dtbpy))PF 6 (0.04 g, 0.04 mmol). The resulted solution was degassed for 15 min. Then, the reaction vial was irradiated by blue LED light at 467 nm at ambient temperature for 17 h. The reaction progress was monitored by TLC (petrol ether/EtOAc; 40%). Then, the reaction mixture was diluted with water and extracted with EtOAc (3x 50 mL). The combined organic layers were washed with brine (3x 50 mL), dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by flash chromatography (cyclohexane/EtOAc; 0-30%) to afford the title compound as colorless resin (425 mg, 85%, diastereomeric mixture). R f = 0.51 (cyclohexane/EtOAc; 30%). 1 H NMR (400 MHz, C DC l 3 ) <54.95 - 4.80 (m, 1H, HT), 4.70 (d, J = 5.2 Hz, 1H, HT), 4.47 - 4.38 (m, 1H, H2'), 4.34 - 4.23 (m, 1H, H2'), 4.08 - 3.97 (m, 1H, -CH 2 CH 2 CACH-), 3.74 - 3.66 (m, 1H, -CH 2 CH 2 CACH-), 3.57 - 3.39 (m, 2H, -NC/7 2 CH 2 CH 2 -), 3.38 - 3.28 (m, 1H, -NC/7 2 CH 2 CH 2 -), 3.24 - 3.09 (m, 1H, -NQ7 2 CH 2 CH 2 -), 2.75 - 2.67 (m, 1H, H4'), 2.67 - 2.59 (m, 1H, H4'), 2.54 - 2.43 (m, 2H, H3'), 2.30 - 2.18 (m, 1H, H4'), 2.15 - 2.05 (m, 1H, H4'), 1.97 - 1.78 (m, 5H, -NCH 2 C/7 2 C/7 2 -), 1.72 - 1.56 (m, 2H, -NCH 2 Q7 2 Q7 2 -), 1.46 (s, 9H, -NCO 2 C(CM) 3 ), 1.45 - 1.41 (m, 12H, -NHCO 2 C(CM) 3 , CH 3 , acetonide), 1.41 (s, 3H, CH 3 , acetonide), 1.35 - 1.33 (m, 3H, CH 3 , acetonide), 1.32 (s, 3H, CH 3 , acetonide). HRMS calcd.: 325.19; found: 348.19 [M+H] + . fe/t- butyl 2-((3a/?,4/?,6a/^-2,2-dimethyl-6-oxotetrahydro-4Z/-cyclopent a[<7][1,3]dioxol-4- yl)piperidine-1-carboxylate (206):

A heat-dried vial was charged with (-)-(3aR,6aR)-3a,6a-Dihydro-2,2-dimethyl-4H-cyclopenta-1,3- dioxol-4-one (0.25 g, 1.54 mmol), Boc-Pip-OH (1.07 g, 4.62 mmol), and anhydrous CsF (0.71 g, 4.62 mmol) under nitrogen atmosphere. Then, dry DMSO (7.70 mL, 0.20 M) was added followed by addition of 3 mol% (I r[d F(CF 3 )ppy] 2 (dtbpy))PF 6 (0.05 g, 0.05 mmol). The resulted solution was degassed for 15 min. Then, the reaction vial was irradiated by blue LED light at 467 nm at ambient temperature for 17 h. The reaction progress was monitored by TLC (petrol ether/EtOAc; 30%). Then, the reaction mixture was diluted with water and extracted with EtOAc (3x 50 mL). The combined organic layers were washed with brine (3x 50 mL), dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by flash chromatography (cyclohexane/EtOAc; 0-30%) to afford the title compound as colorless resin (435 mg, 94%, d.r. 2.3:1). R f = 0.54 (petrol ether/EtOAc; 30%). 1 H NMR (400 MHz, CDCI 3 ) 54.53 - 4.47 (m, 2H, HT), 4.43 - 4.30 (m, 2H, H2'), 4.10 - 3.91 (m, 2H, -CH 2 CH 2 CACH-), 2.98 - 2.67 (m, 2H, H3'), 2.64 - 2.46 (m, 2H, H4', -NCHCA 2 -), 2.27 - 2.07 (m, 2H, H4'), 1.95 - 1.83 (m, 2H, -NC/7 2 C/7 2 -), 1.75 - 1.54 (m, 12H, -NC^C^C^CAH 1-46 (s, -NHCO 2 C(Q7 3 ) 3 ), 1.45 (s, 3H, CH 3 , acetonide), 1.43 (s, 3H, CH 3 , acetonide), 1.41 (s, -NHCO 2 C(CM) 3 ), 1.35 (s, 3H, CH 3 , acetonide), 1.30 (s, 3H, CH 3 , acetonide). HRMS calcd.: 339.20; found: 378.19 [M + Na] + . fe/t- butyl (3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carba mate (207):

A three-necked round bottom flask was charged with te/f-butyl (3-bromobenzyl)carbamate (5.00 g, 17.30 mmol), Kac (5.15 g, 51.89 mmol), B 2 Pin 2 (5.32 g, 20.76 mmol), and Pd(dppf)CI 2 (1.28 g, 1.73 mmol) under nitrogen atmosphere. Then, 1,4-dioxane (0.30 M, 57.70 mL) was added, and the resulted mixture was degassed. Then, the mixture was heated to 80 °C and stirred for 17 h. before, it was diluted with water and extracted with EtOAc. The combined organic layers were washed with water, dried over sodium sulfate, and concentrated under vacuo. The crude product was purified over silica gel chromatography (cyclohexane/EtOAc; 0-20%) to afford the desired compound x as white solid (5.49 g, 95%). 1 H NMR (400 MHz, DMSO-<5 6 ) <57.58 (s, 1H, H6 aryl), 7.55 - 7.51 (m, 1H, H4 aryl), 7.40 (t, J= 6.1 Hz, 1H, -NACO 2 -), 7.37 - 7.30 (m, 2H, H2, H3 aryl), 4.13 (d, 7 = 6.2 Hz, 2H, -C# 2 NH-), 1.40 (s, 9H, -NHCO 2 C(C# 3 ) 3 ), 1-30 (s, 12H, -BO 2 (C(C #3)2)2). APCI: calc, for C 18 H 29 BNO 4 [M + H] + : 334.21, found: 567.2 [2M + H -Boc] + . -tetramethyl-1,3 ; 2-dioxaborolan-2-yl)phenoxy)silane (208):

To a solution of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (1.21 g, 5.52 mmol, 1.0 eq.) in dry DMF (12 mL) was added imidazole (938.6 mg, 13.79 mmol, 2.6 eq.), then TBSCI (984.9 mg, 6.54 mmol, 1.2 eq.). The solution was stirred for 18.6 h at RT, then the reaction mixture was quenched with ice water and extracted two times with EtOAc. Afterwards the combined organic layers were washed with brine, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with Cyclohexane/EtOAc (0— >1 %) to afford tert-butyldimethyl(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan -2- yl)phenoxy)silane (yield: 1.43 g, 4.29 mmol, 79 %) as a transparent oil. R f = 0.62 (Cyclohexane/EtOAc 96:4). APCI: calcd. for C 18 H 3 iBO 3 Si [M + H] + : 335.2 found 335.1. 1 H NMR (400 MHz, DMSO-d6) 5 7.30 - 7.25 (m, 2H, oH, /77-H), 7.09 - 7.07 (m, 1H, />H), 7.00 - 6.95 (m, 1H, o- H), 1.28 (s, 12H, 4 x CH 3 ), 0.95 (s, 9H, C(CH 3 ) 3 ), 0.17 (s, 6H, Si(CH 3 ) 2 ). -tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)silane (209):

To a solution of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (1.21 g, 5.50 mmol) in dry DMF (12 mL) was added imidazole (934 mg, 13.72 mmol, 2.5 eq.) followed by TBSCI (981 mg, 6.51 mmol, 1.2 eq.). After 18.3 h stirring at rt, more TBSCI (334 mg, 2.21 mmol, 0.4 eq.) was added. The solution was stirred for 24 h, then concentrated to remove DMF. 100 mL ice water was added, then extracted two times with ethyl acetate. The combined organic layers were washed with brine, dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by flash chromatography eluting with Cyclohexane/EtOAc (0->10 %) to give tert-butyldimethyl(4-(4, 4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)silane (yield: 1.53 g, 4.58 mmol, 83 %), as a transparent oil that solidified after a few days in the fridge. R f = 0.31 (Cyclohexane/EtOAc 98:2). APCI: calcd. for C 18 H 31 BO 3 Si [M + H] + : 335.2 found 335.1 1 H NMR (400 MHz, DMSO-d6) 5 7.59-7.56 (m, 2H, 2 x oH), 6.86-6.83 (m, 2H, 2 x /77-H), 1.27 (s, 12H, 4 x CH 3 ), 0.94 (s, 9H, C(CH 3 ) 3 ), 0.18 (s, 6H, Si(C# 3 ) 2 ).

4,4,5,5-tetramethyl-2-(3-(2-methyl-1,3-dioxolan-2-yl)phen yl)-1,3,2-dioxaborolane (210): r x ° K °~7\

To a mixture of 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)eth an-1-one (999 mg, 4.06 mmol, 1 eq.) and ethylene glycol (2.2 mL, 39 mmol, 9.7 equiv) in toluene (40 mL) was added p-tolylsulfonic acid trihydrate (39 mg, 0.2 mmol, 0.05 eq.). The mixture was refluxed (at 140 °C) for 18 h over a Dean-Stark apparatus to remove generated water. Then, the solvent was removed under reduced pressure and the residue was purified by silica chromatography eluting with Cyclohexane/EtOAc (1->15 %) to give 4,4,5,5-tetramethyl-2-(3-(2-methyl-1,3-dioxolan-2- yl)phenyl)-1,3,2-dioxaborolane (yield: 433 mg, 1.49 mmol, 37 %) as a white solid. R f = 0.25 (Cyclohexane/EtOAc 95:5). APCI: calcd. for C 16 H 23 BO 4 [M + H] + : 291.2 found 290.8. 1 H NMR (400 MHz, DMSO-<7 6 ) 5 7.75-7.72 (m, 1H, oH), 7.61 (dt, 7= 7.4, 1.3 Hz, 1H, oH), 7.55-7.52 (m, 1H, />H), 7.40-7.35 (m, 1H, /77-H), 3.98 (td, 7 = 6.1 Hz, 4.2 Hz, 2H, CH 2 . ketal), 3.67 (td, 7 = 6.0 Hz, 4.1 Hz, 2H, CH 2 , ketal), 1.54 (s, 3H, CH 3 , ketal), 1.30 (s, 12H, 4 x CH 3 , pinacol ester). fe/t- butyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carba mate (211):

2190 mg (10.00 mmol; 1.00 eq) of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline were dissolved in 50 mL of DMF. 2728 mg (12.50 mmol; 1.25 eq) of Boc 2 O and 2.77 mL (20.00 mmol; 2.00 eq) of Et 3 N were added. The reaction mixture was heated at 90 °C for 72 h. The solvent was removed under reduced pressure and the residue was purified by column chromatography (Petrolether/EtOAc 99:1% to 65:35%) to give 2700 mg (8.46 mmol; 85%) of the title compound in the form of a colorless solid. 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 9.52 (s, 1H), 7.58-7.51 (m, 2H), 7.50-7.43 (m, 2H), 1.47 (s, 9H), 1.27 (s, 12H) ppm. fe/t- butyl (3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carba mate (212):

2190 mg (10.00 mmol; 1.00 eq) of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline were dissolved in 50 mL of DMF. 2728 mg (12.50 mmol; 1.25 eq) of Boc 2 O and 2.77 mL (20.00 mmol; 2.00 eq) of Et 3 N were added. The reaction mixture was heated at 90 °C overnight. The solvent was removed under reduced pressure and the residue was purified by column chromatography (Petrolether/EtOAc 99:1% to 65:35%) to give 2380 mg (7.45 mmol; 75%) of the title compound in the form of a colorless solid. TLC: Rf = 0.80 (Petrolether/EtOAc 3:1). 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 9.32 (s, 1H), 7.90 (s, 1H), 7.48-7.42 (m, 1H), 7.27-7.22 (m, 2H), 1.47 (s, 9H), 1.29 (s, 12H) ppm. -dichlorophenyl)-2,2-dimethyltetrahydro-4//-cyclopenta[<7 |[1,3]dioxol-4-one

Following the general procedure, compound 213 was obtained starting from (3a/?,6aA)-2,2- dimethyl-3a,6a-dihydro-4//-cyclopenta[<7|[1,3]dioxol-4-on e (1.00 g, 6.16 mmol), 2-(3,5- dichlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.55 mg, 9.24 mmol), [Cp*RhCI 2 ] 2 (0.31 g, 0.62 mmol), and KOH (0.07 g, 1.23 mmol) in dry degassed 1,4-dioxane (0.15 M, 41.10 mL) and degassed water (5.00 M, 1.20 mL) after column chromatography on silica (cyclohexane/EtOAc; 0-20%) as yellowish resin (1190 mg, 64%). R f = 0.44 (cyclohexane/EtOAc; 20%). 1 H NMR (400 MHz, DMSO-o6) 57.52 (t, 7 = 1.9 Hz, 1H, p-k\\ 7.40 - 7.39 (m, 2H, oAr), 4.75 (dd, 7 = 6.1, 3.5 Hz, 1H, H1'), 4.66 - 4.62 (m, 1H, H2'), 3.56 (td, 7 = 8.7, 3.8 Hz, 1H, H3'), 2.90 (dd, 7 = 18.3, 8.6 Hz, 1H, H4'), 2.65 (ddd, 7= 18.2, 8.0, 1.5 Hz, 1H, H5'), 1.41 (s, 3H, CM, acetonide), 1.28 (s, 3H, CM, acetonide). APCI: calc, for C 14 H 15 CI 2 O 3 [M + H] + : 301.03, found: 301.20/303.20.

(6/^-2, 2-dimethyl-6-phenyltetrahydro-4M-cyclopenta[d|[1,3]dioxol-4- one (214):

Following the general procedure H, compound 214 was obtained starting from (3a/?,6aA)-2,2- dimethyl-3a,6a-dihydro-4M-cyclopenta[5|[1,3]dioxol-4-one (1.00 g, 6.16 mmol), 4, 4,5,5- tetramethyl-2-phenyl-1,3,2-dioxaborolane (1.95 g, 9.24 mmol), [Cp*RhCI 2 ]2 (0.31 g, 0.62 mmol), and KOH (0.07 g, 1.23 mmol) in dry degassed 1,4-dioxane (0.15 M, 41.10 mL) and degassed water (5.00 M, 1.20 mL) after column chromatography on silica (cyclohexane/EtOAc; 0-30%) as yellowish resin (1143 mg, 80%). R f = 0.57 (cyclohexane/EtOAc; 30%). 1 H NMR (400 MHz, DMSO-o6) 57.38 - 7.32 (m, 2H, /77-Ar), 7.29 - 7.25 (m, 1H, />Ar), 7.25 - 7.21 (m, 2H, oAr), 4.72 (dd, 7 = 5.8, 2.5 Hz, 1H, H1'), 4.57 (dt, 7 = 5.8, 0.9 Hz, 1H, H2'), 3.55 (ddd, 7 = 8.7, 5.8, 2.6 Hz, 1H, H3'), 3.02 - 2.90 (m, 1H, H4'), 2.54 (dd, 7 = 5.7, 1.7 Hz, 1H, H4'), 1.42 - 1.39 (m, 3H, CM 3 , acetonide), 1.28 (d, 7 = 0.7 Hz, 3H, CM, acetonide). APCI: calc, for C 14 H 16 O 3 [M + H] + : 233.11, found: 233.20. -dimethyl-6-(naphthalen-2-yl)tetrahydro-4M-cyclopenta [o][1,3]dioxol-4-one

Following the general procedure H, compound 215 was obtained starting from (3a/?,6aA)-2,2- dimethyl-3a,6a-dihydro-4M-cyclopenta[5|[1,3]dioxol-4-one (1.00 g, 6.16 mmol), 4, 4,5,5- tetramethyl-2-(naphthalen-2-yl)-1,3,2-dioxaborolane (1.95 g, 9.24 mmol), [Cp*RhCI 2 ] 2 (0.31 g, 0.62 mmol), and KOH (0.07 g, 1,23 mmol) in dry degassed 1,4-dioxane (0.15 M, 41.10 mL) and degassed water (5.00 M, 1.20 mL) after column chromatography on silica (cyclohexane/EtOAc; 0- 30%) as yellowish resin (1290 mg, 62%). R f = 0.47 (cyclohexane/EtOAc; 20%). 1 H NMR (400 MHz, DMSO-o6) 5 7.94 - 7.86 (m, 3H, H4/5/8 naphthyl), 7.73 - 7.69 (m, 1H, H1, naphthyl), 7.54 - 7.48 (m, 2H, H3/H6 naphthyl), 7.48 - 7.43 (m, 1H, H7 naphthyl), 4.85 (dd, 7 = 5.8, 2.5 Hz, 1H, H1'), 4.64 (dt, 7 = 5.8, 0.9 Hz, 1H, H2'), 3.73 (ddd, 7 = 8.7, 5.9, 2.6 Hz, 1H, H3'), 3.08 - 2.99 (m, 1H, H4'), 2.66 (ddd, 7 = 18.3, 5.8, 1.2 Hz, 1H, H4'), 1.43 (s, 3H, CM 3 , acetonide), 1.31 (s, 3H, CM 3 , acetonide). APCI: calc, for C 18 H 19 O 3 [M + H] + : 283.13, found: 283.20.

(3a/?,6/?,6a/tO-2,2-dimethyl-6-(pyridin-4-yl)tetrahydro-4 M-cyclopenta[d|[1,3]dioxol-4-one (216): Following the general procedure H, compound 216 was obtained starting from (3a/?,6aA)-2,2- dimethyl-3a,6a-dihydro-4M-cyclopenta[5|[1,3]dioxol-4-one (1.00 g, 6.16 mmol), 4-(4, 4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.95 g, 9.24 mmol), [Cp*RhCI 2 ] 2 (0.31 g, 0.62 mmol), and KOH (0.07 g 1.23 mmol) in dry degassed 1,4-dioxane (0.15 M, 41.10 mL) and degassed water (5.00 M, 1.20 mL) after column chromatography on silica (cyclohexane/EtOAc; 100%) as yellowish resin (1099 mg, 76%). R f = 0.37 (cyclohexane/EtOAc; 100%). 1 H NMR (400 MHz, DMSO-o6) 58.55 - 8.51 (m, 2H, H2/6 pyridine), 7.33 - 7.28 (m, 2H, H3/5, pyridine), 4.75 (dd, 7 = 5.9, 3.1 Hz, 1H, H1'), 4.60 (dt, 7 = 5.9, 0.9 Hz, 1H, H2'), 3.56 (ddd, 7 = 9.4, 6.7, 3.1 Hz, 1H, H3'), 3.01 - 2.89 (m, 1H), 2.60 (ddd, 7 = 18.3, 6.8, 1.6 Hz, 1H, H4'), 1.41 (s, 3H, CM, acetonide), 1.29 (s, 3H, CM, acetonide). APCI: calc, for C 13 H 16 NO 3 [M + H] + : 234.11, found: 234.30.

(3a/?,6S,6aA0-2,2-dimethyl-6-(thiophen-2-yl)tetrahydro-4M cyclopenta[<^[1,3]dioxol-4-one (217):

Following the general procedure H, compound 217 was obtained starting from (3a/?,6aA)-2,2- dimethyl-3a,6a-dihydro-4Mcyclopenta[<7|[1,3]dioxol-4-one (1.00 g, 6.16 mmol), 4, 4,5,5- tetramethyl-2-(thiophen-2-yl)-1,3,2-dioxaborolane (2.00 g, 9.24 mmol), [Cp*RhCI 2 ]2 (0.16 g, 0.31 mmol), and KOH (0.07 g, 1.23 mmol) in dry degassed 1,4-dioxane (0.15 M, 41.10 mL) and degassed water (5.00 M, 1.20 mL) after column chromatography on silica (cyclohexane/EtOAc; 0- 30%) as colorless resin (320 mg, 22%). R f = 0.27 (cyclohexane/EtOAc; 20%). 1 H NMR (400 MHz, DMSO-o6) <5 1 H NMR (400 MHz, DMSO-M) S 7.45 (dd, 7 = 5.1, 1.2 Hz, 1H, H5 thiophene), 7.01 - 6.98 (m, 1H, H4 thiophene), 6.95 (dt, 7 = 3.5, 1.1 Hz, 1H, H3 thiophene), 4.82 (dd, 7 = 5.7, 2.3 Hz, 1H, H1'), 4.46 (ddt, 7 = 5.7, 1.6, 0.8 Hz, 1H, H2'), 3.84 - 3.78 (m, 1H, H3'), 3.09 - 3.01 (m, 1H, H4'), 2.58 - 2.51 (m, 1H, H4'), 1.39 (s, 3H, CH 3 , acetonide), 1.30 (s, 3H, CH 3 , acetonide). APCI: calc, for +: 239.07, found: 239.10. -dimethyl-6-(1Mpyrazol-5-yl)tetrahydro-4Mcyclopenta[d|[1,3]d ioxol-4-one

Following the general procedure H, compound 218 was obtained starting from (3a/?,6aA)-2,2- dimethyl-3a,6a-dihydro-4Mcyclopenta[<7|[1,3]dioxol-4-one (0.80 g, 4.93 mmol), terf-butyl 5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1Mpyrazole-1-c arboxylate (2.24 g, 7.39 mmol), [Cp*RhCI 2 ]2 (0.25 g, 0.49 mmol), and KOH (0.06 g, 0.99 mmol) in dry degassed 1,4-dioxane (0.15 M, 32.90 mL) and degassed water (5.00 M, 1.00 mL) after column chromatography on silica (cyclohexane/EtOAc, 0-60%) as colorless resin (500 mg, 46%). Under standard conditions the boc group was cleaved off. 1 H NMR (400 MHz, DMSO-o6) <57.91 (dd, 7 = 2.3, 0.6 Hz, 1H, H3 pyrazol), 7.49 (d, 7 = 1.8 Hz, 1H, H4 pyrazol), 6.27 (t, 7 = 2.1 Hz, 1H, NM pyrazol), 5.17 (d, 7 = 7.6 Hz, 1H, H1'), 4.72 - 4.65 (m, 1H, H2'), 4.50 - 4.45 (m, 1H, H3'), 3.14 (dd, 7 = 18.1, 7.5 Hz, 1H, H4'), 2.39 - 2.31 (m, 1H, H4'), 1.40 (s, 3H, CH 3 , acetonide), 1.28 (s, 3H, CH 3 , acetonide). APCI: calc, for C 11 H 15 N 2 O 3 [M + H] + : 223.10, found: 223.20. dimethyl-6-(quinolin-6-yl)tetrahydro-4Mcyclopenta[o][1,3]dio xol-4-one (219):

Following the general procedure H, compound 219 was obtained starting from (3a/?,6aA)-2,2- dimethyl-3a,6a-dihydro-4Mcyclopenta[<7|[1,3]dioxol-4-one (0.80 g, 4.93 mmol), 6-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (1.95 g, 7.39 mmol), [Cp*RhCI 2 ]2 (0.25 g, 0.49 mmol), and KOH (0.06 g, 0.99 mmol) in dry degassed 1,4-dioxane (0.15 M, 32.90 mL) and degassed water (5.00 M, 1.00 mL) after column chromatography on silica (petrol ether/EtOAc; 0- 50%) as colorless resin (1066 , 76.3%). 1 H NMR (400 MHz, DMSO-o6) 58.89 (dd, 7 = 4.2, 1.7 Hz, 1H, H2 quinolin), 8.34 (ddd, 7 = 8.3, 1.5, 0.6 Hz, 1H, H3 quinolin ), 8.03 (d, 7 = 8.7 Hz, 1H, H8 quinolin), 7.81 (d, 7 = 2.0 Hz, 1H, H5 quinolin), 7.73 (dd, 7 = 8.7, 2.1 Hz, 1H, H7 quinolin), 7.54 (dd, 7 = 8.3, 4.2 Hz, 1H, H4 quinolin), 4.87 (dd, 7= 5.9, 2.7 Hz, 1H, H1'), 4.69 - 4.65 (m, 1H, H2'), 3.78 (ddd, 7 = 8.9, 6.1, 2.7 Hz, 1H, H3'), 3.10 - 3.01 (m, 1H, H4'), 2.70 (ddd, 7 = 18.3, 6.1, 1.4 Hz, 1H, H4'), 1.44 (s, 3H, CM, acetonide), 1.32 (s, 3H, CM, acetonide). APCI: calc, for C 17 H 18 NO 3 [M + H] + : 284.12, found: 283.90. fe/A butyl (3-((3a/?,4/?,6a/tO-2,2-dimethyl-6-oxotetrahydro-4Mcyclopent a[<7][1,3]dioxol-4- yl)benzyl)carbamate (220):

Following the general procedure H, compound 220 was obtained starting from (3a/?,6aA)-2,2- dimethyl-3a,6a-dihydro-4Mcyclopenta[5|[1,3]dioxol-4-one (1.65 g, 10.17 mmol), compound 207 (5.24 g, 15.25 mmol), [Cp*RhCI 2 ]2 (0.51 g, 1.02 mmol), and KOH (0.12 g, 2.03 mmol) in dry degassed 1,4-dioxane (0.15 M, 67.80 mL) and degassed water (5.00 M, 2.00 mL) after column chromatography on silica (n-heptane/EtOAc; 0-50%) as colorless resin (3160 mg, 86%). 1 H NMR (400 MHz, DMSO-o6) 57.31 (t, 7 = 6.0 Hz, 1H- NA), 7.27 - 7.21 (m, 1H, /77-Ar), 7.10 - 7.01 (m, 3H, o,/>Ar), 4.65 (dd, 7 = 5.8, 2.5 Hz, 1H, H1'), 4.52 - 4.48 (m, 1H, H2'), 4.06 (d, 7 = 6.1 Hz, 2H, - NHCMO, 3.48 (ddd, 7 = 8.5, 5.6, 2.4 Hz, 1H, H3'), 2.91 (dd, 7 = 18.1, 8.8 Hz, 1H, H4'), 2.48 - 2.41 (m, 1H, H4', under DMSO peak) 1.35 (s, 12H, -NCO 2 C(CM) 3 , CM3, acetonide), 1.23 (s, 3H, CM3, acetonide). APCI: calc, for C20H28NO5 [M + H] + : 362.19, found: 623.10 [2M + H, -Boc] + .

(3a/?,6/?,6a/^-6-(3-((7e/Abutyldimethylsilyl)oxy)phenyl)- 2,2-dimethyltetrahydro-4M cyclopenta[o][1,3]dioxol-4-one (221):

Following the general procedure H, compound 221 was obtained starting from (3a/?,6aA)-2,2- dimethyl-3a,6a-dihydro-4Mcyclopenta[5|[1,3]dioxol-4-one (0.45 g, 2.94 mmol), compound 208 (1.49 g, 4.46 mmol), [Cp*RhCI 2 ]2 (0.15 g, 0.30 mmol), and KOH (0.04 g, 0.68 mmol) in dry degassed 1,4-dioxane (10.00 mL) and degassed water (0.50 mL) after column chromatography on silica (cyclohexane/EtOAc; 1-15%) as yellow resin (857 mg, 85%). R f = 0.26 (Cyclohexane/EtOAc 9:1). APCI: calcd. for C 2 oH3o0 4 Si [M + H] + : 363.2 found 263.0, 305.0, 363.1. 1 H NMR (400 MHz, DMSO-d6) 5 7.23 (t, 7 = 7.9 Hz, 1H, /77-H), 6.82 - 6.80 (m, 1H, oH), 6.74 (ddd, 7 = 8.1, 2.4, 0.9 Hz, 1H, oH), 6.70 - 6.69 (m, 1H, />H), 4.70 (dd, 7 = 5.8, 2.7 Hz, 1H, H3'), 4.51 (dt, 7 = 5.8 Hz, 1H, H2'), 3.52-3.48 (m, 1H, H4'), 2.94 (dd, 7= 18.0, 8.9 Hz, 1H, H5' A ), 2.47 (m, 1H, H5' B ), 1.40 (s, 3H, CH 3 , acetonide), 1.28 (s, 3H, CH 3 , acetonide), 0.95 (s, 9H, C(CH 3 ) 3 ), 0.18 (s, 6H, Si(CH 3 ) 2 ).

(3a/?,6/?,6a/^-6-(4-((7e/7-butyldimethylsilyl)oxy)phenyl) -2,2-dimethyltetrahydro-4Z/- cyclopenta[o][1,3]dioxol-4-one (222):

Following the general procedure H, compound 222 was obtained starting from (3a/?,6aA)-2,2- dimethyl-3a,6a-dihydro-4//-cyclopenta[<7|[1,3]dioxol-4-on e (0.50 g, 3.21 mmol), 209 (1.51 g, 4.48 mmol), [Cp*RhCI 2 ] 2 (0.16 g, 0.32 mmol), and KOH (0.03 g, 0.60 mmol) in dry degassed 1,4- dioxane (10.00 mL) and degassed water (0.60 mL) after column chromatography on silica (cyclohexane/EtOAc; 1-10%) as orange resin (1000 mg). R f = 0.16 (Cyclohexane/EtOAc 9:1). APCI: calcd. for C 2 oH 30 0 4 Si [M + H] + : 363.2 found 263.0, 304.9. -chlorophenyl)-2,2-dimethyltetrahydro-4//-cyclopenta[<7|[ 1,3]dioxol-4-one

Following the general procedure H, compound 223 was obtained starting from (3a/?,6aA)-2,2- dimethyl-3a,6a-dihydro-4//-cyclopenta[<7|[1,3]dioxol-4-on e (0.61 g, 3.92 mmol), 2-(3- chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.31 g, 5.51 mmol), [Cp*RhCI 2 ]2 (0.19 g, 0.37 mmol), and KOH (0.04 g, 0.78 mmol) in dry degassed 1,4-dioxane (25.00 mL) and degassed water (0.70 mL) after column chromatography on silica (petrol ether/EtOAc; 0-12%) as yellowish solid (718 mg, 69%). R f = 0.14 (Petrolether/EtOAc 9:1). APCI: calcd. for C 14 H 15 CIO 3 [M + H] + : 267.1 found 250.7 (-H 2 O) 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 7.41 - 7.32 (m, 3H, oH, /77-H, />H), 7.24- 7.20 (m, 1H, oH), 4.74 (dd, 7= 6.0, 3.1 Hz, 1H, H3'), 4.62-4.58 (m, 1H, H2'), 3.59-3.52 (m, 1H, H4'), 2.97-2.88 (m, 1H, H5 A ‘), 2.59 (ddd, 7 = 18.2, 7.0, 1.6 Hz, 1H, H5 B '), 1.40 (s, 3H, CH 3 , acetonide), 1.28 (s, 3H, CH 3 , acetonide).

(3a/?,6/?,6a/^-2,2-dimethyl-6-(3-(2-methyl-1,3-dioxolan-2 -yl)phenyl)tetrahydro-4Z/- cyclopenta[o][1,3]dioxol-4-one (224):

Following the general procedure H, compound 224 was obtained starting from (3a/?,6aA)-2,2- dimethyl-3a,6a-dihydro-47/-cyclopenta[<7|[1,3]dioxol-4-on e (0.16 g, 1.02 mmol), compound 210 (0.43 g, 1.46 mmol), [Cp*RhCI 2 ] 2 (0.05 g, 0.10 mmol), and KOH (0.01 g, 0.23 mmol) in dry degassed 1,4-dioxane (6.50 mL) and degassed water (0.20 mL) after column chromatography on silica (cyclohexane/EtOAc; 1-50%) as yellow liquid (238 mg, 73%). R f = 0.21 (Petrolether/EtOAc 8:2). APCI: calcd. for C 18 H 22 O 5 [M + H] + : 319.2 found 318.8 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 7.38 - 7.28 (m, 3H, oH, />H, /77-H), 7.17 (dt, 7 = 7.1, 1.8 Hz, 1H, oH), 4.73 (dd, 7 = 5.9, 2.8 Hz, 1H, H3'), 4.58-4.54 (m, 1H, H2'), 3.98 (td, 7 = 6.3 Hz, 3.9 Hz, 2H, CH 2 , ketal), 3.69 (td, 7 = 5.9 Hz, 3.7 Hz, 2H, CH 2 , ketal), 3.60-3.52 (m, 1H, H4'), 2.96 (dd, 7 = 18.2 Hz, 8.8 Hz, 1H, H5' A ), 2.60 - 2.52 (m, 1H, H5' B ), 1.55 (s, 3H, CH3, ketal), 1.41 (s, 3H, CH3, acetonide), 1.29 (s, 3H, CH3, acetonide). fe/t- butyl (4-((3ar,4r,6ar)-2,2-dimethyl-6-oxotetrahydro-4//-cyclopenta [d][1,3]dioxol-4- yl)phenyl)carbamate (225):

570 mg (5.64 mmol; 1.00 eq) of (3ar,6ar)-2,2-dimethyl-3a,6a-dihydro-4/7- cyclopenta[d][1,3]dioxol-4-one were dissolved in 50 mL of Dioxane and 5 mL of dist. H 2 O.

2700 mg (8.46 mmol; 1.50 eq) of te/f-butyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)carbamate, 63 mg (1.12 mmol; 0.20 eq) of KOH and 276 mg (0.56 mmol; 0.10 eq) of Rh((COD)CI) 2 were added. The reaction mixture was heated under refluxation and inert gas atmosphere overnight. The solvent was removed under reduced pressure and the residue was purified by column chromatography (Cyclohexane/EtOAc 99:1% to 0:100%). The product was used without further characterization. TLC: R/ = 0.52 (Cyclohexane/EtOAc 2:1). fe/t- butyl (3-((3ar,4r,6ar)-2,2-dimethyl-6-oxotetrahydro-4//-cyclopenta [d][1,3]dioxol-4- yl)phenyl)carbamate (226):

1044 mg (6.77 mmol; 1.00 eq) of (3ar,6ar)-2,2-dimethyl-3a,6a-dihydro-4/7- cyclopenta[d][1,3]dioxol-4-one were dissolved in 50 mL of Dioxane and 5 mL of dist. H 2 O.

2380 mg (7.45 mmol; 1.10 eq) of terf-butyl (3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)carbamate, 77 mg (1.35 mmol; 0.20 eq) of KOH and 341 mg (0.68 mmol; 0.10 eq) of Rh((COD)CI) 2 were added. The reaction mixture was heated under refluxation and inert gas atmosphere overnight. The solvent was removed under reduced pressure and the residue was purified by column chromatography (Cyclohexane/EtOAc 99:1% to 50:50%). The product (1100 mg; 3.16 mmol; 47%) was used without further characterization. TLC: R/ = 0.76 (Cyclohexane/EtOAc 1:1). -dichlorophenyl)-2,2-dimethyltetrahydro-4//-cyclopenta[d|[1, 3]dioxol-4-ol

Following the general procedure for ketone reduction I, compound 227 was obtained starting from compound 213 (0.86 g, 2.82 mmol), NaBH 4 (0.16 g, 4.24 mmol) in dry MeOH (0.20 M, 14.10 mL) after column chromatography on silica (cyclohexane/EtOAc; 0-100%) as colorless resin (731 mg, 85%). R f = 0.44 (cyclohexane/EtOAc; 30%). 1 H NMR (400 MHz, DMSO-o6) 67.47 - 7.45 (m, 1H, p-Ar), 7.29 (dd, 7 = 1.9, 0.6 Hz, 2H, oAr), 4.65 - 4.57 (m, 1H, H3', 4.59 - 4.52 (m, 1H, H2'), 4.51 (d, 7 = 5.2 Hz, 1H, -OH), 3.96 (dq, 7 = 7.3, 5.1 Hz, 1H, HT), 3.25 (td, 7 = 6.9, 2.9 Hz, 1H, H4'), 2.11 (dt, 7 = 12.7, 7.4 Hz, 1H, H5'), 1.81 (dt, 7 = 12.7, 5.5 Hz, 1H, H5'), 1.46 (s, 3H, CM, acetonide), 1.28 (s, 3H, CM, acetonide). APCI: calc, for C 14 H 17 CI 2 O 3 [M + H] + : 303.05, found: 303.10/305.10. dimethyl-6-phenyltetrahydro-4M-cyclopenta[d|[1,3]dioxol-4-ol (228):

Following the general procedure for ketone reduction I, compound 228 was obtained starting from compound 214 (1.13 g, 4.82 mmol), NaBH 4 (0.28 g, 7.22 mmol) in dry MeOH (0.20 M,

24.10 mL) after column chromatography on silica (cyclohexane/EtOAc; 0-50%) as colorless resin (954 mg, 85%). R f = 0.22 (cyclohexane/EtOAc; 30%). 1 H NMR (400 MHz, DMSO-M) <57.33 - 7.28 (m, 2H, /77-Ar), 7.22 - 7.17 (m, 3H, o,/>Ar), 4.60 (dd, 7 = 6.3, 2.3 Hz, 1H, H3'), 4.57 - 4.49 (m, 1H, H2'), 4.45 (d, 7 = 5.7 Hz, 1H, -OH), 4.04 - 3.95 (m, 1H, H1'), 3.19 (ddd, 7= 7.5, 5.1, 2.3 Hz, 1H, H4'),

2.10 (dt, 7 = 12.5, 7.8 Hz, 1H, H5'), 1.79 (dt, 7 = 12.5, 5.2 Hz, 1H, H5'), 1.46 (s, 3H, CM 3 , acetonide), 1.27 (s, 3H, CM 3 , acetonide). APCI: calc, for C 14 H 19 O 3 [M + H] + : 235.13, found: 235.20. -dimethyl-6-(naphthalen-2-yl)tetrahydro-4M-cyclopenta[d|[1,3 ]dioxol-4-ol

Following the general procedure for ketone reduction I, compound 229 was obtained starting from compound 215 (2.17 g, 7.60 mmol), NaBH 4 (0.44 g, 11.40 mmol) in dry MeOH (0.20 M, 38.00 mL) after column chromatography on silica (cyclohexane/EtOAc; 0-60%) as colorless resin (2251 mg, 7.92 mmol). R f = 0.85 (cyclohexane/EtOAc; 50%). APCI: calc, for C 18 H 2 IO 3 [M + H] + : 285.13, found: 285.10. -dimethyl-6-(pyridin-4-yl)tetrahydro-4M-cyclopenta[a][1,3]di oxol-4-ol (230):

Following the general procedure for ketone reduction I, compound 230 was obtained starting from compound 216 (1.09 g, 4.63 mmol), NaBH 4 (0.27 g, 6.94 mmol) in dry MeOH (0.20 M,

23.10 mL) after column chromatography on silica (CH 2 CI 2 /MeOH; 0-10%) as colorless resin (862 mg, 79%). R f = 0.22 (EtOAc; 100%). 1 H NMR (400 MHz, DMSO-M) <58.49 - 8.46 (m, 2H, H2, H6 pyridine), 7.25 - 7.22 (m, 2H, H3, H5 pyridine), 4.62 (dd, 7 = 6.2, 2.4 Hz, 1H, H3'), 4.56 (d, 7 = 5.6 Hz, 1H, -OH), 4.55 - 4.51 (m, 1H, H2'), 4.00 - 3.92 (m, 1H, H1'), 3.19 (ddd, 7 = 7.6, 5.1, 2.4 Hz, 1H, H4'), 2.12 (dt, 7 = 12.7, 7.9 Hz, 1H, H5'), 1.82 (dt, 7 = 12.5, 5.2 Hz, 1H, H5'), 1.46 (s, 3H, CM 3 , acetonide), 1.28 (s, 3H, CM, acetonide). APCI: calc, for C 13 H 18 NO 3 [M + H] + : 236.12, found: 236.30. -dimethyl-6-(thiophen-2-yl)tetrahydro-4M-cyclopenta[a][1,3]d ioxol-4-ol (231): Following the general procedure for ketone reduction I, compound 231 was obtained starting from compound 217 (0.32 g, 0.79 mmol), NaBH 4 (0.05 g, 1.19 mmol) in dry MeOH (0.20 M, 4.00 mL) after column chromatography on silica (cyclohexane/EtOAc; 0-50%) as colorless resin (265 mg, 84%). R f = 0.72 (cyclohexane/EtOAc; 50%). 1 H NMR: (400MHz DMSO-d 6 ): 5 7.37 (dd, J = 5.1, 1.2 Hz, 1H, H5-thiophene), 6.95 (dd, J = 5.1, 3.5 Hz, 1H, H4 thiophene), 6.91 (dt, J = 3.5, 1.2 Hz, 1H, H3-thiophene), 4.50 - 4.45 (m, 1H, H1'), 4.05 - 3.96 (m, 1H, H3'), 3.42 - 3.24 (m, 1H, H4'), 2.17 - 2.06 (m, 1H. H5'), 1.89 (m, 1H, H5'), 1.47 - 1.41 (m, 3H, CM), 1.27 (d, J = 0.7 Hz, 3H, CM). APCI: calc, for C 12 H 17 O 3 S [M + H] + : 241.08, found: 241.20. -dimethyl-6-(1M-pyrazol-5-yl)tetrahydro-4M-cyclopenta[<7] [1,3]dioxol-4-ol

Following the general procedure for ketone reduction I, compound 232 was obtained starting from compound 218 (0.59 g, 1.81 mmol), NaBH 4 (0.10 g, 2.72 mmol) in dry MeOH (0.20 M, 9.10 mL) after column chromatography on silica (cyclohexane/EtOAc; 0-50%) as colorless resin (315 mg, 76%). R f = 0.44 (cyclohexane/EtOAc; 50%). 1 H NMR (400 MHz, DMSO-M) S 8.70 (s, 1H, H2), 8.07 (d, 7 = 3.7 Hz, 1H, H6), 7.90 (dd, 7= 2.3, 0.6 Hz, 1H, H3 pyrazol), 7.56 (dd, 7 = 1.8, 0.5 Hz, 1H, -NM pyrazol), 6.77 (d, 7 = 3.7 Hz, 1H, H5), 6.32 (dd, 7 = 2.3, 1.9 Hz, 1H, H4 pyrazol), 5.32 - 5.25 (m, 1H, H1'), 5.10 (dd, 7 = 7.7, 5.6 Hz, 1H, H2'), 5.02 (dd, 7 = 7.7, 5.4 Hz, 1H, H3'), 4.93 - 4.85 (m, 1H, H4'), 3.01 (q, 7 = 12.2 Hz, 1H, H5'), 2.76 - 2.66 (m, 1H, H5'), 1.56 (s, 3H, CM 3 , acetonide), 1.40 (s, 3H, CM, acetonide). APCI: calc, for CnH^N^ [M + H] + : 225.12, found: 225.00. -dimethyl-6-(quinolin-6-yl)tetrahydro-4M-cyclopenta[d|[1,3]d ioxol-4-ol (233):

Following the general procedure for ketone reduction I, compound 233 was obtained starting from compound 219 (0.45 g, 1.57 mmol), NaBH 4 (0.09 g, 2.36 mmol) in dry MeOH (0.20 M, 7.90 mL) after column chromatography on silica (petrol ether /EtOAc; 0-100%) as colorless resin (370 mg, 1.30 mmol). R f = 0.09 (cyclohexane/EtOAc; 60%). APCI calcd.: 285.14; found: 285.90 [M + H] + . 1 H NMR (400 MHz, DMSO-M) S 8.85 (dd, 7 = 4.2, 1.7 Hz, 1H, H2 quinoline), 8.35 - 8.30 (m, 1H, H4 quinoline), 7.97 (d, 7 = 8.7 Hz, 1H, H8 quinoline), 7.78 - 7.76 (m, 1H, H5 quinoline), 7.64 (dd, 7 = 8.8, 2.1 Hz, 1H, H7 quinoline), 7.51 (dd, 7 = 8.3, 4.2 Hz, 1H, H3 quinoline), 4.73 (dd, 7 = 6.2, 2.3 Hz, 1H, H3'), 4.62 - 4.57 (m, 1H, H2'), 4.56 - 4.49 (m, 1H, -CHOA), 4.10 - 4.05 (m, 1H, H1'), 3.43 - 3.37 (m, 1H, H4'), 2.19 (dt, 7 = 12.6, 7.9 Hz, 1H, H5'), 1.99 - 1.89 (m, 1H, H5'), 1.49 (s, 3H, CM, acetonide), 1.30 (s, 3H, CM, acetonide). Note: product contained 30% of the unfavored alcohol. fe/A butyl (3-((3a/?,4/?,6S,6a5)-6-hydroxy-2,2-dimethyltetrahydro-4M-cy clopenta[d|[1,3]dioxol-4- yl)benzyl)carbamate (234):

Following the general procedure for ketone reduction I, compound 234 was obtained starting from compound 220 (3.15 g, 8.63 mmol), NaBH 4 (0.50 g, 12.94 mmol) in dry MeOH (0.20 M, 43.10 mL) after column chromatography on silica (n-heptane/EtOAc; 0-50%) as white solid (2311 mg, 74%). R f = 0.32 (n-heptane/EtOAc; 50%). 1 H NMR (400 MHz, DMSO-o6) 57.38 (t, 7 = 6.0 Hz, 1H, -NA), 7.28 - 7.21 (m, 1H, /77-Ar), 7.10 - 7.03 (m, 3H, o,/>Ar), 4.58 (dd, 7 = 6.1, 2.1 Hz, 1H, H3'), 4.54 - 4.49 (m, 1H, H2'), 4.11 (d, 7 = 6.2 Hz, 1H, H1'), 4.03 - 3.97 (m, 2H, -NHCM-), 3.20 - 3.13 (m, 1H, H4'), 2.09 (dt, 7 = 12.5, 7.9 Hz, 1H, H5'), 1.80 (dt, 7 = 12.3, 5.1 Hz, 1H, H5'), 1.47 (s, 3H, CM, acetonide), 1.41 (s, 9H, -NCO 2 C(CM) 3 ), 1-28 (s, 3H, CM, acetonide). APCI: calc, for C 2 oH 3 oN0 5 [M + H] + : 364.20, found: 623.10 [2M + H, -Boc] + . fe/A butyl 2-((3a/?,4/?,6S,6a5)-6-hydroxy-2,2-dimethyltetrahydro-4Mcycl openta[<7][1,3]dioxol-4- yl)pyrrolidine-1-carboxylate (235):

Following the general procedure for ketone reduction I, compound 235 was obtained starting from compound 205 (0.35 g, 1.07 mmol), NaBH 4 (0.06 g, 1.60 mmol) in dry MeOH (0.20 M, 5.30 mL) after column chromatography on silica (cyclohexane/EtOAc; 0-40%) as a colorless resin (260 mg, 75%). Rf = 0.15 (petrol ether/EtOAc; 30%). 1 H NMR (400 MHz, CDCI 3 ) 54.66 - 4.30 (m, 4H, H2', H3'), 4.21 - 4.03 (m, 2H, HT), 3.86 - 3.59 (m, 2H, -NCM-), 3.58 - 3.28 (m, 3H, - NCM 2 CH 2 CH 2 -), 3.25 (ddd, 7= 11.7, 8.0, 3.7 Hz, 1H, -NCM 2 CH 2 CH 2 -), 2.41 (s, 2H, -OH), 2.20 - 2.09 (m, 1H, H4'), 2.03 - 1.60 (m, 13H, H4', H5', -NCH 2 CM 2 CM 2 -), 1-49 (s, 3H, CH 3 , acetonide), 1.49 - 1.42 (m, 21H, -NCO 2 C(CM) 3 , CM acetonide), 1.34 (s, 3H, CM acetonide), 1.32 (s, 3H, CM acetonide). HRMS calcd.: 327.20; found: 350.19 [M + Na] + . fe/A butyl 2-((3a/?,4/?,6S,6a5)-6-hydroxy-2,2-dimethyltetrahydro-4Mcycl openta[<7][1,3]dioxol-4- yl)piperidine-1-carboxylate (236):

Following the general procedure for ketone reduction I, compound 236 was obtained starting from compound 206 (0.40 g, 1.17 mmol), NaBH 4 (0.07 g, 1.75 mmol) in dry MeOH (0.20 M, 5.80 mL) after column chromatography on silica (cyclohexane/EtOAc; 0-40%) as a colorless resin (300 mg, 75%). R f = 0.26 (petrol ether/EtOAc; 30%). 1 H NMR (400 MHz, Chloroform-o) 54.51 (dd, 7 = 6.6, 5.2 Hz, 1H, H2'), 4.27 (dd, 7 = 6.7, 3.1 Hz, 1H, H3'), 4.17 - 3.72 (m, 3H, H1', H6 piperidine), 2.76 - 2.58 (m, 2H, H4', H2 piperidine), 2.54 - 2.36 (m, 1H, H2 piperidine), 1.85 - 1.74 (m, 2H, H5', H5 piperidine), 1.70 - 1.53 (m, 5H, H3, H4, H5 piperidine), 1.51 (s, 3H, CM acetonide), 1.49 (s, 3H (1.4), CH 3 , acetonide), 1.47 - 1.41 (m, 9H, -NCO 2 C(C// 3 ) 3 ), 1-34 (s, 3H, CH 3 , acetonide),

1.29 (s, 3H (1.7), CH 3 , acetonide).

(3aS,4S,6/?,6a/^-6-(3-((7e/7-butyldimethylsilyl)oxy)pheny l)-2,2-dimethyltetrahydro-4Z/- cyclopenta[o] [1, 3] d ioxo I -4-o I (237):

Following the general procedure for ketone reduction I, compound 237 was obtained starting from compound 221 (0.84 g, 2.33 mmol), NaBH 4 (0.18 g, 4.68 mmol) in dry MeOH (0.20 M, 6.00 mL) after column chromatography on silica (cyclohexane/EtOAc; 1-21%) as a colorless resin (506 mg, 60%). R f = 0.29 (Cyclohexane/EtOAc 8:2). APCI: calcd. for C 2 oH 3 20 4 Si [M + H] + : 365.2 found 289.0, 363.9, 364.9. 1 H NMR (400 MHz, DMSO-d6) 5 7.18 (t, J = 7.8 Hz, 1H, /77-H), 6.78 (d, J = 7.7 Hz, 1H, oH), 6.70 - 6.67 (m, 1H, oH), 6.64-6.63 (m, 1H, />H), 4.58-4.54 (m, 1H, H3'), 4.52 - 4.50 (m, 1H, H2'), 4.47 (d, J = 5.6 Hz, 1H, OH), 3.98 (dq, J = 8.1, 5.3 Hz, 1H, HT), 3.16-3.12 (m, 1H, H4'), 2.08 (dt, J = 12.6, 7.9 Hz, 1H, H5' A ), 1.77 (dt, J = 12.5, 5.2 Hz, 1H, H5' B ), 1.46 (s, 3H, CH 3 . acetonide), 1.28 (s, 3H, CH 3 , acetonide), 0.95 (s, 9H, C(CH 3 ) 3 ), 0.18 (s, 6H, Si(CH 3 ) 2 ) (3aS,4S,6/?,6a/^-6-(4-((7e/7-butyldimethylsilyl)oxy)phenyl)- 2,2-dimethyltetrahydro-4Z/- cyclopenta[o] [1, 3] d ioxo I -4-o I (238):

Following the general procedure for ketone reduction I, compound 238 was obtained starting from compound 222 (0.99 g, 2.71 mmol), NaBH 4 (0.22 g, 5.74 mmol) in dry MeOH (0.20 M, 7.00 mL) after column chromatography on silica (CH 2 CI 2 /MeOH; 0.1-1%) as a colorless resin (612 mg). R f = 0.32 (Petrolether/EtOAc 8:2). APCI: calcd. for C 20 H 32 O 4 Si [M + H] + : 365.2 found 289.0, 364.0, 365.0. 1 H NMR (400 MHz, DMSO-d6) 5 7.08-7.03 (m, 2 H, 2 x oH), 6.79-6.75 (m, 2H, 2 x /77-H), 4.56-4.52 (m, 1H, H3'), 4.52-4.48 (m, 1H, H2'), 4.42 (d, J = 5.6, 1H, OH), 4.00 - 3.94 (m, 1H, HT), 3.14 - 3.10 (m, 1H, H4-), 2.05 (dt, 7 = 12.6 Hz, 7.8 Hz, 1H, H5' A ), 1.80 - 1.72 (m, 1H, H5' B ), 1.45 (s, 3H, CH 3 , acetonide), 1.26 (s, 3H, CH 3 , acetonide), 0.94 (s, 9H, C(C// 3 ) 3 ), 0.16 (s, 6H, Si(C/V 3 ) 2 ). s from cyclohexane (used for flash chromatography) were detected at 1.5 3.6 ppm by NMR 3-chlorophenyl)-2,2-dimethyltetrahydro-4//-cyclopenta[d|[1,3 ]dioxol-4-ol

Following the general procedure for ketone reduction I, compound 239 was obtained starting from compound 223 (0.71 g, 2.65 mmol), NaBH 4 (0.21 g, 5.42 mmol) in dry MeOH (0.20 M, 7.00 mL) after column chromatography on silica (CH 2 CI 2 /MeOH; 0.1-1%) as a colorless resin (181 mg, 25%). R f = 0.21 (Petrolether/EtOAc 8:2). APCI: calcd. for C 14 H 17 CIO 3 [M + H] + : 269.1 found 253 (-H 2 O) 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 7.37-7.32 (m, 1H, /77-H), 7.30-7.26 (m, 2H, />H, oH), 7.19-7.16 (m, 1H, oH), 4.62-4.58 (m, 1H, H3'), 4.57-4.52 (m, 1H, H2'), 4.49 (d, 7 = 5.4 Hz, 1H, OH), 3.98 (dq, 7 = 7.7, 5.2 Hz, 1H, HT), 3.25-3.20 (m, 1H, H4'), 2.11 (dt, 7 = 12.7, 7.6 Hz, 1H, H5 A '), 1.80 (dt, 7 = 12.7, 5.5 Hz, 1H, H5 B '), 1.47 (s, 3H, CH 3 , acetonide), 1.28 (s, 3H, CH 3 , acetonide).

(3aS,4S,6/?,6a/^-2,2-dimethyl-6-(3-(2-methyl-1,3-dioxolan -2-yl)phenyl)tetrahydro-4//- cyclopenta[o] [1, 3] d ioxo I -4-o I (240):

Following the general procedure for ketone reduction I, compound 240 was obtained starting from compound 224 (0.23 g, 0.72 mmol), NaBH 4 (0.04 g, 1.08 mmol) in dry MeOH (0.20 M, 7.00 mL) after column chromatography on silica (cyclohexane/EtOAc; 5-50%) as a colorless resin (200 mg). APCI: calcd. for C 18 H 24 O 5 [M + H] + : 321.2 found 320.8/366.7. fe/t- butyl (4-((3a/?,4/?,6S,6a5)-6-hydroxy-2,2-dimethyltetrahydro-4//-c yclopenta[d|[1,3]dioxol-4- yl)phenyl)carbamate (241):

3330 mg (9.59 mmol; 1.00 eq) of te/f-butyl (4-((3ar,4r,6ar)-2,2-dimethyl-6-oxotetrahydro-4/7- cyclopenta[d][1,3]dioxol-4-yl)phenyl)carbamate were dissolved in 40 mL of MeOH. After cooling with an ice-bath to 0 °C, 545 mg (14.39 mmol; 1.50 eq) of NaBH 4 were added portionwise. The reaction mixture was warmed to RT and thereby continuously stirred for 4 h. The solvent was then removed under reduced pressure and the resulting residue was purified by flash chromatography (Cyclohexane/EtOAc 99:1% to 50:50%) to give the desired compound (300 mg; 0.86 mmol; 9%) in the form of a colorless liquid. TLC: R/ = 0.63 (Cyclohexane/EtOAc 1:1). 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 9.26 (s, 1H), 7.41-7.33 (m, 2H), 7.09-7.01 (m, 2H), 4.57-4.53 (m, 1H), 4.51- 4.48 (m, 1H), 4.42 (d, 7 = 5.8 Hz, 1H), 4.00-3.93 (m, 1H), 3.13-3.07 (m, 1H), 2.08-2.01 (m, 1H), 1.79- 1.72 (m, 1H), 1.46 (s, 9H), 1.45 (s, 3H), 1.27 (s, 3H) ppm. fe/t- butyl (3-((3a/?,4/?,6S,6a5)-6-hydroxy-2,2-dimethyltetrahydro-4//-c yclopenta[d|[1,3]dioxol-4- yl)phenyl)carbamate (242):

1100 mg (3.16 mmol; 1.00 eq) of terf-butyl (3-((3ar,4r,6ar)-2,2-dimethyl-6-oxotetrahydro-4/7- cyclopenta[d][1,3]dioxol-4-yl)phenyl)carbamate were dissolved in 40 mL of MeOH. After cooling with an ice-bath to 0 °C, 179 mg (4.74 mmol; 1.50 eq) of NaBH 4 were added portionwise. The reaction mixture was warmed to RT and thereby continuously stirred for 2 h. The solvent was then removed under reduced pressure and the resulting residue was purified by flash chromatography (Cyclohexane/EtOAc 99:1% to 75:25%) to give the desired compound (950 mg; 2.72 mmol; 86%) in the form of a colorless liquid, which was used without further characterization. TLC: R/= 0.48 (Cyclohexane/EtOAc 1:1). fe/t- butyl (4-((3a/?,4/?,6/?,6a5)-6-(4-chloro-7Mpyrrolo[2,3-</|pyrim idin-7-yl)-2,2- dimethyltetrahydro-4Mcyclopenta[5|[1,3]dioxol-4-yl)phenyl)ca rbamate (243):

300 mg (0.86 mmol; 1.00 eq) of te/f-butyl (4-((3ar,4r,6as)-6-hydroxy-2,2-dimethyltetrahydro-4M cyclopenta[d][1,3]dioxol-4-yl)phenyl)carbamate were dissolved in 30 mL of Toluene under inert gas atmosphere. At 0 °C, 450 mg (1.72 mmol; 2.00 eq) of PPh 3 were added. 10 minutes later 400 mg (1.72 mmol; 2.00 eq) of Di-te/f-butyl-azodicarboxylate were attached. The reaction solution was stirred for further 10 minutes before 170 mg (1.12 mmol; 1.30 eq) of 4-chloro-7M pyrrolo[2,3-d]pyrimidine were added and the whole was heated to 80 °C overnight. The solvent was removed under reduced pressure and the crude was purified by column chromatography (Petrolether/EtOAc 99:1% to 60:40%; R f = 0.83 in Petrolether/EtOAc 1:1). The product was directly used without further characterization. Therefore 20 mL of Dioxane and 20 mL of a 25% aqueous solution of NH 3 were added. The reaction solution was heated to 100 °C in a sealed tube overnight. The solvent was then removed under reduced pressure and the resulting residue was adsorbed on silica and purified by flash chromatography (DCM/MeOH 99:1% to 90:10%). 260 mg (0.56 mmol; 65% over 2 steps) of the title compound were obtained in the form of a colorless foam. TLC: R/= 0.29 (DCM/MeOH 10:1). APCI-MS(+) m/z for Q5M9CIN4O4: calc.: 484.98; found: 485.0 and 487.0. APCI-MS(+) m/z for C 2 5H 31 N 5 O 4 : calc.: 465.55; found: 466.0 and 467.0.

4-chloro-7-((3aS,4/?,6/?,6aA)-6-(3,5-dichlorophenyl)-2,2- dimethyltetrahydro-4M cyclopenta[<^[1,3]dioxol-4-yl)-7Mpyrrolo[2,3-5|pyrimidine (244):

Following the general procedure for substitution/esterification J, compound 244 was obtained from first esterification of the alcohol 227 (0.36 g, 0.81 mmol) with Tf 2 O (2.00 eq.), dry pyridine (3.00 eq.) in CH 2 CI 2 (0.10 M) followed by substitution with NaH (60%, 0.07 g, 1.62 mmol), 6- chloro-7-deazapurine (0.15 g, 0.97 mmol) in dry DMF (0.08 M, 10.10 mL). After column chromatography on silica (petrol ether/EtOAc; 0-50%) as white foam (202 mg, 57%). 1 H NMR (400 MHz, DMSO-M) 58.68 (s, 1H, H2), 8.14 (d, 7 = 3.7 Hz, 1H, H6), 7.53 - 7.50 (m, 3H, o, />Ar), 6.79 (d, 7 = 3.7 Hz, 1H, H5), 5.36 - 5.25 (m, 1H, H1'), 4.94 (dd, 7 = 7.5, 5.3 Hz, 1H, H2'), 4.79 (t, 7 = 7.2 Hz, 1H, H3'), 3.41 - 3.34 (m, 1H, H4'), 2.63 - 2.53 (m, 2H, H5'), 1.54 (s, 3H, CM, acetonide), 1.23 (s, 3H, CM, acetonide).

5-bromo-4-chloro-7-((3aS,4/?,6/?,6a/i)-6-(3,5-dichlorophe nyl)-2,2-dimethyltetrahydro-4M cyclopenta[o][1,3]dioxol-4-yl)-7Mpyrrolo[2,3-</|pyrimidin e (245):

Following the general procedure for substitution/esterification J, compound 245 was obtained from first esterification of the alcohol 227 (0.65 g, 1.48 mmol) with Tf 2 O (2.00 eq.), dry pyridine (3.00 eq.) in CH 2 CI 2 (0.10 M) followed by substitution with NaH (60%, 0.12 g, 2.96 mmol), 6- chloro-7-deazapurine (0.42 g, 1.77 mmol) in dry DMF (0.08 M, 18.50 mL). After column chromatography on silica (petrol ether/EtOAc; 0-40%) as white foam (240 mg, 31%). 1 H NMR (400 MHz, DMSO-M) 58.72 (s, 1H, H2 adenine), 8.44 (s, 1H, H6 adenine), 7.54 - 7.50 (m, 3H, o,p- Ar), 5.33 (ddd, J = 11.8, 7.4, 5.0 Hz, 1H, H1'), 4.91 (dd, J = 7.6, 5.1 Hz, 1H, H2'), 4.75 (t, J = 72 Hz, 1H, H3'), 3.40 - 3.32 (m, 1H, H4'under water peak), 2.62 - 2.52 (m, 2H, H5'), 1.54 (s, 3H, CM, acetonide), 1.22 (s, 3H, CM, acetonide).

4-chloro-7-((3aS,4/?,6/?,6a/t)-2,2-dimethyl-6-phenyltetra hydro-4M-cyclopenta[d|[1,3]dioxol-4-yl)- 7M-pyrrolo[2,3-d|pyrimidine (246):

Following the general procedure for substitution/esterification J, compound 246 was obtained from first compound 228 (0.31 g, 0.72 mmol) with Tf 2 O (2.00 eq.), dry pyridine (3.00 eq.) in CH 2 CI 2 (0.10 M) followed by substitution with NaH (60%, 0.06 g, 1.45 mmol), 6-chloro-7-deazapurine (0.14 g, 0.87 mmol) in dry DMF (0.08 M, 9.00 mL) after column chromatography on silica (cyclohexane/EtOAc; 0-50%) as white foam (189 mg, 59%). R f = 0.59 (cyclohexane/EtOAc; 40%). 1 H NMR (400 MHz, DMSO-5 6 ) S 8.68 (s, 1H, H2), 8.12 (d, J = 3.7 Hz, 1H, H6), 7.43 - 7.33 (m, 4H, 0,/77-Ar), 7.29 - 7.24 (m, 1H, />Ar), 6.77 (d, J = 3.6 Hz, 1H, H5), 5.29 (ddd, 7 = 11.3, 7.6, 5.5 Hz, 1H, H1'), 5.00 (dd, J = 7.6, 5.5 Hz, 1H, H2'), 4.78 (t, J = 7.2 Hz, 1H, H3'), 3.34 - 3.26 (m, 1H, H4'), 2.64 - 2.54 (m, 2H, H5'), 1.54 (s, 3H, CM 3 , acetonide), 1.23 (s, 3H, CM, acetonide).

5-bromo-4-chloro-7-((3a5;4/?,6/?,6a/t)-2,2-dimethyl-6-phe nyltetrahydro-4M- cyclopenta[<^[1,3]dioxol-4-yl)-7M-pyrrolo[2,3-5|pyrimidin e (247):

Following the general procedure K for Mitsunobu-type glycosylation, compound 247 was obtained starting from compound 228 (0.62 g, 2.63 mmol), 6-chloro-7-deazapurine (0.86 g, 3.68 mmol), PPh 3 (1.39 g, 5.26 mmol), and DIAD (0.94 mL, 4.73 mmol) in dry THF (0.10 M, 26.30 mL) after column chromatography on silica (petrol ether/EtOAc; 0-40%) as white foam (673 mg, 57%). R f = 0.60 (cyclohexane/EtOAc; 30%). 1 H NMR (400 MHz, DMSO-M) 58.72 (s, 1H, H2), 8.43 (s, 1H, H5), 7.43 - 7.33 (m, 4H, o, m-kr), 7.30 - 7.22 (m, 1H, />Ar), 5.32 (ddd, 7 = 11.3, 7.6, 5.3 Hz, 1H, H1'), 4.96 (dd, 7 = 7.6, 5.3 Hz, 1H, H2'), 4.75 (t, 7 = 7.2 Hz, 1H, H3'), 3.32 - 3.25 (m, 1H, H4'), 2.63 - 2.51 (m, 2H, H5'), 1.53 (s, 3H, CM, acetonide), 1.22 (s, 3H, CM 3 , acetonide). 4-chloro-7-((3aS,4/?,6/?,6aA)-2,2-dimethyl-6-(naphthalen-2-y l)tetrahydro-4M cyclopenta[<^[1,3]dioxol-4-yl)-7Mpyrrolo[2,3-</|pyrimi dine (248):

Following the general procedure K for Mitsunobu-type glycosylation, compound 248 was obtained starting from compound 229 (0.20 g, 0.70 mmol), 6-chloro-7-deazapurine (0.15 g, 0.98 mmol), PPh 3 (0.37 g, 1.39 mmol), and DIAD (0.25 mL, 1.25 mmol) in dry THF (0.10 M, 7.00 mL) after column chromatography on silica (petrol ether/EtOAc; 0-50%) as white foam (210 mg, 0.50 mmol). R f = 0.71 (cyclohexane/EtOAc; 50%). 1 H NMR (400 MHz, DMSO-ofe) <58.70 (s, 1H, H2 adenine), 8.17 (d, 7 = 3.7 Hz, 1H, H6 adenine), 7.96 - 7.85 (m, 4H, H1, H4, H5, H8 naphthyl), 7.62 (dd, 7 = 8.5, 1.8 Hz, 1H, H3 naphthyl), 7.54 - 7.45 (m, 2H, H6, H7 naphthyl), 6.79 (d, 7 = 3.7 Hz, 1H, H5 adenine), 5.36 (dt, 7 = 12.1, 6.3 Hz, 1H, H1'), 5.05 (dd, 7 = 7.5, 5.5 Hz, 1H, H2'), 4.94 - 4.85 (m, 1H, H3'), 3.51 (dt, 7 = 13.0, 6.4 Hz, 1H, H4'), 2.79 - 2.62 (m, 2H, H5'), 1.58 (s, 3H, CM, acetonide), 1.25 (s, 3H, CM, acetonide).

2,4-dichloro-7-((3aS,4/?,6/?,6a/i)-2,2-dimethyl-6-(naphth alen-2-yl)tetrahydro-4M cyclopenta[o][1,3]dioxol-4-yl)-7Mpyrrolo[2,3-</|pyrimidin e (249):

Following the general procedure K for Mitsunobu-type glycosylation, compound 249 was obtained starting from compound 229 (0.44 g, 1.53 mmol), 6-chloro-7-deazapurine (0.41 g, 2.14 mmol), PPh 3 (0.81 g, 3.10 mmol), and DIAD (0.54 mL, 2.75 mmol) in dry THF (0.10 M, 15.20 mL) after column chromatography on silica (petrol ether/EtOAc; 0-50%) as white foam (268 mg, 39%). 1 H NMR (400 MHz, DMSO-M) <57.93 - 7.84 (m, 4H, H4, H5, H8 naphthyl, H6 adenine), 7.83 - 7.81 (m, 1H, H1 naphthyl), 7.54 - 7.45 (m, 4H, H3, H6, H7 naphthyl, H5 adenine), 4.83 - 4.75 (m, 2H, H2', H3'), 4.38 - 4.31 (m, 1H, H1'), 3.38 - 3.30 (m, 1H, H4' under water peak), 2.75 (dt, 7 = 12.7, 6.3 Hz, 1H, H5'), 2.26 (td, 7 = 12.4, 11.0 Hz, 1H, H5'), 1.52 (s, 3H, CH 3 , acetonide), 1.28 (s, 3H, CM, acetonide).

4-chloro-7-((3aS,4/?,6/?,6aA)-2,2-dimethyl-6-(pyridin-4-y l)tetrahydro-4Mcyclopenta[<^[1,3]dioxol- 4-yl) -7M pyrrole [2, 3 - d\ pyri m id i ne (250) :

Following the general procedure K for Mitsunobu-type glycosylation, compound 250 was obtained starting from compound 230 (0.20 g, 0.84 mmol), 6-chloro-7-deazapurine (0.19 g, 1.18 mmol), PPh 3 (0.45 g, 1.68 mmol), and DIAD (0.30 mL, 1.52 mmol) in dry THF (0.15 M, 5.60 mL) after column chromatography on silica (petrol ether/EtOAc; 0-100%) as white foam (359 mg, 0.97 mmol). R f = 0.78 (cyclohexane/EtOAc; 50%). 1 H NMR (400 MHz, DMSO-M) <58.68 (s, 1H, H2 adenine), 8.56 - 8.52 (m, 2H, H2, H6 pyridine), 8.11 (d, 7 = 3.7 Hz, 1H, H6 adenine), 7.45 - 7.41 (m, 2H, H3, H5 pyridine), 6.78 (d, 7 = 3.7 Hz, 1H, H5), 5.39 - 5.27 (m, 1H, H1'), 4.99 (dd, 7 = 7.5, 5.3 Hz, 1H, H2'), 4.82 (t, 7 = 7.2 Hz, 1H, H3'), 3.39 - 3.34 (m, 1H, H4'), 2.65 - 2.57 (m, 2H, H5'), 1.55 (s, 3H, C// 3 , acetonide), 1.24 (s, 3H, C// 3 , acetonide).

4-chloro-7-((3aS,4/?,6S,6a/^-2,2-dimethyl-6-(thiophen-2-y l)tetrahydro-4//- cyclopenta[<^[1,3]dioxol-4-yl)-7//-pyrrolo[2,3-5|pyrimidi ne (251):

Following the general procedure K for Mitsunobu-type glycosylation, compound 251 was obtained starting from compound 231 (0.25 g, 1.03 mmol), 6-chloro-7-deazapurine (0.34 g, 1.44 mmol), PPh 3 (0.55 g, 2.06 mmol), and DIAD (0.37 mL, 1.85 mmol) in dry THF (0.25 M, 4.10 mL) after column chromatography on silica (petrol ether/EtOAc; 0-50%) as colorless resin (197 mg, 51%). R f = 0.73 (cyclohexane/EtOAc; 50%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.68 (s, 1H, H2), 8.08 (d, 7 = 3.7 Hz, 1H, H6), 7.42 (dd, 7 = 4.8, 1.5 Hz, 1H, H5 thiophene), 7.04 - 6.99 (m, 2H, H3, H4 thiophene), 6.75 (d, 7 = 3.6 Hz, 1H, H5), 5.28 (ddd, 7= 10.7, 8.1, 5.2 Hz, 1H, H1'), 5.00 (dd, 7 = 7.5, 5.2 Hz, 1H, H2'), 4.77 (t, 7 = 7.2 Hz, 1H, H3'), 3.56 (dt, 7 = 11.3, 7.3 Hz, 1H, H4'), 2.68 - 2.59 (m, 2H, H5'), 1.54 (s, 3H, CH 3 , acetonide), 1.24 (s, 3H, CH 3 , acetonide).

4-chloro-7-((3aS,4/?,6/?,6a/^-2,2-dimethyl-6-(1Z/-pyrazol -5-yl)tetrahydro-4Z/- cyclopenta[o][1,3]dioxol-4-yl)-7//-pyrrolo[2,3-d|pyrimidine (252):

Following the general procedure K for Mitsunobu-type glycosylation, compound 252 was obtained starting from compound 232 (0.26 g, 0.79 mmol), 6-chloro-7-deazapurine (0.31 g, 1.11 mmol), PPh 3 (0.42 g, 1.59 mmol), and DIAD (0.29 mL, 1.43 mmol) in dry THF (0.15 M, 5.30 mL) after column chromatography on silica (petrol ether/EtOAc; 0-50%) as white foam (267 mg, 0.58 mmol). R f = 0.42 (petrol ether/EtOAc; 50%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.70 (s, 1H, H2), 8.07 (d, 7 = 3.7 Hz, 1H, H6), 7.90 (dd, 7 = 2.3, 0.6 Hz, 1H, H3 pyrazol), 7.56 (dd, 7 = 1.8, 0.5 Hz, 1H, - N/7 pyrazol), 6.77 (d, 7 = 3.7 Hz, 1H, H5), 6.32 (dd, 7 = 2.3, 1.9 Hz, 1H, H4 pyrazol), 5.32 - 5.25 (m, 1H, HT), 5.10 (dd, 7 = 7.7, 5.6 Hz, 1H, H2'), 5.02 (dd, 7 = 7.7, 5.4 Hz, 1H, H3'), 4.93 - 4.85 (m, 1H, H4'), 3.01 (q, 7 = 12.2 Hz, 1H, H5'), 2.76 - 2.66 (m, 1H, H5'), 1.56 (s, 3H, CH 3 , acetonide), 1.40 (s, 3H, CH 3 , acetonide).

6-((3a/?,4/?,6/?,6a5)-6-(2,4-dichloro-7//-pyrrolo[2,3-5|p yrimidin-7-yl)-2,2-dimethyltetrahydro-4//- cyclopenta[o][1,3]dioxol-4-yl)quinoline (253):

Following the general procedure K for Mitsunobu-type glycosylation, compound 253 was obtained starting from compound 233 (0.25 g, 0.87 mmol), 6-chloro-7-deazapurine (0.23 g, 1.21 mmol), PPh 3 (0.46 g, 1.74 mmol), and DIAD (0.32 mL, 1.56 mmol) in dry THF (0.15 M, 5.80 mL) after column chromatography on silica (petrol ether/EtOAc; 0-40%) as white foam (100 mg, 25%). 1 H NMR (400 MHz, DMSO-5 6 ) 5 8.90 - 8.86 (m, 1H, H2 quinoline), 8.35 (d, 7 = 8.6 Hz, 1H. H4 quinoline), 8.21 (d, 7 = 3.7 Hz, 1H, H6 adenine), 8.05 (d, 7 = 8.8 Hz, 1H, H8 quinoline), 7.94 (d, 7 = 1.8 Hz, 1H, H5 quinoline), 7.87 (dd, 7 = 8.8, 2.0 Hz, 1H, H7 quinoline), 7.58 - 7.51 (m, 1H, H3 quinoline), 6.87 (d, 7 = 3.7 Hz, 1H, H5, adenine), 5.34 - 5.25 (m, 1H, H1'), 5.03 - 4.99 (m, 1H, H2'), 4.92 - 4.87 (m, 1H, H3'), 3.62 - 3.53 (m, 1H, H4'), 2.72 - 2.64 (m, 2H, H5'), 1.59 (s, 3H, CM, acetonide), 1.26 (s, 3H, CM, acetonide). fe/t- butyl (3-((3a/?,4/?,6/?,6a5)-6-(5-bromo-2,4-dichloro-7M-pyrrolo[2, 3-o]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4M-cyclopenta[d|[1,3]dioxol-4-yl)benzyl)c arbamate (254):

Following the general procedure L for Mitsunobu-type glycosylation, compound 254 was obtained starting from 5-bromo-2,4-dichloro-7M-pyrrolo[2,3-t/|pyrimidine (0.62 g, 2.30 mmol), compound 234 (1.27 g, 3.45 mmol), PPh 3 (1.22 g, 4.60 mmol), and DBAD (0.56 M, 1.07 g, 4.60 mmol) in dry toluene (0.40 M, 5.70 mL) after column chromatography on silica (petrol ether/THF; 0-30%) as yellowish foam (525 mg, 37%). 1 H NMR (400 MHz, DMSO-o6) 58.45 (s, 1H, H6), 7.39 (t, 7 = 6.2 Hz, 1H, -CH 2 NACO 2 C(CH 3 ) 3 ), 7.34 - 7.23 (m, 1H, H2, H4, H5 aryl), 7.16 - 7.11 (m, 1H, H6 aryl), 5.28 - 5.17 (m, 1H, HT), 4.94 (dd, 7= 7.5, 5.2 Hz, 1H, H2'), 4.73 (t, 7 = 7.2 Hz, 1H, H3'), 4.13 (d, 7 = 6.2 Hz, 2H, -CM 2 NHCO 2 C(CH 3 ) 3 ), 3.32 - 3.25 (m, 1H, H4'), 2.58 - 2.51 (m, 2H, H5'), 1.54 (s, 3H, CM 3 , acetonide), 1.40 (s, 9H, -NHCO 2 C(CM 3 ) 3 ), 1.22 (s, 3H, CM, acetonide). fe/t- butyl 2-((3a/?,4/?,6/?,6a5)-6-(4-chloro-7M-pyrrolo[2,3-5|pynmidin- 7-yl)-2,2- dimethyltetrahydro-4M-cyclopenta[d|[1,3]dioxol-4-yl)pyrrolid ine-1-carboxylate (255):

Following the general procedure L for Mitsunobu-type glycosylation, compound 255 was obtained starting from 4-chloro-7M-pyrrolo[2,3-5|pyrimidine (0.10 g, 0.62 mmol), compound 235 (0.31 g, 0.93 mmol), PPh 3 (0.33 g, 1.24 mmol), and DBAD (1.10 M, 0.29 g, 1.24 mmol) in dry toluene (0.20 M, 3.10 mL) after column chromatography on silica (petrol ether/THF; 0-30%) as white foam (diastereomeric mix, 182 mg, 64%, d.r. 1.5:1). R f = 0.24 (petrol ether/THF; 30%). 1 H NMR (400 MHz, DMSO-o6) 5 8.65 (s, 2H, H2), 8.03 (d, 7 = 3.7 Hz, 1H, H6), 7.96 (bs, 1H, H6), 6.74 (d, 7 = 3.6 Hz, 2H, H5), 5.10 - 4.90 (m, 3H, HT, H2'), 4.89 - 4.66 (m, 1H, H3'), 4.60 - 4.52 (m, 1H, H3'), 4.47 - 4.16 (m, 1H, H2'), 4.06 - 3.96 (m, 1H, -NCM-), 3.96 - 3.89 (m, 1H, -NCM-), 3.41 - 3.12 (m, 4H, -NCM 2 CH 2 CH 2 -), 2.47 - 2.05 (m, 6H, H4', H5'), 2.03 - 1.66 (m, 8H, -NCH 2 CM 2 CM 2 -), 1.47 (s, 3H, CM?, acetonide), 1.48 - 1.36 (m, 15H, -NCO 2 C(CM 3 ) 3 , CH 3 , acetonide), 1.34 (s, 9H, - NCO 2 C(CM 3 ) 3 ), 1.23 (s, 3H, CH 3 , acetonide). APCI calc.: 462.20; found: 463.00/465.00 [M + H] + . fe/t- butyl (/^-2-((3a/?,4/?,6/?,6a5)-6-(4-chloro-7M-pyrrolo[2,3-d|pyrim idin-7-yl)-2,2- dimethyltetrahydro-4M-cyclopenta[d|[1,3]dioxol-4-yl)piperidi ne-1-carboxylate (256):

Following the general procedure L for Mitsunobu-type glycosylation, compound 256 was obtained starting from 4-chloro-7//-pyrrolo[2,3-5|pyrimidine (0.11 g, 0.71 mmol), compound 236 (0.37 g, 1.06 mmol), PPh 3 (0.38 g, 1.42 mmol), and DBAD (1.10 M, 0.33 g, 1.42 mmol) in dry toluene (0.50 M, 1.40 mL) after column chromatography on silica (petrol ether/THF; 0-30%) as white foam (165 mg, 49%). 1 H NMR (400 MHz, DMSO-o6) 58.64 (s, 1H, H2), 7.93 (d, 7 = 22.6 Hz, 1H, H6), 6.73 (d, 7 = 3.7 Hz, 1H, H5), 5.18 - 4.94 (m, 2H, HT, H2'), 4.54 - 4.46 (m, 1H, H3'), 4.29 - 4.07 (m, 1H, - CANCO 2 C(CH 3 ) 3 ), 3.92 - 3.71 (m, 1H, -NCO 2 C(CH 3 ) 3 Q7 2 -), 2.97 - 2.68 (m, 2H, NCO 2 C(CH 3 ) 3 Q7 2 -, H4'), 2.31 - 2.19 (m, 1H, H5'), 2.10 - 2.01 (m, 1H, H5'), 1.83 (d, 7 = 11.7 Hz, 1H, - NCO 2 C(CH 3 ) 3 CH 2 C7/ 2 -), 1.57 (s, 5H, -NCO 2 C(CH 3 ) 3 CH 2 C// 2 C// 2 C// 2 -), 1.49 (s, 3H, CH 3 , acetonide), 1.30 (s, 9H, -NCO 2 C(CM) 3 ), 1.22 (s, 3H, CH 3 , acetonide). fe/t- butyl 3-((3a/?,4/?,6/?,6a5)-6-(5-iodo-7Z/-pyrrolo[2 / 3-5|pynmidin-7-yl)-2,2-dimethyltetrahydro- 4//-cyclopenta[d|[1,3]dioxol-4-yl)piperidine-1-carboxylate (257):

Following the general procedure L for Mitsunobu-type glycosylation, compound 257 was obtained starting from 5-iodo-77/-pyrrolo[2,3-5|pyrimidine (0.20 g, 0.81 mmol), compound 197 (0.42 g, 1.21 mmol), PPh 3 (0.43 g, 1.62 mmol), and DBAD (1.10 M, 0.38 g, 1.62 mmol) in dry toluene (0.50 M, 1.60 mL) after column chromatography on silica (petrol ether/THF; 0-30%) as white foam (269 mg, 59%). fe/t- butyl 3-((3a/?,4/?,6/?,6a5)-2,2-dimethyl-6-(5-(thiazol-2-yl)-7Z/-p yrrolo[2 / 3-d|pyrimidin-7- yl)tetrahydro-4//-cyclopenta[5|[1,3]dioxol-4-yl)piperidine-1 -carboxylate (258):

Compound 257 (0.26 g, 0.45 mmol) was added to a heat-dried vial under nitrogen. Then, Pd(Ph 3 ) 2 CI 2 (0.03 g, 0.05 mmol) was added under nitrogen. Afterwards, dry toluene (4.50 mL) was added and the resulted mixture was degassed. At last, 2-(tributylstannyl)thiazole (0.29 mL, 0.90 mmol) was added and the mixture was heated to 100 °C and stirred for 17 h. The reaction mixture was allowed to cool down to room temperature and concentrated to complete dryness. The crude product was purified over silica gel chromatography (0-100%) to afford the title product (150 mg, 64%). fe/t- butyl 3-((3a/?,4/?,6/?,6a5)-6-(4-(difluoromethyl)-7//-pyrrolo[2,3- d|pyrimidin-7-yl)-2,2- dimethyltetrahydro-4//-cyclopenta[d|[1,3]dioxol-4-yl)piperid ine-1-carboxylate (259): Following the general procedure L for Mitsunobu-type glycosylation, compound 259 was obtained starting from 4-(difluoromethyl)-7//-pyrrolo[2,3-</|pyrimidine (0.13 g, 0.73 mmol), compound 197 (0.38 g, 1.10 mmol), PPh 3 (0.39 g, 1.46 mmol), and DBAD (1.10 M, 0.34 g, 1.46 mmol) in dry toluene (0.20 M, 3.70 mL) after column chromatography on silica

(cyclohexane/EtOAc; 0-30%) as white foam (199 mg, 55%).

7-((3aS,4/?,6/?,6a/^-6-(3-((7e/7-butyldimethylsilyl)oxy)p henyl)-2,2-dimethyltetrahydro-4Z/- l 3 dioxol-4-yl)-4-chloro-7//-pyrrolo[2,3-</|pyrimidine (260):

In the first step, PPh 3 (521 mg, 1.99 mol, 2 eq.) and DBAD (454 mg, 1.97 mol, 2 eq.) in toluene (10 mL) were stirred for 30 min at 0 °C under N 2 atmosphere. A solution of (3aS,4S,6R,6aR)-6-(3- ((tert-butyldimethylsilyl)oxy)phenyl)-2,2-dimethyltetrahydro -4H-cyclopenta[d][1,3]dioxol-4-ol (360 mg, 0.99 mol, 1 eq.) in toluene (5 mL) was added dropwise and stirred for 30 min at 0 °C. Then, 4-chloro-7Hpyrrolo[2,3-d]pyrimidine (153 mg, 1.00 mol, 1 eq.) was added to the reaction mixture and heated up to 80 °C and stirred for 15.5 h. After the reaction mixture was allowed to cool down to RT, the solvent was evaporated. Then, water was added and the residue was extracted three times with EtOAc, the combined organic phases were once washed with brine and then dried over Na 2 SO 4 . After filtration and concentration, the residue was purified by flash chromatography eluting with PE/EtOAc (0.2 % -> 4 %) to give 7-((3aS,4R,6R,6aR)-6- (3((tertbutyldimethylsilyl)oxy)phenyl)-2,2-dimethyltetrahydr o-4Hcyclopenta[d][1,3]dioxol-4-yl)-4- chloro-7Hpyrrolo[2,3-d]pyrimidine (221 mg) as a transparent oil. R f = 0.25 (Petrolether/EtOAc 9:1). APCI: calcd. for C 26 H 34 CIN 3 O 3 Si [M + H] + : 500.2 found 499.9/441.

7-((3aS,4/?,6/?,6a/^-6-(4-((7e/7-butyldimethylsilyl)oxy)p henyl)-2,2-dimethyltetrahydro-4Z/- cyclopenta[<^[1,3]dioxol-4-yl)-4-chloro-7//-pyrrolo[2,3-& lt;/|pyrimidine (261):

In the first step, PPh 3 (721 mg, 2.74 mmol, 2 eq.) and DBAD (632 mg, 2.75 mmol, 2 eq.) were dissolved in toluene (7 mL) at 0 °C under nitrogen and stirred for 30 min. A solution of (3aS,4S,6R,6aR)-6-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2 ,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-ol (504 mg, 1.38 mmol, 1 eq.) in toluene (7 mL) was added at 0 °C. After 30 min stirring at this temperature, 4-chloro-7//-pyrrolo[2,3-d]pyrimidine (216 mg, 1.41 mmol, 1 eq.) was added to the yellow solution. The reaction mixture was stirred for 17.6 h at 110 °C. After evaporation of the solvent, water was added and the mixture was extracted three times with EtOAc. The combined organic layers were washed with brine and dried over Na 2 SO 4 . After filtration and concentration, the residue was purified twice by flash chromatography eluting with Petrolether/EtOAc (1-> 5 %) to give 7-((3aS,4R,6R,6aR)-6-(4-((tert- butyldimethylsilyl)oxy)phenyl)-2,2-dimethyltetrahydro-4H-cyc lopenta[d][1,3]dioxol-4-yl)-4- chloro-7H-pyrrolo[2,3-d]pyrimidine (300 mg), as a viscose and transparent oil. R f = 0.10

(Petrolether/EtOAc 9:1). APCI: calcd. for C 26 H 34 CIN 3 O 3 Si [M + H] + : 500.2 found 500.0 4-chloro-7-((3aS,4/?,6/?,6aA)-6-(3-chlorophenyl)-2,2-dimethy ltetrahydro-4Z/- cyclopenta[<^[1,3]dioxol-4-yl)-7//-pyrrolo[2,3-5|pyrimidi ne (262):

To a stirred solution of PPh 3 (237 mg, 0.90 mmol, 2 eq.), 4-chloro-77/-pyrrolo[2,3-d]pyrimidine (69 mg, 0.45 mmol, 1 eq.) and (3aS,4S,6R,6aR)-6-(3-chlorophenyl)-2,2-dimethyltetrahydro-4H - cyclopenta[d][1,3]dioxol-4-ol (181mg, 0.67 mmol, 1.5 eq.) in toluene (4 mL) was added DBAD (207 mg, 0.90 mmol, 2 eq.) portionwise at 0 °C under N 2 . The reaction mixture was stirred at 0 °C for 10 min, then it was heated up to 60 °C and stirred for 22 h at this temperature. Then, the mixture was concentrated under reduced pressure and was purified by flash chromatography eluting with Petrolether/EtOAc (1-> 10 %) to give 4-chloro-7-((3aS,4R,6R,6aR)-6-(3-chlorophenyl)- 2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)-7H- pyrrolo[2,3-d]pyrimidine (125 mg), as a transparent oil. APCI: calcd. for C2oH 1 9CI 2 N 3 02 [M + H] + : 404.1 found 403.6.

4-chloro-7-((3aS,4/?,6/?,6aA)-2,2-dimethyl-6-(3-(2-methyl -1,3-dioxolan-2-yl)phenyl)tetrahydro- 4//-cyclopenta[d|[1,3]dioxol-4-yl)-7//-pyrrolo[2,3-a]pyrimid ine (263):

To a stirred solution of PPh 3 (213 mg, 0.81 mmol, 2 eq.), 4-chloro-77/-pyrrolo[2,3-d]pyrimidine (61 mg, 0.40 mmol, 1 eq.) in toluene (0.6 mL) was added solution of (3aS,4S,6R,6aR)-2,2-dimethyl-6- (3-(2-methyl-1,3-dioxolan-2-yl)phenyl)tetrahydro-4H-cyclopen ta[d][1,3]dioxol-4-ol (188 mg, 0.59 mmol, 1.5 eq.) in toluene (1.4 ml) under N 2 . To this, solution of DBAD (180 mg, 0.78 mmol, 2 eq.) in toluene (1.6 ml) was added dropwise at 0 °C under N 2 . The reaction mixture was stirred at 0 °C for 20 min, then it was heated up to 60 °C and stirred for 4 h at this temperature. Then, the mixture was concentrated under reduced pressure and was purified by flash chromatography eluting with Cyclohexane/EtOAc (1-> 20 %) to give 4-chloro-7-((3aS,4R,6R,6aR)-2,2-dimethyl-6- (3-(2-methyl-1,3-dioxolan-2-yl)phenyl)tetrahydro-4H-cyclopen ta[d][1,3]dioxol-4-yl)-7H- pyrrolo[2,3-d]pyrimidine (200 mg), as a transparent foam. APCI: calcd. for C 24 H 26 CIN 3 O4 [M + H] + : 456.2 found 455.8.

7-((3aS,4/?,6/?,6a/^-6-(3,5-dichlorophenyl)-2,2-dimethylt etrahydro-4//-cyclopenta[o][1,3]dioxol-4- yl)-7//-pyrrolo[2,3-o]pyrimidin-4-amine (264):

Following the general procedure M for aromatic substitution, compound 264 was obtained starting from compound 244 (0.19 g, 0.43 mmol) in a mixture of 1,4-dioxane and ammonia (0.05 M, 8.60 mL, 1:2) after column chromatography on silica (cyclohexane/EtOAc; 0-100%) as white foam (160 mg, 98%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.07 (s, 1H, H2), 7.52 - 7.47 (m, 4H, H6, o,p- Ar), 7.00 (s, 2H, -CN// 2 ), 6.60 (d, 7 = 3.5 Hz, 1H, H5), 5.14 (td, 7 = 9.5, 5.1 Hz, 1H, H1'), 4.89 (dd, 7 = 7.6, 5.2 Hz, 1H, H2'), 4.76 (t, 7 = 7.2 Hz, 1H, H3'), 3.32 - 3.27 (m, 1H, H4'), 2.53 - 2.44 (m, 2H, H5'under DMSO peak), 1.52 (s, 3H, C// 3 , acetonide), 1.22 (s, 3H, C// 3 , acetonide).

5-bromo-7-((3aS,4/?,6/?,6a/^-6-(3,5-dichlorophenyl)-2,2-d imethyltetrahydro-4//- cyclopenta[o][1,3]dioxol-4-yl)-7//-pyrrolo[2,3-d|pyrimidin-4 -amine (265):

Following the general procedure M for aromatic substitution, compound 265 was obtained starting from compound 245 (0.24 g, 0.45 mmol) in a mixture of 1,4-dioxane and ammonia (0.05 M, 9.00 mL, 1:2) after column chromatography on silica (cyclohexane/EtOAc; 0-100%) as white foam (88 mg, 39%). 1 H NMR (400 MHz, DMSO-5 6 ) <58.12 (s, 1H, H2 adenine), 7.84 (s, 1H, H6 adenine), 7.52 - 7.49 (m, 3H, ,o,/>Ar), 5.19 (td, 7= 9.3, 5.0 Hz, 1H, H1'), 4.85 (dd, 7 = 7.5, 5.0 Hz, 1H, H2'), 4.75 - 4.69 (m, 1H, H3'), 3.32 - 3.25 (m, 1H, H4' under water peak), 2.52 - 2.44 (m, 2H, H5' under DMSO peak), 1.52 (s, 3H, CM, acetonide), 1.21 (s, 3H, CM, acetonide).

7-((3aS,4/?,6/?,6a/tO-2,2-dimethyl-6-phenyltetrahydro-4Mc yclopenta[d|[1,3]dioxol-4-yl)-7M pyrrolo[2,3-5|pyrimidin-4-amine (266):

Following the general procedure M for aromatic substitution, compound 266 was obtained starting from compound 246 (0.18 g, 0.45 mmol) in a mixture of 1,4-dioxane and ammonia (0.05 M, 9.60 mL, 1:2) after column chromatography on silica (cyclohexane/EtOAc; 0-100%) as white foam (72 mg, 89%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.07 (s, 1H, H2), 7.44 (d, 7 = 3.6 Hz, 1H, H6), 7.41 - 7.32 (m, 4H, o,/77-Ar ), 7.29 - 7.22 (m, 1H, />Ar), 6.98 (s, 2H, -CN/7 2 ), 6.59 (d, 7 = 3.6 Hz, 1H, H5), 5.12 (ddd, 7 = 10.8, 8.1, 5.4 Hz, 1H, H1'), 4.96 (dd, 7 = 7.6, 5.4 Hz, 1H, H2'), 4.75 (t, 7 = 7.2 Hz, 1H, H3'), 3.29 - 3.22 (m, 1H, H4'), 2.54 - 2.45 (m, 2H, H5' under DMSO peak), 1.52 (s, 3H, CH 3 , acetonide), 1.22 (s, 3H, CH 3 , acetonide).

5-bromo-7-((3aS,4/?,6/?,6aA)-2,2-dimethyl-6-phenyltetrahy dro-4Mcyclopenta[5|[1,3]dioxol-4-yl)- -amine (267):

Following the general procedure M for aromatic substitution, compound 267 was obtained starting from compound 247 (0.20 g, 0.44 mmol) in a mixture of 1,4-dioxane and ammonia (0.20 M, 2.20 mL, 1:2) after column chromatography on silica (cyclohexane/EtOAc; 0-100%) as white foam (72 mg, 89%). R f = 0.69 (CH 2 CI 2 /MeOH; 10%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.13 (s, 1H, H2), 7.81 (s, 1H, H6), 7.43 - 7.31 (m, 4H, o, m-kr), 7.31 - 7.22 (m, 1H, />Ar), 5.17 (td, 7 = 9.8, 9.3, 5.3 Hz, 1H, H1'), 4.92 (dd, 7= 7.5, 5.3 Hz, 1H, H2'), 4.72 (t, 7 = 7.2 Hz, 1H, H3'), 3.29 - 3.16 (m, 1H, H4'), 2.53 - 2.47 (m, 2H, H5' under DMSO peak), 1.52 (s, 3H, CH 3 , acetonide), 1.22 (s, 3H, CH 3 , acetonide). 7-((3aS,4/?,6/?,6aA)-2,2-dimethyl-6-(naphthalen-2-yl)tetrahy dro-4Mcyclopenta[5|[1,3]dioxol-4- yl)-7M-pyrrolo[2,3-<^pyrimidin-4-amine (268):

Following the general procedure M for aromatic substitution, compound 268 was obtained starting from compound 248 (0.20 g, 0.47 mmol) in a mixture of 1,4-dioxane and ammonia (0.20 M, 2.40 mL, 1:2) after column chromatography on silica (cyclohexane/EtOAc; 0-100%) as white foam (72 mg, 89%). R f = 0.73 (CH 2 CI 2 /MeOH; 10%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.09 (s, 1H, H2 adenine), 7.96 - 7.83 (m, 4H, H1, H4, H5, H8 naphthyl), 7.70 (dd, 7 = 3.5, 2.4 Hz, 1H, H6 adenine), 7.61 (dd, 7 = 8.5, 1.8 Hz, 1H, H3 naphthyl), 7.55 - 7.45 (m, 2H, H6, H7 naphthyl), 6.62 - 6.60 (m, 1H, H5 adenine), 5.19 (dt, 7 = 12.0, 6.2 Hz, 1H, H1'), 5.01 (dd, 7 = 7.5, 5.4 Hz, 1H, H2'), 4.86 (t, 7 = 7.2 Hz, 1H, H3'), 3.52 - 3.40 (m, 1H, H4'), 2.73 - 2.55 (m, 2H, H5'), 1.56 (s, 3H, CM, acetonide), 1.25 (s, 3H, CM, acetonide).

2-chloro-7-((3aS,4/?,6/?,6aA)-2,2-dimethyl-6-(naphthalen- 2-yl)tetrahydro-4M cyclopenta[o][1,3]dioxol-4-yl)-7Mpyrrolo[2,3-d|pyrimidin-4-a mine (269):

Following the general procedure M for aromatic substitution, compound 269 was obtained starting from compound 249 (0.26 g, 0.35 mmol) in a mixture of 1,4-dioxane and ammonia (0.10 M, 3.50 mL, 1:2) after column chromatography on silica (cyclohexane/EtOAc; 0-100%) as white foam (242 mg, 0.56 mmol, impurity in cyclohexane). R f = 0.60 (cyclohexane/EtOAc; 70%). 1 H NMR (400 MHz, DMSO-M) 57.96 - 7.84 (m, 4H, H1, H4, H5, H8 naphthyl), 7.62 (dd, 7 = 8.4, 1.6 Hz, 1H, H6 naphthyl), 7.57 - 7.44 (m, 5H, -CNM, H3, H7 naphthyl, H6 adenine), 6.64 (d, 7= 3.6 Hz, 1H, H5 adenine), 5.16 - 5.06 (m, 1H, H1'), 4.94 (dd, 7 = 7.4, 5.2 Hz, 1H, H2'), 4.88 - 4.83 (m, 1H, H3'), 3.51 - 3.44 (m, 1H, H4'), 2.68 - 2.65 (m, 1H, H5'), 2.62 - 2.58 (m, 1H, H5'), 1.57 (s, 3H, CH 3 , acetonide), 1.25 (s, 3H, CH 3 , acetonide). APCI calc.: 394.12; found: 434.90/436.90 [M + H] + .

7-((3aS,4/?,6/?,6aA)-2,2-dimethyl-6-(pyridin-4-yl)tetrahy dro-4Mcyclopenta[<^[1,3]dioxol-4-yl)-7M pyrrolo[2,3-5|pyrimidin-4-amine (270):

Following the general procedure M for aromatic substitution, compound 270 was obtained starting from compound 250 (0.35 g, 0.93 mmol) in a mixture of 1,4-dioxane and ammonia (0.10 M, 9.40 mL, 1:2) after column chromatography on silica (CH 2 CI 2 ; 0-10%) as white foam (66.20 mg, 20%). R f = 0.59 (CH 2 CI 2 /MeOH; 10%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.55 - 8.51 (m, 2H, H2, H6 pyridine), 8.07 (s, 1H, H2 adenine), 7.44 (d, 7 = 3.6 Hz, 1H, H6 adenine), 7.42 - 7.39 (m, 2H, H3, H5 pyridine), 7.00 (s, 2H, -CNM), 6.60 (d, 7 = 3.5 Hz, 1H, H5 adenine), 5.14 (ddd, 7 = 11.0, 7.8, 5.2 Hz, 1H, H1'), 4.95 (dd, 7 = 7.5, 5.2 Hz, 1H, H2'), 4.79 (t, 7= 7.2 Hz, 1H, H3'), 3.31 - 3.24 (m, 1H, H4'), 2.52 (s, 2H, H5' under DMSO peak), 1.53 (s, 3H, CM, acetonide), 1.23 (s, 3H, CM, acetonide). 7-((3aS,4/?,65;6a/i)-2,2-dimethyl-6-(thiophen-2-yl)tetrahydr o-4Mcyclopenta[5|[1 ; 3]dioxol-4-yl)-

7M-pyrrolo[2,3-5|pynmidin-4-amine (271):

Following the general procedure M for aromatic substitution, compound 271 was obtained starting from compound 251 (0.20 g, 0.52 mmol) in a mixture of 1,4-dioxane and ammonia (0.10 M, 5.20 mL, 1:2) after column chromatography on silica (cyclohexane/EtOAc; 0-100%) as white foam (27 mg, 15%). R f = 0.67 (CH 2 CI 2 /MeOH; 10%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.06 (s, 1H, H2), 7.42 - 7.38 (m, 2H, H6, H5 thiophene), 7.03 - 6.96 (m, 4H, -CN//2, H3, H4 thiophene), 6.58 (d, 7 = 3.5 Hz, 1H, H5), 5.15 - 5.04 (m, 1H, H1'), 4.96 (dd, 7 = 7.5, 5.2 Hz, 1H, H2'), 4.73 (t, 7 = 7.2 Hz, 1H, H3'), 3.49 (dt, 7 = 11.3, 7.3 Hz, 1H, H4'), 2.60 - 2.52 (m, 2H, H5'), 1.52 (s, 3H, CM, acetonide), 1.23 (s, 3H, CM, acetonide).

7-((3aS,4/?,6/?,6aA)-2,2-dimethyl-6-(1Mpyrazol-5-yl)tetra hydro-4Mcyclopenta[<^[1,3]dioxol-4-yl)- amine (272):

Following the general procedure M for aromatic substitution, compound 272 was obtained starting from compound 252 (0.26 g, 0.50 mmol) in a mixture of 1,4-dioxane and ammonia (0.10 M, 5.00 mL, 1:2) after column chromatography on silica (CH 2 CI 2 , MeOH; 0-20%) as white foam (27 mg, 0.08 mmol). R f = 0.43 (CH 2 CI 2 , MeOH; 10%). APCI calc.: 340.16; found: 340.90 [M + H] + .

2-chloro-7-((3aS,4/?,6/?,6aA)-2,2-dimethyl-6-(quinolin-6- yl)tetrahydro-4M cyclopenta[o][1,3]dioxol-4-yl)-7Mpyrrolo[2,3-d|pyrimidin-4-a mine (273):

Following the general procedure M for aromatic substitution, compound 273 was obtained starting from compound 253 (0.07 g, 0.15 mmol) in a mixture of 1,4-dioxane and ammonia (0.10 M, 1.50 mL, 1:2) after column chromatography on silica (cyclohexane/EtOAc; 0-100%) as white foam (53 mg, 80%). 1 H NMR (400 MHz, DMSO-M) 58.87 (dd, 7 = 4.1, 1.6 Hz, 1H, H2 quinoline), 8.35 (d, 7 = 8.3 Hz, 1H, H4 quinoline), 8.03 (d, 7 = 8.8 Hz, 1H, H8 quinoline), 7.94 (d, 7 = 10.5 Hz, 1H, H5 quinoline), 7.86 (dd, 7 = 8.7, 1.8 Hz, 1H, H7 quinoline), 7.58 - 7.50 (m, 2H, H3 quinoline, H6 adenine), 6.64 (d, 7 = 3.6 Hz, 1H, H5 adenine), 5.13 (dt, 7 = 11.8, 6.6 Hz, 1H, H1'), 4.94 (dd, 7 = 7.3, 5.2 Hz, 1H, H2'), 4.87 (t, 7 = 7.1 Hz, 1H, H3'), 3.51 (dt, 7 = 13.1, 6.9 Hz, 1H, H4'), 2.65 - 2.53 (m, 2H, H5'), 1.57 (s, 3H, CM, acetonide), 1.25 (s, 3H, CM, acetonide). APCI calc.: 435.15; found: 435.60/437.60 [M + H] + . fe/A butyl (3-((3a/?,4/?,6/?,6a5)-6-(4-amino-5-bromo-2-chloro-7Mpyrrolo [2,3-o]pyrimidin-7-yl)- 2,2-dimethyltetrahydro-4Mcyclopenta[o][1,3]dioxol-4-yl)benzy l)carbamate (274):

Following the general procedure M for aromatic substitution, compound 274 was obtained starting from compound 254 (0.52 g, 0.84 mmol) in a mixture of 1,4-dioxane and ammonia (0.10 M, 8.40 mL, 1:2) after column chromatography on silica (n-heptane/EtOAc; 0-100%) as white foam (230 mg, 46%). 1 H NMR (400 MHz, DMSO-o6) 57.84 (s, 1H, H6 adenine), 7.39 (t, 7 = 6.2 Hz, 1H, - CH 2 NMZO 2 C(CH 3 ) 3 ), 7.32 - 7.22 (m, 3H, H2, H4, H5 aryl), 7.15 - 7.10 (m, 1H, H6 aryl), 5.11 - 5.03 (m, 1H, HT), 4.87 (dd, 7= 7.5, 5.3 Hz, 1H, H2'), 4.70 (t, 7 = 7.2 Hz, 1H, H3'), 4.13 (d, 7= 6.2 Hz, 2H, - CM 2 NHCO 2 C(CH 3 ) 3 ), 3.24 (dt, 7 = 13.6, 6.6 Hz, 1H, H4'), 2.48 - 2.38 (m, 2H, H5'), 1.52 (s, 3H, CH 3 , acetonide), 1.39 (s, 9H, -NHCO 2 C(CH 3 ) 3 ), 1.22 (s, 3H, CM, acetonide). fe/t- butyl 2-((3a/?,4/?,6/?,6a5)-6-(4-amino-7Mpyrrolo[2,3-5|pyrimidin-7 -yl)-2,2- dimethyltetrahydro-4Mcyclopenta[5|[1,3]dioxol-4-yl)pyrrolidi ne-1-carboxylate (275):

Following the general procedure M for aromatic substitution, compound 275 was obtained starting from compound 255 (0.16 g, 0.34 mmol) in a mixture of 1,4-dioxane and ammonia (0.10 M, 3.40 mL, 1:2) after column chromatography on silica (CH 2 CI 2 /MeOH; 0-10%) afforded the desired product as white foam (101 mg, 67%, diastereomeric mixture; d.r. 1.5:1). R f = 0.68 (CH 2 CI 2 /MeOH; 10%). 1 H NMR (400 MHz, DMSO) 58.04 (s, 2H, H2), 7.34 (d, 7 = 3.5 Hz, 1H, H6), 7.31 - 7.25 (m, 1H, H6), 6.98 (bs, 2H, 2H, -CNM 2 ), 6.57 - 6.54 (m, 2H, H5), 4.96 - 4.75 (m, 4H, HT, H2'), 4.55 - 4.47 (m, 2H, H3'), 4.01 - 3.93 (m, 1H, -CH 2 CH 2 CACH-), 3.93 - 3.85 (m, 1H, -

CH 2 CH 2 CACH-), 3.50 - 3.37 (m, 1H, -NCM 2 CH 2 CH 2 -), 3.26 - 3.11 (m, 1H, -NCM 2 CH 2 CH 2 -), 2.40 -

2.26 (m, 2H, H4', H5'), 2.25 - 2.14 (m, 2H, H4', H5'), 2.12 - 2.00 (m, 2H, H5'), 1.95 - 1.71 (m, 8H, -

NCH 2 CM 2 CM-), 1.44 (s, 6H, CM, acetonide), 1.42 (s, 9H, -NCO 2 C(CM) 3 ), 1.33 (s, 9H, -

NCO 2 C(CM 3 ) 3 ), 1.21 (s, 6H, CH 3 , acetonide). APCI calcd.: 443.25; found: 444.30 [M + H] + . fe/t- butyl (/^-2-((3a/?,4/?,6/?,6a5)-6-(4-amino-7Mpyrrolo[2,3-<T]pyr imidin-7-yl)-2,2- 4Mcyclopenta[o][1,3]dioxol-4-yl)piperidine-1-carboxylate (276):

Following the general procedure M for aromatic substitution, compound 276 was obtained starting from compound 256 (0.15 g, 0.31 mmol) in a mixture of 1,4-dioxane and ammonia (0.10 M, 3.10 mL, 1:2) after column chromatography on silica (CH 2 CI 2 /MeOH; 0-10%) afforded the desired product as white foam (52 mg, 37%, 43 mg starting material recovered). R f = 0.38 (CH 2 CI 2 /MeOH; 10%). 1 H NMR (400 MHz, DMSO-o6) 58.03 (s, 1H, H2), 7.25 (d, 7 = 20.2 Hz, 1H, H6), 6.97 (s, 2H, -NM 2 ), 6.55 (d, 7 = 3.4 Hz, 1H, H5), 5.05 - 4.77 (m, 2H, HT, H2'), 4.46 (t, 7 = 6.7 Hz, 1H, H3'), 4.25 - 4.04 (m, 1H, -CH 2 CH 2 CH 2 C//-), 3.95 - 3.71 (m, 1H, -NC// 2 CH 2 CH 2 CH 2 -), 2.93 - 2.58 (m, 1H, -NC// 2 CH 2 CH 2 CH 2 -, H4'), 2.38 - 2.22 (m, 1H, H5'), 2.03 - 1.91 (m, 1H, H5'), 1.83 (d, 7 = 12.0 Hz, 1H, -NCH 2 C// 2 CH 2 CH 2 -), 1.63 - 1.41 (m, 5H, -NCH 2 C// 2 C// 2 C// 2 -), 1.48 (s, 3H, CH 3 , acetonide), 1.30 (s, 9H, -NCO 2 C(CM) 3 ), 1.22 (s, 3H, CH 3 , acetonide).

3-((3a/?,4/?,6/?,6a5)-6-(4-amino-7//-pyrrolo[2,3-</|py rimidin-7-yl)-2,2-dimethyltetrahydro-4//- cyclopenta[o][1,3]dioxol-4-yl)phenol (277):

The product from previous step (210) was dissolved in dioxane (0.5 mL) in a pressure flask. Aqueous ammonia (25 %, 0.5 mL) was added and the solution was stirred for 16 h at 100 °C. After evaporation under reduced pressure, the residue was purified by flash chromatography eluting DCM/MeOH and besides the corresponding product, TBS deprotected, but not substituted intermediate was recovered and the reaction was relaunched with aq. ammonia (50%, 1 mL) and dioxane (1 mL) for 2 days at 100 °C. Then, the residue was purified by flash chromatography eluting with DCM/MeOH (0.3%-> 7%) to afford product (yield: 65 mg, 0.18 mmol, 13 % over 2 steps), as a yellow oil. R f = 0.53 (DCM/MeOH 9:1). APCI: calcd. for C 26 H36N 4 O 3 Si [M + H] + : 367.2 found 366.9 1 H NMR (400 MHz, DMSO-d6) 5 9.34 (s, 1H, phenyl OH), 8.07 (s, 1H, H2), 7.42 (d, 7 = 3.6 Hz, 1H, H8), 7.15 - 7.10 (m, 1H, /77-H), 6.99 (bs, 2H, NH 2 ), 6.80-6.76 (m, 2H, 2 x oH, ), 6.64 (ddd, 7 = 8.1 Hz, 2.5 Hz, 1.1 Hz, 1H, />H), 6.59 (d, 7= 3.5, 1H, H7), 5.12 - 5.05 (m, 1H, HT), 4.95 (dd, 7 = 7.6 Hz, 5.4 Hz, 1H, H2'), 4.70 (t, 7 = 7.2 Hz, 1H, H3'), 3.17 (dt, 7 = 12.4, 6.9 Hz, 1H, H4'), 2.47 - 2.42 (m, 2H, H5'), 1.52 (s, 3H, CH 3 , acetonide), 1.22 (s, 3H, CH 3 , acetonide ). 1.75 eq. ofDMF(24 % of the overall mass) was observed by NMR. The yield was calculated on the 76 % of the overall mass, corresponding to the pure target compound.

4-((3a/?,4/?,6/?,6a5)-6-(4-amino-7//-pyrrolo[2,3-</|py rimidin-7-yl)-2,2-dimethyltetrahydro-4//- cyclopenta[o][1,3]dioxol-4-yl)phenol (278):

To a solution of the product from previous step (151 mg) in dioxane (0.54 mL) in a pressure flask was added aqueous ammonia (25 %, 0.54 mL). The reaction mixture was stirred for 16.3 h at 100 °C. After evaporation under reduced pressure, the residue was purified by flash chromatography eluting with DCM/MeOH (0.3— >10 %) to give product (yield: 30.8 mg, 0.08 mmol, 11 % over 2 steps), a white to yellowish solid. R f = 0.34 (DCM/MeOH 9:1). APCI: calcd. for C 26 H 36 N 4 O 3 Si [M + H] + : 367.2 found 366.8. 1 H NMR (400 MHz, DMSO-d6) 5 9.26 (s, 1H, phenyl OH), 8.06 (s, 1H, H2), 7.42 (d, 7 = 3.6 Hz, 1H, H8), 7.19-7.13 (m, 2H, 2 x oH), 6.99 (br s, 2H, NH 2 ), 6.76-6.70 (m, 2H, /77-H), 6.59 (d, 7 = 3.5 Hz, 1H, H7), 5.12-5.03 (m, 1H, HT), 4.93 (dd, 7 = 7.5 Hz, 5.5 Hz, 1H, H2'), 4.66 (t, 7 = 7.2 Hz, 1H, H3'), 3.19-3.10 (m, 1H, H4'), 2.47-2.38 (m, 2H, H5'), 1.51 (s, 3H, CH 3 , acetonide), 1.21 (s, 3H, CH 3 , acetonide).

7-((3aS,4/?,6/?,6a/^-6-(4-((7e/7-butyldimethylsilyl)oxy)p henyl)-2,2-dimethyltetrahydro-4Z/- cyclopenta[^[1,3]dioxol-4-yl)-A/-methyl-7//-pyrrolo[2,3-a]py rimidin-4-amine (279):

To the solution of 7-((3aS,4R,6R,6aR)-6-(4-((tert-butyldimethylsilyl)oxy)phenyl )-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)-4-chlor o-7H-pyrrolo[2,3-d]pyrimidine (145 mg, 0.29 mmol, 1 eq.) in /7-BuOH (0.7 mL) was added solution of methylamine in EtOH (33%, 0.7 mL) in a microwave vial. The reaction mixture was stirred under p-waves irradiation at 120 °C (100 W) for 15 min. After full conversion of starting material, the solvent was evaporated and the brown residue was purified by flash chromatography eluting with Petrolether/EtOAc (2-> 70 %) to afford 7-((3aS,4R,6R,6aR)-6-(4-((tert-butyldimethylsilyl)oxy)phenyl )-2,2-dimethyltetrahydro- 4H-cyclopenta[d][1,3]dioxol-4-yl)-N-methyl-7H-pyrrolo[2,3-d] pyrimidin-4-amine (53 mg ) as a brown oil . R f = 0.18 (Petrolether/EtOAc 1:1). APCI: calcd. for C^HssN^Si [M + H] + : 495.3 found 494.8.

7-((3aS,4/?,6/?,6a/^-6-(3-chlorophenyl)-2,2-dimethyltetra hydro-4//-cyclopenta[d|[1,3]dioxol-4-yl)- 7//-pyrrolo[2,3-</|pynmidin-4-amine (280):

To a solution of the product from previous step (113 mg) in dioxane (1.3 mL) in a pressure flask was added aqueous ammonia (50 %, 1.3 mL). The reaction mixture was stirred for 67 h at 100 °C. After concentration, the residue was purified by flash chromatography eluting with DCM/MeOH (0.5->5 %) to give 7-((3aS,4R,6R,6aR)-6-(3-chlorophenyl)-2,2-dimethyltetrahydro -4H- cyclopenta[d][1,3]dioxol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4- amine (yield: 28 mg, 0.072 mmol, 11 % over 2 steps), a brown oil. R f = 0.16 (DCM/MeOH 95:5). APCI: calcd. for C 20 H 21 CIN 4 O 2 [M + H] + : 385.1 found 384.7 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.06 (s, 1H, H2), 7.49 - 7.47 (m, 1H, /77-H), 7.45 (d, 7 = 3.6 Hz, H8), 7.40 - 7.30 (m, 3H, 2 x oH, />H), 6.99 (bs, 2H, NH 2 ), 6.59 (d, 7 = 3.5 Hz, 1H, H7), 5.12 (td, 7 = 9.3, 5.2 Hz, 1H, HT), 4.91 (dd, 7 = 7.6, 5.2 Hz, 1H, H2'), 4.75 (t, 7 = 7.2 Hz, 1H, H3'), 3.30-3.23 (m,1H, H4'), 2.59-2.52 (m, 2H, H5', under DMSO peak), 1.52 (s, 3H, CH 3 , acetonide), 1.21 (s, 3H, CH 3 , acetonide). 0.5 eq. ofEtOAc and 0.3 eq. of DMF were observed on NMR spectra 7-((3aS,4/?,6/?,6a/tO-2,2-dimethyl-6-(3-(2-methyl-1,3-dioxol an-2-yl)phenyl)tetrahydro-4//- cyclopenta[o][1,3]dioxol-4-yl)-7//-pyrrolo[2,3-</|pyrimid in-4-amine (281):

To a solution of the product from previous step (200 mg) in dioxane (4.4 mL) in a pressure flask was added aqueous ammonia (25 %, 9 mL). The reaction mixture was stirred for 15 h at 100 °C. After concentration, the residue was purified by flash chromatography eluting with DCM/MeOH (0.3->5.2 %) to give 7-((3aS,4R,6R,6aR)-2,2-dimethyl-6-(3-(2-methyl-1,3-dioxolan- 2- yl)phenyl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)-7H-py rrolo[2,3-d]pyrimidin-4-amine (yield: 74 mg, 0.17 mmol, 23 % over 3 steps), a yellow to brown solid. R f = 0.26 (DCM/MeOH 95:5). APCI: calcd. for C 24 H 28 N 4 O4 [M + H] + : 437.2 found 436.7 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.07 (s, 1H, H2), 7.46 (d, 7 = 3.6 Hz, 1H, H8), 7.43-7.41 (m, 1H, /77-H), 7.34 - 7.27 (m, 3H, oH, />H), 6.98 (br s, 2H, NH 2 ), 6.58 (d, 7 = 3.5 Hz, 1H, H7), 5.15-5.06 (m,1H, HT), 4.97 (dd, 7 = 7.6, 5.4 Hz, 1H, H2'), 4.75 (t, 7 = 7.2 Hz, 1H, H3'), 4.00 - 3.95 (m, 2H, CH 2 , ketal), 3.74 - 3.64 (m, 2H, CH 2 , ketal), 3.31-3.22 (m, 1H, H4'), 2.5 (m, 2H, H5' z under DMSO pea^, 1.55 (s, 3H, CH 3 , ketal), 1.52 (s, 3H, CH 3J acetonide), 1.22 (s, 3H, CH 3 , acetonide). fe/t- butyl (4-((3ar,4r,6as)-6-hydroxy-2,2-dimethyltetrahydro-4//-cyclop enta[d][1,3]dioxol-4- yl)phenyl)carbamate (282):

950 mg (2.72 mmol; 1.00 eq) of terf-butyl (3-((3ar,4r,6as)-6-hydroxy-2,2-dimethyltetrahydro-4/7- cyclopenta[d][1,3]dioxol-4-yl)phenyl)carbamate were dissolved in 30 mL of Toluene under inert gas atmosphere. At 0 °C, 1427 mg (5.44 mmol; 2.00 eq) of PPh 3 were added. 10 minutes later 1253 mg (5.44 mmol; 2.00 eq) of Di-terAbutyl-azodicarboxylate were attached. The reaction solution was stirred for further 10 minutes before 544 mg (3.54 mmol; 1.30 eq) of 4-chloro-7/7- pyrrolo[2,3-d]pyrimidine were added and the whole was heated to 80 °C overnight. The solvent was removed under reduced pressure and the crude was purified by column chromatography (Cyclohexane/EtOAc 99:1% to 60:40%). The product was directly used without further characterization. Therefore 20 mL of Dioxane and 20 mL of a 25% aqueous solution of NH 3 were added. The reaction solution was heated to 100 °C in a sealed tube overnight. The solvent was then removed under reduced pressure and the resulting residue was adsorbed on silica and purified by flash chromatography (DCM/MeOH 99%/1% to 90%/10%). 170 mg (0.36 mmol; 13% over 2 steps) of the title compound were obtained in the form of a colorless foam. TLC: R/ = 0.41 (DCM/MeOH 10:1). 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 9.30 (s, 1H), 8.08 (s, 1H), 7.48 (s, 1H), 7.43 (d, 7 = 3.6 Hz, 1H), 7.33-7.26 (m, 1H), 7.24-7.20 (m, 1H), 7.03-6.98 (m, 1H), 6.60 (d, 7 = 3.5 Hz, 1H), 5.12-5.06 (m, 1H), 4.99-4.96 (m, 1H), 4.72 (t, 7 = 7.2 Hz, 1H), 3.24-3.14 (m, 2H), 2.46-2.41 (m, 1H), 1.52 (s, 3H), 1.47 (s, 9H), 1.22 (s, 3H) ppm. APCI-MS(+) m/z for C 25 H 29 CIN 4 O 4 : calc.: 484.98; found: 484.6 and 485.5. APCI-MS(+) m/z for C 25 H 31 N 5 O 4 : calc.: 465.55; found: 465.7 and 466.7.

7-((3aS,4/?,6/?,6a/^-6-(3,5-dichlorophenyl)-2,2-dimethylt etrahydro-4//-cyclopenta[o][1,3]dioxol-4- yl)-5-(thiazol-2-yl)-7//-pyrrolo[2,3-d|pyrimidin-4-amine (283):

To a solution of compound 265 (0.09 g, 0.17 mmol) in dry toluene (0.01 M, 1.70 mmol) was added Pd(PPh 3 ) 2 CI 2 (0.04 g, 0.05 mmol) under nitrogen atmosphere, Then, 2-(tributylstannyl)thiazole (0.16 mL, 0.51 mmol) was added and the resulted mixture was degassed. The reaction mixture was heated to 120 °C and stirred for 17 h. The mixture was cooled down to ambient temperature and concentrated to complete dryness. The obtained residue was purified over silica gel chromatography (cyclohexane/EtOAc; 0-80%) to afford the title compound as yellowish foam (15 mg, 18%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.40 (s, 1H, H2 adenine), 8.14 (s, 1H, H6 adenine), 7.84 (d, 7 = 3.4 Hz, 1H, H4 thiazole), 7.66 (d, 7 = 3.4 Hz, 1H, H5 thiazole), 7.54 - 7.51 (m, 3H, o,p- Ar), 5.25 (dt, 7 = 12.1, 6.1 Hz, 1H, H1'), 4.96 (dd, 7= 7.6, 5.2 Hz, 1H, H2'), 4.78 (t, 7= 7.2 Hz, 1H, H3'), 3.41 - 3.35 (m, 1H, H4'), 2.63 - 2.50 (m, 2H, H5'), 1.54 (s, 3H, CM, acetonide), 1.24 (s, 3H, CM, acetonide).

7-((3aS,4/?,6/?,6a/^-2,2-dimethyl-6-phenyltetrahydro-4M-c yclopenta[d|[1,3]dioxol-4-yl)-5-(thiazol- amine (284):

A heat-dried flask was charged with compound 267 (0.09 g, 0.21 mmol) and Pd(PPh 3 ) 2 CI 2 (0.04 g, 0.06 mmol) under nitrogen atmosphere. Then, dry toluene (0.01 M, 2.10 mmol) was added followed by 2-(tributylstannyl)thiazole (0.20 mL, 0.62 mmol). The resulted mixture was degassed before heated to 120 °C. The reaction mixture was refluxed for 17 h before cooled down to ambient temperature. The mixture was concentrated to complte dryness over vacuo and the obtained residue was purified by flash chromatography (cyclohexane/EtOAc; 0-80%) to afford the desired product as yellowish foam (23 mg, 25.6%). R f = 0.33 (cyclohexane/EtOAc; 50%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.41 (s, 1H, H2), 8.14 (s, 1H, H6), 7.84 (d, 7 = 3.4 Hz, 1H, H4 thiazole), 7.65 (d, 7 = 3.4 Hz, 1H, H5 thiazole), 7.45 - 7.34 (m, 4H, o, m-kr), 7.30 - 7.24 (m, 1H, p-Ar), 5.24 (dt, 7 = 12.1, 6.3 Hz, 1H, H1'), 5.02 (dd, 7 = 7.6, 5.4 Hz, 1H, H2'), 4.77 (t, 7 = 7.2 Hz, 1H, H3'), 3.29 (dt, 7 = 13.0, 6.8 Hz, 1H, H4'), 2.63 - 2.52 (m, 2H, H5'), 1.54 (s, 3H, CM 3 , acetonide), 1.24 (s, 3H, CM 3 , acetonide).

7-((3aS,4/?,6/?,6a/tO-2,2-dimethyl-6-phenyltetrahydro-4M- cyclopenta[d|[1,3]dioxol-4-yl)-5-vinyl- 7M-pyrrolo[2,3-d|pyrimidin-4-amine (285):

A heat-dried two-round bottom flask was charged with compound 267 (0.10 g, 0.23 mmol), Pd(dtbpf)CI 2 (0.01 g, 0.01 mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (0.05 mL, 0.28 mmol), and < 3 PO 4 (0.10 g, 0.46 mmol) under nitrogen atmosphere. Then, 1,4-dioxane (0.10 M, 2.30 mmol) was added and the mixture was degassed. Afterwards, degassed water (1.50 M, 0.20 mmol) was added and the reaction mixture was placed into a pre-heated heating plate (50 °C). The reaction mixture was then heated to 80 °C and stirred for 17 h at this temperature. After cooling down to ambient temperature, the mixture was diluted with water and the aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified over silica (cyclohexane/EtOAc; 0-100%) to afford the title product as white foam (17 mg, 20%, 50 mg starting material recovered).

7-((3aS,4/?,6/?,6a/^-2,2-dimethyl-6-phenyltetrahydro-4M-c yclopenta[d|[1,3]dioxol-4-yl)-5-ethyl- 7M-pyrrolo[2,3-d|pyrimidin-4-amine (286):

Compound 285 (0.02 g, 0.05 mmol) was dissolved in a mixture of EtOAC/MeOH (1:1, 0.01 M, 4.50 mL) under nitrogen atmosphere. Then, palladium on activated charcoal moistened with water (0.01 g, 10 mol%) was added and the mixture was degassed. The reaction mixture was then purged with hydrogen (balloon) and stirred upon complete consumption. After 3 h, the reaction mixture was set under nitrogen atmosphere and was filtered over celite. The filter cake was rinsed with MeOH and the filtrate was concentrated under reduced pressure to give a colorless oil. The obtained residue was directly used for the next step.

Synthesis of final compounds fe/t- butyl (7-((3a5,4/?,6/?,6a7)-6-(((3-((fe/?-butoxycarbonyl)(3- phenoxyphenethyl)amino)propyl)amino)methyl)-2,2-dimethyltetr ahydro-4/7- cyclopenta[<^[1,3]dioxol-4-yl)-7//-pyrrolo[2,3-</|pyri midin-4-yl)(methyl)carbamate (286) &

(1/?,25)3/?,5A)-3-(4-(methylamino)-7/-/-pyrrolo[2,3-c^pyr imidin-7-yl)-5-(((3-((3- phenoxyphenethyl)amino)propyl)amino)methyl)cyclopentane-1,2- diol (287):

According to general procedure A. Reductive amination (286): yield: 42 mg, 0.071 mmol, 77 %. C 43 H 58 N 6 O 7 (770.97 g/mol). APCI: calc, for C 43 H 58 N 6 O 7 [M + H] + : 770.4, found: 771.5. According to general procedure Q. Deprotection (287): yield: 20.00 mg, 0.037 mmol, 100 % (2 TFA salt). C 20 H 34 N 8 O 5 (466.54 g/mol). The crude product was purified according to method D. yield: 8.15 mg, 0.02 mmol, 42 % (2 TFA salt). C 30 H 38 N 6 O 3 (530.67 g/mol). 1 H NMR (400 MHz, DMSO-t/ 6 ) <59.57 (bs, 1H, NH), 8.89 - 8.80 (m, 2H, NH 2 + ), 8.80 - 8.67 (m, 2H, NH 2 + ), 8.36 (s, 1H, H2), 7.66 - 7.59 (m, 1, H6), 7.43 - 7.38 (m, 2H, m"), 7.38 - 7.33 (m, 1H, m'), 7.15 (tt, J = 72, 1.1 Hz, 1H, p"), 7.06 - 7.03 (m, 1H, o'), 7.03 - 6.99 (m, 2H, o"), 6.96 (t, J = 2.1 Hz, 1H, o'), 6.93 - 6.91 (m, 1H, H5), 6.89 (ddd, J = 8.1, 2.5, 0.9 Hz, 1H, p'), 4.94 (q, J = 8.5 Hz, 1H, H1'), 4.17 (dd, J = 7.3, 5.9 Hz, 1H, H2'), 3.88 (t, J = 5.3 Hz, 1H, H3'), 3.22 - 3.11 (m, 2H, CH 2 , H4"), 3.12 - 2.98 (m, 9H, H5', H1", H3", NMe), 2.95 - 2.87 (m, 2H, CH 2 , H5"), 2.37 - 2.22 (m, 2H, H4', H6-cyclopentane), 1.97 (p, J = 7.8 Hz, 2H, CH 2 , H3"), 1.67 - 1.55 (m, 1H, H6-cyclopentane). APCI: calc, for C 30 H 38 N 6 O 3 [M + H] + : 530.3, found: 530.4. HPLC: f R = 13.275 min (Method A). UV-purity at 210 nm = 96.4%. fe/t- butyl (7-((3aS,4/?,6/?,6aA)-6-(((3-((7e/t-butoxycarbonyl)(3- (methyl(phenyl)amino)phenethyl)amino)propyl)amino)methyl)-2, 2-dimethyltetrahydro-4/7- cyclopenta[<^[1,3]dioxol-4-yl)-7//-pyrrolo[2,3-</|pyri midin-4-yl)(methyl)carbamate (288) & (1S,2/?,3/?,5A)-3-(((3-((3-(methyl(phenyl)amino)phenethyl)am ino)propyl)amino)methyl)-5-(4- (methylamino)-7//-pyrrolo[2,3-o]pyrimidin-7-yl)cyclopentane- 1,2-diol (289):

According to general procedure A. Reductive amination (288): yield: 21.00 mg, 0.03 mmol, 23 %. C 44 H 61 N 7 O 6 (784.02 g/mol). APCI: calc, for C 44 H 61 N 7 O 6 [M + H] + : 784.5, found: 785.2. According to general procedure Q. Deprotection (289): C 31 H 41 N 7 O 2 (543.72 g/mol). The crude product was purified by preparative HPLC according to method A. yield: 8.00 mg, 0.02 mmol, 42 % (2 TFA salt). 1 H NMR (400 MHz, DMSO-5 6 ) 58.77 (s, 2H, NH 2 + ), 8.70 (s, 2H, NH 2 + ), 8.32 (s, 1H, H2), 7.55 (s, 1H, H6), 7.32 - 7.27 (m, 2H, m"), 7.27 - 7.22 (m, 1H, m'), 7.05 - 7.01 (m, 2H, o"), 6.98 (tt, 7 = 7.6, 1.1 Hz, 1H, p"), 6.91 - 6.80 (m, 4H, H5, o', p'), 4.92 (q, 7 = 8.5 Hz, 1H, H1'), 4.18 (dd, 7 = 7.3, 5.8 Hz, 1H, H2'), 3.92 - 3.87 (m, 1H, H3'), 3.27 (s, 3H, CH 3 , NMe (Ar)), 3.21 - 3.10 (m, 3H, CH 2 , H4", H5'), 3.11 - 2.98 (m, 8H, CH 2 , CH 3 , NMe, 1", 3", H5'), 2.90 - 2.81 (m, 2H CH 2 , H5"), 2.38 - 2.21 (m, 2H, H4', H6-cyclopentane), 1.97 (p, 7 = 7.9 Hz, 2H CH 2 , H2"), 1.67 - 1.56 (m, 1H, H6-cyclopentane). APCI: calc, for C 31 H 41 N 7 O 2 [M + H] + : 544.7, found: 545.1. HPLC: t R = 13.802 min (Method A). UV- purity at 210 nm = 95.7%. te/T-butyl (7-((3aS,4/?,6/?,6a/t)-6-(((3-((te/t- butoxycarbonyl)(phenethyl)amino)propyl)amino)methyl)-2,2-dim ethyltetrahydro-4Z/- cyclopenta[<^[1,3]dioxol-4-yl)-7//-pyrrolo[2,3-</|pyri midin-4-yl)(methyl)carbamate (290) &

(1/?,2S,3/?,5/^-3-(4-(methylamino)-7//-pyrrolo[2,3-o]pyri midin-7-yl)-5-(((3-

(phenethylamino)p

According to general procedure A. Reductive amination (290): yield: 32.00 mg, 0.05 mmol, 52 %. C 37 H 54 N 6 O 6 (678.88 g/mol). APCI: calc, for C 37 H 54 N 6 O 6 [M + H] + : 679.4, found: 679.7. According to general procedure Q. Deprotection (291): C 24 H 34 N 6 O 2 (438.27 g/mol). The crude product was purified by preparative HPLC according to method A. yield: 12.70 mg, 0.03 mmol, 65 % (2 TFA salt). 1 H NMR (400 MHz, DMSO-5 6 ) 5 8.94 - 8.81 (m, 2H, NH 2 + ), 8.78 - 8.64 (m, 2H, NH 2 + ), 8.32 (s, 1H, H2), 7.55 (s, 1H, H6), 7.40 - 7.32 (m, 2H, m'-Ar), 7.31 - 7.23 (m, 3H, o'/p'-Ar), 6.84 (s, 1H, H5), 4.92 (q, 7= 8.6 Hz, 1H, H1'), 4.18 (dd, 7 = 7.3, 5.8 Hz, 1H, H2'), 3.90 (t, 7 = 5.4 Hz, 1H, H3'), 3.24 - 3.13 (m, 2H, CH 2 , H4"), 3.13 - 3.00 (m, 9H, CH 2 & CH 3 , H5', H1", H3", NMe), 2.97 - 2.89 (m, 2H, CH 2 , H5"), 2.39 - 2.21 (m, 2H, H4', H6-cyclopentane), 1.99 (p, 7 = 8.0 Hz, 2H, CH 2 , H2"), 1.68 - 1.57 (m, 1H, H6-cyclopentane). APCI: calc, for C 24 H 34 N 6 O 2 [M + H] + : 439.3, found: 439.4. HPLC: ZR = 9.836 min (Method A). UV-purity at 210 nm = 96.6%. fe/t- butyl (((3a/?,4/?,6/?,6aA)-6-(6-((7e/t-butoxycarbonyl)amino)-9//-p urin-9-yl)-2,2- dimethyltetrahydrofuro[3,4-5|[1,3]dioxol-4-yl)methyl)(3-((4- ((1-(2-methoxyethyl)-1//-1,2 ; 3-tnazol-

4-yl)methoxy)benzyl)amino)propyl)carbamate (292) & (2/?,3/?,45,5/t)-2-(6-amino-9AApurin-9-yl)-

5-(((3-((4-((1-(2-methoxyethyl)-1AA1,2,3-triazol-4- yl)methoxy)benzyl)amino)propyl)amino)methyl)tetrahydrofuran- 3,4-diol (293)

According to general procedure G. CuAAC (292): yield: 17.00 mg, 0.02 mmol, 75 %.

C39H 56 N 10 O9 (808.94 g/mol). APCI: calc. For C39H 56 N 10 : 809.4, found: 809.5. According to general procedure Q. Deprotection (293): C26H 36 N 4 g/mol). yield: 12.08 mg, 0.02 mmol, quant. (2 TFA salt). 1 H NMR (400 MHz, D 8.95 - 8.62 (m, 4H, NH 2 + ), 8.47 (s, 1H, H2), 8.29 (s, 1H, H8), 8.21 (s, 1H, H-triazol), 7.92 -amine), 7.43 - 7.38 (m, 2H, m'), 7.15 - 7.10 (m, 2H, o'), 5.99 (d, 7 = 5.2 Hz, 1H, H1'), 5.16 (s, 2H, CH 2 , O-CH 2 ), 4.70 (t, 7 = 5.1 Hz, 1H, H2'), 4.55 (dd, 7 = 5.6, 4.6 Hz, 2H, CH 2 , H1'"), 4.27 (t, 7 = 4.5 Hz, 1H, H3'), 4.24 - 4.18 (m, 1H, H4'), 4.07 (d, 7 = 6.2 Hz, 2H, CH 2 , benzylic), 3.74 (dd, 7 = 5.6, 4.7 Hz, 2H, CH 2 , H2'"), 3.48 - 3.30 (m, 2H, CH 2 , H5'), 3.25 (s, 3H, CH 3 , OMe), 3.07 - 3.00 (m, 2H, CH 2 , H3"), 2.99 - 2.91 (m, 2H, CH 2 , H2"),

1.95 (p, 7 = 6.9 Hz, 2H, CH 2 , H2"). APCI: calc, for C 26 H36N 10 O 5 [M + H] + : 569.3, found: 569.6. HPLC:

ZR = 8.884 min (Method A). UV-purity at 210 nm = 86.8%. fe/A butyl (((3a/?,4/?,6/?,6aA)-6-(6-((7e/Abutoxycarbonyl)amino)-9//-pu rin-9-yl)-2,2- dimethyltetrahydrofuro[3,4-</|[1,3]dioxol-4-yl)methyl)(3- ((4-(1-(2-methoxyethyl)-1//-1,2 ; 3-tnazol- 4-yl)phenethyl)amino)propyl)carbamate (294) & (2/?,3/?,4S,5/^-2-(6-amino-9//-purin-9-yl)-5-(((3- ((4-(1-(2-methoxyethyl)-1//-1,2 ; 3-triazol-4- yl)phenethyl)amino)propyl)amino)methyl)tetrahydrofuran-3,4-d iol (295):

According to general procedure G. CuAAC (294): yield: 15.00 mg, 0.01 mmol, 19 %. C39H5 6 N 10 O 8 (792.94 g/mol). APCI: calc. For C39H5 6 N 10 O 8 [M+H] + : 793.4, found: 793.8. According to general procedure Q. Deprotection (295): C 26 H3 6 N 10 O4 (552.64 g/mol). yield: 2.08 mg, 0.004 mmol, quant. (2 TFA salt). 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.94 - 8.66 (m, 4H, NH 2 + ), 8.54 (s, 1H, H2), 8.44 (s, 1H, H8), 8.26 (s, 1H, H-triazol), 7.87 - 7.81 (m, 2H, m'), 7.71 (s, 2H, N6-amine), 7.38 - 7.32 (m, 2H, o'), 5.99 (d, 7 = 5.3 Hz, 1H, H1'), 4.72 (t, 7 = 5.2 Hz, 1H, H2'), 4.58 (t, 7 = 5.2 Hz, 2H, CH 2 , H1'"), 4.28 (t, 7= 4.6 Hz, 1H, H3'), 4.25 - 4.19 (m, 1H, H4'), 3.78 (dd, 7 = 5.7, 4.7 Hz, 2H, CH 2 , H2'"), 3.49 - 3.40 (m, 2H, CH 2 , H5'), 3.27 (s, 3H, CH 3 , OMe), 3.20 - 3.16 (m, 2H, CH 2 , H4"), 3.03 (d, 7 = 6.5 Hz, 4H, CH 2 , H1", H3"), 2.97 - 2.90 (m, 2H, CH 2 , H5"), 2.03 - 1.90 (m, 2H, CH 2 , H2"). APCI: calc, for C 26 H36N 10 O 4 [M + H] + : 553.3, found 553.5. HPLC: t R = 9.449 min (Method A). UV-purity at 210 nm = 75.5%. fe/A butyl (3-((3aS,4S,6/?,6a/^-6-(6-amino-9//-purin-9-yl)-2,2-dimethyl tetrahydrofuro[3,4- d|[1 ; 3]dioxole-4-carboxamido)propyl)(4-phenoxyphenethyl)car bamate (296) & (25, 35, 4/?, 5/^-5- (6-amino-9//-purin-9-yl)-3,4-dihydroxy-/V-(3-((4- phenoxyphenethyl)amino)propyl)tetrahydrofuran-2-carboxamide (297):

According to general procedure E. Amide coupling (296): yield: 67.00 mg, 0.10 mmol, 89 %. C35H43N7O7 (673.77 g/mol). APCI: calc. C35H43N7O7 [M + H] + : 674.3, found: 674.4. According to general procedure Q. Deprotection (297): C27H 31 N7O 5 (533.59 g/mol). yield: 23.00 mg, 0.04 mmol, 53% (1 TEA salt). 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 9.25 (t, 7 = 6.0 Hz, 1H, NH, amide), 8.53 (s, 2H, NH 2 + ), 8.39 (s, 1H, H2), 8.27 (s, 1H, H8), 7.51 (s, 2H, NH 2 , N6-amine), 7.43 - 7.36 (m, 2H, m"), 7.31 - 7.25 (m, 2H, m'), 7.17 - 7.11 (m, 1H, p"), 7.02 - 6.96 (m, 4H, o', o"), 5.98 (d, 7 = 7.8 Hz, 1H, H1'), 5.87 - 5.81 (m, 1H, 3'OH), 5.65 - 5.58 (m, 1H, 2'OH), 4.64 - 4.57 (m, 1H, H2'), 4.35 (d, 7 = 1.4 Hz, 1H, H4'), 4.17 (d, 7 = 4.6 Hz, 1H, H3'), 3.31 (q, 7 = 6.5 Hz, 2H, CH 2 , H1"), 3.21 - 3.11 (m, 2H, CH 2 , H4"), 3.02 - 2.92 (m, 2H, CH 2 , H3"), 2.91 - 2.84 (m, 2H, CH 2 , H5"), 1.83 (p, 7 = 7.0 Hz, 2H, CH 2 , H2"). APCI: calc, for C^H^NyOs [M + H] + : 534.2, found: 534.3. HPLC: t R = 14.071 min (Method A). UV-purity at 210 nm = 89.0%. fe/A butyl (3-((3aS,4S,6/?,6a/^-6-(6-amino-9//-purin-9-yl)-2,2-dimethyl tetrahydrofuro[3,4- </|[1 ; 3]dioxole-4-carboxamido)propyl)(3-phenoxyphenethyl)car bamate (298) & (25, 35, 4/?, 5/^-5- (6-amino-9//-purin-9-yl)-3,4-dihydroxy-/V-(3-((3- phenoxyphenethyl)amino)propyl)tetrahydrofuran-2-carboxamide (299):

According to general procedure E. Amide coupling (298): yield: 32.00 mg, 0.05 mmol, 39 %. C35H43N7O7 (673.77 g/mol). APCI: calc. C35H43N7O7 [M + H] + : 674.3, found: 674.7. According to general procedure Q. Deprotection (299): C 27 H3iN 7 O5 (533.59 g/mol). The crude product was purified by preparative HPLC according to method A. yield: 17.80 mg, 0.03 mmol, 81% (1 TEA salt). 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.96 (t, 7 = 6.1 Hz, 1H, NH, amide), 8.59 (s, 1H, H2), 8.48 (s, 2H, NH 2 + ), 8.38 (s, 1H, H8), 8.25 (s, 2H, NH 2 , N6-amino), 7.43 - 7.38 (m, 2H, m"), 7.36 (t, 7 = 7.9 Hz, 1H, m'), 7.18 - 7.13 (m, 1H, p"), 7.06 - 7.03 (m, 1H, p'), 7.03 - 7.00 (m, 2H, o"), 6.97 - 6.95 (m, 1H, o'), 6.92 - 6.87 (m, 1H, o'), 6.02 (d, 7 = 7.2 Hz, 1H, H1'), 4.60 (dd, 7 = 7.2, 4.5 Hz, 1H, H2'), 4.38 (d, 7 = 1.8 Hz, 1H, H4'), 4.20 (dd, 7 = 4.6, 1.9 Hz, 1H, H3'), 3.27 (q, 7 = 6.6 Hz, 2H, CH 2 , H1"), 3.22 - 3.12 (m, 2H, CH 2 , H4"), 3.00 - 2.92 (m, 2H, CH 2 , H3"), 2.92 - 2.85 (m, 2H, H5"), 1.80 (p, 7 = 6.7 Hz, 2H, CH 2 , H2"). APCI: calc, for C^H^NyOs [M + H] + : 534.2, found: 534.5. HPLC: t R = 13.888 min (Method A). UV-purity at 210 nm = 99.7%. fe/A butyl (3-((3aS,4S,6/?,6a/^-6-(6-amino-9//-purin-9-yl)-2,2-dimethyl tetrahydrofuro[3,4- d|[1 ; 3]dioxole-4-carboxamido)propyl)(phenethyl)carbamate (300) & (2S,35;4/?,5/i)-5-(6-amino- 9/Apurin-9-yl)-3,4-dihydroxy-/V-(3-(phenethylamino)propyl)te trahydrofuran-2-carboxamide (301):

According to general procedure E. Amide coupling (300): yield: 20.00 mg, 0.03 mmol, 51 %. C29H39N7O6 (581.67 g/mol). APCI: calc. C 2 9H 39 N 7 O 6 [M + H] + : 582.3, found: 582.6. According to general procedure Q. Deprotection (301): C21H27N7O4 (441.49 g/mol). The crude product was purified by preparative HPLC according to method D. yield: 7.80 mg, 0.02 mmol, 83% (1 TEA salt) 1 H NMR (400 MHz, DMSO-5 6 ) 5 9.09 (t, 7 = 5.9 Hz, 1H, NH, amide), 8.50 (s, 3H, H2, NH 2 + ), 8.33 (s, 1H, H8), 7.92 (bs, 2H, NH 2 , N6-amine), 7.39 - 7.31 (m, 3H, m/p-Ar), 7.31 - 7.22 (m, 2H, o-Ar), 6.00 (d, 7 = 7.4 Hz, 1H, H1'), 4.61 (dd, 7 = 7.5, 4.6 Hz, 1H, H2'), 4.37 (d, 7 = 1.7 Hz, 1H, H4'), 4.19 (dd, 7 = 4.6, 1.7 Hz, 1H, H3'), 3.29 (q, 7 = 6.6 Hz, 2H, CH 2 , H1"), 3.22 - 3.12 (m, 2H, CH 2 , H4"), 3.02 - 2.92 (m, 2H, CH 2 , H3"), 2.92 - 2.86 (m, 2H, CH 2 , H5"), 1.82 (p, 7 = 6.7 Hz, 2H, CH 2 , H2"). APCI: calc, for C 21 H 27 N 7 O 4 [M+H] + : 442.2, found: 442.2. HPLC: t R = 10.084 min (Method A). UV-purity at 210 nm = 98.8%.

(3aS,4S,6/?,6a/t)-6-(6-amino-9//-purin-9-yl)-2,2-dimethyl -/V-(3-(2- phenylacetamido)propyl)tetrahydrofuro[3,4-5|[1,3]dioxole-4-c arboxamide (302) & 25, 35,4/?, 5A)- 5-(6-amino-9//-purin-9-yl)-3,4-dihydroxy-/V-(3-(2-phenylacet amido)propyl)tetrahydrofuran-2- carboxamide

According to general procedure E. Amide coupling (302): yield: 136.00 mg, 0.27 mmol, 53 %. C24H29N7O5 (495.54 g/mol). APCI: calc. C24H29N7O5 [M + H] + : 496.2, found: 496.1. According to general procedure Q. Deprotection (303): C21H25N7O5 (455.48 g/mol). The crude product was purified by preparative HPLC according to method D. yield: 84.90 mg, 0.19 mmol, 93% (1 TEA salt). 1 H NMR (400 MHz, DMSO-5 6 ) 58.70 (s, 1H, H2), 8.62 (t, 7 = 5.7 Hz, 1H, NH, amide), 8.40 (s, 1H, H8), 8.07 (t, 7 = 5.6 Hz, 1H, NH, amide), 7.33 - 7.17 (m, 5H, Ar), 6.03 (d, 7 = 7.0 Hz, 1H, H1'), 4.61 (dd, 7 = 7.0, 4.5 Hz, 1H, H2'), 4.37 (d, 7 = 2.1 Hz, 1H, H4'), 4.19 (dd, 7 = 4.5, 2.1 Hz, 1H, H3'), 3.39 (s, 2H, CH2, benzylic), 3.21 - 3.12 (m, 2H, CH 2 , H3"), 3.07 (q, 7 = 6.5 Hz, 2H, CH 2 , H1"), 1.60 (p, 7 = 7.0 Hz, 2H, CH 2 , H2"). APCI: calc, for C21H25N7O5 [M + H] + : 456.2, found: 456.4. HPLC: ZR = 10.899 min (Method A). UV-purity at 210 nm = 98.7%.

(3aS,4S,6/?,6a/^-6-(6-amino-9//-purin-9-yl)-2,2-dimethyl- /V-(3-(3- phenylureido)propyl)tetrahydrofuro[3,4-o][1,3]dioxole-4-carb oxamide (683) & (2S,35;4/?,5/i)-5-(6- amino-9//-purin-9-yl)-3,4-dihydroxy-/V-(3-(3-phenylureido)pr opyl)tetrahydrofuran-2- carboxamide

According to general procedure E. Amide coupling (683): yield: 44.00 mg, 0.09 mmol, 17 %. C23H28N8O5 (496.53 g/mol). APCI: calc. [M + H] + : 497.2, found: 497.1. According to general procedure Q. Deprotection (684): C20H24N8O5 (456,46 g/mol). The crude product was purified by preparative HPLC according to method D. yield: 13.30 mg, 0.03 mmol, 37% (1 TFA salt). 1 H NMR (400 MHz, DMSO-of) 5 8.70 (s, 1H, H2), 8.63 (t, 7 = 5.7 Hz, 1H, NH, amide), 8.51 (s, 1H, NH, urea),

8.41 (s, 1H, H8), 7.39 - 7.34 (m, 2H, o'), 7.23 - 7.16 (m, 2H, m'), 6.87 (tt, 7 = 7.4, 1.2 Hz, 1H, p'), 6.24 - 6.16 (m, 1H, NH, urea), 6.03 (d, 7 = 7.0 Hz, 1H, H1'), 4.62 (dd, 7 = 6.9, 4.5 Hz, 1H, H2'), 4.38 (d, 7 =

2.1 Hz, 1H, H4'), 4.21 (dd, 7 = 4.6, 2.1 Hz, 1H, H3'), 3.21 (p, 7 = 6.8 Hz, 2H, CH 2 , H1"), 3.13 - 3.05 (m, 2H, CH 2 , H3"), 1.61 (p, 7 = 6.8 Hz, 2H, CH 2 , H2"). APCI: calc, for C20H24N8O5 [M + H] + : 457.2, found: 457.4. HPLC: t R = 10.460 min (Method A). UV-purity at 210 nm = 95.9%.

(3aS,4S,6/?,6a/^-6-(6-amino-9//-purin-9-yl)-2,2-dimethyl- /V-(3- propionamidopropyl)tetrahydrofuro[3,4-d|[1,3]dioxole-4-carbo xamide (304) & (25, 35, 4/?, 5/^-5- (6-amino-9//-purin-9-yl)-3,4-dihydroxy-/V-(3-propionamidopro pyl)tetrahydrofuran-2- carboxamide (305):

According to general procedure E. Amide coupling (304): yield: 36.00 mg, 0.08 mmol, 20 %. C19H27N7O5 (433.47 g/mol). APCI: calc. [M + H] + : 434.2, found: 434.1. According to general procedure Q. Deprotection (305): C 16 H23N7O 5 (448,48 g/mol). The crude product was purified by preparative HPLC according, yield: 33.02 mg, 0.08 mmol, 100% (1 TFA salt). 1 H NMR (400 MHz, DMSO-aL) 5 8.75 (s, 1H, H2), 8.53 (t, 7 = 5.8 Hz, 1H, NH, amide), 8.44 (s, 1H, H8), 7.76 (t, 7 = 5.6 Hz, 1H, NH, amide), 6.04 (d, 7 = 6.8 Hz, 1H, H1'), 4.62 (dd, 7 = 6.9, 4.5 Hz, 1H, H2'), 4.37 (d, 7 = 2.2 Hz, 1H, H4'), 4.21 (dd, 7 = 4.6, 2.2 Hz, 1H, H3'), 3.16 (q, 7 = 6.8 Hz, 2H, CH 2 , H1"), 3.05 (q, 7 = 6.7 Hz, 2H, CH 2 , H3"), 2.05 (q, 7 = 7.6 Hz, 2H, CH 2 , H • ), 1.58 (p, 7 = 6.9 Hz, 2H, CH 2 , H2"), 0.98 (t, 7 = 7.6 Hz, 3H, CH 3 , HP). APCI: calc, for C 16 H 2 3N 7 O 5 [M + H] + : 394.2, found: 393.8. HPLC: t R = 4.881 min (Method B). UV-purity at 210 nm = 97.1%.

(3aS,45;6/?,6a/tO-6-(6-amino-9//-purin-9-yl)-/V-(3-(3-eth ylureido)propyl)-2,2- dimethyltetrahydrofuro[3,4-d|[1,3]dioxole-4-carboxamide (306) & (2S,3S,4/?,5/tO-5-(6-amino-9//- purin-9-yl)-/V-(3-(3-ethylureido)propyl)-3,4-dihydroxytetrah ydrofuran-2-carboxamide (307):

According to general procedure E. Amide coupling (306): yield: 46.00 mg, 0.10 mmol, 27 %. C19H28N8O5 (448.48 g/mol). APCI: calc. [M + H] + : 449.2, found: 448.9. According to general procedure Q. Deprotection (307): C 16 H 2 4N 8 O5 (408.42 g/mol). The crude product was purified by preparative HPLC according to method E. yield: 46.00 mg, 0.11 mmol, 100% (1 TFA salt). 1 H NMR (400 MHz, DMSO-of) 5 8.71 (s, 1H, H2), 8.60 (t, 7 = 5.9 Hz, 1H, NH, amide), 8.40 (s, 1H, H8), 6.03 (d, 7 = 6.9 Hz, 1H, H1'), 4.61 (dd, 7 = 6.9, 4.5 Hz, 1H, H2'), 4.37 (d, 7 = 2.1 Hz, 1H, H4'), 4.20 (dd, 7 = 4.6, 2.2 Hz, 1H, H3'), 3.16 (qd, 7 = 6.7, 2.8 Hz, 2H, CH 2 , H1"), 2.98 (q, 7 = 7.1 Hz, 4H, CH 2 , H3", H • -urea), 1.54 (p, 7 = 6.9 Hz, 2H, CH 2 , H2"), 0.97 (t, 7 = 7.2 Hz, 3H, CH 3 , H • -urea). APCI: calc. for C 16 H 24 N 8 O 5 [M + H] + : 408.2, found: 408.9. HPLC: f R = 4.284 min (Method B). UV-purity at 210 nm = 100%.

(3aS,45;6/?,6a/i)-6-(6-amino-9Z/-punn-9-yl)-/V-(3-(3-ethy lureido)propyl)-2,2- dimethyltetrahydrofuro[3,4-5|[1,3]dioxole-4-carboxamide (685) & (2S35,4/?,5/t)-5-(6-amino-9/7- purin-9-yl)-/V-(3-(3-ethylureido)propyl)-3,4-dihydroxytetrah ydrofuran-2-carboxamide (686):

According to general procedure E. Amide coupling (685): yield: 46.00 mg, 0.10 mmol, 27 %. C 19 H 28 N 8 O 5 (448.48 g/mol). APCI: calc. [M + H] + : 449.2, found: 448.9. According to general procedure Q. Deprotection (686): C 16 H 24 N 8 O 5 (408.42 g/mol). The crude product was purified by preparative HPLC according to method E. yield: 46.00 mg, 0.11 mmol, 100% (1 TFA salt). 1 H NMR (400 MHz, DMSO-rt) 5 8.71 (s, 1H, H2), 8.60 (t, 7 = 5.9 Hz, 1H, NH, amide), 8.40 (s, 1H, H8), 6.03 (d, 7 = 6.9 Hz, 1H, H1'), 4.61 (dd, 7 = 6.9, 4.5 Hz, 1H, H2'), 4.37 (d, 7 = 2.1 Hz, 1H, H4'), 4.20 (dd, 7 = 4.6, 2.2 Hz, 1H, H3'), 3.16 (qd, 7 = 6.7, 2.8 Hz, 2H, CH 2 , H1"), 2.98 (q, 7 = 7.1 Hz, 4H, CH 2 , H3", H • -urea), 1.54 (p, 7 = 6.9 Hz, 2H, CH 2 , H2"), 0.97 (t, 7 = 7.2 Hz, 3H, CH 3 , H • -urea). APCI: calc, for C 16 H 24 N 8 O 5 [M + H] + : 408.2, found: 408.9. HPLC: t R = 4.284 min (Method B). UV-purity at 210 nm = 100%. tert-butyl (7-((3a/?,4/?,6/?,6aA)-6-(((3-((tert- butoxycarbonyl)(phenethyl)amino)propyl)amino)methyl)-2,2-dim ethyltetrahydrofuro[3,4-

</|[1,3]dioxol-4-yl)-7//-pyrrolo[2,3-<^pyrimidin-4- yl)(methyl)carbamate (308) & (2/?,3/?,4S,5A)-2-

(4-(methylamino)-7Z/-pyrrolo[2,3-o]pyrimidin-7-yl)-5-(((3 -

(phenethylamino)propyl)amino)methyl)tetrahydrofuran-3,4-d iol (309)

According to general procedure A. Reductive amination (308): yield: 44.00 mg, 0.07 mmol, 27 %. C36H 52 N 6 O7 (680.85 g/mol). APCI: calc. [M + H] + : 680.4, found: 680.6. According to general procedure Q. Deprotection (309): C 23 H 32 N 6 O3 (440.55 g/mol). The crude product was purified by preparative HPLC according to method D. yield: 27.00 mg, 0.06 mmol, 100% (1 TFA salt). 1 H NMR (400 MHz, DMSO-rt) 58.93 (s, 2H, NH 2 + ), 8.82 (s, 2H, NH 2 + ), 8.34 (s, 1H, H2), 7.57 (s, 1H, H6), 7.38 - 7.32 (m, 2H, o'), 7.30 - 7.24 (m, 3H, m'/p'), 6.84 (s, 1H, H5), 6.12 (d, 7 = 5.1 Hz, 1H, H1'), 4.47 (t, 7 = 4.9 Hz, 1H, H2'), 4.21 - 4.13 (m, 2H, H3', H4'), 3.41 - 3.28 (m, 2H, CH 2 , H5'), 3.15 (d, 7 = 6.0 Hz, 2H, CH 2 , H4"), 3.10 - 2.97 (m, 7H, CH 3 , CH 2 , NMe, H1", H3"), 2.95 - 2.87 (m, 2H, CH 2 , H5"), 2.01 - 1.91 (m, 2H, CH 2 , H2"). APCI: calc, for C 23 H 32 N 6 O 3 [M + H] + : 440.3, found: 440.5. HPLC: ZR = 8.816 min (Method A). UV-purity at 210 nm = 98.3%. te/T-butyl (7-((3a/?,4/?,6/?,6aA)-6-(((3-((tert- butoxycarbonyl)(phenethyl)amino)propyl)amino)methyl)-2,2-dim ethyltetrahydrofuro[3,4- 5|[1,3]dioxol-4-yl)-5-methyl-7//-pyrrolo[2,3-<^pyrimidin- 4-yl)(methyl)carbamate (310) & (2/?,3/?,45;5/i)-2-(5-methyl-4-(methylamino)-7//-pyrrolo[2,3 -<^pyrimidin-7-yl)-5-(((3-

(phenethylamino)propyl)amino)methyl)tetrahydrofuran-3,4-d iol (311):

According to general procedure D. Reductive amination (310): yield: 98.00 mg, 0.14 mmol, 62 %.

C37H 54 N 6 O7 (694.87 g/mol). APCI: calc. [M + H] + : 694.4, found: 694.8. According to general procedure Q. Deprotection (311): C24H 34 N 6 O3 (454.58 g/mol). The crude product was purified by preparative HPLC according to method D. yield: 6.87 mg, 0.02 mmol, 70% (2 TFA salt). 1 H NMR (400 MHz, DMSO-of) 5 8.84 (bs, 2H, NH 2 + ), 8.74 (bs, 2H, NH 2 + ), 8.26 (s, 1H, H2), 7.39 - 7.32 (m,

2H, o'), 7.31 - 7.23 (m, 4H, m', p', H6), 6.09 (d, 7 = 5.0 Hz, 1H, H1'), 4.40 (t, 7 = 4.8 Hz, 1H, H2'), 4.16 - 4.10 (m, 2H, H3', H4'), 3.39 - 3.24 (m, 2H, CH 2 , H5'), 3.20 - 3.10 (m, 2H, CH 2 , H4"), 3.06 - 2.97 (m, 4H, CH 2 , H1", H3"), 3.02 (d, 7= 4.6 Hz, 3H, CH 3 , NMe), 2.94 - 2.86 (m, 2H, CH 2 , H5"),

2.39 (d, 7 = 1.2 Hz, 3H, CH 3 , 5'-Me), 2.00 - 1.89 (m, 2H, CH 2 , H2"). APCI: calc, for C 24 H 34 N 6 O3

[M + H] + : 454.3, found: 454.5. HPLC: f R = 9.136 min (Method A). UV-purity at 210 nm = 98.0%. fe/'A butyl (((3a/?,4/?,6/?,6aA)-6-(6-((fe/t-butoxycarbonyl)amino)-9//-p urin-9-yl)-2,2- dimethyltetrahydrofuro[3,4-d|[1,3]dioxol-4-yl)methyl)(3-prop ionamidopropyl)carbamate (312) & A/-(3-((((2/?,3S,4/?,5/^-5-(6-amino-9//-purin-9-yl)-3,4-dihy droxytetrahydrofuran-2- yl)methyl)amino)propyl)propionamide (313):

According to general procedure C. Acylation/urea synthesis (312): yield: 8.00 mg, 0.01 mmol,

26 %.

C 29 H 45 N 7 O 8 (619.72 g/mol). APCI: calc. [M + H] + : 619.3, found: 619.5. According to general procedure Q. Deprotection (313): C 16 H 25 N7O 4 (379.42 g/mol). yield: 8.61 mg, 0.02 mmol, quant. (1 TFA salt). 1 H NMR (400 MHz, DMSO-5 6 ) 58.84 - 8.56 (m, 2H, NH 2 + ), 8.60 (s, 1H, H2), 8.40 (s, 1H, H8), 8.35 (s, 2H, N6-NH 2 ), 8.00 (t, 7 = 5.8 Hz, 1H, NH, amide), 6.06 (d, 7 = 5.5 Hz, 1H, H1'), 4.81 - 4.71 (m, 1H, H2'), 4.32 - 4.23 (m, 2H, H3', H4'), 3.54 - 3.34 (m, 2H, CH 2 , H5'), 3.14 (q, 7 = 6.5 Hz, 2H, CH 2 , H3"), 2.99 (p, 7 = 7.1 Hz, 2H, CH 2 , H1"), 2.12 (q, 7 = 7.6 Hz, 2H, CH 2 , Ha), 1.77 (dq, 7 = 13.3, 6.6 Hz, 2H, CH 2 , H2"), 1.04 (t, 7 = 7.6 Hz, 3H, CH 3 , Hp). APCI: calc, for C 16 H 25 N 7 O 4 [M + H] + : 379.2, found: 379.3. HPLC: f R = 3.063 min (Method B). UV-purity at 210 nm = 91.8%. fe/t- butyl (((3a/?,4/?,6/?,6aA)-6-(6-((fe/7-butoxycarbonyl)amino)-9//-p urin-9-yl)-2,2- dimethyltetrahydrofuro[3,4-5|[1,3]dioxol-4-yl)methyl)(2-prop ionamidoethyl)carbamate (314) & /V- (2-((((2/?,3S,4/?,5/^-5-(6-amino-9//-purin-9-yl)-3,4-dihydro xytetrahydrofuran-2- yl)methyl)amino)ethyl)propionamide (315): According to general procedure C. Acylation/urea synthesis (314): yield: 13.00 mg, 0.02 mmol,

17 %.

C28H43N7O8 (605.69 g/mol). APCI: calc. [M + H] + : 605.3, found: 605.5. According to general procedure Q. Deprotection (315): C15H23N7O4 (365.39 g/mol). yield: 8.33 mg, 0.02 mmol, 100% (1 TFA salt). 1 H NMR (400 MHz, DMSO-5 6 ) 58.80 - 8.53 (m, 2H, NH 2 + ), 8.50 (s, 1H, H2), 8.31 (s, 1H, H8), 8.09 (s, 2H, N6-amine), 8.00 (t, 7 = 5.7 Hz, 1H, NH, amide), 5.99 (d, 7 = 5.6 Hz, 1H, H1'), 4.69 (dd, 7 = 5.5, 4.4 Hz, 1H, H2'), 4.26 - 4.18 (m, 2H, H3', H4'), 3.50 - 3.36 (m, 2H, CH 2 , H5'), 3.32 (q, 7 = 6.3 Hz, 2H, CH 2 , H2"), 3.03 (t, 7 = 6.2 Hz, 2H, CH 2 , H1"), 2.07 (q, 7 = 7.5 Hz, 2H, CH 2 , Ha), 0.96 (t, 7 = 7.6 Hz, 3H, CH 3 , Hp). APCI: calc, for C 15 H2 3 N 7 O4 [M + H] + : 365.2, found: 366.1. HPLC: ZR = 6.431 min (Method B). UV-purity at 210 nm = 86.0%.

Ze/t- butyl (((3a/?,4/?,6/?,6a5)-6-(5-bromo-4-((4-methoxybenzyl)amino)-7 //-pyrrolo[2,3- </|pyrimidin-7-yl)-2,2-dimethyltetrahydro-4//-cyclopenta[ </|[1,3]dioxol-4-yl)methyl)(3-((3- fluorophenethyl)amino)propyl)carbamate (316) & (1/?,25,3/?,5/t)-3-(4-amino-5-bromo-7A/- pyrrolo[2,3-5|pyrimidin-7-yl)-5-(((3-((3- fluorophenethyl)amino)propyl)amino)methyl)cyclopentane-1,2-d iol (317): uivie

According to general procedure D. Reductive amination (316): yield: 20.00 mg, 0.03 mmol, 43 %. QgHsoBrFNeOs (781.77 g/mol). APCI: calc. [M + H] + : 780.30, found:. According to general procedure O. Deprotection (317): C2 3 H 30 BrFN 6 O2 (521.44 g/mol). The crude product was purified by preparative HPLC according to method D. yield: 12.61 mg, 0.02 mmol, 100% (2 TFA salt). 1 H NMR (400 MHz, DMSO-5 6 ) 5 8.81 (bs, 2H, NH 2 + ), 8.65 (bs, 2H, NH 2 + ), 8.30 (s, 1H, H2), 7.83 (s, 1H, H6), 7.44 - 7.37 (m, 1H, m'), 7.19 - 7.09 (m, 3H, o', p'), 4.95 (dt, 7 = 10.4, 7.9 Hz, 1H, H1'), 4.18 (dd, 7 = 7.6, 5.7 Hz, 1H, H2'), 3.88 (t, 7 = 5.2 Hz, 1H, H3'), 3.26 - 3.14 (m, 2H, CH 2 , H5', H4"), 3.10 - 2.99 (m, 5H, CH 2 , H5', H1", H2"), 2.99 - 2.91 (m, 2H, CH 2 , H5"), 2.36 - 2.21 (m, 2H, H4', H6'- cyclopentane-axial), 2.04 - 1.92 (m, 2H, CH 2 , H2"), 1.66 - 1.54 (m, 1H, H6'-cyclopentante- equatorial). APCI: calc, for C 23 H3oBrFN 6 0 2 [M + H] + : 520.2, found: 520.6/522.5. HPLC: ZR = 10.499 min (Method A). UV-purity at 210 nm = 97.0%.

Ze/t- butyl (((3a/?,4/?,6/?,6a5)-6-(5-bromo-4-((4-methoxybenzyl)amino)-7 //-pyrrolo[2,3- </|pyrimidin-7-yl)-2,2-dimethyltetrahydro-4//-cyclopenta[ </|[1,3]dioxol-4-yl)methyl)(3-((4- fluorophenethyl)amino)propyl)carbamate (318) & (1/?,25,3/?,5/t)-3-(4-amino-5-bromo-7A/- pyrrolo[2,3-5|pyrimidin-7-yl)-5-(((3-((4- fluorophenethyl)amino)propyl)amino)methyl)cyclopentane-1,2-d iol (319):

According to general procedure D. Reductive amination (318): yield: 36.7 mg, 0.05 mmol, 78 %. C 3 9H5 0 BrFN 6 O5 (781.77 g/mol). APCI: calc. [M + H] + : 780.3, found: 780.5. According to general procedure O. Deprotection (319): C 2 3H3 0 BrFN 6 O 2 (521.44 g/mol). The crude product was purified by preparative HPLC according to method D. yield: 19.24 mg, 0.04 mmol, 97% (2 TFA salt). 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.85 (bs, 2H, NH 2 + ), 8.69 (bs, 2H, NH 2 + ), 8.30 (s, 1H, H2), 7.83 (s, 1H, H6), 7.37 - 7.27 (m, 2H, m'), 7.24 - 7.14 (m, 2H, o'), 4.95 (dt, 7 = 10.4, 7.9 Hz, 1H, H1'), 4.18 (dd, 7 = 7.6, 5.6 Hz, 1H, H2'), 3.88 (t, 7 = 5.2 Hz, 1H, H3'), 3.22 - 3.13 (m, 2H, CH 2 , H5', H4"), 3.09 - 2.99 (m, 4H, CH 2 , H1", H3"), 2.96 - 2.88 (m, 2H, CH 2 , H5"), 2.37 - 2.20 (m, 2H, H4', H6-cyclopentane- axial), 1.98 (p, 7 = 7.5 Hz, 2H, CH 2 , H2"), 1.66 - 1.55 (m, 1H, H6, cyclopentane-equatorial). APCI: calc, for C 23 H 30 BrFN 6 O 2 [M + H] + : 520.2, found: 520.6/522.5. HPLC: t R = 10.562 min (Method A).

UV-purity at 210 nm = 95.3%. fe/t- butyl (4-(benzyloxy)benzyl)(3-((((3a/?,4/?,6/?,6a/^-6-(6-((fe/t-bu toxycarbonyl)amino)-9/7- purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-<^[1,3]dioxol- 4-yl)methyl)amino)propyl)carbamate

(320) & (2/?,3/?,4S,5/t)-2-(6-amino-9A/-purin-9-yl)-5-(((3-((4-

(benzyloxy)benzyl)amino)propyl)amino)methyl)tetrahydrofur an-3,4-diol (321):

According to general procedure A. Reductive amination (320): yield: 37.80 mg, 6 %.

C40H53N7O8 (759.91 g/mol). According to general procedure Q. Deprotection (321): C27H33N7O4 (519.61 g/mol). yield: 11.60 mg, 30% (2 TFA salt). 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.87 (bs, 2H, NH 2 + ), 8.69 (bs, 2H, NH 2 + ), 8.45 (s, 1H, H2), 8.27 (s, 1H, H8), 7.83 (s, 2H, NH2, N6-amine), 7.47 - 7.43 (m, 2H, o"), 7.42 - 7.37 (m, 4H, m', m"), 7.37 - 7.31 (m, 1H, p"), 7.11 - 7.06 (m, 2H, o'), 5.99 (d, 7 = 5.3 Hz, 1H, H1'), 5.14 (s, 2H, CH 2 , OBn), 4.71 (t, 7 = 5.1 Hz, 1H, H2'), 4.27 (t, 7 = 4.5 Hz, 1H, H3'), 4.24 - 4.18 (m, 1H, H4'), 4.06 (t, 7 = 5.7 Hz, 2H, CH 2 , H4"), 3.49 - 3.28 (m, 2H, CH 2 , H5'), 3.08 - 2.98 (m, 2H, CH 2 , H3"), 2.98 - 2.90 (m, 2H, CH 2 , H1"), 2.00 - 1.89 (m, 2H, CH 2 , H2"). HRMS: calc, for C 27 H33N 7 O4 [M+H] + : 520.3, found: 520.3. HPLC: t R = 8.323 min (Method A). UV-purity at 210 nm = 95.1%. fe/t- butyl (3-((((3a/?,4/?,6/?,6aA)-6-(6-((7e/t-butoxycarbonyl)amino)-9 Z/-purin-9-yl)-2,2- dimethyltetrahydrofuro[3,4-</|[1,3]dioxol-4-yl)methyl)ami no)propyl)(naphthalen-2- ylmethyl)carbamate (322) & (2/?,3/?,45;5/i)-2-(6-amino-9//-punn-9-yl)-5-(((3-((naphthal en-2- ylmethyl)amino)propyl)amino)methyl)tetrahydrofuran-3,4-diol (323):

According to general procedure A. Reductive amination (322): yield: 90.30 mg, 16 %.

C37H49N7O7 (703.84 g/mol). According to general procedure Q. Deprotection (323): C24H39N7O3 (463.54 g/mol). yield: 19.00 mg, 22% (2 TFA salt). 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 9.13 (bs, 2H, NH 2 + ), 8.98 - 8.65 (m, 2H, NH 2 + ), 8.48 (s, 1H, H2), 8.30 (s, 1H, H8), 8.05 - 7.90 (m, 5H, naphtyl (H1"', H3'", H5'"), N6-amine), 7.63 - 7.57 (m, 3H, naphtyl (H4'", H6'", H7'"), 5.99 (d, 7 = 5.3 Hz, 1H, H1'), 4.70 (t, 7 = 5.1 Hz, 1H, H2'), 4.33 (t, 7 = 5.6 Hz, 2H, CH 2 , H4"), 4.28 - 4.24 (m, 1H, H3'), 4.24 - 4.19 (m, 1H, H4'), 3.50 - 3.27 (m, 2H, CH 2 , H5'), 3.11 - 2.97 (m, 4H, CH 2 , H1", H3"), 2.07 - 1.92 (m, 2H, CH 2 , H2"). HRMS: calc, for C 2 4H 29 N 7 O3 [M + H] + : 464.2, found: 464.2. HPLC:

ZR = 7.029 min (Method A). UV-purity at 210 nm = 95.1%.

(3aS,4S,6/?,6a/tO-6-(6-amino-9//-purin-9-yl)-2,2-dimethyl -/V-(1-phenethylpiperidin-4- yl)tetrahydrofuro[3,4-o][1,3]dioxole-4-carboxamide (324) & (2S,3S,4/?,5/tO-5-(6-amino-9//-purin-

9-yl)-3,4-dihydroxy-/V-(1-phenethylpiperidin-4-yl)tetrahy drofuran-2-carboxamide (325):

According to general procedure E. Peptidic coupling (324): yield: 66.30 mg, 41 %.

C 2 6H 33 N7O 4 (507.60 g/mol). According to general procedure Q. Deprotection (325): C 23 H 2 9N 7 O 4 (467.53 g/mol). yield: 85 mg, quant. (1 TFA salt). 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 9.54 (s, 1H, NH + ), 8.90 (d, 7 = 8.1 Hz, 1H, NH, amide), 8.60 (s, 1H, H2), 8.49 (s, 1H, H8), 8.17 (s, 2H, N6-amine),

7.45 - 7.37 (m, 2H, o'), 7.36 - 7.30 (m, 3H, m', p'), 6.04 (d, 7 = 7.4 Hz, 1H, H1'), 4.64 (dd, 7 = 7.4,

4.5 Hz, 1H, H2'), 4.41 (d, 7 = 1.7 Hz, 1H, H4'), 4.22 (dd, 7 = 4.6, 1.7 Hz, 1H, H3'), 4.05 - 3.97 (m, 1H,

H1"), 3.69 (t, 7 = 11.2 Hz, 2H, H5", CH 2 , piperidine), 3.40 - 3.31 (m, 2H, CH 2 NH + ), 3.23 - 3.10 (m, 2H, H3", CH 2 , piperidine), 3.09 - 2.99 (m, 2H, CH 2 Ph), 2.17 - 1.98 (m, 2H, H6", CH 2 , piperidine), 1.86 - 1.70 (m, 2H, H2", CH 2 , piperidine). HRMS: calc, for C 2 3H 29 N 7 O4 [M+H] + : 468.2, found:468.2. HPLC: ZR = 7.029 min (Method A). UV-purity at 210 nm = 95.1%.

Ze/t- butyl (3-((3aS,4S,6/?,6a/^-6-(6-amino-9//-purin-9-yl)-2,2-dimethyl tetrahydrofuro[3,4- </|[1 ; 3]dioxole-4-carboxamido)propyl)(2-(naphthalen-2-yl)eth yl)carbamate (687) & (2S,35;4/?,5/iO- 5-(6-amino-9//-purin-9-yl)-3,4-dihydroxy-/V-(3-((2-(naphthal en-2- yl)ethyl)amino)propyl)tetrahydrofuran-2-carboxamide (688):

According to general procedure E. Peptidic coupling (687): yield: 111.8 mg, 58 %.

C 33 H 4 IN 7 O 6 (631.73 g/mol). According to general procedure Q. Deprotection (688): C 2 5H 2 9N 7 O 4 (491.55 g/mol). yield: 47.00 mg, 100% (1 TFA salt). 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.98 (t, 7 = 5.9 Hz, 1H, NH, amide), 8.59 (s, 3H, H2, NH 2 + ), 8.40 (s, 1H, H8), 8.26 (bs, 2H, N6-amine), 7.94 - 7.85 (m, 3H, naphtyl, H4'", H5'", H8'"), 7.80 - 7.76 (m, 1H, H1'", naphtyl), 7.56 - 7.47 (m, 2H, H6'", H7'", naphtyl), 7.44 (dd, 7 = 8.4, 1.8 Hz, 1H, H3'", naphtyl), 6.02 (d, 7 = 7.2 Hz, 1H, H1'), 4.61 (dd, 7 = 7.2, 4.5 Hz, 1H, H2'), 4.38 (d, 7 = 1.9 Hz, 1H, H4'), 4.21 (dd, 7 = 4.5, 1.9 Hz, 1H, H3'), 3.34 - 3.22 (m, 4H, CH 2 , H1", H4"), 3.13 - 3.04 (m, 2H, CH 2 , H5"), 3.04 - 2.95 (m, 2H, CH 2 , H3"), 1.83 (d, 7 = 6.7 Hz, 2H, CH 2 , H2"). HRMS: calc, for C 25 H 2 9N 7 O4 [M + H] + : 492.2, found: 492.2. HPLC: ZR = 9.854 min (Method A). UV-purity at 210 nm = 93.2%.

(1R,2S,3R,5R)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-((2-(3-((3- phenoxyphenethyl)amino)propyl)-1H-imidazol-1-yl)methyl)cyclo pentane-1,2-diol (326)

To a solution of terf-butyl (7-((3aS)4/?,6/?,6aA)-2,2-dimethyl-6-((2-(3-((3- phenoxyphenethyl)amino)propyl)-17/-imidazol-1-yl)methyl)tetr ahydro-47/- cyclopenta[<7|[1,3]dioxol-4-yl)-7A , -pyrrolo[2,3-<7|pyrimidin-4-yl)(methyl)carbamate (10 mg, 0.01 mmol) in DCM (3 mL) was added TFA (3 mL). The solution was stirred at room temperature for 3 hrs. The mixture was concentrated to dryness and the residue was purified by prep-HPLC (TFA buffer) to give 326 (1.04 mg, yield: 12.5%) as a white solid. 1 H NMR (400 MHz, CD 3 OD): 5 = 8.21 (s ,1H), 7.51-7.46 (m, 2H), 7.36-7.32 (m, 4H) , 7.13-6.83 (m, 7H), 5.01-4.95 (m, 1 H), 4.44-4.26 (m,

3H), 4.07 (t, 7 = 6.4 Hz, 1H), 3.31-3.27 (m, 2H), 3.24-3.11 (m, 7H), 3.00 (t, 7 = 8 Hz, 2H), 2.54-2.48 (m, 1H), 2.39-2.32 (m, 1H), 2.22-2.18 (m, 2H), 1.90-1.81 (m, 1H). MS Calc.: 581.3; MS Found: 582.4 [M + H + ], tert-butyl (7-((3aS,4R,6R,6aR)-6-(((3-((4-(benzyloxy)benzyl)(tert- butoxycarbonyl)amino)propyl)amino)methyl)-2,2-dimethyltetrah ydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)(methyl)carbamate (327) & (1S,2R,3R,5R)-3-(((3-((4-(benzyloxy)benzyl)amino)propyl)amin o)methyl)-5-(4-(methylamino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol (328):

According to general procedure D. Reductive amination (327): yield: 54.00 mg, 26 %. C 43 H 58 N 6 O 7 (770.97 g/mol). According to general procedure Q. Deprotection (328): C 27 H 34 N 8 O 2 (502.62 g/mol). yield: 5 mg, 10% (2 TFA salt). 1 H NMR (400 MHz, DMSO-A 6 ) 5 8.93 (bs, 2H, NH 2 + ), 8.66 (bs, 2H, NH 2 + ), 8.29 (s, 1H, H2), 7.50 (bs, 1H, H8), 7.47-7.37 (m, 6H, o -H, /A-H, /T7-H ) 7.36- 7.31 (m, 1H, p'-H) 7.11-7.07 (m, 2H, oH), 6.80 (bs,1H, H7), 5.14 (s, 2H, Ph-CH 2 -O-), 4.94-4.83 (m, 1H, HT), 4.20-4.14 (m, 1H, H2'), 4.11-4.05 (m, 2H, -Ar-CH 2 -NH-), 3.88 (t, 7 = 5.4 Hz, 1H, H3'), 3.22- 3.13 (m, 2H, H5'), 3.12-2.90 (m, 8H, H5', H1", H3", -NH-CH 3 ) 2.30-2.16 (m, 2H, H4', H6' A ), 2.04- 1.89 (m, 2H, H2"), 1.71 - 1.53 (m, 1H, H6' B ). HRMS: calc, for C 30 H 38 N 6 O 3 | M i H r : 530.3 found: 530.1. HPLC: t R = 8.090 min. UV purity at 210 nm= 99 %. tert-butyl (7-((3aS,4R,6R,6aR)-6-(((3-((tert-butoxycarbonyl)(phenethyl) amino)propyl)(2,2,2- trifluoroethyl)amino)methyl)-2,2-dimethyltetrahydro-4H-cyclo penta[d][1,3]dioxol-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)carbamate (329) & (1R,2S,3R,5R)-3-(4-(methylamino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-5-(((3-(phenethylamino)propyl) (2,2 / 2- trifluoroethyl)amino)methyl)cyclopentane-1,2-diol (330):

According to general procedure D. Reductive amination (329): yield: 85.00 mg, 80 %. C 39 H 55 F 3 N 6 O 6 (760.90 g/mol). APCI: calc, for C 39 H 5 5F 3 N 6 O 6 [M + H] + : 760.4, found: 660/560. According to general procedure Q. Deprotection (330): C 2 6H 3 5F 3 N 6 O 2 (502.62 g/mol). yield: 84 mg, quantitative (1 TFA salt). 1 H NMR (400 MHz, DMSO-ofe) S 9.61 (bs, 1H, -NH-CH 3 ), 8.62 (bs, 2H, NH 2 + ), 8.36 (s, 1H, H2), 7.67-7.60 (m, 1H, H8), 7.37-7.31 (m, 2H, /77-H), 7.29-7.22 (m, 3H, oH, />H), 6.96-6.87 (m, 1H, H7), 4.97 (q, 7 = 9.2 Hz, 1H, H1'), 4.22 (dd, 7 = 8.9, 5.4 Hz, 1H, H2'), 3.75 (dd, 7 = 5.4, 3.1 Hz, 1H, H3'), 3.30 (q, 7 = 10.0 Hz, 2H, -CH 2 -CF 3 ), 3.18 - 3.13 (m, 2H, H4"), 3.12-3.05 (m, 3H, -NH-CH 3 ), 3.00-2.93 (m, 2H, H3"), 2.92-2.85 (m, 2H, H5"), 2.81 (dd, 7= 12.8, 7.2 Hz, 1H, H5' A ), 2.72 - 2.65 (m, 2H, H1"), 2.62 - 2.56 (m, 1H, H5' B ), 2.28 - 2.18 (m, 1H, H6'), 2.14 (td, 7= 8.3, 3.2 Hz, 1H, H4'), 1.77 (p, 2H, J = 7.82 Hz, 2H, H2"), 1.51-1.41 (m, 1H, H6'). APCI calc, for C 26 H 35 F 3 N 6 O 2 [M + H] + : 520.3, found: 520.9. HPLC: t R = 13.08 min, UV purity at 210 nm = 90%.

(1R,2S,3R,5R)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-(((3-((4- phenoxybenzyl)amino)propyl)amino)methyl)cyclopentane-1,2-dio l (331) & (1R,2S,3R,5R)-3-(4- (methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(((3-((4- phenoxybenzyl)amino)propyl)amino)methyl)cyclopentane-1,2-dio l (332):

According to general procedure D. Reductive amination (331): yield: 11.00 mg, 7 %. C 42 H 5 6N 6 O 7 (756.95 g/mol). APCI: calc, for C 42 H 5 6N 6 O 7 [M + H] + : 756.4, found: 756.9/656.9. According to general procedure Q. Deprotection (332): C 29 H 36 N 6 O 3 (516.65 g/mol). yield: 4.20 mg, 42% (2 TFA salt). 1 H NMR (400 MHz, DMSO-ofe) S 9.32 (bs, 1H, -NH-CH 3 ), 9.02 (bs, 2H, NH 2 + ), 8.70 (bs, 2H, NH 2 + ), 8.33 (s, 1H, H2), 7.58 (bs, 1H, H8), 7.52 - 7.46 (m, 2H, m-H), 7.45 - 7.38 (m, 2H, /77-H ), 7.21-7.16 (m, 1H, />H'), 7.10 - 7.04 (m, 2H, oH), 7.04 - 6.99 (m, 2H, oH'), 6.87 (bs, 1H, H7), 4.92 (q, 7 = 7.36 Hz, 1H, H1'), 4.21 - 4.08 (m, 3H, H2'), 3.88 (t, 7 = 5.4 Hz, 1H, H3'), 3.24- 3.13 (m, 1H, H4"), 3.12-2.90 (m, 8H, H5', H1", H3", -NH-CH 3 ) ,2.33-2.21 (m, 1H, H4'), 2.35-2.28 (m, 1H, H6' A ), 2.05 - 1.90 (m, 2H, H2"), 1.60 (q, 7 = 10.2 Hz, 1H, H6' B ). APCI calc, for C 29 H 36 N 6 O 3 [M + H] + : 516.3, found: 516.7. ). HPLC: t R = 12.997 min, UV purity at 210 nm = 99%. tert-butyl (((3aR,4R,6R,6aS)-6-(5-bromo-4-((4-methoxybenzyl)amino)-7H-p yrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)(3-((2,4- difluorophenethyl)amino)propyl)carbamate (333) & (1R,2S,3R,5R)-3-(4-amino-5-bromo-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-5-(((3-((2,4- difluorophenethyl)amino)propyl)amino)methyl)cyclopentane-1,2 -diol (334):

According to general procedure D. Reductive amination (333): yield: 19.00 mg, 52 %.

C 3 9H49BrF2N 6 O 3 (799.76 g/mol). APCI: calc. [M + H] + : 798.3, found: 800.5/798.5.. According to general procedure O. Deprotection (334): C2 3 H29BrF 2 N 6 O2 (539.43 g/mol). The crude product was purified by preparative HPLC according to method D. yield: 12.00 mg, 80% (2 TFA salt). 1 H NMR (400 MHz, DMSO-c/ 6 ) 5 8.80 (bs, 2H, NH 2 + ), 8.61 (bs, 2H, NH 2 + ), 8.23 (s, 1H, H2), 7.79 (s, 1H, H6), 7.42-7.35 (m, 1H, /77-H,), 7.30-7.22 (m,1H, /77-H), 7.12-7.05 (td, 7 = 8.7, 2.7 Hz, 1H, o-H ), 4.94 (dt, 7 = 9.6 Hz, 1H, HT), 4.16 (dd, 7 = 7.6, 5.6 Hz, 1H, H2'), 3.86 (t, 7 = 5.2 Hz, 1H, H3' ), 3.20-3.08 (m, 2H, H4" ), 3.07 - 2.96 (m, 6H, H5', H1", H3"), 2.95 - 2.88 (m, 2H, H5"), 2.34 - 2.16 (m, 2H, H4', H6- cyclopentane-axial ), 2.03 - 1.88 (m, 2H, CH 2 , H2"), 1.62 - 1.52 (m, 1H, H6, cyclopentane- equatorial). APCI: calc. For C2 3 H29BrF 2 N 6 O2 iM + Hp : 538,2, found: 538.5/540.5. HPLC: ZR = 9.840 min. UV-purity at 210 nm = 97 %. tert-butyl (((3aR,4R,6R,6aS)-6-(5-bromo-4-((4-methoxybenzyl)amino)-7H-p yrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)(3-((4- (trifluoromethyl)phenethyl)amino)propyl)carbamate (335) & (1R,2S,3R,5R)-3-(4-amino-5-bromo- 7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(((3-((4- (trifluoromethyl)phenethyl)amino)propyl)amino)methyl)cyclope ntane-1,2-diol (336):

According to general procedure D. Reductive amination (335): yield: 17.00 mg, 58 %. C 40 H5oBrF 3 N 6 05 (831.73 g/mol). APCI: calc. [M + H]+: 830.3, found: 832/830. According to general procedure O. Deprotection (336): C24H 30 BrF 3 N 6 O 2 (571.44 g/mol). The crude product was purified by preparative HPLC according to method D. yield: 10.00 mg, 77% (2 TFA salt). 1 H NMR (400 MHz, DMSO-c/ 6 ) 5 8.79 (bs, 2H, NH 2 + ), 8.59 (bs, 2H, NH 2 + ), 8.22 (s, 1H, H2), 7.75-7.70 (m, 3H, H6, /77-H), 7.53-7.48 (d, 7 = 8.1 Hz, 2H, oH), 4.90 (dt, 7= 10.2 Hz, 7.8 Hz, 1H, H1'), 4.16 (dd, 7 = 7.6, 5.6 Hz, 1H, H2'), 3.86 (t, 7 = 5.2 Hz, 1H, H3'), 3.26-3.16 (m, 2H, H4", H5'), 3.08 - 2.95 (m, 7H, CH 2 , H5', H1", H3", H5"), 2.32 - 2.16 (m,2H, H4', H6'-axial ), 2.00 - 1.88 (m, 2H, CH 2 , H2"), 1.63 - 1.52 (m, 1H, H6'-equatorial). APCI: calc. For C 24 H3oBrF 3 N 6 0 2 [M + H] + : 570.2, found: 570.4/572.4. HPLC: ZR = 11.953. UV-purity at 210 nm = 96 %.

Ze/t- butyl (3-((((3aR,4R,6R,6as)-6-(5-bromo-4-((4-methoxybenzyl)amino)- 7//-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4//-cyclopenta[d][1 ,3]dioxol-4- yl)methyl)amino)propyl)(2-fluorophenethyl)carbamate (337) & (1R,2s,3R,5R)-3-(4-amino-5- bromo-7//-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(((3-((2- fluorophenethyl)amino)propyl)amino)methyl)cyclopentane-1,2-d iol (338):

According to general procedure D. Reductive amination (337): yield: 45.00 mg, 64 %. C 3 9H 5 oBrFN 6 05 (781.77 g/mol). APCI: calc. [M + H] + : 781.8, found: 780.4/782.3/784.4. According to general procedure O. Deprotection (338): C 23 H 30 BrFN 6 O 2 (521.44 g/mol). The crude product was purified by preparative HPLC according to method D. yield: 35.00 mg, 81% (2 TFA salt). 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 8.87 (bs, 2H), 8.63 (bs, 2H), 8.25 (s, 1H), 7.77 (s, 1H), 7.39-7.32 (m, 2H), 7.25-7.17 (m, 2H), 4.96-4.89 (m, 1H), 4.20-4.14 (m, 1H), 3.89-3.84 (m, 1H), 3.25-3.11 (m, 3H), 3.10- 2.91 (m, 8H), 2.35-2.32 (m, 1H), 2.31-2.18 (m, 2H), 2.01-1.93 (m, 2H), 1.63-1.55 (m, 1H) ppm. APCI: calc. For C 23 H 30 BrFN 6 O 2 [M + H] + : 521.4, found: 520.5/522.4. HPLC: ZR = 10.02 min. UV-purity at 210 nm = 99 %.

Ze/t- butyl (3-((((3aR,4R,6R,6as)-6-(4-((4-methoxybenzyl)amino)-5-phenyl -7//-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4//-cyclopenta[d][1 ,3]dioxol-4- yl)methyl)amino)propyl)(phenethyl)carbamate (339) & (1/?,2S,3/?,5/t)-3-(4-amino-5-phenyl-7A/- pyrrolo[2,3-</|pyrimidin-7-yl)-5-(((3-((4- fluorophenethyl)amino)propyl)amino)methyl)cyclopentane-1,2-d iol (340):

According to general procedure D. Reductive amination (339): yield: 160.00 mg, 37 %.

C45H55FN6O5 (778.97 g/mol). APCI: calc. [M + H]+: 778.9, found: 778.7 /779.7. According to general procedure O. Deprotection (340): C 2 9H 35 FN 6 O 2 (518.64 g/mol). The crude product was purified by preparative HPLC according to method D. yield: 51.00 mg, 33% (2 TFA salt). 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 8.88 (bs, 2H), 8.75 (bs, 2H), 8.48 (s, 1H), 7.84 (s, 1H), 7.57-7.47 (m, 4H), 7.46-7.40 (m, 1H), 7.34-7.27 (m, 2H), 7.22-7.14 (m, 2H), 5.10-5.00 (m, 1H), 4.28-4.22 (m, 1H), 3.94-3.88 (m, 1H), 3.25-3.11 (m, 3H), 3.10-2.97 (m, 5H), 2.95-2.87 (m, 2H), 2.40-2.35 (m, 1H), 2.34-2.24 (m, 1H), 2.04-1.91 (m, 2H), 1.75-1.60 (m, 1H) ppm. APCI: calc. For C 29 H 3 5FN 6 O 2 [M + H] + : 518.6, found:

518.9/519.9. HPLC: ZR = 11.76 min. UV-purity at 210 nm = 99 %.

Ze/t- butyl (3-((((3aR,4R,6R,6as)-6-(5-iodo-4-((4-methoxybenzyl)amino)-7 //-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4//-cyclopenta[d][1 ,3]dioxol-4-yl)methyl)- amino)propyl)(phenethyl)carbamate (341) & (lR,2s,3R,5R)-3-(4-amino-5-iodo-7//-pyrrolo[2,3- d]pyrimidin-7-yl)-5-(((3 (phenethylamino)-propyl)amino)methyl)cyclopentane-1,2-diol (342):

According to general procedure D. Reductive amination (342): yield: 83.00 mg, 51 %. C39H 51 IN 6 O5 (810.78 g/mol). APCI: calc. [M + H]+: 810.8, found: 810.4. According to general procedure O. Deprotection (342): C 23 H 31 IN 6 O 2 (550.45 g/mol). The crude product was purified by preparative HPLC according to method D. yield: 40.00 mg, 53% (2 TFA salt). 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 8.82 (s, 2H), 8.64 (s, 2H), 8.30 (s, 1H), 7.84 (s, 1H), 7.39-7.32 (m, 2H), 7.30-7.24 (m, 3H), 4.97-

4.88 (m, 1H), 4.21-4.14 (m, 1H), 3.90-3.84 (m, 1H), 323-3.11 (m, 3H), 3.09-2.98 (m, 5H), 2.95-

2.88 (m, 2H), 2.36-2.32 (m, 1H), 2.31-2.15 (m, 3H), 2.02-1.91 (m, 2H), 1.65-1.55 (m, 1H) ppm. APCI: calc. For C 23 H 31 IN 6 O 2 [M + H] + : 550.5, found: 550.5. HPLC: ZR = 10.25 min. UV-purity at 210 nm = 99 %.

Ze/t- butyl (3-((((3aR,4R,6R,6as)-6-(5-bromo-4-((4-methoxybenzyl)amino)- 7//-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4//-cyclopenta[d][1 ,3]dioxol-4- yl)methyl)amino)propyl)(4-fluorobenzyl)carbamate (343) & (1R,2s,3R,5R)-3-(4-amino-5-bromo- 7//-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(((3-((4- fluorobenzyl)amino)propyl)amino)methyl)cyclopentane-1,2-diol (344):

According to general procedure D. Reductive amination (343): yield: 99.00 mg, 32 %.

C 3 H 48 BrFN 6 O 5 (767.74 g/mol). APCI: calc. [M + H] + : 767.7, found: 766.8/768.8/769.6/770.7.

According to general procedure O. Deprotection (344): C 22 H 28 BrFN 6 O 2 (507.41 g/mol). The crude product was purified by preparative HPLC according to method D. yield: 63.00 mg, 66% (2 TFA salt). 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 8.99 (bs, 2H), 8.59 (bs, 2H), 8.27 (s, 1H), 7.80 (s, 1H), 7.57-

7.52 (m, 2H), 7.39-7.27 (m, 2H), 4.98-4.87 (m, 2H), 4.20-4.13 (m, 4H), 3.89-3.84 (m, 1H), 3.22-3.10 (m, 1H), 3.08-2.92 (m, 5H), 2.35-2.32 (m, 1H), 2.31-2.18 (m, 1H), 2.02-1.93 (m, 2H), 1.62-1.54 (m, 1H) ppm. APCI: calc. For C 22 H 28 BrFN 6 O 2 [M + H] + : 507.4, found: 506.9/508.9.4. HPLC: ZR = 9.32 min. UV-purity at 210 nm = 98 %. fe/t- butyl 4-(((15,2/?,35,47)-2,3-dihydroxy-4-(4-(methylamino)-7//-pyrr olo[2,3-(7|pyrimidin-7- yl)cyclopentane-1-carboxamido)methyl)piperidine-1-carboxylat e (345) & (1S,2/?,35,4A)-2,3- dihydroxy-4-(4-(methylamino)-7//-pyrrolo[2,3-<^pyrimidin- 7-yl)-/V-(piperidin-4- ylmethyl)cyclopentane-1-carboxamide (346):

According to general procedure F. Peptidic coupling (345): yield: 50 mg, 60 %. C24H 36 N 6 O5 (488.59 g/mol). MS calc. [M + H] + : 488.3, found: 489.5. According to general procedure P. Deprotection (346): yield: 36.50 mg, 95% (1 TFA salt). 1 H NMR (400 MHz, CD 3 OD): 5 = 8.27 (s, 1H), 7.71 (d, 7 = 2.8 Hz, 1H), 6.93 (s, 1H), 5.20-5.17 (m, 1H), 4.40-4.32(m, 1H), 4.28-4.25 (m, 1H), 3.40-

3.15 (m, 8H), 2.97-2.91 (m, 2H), 2.77-2.71 (m, 1H), 2.58-2.54 (m, 1H), 2.18-1.77 (m, 5H). Mass calc. for C 19 H 2 8N 6 O 3 . MS calc.: 388.2; MS Found: 389.3 [M + H] + . Purified by method C. UV-purity >93%. fe/t- butyl 3-(((1S,2/?,3S,4/^-2,3-dihydroxy-4-(4-(methylamino)-7Z/-pyrr olo[2,3-a]pyrimidin-7- yl)cyclopentane-1-carboxamido)methyl)piperidine-1-carboxylat e (347) & (1S,2R,3S,4R)-2,3- dihydroxy-4-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-N-(piperidin-3- ylmethyl)cyclopentane-1-carboxamide (348):

According to general procedure F. Peptidic coupling (347): yield: 50 mg, 60 %. C24H 36 N 6 O 5

(488.59 g/mol). MS calc. [M + H] + : 488.3, found: 489.3. According to general procedure P. Deprotection (348): yield: 36.00 mg, 95% (1 TFA salt). 1 H NMR (400 MHz, DMSO-t/6): 5 = 9.98 (brs, 1H), 9.07 (brs, 1H), 8.86-8.83 (m, 1H), 8.36 (s, 1H), 8.29 (t, 7 = 7.2 Hz, 1H), 7.73 (d, 7 = 3.6 Hz,

1H), 7.07 (d, 7 = 4.4 Hz, 1H), 5.02 (q, 7 = 11.2 Hz,1H), 4.24-4.19 (m, 1H), 4.08-4.05 (m, 1H), 3.06-2.58 (m, 8H), 2.58-2.53 (m, 2H) 2.00-1.50 (m, 6H), 1.32-1.05 (m, 1H). Mass calc, for C 19 H 28 N 6 O 3 . MS

Calc.: 388.2; MS Found: 389.2 [M + H] + . Purified by method C. UV-purity >95%. fe/t- butyl 2-(((1S,2/?,3S,4/^-2,3-dihydroxy-4-(4-(methylamino)-7//-pyrr olo[2,3-a]pyrimidin-7- yl)cyclopentane-1-carboxamido)methyl)piperidine-1-carboxylat e (349) & (1S,2/?,35,4A)-2,3- dihydroxy-4-(4-(methylamino)-7//-pyrrolo[2,3-o]pyrimidin-7-y l)-/V-(piperidin-2- ylmethyl)cyclopentane-1-carboxamide (350):

According to general procedure F. Peptidic coupling (349): yield: 50 mg, 60 %. C24H 36 N 6 O 5 (488.59 g/mol). MS calc. [M + H] + : 488.3, found: 489.3. According to general procedure P. Deprotection (350): yield: 30.00 mg, 78% (1 TFA salt). 1 H NMR (400 MHz, CD 3 OD): 5 = 8.16 (s, 1H), 7.60 (d, 7 = 3.2 Hz, 1H), 6.81 (s, 1H), 5.07 (q, 7 = 7.2 Hz, 1H), 4.28-4.17 (m, 2H), 3.40-3.32 (m, 3H),

3.29-3.01 (m, 4H), 2.92-2.83 (m, 2H), 2.50-2.43 (m, 1H), 2.11-2.08 (m, 1H), 1.88-1.77 (m, 3H), 1.63- 1.50 (m, 3H). Mass calc, for C 19 H28N 6 O3. MS Calc.: 388.2; MS Found: 389.2 [M + H] + . Purified by method C. UV-purity >99%.

(15,2/?,35,47)-2,3-dihydroxy-A/-methyl-4-(4-(methylamino) -77/-pyrrolo[2,3-(^pyrimidin-7-yl)-/V-

(3-((3-phenoxyphenethyl)amino)propyl)cyclopentane-1-carbo xamide (351)

'NH

According to general procedure F. Peptidic coupling (351): yield: 15 mg, 28 % (HOAc salt). 1 H NMR (400 MHz, CD 3 OD): 5 = 8.04 (s, 1H), 7.26-7.19 (m, 4H), 7.01-6.99 (m, 1H), 6.94-6.92 (m, 1H), 6.89-6.84 (m, 3H), 6.78-6.75 (m, 1H), 6.47-6.46 (m, 1H), 4.96-4.92 (m, 1H), 4.19-4.16 (m, 2H), 3.46- 3.43 (m, 2H), 3.29-3.28 (m, 1H) , 3.09-3.06 (m, 4H), 2.96-2.95 (m, 3H), 2.88-2.80 (m, 5H), 2.44 (m, 1H), 2.01-1.97 (m, 1H), 1.86-1.82 (m, 2H). Mass calc, for C 19 H 28 N 6 O 3 (388.47 g/mol). Mass calc, for C 31 H 38 N 6 O 4 . MS calc. [M + H] + : 558.3, found: 559.3 [M + H] + . Purified by method C (NH 4 OAc buffer). UV-purity >91%.

(1S,2/?,35;4/i)-/V-(3-((4-(4-chlorophenoxy)-3-fluorobenzy l)amino)propyl)-2,3-dihydroxy-4-(4- (methylamino)-7Z/-pyrrolo[2,3-o]pyrimidin-7-yl)cyclopentane- 1-carboxamide (352)

'NH

According to general procedure F. Peptidic coupling (352): yield: 20 mg, 25 % (free base). 1 H NMR (400 MHz, CD 3 OD): 5 = 8.17 (s ,1H), 7.37-7.31 (m, 4 H), 7.20 (d, 7 = 8.0 Hz ,1H), 7.08(t, 7 = 8.4 Hz ,1H), 6.92 (d, 7 = 8.4 Hz, 2H), 6.60 (d, 7= 3.2 Hz, 1H), 5.04 (dd, 7= 16.0, 6.8 Hz, 1H), 4.34- 4.25(m, 2H), 3.82 (s, 2H), 3.31-3.30 (m, 2H), 3.08(s, 3H), 2.91-2.86 (m, 1H), 2.72-2.69 (m, 2H), 2.53- 2.50 (m, 1H), 2.12-2.06 (m, 1H), 1.82-1.79 (m, 2H). Mass calc, for C 29 H 32 CIFN 6 O 4 . MS calc. [M + H] + : 582.2, found: 583.2 [M + H] + . Purified by method C (NH 4 HCO 3 buffer). UV-purity >94%.

(1S,2/?,3S,4/^-2,3-dihydroxy-4-(4-(methylamino)-7Z/-pyrro lo[2,3-<7]pyrimidin-7-yl)-/V-(3-((3- phenoxybenzyl)amino)propyl)cyclopentane-1-carboxamide (353):

' NH

According to general procedure F. Peptidic coupling (353): yield: 20 mg, 22.2 % (TFA salt). 1 H NMR (400 MHz, DMSO-t/d): 5 = 8.76 (brs, 2H), 8.30 (s, 1H), 8.20 (t, 7 = 6.0 Hz, 1H), 8.19 (s, 1H), 7.59 (brs, 1H), 7.50-7.37 (m, 3H), 7.25 (d, 7 = 7.6 Hz, 1H), 7.23-7.14 (m, 2H), 7.05-7.00 (m, 3H), 6.84 (brs, 1H), 5.02-4.92 (m, 3H), 4.19-4.13 (m, 3H), 4.04 (t, 7 = 4.8 Hz, 1H), 3.29-3.26 (m, 2H), 3.17 (s, 3H), 2.91-2.89 (m, 2H), 2.76-2.70 (m, 1H), 2.37-2.33 (m, 1H), 1.95-1.92 (m, 1H), 1.79-1.75 (m, 2H). Mass calc, for C 29 H 34 N 6 O 4 . MS calc. [M + H] + : 530.3, found: 531.3 [M + H] + . Purified by method C (TFA buffer). UV-purity >85%. (1S,2/?,35;4/i)-2,3-dihydroxy-4-(4-(methylamino)-7Z/-pyrrolo [2,3-<7]pyrimidin-7-yl)-/V-(3-((3- phenoxyphenethyl)amino)propyl)cyclopentane-1-carboxamide (354):

'NH

According to general procedure F. Peptidic coupling (354): yield: 15 mg, 27.5 % (HOAc salt). 1 H NMR (400 MHz, CD 3 OD): 5 = 8.04 (s, 1H), 7.25-7.19 (m, 4H), 7.02-7.00 (m, 1H), 6.94-6.92 (m, 1H), 6.88-6.83 (m, 3H), 6.78-6.76 (m, 1H), 6.48-6.47 (m, 1H), 4.93-4.87 (m, 1H), 4.20-4.14 (m, 2H), 3.27- 3.24 (m, 2H), 3.07-3.03 (m, 2H) , 2.96 (s, 3H), 2.86-2.83 (m, 4H), 2.79-2.75 (m, 1H), 2.45-2.38 (m, 1H), 2.02-1.97 (m, 1H), 1.78-1.75 (m, 2H). Mass calc, for C 3 oH36N 6 0 4 . MS calc. [M + H] + : 544.2, found: 545.3 [M + H] + . Purified by method C (NH 4 OAc buffer). UV-purity >96%.

(1S,2/?,3S,4/^-/V-(3-((4-(4-chlorophenoxy)-3-fluorophenet hyl)amino)propyl)-2,3-dihydroxy-4-(4- (methylamino)-7Z/-pyrrolo[2,3-o]pyrimidin-7-yl)cyclopentane- 1-carboxamide (355):

According to general procedure F. Peptidic coupling (355): yield: 12 mg, 15 % (TFA salt). 1 H NMR (400 MHz, CD 3 OD): 5 = 8.26 (s ,1H), 7.64 (s ,1H), 7.33-7.26 (m, 3 H), 7.18-7.12 (m, 2H), 6.94-6.88 (m, 3H), 5.15 (dd, J = 16.0, 6.8 Hz 1H), 4.38-4.27(m, 2H), 3.43-3.30 (m, 3H), 3.21(s, 3H), 3.16-3.08 (m, 5H), 2.95-2.90 (m, 1H), 2.57-2.54 (m, 1H), 2.19-2.13(m, 1H), 1.98-1.94 (m, 2H). MS calc, for C 30 H 34 CIFN 6 O 4 .MS calc. [M + H] + : 596.2, found: 597.3 [M + H] + . Purified by method C (TFA buffer). UV-purity >98%.

(1S,2/?,3S,4/^-2,3-dihydroxy-4-(4-(methylamino)-7Z/-pyrro lo[2,3-<7]pyrimidin-7-yl)-/V-(2-((3- phenoxyphenethyl)amino)ethyl)cyclopentane-1-carboxamide (356):

'NH

According to general procedure F. Peptidic coupling (356): yield: 15 mg, 28.3 % (TFA salt). 1 H NMR (400 MHz, CD 3 OD): 5 = 8.04 (s, 1H), 7.24-7.22 (m, 3H), 7.12 (t, 7 = 8.0 Hz, 1H), 6.98 (t, 7 = 6.8 Hz, 1H), 6.88-6.76 (m, 3H), 6.76 (s, 1H), 6.68-6.65 (m, 1H), 6.48 (m, 1H), 4.92 (m, 1H), 4.19-4.16 (m, 1H), 4.13-4.11 (m, 1H), 3.26-3.24 (m, 2H), 2.96 (s, 3H), 2.77-2.65 (m, 7H), 2.39-2.35 (m, 1H), 2.09- 2.07 (m, 1H). MS calc, for C 29 H 34 N 6 O 4 . MS calc. [M + H] + : 530.3, found: 531.3 [M + H] + . Purified by method C (NH 4 HCO 3 buffer). UV-purity >85%.

(1S,2/?,3/?,5A)-3-(((2,2-difluoro-3-((2-(naphthalen-2-yl) ethyl)amino)propyl)amino)methyl)-5-(4- (methylamino)-7Z/-pyrrolo[2,3-o]pyrimidin-7-yl)cyclopentane- 1,2-diol (357):

According to general procedure N. Deprotection (357): yield: 13.3 mg, 48 % (TFA salt). 1 H NMR (400 MHz, CD 3 OD): 5 = 8.25 (s ,1H), 7.90-7.83 (m, 3H) , 7.77 (s ,1H), 7.53-7.47 (m, 3 H), 7.43 (dd, 7 = 1.6, 8.4 Hz, 1H), 6.89 (brs, 1H), 5.04-4.86 (m, 1H), 4.32-4.28 (m, 1H), 4.06-4.02 (m, 1H), 3.89- 3.65 (m, 4H), 3.46-3.44 (m, 2H), 3.23-3.09 (m, 7H), 2.40-2.36 (m, 2H), 1.78-1.72 (m, 1H). MS calc, for C 28 H 34 F2N 6 O 2 . MS calc. [M + H] + : 524.2, found: 525.3 [M + H] + . Purified by method C (TFA buffer). UV-purity >92%. fe/t- butyl ((£)-5-((3a/?,4/?,6/?,6a5)-6-(4-((4-methoxybenzyl)(methyl)a mino)-7Z/-pyrrolo[2,3- <7|pyrimidin-7-yl)-2,2-dimethyltetrahydro-47/-cyclopenta[ (7|[1,3]dioxol-4-yl)pent-4-en-1- yl)(phenethyl)carbamate (358) & (1/?,2S,3/?,5/^-3-(4-(methylamino)-7Z/-pyrrolo[2,3-o]pyrimid in-7- yl)-5-((£)-5-(phenethylamino)pent-1-en-1-yl)cyclopentane-1, 2-diol (359):

A solution of 122 (7 mg, 0.01 mmol) in TFA (6 mL) was stirred at room temperature for 16 hrs. The mixture was concentrated at low temperature to give 358 (5 mg, crude) as a clear oil. MS Calc.: 531.3; MS Found: 532.0 [M + H + ], To a solution of 358 (5 mg, 0.01 mmol) in MeOH (2 mL) was added K 2 CO 3 (4 mg), and the solution was stirred at room temperature for 1 hr. The mixture was concentrated to dryness and the residue was purified by prep-HPLC (TFA buffer) to give 359 (2.6 mg, yield: 60%) as a white solid. 1 H NMR (400 MHz, CD 3 OD): 5 = 8.13 (s ,1H), 7.41 (d, 7 = 3.6 Hz, 1H), 7.25 (t, 7 = 8.4 Hz, 2H), 7.17 (t, 7 = 7.6 Hz, 3H), 6.76 (brs, 1H), 5.50-5.40 (m, 2H), 4.97-4.87 (m, 1H), 4.24 (t, 7 = 6.4 Hz, 1H), 3.85 (t, 7 = 6.0 Hz, 1H), 3.18-2.87 (m, 10H), 2.28-2.12 (m, 3H), 1.74-1.67 (m, 3H). MS Calc.: 435.3; MS Found: 436.3 [M + H + ],

(1R,2S,3R,5R)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-((3-(((2-(naphthalen-2- yl)ethyl)amino)methyl)azetidin-1-yl)methyl)cyclopentane-1,2- diol (360):

According to general procedure N. Deprotection (360): yield: 14.00 mg, 21 % (TFA salt). 1 H NMR (400 MHz, CD3OD): 5 = 8.25 (s ,1H), 7.90-7.78 (m, 4H), 7.53-7.42 (m, 4H), 6.88 (s, 1H), 5.04-4.98 (m, 1H), 4.42 (s, 2H), 4.31 (t, 7 = 6.4 Hz, 1H), 4.17-4.08 (m, 3H), 3.57-3.38 (m, 7H), 3.22-3.170 (m, 5H), 2.46-2.29 (m, 2H), 1.86-1.77 (m, 1H). MS calc, for C 29 H 3 6N 6 O 2 . MS calc. [M + H] + : 500.3, found: 501.3 [M + H] + . Purified by method C (TFA buffer). UV-purity >96%. tert-butyl (7-((3aS,4R,6R,6aR)-6-(((3-((tert-butoxycarbonyl)(3- phenoxyphenethyl)amino)propyl)(isopropyl)amino)methyl)-2,2-d imethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)(methyl)carbamate (361) & (1S,2R,3R,5R)-3-((isopropyl(3-((3-phenoxyphenethyl)amino)pro pyl)amino)methyl)-5-(4-

(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentan e-1,2-diol (362):

According to general procedure B. Reductive amination (361): two-step yield: 30 mg, 13.5 %. C 4 IH 5 6N 6 O 5 (712.94 g/mol). MS calc. [M + H] + : 712.40, found: 713.40. Prep HPLC (NH 4 OAc buffer). According to general procedure N. Deprotection (362): yield: 10.00 mg, 41.6 % (TFA salt). 1 H NMR (400 MHz, CD 3 OD): 5 = 8.24 (s, 1H), 7.42-7.34 (m , 4H), 7.18-7.16 (m, 1H), 7.09-7.07 (m, 1H), 7.03- 7.00 (m, 3H), 6.94-6.90 (m, 1H), 6.80 (s, 1H), 5.02-4.97 (m, 1H), 4.34-4.33 (m, 1H), 4.19-4.15 (m, 1H), 3.87-3.82 (m, 1H), 3.46-3.30 (m, 6H), 3.30-3.24 (m, 5H), 3.06-3.01 (m, 2H), 2.56-2.54 (m, 2H), 2.28 (m, 2H), 1.87-1.84 (m, 1H), 1.46-1.42 (m, 6H). MS calc, for C 33 H 44 N 6 O 3 . [M + H] + : 572.3, found: 573.4 [M + H] + . Purified by method C (TFA buffer). UV-purity >95%. tert-butyl (7-((3aS,4R,6R,6aR)-6-(((3-((tert-butoxycarbonyl)(3- phenoxyphenethyl)amino)propyl)(ethyl)amino)methyl)-2,2-dimet hyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl)(methyl)carbamate (363) & (1S,2R,3R,5R)-3-((ethyl(3-((3-phenoxyphenethyl)amino)propyl) amino)methyl)-5-(4- (methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1 ,2-diol (364):

According to general procedure B. Reductive amination (363): two-step yield: 30 mg, 13.5 %. C 40 H 54 N 6 O 5 (698.91 g/mol). MS calc. [M + H] + : 698.40, found: 699.40. Prep HPLC (NH 4 OAc buffer). According to general procedure N. Deprotection (364): yield: 10.00 mg, 42.7 % (OAc salt). 1 H NMR (400 MHz, CD 3 OD) 5: 8.15 (s, 1H), 7.40-7.27 (m , 3H), 7.19 (d, 7 = 3.6 Hz, 1H), 7.10 (t, 7 = 8.0 Hz, 1H), 7.01-6.95 (m, 3H), 6.94 (t, 7 = 2.0 Hz, 1H), 6.85 (dd, 7 = 8.0, 2.0 Hz, 1H), 6.57 (d, 7 = 7.6 Hz, 1H), 4.87-4.83 (m, 1H, overlap with water peak), 4.35 (t, 7 = 6.8 Hz, 1H), 3.90 (t, 7 = 5.4 Hz, 1H), 3.32-3.15 (m, 4H), 3.07 (s, 3H), 2.95 (t, 7 = 7.6 Hz, 2H), 2.83-2.55 (m, 6H), 2.34-2.30 (m, 2H), 1.90- 1.87 (m, 3H), 1.11 (t, 7 = 6.8 Hz, 3H). MS calc, for C 32 H 42 N 6 O 3 . [M + H] + : 559.3, found: 559.4 [M + H] + . Purified by method C (NH 4 OAc buffer). UV-purity >97%. fe/A butyl (7-((3aS,4/?,6/?,6aA)-6-(((3-((fe/Abutoxycarbonyl)(3- phenoxyphenethyl)amino)propyl)(cyclopropylmethyl)amino)methy l)-2,2-dimethyltetrahydro-4/7- cyclopenta[<^[1,3]dioxol-4-yl)-7//-pyrrolo[2,3-d|pyrimidi n-4-yl)(methyl)carbamate (365) & (1S,2R,3R,5R)-3-(((cyclopropylmethyl)(3-((3-phenoxyphenethyl )amino)propyl)amino)methyl)-5-(4- (methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1 ,2-diol (366): According to general procedure B. Reductive amination (365): two-step yield: 30 mg, 13.3 %. C42H 5 6N 6 O 5 (724.95 g/mol). MS calc. [M + H] + : 724.40, found: 725.40. Prep HPLC (NH 4 OAc buffer). According to general procedure N. Deprotection (366): yield: 10.00 mg, 40.7 % (TFA salt). 1 H NMR (400 MHz, CD 3 OD): 5 = 8.08 (s, 1H), 7.27-7.19 (m, 4H), 7.02 (t, 7 = 7.6 Hz, 1H), 6.95-6.84 (m, 4H), 6.77 (dd, 7 = 8.0, 2.0 Hz, 1H), 6.59 (d, 7 = 3.2 Hz, 1H), 4.83-4.76 (m, 1H), 4.22 (t, 7 = 6.0 Hz, 1H), 4.02 (t, 7 = 6.4 Hz, 1H), 3.40-3.33 (m, 1H), 3.20-3.18 (m, 5H), 3.08 (t, 7 = 7.2 Hz, 2H), 3.01 (s, 3H), 3.01-2.95 (m, 3H), 2.92-2.86 (m, 2H), 2.37-2.33 (m, 2H), 2.06-2.05 (m, 2H), 1.02-0.98 (m, 1H), 0.67- 0.65 (m, 2H), 0.35-0.34 (m, 2H). MS calc, for C34H44N6O3. [M + H] + : 584.3, found: 585.4 [M + H] + . Purified by method C (TFA buffer). UV-purity >99%.

(1S,2/?,3/?,5/^-3-((2-methyl-1-(3-((3-phenoxyphenethyl)am ino)propyl)hydrazineyl)methyl)-5-(4- (methylamino)-7Z/-pyrrolo[2,3-o]pyrimidin-7-yl)cyclopentane- 1,2-diol (367):

According to general procedure N. Deprotection (367): yield: 10.00 mg, 35.7 % (TFA salt). 1 H NMR (400 MHz, CD3OD): 5 = 8.24 (s, 1H), 7.55 (d, 7 = 3.2 Hz, 1H), 7.39-7.32 (m, 3H), 7.16-7.14 (m, 1H), 7.12 (m, 1H), 7.00-6.96 (m, 3H), 6.91-6.88 (m, 2H), 5.09-5.06 (m, 1H), 4. 37 (d, 7 = 6.8 Hz, 1H), 4.07 (d, 7 = 5.6 Hz, 1H), 3.29-3.27 (m, 3H), 3.19-3.03 (m, 11H), 2.89-2.88 (m, 2H), 2.45-2.39 (m, 2H), 1.96-2.11 (m, 2H), 1.74-1.69 (m, 1H). MS calc, for C31H41N7O3. [M + H] + : 559.3, found: 560.4 [M + H] + . Purified by method C (TFA buffer). UV-purity >99%.

(1/?,2S,3/?,5/^-3-(4-(methylamino)-7Z/-pyrrolo[2,3-<^p yrimidin-7-yl)-5-(((3-((2-(naphthalen-2- yl)ethyl)amino)propyl)amino)methyl)cyclopentane-1,2-diol (368):

According to general procedure N. Deprotection (368): yield: 10.00 mg, 42.7 % (TFA salt). 1 H NMR (400 MHz, D 2 O): 5 = 8.13 (s, 1H), 7.78-7.72 (m, 3H), 7.67 (s, 1H), 7.40-7.36 (m, 3H), 7.31 (dd, 7 = 8.4, 2.0 Hz, 1H), 6.76 (brs, 1H), 4.93-4.92 (m, 1H), 4.22 (t, 7 = 6.4 Hz, 1H), 4.01 (t, 7 = 6.0 Hz, 1H), 3.31-3.21 (m, 3H), 3.17-3.07 (m, 10H), 2.40-2.32 (m, 2H), 2.09-2.06 (m, 2H), 1.74-1.72 (m, 1H). MS calc, for C28H 36 N 6 O2. [M+H] + : 448.3, found: 489.3 [M + H] + . Purified by method C (TFA buffer). UV- purity >97%. tert-butyl (4-(4-chlorophenoxy)-3-fluorophenethyl)(3-((((3aR,4R ; 6R,6aS)-2,2-dimethyl-6-(4- (methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydro-4H- cyclopenta[d][1,3]dioxol-4- yl)methyl)amino)propyl)carbamate (369) & (1S,2/?,3/?,5/tO-3-(((3-((4-(4-chlorophenoxy)-3- fluorophenethyl)amino)propyl)amino)methyl)-5-(4-(methylamino )-7Z/-pyrrolo[2,3-o]pyrimidin-7- yl)cyclopentane-1,2-diol (370):

According to general procedure B. Reductive amination (369): yield: 30 mg, 44%. C38H48CIFN6O5 (723.29 g/mol). Prep HPLC (TFA buffer). According to general procedure N. Deprotection (370): yield: 20.00 mg, 83.0 % (TFA salt). 1H NMR (400 MHz, DMSO-d6): 5 = 9.13 (brs, 1H), 9.00 (brs, 2H), 8.75 (brs, 2H), 8.32 (s ,1H), 7.55 (brs ,1H), 7.44-7.35 (m, 3H), 7.21 (t, J = 8.0 Hz, 1H), 7.16-7.14 (m, 1H), 6.99-6.97 (m, 2H), 6.85 (brs, 1H), 4.95-4.89 (m, 1H), 4.18 (t, J = 6.4 Hz,

1H), 3.90 (t, J = 6.4 Hz, 1H), 3.15-2.94 (m, 13H), 2.38-2.25(m, 2H), 2.03-1.96 (m, 2H), 1.67-1.59 (m, 1H). MS calc, for C30H36CIFN6O3. [M + H] +: 582.3, found: 583.3 [M + H]+. Purified by method C (TFA buffer). UV-purity >98%. fe/t- butyl (3-((((3a/?,4/?,6/?,6a5)-2,2-dimethyl-6-(4-(methylamino)-7// -pyrrolo[2,3-d|pyrimidin-7- yl)tetrahydro-4//-cyclopenta[</|[1,3]dioxol-4-yl)methyl)a mino)propyl)(3-

(phenylthio)phenethyl)carbamate (371) & (1/?,2S,3/?,5/^-3-(4-(methylamino)-7//-pyrrolo[2,3- d|pyrimidin-7-yl)-5-(((3-((3-(phenylthio)phenethyl)amino)pro pyl)amino)methyl)cyclopentane-1,2- diol (372):

According to general procedure B. Reductive amination (371): yield: 30 mg, 16.8 %. C38H50N6O4S (686.92 g/mol). MS calc. [M + H] + : 686.40, found: 687.40. Prep HPLC (TFA buffer). According to general procedure N. Deprotection (372): yield: 15.00 mg, 63.9 % (TFA salt). 1H NMR (400 MHz, D2O): 5 = 8.25 (s, 1H), 7.52-7.49 (m, 1H), 7.37-7.29 (m, 7H), 7.21 (t, J = 6.8 Hz,

2H), 6.88 (s, 1H), 5.05-5.04 (m, 1H), 4.36-4.33 (t, J = 6.4 Hz, 1H), 4.14-4.11 (t, J = 6.0 Hz, 1H), 3.39-

3.34 (m, 1H), 3.29-3.16 (m, 10H), 3.01-2.97 (m, 2H), 2.51-2.44 (m, 2H), 2.19-2.17 (m, 2H), 1.86-1.83 (m, 1H). MS calc, for C30H38N6O2S. [M + H]+: 546.3, found: 547.4 [M + H]+. Purified by method C (TFA buffer). UV-purity >95%. fe/t- butyl (3-((((3a/?,4/?,6/?,6a5)-2,2-dimethyl-6-(4-(methylamino)-7// -pyrrolo[2,3-d|pyrimidin-7- yl)tetrahydro-4//-cyclopenta[</|[1,3]dioxol-4-yl)methyl)a mino)propyl)(3- phenethylphenethyl)carbamate (373) & (1/?,2S,3/?,5/^-3-(4-(methylamino)-7Z/-pyrrolo[2,3- d|pyrimidin-7-yl)-5-(((3-((3-phenethylphenethyl)amino)propyl )amino)methyl)cyclopentane-1,2- diol (374):

According to general procedure B. Reductive amination (373): yield: 30 mg, 44 %.

C 40 H 54 N 6 O 4 (682.91 g/mol). MS calc. [M + H] + : 682.4, found: 683.1. According to general procedure N. Deprotection (374): yield: 16.00 mg, 67.0 % (TFA salt). 1 H NMR (400 MHz, CD 3 OD): 5 = 8.24 (s ,1H), 7.49 (s ,1H), 7.26-7.14 (m, 9 H), 6.86 (s, 1H), 5.04-5.02 (m, 1H), 4.34(t, 7 = 6.4 Hz, 1H), 4.13(t, 7 = 6.4 Hz, 1H), 3.39-3.19 (m, 11H), 3.01-2.97 (m, 2H), 2.91(s, 4H), 2.52-2.44 (m, 2H), 2.22-2.14(m, 2H), 1.86-1.83 (m, 1H). MS calc, for C32H 42 N 6 O 2 . [M+H] + : 542.3, found: 547.4 [M + H] + . Purified by method C (TFA buffer). UV-purity >97%.

(1S,2/?,3/?,5/^-3-((ethyl(3-((2-(naphthalen-2-yl)ethyl)am ino)propyl)amino)methyl)-5-(4- (methylamino)-7Z/-pyrrolo[2,3-o]pyrimidin-7-yl)cyclopentane- 1,2-diol (375):

According to general procedure N. Deprotection (375): yield: 10.00 mg, 43.0 % (TFA salt). 1 H NMR (400 MHz, D 2 O): 5 = 8.13 (s, 1H), 7.79-7.72 (m, 3H), 7.68 (s, 1H), 7.40-7.37 (m, 3H) 7.34-7.31 (m, 1H), 6.76 (m, 1H), 4.90 (m, 1H), 4.22-4.19 (m, 1H), 4.03-4.00 (m, 1H), 3.33-3.23 (m, 8H), 3.12-3.08 (m, 7H), 2.41-2.38 (m, 2H), 2.12-2.09 (m, 2H), 1.75 (m, 1H), 1.29-1.26 (m, 3H). MS calc, for C 30 H 40 N 6 O 2 . [M + H] + : 516.3, found: 517.5 [M + H] + . Purified by method C (TFA buffer). UV-purity >94%. fe/t- butyl (3-((((3a/?,4/?,6/?,6a5)-2,2-dimethyl-6-(4-(methylamino)-7Z/ -pyrrolo[2,3-<T]pyrimidin-7- yl)tetrahydro-4Z/-cyclopenta[<7][1,3]dioxol-4-yl)methyl)( 2 / 2 / 2-trifluoroethyl)amino)propyl)(2- (naphthalen-2-yl)ethyl)carbamate (376) & (1/?,2S,3/?,5/^-3-(4-(methylamino)-7Z/-pyrrolo[2,3- <7|pyrimidin-7-yl)-5-(((3-((2-(naphthalen-2-yl)ethyl)amin o)propyl)(2,2,2- trifluoroethyl)amino)methyl)cyclopentane-1,2-diol (377):

To a solution of compound 129 (50 mg, 0.08 mmol) and TEA (0.1 mL) in DMF (2.00 mL) was added 2,2,2-trifluoroethyl trifluoromethanesulfonate (37 mg, 0.16 mmol), and the mixture was stirred at 60 °C for 1 hr. Then The mixture was purified by prep-HPLC (TFA buffer) to give compound 376 (10 mg, yield: 17.8%) as a white solid. According to general procedure Q. Deprotection (377): yield: 1.50 mg, 18.8 % (TFA salt). 1 H NMR (400 MHz, D 2 O): 5 = 8.22 (s, 1H), 7.89-7.84 (m, 3H), 7.83 (s, 1H), 7.76-7.51 (m, 3H) 7.41 (dd, 7 = 8.4, 1.6 Hz, 1H), 6.85 (brs, 1H), 5.09- 5.02 (m, 1H), 4.40-4.36 (m, 1H), 3.98-3.96 (m, 1H), 3.50-3.36 (m, 2H), 3.29-3.12 (m, 9H), 2.91-2.69 (m, 4H), 2.40-2.35 (m, 1H), 2.30-2.28 (m, 1H), 1.98-1.86 (m, 2H) 1.71-1.62 (m, 1H). MS calc, for C 30 H 37 F 3 N 6 O 2 . [M + H] + : 570.3, found: 571.4 [M + H] + . Purified by method C (TFA buffer). UV-purity >97%. fe/t- butyl (3-((((3a/?,4/?,6/?,6a5)-6-(5-ethyl-4-((4-methoxybenzyl)amin o)-7Z/-pyrrolo[2,3- o]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4Z/-cyclopenta[< 7][1,3]dioxol-4- yl)methyl)amino)propyl)(4-(trifluoromethyl)phenethyl)carbama te (378) & (1/?,2S,3/?,5A)-3-(4- amino-5-ethyl-7Z/-pyrrolo[2,3-<T]pyrimidin-7-yl)-5-(((3-( (4- (trifluoromethyl)phenethyl)amino)propyl)amino)methyl)cyclope ntane-1,2-diol (379):

According to general procedure D. Reductive amination (378): yield: 100.00 mg, 37 %. APCI: calc. [M + H] + : 780.93, found: 781.6. 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 8.06 (s, 1H), 7.68-7.57 (m, 2H), 7.45-7.36 (m, 2H), 7.30-7.22 (m, 2H), 7.10 (s, 1H), 6.91 (t, 7 = 6.1 Hz, 1H), 6.87-6.80 (m, 2H), 4.97-

4.88 (m, 1H), 4.87-4.80 (m, 1H), 4.69-4.61 (m, 2H), 4.51-4.40 (m, 1H), 3.70 (s, 3H), 3.44-3.25 (m, 5H), 3.23-3.10 (m, 2H), 2.83 (q, 7 = 7.3 Hz, 2H), 2.81-2.66 (m, 2H), 2.28-2.10 (m, 2H), 2.02-1.87 (m, 2H), 1.68-1.54 (m, 2H), 1.44 (s, 3H), 1.35 and 1.25 (s, 9H), 1.22 (t, 7 = 7.4 Hz, 3H), 1.20 (s, 3H) ppm. According to general procedure O. Deprotection (379): The crude product was purified by preparative HPLC according to method D. yield: 76.00 mg, 79% (2 TFA salt). APCI-MS(+) m/z for C 26 H 35 F 3 N 6 O 2 : calc.: 520.60; found: 521.3 and 522.4. 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 8.91 (bs, 2H), 8.73 (bs, 2H), 8.35 (s, 1H), 7.72 (d, 7= 8.1 Hz, 2H), 7.51 (d, 7 = 8.0 Hz, 2H), 7.45 (s, 1H), 4.97- 4.90 (m, 1H), 4.18-4.14 (m, 1H), 3.89-3.84 (m, 1H), 3.26-3.17 (m, 3H), 3.05-2.97 (m, 7H), 2.84 (q, 7 = 7.1 Hz, 2H), 2.30-2.22 (m, 2H), 2.02-1.94 (m, 2H), 1.64-1.56 (m, 1H), 1.23 (t, 7 = 7.4 Hz, 3H) ppm. T R = 11.87 min; UV-purity at 210, 230, 254, 242 and 275 nm > 97%. fe/t- butyl (3-((((3a/?,4/?,6/?,6a5)-6-(5-ethyl-4-((4-methoxybenzyl)amin o)-7Z/-pyrrolo[2,3- </|pyrimidin-7-yl)-2,2-dimethyltetrahydro-4//-cyclopenta[ </|[1,3]dioxol-4- yl)methyl)amino)propyl)(4-fluorophenethyl)carbamate (380) & (1/?,2S,3/?,5/t)-3-(4-amino-5-ethyl- 77/-pyrrolo[2,3-d|pyrimidin-7-yl)-5-(((3-((4- fluorophenethyl)amino)propyl)amino)methyl)cyclopentane-1,2-d iol (381):

According to general procedure D. Reductive amination (380): yield: 140.00 mg, 62 %. APCI: calc. [M + H] + : 730.93, found: 731.6 and 732.6. 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 8.06 (s, 1H), 7.28-

7.24 (m, 2H), 7.22-7.15 (m, 2H), 7.12-7.03 (m, 3H), 6.89 (t, 7 = 6.2 Hz, 1H), 6.86-6.82 (m, 2H), 4.94- 4.87 (m, 1H), 4.85-4.82 (m, 1H), 4.65 (d, 7 = 6.1 Hz, 2H), 4.45-4.41 (m, 1H), 3.70 (s, 3H), 3.40-

3.24 (m, 6H), 3.19-3.09 (m, 2H), 2.83 (q, 7 = 7.2 Hz, 2H), 2.75-2.71 (m, 2H), 2.26-2.21 (m, 2H), 1.98- 1.91 (m, 1H), 1.62-1.54 (m, 2H), 1.44 (s, 3H), 1.36 and 1.32 (s, 9H), 1.22 (t, 7 = 7.4 Hz, 3H), 1.20 (s, 3H) ppm. According to general procedure O. Deprotection (381): The crude product was purified by preparative HPLC according to method D. yield: 98.00 mg, 73% (2 TFA salt). APCI-MS(+) m/z for C 25 H 35 FN 6 O 2 : calc.: 470.59; found: 471.4 and 472.4. 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 8.81 (bs, 2H), 8.68 (bs, 2H), 8.34 (s, 1H), 7.43 (s, 1H), 7.33-7.28 (m, 2H), 7.21-7.15 (m, 2H), 4.96-4.90 (m, 1H), 4.18-4.14 (m, 1H), 3.89-3.85 (m, 1H), 3.23-3.12 (m, 3H), 3.09-2.98 (m, 5H), 2.94-2.88 (m, 2H), 2.84 (q, 7= 7.3 Hz, 2H), 2.30-2.20 (m, 2H), 2.01-1.93 (m, 2H), 1.63-1.57 (m, 1H), 1.23 (t, 7 = 7.4 Hz, 3H) ppm. T R = 10.56 min; UV-purity at 210, 230, 254, 242 and 275 nm > 97%). fe/t- butyl (2,4-difluorophenethyl)(3-((((3a/?,4/?,6/?,6a5)-6-(5-ethyl-4 -((4-methoxybenzyl)amino)- 7//-pyrrolo[2,3-</|pynmidin-7-yl)-2,2-dimethyltetrahydro- 4//-cyclopenta[</|[1,3]dioxol-4- yl)methyl)amino)propyl)carbamate (382) & (1/?,2S,3/?,5/^-3-(4-amino-5-ethyl-7//-pyrrolo[2,3- oJpyrimidin-7-yl)-5-(((3-((2,4-difluorophenethyl)amino)propy l)amino)methyl)cyclopentane-1,2- diol (383):

According to general procedure D. Reductive amination (382): yield: 60.00 mg, 40 %. APCI-MS(+) m/z for C 4 IH54F2N 6 O 5 : calc.: 748.92; found: 749.5 and 750.5. 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 8.06 (s, 1H), 7.30-7.22 (m, 3H), 7.20-7.12 (m, 1H), 7.09 (s, 1H), 7.03-6.94 (m, 1H), 6.90 (t, 7 = 6.1 Hz, 1H), 6.87-6.81 (m, 2H), 4.93-4.87 (m, 1H), 4.85-4.81 (m, 1H), 4.65 (d, 7 = 6.1 Hz, 2H), 4.41-4.44 (m, 1H), 3.70 (s, 3H), 3.22-3.05 (m, 2H), 2.79-2.72 (m, 2H), 2.83 (q, 7 = 7.3 Hz, 2H), 2.66- 2.61 (m, 1H), 2.25-2.09 (m, 2H), 1.99-1.88 (m, 1H), 1.63-1.52 (m, 2H), 1.44 (s, 3H), 1.34 and 1.26 (s, 9H), 1.23 (t, 7 = 7.4 Hz, 3H), 1.20 (s, 3H) ppm; signal of five Protons overlayed by the H 2 O-peak. According to general procedure O. Deprotection (383): The crude product was purified by preparative HPLC according to method D. yield: 45.00 mg, 79% (2 TFA salt). APCI-MS(+) m/z for C 25 H 34 F 2 N 6 O 2 : calc.: 488.58; found: 489.3 and 490.4. 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 8.86 (bs, 2H), 8.68 (bs, 2H), 8.35 (s, 1H), 7.43 (s, 1H), 7.45-7.38 (m, 1H), 7.33-7.26 (m, 1H), 7.14-7.09 (m, 1H), 4.98-4.91(m, 1H), 4.18-4.14 (m, 1H), 3.89-3.85 (m, 1H), 3.23-3.11 (m, 3H), 3.09-2.99 (m, 5H), 2.98- 2.93 (m, 2H), 2.85 (q, 7 = 7.4 Hz, 2H), 2.31-2.24 (m, 2H), 2.01-1.93 (m, 2H), 1.64-1.55 (m, 1H), 1.24 (t, 7 = 7.4 Hz, 3H) ppm. T R = 10.78 min; UV-purity at 210, 230, 254, 242 and 275 nm > 97%.

(1/?,25‘,3/?,5/^-3-(4-amino-7//-pyrrolo[2 / 3-5|pynmidin-7-yl)-5-(3 ; 5-dichlorophenyl)cyclopentane- 1,2-diol (384):

Following the general procedure for deprotection Q, compound 384 was obtained starting from compound 264 (0.03 g, 0.07 mmol) in a mixture of water and TFA (0.05 M, 2.00 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as white foam (16.0 mg, 60%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.37 (s, 1H, H2), 7.81 (d, 7 = 3.6 Hz, 1H, H6), 7.49 (s, 3H, o, /Mr), 6.96 (d, 7 = 3.6 Hz, 1H, H5), 4.98 (dt, 7 = 11.2, 7.1 Hz, 1H, H1'), 4.22 (t, 7 = 6.6 Hz, 1H, H2'), 4.06 (t, 7 = 7.2 Hz, 1H, H3'), 3.14 (dt, 7 = 12.1, 7.0 Hz, 1H, H4'), 2.37 (dt, 7 = 12.5, 7.4 Hz, 1H, H4'), 2.03 (q, 7 = 12.0 Hz, 1H, H5'). HPLC: f R = 15.500 min (Method A). UV-purity at 210 nm = 100.0%.

(1/?,25‘,3/?,5/^-3-(4-amino-7//-pyrrolo[2 / 3-5|pynmidin-7-yl)-5-phenylcyclopentane-1,2-diol (385):

Following the general procedure for deprotection Q, compound 385 was obtained starting from compound 266 (0.02 g, 0.003 mmol) in a mixture of water and TFA (0.03 M, 1.00 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as white foam (15 mg, 83%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.06 (s, 1H, H2), 7.41 - 7.30 (m, 5H, H5, o, m-kr), 7.25 - 7.19 (m, 1H, p-Ar), 6.94 (s, 2H, -CN// 2 ), 6.56 (d, 7 = 3.5 Hz, 1H, H5), 4.97 (d, 7 = 5.9 Hz, 1H, 3'OH), 4.92 - 4.88 (m, 1H, H1'), 4.87 (d, 7 = 6.3 Hz, 1H, 2'OH), 4.28 (d, 7 = 6.3 Hz, 1H, H2'), 4.13 - 4.05 (m, 1H, H3'), 3.08 (dt, 7 = 11.8, 7.3 Hz, 1H, H4'), 2.34 (dt, 7 = 12.4, 7.6 Hz, 1H, H5'), 2.01 (q, 7 = 11.9 Hz, 1H, H5'). HPLC: t R = 12.771 min (Method A). UV-purity at 210 nm = 100.0%. (1/?,2S,3/?,5A)-3-(4-amino-5-bromo-7//-pyrrolo[2 / 3-5|pyrimidin-7-yl)-5-phenylcyclopentane-1,2- diol (386):

Following the general procedure for deprotection Q, compound 386 was obtained starting from compound 267 (0.02 g, 0.05 mmol) in a mixture of water and TFA (0.05 M, 0.90 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as white foam (10.4 mg, 58%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.33 (s, 1H, H2), 8.03 (s, 1H, H6), 7.42 - 7.37 (m, 2H, oAr), 7.36 - 7.31 (m, 2H, /77-Ar), 7.27 - 7.20 (m, 1H, />Ar), 5.00 (dt, 7 = 11.4, 7.3 Hz, 1H, H1'), 4.28 (t, 7 = 7.1 Hz, 1H, H2'), 4.01 (t, 7 = 6.5 Hz, 1H, H3'), 3.08 (dt, 7 = 11.7, 6.9 Hz, 1H, H4'), 2.39 - 2.30 (m, 1H, H5'), 2.00 (q, 7 = 11.8 Hz, 1H, H5'). HPLC: t R = 13.777 min (Method A). UV-purity at 210 nm = 94.6%. (1/?,2S,3/?,5/t)-3-(4-amino-7//-pyrrolo[2,3-d|pyrimidin-7-yl )-5-(naphthalen-2-yl)cyclopentane-1,2- diol (387):

Following the general procedure for deprotection Q, compound 387 was obtained starting from compound 268 (0.02 g, 0.04 mmol) in a mixture of water and TFA (0.03 M, 1.40 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as white foam (9.10 mg, 57%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.40 (s, 1H, H2, adenine), 7.94 - 7.85 (m, 4H, H1, H4, H5, H8 naphthyl), 7.83 (d, 7 = 3.6 Hz, 1H, H6 adenine), 7.61 (dd, 7 = 8.5, 1.8 Hz, 1H, H3 naphthyl), 7.54 - 7.44 (m, 2H, H6, H7 naphthyl), 6.97 (d, 7 = 3.6 Hz, 1H, H5 adenine), 5.06 (dt, 7 = 11.3, 7.3 Hz, 1H, H1'), 4.36 (t, 7 = 6.9 Hz, 1H, H2'), 4.16 (t, 7 = 6.6 Hz, 1H, H3'), 3.30 (dt, 7 = 11.6, 6.9 Hz, 1H, H4'), 2.47 - 2.41 (m, 1H, H5'), 2.16 (q, 7 = 11.7 Hz, 1H, H5'). HPLC: t R = 15.349 min (Method A). UV-purity at 210 nm = 99.2%.

(1/?,2S,3/?,5/t)-3-(4-amino-2-chloro-7//-pyrrolo[2,3-d|py rimidin-7-yl)-5-(naphthalen-2- yl)cyclopentane-1,2-diol (388):

Following the general procedure for deprotection Q, compound 388 was obtained starting from compound 269 (0.24 g, 0.55 mmol) in a mixture of water and TFA (0.05 M, 10.90 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as white foam (18.29 mg, 0.05 mmol). 1 H NMR (400 MHz, DMSO-5 6 ) 5 7.92 - 7.86 (m, 4H, H1, H4, H5, H8 naphthyl), 7.64 (dd, 7 = 8.6, 1.7 Hz, 1H, H6 naphthyl), 7.53 - 7.46 (m, 4H, -CN// 2 , H3, H7 naphthyl), 7.45 (d, 7 = 3.6 Hz, H6 adenine), 6.61 (d, 7 = 3.5 Hz, 1H, H5 adenine), 4.88 (dt, 7 = 10.5, 7.1 Hz, 1H, H1'), 4.32 (t, 7 = 6.7 Hz, 1H, H2'), 4.14 (t, 7 = 6.5 Hz, 1H, H3'), 3.27 (dt, 7 = 11.8, 7.3 Hz, 1H, H4'), 2.47 - 2.40 (m, 1H, H5'), 2.12 (q, 7 = 11.4 Hz, 1H, H5'). APCI calc.: 394.12; found: 395.20 [M + H] + . HPLC: t R = 18.589 min (Method A). UV-purity at 210 nm = 100.0%.

(1/?,2S,3/?,5A)-3-(4-amino-7//-pyrrolo[2 / 3-5|pynmidin-7-yl)-5-(pyridin-4-yl)cyclopentane-1,2-di ol (389):

Following the general procedure for deprotection Q, compound 389 was obtained starting from compound 270 (0.02 g, 0.06 mmol) in a mixture of water and TFA (0.05 M, 10.90 mL, 1:4) after preparative HPLC using method E (water/MeCN; 0.05% TFA) as white foam (16.20 mg, 89%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.83 - 8.79 (m, 2H, H2, H6 pyridine), 8.41 (s, 1H, H2 adenine), 7.96 - 7.92 (m, 2H, H3, H5 pyridine), 7.80 (d, 7 = 3.6 Hz, 1H, H6 adenine), 6.99 (d, 7 = 3.6 Hz, 1H, H5 adenine), 5.05 (dt, 7 = 11.0, 7.3 Hz, 1H, H1'), 4.26 (t, 7 = 6.3 Hz, 1H, H2'), 4.17 (t, 7 = 7.1 Hz, 1H, H3'), 3.38 (dt, 7 = 11.8, 7.2 Hz, 1H, H4'), 2.54 - 2.44 (m, 1H, H5' under DMSO peak), 2.18 - 2.07 (m, 1H, H5'). HPLC: t R = 6.948 min (Method B). UV-purity at 210 nm = >95%.

(1/?,2S,3/?,55)-3-(4-amino-7//-pyrrolo[2,3-d|pyrimidin-7- yl)-5-(thiophen-2-yl)cyclopentane-1,2- diol (390):

Following the general procedure for deprotection Q, compound 390 was obtained starting from compound 271 (0.02 g, 0.05 mmol) in a mixture of water and TFA (0.03 M, 1.60 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as white foam (10 mg, 55.6%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.39 (s, 1H, H2), 7.71 (d, 7 = 3.7 Hz, 1H, H6), 7.38 (dd, 7 = 4.9, 1.4 Hz, 1H, H5 thiophene), 7.03 - 6.98 (m, 2H, H3, H4 thiophene), 6.96 (d, 7 = 3.6 Hz, 1H, H5), 4.99 (dt, 7 = 10.9, 7.3 Hz, 1H, HT), 4.26 (t, 7 = 6.7 Hz, 1H, H2'), 4.03 (t, 7 = 6.5 Hz, 1H, H3'), 3.35 (dt, 7 = 11.0, 7.0 Hz, 1H, H4'), 2.59 - 2.51 (m, 1H, H5'), 2.05 (dt, 7 = 12.4, 11.0 Hz, 1H, H5'). HPLC: t R = 12.673 min (Method A). UV-purity at 210 nm = 96.0%.

(1/?,25‘,3/?,5A0-3-(4-amino-7/7-pyrrolo[2 / 3-5|pynmidin-7-yl)-5-(1//-pyrazol-5-yl)cyclopentane-1, 2- diol (391):

Following the general procedure for deprotection Q, compound 391 was obtained starting from compound 272 (0.03 g, 0.07 mmol) in a mixture of water and TFA (0.05 M, 1.50 mL, 1:4) after preparative HPLC using method E (water/MeCN; 0.05% TFA) as white foam (17.30 mg, 79%). 1 H NMR (400 MHz, DMSO-5 6 ) 5 8.39 (s, 1H, H2), 7.87 (dd, 7 = 2.3, 0.7 Hz, 1H, H3 pyrazol), 7.83 (d, 7 = 3.6 Hz, 1H, H6 ), 7.56 (d, 7 = 1.7 Hz, 1H, -N/7 pyrazol), 7.00 (d, 7 = 3.6 Hz, 1H, H5), 6.29 (dd, 7 = 1.9 Hz, 1H, H4 pyrazol), 5.12 - 5.04 (m, 1H, H1'), 4.68 (td, 7 = 8.2, 4.5 Hz, 1H, H4'), 4.42 (dd, 7 = 7.2, 5.8 Hz, 1H, H2'), 4.13 - 4.09 (m, 1H, H3'), 2.75 (dt, 7= 13.6, 8.7 Hz, 1H, H5'), 2.39 - 2.31 (m, 1H, H5'). APCI calcd.: 300.13; found: 300.90 [M + H] + . HPLC: t R = 8.818 min (Method B). UV-purity at 210 nm = 100%.

(1/?,2S,3/?,5/tO-3-(4-amino-2-chloro-7/7-pyrrolo[2 / 3-d|pyrimidin-7-yl)-5-(quinolin-6- yl)cyclopentane-1,2-diol (392): Following the general procedure for deprotection Q, compound 392 was obtained starting from compound 273 (0.07 g, 0.15 mmol) in a mixture of water and TFA (0.05 M, 2.00 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as white foam (28 mg, 69%). 1 H NMR (400 MHz, DMSO-t/ 6 ) <59.11 (dd, 7 = 4.8, 1.5 Hz, 1H, H2 quinoline), 8.81 (d, 7 = 9.5 Hz, 1H, H4, quinoline), 8.19 - 8.11 (m, 3H, H5, H6, H7 quinoline), 7.86 (dd, 7 = 8.3, 4.9 Hz, 1H, H3 quinoline), 7.50 (bs, 2H, -CN// 2 ), 7.43 (d, 7 = 3.6 Hz, 1H, H6), 6.62 (d, 7 = 3.5 Hz, 1H, H5), 4.90 (dt, 7 = 11.0, 7.5 Hz, 1H, HT), 4.31 (t, 7 = 6.5 Hz, 1H, H2'), 4.18 (t, 7 = 6.7 Hz, 1H, H3'), 3.38 (dt, 7 = 11.1, 7.2 Hz, 1H, H4'), 2.53 - 2.43 (m, 1H, H5' under DMSO peak), 2.19 - 2.09 (m, 1H, H5'). APCI calc.: 395.11; found: 395.60/397.50.60 [M + H] + . HPLC: t R = 10.879 min (Method A). UV-purity at 210 nm = 100%.

(1/?,2S,3/?,5/^-3-(4-amino-5-bromo-2-chloro-7//-pyrrolo[2 ,3-d|pyrimidin-7-yl)-5-(3- (aminomethyl)phen-yl)cyclopentane-1,2-diol (393):

Following the general procedure for deprotection Q, compound 393 was obtained starting from compound 274 (0.21 g, 0.35 mmol) in a mixture of water and TFA (0.10 M, 3.50 mL, 1:4). 36 mg of the crude product were purified over preparative HPLC using method D (water/MeCN; 0.05% TFA) as white foam (13.30 mg, 0.03 mmol). 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.21 - 8.11 (m, 3H, - CH 2 N// 3 + ), 7.73 (s, 1H, H6, adenine), 7.49 - 7.44 (m, 2H, H4, H5 aryl), 7.41 (t, 7 = 7.5 Hz, 1H, H2 aryl), 7.35 - 7.30 (m, 1H, H6 aryl), 4.90 (dt, 7 = 11.5, 7.5 Hz, 1H, H1'), 4.33 - 4.27 (m, 1H, H2'), 4.08 - 4.02 (m, 2H, -C// 2 NH 3 + ), 3.98 (dd, 7 = 8.3, 4.0 Hz, 1H, H3'), 3.10 (ddd, 7 = 11.4, 7.5, 6.0 Hz, 1H, H4'), 2.41 - 2.32 (m, 1H, H5'), 1.96 (q, 7 = 11.5 Hz, 1H, H5'). HPLC: t R = 9.987 min (Method A-XBridge). UV-purity at 210 nm = 95.5%.

(1/?,25)3/?,5A)-3-(4-amino-5-(thiazol-2-yl)-7/-/-pyrrolo[ 2,3-<5|pyrimidin-7-yl)-5-(3,5- dichlorophenyl)cyclo-pentane-1,2-diol (394):

Following the general procedure for deprotection Q, compound 394 was obtained starting from compound 283 (0.06 g, 0.13 mmol) in a mixture of water and TFA (0.05 M, 2.50 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as white foam (13.30 mg, 0.03 mmol). 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.62 (s, 1H, H2), 8.39 (s, 1H, H6), 7.90 (d, 7 = 3.4 Hz, 1H, H4 thiazole), 7.77 (d, 7 = 3.4 Hz, 1H, H5 thiazole), 7.52 - 7.49 (m, 3H, o//>Ar), 5.05 (dt, 7 = 11.4, 7.0 Hz, 1H, HT), 4.32 (t, 7 = 6.9 Hz, 1H, H2'), 4.08 (t, 7 = 7.1 Hz, 1H, H3'), 3.15 (dt, 7 = 12.3, 7.0 Hz, 1H, H4'), 2.37 (dt, 7 = 12.3, 7.2 Hz, 1H, H5'), 2.13 (q, 7 = 12.0 Hz, 1H, H5'). APCI calc.: 461.05; found: 462.20/464.20 [M + H] + . HPLC: t R = 18.268 min (Method A). UV-purity at 210 nm = 98.9%.

(1/?,25)3/?,5A)-3-(4-amino-5-(thiazol-2-yl)-7/-/-pyrrolo[ 2,3-c/|pyrimidin-7-yl)-5- phenylcyclopentane-1,2-diol (395):

Following the general procedure for deprotection Q, compound 395 was obtained starting from compound 284 (0.02 g, 0.05 mmol) in a mixture of water and TFA (0.03 M, 1.60 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as white foam (17.30 mg, 96%). 1 H NMR (400 MHz, DMSO-5 6 ) 58.68 (s, 1H, H2), 8.43 (s, 1H, H6), 7.90 (d, 7 = 3.4 Hz, 1H, H4 thiazole), 7.78 (d, 7 = 3.4 Hz, 1H, H5 thiazole), 7.45 - 7.40 (m, 2H, oAr), 7.35 (dd, 7 = 8.4, 6.9 Hz, 2H, /77-Ar), 7.29 - 7.21 (m, 1H, />Ar), 5.07 (dt, 7 = 11.6, 7.3 Hz, 1H, H1'), 4.40 (t, 7 = 7.2 Hz, 1H, H2'), 4.07 (t, 7 = 6.6 Hz, 1H, H3'), 3.11 (dt, 7 = 12.8, 6.9 Hz, 1H, H4'), 2.42 - 2.33 (m, 1H, H5'), 2.12 (q, 7 = 11.9 Hz, 1H, H5'). HPLC: t R = 15.374 min (Method A). UV-purity at 210 nm = 100.0%.

(1/?,2S,3/?,5/^-3-(4-amino-5-ethyl-7Z/-pyrrolo[2,3-o]pyri midin-7-yl)-5-phenylcyclopentane-1,2- diol (396):

Following the general procedure for deprotection Q, compound 396 was obtained starting from crude compound 286 in a mixture of water and TFA (0.01 M, 4.50 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as white foam (13.6 mg, 90%). 1 H NMR (400 MHz, DMSO-aL) 58.35 (s, 1H, H2), 8.28 (s, 2H, -CN// 2 ), 7.60 (d, 7 = 1.2 Hz, 1H, H6), 7.42 - 7.37 (m, 2H, oAr), 7.34 (dd, 7 = 8.4, 6.8 Hz, 2H, /77-Ar), 7.27 - 7.20 (m, 1H, />Ar), 4.98 (dt, 7 = 11.4, 7.3 Hz, 1H, H1'), 4.27 (t, 7 = 7.0 Hz, 1H, H2'), 4.03 (t, 7 = 6.7 Hz, 1H, H3'), 3.09 (dt, 7 = 11.8, 7.0 Hz, 1H, H4'), 2.85 (qd, 7 = 7.4, 1.1 Hz, 2H, -C// 2 CH 3 ), 2.32 (dt, 7 = 12.4, 7.3 Hz, 1H, H5'), 2.01 (q, 7 = 11.9 Hz, 1H, H5'), 1.25 (t, 7 = 7.4 Hz, 3H, -CH 2 C// 3 ). HPLC: t R = 14.398 min (Method A). UV-purity at 210 nm = 100%.

(1/?,25',3/?,5/t0-3-(4-amino-7//-pyrrolo[2 / 3-d|pyrimidin-7-yl)-5-(piperidin-4-yl)cyclopentane-1,2 - diol (397):

Following the general procedure for deprotection Q, compound 397 was obtained starting from compound 194 (0.05 g, 0.11 mmol) in a mixture of water and TFA (0.10 M, 1.10 mL, 1:4) after preparative HPLC using method E (water/MeCN; 0.05% TFA) as white foam (22.32 mg, 48%, 1 TFA salt,). 1 H NMR (400 MHz, DMSO) 58.58 - 8.50 (m, 1H, -NH 2 + ), 8.36 (s, 1H, H2), 8.32 - 8.21 (m, 1H, -NH 2 + ), 7.65 (d, 7 = 3.7 Hz, 1H, H6), 6.94 (d, 7 = 3.7 Hz, 1H, H5), 4.85 (dt, 7 = 11.5, 8.0 Hz, 1H, HT), 4.13 (dd, 7 = 8.8, 6.4 Hz, 1H, H2'), 3.80 (dd, 7 = 6.5, 4.3 Hz, 1H, H3'), 3.36 - 3.24 (m, 2H, - N(C// 2 ) 2 (CH 2 ) 2 ), 2.93 - 2.76 (m, 2H, -N(Q/ 2 ) 2 (CH 2 ) 2 ), 2.16 - 1.99 (m, 2H, H5', -N(CH 2 ) 2 (CH 2 ) 2 C//_-), 1.81 - 1.66 (m, 2H, H4', -N(CH 2 ) 2 (C// 2 ) 2 CH-), 1.66 - 1.51 (m, 1H, H5', -N(CH 2 ) 2 (C// 2 ) 2 CH-), 1.47 - 1.28 (m, 2H, -N(CH 2 ) 2 (C// 2 ) 2 CH-). APCI calc, for C 16 H 24 N 5 O 2 . HPLC: t R = 6.633 min (Method B). UV- purity at 210 nm = 96.4%.

(1/?,25',3/?,5/t0-3-(4-amino-7//-pyrrolo[2 / 3-d|pyrimidin-7-yl)-5-((/t0-pyrrolidin-2-yl)cyclopenta ne- 1,2-diol (398) & (1/?,25‘,3/?,5/^-3-(4-amino-7//-pyrrolo[2 / 3-5|pynmidin-7-yl)-5-((5)-pyrrolidin-2- yl)cyclopentane-1,2-diol (399):

Following the general procedure for deprotection Q, compounds 398 & 399 were obtained starting from compound 275 (0.09 g, 0.20 mmol) in a mixture of water and TFA (0.05 M, 4.00 mL, 1:4) after preparative HPLC using method E (water/MeCN; 0.05% TFA) as white foams (1 TFA salt,).

1 H NMR (400 MHz, DMSO) 5 9.33 - 9.19 (m, 1H, NH 2 + ), 8.58 - 8.47 (m, 1H, NH 2 + ), 8.36 (s, 1H, H2), 7.62 (d, 7 = 3.5 Hz, 1H, H6), 6.94 (d, 7 = 3.5 Hz, 1H, H5), 4.91 (dt, 7 = 10.8, 7.9 Hz, 1H, HT), 4.20 (dd, 7 = 8.2, 6.1 Hz, 1H, H2'), 3.88 - 3.83 (m, 1H, H3'), 3.57 - 3.44 (m, 1H, -NH 2 + CH 2 CH 2 Q7-), 3.26 - 3.09 (m, 2H, -NH 2 + C/7 2 CH 2 CH 2 CH-), 2.35 - 2.20 (m, 2H, H5', -NH 2 + CH 2 C/7 2 CH 2 -), 2.20 - 2.10 (m, 1H, H4'), 2.04 - 1.81 (m, 2H, -NH 2 + CH 2 C/7 2 C/y 2 -), 1.80 - 1.63 (m, 2H, H5', -NH 2 + CH 2 CH 2 C/7 2 -). HPLC: ZR = 6.429 min (Method B). UV-purity at 210 nm = 100%.

1 H NMR (400 MHz, DMSO) 59.28 - 9.18 (m, 1H, -NH 2 + ), 8.49 - 8.40 (m, 1H, -NH 2 + ), 8.38 (s, 1H, H2), 7.67 (d, 7= 3.6 Hz, 1H, H6), 6.96 (d, 7 = 3.6 Hz, 1H, H5), 4.94 (dt, 7 = 10.9, 7.5 Hz, 1H, HT), 4.18 (dd, 7 = 7.5, 6.0 Hz, 1H, H2'), 3.98 (t, 7 = 5.5 Hz, 1H, H3'), 3.56 - 3.43 (m, 1H, -NH 2 + CH 2 CH 2 CM), 3.28 - 3.12 (m, 2H, -NH 2 + C/7 2 CH 2 CH 2 CH-), 2.30 - 2.14 (m, 2H, H4', H5'), 2.12 - 2.01 (m, 1H, - NH 2 + CH 2 C7/ 2 CH 2 -), 1.99 - 1.78 (m, 1H, -NH 2 + CH 2 C/7 2 CH 2 CH-), 1.70 - 1.50 (m, 2H, H5', - NH 2 + CH 2 C7/ 2 CH-). HPLC: t R = 7.316 min (Method B). UV-purity at 210 nm = 95.0%.

(1/?,25',3/?,5/tO-3-(4-amino-7Z/-pyrrolo[2 / 3-<7]pyrimidin-7-yl)-5-((/tO-piperidin-2-yl)cyclope ntane- 1,2-diol (400):

Following the general procedure for deprotection Q, compound 400 were obtained starting from compound 276 (0.04 g, 0.09 mmol) in a mixture of water and TFA (0.05 M, 1.90 mL, 1:4) after preparative HPLC using method E (water/MeCN; 0.05% TFA) as white foam (34.4 mg, 86%, 1 TFA salt). 1 H NMR (400 MHz, DMSO-o6) 58.49 - 8.40 (m, 2H, -NH 2 + ), 8.39 (s, 1H, H2), 7.63 (d, 7 = 3.6 Hz, 1H, H6), 6.96 (d, 7 = 3.6 Hz, 1H, H5), 4.94 - 4.84 (m, 1H, HT ), 4.13 (dd, 7 = 8.4, 6.4 Hz, 1H, H2'), 3.93 (dd, 7 = 6.2, 4.6 Hz, 1H, H3'), 3.26 (d, 7 = 12.5 Hz, 1H, -NH 2 + C/7 2 CH 2 CH 2 CH 2 CH-), 3.19 - 3.08 (m, 1H, -NH 2 + CH 2 CH 2 CH 2 CH 2 Q7-), 2.94 - 2.80 (m, 1H, -NH 2 + C/7 2 CH 2 CH 2 CH-), 2.24 - 2.05 (m, 3H, H5', H4', -NH 2 + CH 2 CH 2 CH 2 CA 2 CH-), 1.85 - 1.70 (m, 3H, H5', -NH 2 + CH 2 C/7 2 CH 2 C/y 2 CH-), 1.67 - 1.52 (m, 1H, NH 2 + CH 2 CA 2 CH 2 CH 2 CH-), 1.52 - 1.37 (m, 2H, NH 2 + CH 2 CH 2 C/7 2 CH 2 CH-). HPLC: ZR = 5.544 min (Method B). UV-purity at 210 nm = 98.8%.

(1S,2/?,3/?,5/^-3-((5)-piperidin-3-yl)-5-(5-(thiazol-2-yl )-7Z/-pyrrolo[2,3-a]pyrimidin-7- yl)cyclopentane-1,2-diol (401) & (15)2/?, 3 /?,5/tO-3-((/t)-piperidin-3-yl)-5-(5-(thiazol-2-yl)-7Z7- pyrrolo[2,3-o]pyrimidin-7-yl)cyclopentane-1,2-diol (402):

Following the general procedure for deprotection Q, compounds 401 & 402 were obtained starting from compound 258 (0.14 g, 0.27 mmol) in a mixture of water and TFA (0.05 M, 5.40 mL, : ) a te p epa atve C us g et od (wate / eCN; 0.05% TFA) as white foams (134.5 mg, 100%, 1 TFA salt). 1 H NMR (400 MHz, DMSO) δ 9.54 (s, 1H, H2), 8.97 (s, 1H, H4), 8.70 – 8.62 (m, 2H, H6, -NH 2 + ), 8.39 – 8.26 (m, 1H, -NH 2 + ), 7.93 (d, J = 3.3 Hz, 1H, H4 thiazole), 7.73 (d, J = 3.3 Hz, 1H, H5 thiazole), 5.05 – 4.95 (m, 1H, H1’), 4.32 (dd, J = 8.9, 6.7 Hz, 1H, H2’), 3.90 (dd, J = 6.7, 4.1 Hz, 1H, H3’), 3.27 – 3.17 (m, 2H, -NH 2 + (CH 2 ) 2 -), 2.89 – 2.77 (m, 1H, -NH 2 + (CH 2 ) 2 -), 2.76 – 2.65 (m, 1H, -NH 2 + (CH 2 ) 2 -), 2.15 (dt, J = 11.7, 6.8 Hz, 1H, H5’), 2.07 – 1.98 (m, 1H, -NH 2 + CH 2 CH-), 1.90 – 1.67 (m, 4H, H4’, H5’, - NH 2 + CH 2 CH 2 CH 2 -), 1.67 – 1.54 (m, 1H, -NH 2 + CH 2 CH 2 CH 2 -), 1.38 – 1.25 (m, 1H, -NH 2 + CH 2 CH 2 CH 2 -). HPLC: t R = 8.120 min (Method B). UV-purity at 210 nm = 100.0%. 1 H NMR (400 MHz, DMSO) δ 9.54 (s, 1H, H2), 8.98 (s, 1H, H4), 8.68 (s, 1H, H6), 8.67 – 8.61 (m, 1H, - NH 2 + ), 8.41 – 8.28 (m, 1H, -NH 2 + ), 7.93 (d, J = 3.3 Hz, 1H, H4 thiazole), 7.73 (d, J = 3.3 Hz, 1H, H5 thiazole), 5.05 – 4.96 (m, 1H, H1’), 4.27 (dd, J = 8.4, 6.7 Hz, 1H, H2’), 3.85 (dd, J = 6.7, 4.5 Hz, 1H, H3’), 3.49 (d, J = 12.2 Hz, 1H, -NH 2 + (CH 2 ) 2 -), 3.25 (d, J = 12.4 Hz, 1H, -NH 2 + (CH 2 ) 2 -), 2.87 – 2.75 (m, 1H, -NH 2 + (CH 2 ) 2 -), 2.72 – 2.60 (m, 1H, -NH 2 + (CH 2 ) 2 -), 2.18 – 2.09 (m, 1H, H5’), 1.86 – 1.70 (m, 5H, H4’, H5’, -NH 2 + CH 2 CH-, -NH 2 + CH 2 CH 2 CH 2 -), 1.66 – 1.51 (m, 1H, -NH 2 + CH 2 CH 2 CH 2 -), 1.28 – 1.15 (m, 1H, -NH 2 + CH 2 CH 2 CH 2 -). HPLC: t R = 8.756 min (Method B). UV-purity at 210 nm = 100.0%. (1R,2S,3R,5R)-3-(4-(difluoromethyl)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-((R)-piperidin-3- yl)cyclopentane-1,2-diol (403): Following the general procedure for d ound 403 were obtained starting from compound 259 (0.19 g, 0.37 mmol) in a mixture of water and TFA (0.05 M, 7.50 mL, 1:4) after preparative HPLC using method E (water/MeCN; 0.05% TFA) as white foams (102.52 mg, 58.9%, 1 TFA salt). 1 H NMR (400 MHz, DMSO) δ 8.89 (s, 1H, H2), 8.70 – 8.60 (m, 1H, -NH 2 + ), 8.37 – 8.25 (m, 1H, -NH 2 + ), 7.97 (d, J = 3.7 Hz, 1H, H6), 7.36 – 7.06 (m, 1H, -CHF 2 ), 6.82 – 6.78 (m, 1H, H5), 5.02 – 4.90 (m, 1H, H1’), 4.24 (dd, J = 8.7, 6.6 Hz, 1H, H2’), 3.88 (dd, J = 6.5, 4.3 Hz, 1H, H3’), 3.26 – 3.16 (m, 2H, -NH 2 + (CH 2 ) 2 -), 2.89 – 2.75 (m, 1H, -NH 2 + (CH 2 ) 2 -), 2.74 – 2.62 (m, 1H, -NH 2 + (CH 2 ) 2 -), 2.13 (dt, J = 11.9, 7.2 Hz, 1H, H5’), 2.01 (d, J = 13.2 Hz, 1H, -NH 2 + CH 2 CH-), 1.88 – 1.53 (m, 5H, H4’, H5’, - NH 2 + CH 2 CH 2 CH 2 -, NH 2 + CH 2 CH 2 CH 2 -), 1.38 – 1.22 (m, 1H, NH 2 + CH 2 CH 2 CH 2 -). HPLC: t R = 7.679 min (Method B). UV-purity at 210 nm = 96.3%. (1R,2S,3R,5R)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5- (3-hydroxyphenyl)cyclopentane-1,2- diol (404): Following the general procedure for de pound 404 was obtained starting from compound 277 (0.06 g, 0.16 mmol) in a mixture of water and TFA (6.80 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as white foam (19.60 mg, 37%). APCI: calcd. for C 17 H 18 N 4 O 3 [M+H] + : 327.1 found 326.8. t R = 10.96 min, UV-purity at 210 nm = 98 %. 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.32 (bs, 1H, phenyl OH), 8.96 - 8.66 (br d, 2H, NH 2 ), 8.39 (s, 1H, H2), 7.77 (d, J = 3.6 Hz, 1H, H8), 7.12 (t, J = 7.8 Hz, 1H, m-H), 6.96 (d, J = 3.6 Hz, 1H, H7), 6.82-6.78 (m, 2H, 2 x o- H), 6.63 (ddd, 7 = 8.1 Hz, 2.3 Hz, 1.0 Hz, 1H, />H), 4.97 (dt, 7 = 11.3 Hz, 7.3 Hz, 1H, HT), 4.29 (t, 7 = 7.0 Hz, 1H, H2'), 4.02 (t, 7 = 7.0 Hz, 1H, H3'), 3.02 (dt, 7 = 11.4 Hz, 7.0 Hz, 1H, H4'), 2.35 (dt, 7 = 12.6 Hz, 7.3 Hz, 1H, H5' A ), 2.00 (q, 7 = 11.8, 1H, H5' B )

(1/?,25‘,3/?,5A)-3-(4-amino-7Z/-pyrrolo[2 / 3-5|pynmidin-7-yl)-5-(4-hydroxyphenyl)cyclopentane- 1,2-diol (405):

Following the general procedure for deprotection Q, compound 405 was obtained starting from compound 278 (0.03 g, 0.07 mmol) in a mixture of water and TFA (2.80 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as white foam (15.01 mg, 71%). APCI: calcd. for C 17 H 18 N 4 O3 [M + H] + : 327.1 found 326.9. HPLC: t R = 9.98 min, UV-purity at 210 nm = 99 %. 1 H NMR (400 MHz, DMSO-ok) 59.36 - 8.46 (s, 1H, NH 2 , phenyl OH), 8.39 (s, 1H, H2), 7.78 (d, 7 = 3.6 Hz,

IH, H8), 7.19-7.14 (m, 2H, oH), 6.96 (d, 7 = 3.6 Hz, 1H, H7), 6.74-6.60 (m, 2H, /77-H), 4.97 (dt, 7 =

II.2 Hz, 7.4 Hz, 1H, HT), 4.27 (t, 7 = 7.0 Hz, 1H, H2'), 3.98-3.93 (m, 1H, H3') 3.00 (dt, 7 = 11.4 Hz, 7.0 Hz, 1H, H4'), 2.37-2.28 (m, H5' A ), 1.95 (q, 7 = 11.8 Hz, 1H, H5' B ).

(1S,2/?,3/?,5/^-3-(4-hydroxyphenyl)-5-(4-(methylamino)-7/ /-pyrrolo[2,3-d|pyrimidin-7- yl)cyclopentane-1,2-diol (406):

Following the general procedure for deprotection Q, compound 406 was obtained starting from compound 279 (0.05 g) in a mixture of water and TFA (3.20 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as a yellowish foam (19.70 mg, 20%). APCI: calcd. for [M + H] + : 341.2 found 340.9. HPLC: t R = 10.57 min, UV-purity at 210 nm = 98 %. 1 H NMR (400 MHz, DMSO-c/j) 59.50 (br s, 1H, -NH-CH 3 ), 9.25 (br s, 1H, -phenyl OH), 8.40 (s, 1H, H2), 7.75 (s, 1H, H8), 7.20-7.15 (m, 2H, 2 x oH), 6.92 (s, 1H, H7), 6.75-6.71 (m, 2H, /77-H), 5.01-4.91 (m, 1H, HT), 4.28 (t, 7 = 6.9 Hz, 1H, H2'), 4.01 - 3.94 (m, 1H, H3'), 3.10 (s, 3H, -NH-CH 3 ), 3.00 (dt, 7 = 11.7, 7.0 Hz, 1H, H4'), 2.38 - 2.28 (m, 1H, H5' A ), 1.96 (q, 7 = 11.7 Hz, 1H, H5' B ).

(1/?,25‘,3/?,5A)-3-(4-amino-7Z/-pyrrolo[2 / 3-5|pynmidin-7-yl)-5-(3-chlorophenyl)cyclopentane-1,2- diol (407):

Following the general procedure for deprotection Q, compound 407 was obtained starting from compound 280 (0.02 g, 0.06 mmol) in a mixture of water and TFA (1.90 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as a white foam (13.00 mg, 65%). APCI: calcd. for C 17 H 17 CIN 4 O 2 [M + H] + : 345.1 found 344.8. HPLC: t R = 14.1 min, UV-purity at 210 nm = 99 %. 1 H NMR (400 MHz, DMSO-5 6 ) 5 9.39-8.44 (br m, 2H, NH 2 ), 8.39 (s, 1H, H2), 7.82 (d, 7 = 3.6 Hz, 1H,

H8), 7.50-7.49 (m 1H, /77-H), 7.41 - 7.35 (m, 2H, oH, />H), 7.34 - 7.29 (m, 1H, oH), 6.97 (d, 7 = 3.7 Hz, 1H, H7), 5.00 (dt, 7 = 11.2, 7.2 Hz, 1H, HT), 4.26 (t, 7 = 6.7 Hz, 1H, H2'), 4.07 (t, 7 = 6.9 Hz, 1H, H3'), 3.14 (dt, 7 = 11.8 Hz, 7.0 Hz, 1H, H4'), 2.39 (dt, 7 = 12.3, 7.3 Hz, 1H, H5' A ), 2.04 (q, 7 = 11.9 Hz, 1H, H5' B ).

1-(3-((1/?,2/?,35,4/j)-4-(4-amino-7/7-pyrrolo[2,3-(7|pyri midin-7-yl)-2,3- dihydroxycyclopentyl)phenyl)ethan-1-one (408):

Following the general procedure for deprotection Q, compound 408 was obtained starting from compound 281 (0.04 g, 0.08 mmol) in a mixture of water and TFA (2.60 mL, 1:4) after preparative HPLC using method D (water/MeCN; 0.05% TFA) as a white foam (21.00 mg, 75%). APCI: calcd. for C 19 H 2 oN 4 0 3 [M + H] + : 353.2 found. 352.8 HPLC (Jung40.): t R = 12.37 min, UV-purity at 210 nm = 98 %. 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 9.33-8.44 (br d, 2H, -NH 2 ), 8.40 (s, 1H, H2), 7.96-7.95 (m, 1H, o-H ), 7.85 (dt, 7 = 7.7, 1.4 Hz, 1H, />H), 7.81 (d, 7 = 3.7 Hz, 1H, H8), 7.68 (dt, 7 = 7.8, 1H, oH), 7.51 (t, 7 = 7.7 Hz, 1H, /77-H), 6.97 (d, 7 = 3.6 Hz, 1H, H7), 5.01 (dt, 7 = 11.2, 7.1 Hz, 1H, HT), 4.30 (t, 7 = 6.8 Hz, 1H, H2'), 4.10 (t, 7 = 6.9 Hz, 1H, H3'), 3.21 (dt, 7 = 11.8, 7.1 Hz, 1H, H4'), 2.60 (s, CH 3 , acetyl), 2.46-2.37 (m, Z 1H, H5' A ), 2.08 (q, 7 = 11.9 Hz, 1H, H5' B ).

(1r,2s,3r,5r)-3-(4-amino-7A/-pyrrolo[2,3-d]pyrimidin-7-yl )-5-(4-aminophenyl)cyclopentane-1,2- diol (409):

260 mg (0.56 mmol; 1.00 eq) of terAbutyl (4-((3ar,4r,6as)-6-hydroxy-2,2-dimethyltetrahydro-4/7- cyclopenta[d][1,3]dioxol-4-yl)phenyl)carbamate were dissolved in 16 mL TFA/H 2 O (1:1) and stirred at RT overnight. The solvent was removed under reduced pressure and the resulting residue was purified by HPLC according to method D (MeCN/H 2 O + 0.1% TFA; 0/100% to 5/95%;

T R = 7.22 min; UV-purity at 210, 230, 254, 242 and 275 nm > 98%). 33 mg (0.10 mmol; 18%) of the title compound were obtained in the form of a colorless foam. APCI-MS(+) m/z for C 17 H 19 N 5 O 2 : calc.: 325.37; found: 325.9 and 327.0. 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 9.14 (bs, 1H), 8.69 (bs, 1H), 8.41 (s, 1H), 7.80 (d, 7 = 3.6 Hz, 1H), 7.41-7.34 (m, 2H), 7.13-7.06 (m, 2H), 6.99 (d, 7 = 3.5 Hz, 1H), 5.04-4.97 (m, 1H), 4.29 (t, 7 = 6.8 Hz, 1H), 4.02 (t, 7 = 6.7 Hz, 1H), 3.13-3.07 (m, 1H), 2.42-2.34 (m, 1H), 2.04-1.94 (m, 1H) ppm.

(1/?,25‘,3/?,5A)-3-(4-amino-7Z/-pyrrolo[2 / 3-</|pyrimidin-7-yl)-5-(3-aminophenyl)cyclopentane- 1,2- diol (410):

170 mg (0.36 mmol; 1.00 eq) of terAbutyl (3-((3ar,4r,6r,6as)-6-(4-amino-7//-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4A L cyclopenta[d][1,3]dioxol-4-yl)phenyl)carbamate were dissolved in 16 mL TFA/H 2 O (1:1) and stirred at RT overnight. The solvent was removed under reduced pressure and the resulting residue was purified by HPLC according to method D (MeCN/H 2 O + 0.1% TFA; 0/100% to 5/95%; T R = 7.86 min; UV-purity at 210, 230, 254, 242 and 275 nm > 99%). 118 mg (0.37 mmol; quantitative) of the title compound were obtained in the form of a colorless foam. APCI-MS(+) m/z for C 17 H 1 9N 5 O 2 : calc.: 325.37; found: 325.8 and 326.8. 1 H-NMR: (400 MHz, DMSO-d 6 ) 5 = 9.16 (bs, 1H), 8.73 (bs, 1H), 8.41 (s, 1H), 7.78 (d, 7 = 3.6 Hz, 1H), 7.30-7.26 (m, 1H), 7.13-7.03 (m, 2H), 6.98 (d, 7= 3.6 Hz, 1H), 6.94-6.88 (m, 1H), 5.03-4.97 (m, 1H), 4.30 (t, 7 = 6.9 Hz, 1H), 4.03 (t, 7 = 6.6 Hz, 1H), 3.17-3.05 (m, 1H), 2.43-2.36 (m, 1H), 2.06-1.97 (m, 1H) ppm.

Preparation of (2R ; 3S,4R,5R)-2-(aminomethyl)-5-(6,7,8 ; 9-tetrahydro-2H-2,3,5,6- tetraazabenzo[cd]azulen-2-yl)tetrahydrofuran-3,4-diol k heat-dried three-necked round bottom flask was equipped with a magnetic stirring bar and the thermometer. Then, the flask was charged with 5-bromo-4-chloro-7H-pyrrolo[2,3- d]pyrimidine (2.80 g,11.92 mmol) under nitrogen atmosphere. The solid was suspended in dry THF (59.60 mL). The resulted suspension was cooled down to -70 °C. Then, a solution of n-BuLi (1.6 M in hexane, 14.91 mL) was added dropwise over 1 h at -70 °C via syringe pump. After addition completed, (3-bromopropoxy)(tert-butyl)dimethylsilane (8.21 mL, 35.77 mmol) was added over 1 h at -70 °C via syringe pump. The cooling bath was removed, and the mixture was allowed to warm up slowly to -10 °C (ice-bath with NaCI). The mixture was stirred at this temperature for 1 h. Then, the beige suspension became a clear brown solution. After 1 h, the solution was stirred one additional hour at ambient temperature before quenched with saturated NH4CI solution. The mixture was extracted with CH 2 CI 2 . The collected organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified over silica (cyclohexane/EtOAc; 0-40%) to afford the product as white solid (1.91 g, 49%).

To a stirred suspension of compound 411 (1.90 g, 5.83 mmol) in MeCN (29.10 mL) was added BSA (1.58 mL, 6.41 mmol) at rt under nitrogen atmosphere. The suspension was stirred 10 min at ambient temperature during which time the reaction mixture became a clear solution. Then, 1-O- Acetyl-2,3,5-tri-O-benzoyl-|3-D-ribofuranose (3.27 g, 6.41 mmol) was added followed by TMSOTf (1.17 mL, 6.41 mmol). The reaction mixture was heated to reflux (85 °C) and stirred 18 h before cooled down to rt. The mixture was diluted with EtOAc and the organic layer was washed with sat. bicarbonate solution and with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. The obtained oil was purified by flash chromatography (cyclohexane/EtOAc; 0-50%) to afford a yellowish foam (1.13 g, 27%).

To a solution of 412 (1.10 g, 1.66 mmol) in dry THE (16.60 mL), phthatlimide (0.32 g, 2.16 mmol), PPh 3 (0.57 g, 2.16 mmol), and a solution of DEAD (40% in toluene, 0.94 g, 2.16 mmol) were added in this order. The solution was stirred magnetically at ambient temperature. The reaction mixture was diluted with CH 2 CI 2 and water. The organic layer was separated, and the aqueous phase was extracted with CH 2 CI 2 . The collected organic layers were washed with brine, dried over sodium sulfate, and concentrated by rotatory evaporation. The obtained residue was purified over silica (cyclohexane/EtOAc; 0-50%) to afford the product as yellowish foam (0.82 g, 63%).

(2R,3S,4R,5R)-2-(hydroxymethyi)-5-(6,7,8,9-tetrahydro-2H- 2,3,5,6-tetraazabenzo[cd]azuien-2- yl)tetrahydrofuran-3,4-diol (414) :

Compound 413 (0.61 g, 0.76 mmol) was suspended in absolute EtOH (38.10 mL). Then, ethylenediamine (0.25 mL, 1.53 mmol) was added and the mixture was heated to 50 °C. The reaction mixture became after 20 min a clear solution and was stirred for 2 d at this temperature. Then, the reaction mixture was concentrated under reduced pressure. The obtained oil was redissolved in 1,4-dioxane (14.00 mL). Then, a solution of MeNH 2 (33 w% in EtOH, 14.00 mL) was added and the mixture was stirred at 60 °C for 2 d. After 2 d, the mixture was allowed to cool down to rt and concentrated under reduced pressure. The obtained crude product was purified over silica (CH 2 CI 2 /MeOH; 0-20%) to give the product was white foam (0.06 g, 25%).

To a solution of compound 414 (0.06 g, 0.18 mmol) in dry THE (3.60 mL) were added PPh 3 (0.19 g, 0.44 mmol), phthalimide (0.07 g, 0.44 mmol). The suspension was cooled down to -10 °C (icebath with NaCI). Then, DIAD (0.09 mL, 0.44 mmol) was added and stirred for 30 min at -10 °C. Afterwards, the solution was allowed to warm up to rt. After 1 h, the solvents were removed in vacuo. The obtained residue was purififed over silica (CH 2 CI 2 /MeOH; 0-10%) to afford the desired product as colorless foam (0.06 g, 82%).

(2/?,35;4/?,5/i0-2-(aminomethyl)-5-(6,7,8,9-tetrahydro-2/ /-2,3,5,6-tetraazabenzo[c</|azulen-2- yl)tetrahydrofuran-3,4-diol (416):

Hydrazine monohydrate (0.07 mL, 1.46 mmol) was added to a suspension of 415 (0.04 g, 0.09 mmol) in EtOH (2.30 mL) and stirred at 90 °C for 1 h. Note that the suspension became clear after approximately 5 min and before a white precipitate is formed after around 15 min. The reaction was cooled down in an ice-bath to rt. The precipitate was filtered off and the filter cake was washed with EtOH. The filtrate was concentrated under reduced pressure. The obtained residue was purified over amino coated silica (DCM/MeOH; 0-10%) to afford the desired product as colorless foam (0.02 g, 72%). 1 H NMR (400 MHz, DMSO) <58.01 (s, 1H, H2), 7.52 (t, 7 = 3.7 Hz, 1H, -NA), 7.13 (s, 1H, H6), 6.02 (d, 7 = 6.1 Hz, 1H, -OH), 5.23 (d, 7 = 6.2 Hz, 1H, HT), 5.08 - 5.01 (m, 1H, -OH), 4.34 (q, 7 = 6.1 Hz, 1H, H2'), 4.06 - 4.01 (m, 1H, H3'), 3.77 (q, 7 = 5.1 Hz, 1H, H4'), 3.41 - 3.28 (m, 2H, -CH 2 CH 2 CA 2 NH-under water peak), 2.81 (t, 7 = 5.6 Hz, 2H, -C// 2 CH 2 CH 2 NH-), 2.74 (dd, 7 = 20.4, 5.2 Hz, 1H, -C// 2 NH 2 -), 2.53 - 2.46 (m, 2H, H5' under DMSO peak), 1.93 - 1.86 (m, 2H, -CH 2 C7/ 2 CH 2 NH-). HPLC: t R = 6.914 min (Method B). UV-purity at 210 nm = 100.0%.

The synthesis of common intermediate A.

Synthesis of ((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-py rrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methanol (Intermediate A)

(1R,4S,5R,6S)-5,6-Dihydroxy-2-azabicyclo[2.2.1]heptan-3-o ne (1a).

To a stirred solution of (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one (8.66 g, 79.4 mmol, 1.00 eq) and 4-methylmorpholine 4-oxide (10.23 g, 87.3 mmol, 1.1 eq) in 3-methylbutan-1-ol (40 mL) and H 2 O (40 mL) was added OsO 4 (0.12 g, 0.48 mmol, 0.006 eq) in t-BuOH (2.0 mL) dropwise at room temperature and the reaction mixture was stirred for 2 h at 70 °C. The resulting mixture was allowed to cool down to room temperature and was diluted with water (100 mL). The resulting mixture was extracted with AcOEt (3 x 100 mL). The combined organic layers were washed with brine and dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (90:10 DCM/MeOH) to afford (1R,4S,5R,6S)-5,6-dihydroxy-2-azabicyclo[2.2.1]heptan-3-one 1a (9.4 g, 83%) as a yellow solid. 1 H NMR (400 MHz, Deuterium Oxide) <54.03 (d, 7= 5.9 Hz, 1H), 3.99 (d, 7 = 5.9 Hz, 1H), 3.75 (p, 7 = 1.6 Hz, 1H), 2.60 (d, 7 = 1.9 Hz, 1H), 2.04 (d, 7 = 1.7 Hz, 2H).

Methyl (1S,2R,3S,4R)-4-amino-2,3-dihydroxycyclopentane-1-carboxylat e hydrochloride (2a).

A solution of (1R,4S,5R,6S)-5,6-dihydroxy-2-azabicyclo[2.2.1]heptan-3-one 1a (9.4 g, 65.7 mmol, 1.0 eq) in HCI(g) in MeOH (100 mL) was stirred for 16 h at room temperature. The resulting mixture was concentrated under reduced pressure and the resulting residue was treated with AcOEt (50 mL). The precipitated solid was collected by filtration and washed with AcOEt (3x50 mL). The resulting solid was dried with an infared lamp. This resulted in methyl (1S,2R,3S,4R)-4-amino-2,3-dihydroxycyclopentane-1-carboxylat e hydrochloride 2a (11.6 g, 83%) as a white solid. 1 H NMR (400 MHz, Deuterium Oxide) 54.27 (t, J = 5.3 Hz, 1H), 4.05 (ddd, J = 7.3, 5.8, 1.7 Hz, 1H), 3.72 (s, 3H), 3.61 - 3.50 (m, 1H), 2.98 (td, J= 9.0, 5.0 Hz, 1H), 2.50 (dt, J = 13.8, 8.6 Hz, 1H), 1.83 (dt, 7 = 13.7, 9.2 Hz, 1H).

(1R,2S,3R,5R)-3-Amino-5-(hydroxymethyl)cyclopentane-1,2-d iol (3a).

H 2 N

To a stirred solution of methyl (1S,2R,3S,4R)-4-amino-2,3-dihydroxycyclopentane-1-carboxylat e hydrochloride 2 (9.0 g, 42.5 mmol, 1.0 eq) in THE (90 mL) was added lithium triethylborohydride (213 mL, 213 mmol, 5.0 eq) dropwise at 0 °C under N 2 atmosphere and the reaction mixture was stirred for 3 h at 0 °C. The reaction was quenched by the addition of water (2 mL) at room temperature and HCI (4 M in MeOH) was added, dropwise, at room temperature. The precipitated solid was collected by filtration and washed with AcOEt (2x10 mL). The resulting solid was dried with an infrared lamp to afford (1R,2S,3R,5R)-3-amino-5- (hydroxymethyl)cyclopentane-1,2-diol hydrochloride 3a (8.50 g, crude) as a white solid.

(1R,2S,3R,5R)-3-(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-5-(hydroxymethyl)cyclopentane-1,2- diol (4a).

To a stirred solution of (1R,2S,3R,5R)-3-amino-5-(hydroxymethyl)cyclopentane-1,2-diol hydrochloride 3a (8.50 g, 46.3 mmol, 1.0 eq) and 2-(4,6-dichloropyrimidin-5-yl)acetaldehyde (9.73 g, 50.9 mmol, 1.1 eq) in EtOH (85 mL) were added TEA (14.1 g, 139 mmol, 3.0 eq) at room temperature under N 2 atmosphere. The resulting mixture was stirred for 3 h at 90 °C. The mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure to afford (1R,2S,3R,5R)-3-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl}-5- (hydroxymethyl)cyclopentane-1,2-diol) as a brown oil 4a (10 g, crude). LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-957oB-2min(+), 1.50 mL/min, ES, m/z]: T R = 1.05 min; [M + H] + : 284, 286

((3aR,4R,6R,6aS)-6-(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methanol To a stirred solution of (1R,2S,3R,5R)-3-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl}-5- (hydroxymethyl)cyclopentane-1,2-diol 4 (crude) and 2,2-dimethoxypropane (50 mL) in acetone (100 mL) were added TsOH (24 g) at room temperature. The reaction mixture was stirred for 2 h at room temperature, concentrated under reduced pressure and then suspended in water (200 mL). The resulting mixture was extracted with AcOEt (3 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered, and the filtrate was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (1:1 Petroleum ether/AcOEt) to afford ((3aR,4R,6R,6aS)-6-(4-chloro-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4-yl)methanol 5a (5.3 g, 18% for 3 steps) as a yellow semi-solid. 1 H NMR (400 MHz, DMSO-c/ 6 ) 5 8.65 (s, 1H), 7.96 (d, 7 = 3.7 Hz, 1H), 6.72 (d, 7 = 3.6 Hz, 1H), 5.10 (dt, 7 = 12.8, 6.3 Hz, 1H), 4.92 (t, 7 = 6.7 Hz, 1H), 4.56 (dd, 7 = 7.3, 4.0 Hz, 1H), 3.53 (d, 7 = 5.0 Hz, 2H), 2.26 (m, 2H), 2.18-2.04 (m, 1H), 1.49 (s, 3H), 1.23 (s, 3H). LCMS [conditions: Kinetex XB-C18, 50*3.0 mm, 2.6 pm, Mobile Phase A: Water/0.05%FA, Mobile Phase B: Acetonitrile/0.05%FA, 5%-100%B-2min(+), 1.50 mL/min, ES, m/z]: T R = 0.95 min; [M + H] + : 324, 326

((3aR,4R,6R,6aS)-6-(4-((4-Methoxybenzyl)(methyl)amino)-7H -pyrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methanol (Intermediate A).

To a stirred solution of ((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methanol 5a (1.50 g, 4.63 mmol, 1.0 eq) and [(4-methoxyphenyl)methyl](methyl)amine (1.05 g, 6.95 mmol, 1.5 eq) in EtOH (15 mL) was added TEA (0.94 g, 9.27 mmol, 2.0 eq) at room temperature and the reaction mixture was stirred for 16 h at 80 °C. The resulting mixture was allowed to cool down to room temperature and was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (AcOEt) to afford ((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4-yl)methanol Intermediate A (1.80 g, 89%) as an off-white solid. LCMS [conditions: Halo C18, 30*3.0 mm, 2.0 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-100%B-1.2min(+), 1.50 L/min, ES, m/z]: T R = 0.55 min; [M + H] + : 439. Chiral-HPLC [Column: YMC Cellulose-SB, 100*4.6mm, Sum, Solvent B: Ethanol, Mobile Phase A : n-Hexane(0.1%DEA). Oven Temperature: 25 °C, Total Flow: 3.00 mL/min]: T R = 2.01 min; dr = >99:1.

Synthesis of N-(((1R,2R,3S,4R)-2,3-dihydroxy-4-(4-(methylamino)-7H-pyrrol o[2,3-d]pyrimidin-7- yl)cyclopentyl)methyl)-N-methyl-3-(methylamino)propanamide (417).

((3aR,4R,6R,6aS)-6-(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methyl 4-methylbenzenesulfonate (6a) To a stirred solution of ((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methanol 5a (200 mg, 0.62 mmol, 1.0 eq) and TsCI (141 mg, 0.74 mmol, 1.2 eq) in DCM (2.0 mL) was added TEA (125 mg, 1.24 mmol, 2.0 eq) and DMAP (15.1 mg, 0.12 mmol, 0.2 eq) and the reaction mixture was stirred for 16 h at room temperature. The crude reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography (3:1 Petroleum ether/AcOEt) to afford ((3aR,4R,6R,6aS)-6- (4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetra hydro-4H-cyclopenta[d][1,3]dioxol- 4-yl)methyl-4-methylbenzenesulfonate 6a (200 mg, 68%) as a light yellow solid.

7-((3aS,4R,6R,6aR)-2,2-Dimethyl-6-((methylamino)methyl)te trahydro-4H- cyclopenta[d][1 / 3]dioxol-4-yl)-/V-methyl-7H-pyrrolo[2,3-d]pyrimidin-4- amine (7a).

A mixture of ((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl 4-methylbenzenesulfonate 6a (0.10 g, 0.21 mmol, 1.0 eq) and methylamine solution (30% in ethanol, 1.5 mL) was stirred overnight at room temperature. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by reverse flash chromatography [column, C18 silica gel; mobile phase: MeCN in water, 10% to 70% gradient in 13 min; detector, UV 254 nm] to afford 7-((3aS,4R,6R,6aR)-2,2-dimethyl-6-((methylamino)methyl)tetra hydro-4H-cyclopenta[d][1,3]dioxol- 4-yl)-A/-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 7a (25 mg, 36%) as a colorless oil. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-2min(+), 1.50 mL/min, ES, m/z]: T R = 1.08 min; [M + H] + : 332.

7e/t-Butyl-(3-((((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methy lamino)-7H-pyrrolo[2,3-d]pyrimidin-7- yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)(methy l)amino)-3- oxopropyl)(methyl)carbamate (8a).

To a solution of 3-[(te/'f-butoxycarbonyl)(methyl)amino]propanoic acid (15 mg, 0.07 mmol, 1.0 eq) and triethylamine (11 mg, 0.11 mmol, 1.5 eq) in DCM (1.5 mL) was added HATU (34 mg, 0.09 mmol, 1.2 eq) and the mixture was stirred for 10 min at room temperature, under nitrogen. After ths time, 7-((3aS,4R,6R,6aR)-2,2-dimethyl-6-((methylamino)methyl)tetra hydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-A/-methyl-7H-pyrrolo[2,3-d]py rimidin-4-amine 7a (25 mg, 0.075 mmol, 1.0 eq) was added and the reaction mixture was stirred for 2 h at room temperature. The resulting crude mixture was evaporated and purified by silica gel column chromatography (9:1 DCM/MeOH) to afford te/'Abutyl-(3-((((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methylam ino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydro-4H-cyclopenta[d][1,3 ]dioxol-4-yl)methyl)(methyl)amino)- 3-oxopropyl)(methyl)carbamate 8a (36 mg, 92%) as a colorless oil. LCMS [conditions: Xbridge Shield RP18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2min(+), 1.50 mL/min, ES, m/z]: T R = 1.11 min; [M + H] + : 517.

A/-(((1R,2R,3S,4R)-2,3-Dihydroxy-4-(4-(methylamino)-7H-py rrolo[2,3-d]pyrimidin-7- yl)cyclopentyl)methyl)-/V-methyl-3-(methylamino)propanamide (417). HO

To a stirred solution of te/'f-butyl-(3-((((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methyla mino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydro-4H-cyclopenta[d][1,3 ]dioxol-4-yl)methyl)(methyl)amino)- 3-oxopropyl)(methyl)carbamate 8a (36 mg, 0.07 mmol, 1.0 eq) in MeOH (1.0 mL) was added HCI (4M in MeOH, 1.0 mL) dropwise at 0 °C. The reaction mixture was stirred overnight at room temperature. The resulting mixture was neutralized to pH = 7-8 with ammonia water and was purified by Prep-HPLC [column, Xbridge Prep C18 OBD column, 5um, 19*150mm; mobile phase, water (0.03% NH 4 OH) and CH 3 CN (20% CH 3 CN up to 40% in 10 min); Detector, UV 220&254 nm] to afford A/-{[(1R,2R,3S,4R)-2,3-dihydroxy-4-[4-(methylamino)pyrrolo[2 ,3-d]pyrimidin-7- yl]cyclopentyl]methyl}-/V-methyl-3-(methylamino)propanamide 417 (11.3 mg, 42%) as a white solid. 1 H NMR (300 MHz, DMSO-t/ 6 ) 5 8.12 (s, 1H), 7.38 (d, 7 = 4.8 Hz, 1H), 7.25 (t, 7 = 3.7 Hz, 1H), 6.54 (d, 7 = 3.5 Hz, 1H), 4.91 - 4.74 (m, 1H), 4.30 - 4.18 (m, 1H), 3.82 - 3.69 (m, 1H), 3.65- 3.51 (m, 1H), 3.35-3.19 (m, 1H), 2.99 (s, 2H), 2.96 (d, 7 = 4.6 Hz, 3H), 2.83 (s, 1H), 2.79 (s, 1H), 2.66 (d, 7 = 7.4 Hz, 1H), 2.51-2.34 (m, 1H), 2.33 - 2.01 (m, 4H), 1.79-1.22 (m, 1H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-30%-95%B-5min, 1.50 mL/min, ES, m/z]: T R = 1.36 min; [M + H] + : 377.

Synthesis of N-(((1R,2R,3S,4R)-2,3-dihydroxy-4-(4-(methylamino)-7H-pyrrol o[2,3-d]pyrimidin-7- yl)cyclopentyl)methyl)piperidine-3-carboxamide (418)

((3aR,4R,6R,6aS)-2,2-Dimethyl-6-(4-(methylamino)-7H-pyrro lo[2,3-d]pyrimidin-7-yl)tetrahydro- 4H-cyclopenta[d][1,3]dioxol-4-yl)methanol (9a).

To ((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methanol 5a (0.55 g, 1.70 mmol, 1.0 eq) was added methylamine (30% in ethanol, 4.0 mL) and the reaction mixture was stirred overnight at room temperature. The resulting mixture was diluted with AcOEt (10 mL) and the resulting solid was filtered and the filter cake was washed with AcOEt. The resulting filtrate was concentrated under reduced pressure to afford ((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyrrolo[ 2,3-d]pyrimidin- 7-yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methanol 9a (0.50 g, 92%) as a light yellow solid. LCMS [conditions: Proshell HPH-C18, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2min, 1.20 mL/min, ES, m/z]: T R = 0.87 min;

[M + H] + : 319.

2-(((3aR / 4R,6R,6aS)-2,2-Dimethyl-6-(4-(methylamino)-7H-pyrrolo[ 2,3-d]pyrimidin-7- yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)isoind oline-1, 3-dione (10a).

To a stirred mixture of ((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyrrolo[ 2,3- d]pyrimidin-7-yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl )methanol 9a (0.50 g, 1.57 mmol, 1.0 eq) and phthalimide (0.46 g, 3.14 mmol, 2.0 eq) and triphenylphosphine (0.82 g, 3.14 mmol, 2.0 eq) in THF was added DIAD (0.64 g, 3.14 mmol, 2.0 eq) dropwise, at 0 °C, under nitrogen. The reaction mixture was stirred for 3 h at room temperature and the resulting mixture was concentrated under reduced pressure and was then purified by silica gel column chromatography (3:1 Petroleum ether/AcOEt) to afford 2-(((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4- (methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydro-4H- cyclopenta[d][1,3]dioxol-4- yl)methyl)isoindoline-1, 3-dione 10a (0.60 g, 85%) as a light yellow solid. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-2min(+), 1.50 mL/min, ES, m/z]: T R = 1.34 min; [M + H] + : 448.

7-((3aS,4R,6R,6aR)-6-(Aminomethyl)-2,2-dimethyltetrahydro -4H-cyclopenta[d][1,3]dioxol-4-yl)- A/-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (11a).

To a stirred solution of 2-(((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyrro lo[2,3- d]pyrimidin-7-yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl )methyl)isoindoline-1, 3-dione 10a (0.60 g, 1.34 mmol, 1.0 eq) in ethanol (10 mL) was added hydrazine hydrate (80% aq., 0.13 g, 2.68 mmol, 2.0 eq) and the reaction mixture was stirred at 80 °C for 3 h. The resulting mixture was allowed to cool to room temperature, filtered and the filter cake was washed with ethanol. The filtrate was concentrated under reduced pressure to afford 7-((3aS,4R,6R,6aR)-6-(aminomethyl)- 2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)-A/- methyl-7H-pyrrolo[2,3-d]pyrimidin- 4-amine 11a (0.40 g, 94%) as a colorless oil. LCMS [conditions: Xbridge Shield RP18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B- 2min(+), 1.50, mL/min, ES, m/z]: T R = 1.06 min; [M + H] + : 318. fe/t- Butyl 3-((((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyrr olo[2,3-d]pyrimidin-7- yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-42yl)methyl)carbam oyl)piperidine-1-carboxylate (12a).

To a stirred solution of racemic 1-(te/'Abutoxycarbonyl)piperidine-3-carboxylic acid (36.1 mg, 0.16 mmol, 1.0 eq) in DCM (1.0 mL) were added TEA (31.9 mg, 0.32 mmol, 2.0 eq) and HATU (71.9 mg, 0.19 mmol, 1.2 eq) at room temperature. To the above mixture was then added 7- ((3aS,4R,6R,6aR)-6-(aminomethyl)-2,2-dimethyltetrahydro-4H-c yclopenta[d][1,3]dioxol-4-yl)-/V- methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 11a (50 mg, 0.16 mmol, 1.00 eq) and the reaction mixture was stirred for 2 h at room temperature. The resulting mixture was purified by silica gel column chromatography (AcOEt) to afford te/f-butyl 3-((((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4- (methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydro-4H- cyclopenta[d][1,3]dioxol-4- yl)methyl)carbamoyl)piperidine-1-carboxylate 12a (50 mg, 60%) as an off-white solid. LCMS [conditions: Proshell HPH-C18, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2min(+-), 1.20 mL/min, ES, m/z]: T R =1.13 min; [M + H] + : 529.

/V-(((1R,2R,3S,4R)-2,3-dihydroxy-4-(4-(methylamino)-7H-py rrolo[2,3-d]pyrimidin-7- yl)cyclopentyl)methyl)piperidine-3-carboxamide (418). r'’N _-(R- A ) '' n n HO

To te/'f-butyl-3-((((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methylam ino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)carb amoyl)piperidine-1-carboxylate 12a (50 mg, 0.08 mmol, 1.0 eq) was added TFA (1.0 mL) and the reaction mixture was stirred for 16 h at room temperature. The resulting mixture was concentrated under reduced pressure and the crude product was purified by Prep-HPLC [Xbridge Prep C18 OBD column, 5um, 19*150mm; mobile phase, Water (0.03% NH 4 OH) and CH 3 CN (10% CH 3 CN up to 35% in 8 min); Detector, UV 220&254 nm] to afford /V-{[(1R,2R,3S,4R)-2,3-dihydroxy-4-[4-(methylamino)pyrrolo[2 ,3- d]pyrimidin-7-yl]cyclopentyl]methyl}piperidine-3-carboxamide 418 (25 mg, 83%) as a white solid. 1 H NMR (400 MHz, DMSO-ofe) 5 8.12 (s, 1H), 8.01 (q, 7 = 5.5 Hz, 1H), 7.38 (q, 7 = 4.8 Hz, 1H), 7.22 (d, 7 = 3.5 Hz, 1H), 6.54 (d, 7 = 3.4 Hz, 1H), 6.12 (s, 1H), 4.81 (q, 7= 8.9 Hz, 1H), 4.19 (t, 7 = 7.0 Hz, 1H), 4.09 - 3.61 (m, 3H), 3.27 (p, 7 = 6.3 Hz, 1H), 3.12 (dq, 7 = 17.3, 5.8 Hz, 1H), 2.96 (d, 7 = 4.3 Hz, 3H), 2.83-2.56 (m, 2H), 2.32-1.97 (m, 3H), 1.79 (dd, 7 = 13.0, 7.3 Hz, 1H), 1.66-1.42 (m, 3H), 1.32 (t, 7 = 12.2 Hz, 1H). LCMS [conditions: L-column3 C18, 50*3.0 mm, 3 urn, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-95%B-3min(+), 1.20 mL/min, ES, m/z]: T R = 0.85 min; [M + H] + : 389.

Synthesis of 7-((3aS,4R ; 6R,6aR)-2,2-dimethyl-6-((2-(phenethylamino)ethoxy)meth yl)tetrahydro- 4H-cyclopenta[d][1,3]dioxol-4-yl)-N-(4-methoxybenzyl)-N-meth yl-7H-pyrrolo[2,3-d]pyrimidin-4- amine (419)

Methyl 2-(((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H -pyrrolo[2,3-d]pyrimidin-

7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol- 4-yl)methoxy)acetate (13a)

To a stirred solution of ((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-py rrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methanol (Intermediate A , 500 mg, 1.14 mmol, 1.0 eq) in THF (5.0 mL) was added NaH (41 mg, 1.71 mmol, 1.5 eq) in small portions at 0 °C. To the reaction mixture was added methyl 2-bromoacetate (436 mg, 2.85 mmol, 2.5 eq) dropwise over 5 min at 0 °C and the resulting mixture was stirred for additional 12 h at room temperature and then quenched with water at 0 °C. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (3:1 Petroleum ether/AcOEt) to afford methyl 2-(((3aR,4R,6R,6aS)-6-(4- ((4-methoxybenzyl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methoxy)acetate 13a (200 mg, 27%) as a white solid. 1 H NMR (400 MHz, DMSO-t4) S 8.18 (s, 1H), 7.37 (d, 7 = 3.6 Hz, 1H), 7.19 (d, 7 = 8.3 Hz, 2H), 6.92-6.84 (m, 2H), 6.58 (t, 7 = 4.0 Hz, 1H), 5.04 (dt, 7 = 12.3, 6.6 Hz, 1H), 4.94 (s, 2H), 4.90 (t, 7 = 6.7 Hz, 1H), 4.56 (dd, 7 = 7.2, 4.7 Hz, 1H), 4.17 (s, 2H), 3.72 (s, 3H), 3.67 (s, 3H), 3.65-3.53 (m, 2H), 3.28 (s, 3H), 2.35 (p, 7 = 5.9 Hz, 1H), 2.24 (dt, 7 = 13.3, 6.7 Hz, 1H), 2.11-1.97 (m, 1H), 1.48 (s, 3H), 1.23 (s, 3H). LCMS [column : Xbridge C18, 50*3.0 mm, 3.5 urn, mobile phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-3min(+), 1.50 mL/min]: T R = 2.14 min; [M + H] + : 511.2.

2-(((3aR / 4R,6R,6aS)-6-(4-((4-Methoxybenzyl)(methyl)amino)-7H-py rrolo[2,3-d]pyrimidin-7-yl)- 2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)meth oxy)ethan-1-ol (14a)

To a stirred solution of methyl 2-(((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H - pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4- yl)methoxy)acetate 13a (200 mg, 0.39 mmol, 1.0 eq) in THE (5 mL) was added LiAIH 4 (29.7 mg, 0.78 mmol, 2.0 eq) in several portions at 0 °C and the reaction mixture was stirred at 0 °C for. The reaction was quenched by the addition of crystalline sodium sulfate (1.0 g) at 0 °C, the mixture was filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (AcOEt) to afford 2-(((3aR,4R,6R,6aS)-6-(4-((4- methoxybenzyl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methoxy)ethan-1-ol 14a (150 mg, 79%) as a white solid. LCMS [column: Xbridge Shield RP18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 10%-95%B-3min(+), 1.50 mL/min, ES, m/z]: T R = 1.59 min; [M + H] + : 483.3.

2-(((3aR / 4R,6R,6aS)-6-(4-((4-Methoxybenzyl)(methyl)amino)-7H-py rrolo[2,3-d]pyrimidin-7-yl)- 2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)meth oxy)ethyl methanesulfonate (15a)

To a stirred solution of 2-(((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H - pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4- yl)methoxy)ethan-1-ol 14a (150 mg, 0.31 mmol, 1.0 eq) and TEA (62.9 mg, 0.62 mmol, 2.0 eq) in DCM (5 mL) was added MsCI (39.2 mg, 0.34 mmol, 1.1 eq) dropwise at 0 °C and the reaction mixture was stirred at 0 °C for 2 h. The resulting mixture was concentrated under reduced pressure to afford 2-(((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H -pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methoxy)ethyl methanesulfonate 15a (300 mg, crude), which was used in the next step directly without further purification. LCMS [column: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH4HCO3, Mobile Phase B: Methanol, 10%-95%B-3min(+), 1.50 mL/min]: T R = 2.09 min; [M + H] + : 561.2.

7-((3aS,4R,6R,6aR)-2,2-Dimethyl-6-((2-(phenethylamino)eth oxy)methyl)tetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-/V-(4-methoxybenzyl)-/V-methy l-7H-pyrrolo[2 / 3-d] pyrimidin-4- amine (16a)

To a stirred solution of 2-(((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H - pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4- yl)methoxy)ethyl methanesulfonate 15a (70 mg, 0.13 mmol, 1.0 eq) and 2-phenylethylamine (22.7 mg, 0.19 mmol, 1.50 eq) in dioxane (3 mL) was added NaH (3.6 mg, 0.15 mmol, 1.1 eq) in several portions at 0 °C and the reaction mixture was stirred at 100 °C for 16 h. The resulting mixture was allowed to cool to room temperature and was quenched with water (0.5 mL). The crude residue was purified by reverse flash chromatography [C18 silica gel; mobile phase, ACN in water, 10% to 80% gradient in 15 min; detector, UV 220 nm]: to afford 7-((3aS,4R,6R,6aR)-2,2-dimethyl-6-((2- (phenethylamino)ethoxy)methyl)tetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)-/V-(4- methoxybenzyl)-A/-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 16a (65 mg, 89%) as a yellow solid. LCMS [column: Xbridge Shield RP18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 10%-95%B-3min(+), 1.50 mL/min, ES, m/z]: T R = 2.01 min; [M + H] + : 586.3.

(1R,2S,3R,5R)-3-[4-(Methylamino)pyrrolo[2,3-d]pyrimidin-7 -yl]-5-({2-[(2- phenylethyl)amino]ethoxy}methyl)cyclopentane-1,2-diol (419)

To 7-((3aS,4R,6R,6aR)-2,2-dimethyl-6-((2-(phenethylamino)ethoxy )methyl)tetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-A/-(4-methoxybenzyl)-A/-methy l-7H-pyrrolo[2,3-d]pyrimidin-4- amine 16a (65 mg, 0.11 mmol) was added TEA (2.0 mL) and the reaction mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under reduced pressure and was purified by reverse flash chromatography [C18 silica gel; mobile phase, ACN in water, 30% to 50% gradient in 10 min; detector, UV 254 nm, 220 nm]: to afford (1R,2S,3R,5R)-3-[4- (methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]-5-({2-[(2- phenylethyl)amino]ethoxy}methyl)cyclopentane-1,2-diol (419, 10 mg, 21%) as a white solid. 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.12 (s, 1H), 7.37 (q, 7= 4.8 Hz, 1H), 7.30-7.07 (m, 6H), 6.54 (d, 7 = 3.4 Hz, 1H), 4.87 (q, 7 = 8.9 Hz, 1H), 4.19 (dd, 7 = 8.4, 5.5 Hz, 1H), 3.80 (s, 1H), 3.49-3.29 (m, 5H), 3.21-3.10 (m, 1H), 2.96 (d, 7 = 4.5 Hz, 3H), 2.84-2.65 (m, 3H), 2.60 (t, 7 = 7.0 Hz, 1H), 2.25-2.06 (m, 2H), 1.78-1.60 (m, 2H), 1.59-1.46 (m, 1H). LCMS (column HPH-C18, 50*3.0 mm2.7um. mobile phase A: water/0.05% ammonia water, mobile phase B: Acetonitrile, 5%-95%B-3.0min(+).lcm, 1.50 mL/min, ES, m/z): T R = 1.36 min; [M + H] + : 426.2. Chiral-SFC [Column Name: SC 100x4.6mm 3.0um Co Solvent: B: MeOH (20mM NH3), Start Cone, of Pump B: 30.0%; Oven Temperature: 35 °C; Total Flow: 3.00 mL/min; BPR Pressure: 15.00 MPa; BPR Temperature: 50 °C]: T R = 1.98 min (4 min run), single peak.

Synthesis of (1R,2S,3R,5R)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-((3- (phenethylamino)propoxy)methyl)cyclopentane-1,2-diol (420)

3-(Phenethylamino)propan-1-ol (56a)

A mixture of 2-bromoethyl benzene (5.00 g, 27.0 mmol, 1.0 eq) and propanolamine (12.2 g, 162 mmol, 6.0 eq) in ethanol (30 mL) was heated at 80 °C for 3 h. The reaction mixture was then concentrated to remove ethanol and the resulting residue was diluted with DCM (100 mL). The organic layer was partitioned with water (100 mL) and the aqueous layer was extracted with DCM (120 mL). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered, and concentrated to afford 3-(phenethylamino)propan-1-ol 56 (4.50 g, 85%) as a light yellow oil. 1 H NMR (300 MHz, DMSO-ofe) 5 7.35-7.24 (m, 2H), 7.23-7.12 (m, 3H), 3.46 (t, 7 = 6.3 Hz, 2H), 2.70 (q, 7 = 5.0, Hz, 4H), 2.60 (t, 7 = 6.8 Hz, 2H), 1.55 (p, 7 = 6.6 Hz, 2H). fe/7-Butyl-(3-hydroxypropyl)(phenethyl)carbamate (57a)

To a stirred mixture of 3-(phenethylamino)propan-1-ol 56 (4.50 g, 25.1 mmol, 1.0 eq) and Et 3 N (5.10 g, 50.3 mmol, 2.0 eq) in DCM (80 mL) was added di- te/f-butyl dicarbonate (6.60 g, 30.2 mmol, 1.2 eq) in several portions, at 0 °C and the reaction mixture was stirred for 3 h at room temperature. The reaction was quenched with water (100 mL) at room temperature and the resulting mixture was extracted with CH 2 CI 2 (60 mL). The organic layer were dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (6:1 Petroleum ether/AcOEt) to afford te/'Abutyl-(3-hydroxypropyl)(phenethyl)carbamate 57a (5.00 g, 71%) as a colorless oil. 1 H NMR (300 MHz, DMSO-d6) 5 7.35-7.25 (m, 2H), 7.24-7.15 (m, 3H), 4.41 (t, 7 = 5.1 Hz, 1H), 3.44- 3.28 (m, 4H), 3.16 (t, 7 = 7.2 Hz, 2H), 2.76 (dd, 7 = 8.6, 6.4 Hz, 2H), 1.68-1.53 (m, 2H), 1.36 (s, 9H). fe/t-Butyl-(3-bromopropyl)(phenethyl)carbamate (58a)

To a stirred solution of te/'Abutyl-(3-hydroxypropyl)(phenethyl)carbamate 57 (1.00 g, 3.58 mmol, 1.0 eq) and triphenylphosphine (1.13 g, 4.30 mmol, 1.2 eq) in DCM was added NBS (0.76 g, 4.30 mmol, 1.2 eq) in several portions, at 0 °C, under nitrogen. The resulting mixture was stirred for 1.5 h at 0 °C before the reaction was quenched by the addition of water (20 mL) at room temperature. The resulting mixture was extracted with DCM (30 mL) and the organic layer was washed with brine (15 mL), dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (10:1 Petroleum ether/AcOEt) to afford terf-butyl (3- bromopropyl)(phenethyl)carbamate 58a (0.4 g, 33%) as a colorless oil. fe/7-Butyl-(3-(((3aR / 4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-py rrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)methoxy)propyl)(phenethyl)

To a stirred solution of ((3aR,4 nzyl)(methyl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methanol (Intermediate A, 50 mg, 0.11 mmol, 1.0 eq) in THE (1 mL) was added NaH (6.8 mg, 0.17 mmol, 1.5 eq) in several portions at 0 °C and the reaction mixture was stirred at 0 °C for 10 min. After this time terAbutyl-(3-bromopropyl)(phenethyl)carbamate 58a (97.5 mg, 0.29 mmol, 2.5 eq) was added and the resulting mixture was stirred for 16 h at room temperature. The reaction mixture was quenched with water (0.2 mL) and purified by silica gel column chromatography (1:1 Petroleum ether/AcOEt) to afford te/'Abutyl-(3-(((3aR,4R,6R,6aS)-6-(4-((4- methoxybenzyl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methoxy)propyl)(phenethyl)carb amate 59 (45 mg, 56%) as a light yellow solid. LCMS [conditions: Kinetex XB-C18, 50*3.0 mm, 2.6 pm, Mobile Phase A: Water/0.05% FA, Mobile Phase B: Acetonitrile/0.05%FA, 5%-100%B-2.0min(+-), 1.50 mL/min, ES, m/z]: T R = 1.44 min; [M + H]+: 600.

(1R,2S,3R,5R)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-((3-

(phenethylamino)propoxy)methyl)cyclopentane-1,2-diol (420)

H

To te/'Abutyl-(3-(((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(meth yl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)methoxy)propyl)(phenethyl)carbamate 59a (45 mg, 0.064 mmol, 1.0 eq) was added trifluoroacetaldehyde (1.0 mL) and the reaction mixture was stirred for 16 h at room temperature. The resulting mixture was concentrated under reduced pressure and the crude product was purified by Prep-HPLC [Column, XBridge Shield RP18 OBD Column, 19*150 mm, 5pm; mobile phase, Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H2O) and ACN (20% ACN up to 74% in 7 min); Detector, UV 220nm]: to afford (1R,2S,3R,5R)-3-(4-(methylamino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-5-((3-(phenethylamino)propoxy)methyl)cyclo pentane-1,2-diol 420 (20 mg, 70%) as an off-white solid. 1 H NMR (400 MHz, DMSO-d6) 5 8.11 (s, 1H), 7.49-7.06 (m, 6H), 6.53 (d, 7 = 3.5 Hz, 1H), 4.86 (q, 7 = 8.9 Hz, 1H), 4.16 (dd, 7 = 8.6, 5.2 Hz, 1H), 3.92-3.72 (m, 1H), 3.70-3.33 (m, 8H), 3.14 (s, 1H), 2.68 (s, 3H), 2.58 (t, 7 = 6.9 Hz, 1H), 2.29-2.03 (m, 2H), 1.66 (q, 7 = 6.8 Hz, 2H), 1.52 (q, 7 = 10.3 Hz, 1H). LCMS [conditions: Halo C18, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.05% FA, Mobile Phase B: Acetonitrile, 5%-30%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 1.14 min; [M + H] + : 440.

Synthesis of (1R,2S,3R / 5R)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-5-((3-((3- phenoxyphenethyl)a mino)propoxy)methyl)cyclopentane-1,2-diol (421)

1-(2-Methoxyvinyl)-3-phenoxybenzene (

To (methoxymethyl)triphenylphosphanium (93.0 g, 302 mmol, 4.0 eq) in dry THE (300 mL), at 0 °C, under nitrogen, was added t-BuOK (34 g, 302 mmol, 4.0 equiv) and the reaction mixture was stirred for 45 minutes at 0 °C. After this time, 3-phenoxybenzaldehyde (15 g, 75.7 mmol, 1.0 eq) was added dropwise, at 0 °C, and the resulting mixture was stirred at room temperature for 3 h. The reaction was quenched with saturated NH 4 CI and extracted with EtOAc (300mL). The organic phase was dried with Na 2 SO 4 , filtered, and concentrated. The crude residue was purified by silica gel column chromatography (Petroleum ether/AcOEt=30/1) to give 1-(2-methoxyvinyl)- 3-phenoxybenzene 44a (12 g, 70%) as a colorless oil. LCMS [column: Kinetex XB-C18, 50*3.0 mm, 2.6 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-100%B-2 min(+), 1.50 mL/min, ES, m/z]: T R = 1.29 min; [M + H] + : 227.

2-(3-Phenoxyphenyl)acetaldehyde (45a).

To a solution of 1-(2-methoxyvinyl)-3-phenoxybenzene 44a (8.0 g, 35.4 mmol, 1.0 eq) in THF (270 mL) was added HCI (5 M, 110 mL), and the reaction mixture was stirred at 70 °C for 30 min. The resulting mixture was diluted with EtOAc (300 mL) and washed with H 2 O (100 mL x2). The organic phase was dried over Na 2 SO 4 and concentrated to afford 2-(3-phenoxyphenyl)acetaldehyde 45a (6.10 g, 81%) as a light yellow oil. 1 H NMR (400 MHz, Chloroform-d) 5 9.76 (t, 7 = 2.3 Hz, 1H), 7.38-7.34 (m, 3H), 7.15 (t, 7 = 7.4 Hz, 1H), 7.08-7.03 (m, 2H), 6.99-6.95 (m, 2H), 6.90 (d, 7 = 2.1 Hz, 1H), 3.68 (d, 7 = 2.3 Hz, 2H).

3-((3-Phenoxyphenethyl)amino)propan-1-ol (46a).

To a solution 2-(3-phenoxyphenyl)acetaldehyde 45a (4.00 g, 18.8 mmol, 1.0 eq) in DCM (40 mL) was added propanolamine (1.70 g, 22.6 mmol, 1.2 eq), at room temperature, and the reaction mixture was stirred at room temperature, under nitrogen, overnight. The resulting mixture was concentrated under reduced pressure, the crude residue was dissolved in MeOH (100 mL) and then Pd/C (0.20 g, 10%) was added, under nitrogen. The resulting mixture was hydrogenated at room temperature for 3.0 h under a hydrogen balloon, filtered through a Celite pad and concentrated under reduced pressure to afford 3-((3- phenoxyphenethyl)amino)propan-1-ol 46a (4.60 g, 90%) as a light yellow oil, which was used in the next step without further purification. LCMS [Kinetex XB-C18, 3.0*30mm, 1.7um, Mobile Phase A: Water/0.1%FA, Mobile Phase B: Acetonitrile/0.05%FA, 5%-100%B-1.2 min(+), 1.20 mL/min, ES, m/z]: T R = 0.53 min; [M + H] + : 271.

7e/t-Butyl-(3-hydroxypropyl)

To a stirred solution of 3-((3-phenoxyphenethyl)amino)propan-1-ol 46a (4.60 g, 17.0 mmol, 1.0 eq) and TEA (5.15 g, 50.9 mmol, 3.0 eq) in DCM (100 mL) was added Boc 2 O (4.44 g, 20.3 mmol, 1.2 eq) in several portions, at room temperature, under nitrogen and the reaction mixture was stirred overnight. The resulting mixture was diluted with water (50 mL) and extracted with DCM (200 mL). The organic phase was washed with brine (50 mL), dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (Petroleum ethenAcOEt, 3:1) to afford terAbutyl-(3- hydroxypropyl)(3-phenoxyphenethyl)carbamate 47a (3.20 g, 51%) as a colorless oil. 1 H NMR (400 MHz, Chloroform-d) 5 7.36 (t, 7 = 7.8 Hz, 2H), 7.26 (d, 7 = 7.8 Hz, 1H), 7.13 (t, 7 = 7.4 Hz, 1H), 7.03 (d, 7 = 8.0 Hz, 2H), 6.95-6.82 (m, 3H), 3.55 (s, 2H), 3.37 (d, 7 = 7.2 Hz, 4H), 2.82 (t, 7 = 7.5 Hz, 2H), 1.65 (s, 2H), 1.46 (s, 9H). LCMS [Column: Proshell HPH-C18, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2.0 min(+), 1.20 mL/min, ES, m/z]: T R = 1.39 min; [M + H] + : 371.

7e/t-Butyl-(3-bromopropyl)(3-phenoxyphenethyl)carbamate (48a). To a stirred mixture of te/'Abutyl-(3-hydroxypropyl)(3-phenoxyphenethyl)carbamate 47a (250 mg, 0.67 mmol, 1.0 eq) and CBr 4 (267.8 mg, 0.81 mmol, 1.2 eq) in DCM (5.0 mL) was added PPh 3 (211 mg, 0.81 mmol, 1.2 eq) at room temperature under nitrogen and the reaction mixture was stirred for 3 h at room temperature. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (5:1 Petroleum ether/AcOEt) to afford te/'Abutyl-(3-bromopropyl)(3-phenoxyphenethyl)carbamate 48a (250 mg, 86%) as a light yellow oil. LCMS [Kinetex XB-C18, 3.0*30mm, 1.7um, Mobile Phase A: Water/0.1%FA, Mobile Phase B: Acetonitrile/0.05%FA, 5%-100%B-1.2 min(+), 1.20 mL/min, ES, m/z]: T R = 0.90 min; [M + H] + : 434.

7e/7-Butyl-(3-(((3aR / 4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-py rrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol- 4yl)methoxy)propyl)(3phenoxyphenethyl)carbamate (49a).

To a solution of ((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-py rrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methanol (Intermediate A, 151 mg, 0.35 mmol, 1.0 eq) in DMF (2.0 mL) was added NaH (60% in mineral oil, 16.6 mg, 0.41 mmol, 1.2 eq) at 0 °C. The resulting mixture was stirred for 30 min at 0 °C, before adding te/f-butyl (3-bromopropyl)(3-phenoxyphenethyl)carbamate 48a (150 mg, 0.35 mmol, 1.0 eq) in DMF (1.0 mL) and the reaction mixture was stirred for 16 h at room temperature. The reaction was quenched with water (10 mL) at 0 °C and extracted with DCM (75 mL). The organic layer was washed with brine (20 mL) and dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (5:1 Petroleum ether/AcOEt) to afford te/7-butyl (3-(((3aR,4R,6R,6aS)-6-(4-((4- methoxybenzyl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methoxy)propyl)(3-phenoxyphene thyl)carbamate 49a (60 mg, 23%) as a light yellow solid. 1 H NMR (400 MHz, Chloroform-d) 5 8.43 (s, 1H), 7.54 (s, 1H), 7.34 (t, J = 7.8 Hz, 2H), 7.20 (d, 7 = 8.1 Hz, 3H), 7.11 (s, 1H), 7.00 (d, 7 = 7.7 Hz, 3H), 6.88-6.83 (m, 4H), 6.49 (d, 7 = 3.2 Hz, 1H), 5.15-5.09 (m, 1H), 5.03-4.98 (m, 2H), 4.92-4.87 (m, 1H), 4.64-4.59 (m, 1H), 3.81 (s, 3H), 3.57-3.53 (m, 2H), 3.49-3.46 (m, 2H), 3.40-3.34 (m, 4H), 2.85-2.76 (m, 2H), 2.50-2.41 (m, 2H), 2.25-2.19 (d, 7 = 12.1 Hz, 1H), 1.85-1.74 (m, 2H), 1.59 (s, 3H), 1.56 (s, 3H),1.44 (s, 9H), 1.28 (s, 3H), 1.02-0.86 (m, 3H). LCMS [Halo C18, 30*3.0 mm, 2.0 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-100%B-1.2 min(+), 1.20 mL/min, ES, m/z]: T R = 0.82 min; [M + H] + : 792.

(1R,2S,3R,5R)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-((3-((3- phenoxyphenethyl)amino)propoxy)methyl)cyclopentane-1,2-diol (421).

To te/'f-butyl-(3-(((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(met hyl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methoxy)propyl)(3- phenoxyphenethyl)carbamate 49a (60 mg, 0.076 mmol, 1.0 eq) was added TEA (6.0 mL) and the reactin mixture was stirred at room temperature, under nitrogen, overnight. The resulting mixture was concentrated under reduced pressure and the crude residue was dissolved in MeOH (5 mL) and purified by prep-HPLC [Column: Sunfire C18 OBD; Mobile phase: A: water (0.01% NH 3 .H 2 O); B: ACN; Gradient: 32-53%B in 5 min; detector: 220 nm; flow rate: 20 ml/min]: to afford (1R,2S,3R,5R)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-((3-((3- phenoxyphenethyl)amino)propoxy)methyl)cyclopentane-1,2-diol 421 (16.2 mg, 38%) as a pale yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) 5 8.11 (s, 1H), 7.38 (t, 7 = 7.9 Hz, 3H), 7.27 (t, 7 = 7.9 Hz, 1H), 7.20 (d, 7 = 3.4 Hz, 1H), 7.12 (t, 7 = 7.4 Hz, 1H), 6.98 (t, 7 = 8.4 Hz, 3H), 6.86 (s, 1H), 6.80 (d, 7 = 8.2 Hz, 1H), 6.53 (d, 7 = 3.2 Hz, 1H), 5.33 (t, 7 = 4.9 Hz, 1H), 4.86 (q, 7 = 8.9 Hz, 1H), 4.78 (d, 7 = 6.5 Hz, 1H), 4.64 (s, 1H), 4.23-4.13 (m, 1H), 3.81-3.77 (m, 1H), 3.48-3.35 (m, 4H), 2.98-2.93 (m, 2H), 2.73-2.65 (m, 2H), 2.60-2.56 (m, 1H), 2.24-2.08 (m, 1H), 2.04-1.98 (m, 1H), 1.67-1.60 (m, 2H), 1.58- 1.42 (m, 2H), 1.34-1.27 (m, 2H), 0.90-0.83 (m, 1H). LCMS [Halo C18, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-50%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 1.19 min; [M + H] + : 532.

Synthesis of (1R,2S,3R,5R)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-((E)-4- (phenethylamino)but-1-en-1-yl)cyclopentane-1,2-diol (422)

(3-((fe/7-Butoxycarbonyl)(phenethyl)amino)propyl)tripheny lphosphonium bromide (60a)

A solution of (3-bromopropyl)triphenylphosphanium bromide (1.00 g, 2.15 mmol, 1.0 eq) and 2- phenylethylamine (0.78 g, 6.46 mmol, 3.0 eq) in EtOH (10 mL) was stirred for 3 h at 78 °C. The reslting mixture was allowed to cool down to room temperature, TEA (1.09 g, 10.8 mmol, 5.0 eq) and (Boc) 2 O (2.82 g, 12.9 mmol, 6.0 eq) was added, the reaction mixture was stirred for 1 h at room temperature and then concentrated under reduced pressure. The resulting mixture was partitioned between DCM and brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (90:10 DCM/MeOH) to afford (3-((te/f- butoxycarbonyl)(phenethyl)amino)propyl)triphenylphosphonium bromide 60a (0.58 g, 45%) as a white solid. 1 H NMR (400 MHz, Chloroform-d) 5 7.94-7.74 (m, 9H), 7.73-7.57 (m, 6H), 7.27-7.16 (m, 4H), 7.15-7.06 (m, 1H), 4.10-3.77 (m, 2H), 3.54 (t, 7 = 5.6 Hz, 4H), 2.84 (q, 7 = 6.5 Hz, 2H), 2.02- 1.63 (m, 2H), 1.31 (s, 9H). fe/t-Butyl-((£)-4-((3aR,4R ; 6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-pyrro lo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)but-3-en-1- yl)(phenethyl)carbamate (61a)

To a stirred solution of (3-((tert-butoxycarbonyl)(phenethyl)amino)propyl)triphenylph osphonium bromide 60 (554 mg, 0.92 mmol, 2.0 eq) in THF (5.0 mL) was added n-BuLi in hexanes (0.37 mL, 0.92 mmol, 2.0 eq) dropwise at -78 oC under N2. The resulting mixture was stirred for 30 min at - 78 oC under N2 and then (3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxole-4- carbaldehyde 19a (200 mg, 0.46 mmol, 1.0 eq) in THF (2.0 mL) was added, dropwise, at -78 oC. The reaction mixture was allowed to warm to room temperature and stirred for an additional 1 h. The resulting mixture was quenched by the addition of water (0.5 mL) at room temperature and then concentrated under reduced pressure. The crude residue (500 mg) was purified by silica gel column chromatography (1:1 Petroleum ether/ AcOEt) to afford tert-butyl-((E)-4-((3aR,4R,6R,6aS)- 6-(4-((4-methoxybenzyl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrim idin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)but-3-en -1-yl)(phenethyl)carbamate 61a (180 mg, 58%) as a yellow semi-solid. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH4HCO3, Mobile Phase B: Methanol, 10%-95%B-2min, 1.00 mL/min, ES, m/z]: TR = 1.70 min; [M + H]+: 682

(1R,2S,3R,5R)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-((£)-4- (phenethylamino)but-1-en-1-yl)cyclopentane-1,2-diol (422)

HO

To te/f-butyl-((£)-4-((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)( methyl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)but-3-en-1- yl)(phenethyl)carbamate 61a (50 mg, 0.07 mmol, 1.0 eq) was added TFA (1.5 mL) and the reaction mixture was stirred for 16 h at room temperature. The resulting mixture was concentrated under reduced pressure and the crude product was purified by Prep-HPLC [Column, XBridge Shield RP18 OBD Column, 19*150 mm, 5pm; mobile phase, Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H2O) and ACN (21% ACN up to 39% in 7 min); Detector, UV 220 nm]: to afford (1R,2S,3R,5R)-3-(4- (methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((£)-4-(ph enethylamino)but-1-en-1- yl)cyclopentane-1,2-diol 293 (13 mg, 42%) as a white solid. 1 H NMR (400 MHz, DMSO-c/ 6 ) 5 8.13 (s, 1H), 7.38 (d, 7 = 5.0 Hz, 1H), 7.30-7.10 (m, 5H), 6.54 (d, 7= 3.4 Hz, 1H), 5.65-5.31 (m, 2H), 4.83 (d, 7 = 10.7 Hz, 2H), 4.17 (s, 1H), 3.77 (t, 7 = 5.7 Hz, 1H), 2.96 (d, 7 = 4.6 Hz, 3H), 2.89-2.82 (m, 1H), 2.79-2.65 (m, 4H), 2.61-2.53 (m, 1H), 2.25-2.13 (m, 3H), 1.65-1.50 (m, 1H). LCMS [conditions: Halo C18, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%- 95%B-3min, 1.50 mL/min, ES, m/z]: T R = 0.77 min; [M + H] + : 422

Synthesis of (1R,2S,3R / 5S)-3-(4-(methy/amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-5-(4- (phenethylamino)butyl)cyclopentane- 1,2-dio! (423) feW-Butyl-(4-((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl )amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)butyl)(phenethyl)carbamate

To a solution of teT7-butyl-((£)-4-((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)( methyl)amino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4-yl)but-3-en- 1-yl)(phenethyl)carbamate 61a (55 mg, 0.08 mmol, 1.0 eq) in 10 mL MeOH was added Pd/C (10%, 20 mg) under nitrogen and the reaction mixture was hydrogenated at room temperature for 30 min under a hydrogen balloon. The resulting mixture was filtered through a Celite pad and concentrated under reduced pressure to afford te/7-butyl-(4-((3aR,4S,6R,6aS)-6-(4-((4- methoxybenzyl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)butyl)(phenethyl)carbamate 62a (40 mg, 72%) as a yellow semisolid. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2min, 1.20 mL/min, ES, m/z]: T R = 1.61 min; [M + H] + : 684

(1R,2S,3R,5S)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-(4- (phenethylamino)butyl)cyclopentane-1,2-diol (423)

HO

To te/'Abutyl-(4-((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(methy l)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)butyl)(phenethyl)carbamate 62a (40 mg, 0.058 mmol, 1.0 eq) was added TEA (1.0 mL) and the reaction mixture was stirred for 16 h at room temperature. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by Prep-HPLC [Column, XBridge Shield RP18 OBD Column, 19*150 mm, 5pm; mobile phase, ACN and Water (10 mmol/L NH4HCO3+0.1%NH3.H2O) (16% up to 40% in 7 min); Detector, UV 220 nm]: to afford (1R,2S,3R,5S)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(4-

(phenethylamino)butyl)cyclopentane-1,2-diol 294 (7.0 mg, 22 %) as a white solid. 1 H NMR (400 MHz, DMSO-aL) 5 8.12 (s, 1H), 7.36 (s, 1H), 7.32-7.10 (m, 6H), 6.53 (d, 7 = 3.4 Hz, 1H), 4.95-4.68 (m, 2H), 4.56 (s, 1H), 4.17 (s, 1H), 3.66 (d, 7 = 5.4 Hz, 1H), 2.95 (d, 7 = 4.6 Hz, 4H), 2.80-2.64 (m, 4H), 2.24-2.11 (m, 2H), 1.90-1.79 (m, 1H), 1.47-1.25 (m, 8H). LCMS [conditions: Halo C18, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 0.76 min; [M + H] + : 424

Synthesis of (1R,2S,3R,5S)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(5- (phenethylamino)pentyl)cyclopentane-1,2-diol (424)

(4-((fe/7-Butoxycarbonyl)(phenethyl)amino)butyl)triphenyl phosphonium bromide (63a)

A solution of (4-bromobutyl)triphenylphosphanium bromide (2 q, 4.18 mmol, 1.0 eq) and 2- phenylethylamine (2.03 q, 16.7 mmol, 4.0 eq) in EtOH (20 mL) was stirred for 3 h at 78 °C under N 2 . The resultinq mixture was allowed to cool down to room temperature and TEA (2.54 q, 25.1 mmol, 6.0 eq) and (Boc) 2 O (4.56 q, 20.9 mmol, 5.0 eq) were added and the reaction mixture was stirred for 1 h at room temperature. The resultinq mixture was concentrated under reduced pressure and the resultinq residue was partitioned between water and DCM. The orqanic layer were washed with brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (90:10 DCM/MeOH) to afford (4-((te/f- butoxycarbonyl)(phenethyl)amino)butyl)triphenylphosphonium bromide 63a (1.3 g, 50%) as a white solid. 1 H NMR (400 MHz, Chloroform-o) 5 7.99-7.83 (m, 6H), 7.78 (dt, 7= 7.5, 3.5 Hz, 3H), 7.69 (td, 7 = 7.7, 3.5 Hz, 6H), 7.25 (d, 7 = 7.2 Hz, 2H), 7.21-7.15 (m, 3H), 4.00 (d, 7 = 15.6 Hz, 2H), 3.36 (s, 2H), 3.27-3.16 (m, 2H), 2.78 (t, 7 = 7.5 Hz, 2H), 1.97 (s, 2H), 1.63 (q, 7 = 7.8 Hz, 2H), 1.35 (s, 9H). fe/t-Butyl-((£)-5-((3aR,4R ; 6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-pyrro lo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)pent-4-en-1- yl)(phenethyl)carbamate (64a)

To a stirred solution of (4-((te/f-butoxycarbonyl)(phenethyl)amino)butyl)triphenylpho sphonium bromide 63a (1.08 q, 1.74 mmol, 2.0 eq) in THF (7 mL) were added n-BuLi in hexanes (0.70 mL, 1.74 mmol, 2.0 eq), dropwise, at -78 °C, under N 2 . The resulting mixture was stirred for 20 min at -78 °C. To this mixture was added (3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxole-4- carbaldehyde 19a (380 mg, 0.87 mmol, 1.0 eq) in THF (3 mL), dropwise, at -78 °C and the reaction mixture was warmed to room temperature stirred for 1 h. The resulting mixture was quenched by the addition of water (0.5 mL) at room temperature and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 Petroleum ether/AcOEt) to afford te/'Abutyl-((£)-5-((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)( methyl)amino)- 7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-c yclopenta[d][1,3]dioxol-4-yl)pent- 4-en-1-yl)(phenethyl)carbamate 64a (190 mg, 30%) as a yellow semi-solid. LCMS [conditions: Kinetex XB-C18, 3.0*30mm, 1.7um, Mobile Phase A: Water/0.1%FA, Mobile Phase B: Acetonitrile/0.05% FA, 5%-95%B-1.2min, 1.50 mL/min, ES, m/z]: T R = 0.86 min; [M + H] + : 696 fe/'AButyl-(5-((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(methy l)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)pentyl)(phenethyl)carbamate

To a solution of te/'Abutyl-((£)-5-((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)( methyl)amino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4-yl) pent-4- en-1-yl)(phenethyl)carbamate 64a (60 mg, 0.086 mmol, 1.0 eq) in 10 mL MeOH was added Pd/C (10%, 20 mq) under nitroqen. The reaction mixture was hydroqenated at room temperature for 30 min under a hydroqen balloon. The resulting mixture was filtered through a Celite pad and concentrated under reduced pressure to afford te/'Abutyl-(5-((3aR,4S,6R,6aS)-6-(4-((4- methoxybenzyl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)pentyl)(phenethyl)carbamate 65a (55 mg, 91%) as a light yellow semi-solid. LCMS [conditions: Kinetex XB-C18, 3.0*30mm, 1.7um, Mobile Phase A: Water/0.1%FA, Mobile Phase B: Acetonitrile/0.05%FA, 5%-95%B-2min, 1.50 mL/min, ES, m/z]: T R = 1.41 min; [M + H] + : 698

(1R ; 2S,3R,5S)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimidi n-7-yl)-5-(5- (phenethylamino)pentyl)cyclopentane-1,2-diol (424)

To te/'f-butyl-(5-((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(meth yl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)pentyl)(phenethyl)carbamate 65a (50 mg, 0.07 mmol, 1.0 eq) was added TFA (1.5 mL) and the reaction mixture was stirred for 16 h at room temperature. The resulting mixture was concentrated under reduced pressure and the crude product was purified by Prep-HPLC [Column, XBridqe Shield RP18 OBD Column, 19*150 mm, 5pm; mobile phase, ACN and Water (10 mmol/L NH4HCO 3 +0.1%NH3.H2O) (16% up to 40% in 7 min); Detector, UV 220 nm]: to afford (1R,2S,3R,5S)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(5- (phenethylamino)pentyl)cyclopentane-1,2-diol 424 (17 mg, 53%) as a white solid. 1 H NMR (400 MHz, DMSO-af) 5 8.12 (s, 1H), 7.36 (d, 7 = 5.0 Hz, 1H), 7.31-7.13 (m, 6H), 6.52 (d, 7= 3.5 Hz, 1H), 4.91-4.71 (m, 2H), 4.56 (s, 1H), 4.27-4.11 (m, 1H), 3.88-3.62 (m, 1H), 2.95 (d, 7 = 4.5 Hz, 3H), 2.76- 2.66 (m, 4H), 2.23-2.09 (m, 1H), 1.83 (s, 1H), 1.56 (s, 1H), 1.50-1.19 (m, 8H). LCMS [(conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min, ES, m/z)]: T R = 1.23 min; [M + H] + : 438. Chiral-HPLC [Column: CHIRALPAK IA-3, 50*4.6mm, Sum IA30CC-UL005, Mobile Phase A: n-Hexane (0.1%DEA), Mobile Phase B: Ethanol; Total Flow: 1.00 mL/min; Cone, of Pump B: 30.0% Oven Temperature: 25 °C]: Two peaks, T R = 3.20 min (major peak), 6.66 min (minor peak); dr = 95.3:4.7.

Synthesis of (1R,2S,3R,5R)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-((E)-5- (phenethylamino)pent-1-en-1-yl)cyclopentane-1,2-diol (425)

(1R,2S,3R,5R)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-((£)-5- (phenethylamino)pent-1-en-1-yl)cyclopentane-1,2-diol (425)

A solution of te/'Abutyl-((£)-5-((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)( methyl)amino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4-yl) pent-4- en-1-yl)(phenethyl)carbamate 64a (20 mg, 0.03 mmol, 1.0 equiv) in TFA (1.0 mL) was stirred for 2 h at rt. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by reverse phase flash chromatography [column, C18 silica gel; mobile phase, ACN in water, 25% to 40% gradient in 10 min; detector, UV 220 nm] to afford (1R,2S,3R,5R)-3-(4- (methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((£)-5-(ph enethylamino)pent-1-en-1- yl)cyclopentane-1,2-diol 425 (4.2 mg, 36%) as a white solid. 1 H NMR (400 MHz, DMSO-c/ 6 ) 5 8.13 (s, 1H), 7.38 (d, 7 = 4.9 Hz, 1H), 7.30-7.13 (m, 6H), 6.53 (d, 7 = 3.5 Hz, 1H), 5.51-5.31 (m, 2H), 4.89- 4.80 (m, 2H), 4.76 (br s, 1H), 4.19 (q, 7 = 6.3 Hz, 1H), 3.76 (t, 7 = 5.7 Hz, 1H), 2.96 (d, 7 = 4.5 Hz, 3H), 2.90-2.78 (m, 1H), 2.74-2.65 (m, 4H), 2.19 (dt, 7 = 12.7, 8.2 Hz, 1H), 2.09 (q, 7 = 7.6 Hz, 2H), 1.57 (dt, 7 = 12.7, 9.9 Hz, 1H), 1.49-1.38 (m, 2H). LCMS [(conditions: HPH-C18, 50*3.0 mm, 2.7 urn, Mobile Phase A: Water/0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-95%B-5min, 1.20 mL/min, ES, m/z)]: T R = 2.18 min; [M + H] + : 436. Chiral-SFC [Column: Solvent B: SC 100x4.6mm 3.0um: MeOH (0.2%MIPA), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min, keep the Cone, of Pump B: 50.0% in 5 mins, BPR Pressure: 15.00 MP]: Two diastereomers, T R = 3.11 min (major peak), T R = 3.27 min (minor isomer); dr = 98:2.

Synthesis of (1R ; 2S,3R,5R)-3-[4-(methylamino)pyrrolo[2,3-d]pyrimidin-7- yl]-5-{3-[(2- phenylethyl)amino]prop-1-yn-1-yl}cyclopentane-1,2-diol (426)

7-((3aS,4R,6R,6aR)-6-Ethynyl-2,2-dimethyltetrahydro-4H-cy clopenta[d][1,3]dioxol-4-yl)-/V-(4- methoxybenzyl)-/V-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (42a)

To a stirred solution of (3aR,4S,6R,6aS)-6-(4-{[(4- methoxyphenyl)methyl](methyl)amino}pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxole-4-carbaldehyde 13a (1.00 g, 2.29 mmol, 1.0 eq) and K 2 CO 3 (0.63 g, 4.58 mmol, 2.0 eq) in THF (10 mL) and MeOH (10 mL) was added dimethyl (1-diazo-2- oxopropyl)phosphonate (0.88 g, 4.58 mmol, 2.0 eq) dropwise at 10 °C and the reaction mixture was stirred at 10 °C for 1 h. The resulting mixture was concentrated under vacuum and the crude residue was purified by silica gel column chromatography (1/1 Petroleum ether/ AcOEt) to afford 7-((3aS,4R,6R,6aR)-6-ethynyl-2,2-dimethyltetrahydro-4H-cyclo penta[d][1,3]dioxol-4-yl)-A/-(4- methoxybenzyl)-/V-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 42a (220 mg, 22%) as a colourless oil. 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.19 (s, 1H), 7.42 (d, 7 = 3.6 Hz, 1H), 7.19 (d, 7 = 8.3 Hz, 2H), 6.93-6.85 (m, 2H), 6.58 (d, 7 = 3.6 Hz, 1H), 5.05 (td, 7 = 6.8, 3.5 Hz, 1H), 4.94 (s, 2H), 4.88 (dd, 7 = 7.2, 4.9 Hz, 1H), 4.75 (t, 7 = 6.8 Hz, 1H), 3.72 (s, 3H), 3.28 (s, 3H), 3.14 (d, 7 = 2.4 Hz, 1H), 2.95-2.85 (m, 1H), 2.48-2.29 (m, 2H), 1.48 (s, 3H), 1.23 (s, 3H).

7-((3aS,4R,6R,6aR)-2,2-Dimethyl-6-(3-(phenethylamino)prop -1-yn-1-yl)tetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-/V-(4-methoxybenzyl)-/V-methy l-7H-pyrrolo[2,3-d]pyrimidin-4- amine (43a)

To a stirred solution of 7-((3aS,4R,6R,6aR)-6-ethynyl-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-A/-(4-methoxybenzyl)-A/-methy l-7H-pyrrolo[2, 3-d] pyrimidin-4- amine 42a (100 mg, 0.23 mmol, 1.0 eq), 2-phenylethylamine (42 mg, 0.35 mmol, 1.5 eq) and CH 2 O (15.3 mg, 0.46 mmol, 2.0 eq) in DMSO (5.0 mL) was added Cui (22.0 mg, 0.12 mmol, 0.5 eq) under N 2 and the reaction mixture was stirred at room temperature for 2 h. The resulting mixture was purified directly by reverse flash chromatography [column, C18 silica gel; mobile phase, ACN in water, 10% to 80% gradient in 15 min; detector, UV 220 nm]: to afford 7-((3aS,4R,6R,6aR)-2,2- dimethyl-6-(3-(phenethylamino)prop-1-yn-1-yl)tetrahydro-4H-c yclopenta[d][1,3]dioxol-4-yl)-/V- (4-methoxybenzyl)-A/-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ami ne 43a (55 mg, 42%) as a yellow oil. LCMS: [column: Xbridge shield RP18, 50*3.0 mm, 3.5um; mobile phase A: water/0.05% ammonia, mobile phase B: ACN, 5%-95%-3 min, ES, m/z]: T R = 2.00 min; [M + H] + : 566.3.

7-[(3aS,4R,6R,6aR)-2,2-Dimethyl-6-{3-[(2-phenylethyl)amin o]prop-1-yn-1-yl}-tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]-A/-[(4-methoxyphenyl)methyl]- /V-methylpyrrolo[2,3-d]pyrimidin-4- amine (426)

To 7-((3aS,4R,6R,6aR)-2,2-dimethyl-6-(3-(phenethylamino)prop-1- yn-1-yl)tetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-A/-(4-methoxybenzyl)-A/-methy l-7H-pyrrolo[2,3-d]pyrimidin-4- amine 43a (55 mg, 0.097 mmol) was added TFA (2.0 mL) and the reaction mixture was stirred for 12 h at room temperature. The resulting mixture was concentrated under vacuum and the crude residue was purified by Prep-HPLC [Xbridge Prep C18 OBD column, 5um, 19*150mm; mobile phase, Water (0.03% NH 4 OH) and CH 3 CN (25% CH 3 CN up to 45% in 12 min); Detector, UV 220&254 nm]: to afford 7-[(3aS,4R,6R,6aR)-2,2-dimethyl-6-{3-[(2-phenylethyl)amino]p rop-1-yn-1- yl]-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]-A/-[(4-met hoxyphenyl)methyl]-/V- methylpyrrolo[2,3-d]pyrimidin-4-amine 426 (10 mg, 25%) as a whitesolid.

1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.12 (s, 1H), 7.40 (d, 7 = 5.4 Hz, 1H), 7.32-7.13 (m, 6H), 6.56 (d, 7 = 3.4 Hz, 1H), 5.08 (d, 7 = 5.1 Hz, 1H), 4.97 (d, 7= 6.1 Hz, 1H), 4.85 (q, 7 = 8.1 Hz, 1H), 4.26 (q, 7 = 6.3 Hz, 1H), 3.99 (q, 7 = 5.2 Hz, 1H), 3.37 (d, 7 = 2.1 Hz, 2H), 2.96 (d, 7 = 4.5 Hz, 3H), 2.85-2.77 (m, 2H), 2.75-2.65 (m, 3H), 2.49-2.41 (m, 1H), 1.96-1.70 (m, 2H). LCMS [column: HPH-C18, 50*3.0 mm, 2.7um; mobile phase A: water/0.05% ammonia water, mobile phase B: ACN, 5%-30%-95%B- 6.0min(+), ES, m/z]: T R = 4.20 min (major isomer), 4.33 min (minor isomer); [M + H] + : 406.2. Chiral- SFC [Column: Solvent B: SC 100x4.6mm 3.0um: MeOH (0.2%MIPA), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min, Start Cone, of Pump B: 10.0%, BPR Pressure: 15.00 MP]: Two diastereomers, T R = 2.66 min (major peak), 2.89 min (minor isomer); dr = 95:5.

Synthesis of 2-{[(1R,2R,3S,4R)-2,3-dihydroxy-4-[4-(Methylamino)pyrrolo[2, 3-d]pyrimidin-7- yl]cyclopentyl]methoxy)-N-(2-phenylethyl)acetamide (689)

2-(((3aR / 4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-py rrolo[2 / 3-d]pyrimidin-7-yl)-

2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)m ethoxy)acetic acid (17h)

A solution of methyl methoxyphenyl)methyl](methyl)amino]pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methoxy}acetate (80 mg, 0.16 mmol, 1.0 eq) and NaOH (12.5 mg, 0.32 mmol, 2.0 eq) in MeOH (2.0 mL) and H 2 O (0.5 mL) was stirred for 2 h at room temperature. The reaction mixture was acidified to pH 2-3 with 1 M HCI. The precipitated solids were collected by filtration and washed with water. The resulting solids was dried by infrared lamp to afford 2-(((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H -pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methoxy)acetic acid 17h (62 mg, 80%) as a white solid. LCMS [column : XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-3min(+), 1.50 mL/min]: T R = 1.61 min; [M + H] + : 497.2. 2-(((3aR / 4R,6R,6aS)-6-(4-((4-Methoxybenzyl)(methyl)amino)-7H-py rrolo[2,3-d]pyrimidin-7-yl)-

2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)m ethoxy)-/V-phenethylacetamide (18h)

To a stirred solution of 2-(((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H - pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4- yl)methoxy)acetic acid 17h (60 mg, 0.12 mmol, 1.0 eq) and HATU (68.9 mg, 0.18 mmol, 1.5 eq) in DMF (2 mL) was added DIEA (31.2 mg, 0.24 mmol, 2.0 eq). To this mixture was then added 2- phenylethylamine (17.6 mg, 0.15 mmol, 1.2 eq) in several portions at room temperature. The reaction mixture was stirred for additional 2 h at room temperature, the resulting mixture was evaporated under reduce pressure and purified by silica gel column chromatography (AcOEt) to afford 2-(((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-TH -pyrrolo[2,3-d]pyrimidin-T- yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl) methoxy)-/V-phenethylacetamide 18h (60 mg, 58%) as a white solid. LCMS [column : XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-3min(+), 1.50 mL/min]: T R = 2.28 min; [M + H] + : 600.4.

2-(((1R,2R,3S,4R)-2,3-Dihydroxy-4-(4-(methylamino)-yH-pyr rolo[2,3-d]pyrimidin-y- yl)cyclopentyl)methoxy)-/V-phenethylacetamide (689)

To 2-(((3aR,4R,6R,6aS)-6-(4-((4-Methoxybenzyl)(methyl)amino)-TH -pyrrolo[2,3-d]pyrimidin-T-yl)- 2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)meth oxy)-/V-phenethylacetamide 18h (20 mg, 0.033 mmol, 1.0 eq) in TEA (1 mL) was stirred for 2 h at room temperature. The resulting mixture was concentrated under reduced pressure and was purified by Prep-HPLC [(Waters I): Column, Xbridge Prep C18 OBD column, 5um, 19*150mm; mobile phase, Water (0.03% NH 4 OH) and CH 3 CN (16% CH 3 CN up to 34% in 10 min); Detector, UV 220&254nm]: to afford 2- (((1R,2R,3S,4R)-2,3-dihydroxy-4-(4-(methylamino)-TH-pyrrolo[ 2,3-d]pyrimidin-T- yl)cyclopentyl)methoxy)-A/-phenethylacetamide 689 (4.3 mg, 29%) as a white solid. 1 H NMR (400 MHz, DMSO-aL) 5 8.13 (s, 1H), T.69 (br s, 1H), T.38 (br s, 1H), 7.30-7.11 (m, 6H), 6.54 (d, 7 = 3.5 Hz, 1H), 4.90-4.82 (m, 1H), 4.81 (d, 7 = 6.5 Hz, 1H), 4.70 (d, 7 = 4.6 Hz, 1H), 4.19 (dt, 7 = 8.1, 6.0 Hz, 1H), 3.87 (s, 2H), 3.83 (d, 7 = 4.6 Hz, 1H), 3.54 (dd, 7 = 9.4, 5.5 Hz, 1H), 3.44 (dd, 7= 9.4, 5.9 Hz, 1H), 3.39-3.33 (m, 1H), 2.96 (d, 7 = 4.6 Hz, 3H), 2.74 (t, 7= 7.5 Hz, 2H), 2.25-2.11 (m, 2H), 1.64-1.50 (m, 1H). LCMS [column HPH-C18, 50*3.0 mm , 2.7um. mobile phase A: water/0.05% ammonia water, mobile phase B:ACN, 5%-95%B-3min(+), 1.20 mL/min]: T R = 1.09 min; [M + H] + : 440.2. Chiral-HPLC [Column: YMC Cellulose-SC, 100*4.6mm, Sum, 119IA70110; Mobile Phase A: n-Hexane (0.1%DEA), Mobile Phase B: Ethanol; Total Flow: 1.00 mL/min; Cone, of Pump B: 50.0%; Oven Temperature: 25 °C]: T R = 2.60 min. dr >99:1.

Synthesis of (1R,2S,3R,5S)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3- (phenethylamino)propyl)thio)methyl)cyclopentane-1,2-diol (427)

S-(((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino) -7H-pyrrolo[2,3-d]pyrimidin-7-yl)- 2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)meth yl) ethanethioate (92a).

To a solution of PPh 3 (448 mg, 1.71 mmol, 1.5 eq) in THE (5.0 mL) was added DEAD (238 mg, 1.37 mmol, 1.2 eq) over 5 min, followed by a solution of [(3aR,4R,6R,6aS)-6-(4-{[(4- methoxyphenyl)methyl](methyl)amino}pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl] methanol (Intermediate A , 500 mg, 1.14 mmol, 1.0 eq) in THE (5.0 mL), dropwise at 0 °C. To the resultant mixture was then added ethanethioic S-acid (122 mg, 1.60 mmol, 1.4 eq) dropwise over 5 min and the reaction mixture was stirred for 1 h at, 0 °C, under nitrogen. The resulting mixture was concentrated under vacuum and purified by silica gel column chromatography (4:1 Petroleum ether/AcOEt) to afford S-(((3aR,4S,6R,6aS)-6-(4-((4- methoxybenzyl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methyl) ethanethioate 92a (550 mg, crude) as a yellow crude oil. LCMS [conditions: Halo C18, 30*3.0 mm, 2.0 pm, Mobile Phase A: Water/5mM TEA, Mobile Phase B: Acetonitrile, 5%-100%B-1.2min(+), 1.50 mL/min, ES, m/z]: T R = 0.64 min; [M + H] + : 497.

7e/t-Butyl-(3-((((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)( methyl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)methyl)thio)propyl)(phenethyl)carbamate (93a).

To S-(((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H -pyrrolo[2,3-d]pyrimidin-7-yl)- 2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)meth yl) ethanethioate 92a (300 mg, 0.60 mmol, 1.0 eq) in MeOH (5.0 mL) was added te/f-butyl-(3- bromopropyl)(phenethyl)carbamate 58a (248 mg, 0.73 mmol, 1.2 eq) and K 2 CO 3 (125 mg, 0.91 mmol, 1.5 eq) and the reaction mixture was stirred for 2 h at room temperature under a nitrogen. The resulting mixture was filtered and the filtrate was concentrated under vacuum. The crude residue was purified by silica gel column chromatography (3:1 Petroleum ether/AcOEt) to afford te/'f-butyl-(3-((((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(me thyl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)methyl)thio)propyl)(phenethyl)carbamate 93a (170 mg, 39%) as a light yellow oil. LCMS [conditions: Halo C18, 30*3.0 mm, 2.0 pm, Mobile Phase A: Water/5mM TFA, Mobile Phase B: Acetonitrile, 5%-100%B-1.2min(+), 1.50 mL/min, ES, m/z]: T R = 0.80 min; [M + H] + : 716.

(1R,2S,3R,5S)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-(((3- (phenethylamino)propyl)thio)methyl)cyclopentane-1,2-diol (427).

To te/'Abutyl-(3-((((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(met hyl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)methyl)thio)propyl)(phenethyl)carbamate 93a (50 mg, 0.07 mmol, 1.0 eq) was added TFA (0.5 mL, 6.73 mmol) and the reaction mixture was stirred overnight at room temperature under nitrogen. The resulting mixture was concentrated and the crude residue was purified by Prep- HPLC [Column, Xselect CSH OBD Column 30 x 150 mm 5um; mobile phase, water (10MMOL/L NH4HCO3) and ACN (10% Phase B up to 50% in 8 min); Detector, UV 220 nm]: to afford (1R,2S,3R,5S)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3- (phenethylamino)propyl)thio)methyl)cyclopentane-1,2-diol 427 (5.0 mg, 15%) as a white solid. 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.12 (s, 1H), 7.37 (d, 7 = 5.6 Hz, 1H), 7.27 (t, 7 = 7.4 Hz, 2H), 7.26-7.13 (m, 4H), 6.53 (d, 7 = 3.5 Hz, 1H), 4.84 (dd, 7 = 13.5, 6.9 Hz, 2H), 4.74-4.68 (m, 1H), 4.23 (q, 7 = 6.5 Hz, 1H), 3.79 (d, 7 = 5.1 Hz, 1H), 2.96 (d, 7 = 4.5 Hz, 3H), 2.76-2.69 (m, 5H), 2.62 (t, 7 = 7.0 Hz, 2H), 2.61-2.57 (m, 2H), 2.26-2.24 (m, 1H), 2.09 (s, 1H), 1.67 (q, 7 = 7.2 Hz, 2H), 1.55 (q, 7 = 10.5 Hz, 1H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min, ES, m/z]: T R =1.20 min; [M + H] + : 456.

CHIRAL_HPLC [Column: YMC Cellulose-SB, 100*4.6mm, Sum. Phase A: Ethanol(0.1%DEA). Phase B: Methanol, keep 50.0% Phase B in 10 min]: T R = 1.75 min; single peak.

Synthesis of (1R,2S,3R,5S)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3- (phenethylamino)propyl)sulfinyl)methyl)cyclopentane-1,2-diol (428)

7e/Y-Butyl-(3-((((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)( methyl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)methyl)thio)propyl)(phenethyl)carbamate (94a)

To a solution of terAbutyl-(3-((((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(meth yl)amino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4- yl)methyl)thio)propyl)(phenethyl)carbamate 93a (200 mg, 0.28 mmol, 1.0 eq) in DCM (5.0 mL) was added m-CPBA (50 mg, 0.29 mmol, 1.05 eq) in several portions at room temperature and the resulting mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum and the crude residue was purified by silica gel column chromatography (2:1 Petroleum ether/AcOEt) to afford te/f-butyl-(3-((((3aR,4S,6R,6aS)-6-(4-((4- methoxybenzyl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methyl)sulfinyl)propyl)(phenet hyl)carbamate 94a (150 mg, 73%) as off white solid. LCMS [conditions: Halo C18, 30*3.0 mm, 2.0 pm, Mobile Phase A: Water/5mM TEA, Mobile Phase B: Acetonitrile, 5%-100%B-1.2min(+), 1.50 mL/min, ES, m/z]: T R = 0.95 min;

[M + H] + : 732.

(1R,2S,3R,5S)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-(((3- (phenethylamino)propyl)sulfinyl)methyl)cyclopentane-1,2-diol (428) Jp

To te/'Abutyl-(3-((((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(met hyl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)methyl)sulfinyl)propyl)(phenethyl)carbamate 94a (80 mg, 0.11 mmol, 1.0 eq) was added TEA (2.0 mL) at room temperature and the reaction mixture was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum and the crude residue was purified by Prep-HPLC [Column: Xselect CSH OBD Column 30 x 150mm 5um; Mobile Phase A: water (0.05% NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 25% B to 63% B in 8 min, 63% B; Wave Length: 220 nm; T R (min): 7]: to afford (1R,2S,3R,5S)-3-(4-(methylamino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-5-(((3-(phenethylamino)propyl)sulfinyl)met hyl)cyclopentane-1,2-diol 428 (25.8 mg, 50%) as an off-white solid. 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.13 (s, 1H), 7.40 (br s, 1H), 7.31- 7.13 (m, 6H), 6.54 (d, 7 = 4.2 Hz, 1H), 4.90 (d, 7 = 6.4 Hz, 2H), 4.84 (d, 7 = 8.1 Hz, 1H), 4.23 (s, 1H), 3.90 (s, 1H), 3.10-2.96 (m, 4H), 2.86-2.77 (m, 2.4H), 2.77-2.69 (m, 4H), 2.68-2.66 (m, 3H), 2.36 (q, 7 = 7.9, 7.0 Hz, 2H), 1.78 (t, 7 = 7.3 Hz, 2H), 1.73-1.65 (m, 1H). LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH4HCO3, Mobile Phase B: Methanol, 10%-95%B- 2min(+), 1.50 mL/min, ES, m/z]: T R = 0.69 min; [M + H] + : 472. CHIRAL_SFC [Column: SC 100x4.6mm 3.0um. 50 dergree, Solvent B: MeOH (20mM NH 3 ), Solvent A: CO 2 , keep 30% solvent B for 4 mins]: T R = 2.72 min (minor peak), 3.13 min (major peak), dr=32:67.

Synthesis of (1R,2S,3R,5S)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3- (phenethylamino)propyl)sulfonyl)methyl)cyclopentane-1,2-diol (429) fe/7'-Butyl-(3-((((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(me thyl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)methyl)sulfonyl)propyl)(phenethyl)carbamate (95a).

To a solution of te/f-butyl (3-((((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)- 7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4- yl)methyl)thio)propyl)(phenethyl)carbamate 93a (100 mg, 0.14 mmol, 1.0 eq) in DCM (3.0 mL) was added m-CPBA (60 mg, 0.35 mmol, 2.5 eq) in several portions at room temperature and the reaction mixture was stirred for 2 h at room temperature. The resultant mixture was concentrated under vacuum and the crude residue was purified by silica gel column chromatography (1:1 Petroleum ether/AcOEt) to afford te/f-butyl- A/-(3-{[(3aR,4S,6R,6aS)-6-(4- {[(4-methoxyphenyl)methyl](methyl)amino]pyrrolo[2,3-d]pyrimi din-7-yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methanesulfonyl]propyl)-A/ -(2-phenylethyl)carbamate 95a (65 mg, 62%) as off-white solid. LCMS [conditions: Halo C18, 30*3.0 mm, 2.0 pm, Mobile Phase A: Water/5mM TEA, Mobile Phase B: Acetonitrile, 5%-100%B-1.2min(+), 1.50 mL/min, ES, m/z]: T R = 0.90; [M + H] + : 748.

(1R,2S,3R,5S)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-(((3- (phenethylamino)propyl)sulfonyl)methyl)cyclopentane-1,2-diol (429) o

HN

To te/'Abutyl-(3-((((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(met hyl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)methyl)sulfonyl)propyl)(phenethyl)carbamate 95a (65 mg, 0.087 mmol, 1.0 eq) was added TEA (2.0 mL) at room temperature and the reaction mixture was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum and the crude residue was purified by Prep-HPLC [Column: Xselect CSH OBD Column 30 x 150mm 5um; Mobile Phase A: water (0.05% NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 33% B to 60% B in 8 min, 60% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5S)-3-(4-(methylamino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-5-(((3-(phenethylamino)propyl)sulfonyl)met hyl)cyclopentane-1,2-diol 429 (19 mg, 45%) as an off-white solid. 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.14 (s, 1H), 7.40 (q, 7 = 4.5 Hz, 1H), 7.31-7.13 (m, 6H), 6.54 (d, 7 = 3.5 Hz, 1H), 4.94 (t, 7 = 6.0 Hz, 2H), 4.88-4.77 (m, 1H), 4.18 (q, 7 = 5.8 Hz, 1H), 3.89 (d, 7 = 5.5 Hz, 1H), 3.41 (dd, 7 = 14.0, 3.7 Hz, 1H), 3.18-3.10 (m, 2H), 2.96 (d, 7 = 4.6 Hz, 3H), 2.70-2.65 (m, 4H), 2.63 (t, 7 = 6.7 Hz, 2H), 2.43-2.40 (m, 2H), 1.87-1.64 (m, 3H). LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-2min(+), 1.50 mL/min, ES, m/z]: T R = 1.13 min; [M + H] + : 488.

CHIRAL_SFC [Column: Lux-4 100x4.6mm 3.0um. 50 dergree, Solvent B: MeOH (20mM NH 3 ), Solvent A: CO 2 , keep 50% solvent B for 4 mins]: T R = 1.58 min, single peak. Synthesis of (1S ; 2R,3S,5R)-3-(((2-Aminoethyl)thio)methyl)-5-(4-(methyla mino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)cyclopentane-1,2-diol (430)

7-((3aS,4R,6S,6aR)-6-(((2-Aminoethyl)thio)methyl)-2,2-dim ethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-/V-(4-methoxybenzyl)-/V-methy l-7H-pyrrolo[2,3-d]pyrimidin-4- amine (96a)

To a mixture of 2-bromoethanamine (599 mg, 4.83 mmol, 3.0 eq) and K 2 CO 3 (1.11 g, 8.06 mmol, 5.0 eq) in MeOH (5.0 mL) was added S-(((3aR,4S,6R,6aS)-6-(4-((4- methoxybenzyl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methyl) ethanethioate 92a (800 mg, 1.61 mmol, 1.0 eq) in MeOH (5.0 mL) dropwise, at room temperature, under nitrogen and the reaction mixture was stirred overnight at room temperature. The resultant mixture was concentrated under vacuum and the crude residue was purified by silica gel column chromatography (1:2 Petroleum ether/AcOEt) to afford 7-((3aS,4R,6S,6aR)-6-(((2-aminoethyl)thio)methyl)-2,2-dimeth yltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-/V-(4-methoxybenzyl)-/V-methy l-7H-pyrrolo[2,3-d]pyrimidin-4- amine 96a (410 mg, 51%) as a brown solid. 1 H NMR (400 MHz, Chloroform-d) 5 8.36 (s, 1H), 7.28- 7.26 (m, 2H), 6.93 (d, 7 = 3.6 Hz, 1H), 6.91-6.85 (m, 2H), 6.47 (d, 7 = 3.6 Hz, 1H), 5.00-4.93 (m, 4H), 4.62-4.56 (m, 1H), 3.81 (s, 3H), 3.32 (s, 3H), 2.98-2.85 (m, 2H), 2.83-2.69 (m, 2H), 2.54-2.48 (m, 1H), 2.45-2.39 (m, 1H), 2.26-2.15 (m, 1H), 1.59 (s, 3H), 1.33 (s, 3H).

(1S,2R,3S,5R)-3-(((2-Aminoethyl)thio)methyl)-5-(4-(methyl amino)-7H-pyrrolo[2,3-d]pyrimidin-7- yl)cyclopentane-1,2-diol (430)

To 7-((3aS,4R,6S,6aR)-6-(((2-aminoethyl)thio)methyl)-2,2-dimeth yltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-/V-(4-methoxybenzyl)-/V-methy l-7H-pyrrolo[2,3-d]pyrimidin-4- amine 96a (50 mg, 0.10 mmol, 1.0 eq) was added TEA (2.0 mL) at room temperature and the reaction mixture was stirred overnight at room temperature under nitrogen. The resulting mixture was concentrated under vacuum and the crude residue was purified by Prep-HPLC [Column: Xselect CSH OBD Column 30 x 150mm 5um; Mobile Phase A: water (0.05% NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 13% B to 43% B in 8 min, 43% B; Wave Length: 220 nm]: to afford (1S,2R,3S,5R)-3-(((2-aminoethyl)thio)methyl)-5-(4-(methylami no)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol 430 (14.3 mg, 42%) as off-white solid. 1 H NMR (400 MHz, DMSO-Og) 5 8.12 (s, 1H), 7.37 (q, 7 = 4.9 Hz, 1H), 7.23 (d, 7 = 3.5 Hz, 1H), 6.53 (d, 7 = 3.5 Hz, 1H), 4.83 (dt, 7 = 10.1, 8.0 Hz, 2H), 4.23 (t, 7 = 6.8 Hz, 1H), 3.79 (t, 7 = 5.0 Hz, 1H), 2.96 (d, 7 = 4.9 Hz, 3H), 2.80 (dd, 7 = 12.7, 6.3 Hz, 1H), 2.69 (t, 7= 6.8 Hz, 1H), 2.59 (dd, 7 = 12.8, 8.5 Hz, 1H), 2.54-2.50 (m, 4H), 2.28 (dt, 7 = 12.8, 8.2 Hz, 1H), 2.13-2.03 (m, 1H), 1.55 (dt, 7 = 12.5, 9.5 Hz, 1H). LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-2min(+), 1.50 mL/min, ES, m/z]: T R = 0.92 min; [M + H] + : 338. CHIRAL_SFC, Column: OJ 100x4.6mm 3.0um. 50 dergree, Solvent B: MeOH (20mM NH 3 ), Solvent A: CO 2 , keep 30% solvent B for 4 mins]: T R = 0.65 min, single peak.

Synthesis of (1R,2S,3R,5S)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((2- (phenethylamino)ethyl)thio)methyl)cyclopentane-1,2-diol (431)

7-((3aS,4R,6S,6aR)-2,2-Dimethyl-6-(((2-(phenethylamino)et hyl)thio)methyl)tetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-/V-(4-methoxybenzyl)-/V-methy l-7H-pyrrolo[2 / 3-d] pyrimidin-4- amine (97a)

To a stirred solution of 7-((3aS,4R,6S,6aR)-6-(((2-aminoethyl)thio)methyl)-2,2-dimeth yltetrahydro- 4H-cyclopenta[d][1,3]dioxol-4-yl)-A/-(4-methoxybenzyl)-A/-me thyl-7H-pyrrolo[2,3-d]pyrimidin-4- amine 96a (400 mg, 0.80 mmol, 1.0 eq) in CH 3 CN (4.0 mL) was added (2-bromoethyl)benzene (148 mg, 0.80 mmol, 1.0 eq) and K 2 CO 3 (222 mg, 1.60 mmol, 2.0 eq) at room temperature. The reaction mixture was stirred for 12 h at 80 °C and the resulting mixture was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (1:12 Petroleum ether/AcOEt) to afford 7-((3aS,4R,6S,6aR)-2,2-dimethyl-6-(((2- (phenethylamino)ethyl)thio)methyl)tetrahydro-4H-cyclopenta[d ][1,3]dioxol-4-yl)-A/-(4- methoxybenzyl)-A/-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 97a (200 mg, 41%) as a light yellow solid. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-2min(+), 1.50 mL/min, ES, m/z]: T R = 1.43 min;

[M + H] + : 602.4.

(1R,2S,3R,5S)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-(((2- (phenethylamino)ethyl)thio)methyl)cyclopentane-1,2-diol (431)

To a solution of 7-((3aS,4R,6S,6aR)-2,2-dimethyl-6-(((2-

(phenethylamino)ethyl)thio)methyl)tetrahydro-4H-cyclopent a[d][1,3]dioxol-4-yl)-A/-(4- methoxybenzyl)-A/-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 97a (0.03 mg, 0.05 mmol, 1.0 eq) in DCM (1.0 mL), at room temperature, was added TFA (1.0 mL) and the reaction mixture was stirred for 16 h. The resulting mixture was concentrated under reduced pressure and the residue was dissolved in water (2.0 mL). The pH value of the solution was adjusted to 8-9 with NH 3 *H 2 O and the mixture was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm,

5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 24% B to 49% B over 7 min, 49% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5S)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((2-

(phenethylamino)ethyl)thio)methyl)cyclopentane-1,2-diol 431 (5.1 mg, 23%) as an off-white solid. 1 H NMR (400 MHz, DMSO-t4) <58.12 (s, 1H), 7.42-7.34 (m, 1H), 7.30-7.12 (m, 6H), 6.53 (d, 7 = 3.5 Hz, 1H), 4.88-4.78 (m, 2H), 4.77-4.68 (m, 1H), 4.29-4.17 (m, 1H), 3.82-3.72 (m, 1H), 2.96 (d, 7 = 4.7 Hz, 3H), 2.84-2.66 (m, 7H), 2.65-2.54 (m, 3H), 2.37-2.19 (m, 1H), 2.14-2.01 (m, 1H), 1.61-1.46 (m, 1H) LCMS [conditions ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 L/min, ES, m/z]: T R = 1.18 min; [M + H] + : 442. CHIRAL_SFC, Column: SC 100x4.6mm 3.0um. 50 dergree, Solvent B: MeOH (20mM NH 3 ), Solvent A: CO 2 , keep 50% solvent B for 4 mins]: T R = 1.41 min, single peak.

Synthesis of (1R,2S,3R,5S)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((2- (phenethylamino)ethyl)sulfinyl)methyl)cyclopentane-1,2-diol (432)

7-((3aS,4R / 6S,6aR)-2,2-Dimethyl-6-(((2-(phenethylamino)ethyl)sulf inyl)methyl)tetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-/V-(4-methoxybenzyl)-/V-methy l-7H-pyrrolo[2,3-d]pyrimidin-4- amine (98a)

To a solution of 7-((3aS,4R,6S,6aR)-2,2-dimethyl-6-(((2-

(phenethylamino)ethyl)thio)methyl)tetrahydro-4H-cyclopent a[d][1,3]dioxol-4-yl)-/V-(4- methoxybenzyl)-/V-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 97a (0.09 g, 0.20 mmol, 1.0 eq) in DCM (2.0 mL) was added /77-CPBA (0.03 g, 0.20 mmol, 1.0 eq) ad the reaction mixture was stirred for 8 h at room temperature. The resulting mixture was concentrated under vacuum and purified by silica gel column chromatography (95:5 dichloromethane:methanol) to afford 7- ((3aS,4R,6S,6aR)-2,2-dimethyl-6-(((2-(phenethylamino)ethyl)s ulfinyl)methyl)tetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)-A/-(4-methoxybenzyl)-A/-methy l-7H-pyrrolo[2,3-d]pyrimidin-4- amine (98a) (50 mg, 54%) as a colorless oil. LCMS [conditions conditions Xbridge Shield C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%- 100%B-2min(+), 1.50 L/min, ES, m/z]: T R = 1.20 min; [M + H] + : 618

(1R,2S,3R,5S)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-(((2- (phenethylamino)ethyl)sulfinyl)methyl)cyclopentane-1,2-diol (432)

To a solution of 7-((3aS,4R,6S,6aR)-2,2-dimethyl-6-(((2-

(phenethylamino)ethyl)sulfinyl)methyl)tetrahydro-4H-cyclo penta[d][1,3]dioxol-4-yl)-/V-(4- methoxybenzyl)-A/-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 98a (45 mg, 0.07 mmol, 1.0 eq) in dichloromethane (2.0 mL) was added TEA (2.0 mL) and the reaction mixture was stirred for 16 h at room temperature. The resulting mixture was concentrated under reduced pressure and the residue was basified to pH 10 with NH 3 *H 2 O. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 24% B to 49% B in 7 min, 49% B; Wave Length: 220 nm]: to afford 1R,2S,3R,5S)-3-(4-(methylamino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-5-(((2-(phenethylamino)ethyl)s ulfinyl)methyl)cyclopentane-1,2-diol 432 (9.8 mg, 30%) as an off-white solid. 1 H NMR (400 MHz, DMSO-r4) <58.13 (s, 1H), 7.44-7.35 (m, 1H), 7.32-7.11 (m, 6H), 6.56-6.50 (m, 1H), 4.94-4.77 (m, 3H), 4.27-4.14 (m, 1H), 3.93-3.82 (m, 1H), 3.10-2.97 ( 1H), 2.96 (d, 7 = 4.7 Hz, 3H), 2.94-2.88 (m, 2H), 2.87-2.81 (m, 1H), 2.79-2.73 (m, 2H), 2.72-2.65 (m, 2H), 2.40-2.29 (m, 2H), 1.74-1.60 (m, 1H). LCMS [conditions Halo C18, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 L/min, ES, m/z]: T R = 0.66 min; [M + H] + : 458. CHIRAL_SFC [Column: SC 100x4.6mm 3.0um. 50 °C, Solvent B: MeOH (20mM NH 3 ), Solvent A: CO 2 , keep Gradient 50% solvent B for 4 mins, two diastereomers]: T R = 2.00 min, T R = 2.95, dr=1:1.

Synthesis of (1R,2S,3R,5S)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((2- (phenethylamino)ethyl)sulfonyl)methyl)cyclopentane-1,2-diol (433)

(1R,2S,3R,5S)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-(((2- (phenethylamino)ethyl)sulfonyl)methyl)cyclopentane-1,2-diol (433)

To a stirred solution of (1R,2S,3R,5S)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((2- (phenethylamino)ethyl)thio)methyl)cyclopentane-1,2-diol 291 (40 mg, 0.10 mmol, 1.0 eq) in DCM (1.0 mL) was added /77-CPBA (39 mg, 0.23 mmol, 2.5 eq) in several portions at room temperature. The reaction mixture was stirred for 0.5 h at room temperature and then concentrated under vacuum. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 25% B to 53% B in 8 min, 53% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5S)-3-[4-(methylamino)pyrrolo[2,3-d]pyrimidin-7-yl ]-5-({2-[(2- phenylethyl)amino]ethanesulfonyl]methyl)cyclopentane-1,2-dio l 433 (7.4 mg, 17%) as a white solid. 1 H NMR (400 MHz, Chloroform-t/+D 2 O) 5 8.31 (s, 1H), 7.35-7.27 (m, 2H), 7.25-7.19 (m, 3H), 6.95 (d, 7 = 3.7 Hz, 1H), 6.38 (s, 1H), 4.67-4.57 (m, 1H), 4.23 (t, 7 = 7.0 Hz, 1H), 4.01 (t, 7 = 6.8 Hz, 1H), 3.60 (dd, 7 = 14.0, 5.0 Hz, 1H), 3.33-3.06 (m, 8H), 2.98-2.89 (m, 2H), 2.86-2.75 (m, 3H), 2.73- 2.68 (m, 1H), 1.95 (q, 7 = 11.6 Hz, 1H). LCMS [conditions Halo C18, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min-1.5.lcm, 1.50 L/min, ES, m/z]: T R = 1.08 min; [M + H] + : 474 CHIRAL_SFC [Column: SC 100x4.6mm 3.0um. 50 °C, Solvent B: MeOH (20mM NH3), Solvent A: CO 2 , keep Gradient 30% solvent B for 4 mins]: T R = 2.41 min, single peak.

Synthesis of 3-((((1R,2R,3S,4R)-2,3-dihydroxy-4-(4-(methylamino)-7H-pyrro lo[2,3-d]pyrimidin-7- yl)cyclopentyl)methyl)amino)-N-phenethylpropanamide (434) 7e/t-Butyl-/V-{2-[(2-phenylethyl)carbamoyl]ethyl}carbamate (39a)

To a stirred mixture of 3-[(te/'Abutoxycarbonyl)amino]propanoic acid (1.87 g, 9.90 mmol, 1.0 eq) and DIEA (2.13 g, 16.5 mmol, 1.5 eq), HATU (4.71 g, 12.4 mmol, 1.2 eq) in DMF (10 mL) was added 2-phenylethylamine (1.0 g, 8.25 mmol, 0.83 eq) in several portions at room temperature and the reaction mixture was stirred at room temperature for 3 h. The resulting mixture was quenched with water (50 mL) and extracted with AcOEt (150 mL). The organic layer was washed with brine (50 mL), dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (AcOEt) to afford te/'Abutyl-/V-{2-[(2-phenylethyl)carbamoyl]ethyl}carbamate 39a (1.00 g, 41%) as a white solid. LCMS [column: Kinetex XB-C18, 30*3.0 mm, 1.7um; mobile phase A: water/0.1%FA, mobile phase B: CAN/0.05%FA, 5%-95%B-2min(+) ES, m/z]: T R = 1.00 min; [M + H] + : 293.2. fe/t- Butyl A/-{2-[(2-phenylethyl)carbamoyl]ethyl}carbamate (40a)

A solution of te/f-butyl A/-{2-[(2-phenylethyl)carbamoyl]ethyl}carbamate 39a (1.0 g, 3.42 mmol, 1.0 eq) in HCI (4M in dioxane, 10 mL) was stirred for 1 h at room temperature. The precipitated solids were collected by filtration and washed with Et 2 O (50 mL) to afford 3-amino-A/-[(4Z)-3- methylidenehex-4-en-1-yl]propanamide 40a (500 mg, 80%) as a white solid. LCMS [column : Kinetex XB-C18, 30*3.0 mm , 1.7um. mobile phase A: water/0.1%FA, mobile phase B:CAN/0.05%FA, 5%-95%B-2min(+), ES, m/z]: T R = 0.50 min; [M + H] + : 193.1.

A mixture of 3-((((3aR,4R ; 6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-pyrro lo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)amino)-/V- phenethylpropanamide and 3-((((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7 H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4- yl)methyl)amino)-/V-phenethylpropanamide (41a)

To a stirred solution of (3aR,4S,6R,6aS)-6-(4-{[(4- methoxyphenyl)methyl](methyl)amino]pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxole-4-carbaldehyde 19a (100 mg, 0.23 mmol, 1.0 eq) and 3-amino-/V- phenethylpropanamide 40a (52.8 mg, 0.28 mmol, 1.2 eq) in DCE (5.0 mL) was added NaBH(AcO) 3 (121 mg, 0.57 mmol, 2.5 eq) in several portions at room temperature and the resulting mixture was stirred for 12 h. The reaction was quenched by the addition of sodium bicarbonate aqueous solution (0.5 mL). The crude mixture was concentrated and purified by silica gel column chromatography (DCM/MeOH =80/20) to afford the mixture of 3-((((3aR,4R,6R,6aS)-6-(4-((4- methoxybenzyl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methyl)amino)-A/-phenethylprop anamide and 3-((((3aR,4S,6R,6aS)-

6-(4-((4-methoxybenzyl)(methyl)amino)-7H-pyrrolo[2,3-d]py rimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)a mino)-/V-phenethylpropanamide

41a (130 mg, 56%) as a white solid. LCMS [column: HPH-C18, 50*3.0 mm , 2.7um. mobile phase A: water/0.05% ammonia water, mobile phase B:ACN, 5%-95%-3 min; ES, m/z]: T R = 1.65 min, 1.69 min; 2 diastereomers (1:1) [M + H] + : 613.2.

The mixture of 3-((((1R,2R,3S,4R)-2,3-dihydroxy-4-(4-(methylamino)-7H-pyrro lo[2,3-d]pyrimidin-

7-yl)cyclopentyl)methyl)amino)-/V-phenethylpropanamide and 3-((((1S,2R,3S,4R)-2,3-dihydroxy- 4-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopent yl)methyl)amino)-/V- phenethylpropanamide

To the mixture of 3-((((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7 H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)amino)-/V- phenethylpropanamide and 3-((((3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7 H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4- yl)methyl)amino)-A/-phenethylpropanamide 41a (100 mg, 0.16 mmol, 1.0 eq) was added TEA (3.0 mL) and the reaction mixture was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum and the crude residue was purified by Prep-HPLC [column, Xbridge Prep C18 OBD column, 5um, 19*150mm; mobile phase, water (0.03% NH 4 OH) and CH 3 CN (15% up to 38% in 10 min); Detector, UV 220&254 nm]: to afford a mixture of 3-((((1R,2R,3S,4R)-2,3- dihydroxy-4-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )cyclopentyl)methyl)amino)-/V- phenethylpropanamide and 3-((((1S,2R,3S,4R)-2,3-dihydroxy-4-(4-(methylamino)-7H-pyrro lo[2,3- d]pyrimidin-7-yl)cyclopentyl)methyl)amino)-A/-phenethylpropa namide 434 (15 mg, 20%) as a white solid. 1 H NMR (300 MHz, DMSO-t/ 6 ) 5 8.11 (d, 7 = 2.8 Hz, 1H), 7.34-7.11 (m, 6H), 6.52 (t, 7 = 3.5 Hz, 1H), 4.90-4.84 (m, 1H), 4.40-4.11 (m, 1H), 3.95-3.74 (m, 1H), 3.32-3.18 (m, 2H), 2.94 (s, 3H), 2.77-2.61 (m, 5H), 2.49-2.38 (m, 1H), 2.30-2.24 (m, 1H), 2.23-2.12 (m, 2H), 2.08-1.40 (m, 2H). LCMS [column: HPH-C18, 50*3.0 mm , 2.7 urn; mobile phase A: water/0.05% ammonia water, mobile phase B:ACN, 5%-95%B-3min(+), ES, m/z]: T R = 1.36 min; [M + H] + : 426.2. Chiral-HPLC [Column: CHIRALPAK IH-3, 50*4.6mm, Sum IH30CC-WH004, Mobile Phase A: n- Hexane(0.1%DEA), Mobile Phase B: Ethanol (0.2%MIPA); Total Flow: 1.00 mL/min; Cone, of Pump B: 30.0% Oven Temperature: 25 °C]: two diastereomers; T R = 2.42, 3.44 min. dr 49:51.

Synthesis of (1R ; 2S,3R,5R)-3-[4-(methylamino)pyrrolo[2,3-d]pyrimidin-7- yl]-5-{[(morpholin-2- ylmethyl)amino]methyl}cyclopentane-1,2-diol (435)

(3aR ; 4S,6R,6aS)-6-(4-((4-Methoxybenzyl)(methyl)amino)-7H-py rrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carbaldehy de (19a)

A solution of [(3aR,4R,6R,6aS)-6-(4-{[(4-methoxyphenyl)methyl](methyl)amin o}pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl] methanol (Intermediate A, 600 mg, 1.37 mmol, 1.0 eq) and DMP (1.16 g, 2.73 mmol, 2.0 eq) in DCM (5.0 mL) and the reaction mixture was stirred for 4 h at room temperature. The crude mixture was purified by silica gel column chromatography (AcOEt) to afford (3aR,4S,6R,6aS)-6-(4-((4- methoxybenzyl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxole-4-carbaldehyde 19a (430 mg, 36%) as a yellow oil. 1 H NMR (300 MHz, DMSO-r ) 5 9.73 (s, 1H), 8.16 (s, 1H), 8.14-7.95 (m, 1H), 7.32 (d, 7 = 3.7 Hz, 1H), 7.25-7.13 (m, 2H), 6.94-6.83 (m, 2H), 6.57 (d, 7 = 3.7 Hz, 1H), 5.15-5.02 (m, 2H), 4.94 (d, 7 = 1.6 Hz, 2H), 3.72 (s, 3H),

3.27 (s, 3H), 3.16-3.02 (m, 1H), 2.48-2.31 (m, 1H), 1.50 (s, 3H), 1.26 (s, 3H).

7e/t-Butyl-2-(((((3aR / 6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-pyrro lo[2,3-d]pyrimidin-

7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol- 4-yl)methyl)amino)methyl)morpholine-

4-carboxylate (20a)

To a stirred solution of (3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-pyr rolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxole-4-carbaldehyde 19 (100 mg, 0.23 mmol, 1.0 eq) and racemic terAbutyl-2-(aminomethyl)morpholine-4-carboxylate (59.5 mg, 0.28 mmol, 1.2 eq) in DCE (3.0 mL) was added NaBH(AcO) 3 (1.21 g, 0.57 mmol, 2.5 eq) in several portions at room temperature and the reaction mixture was stirred for 2 h at room temperature. The reaction was quenched with water (0.3 mL) and the resulting mixture was purified by silica gel column chromatography (80:20 DCM/MeOH) to afford te/f-butyl-2- (((((3aR,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-py rrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)a mino)methyl)morpholine-4- carboxylate 20a (150 mg, 82%) as a yellow oil. LCMS [column : Kinetex XB-C18,3.0*30 mm , 1.7um, Mobile Phase A: water/0.1% FA, Mobile Phase B: ACN/0.05% FA, 5%-95%B-2 min(+), 1.50 mL/min, ES, m/z]: T R = 0.86 min; [M + H] + : 637. Epimerisation occured at this step but we saw no evedince by LCMS or chiral HPLC.

The mixture of (1R,2S,3R,5R)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5- (((morpholin-2-ylmethyl)amino)methyl)cyclopentane-1,2-diol and (1R,2S,3R,5S)-3-(4- (methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(((morpholi n-2- ylmethyl)amino)methyl)cy To te/'f-butyl-2-(((((3aR,4R,6R,6aS)-2,2-dimethyl-6-(4-(methyla mino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)amin o)methyl)morpholine-4-carboxylate 20 (100 mg, 0.21 mmol, 1.0 eq) was added TEA (3.0 mL) and the reaction mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum and the crude residue was purified by Prep-HPLC [column: Xbridge Prep C18 OBD column, 5um, 19*150mm; mobile phase, Water (0.03% NH 4 OH) and CH 3 CN (10% up to 35% in 8 min); Detector, UV 220&254 nm]: to afford a mixture of (1R,2S,3R,5R)-3-[4-(methylamino)pyrrolo[2,3-d]pyrimidin-7- yl]-5-{[(morpholin-2-ylmethyl)amino]methyl}cyclopentane-1,2- diol and (1R,2S,3R,5S)-3-(4- (methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(((morpholi n-2- ylmethyl)amino)methyl)cyclopentane-1,2-diol 435 (22 mg, 28%) as a white solid. 1 H NMR (300 MHz, Methanol-^) S 8.15 (s, 1H), 7.26-7.18 (m, 1H), 6.58 (br s, 1H), 5.06-4.94 (m, 0.4H), 5.53-4.45 (m, 0.6H), 4.32-4.08 (m, 1H), 4.07-3.81 (m, 2H), 3.73-3.54 (m, 2H), 3.07 (br s, 3H), 3.06-2.67 (m, 7H), 2.63-2.48 (m, 1H), 2.47-2.20 (m, 1H), 2.17-2.02 (m, 1H), 1.79-1.51 (m, 1H). LCMS [column : L- column C18, 50*3.0 mm, 3 urn. mobile phase A: water/0.05% ammonia water, mobile phase B: ACN, 5%-40%-95%B-5.0min(+); 1.50 mL/min, ES, m/z]: T R = 1.31 min, T R = 1.35 min; [M + H] + : 377.2. Chiral-HPLC [Column: CHIRALPAK IG-3, 100*4.6mm, Sum IG30CS-UL011; Mobile Phase A: n-Hexane/DCM=3/1; Mobile Phase B: Ethanol (0.2%MIPA), Total Flow: 1.00 mL/min; Cone, of Pump B: 50.0%; Oven Temperature: 25 °C, (12 min run)]: 4 diastereomers; T R = 4.32, 5.22, 7.18, 8.91 min; dr = 21:30:20:29.

Synthesis of (1R ; 2S,3R,5R)-3-[4-(methylamino)pyrrolo[2,3-d]pyrimidin-7- yl]-5-({[(3S)-piperidin-3- ylmethyl]amino}methyl)cyclopentane-1,2-diol (436)

(3aR,4S,6R,6aS)-6-{4-Chloropyrrolo[2,3-d]pyrimidin-7-yl}- 2,2-dimethyl-tetrahydro-3aH- cyclopenta[d][1,3]dioxole-4-carbaldehyde

To [(3cxR,4R,6R,6cxS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl}- 2,2-dimethyl-tetrahydro-3cxH- cyclopenta[d][1,3]dioxol-4-yl]methanol 5 (0.50 g, 1.50 mmol, 1.0 eq) in DCM (5.0 mL) was added DMP (0.85 g, 2.00 mmol, 1.3 eq) and the reaction mixture was stirred for 1 h at room temperature. The crude residue was purified by silica gel column chromatography (80:20 Petroleum ether/AcOEt) to afford (3aR,4S,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2 - dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxole-4-carbalde hyde 77a (0.25 g, 50%) as an off- white solid. LCMS [conditions XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH4HCO3, Mobile Phase B: Methanol, 10%-95%B-2min(+), 1.50 L/min, ES, m/z]: T R = 1.58 min; [M + H] + : 322. fe/AButyl-(3R)-3-[({[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3ocH-cyclopenta[d][1,3]dioxol-4-yl]methyl}amino)m ethyl]piperidine-1-carboxylate (78a) To a solution of te/'Abutyl-(3R)-3-(aminomethyl)piperidine-1-carboxylate (0.18 g, 0.90 mmol, 1.2 eq) in DCM (1.0 mL) was added NaBH(OAc) 3 (0.30 g, 1.40 mmol, 2.0 eq) and HOAc (0.43 g, 7.10 mmol, 10.0 eq) and the reaction mixture was stirred for 10 min at room temperature. To this mixture was added (3aR,4S,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2 -dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxole-4-carbaldehyde 77 (0.23 g, 0.70 mmol, 1.0 eq) in DCM (1.0 mL), dropwise over 2 min, at 0 °C, and the reaction mixture was stirred for 30 min at room temperature and the resulting mixture was concentrated under vacuum. The crude residue was dissolved in water (2.0 mL) and basified to pH >7 with TEA and purified by Prep-HPLC [ Column : Xtimate C18 50x250mm, 10um; Mobile Phase A: Water(0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 90 mL/min; Gradient: 35% B to 65% B in 12 min, 65% B; Wave Length: 220 nm]: to afford te/'f-butyl-(3R)-3-[({[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2, 3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3cxH-cyclopenta[d][1,3]dioxol-4-yl]methy l}amino)methyl]piperidine-1- carboxylate 78a (0.16 g, 43%) as an off-white solid. LCMS (conditions XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-2min(+), 1.50 L/min, ES, m/z): T R = 3.81 min; [M + H] + : 520. fcW-Butyl(3R)-3-[({[(3aR,4R,6R,6c6)-6-(4-{[(4-methoxyphenyl) methyl](methyl)amino}pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyl-tetrahydro-3ocH-cyclopenta[d] [1,3]dioxol-4- yl]methyl}amino)methyl]piperidine-1-carboxylate (79a)

To te/'f-butyl-(3R)-3-[({[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2, 3-d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3cxH-cyclopenta[d][1,3]dioxol-4-yl]methyl}amino)m ethyl]piperidine-1-carboxylate 78a (0.16 g, 0.30 mmol, 1.0 eq), in ethanol (2.0 mL), was added [(4- methoxyphenyl)methyl](methyl)amine (0.28 g, 1.80 mmol, 6.0 eq) at room temperature and the resulting mixture was stirred at 80 °C for 16 h. The crude residue was purified by Prep-HPLC to afford teW-butyl(3R)-3-[({[(3aR,4R,6R,6aS)-6-(4-{[(4- methoxyphenyl)methyl](methyl)amino}pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}amino)methyl]piperi dine-1-carboxylate 79a (0.90 g, 46%) as an off-white solid. LCMS [conditions XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-5min (+), 1.50 L/min, ES, m/z]: T R = 4.00 min; [M + H] + : 635.

(1R,2S,3R,5R)-3-[4-(Methylamino)pyrrolo[2,3-d]pyrimidin-7 -yl]-5-({[(3S)-piperidin-3- ylmethyl]amino)methyl)cyclopentane-1,2-diol (436)

To teW-butyl-(3R)-3-[({[(3aR,4R,6R,6aS)-6-(4-{[(4- methoxyphenyl)methyl](methyl)amino}pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro-

3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}amino)methyl]pip eridine-1-carboxylate 79a (0.04 g, 0.10 mmol, 1.0 eq) was added TFA (1.0 mL) at room temperature and the reaction mixture was stirred for 30 min at 50 °C. The resulting mixture was concentrated under vacuum and the crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 24% B to 60% B in 7 min, 60% B; Wave Length: 220 nm; T R (min): 6.9]: to afford (1R,2S,3R,5R)-3-[4-(methylamino)pyrrolo[2,3-d]pyrimidin-7-yl ]-5-({[(3S)-piperidin-3- ylmethyl]amino}methyl)cyclopentane-1,2-diol 436 (10 mg, 42%) as an off-white solid. 1 H NMR (300MHz, DMSO-ok) <58.11 (s, 1H), 8.09 (s, 1H), 7.21 (d, 7 = 3.5 Hz, 1H), 6.52 (d, 7 = 3.5 Hz, 1H), 4.87-4.73 (m, 1H), 4.18-4.11 (m, 1H), 3.80-3.71 (m, 1H), 3.05-2.77 (m, 5H), 2.75-2.59 (m, 1H), 2.58- 2.48 (m, 1H), 2.44-2.26 (m, 3H), 2.25-1.91 (m, 3H), 1.87-1.64 (m, 1H), 1.61-1.43 (m, 3H), 1.42-1.24 (m, 1H), 1.11-0.85 (m, 1H). LCMS [conditions Atlantis T3, 100*4.6 mm, 3 pm, Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 0%-30%-95%B-7min, 1.50 L/min, ES, m/z]: T R = 3.35 min; [M + H] + : 375. Chiral-SFC [Column: Lux-4 100x4.6mm 3.0um, Solvent B: MeOH (20 mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min]: T R =2.54 min, single peak.

Synthesis of (1S,2R,3R,5R)-3-{[(3-aminopropyl)(1,3-thiazol-5-yl)amino]met hyl}-5-[4- (methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentane-1,2-d iol (437)

A/-{[(3aR ; 4R,6R,6aS)-6-{4-Chloropyrrolo[2,3-d]pyrimidin-7-yl}-2, 2-dimethyl-tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]methyl}-1,3-thiazol-5-amine (89a)

To a solution of 1,3-thiazol-5-amine hydrochloride (95 mg, 0.70 mmol, 1.5 eq) in DCM (1.0 mL), at 0 °C, was added AcOH (0.28 g, 4.70 mmol, 10 eq) and NaBH(OAc) 3 (0.20 g, 0.90 mmol, 2.0 eq) and the resulting mixture was stirred for 30 min at 0 °C. Then (3aR,4S,6R,6aS)-6-{4- chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxole-4- carbaldehyde 77 (0.15 g, 0.50 mmol, 1.0 eq) in DCM (1.0 mL) were added dropwise, over 3 min at 0 °C and the reaction mixture was stirred for 30 min at 0 °C. The resulting mixture was concentrated under vacuum and the crude residue was purified by silica gel column chromatography (96:4 DCM:MeOH) to afford A/-{[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}-1,3-thiazol- 5-amine 89a (0.15 g, 79%) as a light brown solid. LCMS [conditions XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-2 min(+), 1.50 L/min, ES, m/z]: T R = 1.21 min; [M + H] + : 406

W-[3-({[(3aR,4R,6R,6aS)-2,2-Dimethyl-6-[4-(methylamino)py rrolo[2,3-d]pyrimidin-7-yl]- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1,3-thi azol-5-yl)amino)propyl]carbamate (90a) To a solution of A/-{[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl ]-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}-1,3-thi azol-5-amine 89a (0.10 g, 0.25 mmol, 1.0 eq) in DCM (1.0 mL), at 0 °C, was added HOAc (0.15 g, 2.50 mmol, 10 eq) and NaBH(OAc) 3 (0.10 g, 0.50 mmol, 2.0 eq) and the resulting mixture was stirred for 30 min at 0 °C. To the above mixture was added a solution of te/'f-butyl-(3S)-3-formylpiperidine-1-carboxylate (0.12 g, 0.60 mmol, 1.5 eq) in DCM (1.0 mL), dropwise over 3 min, at 0 °C and the reaction mixture was stirred for an additional 30 min at 0 °C. The resulting mixture was concentrated under vacuum and the crude mixture was purified by silica gel column chromatography (95:5 DCM:MeOH) to afford terAbutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d] pyrimidin-7-yl]-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1,3-thi azol-5-yl)amino)propyl] carbamate 90a (0.10 g, 72%) as a light brown oil. LCMS [conditions XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-2min (+), 1.50 L/min, ES, m/z]: T R = 1.50 min; [M + H] + : 563.

7e/t-Butyl-AA[3-({[(3aR ; 4R,6R,6aS)-2,2-dimethyl-6-[4-(methylamino)pyrrolo[2 / 3-d]pyrimidin-7-yl]- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1,3-thi azol-5-yl)amino)propyl]carbamate

(91a)

To te/'Abutyl-A/-[3-({[(3cxR,4R,6R,6cxS)-6-{4-chloropyrrolo[2,3 -d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1,3-thi azol-5-yl)amino)propyl] carbamate 90a (0.10 g, 0.20 mmol, 1.0 eq) was added methylamine (30% in ethanol, 2.0 mL) and the reaction mixture was stirred for 2 h at 80 °C. The resulting mixture was concentrated under vacuum and the residue was purified by Prep-HPLC [Column : Xtimate C18 50x250mm, 10um; Mobile Phase A: Water(0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 90 mL/min; Gradient: 35% B to 60% B in 12 min, 60% B; Wave Length: 220 nm]: to afford te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-2,2-dimethyl- 6-[4-(methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]-tetrahydro-3 aH-cyclopenta[d][1,3]dioxol-4- yl]methyl}(1,3-thiazol-5-yl)amino)propyl]carbamate 91a (80 mg, 81%) as an off-white solid. LCMS [conditions Cortecs C18+, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-5min, 1.50 L/min, ES, m/z]: T R = 2.64 min; [M + H] + : 558.

(1S,2R,3R,5R)-3-{[(3-Aminopropyl)(1,3-thiazol-5-yl)amino] methyl}-5-[4-(methylamino)pyrrolo[2 / 3- d]pyrimidin-7-yl]cyclopentane-1,2-diol

To te/'Abutyl-A/-[3-({[(3cxR,4R,6R,6cxS)-2,2-dimethyl-6-[4-(met hylamino)pyrrolo[2,3-d]pyrimidin-7- yl]-tetrahydro-3cxH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1, 3-thiazol-5-yl)amino)propyl] carbamate 91a (80 mg, 0.14 mmol, 1.0 eq) was added HCI (4M in 1,4-dioxane, 2.0 mL) and the reaction mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum, the residue was dissolved in methanol (1.0 mL) and neutralized to pH>7 with NH 3 *H 2 O. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 *H 2 O), Mobile Phase B: Acetonitrile; Flow rate: 30 mL/min; Gradient: 24% B to 45% B in 7 min, 45% B; Wave Length: 220 nm]: to afford (1S,2R,3R,5R)-3-{[(3-aminopropyl)(1,3-thiazol-5-yl)amino]met hyl}-5-[4- (methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentane-1,2-d iol 437 (31.1 mg, 52%) as an off- white solid. 1 H NMR (300 MHz, DMSO-okW} <58.18 (s, 1H), 8.09 (s, 1H), 7.24 (d, 7 = 3.6 Hz, 1H), 6.91 (s, 1H), 6.52 (d, 7 = 3.5 Hz, 1H), 4.79 (q, 7 = 8.8 Hz, 1H), 4.32-4.22 (m, 1H), 3.77 (t, 7 = 4.9 Hz, 1H), 3.53-3.34 (m, 1H), 3.31-3.12 (m, 3H), 2.93 (s, 3H), 2.61-2.52 (m, 2H), 2.29 (s, 1H), 2.23-2.07 (m, 1H), 1.71-1.57 (m, 2H), 1.56-1.40 (m, 1H). LCMS [conditions ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 L/min, ES, m/z]: T R = 0.93 min; [M + H] + : 418. Chiral HPLC [CHIRALPAK IC-3, 50*4.6mm, Sum, Mobile Phase A: Water/0.05% MSA, Mobile Phase B: CAN, Total Flow: 1.00 mL/min]: T R = 0.87 (major isomer), T R = 2.08 (minor isomer), dr>99:1.

Synthesis of (IR^S^KSRj-S-tA-fMethylaminojpyrrolo^S-dlpyrimidin-y-yO-S-Gt fSSj-piperidin-S- ylmethyl](1,3-thiazol-5-yl)amino}methyl)cyclopentane-1,2-dio l (438)

/V-{[(3aR ; 4R / 6R,6aS)-6-{4-chloropyrrolo[2 / 3-d]pyrimidin-7-yl)-2,2-dimethyl-tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]methyl}-1,3-thiazol-5-amine (80a)

To 1,3-thiazol-5-amine hydrochloride (0.09 g, 0.70 mmol, 1.5 eq), in DCM (1.0 mL) and AcOH (0.28 g, 4.70 mmol, 10.0 eq), was added NaBH(OAc) 3 (0.20 g, 0.90 mmol, 2.0 eq) and the resulting mixture was stirred for 30 min at 0 °C. To this mixture was added (3aR,4S,6R,6aS)-6-{4- chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxole-4- carbaldehyde 5 (0.15 g, 0.50 mmol, 1.0 eq) in DCM (1.0 mL), dropwise, over 3 min, at 0 °C, and the reaction mixture was stirred for 30 min at 0 °C. The crude residue was purified by silica gel column chromatography (94:6 DCM:MeOH) to afford A/-{[(3cxR,4R,6R,6cxS)-6-{4- chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4- yl]methyl}-1,3-thiazol-5-amine 80a (0.15 g, 79%) as a light brown solid. LCMS [conditions Cortecs C18+, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol,

10%-95%B-2min (+), 1.50 L/min, ES, m/z, ES, m/z]: T R = 1.33 min; [M + H] + : 406 feW-Butyl-(3S)-3-[({[(3aR ; 4R / 6R,6aS)-6-{4-chloropyrrolo[2 / 3-d]pyrimidin-7-yl)-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1,3-thi azol-5-yl)amino)methyl]piperidine-1- carboxylate (81a)

To A/-{[(3cxR,4R,6R,6cxS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7- yl}-2,2-dimethyl-tetrahydro-3cxH- cyclopenta[d][1,3]dioxol-4-yl]methyl}-1,3-thiazol-5-amine 80a (0.15 g, 0.40 mmol, 1.0 eq) in DCM (1.0 mL) and AcOH (0.22 g, 3.70 mmol, 10.0 eq) was added NaBH(OAc) 3 (0.16 g, 0.70 mmol, 2.0 eq) and the resulting mixture was stirred for 30 min at 0 °C. To the above mixture was added te/'Abutyl-(3S)-3-formylpiperidine-1-carboxylate (0.12 g, 0.50 mmol, 1.5 eq) in DCM (1.0 mL), dropwise over 3 min, at 0 °C and the reaction mixure was stirred for 30 mins at 0 °C. The resulting mixture was purified by silica gel column chromatography (93:7 DCM:MeOH) to afford te/'f-butyl-(3S)-3-[({[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2, 3-d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1,3-thi azol-5-yl)amino)methyl]piperidine-1- carboxylate 81a (0.12 g, 54%) as a light brown oil. LCMS [conditions XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-2min (+), 1.50 L/min, ES, m/z): T R = 1.51 min; [M + H] + : 603.

(3S)-3-[({[(3aR ; 4R,6R,6aS)-2,2-Dimethyl-6-[4-(methylamino)pyrrolo[2,3- d]pyrimidin-7-yl]- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1,3-thi azol-5-yl)amino)methyl]piperidine-1- carboxylate (82a)

To te/'f-butyl-(3S)-3-[({[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2, 3-d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3cxH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1,3-th iazol-5-yl)amino)methyl]piperidine-1- carboxylate 81a (0.12 g, 0.20 mmol, 1.0 eq) in methylamine (30% in ethanol, 2.0 mL). The resulting mixture was stirred for 2 h at 80 °C. The residue was purified by Prep-HPLC to afford te/f-butyl (3S)-3-[({[(3cxR,4R,6R,6cxS)-2,2-dimethyl-6-[4-(methylamino) pyrrolo[2,3-d]pyrimidin-7-yl]- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1,3-thi azol-5-yl)amino)methyl]piperidine-1- carboxylate 82a (0.10 g, 84%) as an off-white solid. LCMS [conditions XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-5min (+), 1.50 L/min, ES, m/z]: T R = 3.57 min; [M + H] + : 598.

(1R,2S,3R,5R)-3-[4-(Methylamino)pyrrolo[2,3-d]pyrimidin-7 -yl]-5-({[(3S)-piperidin-3- ylmethyl](1,3-thiazol-5-yl)amino}methyl)cyclopentane-1,2-dio l (438)

To terAbutyl-(3S)-3-[({[(3aR,4R,6R,6aS)-2,2-dimethyl-6-[4-(meth ylamino)pyrrolo[2,3-d]pyrimidin- 7-yl]-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1 ,3-thiazol-5- yl)amino)methyl]piperidine-1-carboxylate 82a (0.10 g, 0.20 mmol, 1.0 eq) was added HCI (4 M in 1,4-dioxane, 2.0 mL) and the reaction mixture was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum, the crude residue was dissolved in methanol and the solution was neutralized to pH >7 with NH 4 *H 2 O. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 50% B in 8 min, 49% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4- (methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]-5-({[(3S)-piperid in-3-ylmethyl](1,3-thiazol-5- yl)amino}methyl)cyclopentane-1,2-diol 438 (32.7 mg, 43%) as an off-white solid. 1 H NMR (300 MHz, DMSO-rVD 2 O) <58.19 (s, 1H), 8.10 (s, 1H), 7.24 (d, 7 = 3.6 Hz, 1H), 6.91 (s, 1H), 6.52 (d, 7 = 3.5 Hz, 1H), 4.84-4.69 (m, 1H), 4.34-4.21 (m, 1H), 3.82-3.73 (m, 1H), 3.49-3.39 (m, 1H), 3.31-3.17 (m, 1H), 3.11-3.03 (m, 2H), 2.94 (s, 3H), 2.90-2.70 (m, 2H), 2.46-2.25 (m, 2H), 2.24-2.09 (m, 2H), 1.93- 1.76 (m, 1H), 1.75-1.61 (m, 1H), 1.60-1.46 (m, 2H), 1.42-1.18 (m, 1H), 1.17-0.96 (m, 1H). LCMS [conditions Cortecs C18+, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 L/min, ES, m/z]: T R = 0.55 min; [M + H] + : 458. Chiral HPLC [YMC Cellulose SB, 100*4.6mm, Sum, Mobile Phase A: Water/0.05% MSA, Mobile Phase B: CAN, Total Flow: 1.00 mL/min]: T R = 1.38 min (major isomer), 1.68 min (minor isomer); dr >99:1.

Synthesis of (1R,2S,3R,5R)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3- (phenethylamino)propyl)(thiazol-5-yl)amino)methyl)cyclopenta ne-1,2-diol (439) feW-Butyl-(3-((((3aR ; 4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-py rrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)(thiazol-5- yl)amino)propyl)(phenethyl)carbamate

To teW-butyl-A/-[3-({[(3aR,4R,6R,6aS)-6-(4-{[(4- methoxyphenyl)methyl](methyl)amino}pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}amino)propyl]-/V-(2 -phenylethyl)carbamate 67a (0.10 g, 0.14 mmol, 1.0 eq) and toluene (5.0 mL) was added 5-bromo-1,3-thiazole (117 mg, 0.72 mmol, 5.0 eq), Pd 2 (dba) 3 (13 mg, 0.02 mmol, 0.1 eq), BINAP (13 mg, 0.02 mmol, 0.15 eq) and ABuONa (69 mg, 0.72 mmol, 5.0 eq) and the reaction mixture was stirred at 100 °C, for 16 h, under N 2 . The resulting mixture was concentrated under reduced pressure and the crude residue was purified by reverse flash chromatography [column, C18 silica gel; mobile phase, MeOH in Water/0.05% ammonia water, 50% to 90% gradient in 15 min; detector, UV 220 nm]: to afford te/'Abutyl-/V-[3- ({[(3cxR,4R,6R,6cxS)-6-(4-{[(4-methoxyphenyl)methyl](methyl) amino}pyrrolo[2,3-d]pyrimidin-7-yl)- 2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]me thyl}(1,3-thiazol-5- yl)amino)propyl]-/V-(2-phenylethyl)carbamate 69a (93 mg, 63%) as a brown solid. LCMS [conditions: Kinetex XB-C18, 50*3.0 mm, 2.6 pm, Mobile Phase A: Water/ 5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B(2min)-4min, 1.50 mL/min, ES, m/z]: T R = 2.49 min; [M + H] + : 782.

(1R,2S,3R,5R)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-(((3- (phenethylamino)propyl)(thiazol-5-yl)amino)methyl)cyclopenta ne-1,2-diol (439)

To teW-butyl- methoxyphenyl)methyl](methyl)amino]pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro-

3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1,3-thiazol-5-y l)amino)propyl]-AA(2- phenylethyl)carbamate 69a (91 mg, 0.12 mmol, 1.0 eq) at 0 °C was added trifluoroacetic acid (2.0 mL) and the reaction mixture was stirred at room temperature for 16 h. The resulting mixture was concentrated under vacuum and the residue was diluted with DMF (2.0 mL) and basified to pH 9- 10 with NH 3 *H 2 O. The crude product was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 «H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 49% B in 7 min, 49% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-(methylamino)pyrrolo[2,3-d]pyrimidin-7-yl ]-5-[({3-[(2- phenylethyl)amino]propyl}(1,3-thiazol-5-yl)amino)methyl]cycl opentane-1,2-diol 439 (16.2 mg, 27%) as an off white solid. 1 H NMR (300 MHz, Chloroform-o) <58.31 (s, 1H), 8.17 (d, J - 0.8 Hz, 1H), 7.41-7.29 (m, 2H), 7.26-7.17 (m, 3H), 7.02 (d, 7= 0.9 Hz, 1H), 6.93 (d, 7 = 3.6 Hz, 1H), 6.37 (d, 7 = 3.6 Hz, 1H), 5.26-5.06 (m, 1H), 4.78-4.58 (m, 1H), 4.33-4.20 (m, 1H), 4.08-3.98 (m, 1H), 3.47-3.08 (m, 6H), 2.94-2.87 (m, 2H), 2.86-2.78 (m, 2H), 2.77-2.62 (m, 2H), 2.60-2.45 (m, 2H), 1.91-1.65 (m, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-50%-95%B-5min, 1.50 mL/min, ES, m/z]: T R = 1.80 min; [M + H] + : 522. Chiral-SFC [Column: Lux-4 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min]: T R =1.44 min (major isomer), 2.08 min (minor isomer); dr > 99:1.

Synthesis of (1R,2S,3R,5R)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3- (phenethylamino)propyl)(phenyl)amino)methyl)cyclopentane-1,2 -diol (440) fe/AButyl-(3-((((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(meth yl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)methyl)amino)propyl)(phenethyl)carbamate (67a)

To 7-[(3aS,4R,6R,6aR)-6-(aminomethyl)-2,2-dimethyl-tetrahydro-3 aH-cyclopenta[d][1,3]dioxol-4- yl]-A/-[(4-methoxyphenyl)methyl]-A/-methylpyrrolo[2,3-d]pyri midin-4-amine (Intermediate A, 0.33 g, 0.75 mmol, 1.0 eq), in NMP (5.0 mL) was added terAbutyl-A/-(3-bromopropyl)-A/-(2- phenylethyl)carbamate 58a (387 mg, 1.13 mmol, 1.5 eq), and < 3 PO 4 (320 mg, 1.51 mmol, 2.0 eq) and the reaction mixture was stirred at 80 °C or 2 h. The mixture was concentrated under vacuum and purified by reverse flash chromatography [column, C18 silica gel; mobile phase, MeOH in Water/0.05% ammonia water, 50% to 90% gradient in 15 min; detector, UV 220 nm]: to afford terAbutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-(4-{[(4- methoxyphenyl)methyl](methyl)amino]pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl]amino)propyl]-A/-(2 -phenylethyl)carbamate 67a (260 mg, 49%) as an off-white solid. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/ 5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-5min, 1.50 mL/min, ES, m/z]: T R = 4.19 min; [M + H] + : 699. feW-Butyl-(3-((((3aR ; 4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-py rrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)methyl)(phenyl)amino)propyl)(phenethyl)carbamate (68a)

Boc— N

To teW-butyl- methoxyphenyl)methyl](methyl)amino}pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}amino)propyl]-/V-(2 -phenylethyl)carbamate 67a (72 mg, 0.10 mmol, 1.0 eq) in toluene (2.0 mL) was added bromobenzene (49 mg, 0.31 mmol, 3.0 eq), t- BuONa (30 mg, 0.31 mmol, 3.0 eq) and P(t-Bu) 3 -PdCI-2nd G (11 mg, 0.02 mmol, 0.2 eq) and the reaction mixture was stirred for 6 h at 80 °C under N 2 . The resulting mixture was concentrated under vacuum and the crude residue was purified by silica gel column chromatography (50:50 petroleum ether:AcOEt) to afford te/'Cbutyl-A/-[3-({[(3cxR,4R,6R,6cxS)-6-(4-{[(4- methoxyphenyl)methyl](methyl)amino}pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(phenyl)amino)propy l]-/V-(2-phenylethyl)carbamate 68a (61 mg, 76%) as an off-white solid. LCMS [conditions: Kinetex XB-C18, 50*3.0 mm, 2.6 pm, Mobile Phase A: Water/ 5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 2.72 min; [M + H] + : 775.

(1R,2S,3R,5R)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-(((3- (phenethylamino)propyl)(phenyl)amino)methyl)cyclopentane-1,2 -diol (440)

To teW-butyl- methoxyphenyl)methyl](methyl)amino}pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(phenyl)amino)propy l]-/V-(2-phenylethyl)carbamate 68a (59 mg, 0.08 mmol, 1.0 eq) was added trifluoroacetic acid (1.0 mL) at 0 °C and the reaction mixture was stirred for 16 h at room temperature. The resulting mixture was concentrated under vacuum and the residue was dissolved in DMF (2.0 mL) and basified to pH 9-

10 with NH 3 *H 2 O. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 «H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 24% B to 49% B in 7 min, 49% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-(methylamino)pyrrolo[2,3-d]pyrimidin-7-yl ]-5-{[phenyl({3- [(2-phenylethyl)amino]propyl})amino]methyl}cyclopentane-1,2- diol 440 (16.2 mg, 41%) as an off- white solid. 1 H NMR (300 MHz, Chloroform-o) 58.32 (s, 1H), 7.35-7.31 (m, 1H), 7.30-7.14 (m, 6H), 6.92 (d, 7 = 3.7 Hz, 1H), 6.85-6.71 (m, 3H), 6.36 (d, 7= 3.6 Hz, 1H), 5.10 (s, 1H), 4.71-4.55 (m, 1H), 4.27 (t, 7 = 7.3 Hz, 1H), 4.09-4.00 (m, 1H), 3.65-3.51 (m, 1H), 3.50-3.36 (m, 2H), 3.33-3.25 (m, 1H), 3.24-3.19 (m, 3H), 2.96-2.78 (m, 4H), 2.76-2.66 (m, 2H), 2.65-2.58 (m, 1H), 2.57-2.46 (m, 1H), 1.88- 1.72 (m, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min-1.5, 1.50 mL/min, ES, m/z]: T R = 1.32 min; [M + H] + : 515. Chiral-SFC [Column: Lux-4 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH3), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min]: T R =1.48 min; single peak.

Synthesis of (1S,2R,3R,5R)-3-(((1-methyl-1H-pyrazol-4-yl)(3- (phenethylamino)propyl)amino)methyl)-5-(4-(methylamino)-7H-p yirolo[2,3-d]pyrimidin-7- yl)cyclopentane-1,2-diol (441)

7-((3aS,4R,6R,6aR)-2,2-Dimethyl-6-(((1-methyl-1H-pyrazol- 4-yl)amino)methyl)tetrahydro-4H- cyclopenta[d][1 ; 3]dioxol-4-yl)-/V-(4-methoxybenzyl)-/V-methyl-7H-pyrro lo[2,3-d]pyrimidin-4- amine (70a)

To 1-methylpyrazol-4-amine (67 mg, 0.69 mmol, 2.0 eq) in DCM (5.0 mL) and AcOH (41 mg, 0.69 mmol, 2.0 eq), was added (3cxR,4S,6R,6cxS)-6-(4-{[(4- methoxyphenyl)methyl](methyl)amino}pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxole-4-carbaldehyde 19a (150 mg, 0.34 mmol, 1.0 eq) and NaBH(OAc) 3 (146 mg, 0.69 mmol, 2.0 eq), at 0 °C, and the reaction mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated under vacuum and the crude residue was purified by reverse flash chromatography [column, C18 silica gel; mobile phase, MeOH in Water/0.05% ammonia water, 50% to 90% gradient in 15 min; detector, UV 220 nm]: to afford A/- {[(3aR,4R,6R,6cxS)-6-(4-{[(4-methoxyphenyl)methyl](methyl)am ino}pyrrolo[2,3-d]pyrimidin-7-yl)- 2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]me thyl}-1-methylpyrazol-4-amine 70a (150 mg, 59%) as a light brown solid. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/ 5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 30%-95%B-5min, 1.50 mL/min, ES, m/z]: T R = 2.89 min; [M + H] + : 518. fe/AButyl-/V-(3-oxopropyl)-/V-(2-phenylethyl)carbamate (71a)

To a solution of te/'f-butyl-/V-(3-hydroxypropyl)-/V-(2-phenylethyl)carbamate 57a (2.0 g, 7.16 mmol, 1.0 eq) in DCM (20.0 mL) was added DMP (3.90 g, 9.31 mmol, 1.3 eq) and the reaction mixture was stirred for 1 h at room temperature. The crude residue was purified by silica gel column chromatography (50:50 Petroleum ether: AcOEt) to afford te/'Abutyl-A/-(3-oxopropyl)-/V- (2-phenylethyl)carbamate 71a (1.30 g, 65%) as a colorless oil. fe/AButyl-(3-((((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(meth yl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)(1-methyl-1H- pyrazol-4-yl)amino)propyl)(phenethyl)carbamate (72a)

To A/-{[(3cxR,4R,6R,6cxS)-6-(4-{[(4-methoxyphenyl)methyl](methy l)amino}pyrrolo[2,3-d]pyrimidin- 7-yl)-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4 -yl]methyl}-1-methylpyrazol-4- amine 70a (150 mg, 0.20 mmol, 1.0 eq) in DCM (3.0 mL) and AcOH (24 mg, 0.41 mmol, 2.0 eq) were added te/'Cbutyl-A/-(3-oxopropyl)-A/-(2-phenylethyl)carbamate 71a (84 mg, 0.30 mmol, 1.5 eq) and NaBH(OAc) 3 (86 mg, 0.41 mmol, 2.0 eq), at 0°C, and the reaction mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated under vacuum and the crude residue was purified by reverse flash chromatography [column, C18 silica gel; mobile phase, MeOH in Water/0.05% ammonia water, 50% to 90% gradient in 15 min; detector, UV 220 nm)]: to afford teW-butyl-A/-[3-({[(3aR,4R,6R,6aS)-6-(4-{[(4- methoxyphenyl)methyl](methyl)amino]pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl](1-methylpyrazol-4- yl)amino)propyl]-A/-(2- phenylethyl)carbamate 72a (120 mg, 76%) as a light brown solid. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/ 5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 30%- 95%B-5min, 1.50 mL/min, ES, m/z]: T R = 4.08 min; [M + H] + : 779.

(1S,2R,3R,5R)-3-(((1-Methyl-1H-pyrazol-4-yl)(3-(phenethyl amino)propyl)amino)methyl)-5-(4- (methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1 ,2-diol (441) HO

To teW-butyl-A/-[3-({[(3aR,4R,6R,6aS)-6-(4-{[(4- methoxyphenyl)methyl](methyl)amino]pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl](1-methylpyrazol-4- yl)amino)propyl]-A/-(2- phenylethyl)carbamate 72a (60 mg, 0.08 mmol, 1.0 eq) was added trifluoroacetic acid (2.0 mL) at 0 °C and the reaction mixture was stirred at room temperature for 16 h. The resulting mixture was concentrated under vacuum, the residue was dissolved in DMF (2.0 mL) and basified to pH 9-10 with NH 3 *H 2 O. The crude product was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 «H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 24% B to 49% B in 9 min, 49% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-(methylamino)pyrrolo[2,3-d]pyrimidin-7-yl ]-5-{[(1- methylpyrazol-4-yl)({3-[(2-phenylethyl)amino]propyl})amino]m ethyl}cyclopentane-1,2-diol 441 (10.9 mg, 27%) as an off-white solid. 1 H NMR (300 MHz, Chloroform-o) 5 8.32 (s, 1H), 7.36-7.30 (m, 2H), 7.25-7.18 (m, 4H), 7.05-6.98 (m, 1H), 6.95 (d, 7 = 3.6 Hz, 1H), 6.37 (d, 7 = 3.6 Hz, 1H), 5.12 (d, 7 = 5.8 Hz, 1H), 4.76-4.60 (m, 1H), 4.29-4.19 (m, 1H), 4.10-3.99 (m, 1H), 3.84 (s, 3H), 3.22 (d, 7 = 5.0 Hz, 3H), 3.18-3.01 (m, 3H), 2.99-2.82 (m, 5H), 2.81-2.65 (m, 2H), 2.56-2.37 (m, 2H), 1.86-1.65 (m, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min-1.5, 1.50 mL/min, ES, m/z]: T R = 1.13 min; [M + H] + : 519. Chiral-SFC [Column: Lux-4 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH3), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min]: T R = 1.09 min; single peak.

Synthesis of (1R,2S,3R,5R)-3-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3- (phenethylamino)propyl)(1H-pyrazol-4-yl)amino)methyl)cyclope ntane-1,2-diol (442)

Synthesis of 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine 4-Nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (76a)

N " y-NO- N-y

To 4-nitropyrazole (0.60 g, 5.3 mmol, 1.0 eq) in THF (10.0 mL) was added NaH (0.64 g, 15.9 mmol, 3.0 eq) in several portions at 0 °C under N 2 and the reaction mixture was stirred at room temperature for 30 min. The resulting mixture was cooled to 0 °C and then SEMCI (1.77 g, 10.6 mmol, 2.0 eq) was added and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of H 2 O (20.0 mL) at 0 °C and the resulting mixture was extracted with AcOEt (2x20 mL). The combined organic layers were dried over anhydrous Na 2 SO 4 , filtered and then the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford 4-nitro-1-{[2- (trimethylsilyl)ethoxy]methyl]pyrazole 76a (1.20 g, 93%) as a colorless oil.

1-((2-(Trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-amine (75a)

To 4-nitro-1-{[2-(trimethylsilyl)ethoxy]methyl]pyrazole 76a (1.20 g, 4.90 mmol, 1.0 eq) in AcOEt (20.0 mL) was added Pd/C (0.20 g, 1.90 mmol, 0.4 eq) and the resulting mixture was stirred for 2 h at room temperature under a H 2 baloon. The resulting mixture was filtered and the filtrate was concentrated under reduced pressure to afford 1-{[2-(trimethylsilyl)ethoxy]methyl]pyrazol-4- amine 75a (1.05 g, 99%) as a light brown oil. LCMS [Poroshell HPH-C18, 50*3.0 mm, 2.7 urn; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-5min(+-), 1.50 mL/min, ES, m/z]: T R = 2.98 min; [M + H] + : 214.

7-((3aS,4R,6R,6aR)-2,2-Dimethyl-6-(((1-((2-(trimethylsily l)ethoxy)methyl)-1H-pyrazol-4- yl)amino)methyl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl) -/V-(4-methoxybenzyl)-/V-methyl-

7H pyrrolo[2,3 d]pyrimidin •4- amin

To 1-{[2-(trimethylsilyl)ethoxy]methyl}pyrazol-4-amine 75a (73 mg, 0.30 mmol, 1.5 eq) in DCM (5.0 mL) and acetic acid (27 mg, 0.5 mmol, 2.0 eq), at 0 °C, were added (3aR,4S,6R,6aS)-6-(4- {[(4-methoxyphenyl)methyl](methyl)amino}pyrrolo[2,3-d]pyrimi din-7-yl)-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxole-4-carbaldehyde 19a (100 mg, 0.20 mmol, 1.0 eq) and NaBH(OAc) 3 (97 mg, 0.5 mmol, 2.0 eq) and the reaction mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated under vacuum and the crude residue was purified by reverse phase flash [column, C18 silica gel; mobile phase, CH 3 CN in Water/0.05% ammonia water, 20% to 60% gradient in 15 min; detector, UV 220 nm)]: to afford A/-{[(3aR,4R,6R,6aS)-6-(4-{[(4- methoxyphenyl)methyl](methyl)amino}pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro-

3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}-1-{[2-(trimethy lsilyl)ethoxy]methyl}pyrazol-4-amine 73a (90 mg, 62%) as an off-white solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B(2min)-4min(+), 1.00 mL/min, ES, m/z]: T R = 2.36 min; [M + H] + : 634. fcW-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(meth yl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)(1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)amino)propyl) (phenethyl)carbamate (74a)

To te/'Abutyl-A/-(3-oxopropyl)-A/-(2-phenylethyl)carbamate 71a (31 mg, 0.10 mmol, 1.2 eq) in DCM (3.0 mL) was added acetic acid (56 mg, 0.10 mmol, 10.0 eq) at room temperature and the resulting mixture was stirred for 30 min at room temperature. After this time /V- {[(3aR,4R,6R,6cxS)-6-(4-{[(4-methoxyphenyl)methyl](methyl)am ino}pyrrolo[2,3-d]pyrimidin-7-yl)- 2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]me thyl}-1-{[2- (trimethylsilyl)ethoxy]methyl}pyrazol-4-amine 73a (60 mg, 0.10 mmol, 1.0 eq) in DCM (1.0 mL) was added and the resulting mixture was stirred for 1 h at room temperature. Then Boc 2 O (31 mg, 0.10 mmol, 1.5 eq) and TEA (144 mg, 1.4 mmol, 15.0 eq) were added and the reaction mixture was stirred for 30 min at room temperature. The resulting mixture was concentrated under reduced pressure and the crude product was purified by HPLC [Column: Xtimate C18 50x250mm, 10um; Mobile Phase A: Water(0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 90 mL/min; Gradient: 75% B to 90% B in 12 min, 90% B; Wave Length: 220 nm]: to afford te/'Cbutyl-A/-[3-({[(3cxR,4R,6R,6cxS)- 6-(4-{[(4-methoxyphenyl)methyl](methyl)amino}pyrrolo[2,3-d]p yrimidin-7-yl)-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1-{[2-( trimethylsilyl)ethoxy]methyl}pyrazol- 4-yl)amino)propyl]-A/-(2-phenylethyl)carbamate 74a (30 mg, 35%) as a yellow solid. LCMS [Poroshell HPH-C18, 50*3.0 mm, 2.7 urn; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-5min(+-), 1.50 mL/min, ES, m/z]: T R = 4.54 min; [M + H] + : 895.

(1R,2S,3R,5R)-3-(4-(Methylamino)-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-(((3- (phenethylamino)propyl)(1H-pyrazol-4-yl)amino)methyl)cyclope ntane-1,2-diol (442)

To teW-butyl-A/-[3-({[(3aR,4R,6R,6aS)-6-(4-{[(4- methoxyphenyl)methyl](methyl)amino]pyrrolo[2,3-d]pyrimidin-7 -yl)-2,2-dimethyl-tetrahydro-

3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1-{[2-(trimethy lsilyl)ethoxy]methyl}-pyrazol-4- yl)amino)propyl]-A/-(2-phenylethyl)carbamate 74a (30 mg, 0.03 mmol, 1.0 eq) was added TEA (1.0 mL), at room temperature, and the reaction mixture was stirred at 50 °C for 2 h. The resulting mixture was concentrated under reduced pressure and the residue was basified to pH 10 with NH 3 .H 2 O. The crude product was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H2O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 55% B in 7 min, 55% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-(methylamino)pyrrolo[2,3-d]pyrimidin-7-yl ]-5-[({3-[(2- phenylethyl)amino]propyl}(1H-pyrazol-4-yl)amino)methyl] cyclopentane-1,2-diol 442 (10.5 mg, 62%) as an off-white solid. 1 H NMR (400 MHz, DMSO-d6) 5 12.16 (s, 1H), 8.12 (s, 1H), 7.41-7.32 (m, 1H), 7.29-7.21 (m, 3H), 7.20-7.12 (m, 5H), 6.56-6.49 (m, 1H), 4.88-4.74 (m, 2H), 4.64 (s, 1H), 4.34- 4.22 (m, 1H), 3.81-3.73 (m, 1H), 3.20-3.10 (m, 1H), 3.07-2.98 (m, 2H), 2.97-2.87 (m, 4H), 2.74-2.63 (m, 4H), 2.57-2.52 (m, 2H), 2.26-2.07 (m, 2H), 1.63-1.42 (m, 3H). LCMS [conditions ZORBAX SB- Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 5%- 95%B-3min, 1.50 mL/min, ES, m/z]: T R = 1.08 min; [M + H] + : 505. Chiral-SFC [Column: SB 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min]: T R = 1.18 min; single peak.

Synthesis of (1R ; 2S,3R,5R)-3-[4-(methylamino)pyrrolo[2,3-d]pyrimidin-7- yl]-5-{[(1-methylpyrazol- 3-yl)({3-[(2-phenylethyl)amino]propyl})amino]methyl}cyclopen tane-1,2-diol (443)

Synthesis of tert-butyl-N-{3-[(1-methylpyrazol-3-yl)amino]propyl}-N-(2-ph enylethyl)carbamate (83a) fe/AButyl-/V-(3-oxopropyl)-/V-(2-phenylethyl)carbamate (71a)

To terAbutyl-A/-(3-hydroxypropyl)-A/-(2-phenylethyl)carbamate 57a (2.00 g, 7.16 mmol, 1.0 eq) in DCM (20 mL) was added DMP (3.90 g, 9.31 mmol, 1.3 eq) and the reaction mixture was stirred for 1 h at room temperature. The crude residue was purified by silica gel column chromatography (50:50 Petroleum ether:AcOEt) to afford terAbutyl-A/-(3-oxopropyl)-A/-(2-phenylethyl)carbamate 71a (1.30 g, 65%) as a colorless oil. fe/AButyl-A/-{3-[(1-methylpyrazol-3-yl)amino]propyl}-/V-(2-p henylethyl)carbamate (83a)

To a solution of 1-methylpyrazol-3-amine (0.13 g, 1.30 mmol, 1.5 eq) in DCM (1.0 mL) was added AcOH (0.05 g, 0.9 mmol, 1.0 eq) and NaBH(OAc) 3 (0.38 mg, 1.8 mmol, 2.0 eq) and the reaction mixture was stirred for 30 min at 0 °C. To the resulting mixture was added terAbutyl- A/-(3- oxopropyl)-A/-(2-phenylethyl)carbamate 71 (0.25 g, 0.90 mmol, 1.0 eq) in DCM (1.0 mL), dropwise, over 3 min, at 0 °C and the reaction mixture was stirred for additional 30 min at 0 °C. The crude residue was purified by silica gel column chromatography (95:5 DCM:MeOH) to afford teW-butyl- A/-{3-[(1-methylpyrazol-3-yl)amino]propyl}-A/-(2-phenylethyl )carbamate 83a (0.20 g, 62%) as a light yellow oil. LCMS [conditions Xbridge Shield C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-5min (+), 1.50 L/min, ES, m/z]: T R = 3.61 min; [M + H] + : 359.

7eW-Butyl-AA[3-({[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1-methy lpyrazol-3-yl)amino)propyl]-/V-(2- phenylethyl)carbamate (84a)

To te/'Abutyl-A/-{3-[(1-methylpyrazol-3-yl)amino]propyl]-A/-(2- phenylethyl)carbamate 83a (0.20 g, 0.60 mmol, 1.5 eq) in DCM (1.0 mL) at 0°C was added AcOH (0.44 g, 7.40 mmol, 20 eq) and NaBH(OAc) 3 (0.16 g, 0.70 mmol, 2.0 eq) and the reaction mixture was stirred for 30 min at 0 °C. To the resultant mixture was added [(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl}- 2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]me thanol 5a (0.12 g, 0.37 mmol, 1.0 eq) in DCM (1.0 mL), dropwise over 3 min, at 0 °C, and the reaction mixture was stirred for additional 30 min at 0 °C. The resulting mixture was concentrated under vacuum, the residue was dissolved in MeOH (2.0 ml) and the crude residue was purified by Prep-HPLC [Column : Xtimate C18 50x250mm, 10um; Mobile Phase A: Water(0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 90 mL/min; Gradient: 45% B to 75% B in 12 min; Wave Length: 220 nm]: to afford tert- butyl-A/-[3-({[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyri midin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl](1-methylpyrazol-3- yl)amino)propyl]-A/-(2- phenylethyl)carbamate 84a (0.12 g, 49%) as a light yellow oil. LCMS [conditions Xbridge Shield C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 10%-95%B-5min(+) , 1.50 L/min, ES, m/z]: T R = 4.16 min; [M + H] + : 664.

7e/t-Butyl-/V-[3-({[(3aR ; 4R / 6R,6aS)-2,2-dimethyl-6-[4-(methylamino)pyrrolo[2 / 3-d]pyrimidin-7-yl]- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1-methy lpyrazol-3-yl)amino)propyl]-/V-(2- phenylethyl)carbamate (85a)

To te/f-butyl-A/-[3-({[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d ]pyrimidin-7-yl]-2,2-dimethyl- tetrahydro-3cxH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1-meth ylpyrazol-3-yl)amino)propyl]-A/-(2- phenylethyl)carbamate 84a (0.12 g, 0.20 mmol, 1.0 eq) was added methylamine (30% in ethanol, 2.0 ml) and the reaction mixture was stirred at 80 °C for 1 h. The resulting mixture was concentrated under vacuum to afford te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-2,2-dimethyl-6-[4- (methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]-tetrahydro-3cxH-c yclopenta[d][1,3]dioxol-4- yl]methyl}(1-methylpyrazol-3-yl)amino)propyl]-A/-(2-phenylet hyl)carbamate 85a (0.12 g, crude) as a light yellow solid. The crude product was used in the next step directly without further purification. LCMS [conditions Xbridge Shield C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-3min (+), 1.50 L/min, ES, m/z]: T R = 1.83 min; [M + H] + : 659 (1R,2S,3R,5R)-3-[4-(Methylamino)pyrrolo[2,3-d]pyrimidin-7-yl ]-5-{[(1-methylpyrazol-3-yl)({3-[(2- phenylethyl)amino]propyl})amino]methyl}cyclopentane-1,2-diol (443)

To te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-2,2-dimethyl-6-[4-(meth ylamino)pyrrolo[2,3-d]pyrimidin-7- yl]-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1-m ethylpyrazol-3-yl)amino)propyl]-/V- (2-phenylethyl)carbamate 85a (0.12 g, 0.20 mmol, 1.0 eq) was added HCI (4M in 1,4-dioxane, 2.0 mL) at room temperature and the resulting mixture was stirred for 1 h at room temperature and concentrated under vacuum. The resultant residue was dissolved in H 2 O (2.0 mL) and the mixture was neutralized to pH >7 with NH 3 *H 2 O. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 «H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 24% B to 50% B in 7 min, 50% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-(methylamino)pyrrolo[2,3- d]pyrimidin-7-yl]-5-{[(1-methylpyrazol-3-yl)({3-[(2- phenylethyl)amino]propyl})amino]methyl}cyclopentane-1,2-diol 443 (45.8 mg, 48 %) as an off- white solid. 1 H NMR (300 MHz, DMSO-A+D 2 O) <58.08 (s, 1H), 7.35-7.30 (m, 1H), 7.29-7.21 (m, 3H), 7.20-7.11 (m, 3H), 6.52 (d, 7 = 3.5 Hz, 1H), 5.56-5.50 (m, 1H), 4.88-4.75 (m, 1H), 4.30-4.20 (m, 1H), 3.79-3.74 (m, 1H), 3.58 (s, 3H), 3.38-3.25 (m, 1H), 3.23-3.07 (m, 3H), 2.92 (s, 3H), 2.67 (s, 3H), 2.49-2.42 (m, 3H), 2.33-2.21 (m, 1H), 2.20-2.01 (m, 1H), 1.68-1.55 (m, 2H), 1.54-1.39 (m, 1H). LCMS [conditions Cortecs C18+, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 0.70 min; [M + H] + : 519. Chiral-SFC [Column: IG 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min]: T R = 2.72 min; single peak.

Synthesis of ((1R,2S,3R,5R)-3-[4-(methylamino)pyrrolo[2,3-d]pyrimidin-7-y l]-5-[({3-[(2- phenylethyl)amino]propyl}(1H-pyrazol-3-yl)amino)methyl]cyclo pentane-1,2-diol (444) fcW-Butyl-/V-(2-phenylethyl)-/V-[3-(1H-pyrazol-3-ylamino)pro pyl]carbamate (86a) ' NH

To a solution of 1H-pyrazol-3-amine (0.11 g, 1.30 mmol, 1.5 eq) in DCM (1.0 mL), at 0 °C, was added AcOH (0.05 g, 0.90 mmol, 1.0 eq) and NaBH(OAc) 3 (0.38 g, 1.80 mmol, 2.0 eq), and the resulting mixture was stirred for 30 min at 0 °C. Then terAbutyl-A/-(3-oxopropyl)-A/-(2- phenylethyl)carbamate 71a (0.25 g, 0.9 mmol, 1.0 eq) in DCM (1.0 mL) was added dropwise over 3 min at 0 °C and the reaction mixture was stirred for 30 min at 0 °C. The crude residue was purified by silica gel column chromatography (96:4 DCM:MeOH) to afford te/f -butyl- A/-(2- phenylethyl)-A/-[3-(1H-pyrazol-3-ylamino)propyl]carbamate 86a (0.20 g, 64%) as a light yellow oil. LCMS [conditions HPH-C18, 30*3.0 mm, 1.9 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-1.2min(+) (+), 1.50 L/min, ES, m/z]: T R = 0.81 min;

[M + H] + : 345. fe/t-Butyl-/V-[3-({[(3aR ; 4R / 6R,6aS)-6-{4-chloropyrrolo[2 / 3-d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1H-pyra zol-3-yl)amino)propyl]-/V-(2- phenylethyl)carbamate (87a).

To a solution of te/'Abutyl-A/-(2-phenylethyl)-A/-[3-(1H-pyrazol-3-ylamino)pr opyl]carbamate 86a (0.29 g, 0.80 mmol, 1.5 eq) in DCM (1.0 mL), at 0 °C, was added AcOH (0.67 g, 11.1 mmol, 20 eq) and NaBH(OAc) 3 (0.23 g, 1.10 mmol, 2.0 eq) and the resulting mixture was stirred for 30 min at 0 °C. A solution of (3aR,4S,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2 -dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxole-4-carbaldehyde 77a (0.18 g, 0.60 mmol, 1.0 eq) in DCM (1.0 mL) was then added, dropwise over 3 min at 0 °C and the reaction mixture was stirred for 30 min at 0 °C. The resulting mixture was concentrated under vacuum and the crude residue was dissolved in MeOH (2.0 ml) and purified by Prep-HPLC [Column : Xtimate C18 50x250mm, 10um; Mobile Phase A: Water (0.1% NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 90 mL/min; Gradient: 35% B to 60% B in 12 min, 60% B; Wave Length: 220 nm]: to afford te/7-butyl-/V-[3- ({[(3aR,4R,6R,6cxS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl} -2,2-dimethyl-tetrahydro-3o(H- cyclopenta[d][1,3]dioxol-4-yl]methyl}(1H-pyrazol-3-yl)amino) propyl]-/V-(2-phenylethyl)carbamate 87a (0.09 g, 25%) as a light yellow oil. LCMS [conditions XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-5min(+), 1.50 L/min, ES, m/z, ES, m/z]: T R = 4.12 min; [M + H] + : 650. fe/'AButyl-/V-[3-({[(3aR,4R,6R,6o:S)-2,2-dimethyl-6-[4-(meth ylamino)pyrrolo[2,3-d]pyrimidin-7-yl]- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1H-pyra zol-3-yl)amino)propyl]-/V-(2- phenylethyl)carbamate (88a)

To te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(1H-pyra zol-3-yl)amino)propyl]-A/-(2- phenylethyl)carbamate 87a (90 mg, 0.14 mmol, 1.0 eq) was added methylamine solution (30% in EtOH, 2.0 mL) and the resulting mixture was stirred at 80 °C for 1 h. The resulting mixture was concentrated under vacuum to afford te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-2,2-dimethyl-6-[4- (methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]-tetrahydro-3cxH-c yclopenta[d][1,3]dioxol-4- yl]methyl}(1H-pyrazol-3-yl)amino)propyl]-A/-(2-phenylethyl)c arbamate 88a (90 mg, crude) as a light yellow solid. The crude product was used in the next step directly without further purification. LCMS [conditions XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH4HCO3, Mobile Phase B: Methanol, 10%-95%B-3min(+), 1.50 L/min, ES, m/z, ES, m/z]: T R = 2.27 min; [M + H] + : 645.

((1R,2S,3R,5R)-3-[4-(Methylamino)pyrrolo[2,3-d]pyrimidin- 7-yl]-5-[({3-[(2- phenylethyl)amino]propyl}(1H-pyrazol-3-yl)amino)methyl]cyclo pentane-1,2-diol (444)

To te/'Abutyl-A/-[3-({[(3cxR,4R,6R,6cxS)-2,2-dimethyl-6-[4-(met hylamino)pyrrolo[2,3-d]pyrimidin-7- yl]-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl](1H- pyrazol-3-yl)amino)propyl]-A/-(2- phenylethyl)carbamate 88a (90 mg, 0.20 mmol, 1.0 eq) was added HCI (4M in dioxane, 2.0 mL) at room temperature and the reaction mixture was stirred for 1 h at room temperature. The resultant mixture was concentrated under vacuum and then dissolved in H 2 O (2.0 mL) and neutralized to pH>7 with NH 3 *H 2 O. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 24% B to 51% B in 8 min, 51% B; Wave Length: 220 nm]: to afford ((1R,2S,3R,5R)-3-[4-(methylamino)pyrrolo[2,3- d]pyrimidin-7-yl]-5-[({3-[(2-phenylethyl)amino]propyl}(1H-py razol-3- yl)amino)methyl]cyclopentane-1,2-diol 444 (45.3 mg, 64%) as an off-white solid. 1 H NMR (300 MHz, DMSO-t4+ D 2 O) <58.08 (s, 1H), 7.39-7.31 (m, 1H), 7.30-7.20 (m, 3H), 7.19-7.11 (m, 3H), 6.52 (d, 7 = 3.6 Hz, 1H), 5.63-5.52 (m, 1H), 4.87-4.72 (m, 1H), 4.30-4.20 (m, 1H), 3.77-3.69 (m, 1H), 3.41- 3.27 (m, 1H), 3.25-3.07 (m, 3H), 2.92 (s, 3H), 2.78-2.67 (m, 4H), 2.51-2.43 (m, 2H), 2.35-2.22 (m, 1H), 2.20-2.06 (m, 1H), 1.72-1.56 (m, 2H), 1.54-1.37 (m, 1H). LCMS [conditions ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.02% TEA, Mobile Phase B: Acetonitrile, 5%-(20%- 50%)-95%B-5min, 1.50 mL/min, ES, m/z]: T R = 1.25 min; [M + H] + : 505. Chiral-SFC [Column: Lux-4 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min]: T R = 1.77 min; single peak.

Synthesis of (1S,2R,3R,5R)-3-((1,6-diazaspiro[3.3]heptan-1-yl)methyl)-5-( 4-(methylamino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol (445) fe/t-Butyl-1-(((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methy l)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)-1,6- diazaspiro[3.3]heptane-6-carboxylate

To a stirred solution of (3aR,4S,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-pyr rolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxole-4-carbaldehyde 19a (70 mg, 0.16 mmol, 1.0 eq) and 3,6-diazaspiro[3.3]heptane-6-carboxylic acid te/f-butyl ester hemioxylate (39 mg, 0.08 mmol, 0.5 eq) in DCM (1.0 mL) were added TEA (16 mq, 0.16 mmol, 1.0 eq) and NaBH(OAc) 3 (51 mq, 0.24 mmol, 1.5 eq) at room temperature and the reaction mixture was stirred for 1 h at room temperature. The resulting mixture was basified to pH 8-9 with 10% NaHCO 3 solution and extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 and filterd. The filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (AcOEt) to afford te/f-butyl-1- (((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methyl)amino)-7H-p yrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)- 1,6-diazaspiro[3.3]heptane-6- carboxylate 180a (75 mg, 76%) as a light yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-3min(+), 1.50 mL/min, ES, m/z]: T R = 2.02 min; [M + H] + : 619.

(1S,2R,3R,5R)-3-((1,6-Diazaspiro[3.3]heptan-1-yl)methyl)- 5-(4-(methylamino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)cyclopentane-1,2-diol

A solution of te/'Abutyl-1-(((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(methy l)amino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4-yl)methyl)- 1,6-diazaspiro[3.3]heptane-6-carboxylate 180a (75 mg, 0.12 mmol, 1.0 eq) in TEA (1.0 mL) was stirred for 16 h at room temperature. The resultinq mixture was concentrated under reduced pressure and the crude product was purified by Prep-HPLC [Column, XBridqe Shield RP18 OBD Column, 19*150 mm, 5pm; mobile phase, ACN and Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O) (18% up to 37% in 8 min); Detector, UV 220 nm]: to afford (1S,2R,3R,5R)-3-((1,6- diazaspiro[3.3]heptan-1-yl)methyl)-5-(4-(methylamino)-7H-pyr rolo[2,3-d]pyrimidin-7- yl)cyclopentane-1,2-diol 445 (14 mg, 32%) as a white solid. 1 H NMR (300 MHz, DMSO-d6) 5 8.12 (s, 1H), 7.45-7.33 (m, 1H), 7.24 (d, 7 = 3.5 Hz, 1H), 6.52 (d, 7 = 3.5 Hz, 1H), 4.94-4.66 (m, 3H), 4.29- 4.17 (m, 1H), 4.16-3.90 (m, 1H), 3.89-3.64 (m, 3H), 3.08-3.00 (m, 2H), 2.95 (d, 7 = 4.6 Hz, 3H), 2.76-2.63 (m, 1H), 2.26-2.13 (m, 3H), 1.95 (s, 1H), 1.56-1.41 (m, 1H). LCMS [conditions: Atlantis T3, 100*4.6 mm, 3 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 0%-20%- 95%B-7min, 1.50 mL/min, ES, m/z]: T R = 2.74 min; [M + H] + : 359. Chiral-SFC [Column: SB 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min: Gradient 50% solvent B for 4 mins]: T R = 1.92 min, single peak.

Synthesis of (1S,2R,3R,5R)-3-{1,6-Diazaspiro[3.4]octan-1-ylmethyl}-5-[4-( methylamino)pyrrolo[2,3- d]pyrimidin-7-yl]cyclopentane-1,2-diol (446) fe/t- Butyl 1-{[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl} -2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}-1,6-diazaspiro[3.4 ]octane-6-carboxylate (181a)

To a stirred solution of (3aR,4S,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl]-2,2 -dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxole-4-carbaldehyde 77a (0.10 g, 0.30 mmol, 1.0 eq) and te/'Abutyl-1,6-diazaspiro[3.4]octane-6-carboxylate (0.07 g, 0.30 mmol, 1.0 eq) in DCM (1.0 mL) was added NaBH(AcO) 3 (0.10g, 0.50 mmol, 1.5 eq) at room temperature and the reaction mixture was stirred for 1 h at room temperature. The resulting mixture was basified to pH 8-9 with 10% NaHCO 3 solution and extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (50:50 Petroleum ether:AcOEt) to afford te/'f-butyl-1-{[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyr imidin-7-yl}-2,2-dimethyl- tetrahydro-3cxH-cyclopenta[d][1,3]dioxol-4-yl]methyl}-1,6-di azaspiro[3.4]octane-6-carboxylate 181a (90 mg, 56%) as a yellow solid. LCMS [conditions Xbridge Shield C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2min(+), 1.50

L/min, ES, m/z]: T R = 1.46 min; [M + H] + : 518. feW-Butyl-1-{[(3aR ; 4R / 6R,6aS)-2,2-dimethyl-6-[4-(methylamino)pyrrolo[2 / 3-d]pyrimidin-7-yl]- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl)-1,6-dia zaspiro[3.4]octane-6-carboxylate (182a)

To te/'f-butyl-1-{[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyr imidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}-1,6-dia zaspiro[3.4]octane-6-carboxylate 181a (0.07 g, 0.13 mmol, 1.0 eq) was added methylamine (30% wt. in EtOH, 2.0 mL) at room temperature and the reaction mixture was stirred at 50 °C for 3 h. The resulting mixture was concentrated under reduced pressure to afford te/'Abutyl-1-{[(3cxR,4R,6R,6cxS)-2,2-dimethyl-6-[4- (methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]-tetrahydro-3aH-cy clopenta[d][1,3]dioxol-4- yl]methyl}-1,6-diazaspiro[3.4]octane-6-carboxylate 182a (50 mg, crude) as light yellow solid. The crude product was used in the next step directly without further purification. LCMS [conditions Xbridge Shield C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2min(+), 1.50 L/min, ES, m/z]: T R = 1.23 min; [M + H] + : 513.

(1S,2R,3R,5R)-3-{1,6-Diazaspiro[3.4]octan-1-ylmethyl}-5-[ 4-(methylamino)pyrrolo[2 / 3-d]pyrimidin-

7-yl]cyclopentane-1,2-diol (446) To a solution of te/'Abutyl-1-{[(3cxR,4R,6R,6cxS)-2,2-dimethyl-6-[4-(methylam ino)pyrrolo[2,3- d]pyrimidin-7-yl]-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4- yl]methyl}-1,6- diazaspiro[3.4]octane-6-carboxylate 182a (0.05 g, 0.10 mmol, 1.0 eq) in DCM (1.0 mL) was added TFA (1.0 mL) and the reaction mixture was stirred for 16 h at room temperature. The resulting mixture was concentrated under reduced pressure and the crude residue was dissolved in water (2.0 mL). The solution was adjusted to pH 9 with NH 3 *H 2 O and the crude product was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H2O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 43% B in 7 min, 42% B; Wave Length: 220 nm]: to afford (1S,2R,3R,5R)-3-{1,6- diazaspiro[3.4]octan-1-ylmethyl}-5-[4-(methylamino)pyrrolo[2 ,3-d]pyrimidin-7-yl]cyclopentane- 1,2-diol 446 (27 mg, 75%) as an off-white solid. 1 H NMR (400 MHz, DMSO-t4) <58.11 (s, 1H), 7.39- 7.31 (m, 1H), 7.26-7.19 (m, 1H), 6.52 (d, 7 = 3.5 Hz, 1H), 4.88-4.59 (m, 2H), 4.22-4.12 (m, 1H), 3.76- 3.69 (m, 1H), 3.25-3.10 (m, 2H), 3.10-2.99 (m, 1H), 2.98-2.93 (m, 3H), 2.91-2.75 (m, 1H), 2.74-2.63 (m, 1H), 2.62-2.54 (m, 1H), 2.46-2.30 (m, 2H), 2.22-2.10 (m, 1H), 2.07-1.77 (m, 5H), 1.53-1.37 (m, 1H). LCMS [conditions ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 2%-2%-95%B-3min, 1.50 L/min, ES, m/z]: T R = 0.79; 0.96 min; [M + H] + : 373. Chiral-SFC [Column: Lux-4 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min, keep Gradient 50% solvent B for 4 mins: two diastereomers]: T R = 1.82 min (major peak), T R = 2.13 (minor peak); dr = 55:45.

Synthesis of (1S,2R,3R,5R)-3-{1,6-Diazaspiro[3.5]nonan-1-ylmethyl}-5-[4- (methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentane-1,2-d iol (447)

Synthesis of fcW-butyl-1-{[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrim idin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}-1,6-dia zaspiro[3.5]nonane-6-carboxylate (183a)

To a stirred solution of (3aR,4S,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2 -dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxole-4-carbaldehyde 77a (0.10 mg, 0.30 mmol, 1.0 eq) and bis{ te/'Abutyl-1,6-diazaspiro[3.5]nonane-6-carboxylate oxalic acid (0.08 g, 0.20 mmol, 0.5 eq) in DCM (1.0 mL) were added TEA (0.03 g, 0.30 mmol, 1.0 eq) and NaBH(AcO) 3 (0.10 g, 0.50 mmol, 1.5 eq) at room temperature and the reaction mixture was stirred for 2 h at room temperature. The resulting mixture was basified to pH 8-9 with 10% NaHCO 3 solution and extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (50:50 Petroleum ethenAcOEt) to afford teW-butyl- 1-{[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl} -2,2-dimethyl-tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]methyl}-1,6-diazaspiro[3.5]non ane-6-carboxylate 183a (90 mg, 54%) as a yellow solid. LCMS [conditions Xbridge Shield C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2 min(+), 1.50 L/min, ES, m/z]: T R = 1.46 min; [M + H] + : 532. feW-Butyl-1-{[(3aR ; 4R / 6R,6aS)-2,2-dimethyl-6-[4-(methylamino)pyrrolo[2 / 3-d]pyrimidin-7-yl]- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl)-1,6-dia zaspiro[3.5]nonane-6-carboxylate (184a)

To ter/ L -butyl-1-{[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d]py rimidin-7-yl]-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}-1,6-dia zaspiro[3.5]nonane-6-carboxylate 183a (0.08 g, 0.15 mmol, 1.0 eq) was added methylamine (30%wt. in EtOH, 2.0 mL) at room temperature and the reaction mixture was stirred for 3 h at 50 °C. The resulting mixture was concentrated under reduced pressure to afford terAbutyl-1-{[(3aR,4R,6R,6aS)-2,2-dimethyl-6-[4- (methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]-tetrahydro-3cxH-c yclopenta[d][1,3]dioxol-4- yl]methyl]-1,6-diazaspiro[3.5]nonane-6-carboxylate 184a (0.07 g, crude) as light yellow solid. The crude product was used in the next step without further purification. LCMS [conditions Xbridge Shield C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2min(+), 1.50 L/min, ES, m/z]: T R = 1.25 min; [M + H] + : 527.

(1S,2R,3R,5R)-3-{1,6-Diazaspiro[3.5]nonan-1-ylmethyl}-5-[ 4-(methylamino)pyrrolo[2,3- d]pyrimidin-7-yl]cyclopentane-1,2-diol

To a solution of terAbutyl-1-{[(3aR,4R,6R,6aS)-2,2-dimethyl-6-[4-(methylamino )pyrrolo[2,3- d]pyrimidin-7-yl]-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4- yl]methyl}-1,6- diazaspiro[3.5]nonane-6-carboxylate 184a (0.07 g, 0.20 mmol, 1.0 eq) in DCM (1.0 mL) was added TEA (1.0 mL) and the reaction mixture was stirred for 16 h at room temperature. The resulting mixture was concentrated under reduced pressure and the crude residue was dissolved in water (2.0 mL). The solution was adjusted to pH 9 with NH 3 *H 2 O and the crude sample was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 51% B in 7 min, 51% B; Wave Length: 220 nm]: to afford (1S,2R,3R,5R)-3-{1,6- diazaspiro[3.5]nonan-1-ylmethyl]-5-[4-(methylamino)pyrrolo[2 ,3-d]pyrimidin-7-yl]cyclopentane- 1,2-diol 447 (34.3 mg, 67%) as an off-white solid. 1 H NMR (400 MHz, DMSO-t/j <58.11 (s, 1H), 7.40-7.32 (m, 1H), 7.22 (d, 7= 3.5 Hz, 1H), 6.52 (d, 7= 3.5 Hz, 1H), 4.85-4.76 (m, 1H), 4.75-4.66 (m, 1H), 4.24-4.11 (m, 1H), 3.75-3.67 (m, 1H), 3.21-3.00 (m, 2H), 2.95 (d, 7 = 4.7 Hz, 3H), 2.86-2.76 (m, 1H), 2.75-2.68 (m, 1H), 2.68-2.60 (m, 1H), 2.48-2.38 (m, 1H), 2.35-2.23 (m, 1H), 2.22-2.09 (m, 1H), 1.93-1.69 (m, 4H), 1.62-1.40 (m, 3H), 1.40-1.24 (m, 1H). LCMS [conditions ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 2%-2%-95%B-3min- 1.5.1cm, 1.50 L/min, ES, m/z]: T R = 1.03; 1.16 min; [M + H] + : 387. Chiral-SFC [Column: Lux-4 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. keep Gradient 50% solvent B for 4 mins: two diastereomers]: T R = 1.94 min (major peak), T R = 2.29 (minor peak); dr = 51.7:48.3.

Synthesis of (1S,2R,3R,5R)-3-{1,6-diazaspiro[3.5]nonan-1-ylmethyl}-5-[4- (methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentane-1,2-d iol (448)

7e/t-Butyl-6-{[(3aR ; 4R,6R,6aS)-6-{4-chloropyrrolo[2 / 3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}-2,6-diazaspiro[4.5 ]decane-2-carboxylate (185a)

To a stirred solution of (3aR,4S,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl]-2,2 -dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxole-4-carbaldehyde 77a (0.10 g, 0.30 mmol, 1.0 eq) and te/'f-butyl-2,6-diazaspiro[4.5]decane-2-carboxylate (0.07 g, 0.30 mmol, 1.0 eq) in DCM (1.0 mL) was added NaBH(AcO) 3 (0.10 g, 0.50 mmol, 1.5 eq) and the reaction mixture was stirred for 1 h at room temperature. The resulting mixture was basified to pH 8-9 with 10% NaHCO 3 solution, and extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (50:50 Petroleum ether:AcOEt) to afford te/f-butyl- 6-{[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl] -2,2-dimethyl-tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]methyl}-2,6-diazaspiro[4.5]dec ane-2-carboxylate 185a (0.10 g, 59%) as a yellow solid. LCMS [conditions Xbridge Shield C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2min (+), 1.50 L/min, ES, m/z]: T R = 1.54 min; [M + H] + : 546.

7e/7-Butyl-6-{[(3aR ; 4R / 6R,6aS)-2,2-Dimethyl-6-[4-(methylamino)pyrrolo[2,3-d]p yrimidin-7-yl]- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}-2,6-dia zaspiro[4.5]decane-2-carboxylate (186a)

To te/'f-butyl-6-{[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyr imidin-7-yl}-2,2-dimethyl- tetrahydro-3cxH-cyclopenta[d][1,3]dioxol-4-yl]methyl}-2,6-di azaspiro[4.5]decane-2-carboxylate 185a (0.08 g, 0.20 mmol, 1.0 eq) and methylamine (30% wt. in ethanol, 2.0 mL) at room temperature and the reaction mixture was stirred at 50 °C for 3 h. The resulting mixture was concentrated under reduced pressure to afford terAbutyl-6-{[(3aR,4R,6R,6aS)-2,2-dimethyl-6-[4- (methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]-tetrahydro-3cxH-c yclopenta[d][1,3]dioxol-4- yl]methyl]-2,6-diazaspiro[4.5]decane-2-carboxylate 186a (60 mg, crude) as a yellow solid. The crude product was used in the next step directly without further purification. LCMS [conditions Xbridge Shield C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2min(+), 1.50 L/min, ES, m/z]: T R = 1.54 min; [M + H] + : 541.

(1S,2R,3R,5R)-3-{1,6-Diazaspiro[3.5]nonan-1-ylmethyl}-5-[ 4-(methylamino)pyrrolo[2,3- d]pyrimidin-7-yl]cyclopentane-1,2-diol (448)

To te/'f-butyl-6-{[(3aR,4R,6R,6aS)-2,2-dimethyl-6-[4-(methylami no)pyrrolo[2,3-d]pyrimidin-7-yl]- tetrahydro-3cxH-cyclopenta[d][1,3]dioxol-4-yl]methyl}-2,6-di azaspiro[4.5]decane-2-carboxylate 186a (60 mg, 0.10 mmol, 1.0 eq) in DCM (1.0 mL) was added TEA (1.0 mL) and the reaction mixture was stirred for 16 h at room temperature. The resulting mixture was concentrated under reduced pressure, dissolved in water (2.0 mL) and the solution was adjusted to pH 9 with NH 3 *H 2 O. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 22% B to 52% B in 7 min, 52% B; Wave Length: 220 nm]: to afford (1S,2R,3R,5R)-3-{2,6-diazaspiro[4.5]decan-6-ylmethyl}-5-[4-( methylamino)pyrrolo[2,3- d]pyrimidin-7-yl]cyclopentane-1,2-diol 448 (37.7 mg, 85%) as an off-white-solid. 1 H NMR (400 MHz, DMSO-t/j <58.15-8.08 (m, 1H), 7.40-7.32 (m, 1H), 7.26-7.19 (m, 1H), 6.55-6.49 (m, 1H), 4.88- 4.68 (m, 2H), 4.29-4.19 (m, 1H), 3.84-3.71 (m, 1H), 3.31-3.10 (m, 2H), 3.00-2.91 (m, 3H), 2.90-2.79 (m, 1H), 2.77-2.64 (m, 1H), 2.62-2.53 (m, 1H), 2.38-2.26 (m, 1H), 2.24-2.09 (m, 1H), 2.08-1.93 (m, 1H), 1.78-1.65 (m, 1H), 1.54-1.33 (m, 7H). LCMS [conditions ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-50%-95%B-5min, 1.50 L/min, ES, m/z]: T R = 0.84; 0.89 min; [M + H] + : 401. Chiral-SFC [Column: Lux-4 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. keep Gradient 50% solvent B for 4 mins]: 2 diastereomers; T R = 2.17 min (major peak), T R = 2.51 (minor peak); dr = 53.5:46.5.

Synthesis of (1S,2R,3R,5R)-3-(((S)-1,7-Diazaspiro[4.5]decan-1-yl)methyl)- 5-(4-(methylamino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol (449) and (1S,2R,3R,5R)-3-(((R)-1,7- diazaspiro[4.5]decan-1-yl)methyl)-5-(4-(methylamino)-7H-pyrr olo[2,3-d]pyrimidin-7- yl)cyclopentane-1,2-diol (450) fe/t-Butyl-1-(((3aR ; 4R / 6R,6aS)-6-(4-chloro-7H-pyrrolo[2 / 3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)- 1,7-diazaspiro[4.5]decane-7- carboxylate (187a) To (3cxR,4S,6R,6cxS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl}-2 ,2-dimethyl-tetrahydro-3cxH- cyclopenta[d][1,3]dioxole-4-carbaldehyde 77 (90 mg, 0.30 mmol, 1.0 eq), te/f-butyl-1,7- diazaspiro[4.5]decane-7-carboxylate (80 mg, 0.40 mmol, 1.2 eq) in DCM (2.0 mL) was added NaBH(OAc) 3 (118 mg, 0.60 mmol, 2 eq) and AcOH (168 mg, 2.80 mmol, 10 eq) and the resulting mixture was stirred for 1 h at room temperature. The resulting mixture was basified to pH 8-9 with 10% NaHCO 3 solution. and extracted with AcOEt. The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (50:50 Petroleum ether:AcOEt) to afford te/'Abutyl-1-{[(3cxR,4R,6R,6cxS)-6-{4-chloropyrrolo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3cxH-cyclopenta[d] [1,3]dioxol-4-yl]methyl}-1,7- diazaspiro[4.5]decane-7-carboxylate 187a (46 mg, 30%) as a yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B- 3min(+), 1.50 mL/min, ES, m/z]: T R = 2.36 min; [M + H] + : 546.

7e/t-Butyl-1-(((3aR ; 4R,6R,6aS)-2,2-dimethyl-6-(4-(methylamino)-7H-pyrrolo[ 2,3-d]pyrimidin-7- yl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)-1,7-d iazaspiro[4.5]decane-7-carboxylate (188a)

To te/'f-butyl-1-{[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyr imidin-7-yl}-2,2-dimethyl- tetrahydro-3cxH-cyclopenta[d][1,3]dioxol-4-yl]methyl}-1,7-di azaspiro[4.5]decane-7-carboxylate 187a (46 mg, 0.08 mmol, 1.0 eq) was added methylamine (30% wt. in EtOH, 2.0 mL) at room temperature and the reaction mixture was stirred at 50 °C for 3 h. The resulting mixture was concentrated under reduced pressure to afford terAbutyl-1-{[(3aR,4R,6R,6aS)-2,2-dimethyl-6-[4- (methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]-tetrahydro-3cxH-c yclopenta[d][1,3]dioxol-4- yl]methyl]-1,7-diazaspiro[4.5]decane-7-carboxylate 188a (35 mg, 77%) as a yellow oil. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-2min(+), 1.50 mL/min, ES, m/z]: T R = 1.53 min; [M + H] + : 541.

(1S,2R,3R,5R)-3-(((S)-1,7-diazaspiro[4.5]decan-1-yl)methy l)-5-(4-(methylamino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)cyclopentane-1,2-diol (449) & (1S,2R,3R,5R)-3-(((R)-1,7-diazaspiro[4.5]decan-1- yl)methyl)-5-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-y l)cyclopentane-1,2-diol (450)

To terAbutyl-1-{[(3aR,4R,6R,6aS)-2,2-dimethyl-6-[4-(methylamino )pyrrolo[2,3-d]pyrimidin-7-yl]- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl]-1,7-dia zaspiro[4.5]decane-7-carboxylate 188a (35 mg, 0.06 mmol, 1.0 eq) in DCM (0.30 mL) was added TEA (0.30 mL) and the reaction mixture was stirred for 16 h at room temperature. The resulting mixture was concentrated under reduced pressure and the mixture was basified to pH 10 with NH 3 *H 2 O. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H2O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 22% B to 58% B in 7 min, 58% B; Wave Length: 220 nm]: to afford (1S,2R,3R,5R)-3-[(5S)- 1,7-diazaspiro[4.5]decan-1-ylmethyl]-5-[4-(methylamino)pyrro lo[2,3-d]pyrimidin-7- yl]cyclopentane-1,2-diol or (1S,2R,3R,5R)-3-[(5R)-1,7-diazaspiro[4.5]decan-1-ylmethyl]-5 -[4- (methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentane-1,2-d iol 449 (5.1 mg, 19%, 1 st eluting isomer) as an off-white solid. 1 H NMR (400 MHz, Chloroform-d) <58.37 (s, 1H), 7.01 (d, J - 3.7 Hz, 1H), 6.39 (d, 7 = 3.7 Hz, 1H), 5.08-4.97 (m, 2H), 4.49-4.41 (m, 1H), 4.38-4.28 (m, 1H), 3.27-3.11 (m, 5H), 3.07-2.96 (m, 1H), 2.83-2.68 (m, 3H), 2.66-2.55 (m, 3H), 2.29-2.19 (m, 1H), 2.18-2.01 (m, 2H), 1.94-1.72 (m, 5H), 1.71-1.39 (m, 4H). LCMS [conditions BEH Phenyl, 100*3.0 mm, 2.5 urn, Mobile Phase A: Water/0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-95%B-8.0min(+), 0.80 mL/min, ES, m/z]: T R = 3.01 min; [M + H] + : 401. UPLC [conditions: Column name: BEH Phenyl, 100*3.0 mm, 2.5 urn, Mobile Phase A: Water/0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-95%B-8.0min(+), 0.80 mL/min: two diastereomers]: T R = 2.97 min, f R = 3.04 min; dr = 25:1.

Prep-HPLC as above also afforded -diazaspiro[4.5]decan-1-ylmethyl]-5- [4-(methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]cyclopentane-1, 2-diol 450 or (1S,2R,3R,5R)-3-[(5S)- 1,7-diazaspiro[4.5]decan-1-ylmethyl]-5-[4-(methylamino)pyrro lo[2,3-d]pyrimidin-7- yl]cyclopentane-1,2-diol (5.0 mg, 19%, 2 nd eluting isomer) as an off-white solid. 1 H NMR (400 MHz, Chloroform-d) 5 8.37 (s, 1H), 7.01 (d, 7 = 3.6 Hz, 1H), 6.39 (d, 7 = 3.6 Hz, 1H), 5.15-4.93 (m, 2H), 4.51-4.38 (m, 1H), 4.33-4.24 (m, 1H), 3.27-3.10 (m, 5H), 3.02-2.94 (m, 1H), 2.87-2.80 (m, 1H), 2.76-2.48 (m, 5H), 2.29-2.19 (m, 1H), 2.18-2.09 (m, 1H), 1.93-1.79 (m, 4H), 1.79-1.45 (m, 6H). LCMS [conditions BEH Phenyl, 100*3.0 mm, 2.5 urn, Mobile Phase A: Water/0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-95%B-8.0min(+), 0.80 mL/min, ES, m/z]: T R = 3.26 min; [M + H] + : 401. UPLC conditions [Column name: BEH Phenyl, 100*3.0 mm, 2.5 urn, Mobile Phase A: Water/0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-95%B-8.0min(+), 0.80 mL/min]: T R = 5.16 min (major peak, KMI1020751b or KM 11020751a), T R = 4.99 min; dr = 18:1.

Synthesis of (1S,2R,3R,5R)-3-((1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(4 -(methylamino)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol (451) fe/7'-Butyl-1-(((3aR,4R,6R,6aS)-6-(4-((4-methoxybenzyl)(meth yl)amino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)-1,8- diazaspiro[4.5]decane-8-carboxylate ( To a solution of (3aR,4S,6R,6aS)-6-(4-{[(4-methoxyphenyl)methyl](methyl)amino ]pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxole-4-carbaldehyde 19a (70 mg, 0.16 mmol, 1.0 eq) and te/'f-butyl-1,8-diazaspiro[4.5]decane-8-carboxylate (38.5 mg, 0.16 mmol, 1.0 eq) in DCM (1.0 mL) were added sodium triacetoxyborohydride (51 mq, 0.24 mmol, 1.5 eq) and AcOH (96 mq, 1.6 mmol, 10 eq) at room temperature and the reaction mixture was stirred for 1 h at room temperature. The resulting mixture was basified to pH 8-9 with 10% NaHCO 3 solution, and extracted with AcOEt. The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (40:60 Petroleum ethenAcOEt) to afford te/'Abutyl-1-(((3aR,4R,6R,6aS)-6-(4-((4- methoxybenzyl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl )-2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methyl)-1,8-diazaspiro[4.5]dec ane-8-carboxylate 189a (70 mg, 66%) as an off-white semi-solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-3min(+), 1.50 mL/min, ES, m/z]: T R = 2.22 min; [M + H] + : 661.

(1S,2R,3R,5R)-3-((1,8-Diazaspiro[4.5]decan-1-yl)methyl)-5 -(4-(methylamino)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)cyclopentane-1,2-diol

To te/'f-butyl-1-{[(3aR,4R,6R,6aS)-6-(4-{[(4-methoxyphenyl)meth yl](methyl)amino}pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}-1,8- diazaspiro[4.5]decane-8-carboxylate 189a (50 mg, 0.076 mmol, 1.0 eq) was added TEA (1.0 mL) and the reaction mixture was stirred for 16 h at room temperature. The resultinq mixture was concentrated under reduced pressure and the crude product was purified by Prep-HPLC [Column, XBridqe Shield RP18 OBD Column, 19*150 mm, 5pm; mobile phase, ACN and Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O) (18% up to 43% in 8 min); Detector, UV 220 nm]: to afford (1S,2R,3R,5R)-3-{1,8-diazaspiro[4.5]decan-1-ylmethyl}-5-[4-( methylamino)pyrrolo[2,3- d]pyrimidin-7-yl]cyclopentane-1,2-diol 451 (16 mg, 52%) as a white solid. 1 H NMR (400 MHz, DMSO-r4) <58.10 (s, 1H), 7.22 (d, 7 = 3.7 Hz, 1H), 6.52 (d, 7 = 3.6 Hz, 1H), 4.89-4.75 (m, 1H), 4.31- 4.20 (m, 1H), 3.97 (s, 1H), 3.80-3.68 (m, 1H), 3.11-2.82 (m, 4H), 2.81-2.68 (m, 2H), 2.65-2.56 (m, 4H), 2.43-2.29 (m, 1H), 2.27-2.13 (m, 1H), 2.09-1.96 (m, 1H), 1.75-1.62 (m, 4H), 1.60-1.38 (m, 4H), 1.26-1.07 (m, 2H). LCMS [conditions: HPH-C18, 50*3.0 mm, 2.7 urn, Mobile Phase A: Water/0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-40%-95%B-5.0min(+), 1.20 mL/min, ES, m/z]: T R = 1.92 min; [M + H] + : 401. Chiral-SFC [Column: IG 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH3), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. Gradient 50% solvent B for 4 mins]: T R = 2.47 min, single peak.

Synthesis of (1S ; 2R,3S,4R)-4-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidi n-7-yl)-2,3-dihydroxy-

N-(3-(phenethylamino)propyl)cyclopentane-1-carboxamide (452) Methyl (1S,2R,3S,4R)-4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2 ,3-dihydroxycyclopentane-1- carboxylate (21a)

To methyl (1S,2R,3S,4R)-4-amino-2,3-dihydroxycyclopentane-1-carboxylat e hydrochloride 2 (500 mg, 2.36 mmol, 1.0 eq) and 2-(4,6-dichloropyrimidin-5-yl)acetaldehyde (496 mg, 2.60 mmol, 1.1 eq) in EtOH (5.0 mL) was added TEA (717 mg, 7.08 mmol, 3.0 eq) at room temperature and the reaction mixture was stirred at 80 °C for 3 h. The resulting mixture was allowed to cool down to room temperature and concentrated under vacuum to afford methyl (1S,2R,3S,4R)-4-{4- chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,3-dihydroxycyclopentan e-1-carboxylate 21a (600 mg, crude) as a brown solid. The crude product was used to the next step directly without further purification. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH4HCO3, Mobile Phase B: Methanol, 10%-95%B-2.5min(+-), 1.50 mL/min, ES, m/z]: T R = 1.35 min; [M + H] + : 312.

Methyl (3aR,4S,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl) -2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxole-4-carboxylate (22a).

To (1S,2R,3S,4R)-4-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,3-d ihydroxycyclopentane-1- carboxylate 21a (600 mg, crude) and 2,2-dimethoxypropane (1.00 g, 9.63 mmol, 5.0 eq) in acetone (10 mL) was added TsOH (663 mg, 3.85 mmol, 2.0 eq) at room temperature and the reaction mixture was stirred for 1 h at this temperature. The resulting mixture was basified to pH>9 with saturated NaHCO 3 solution and then extracted with AcOEt (45 mL). The organic layer was washed with brine (15 mL) and dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (2/1 Petrolium ether/AcOEt) to afford methyl (3aR,4S,6R,6aS)-6-{4- chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxole-4- carboxylate 22a (500 mg, 74%) as a light yellow solid. LCMS [conditions: Cortecs C18+, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 2%-100%B- 2.5min(+)-P, 1.50 mL/min, ES, m/z]: T R = 1.43 min; [M + H] + : 352, 354.

Methyl (3aR,4S,6R,6aS)-6-(5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carboxylat e (23a).

Br

To a stirred solution of methyl (3aR,4S,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2 - dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxole-4-carboxyl ate 22a (500 mg, 1.42 mmol, 1.0 eq) in DMF (5.0 mL), at room temperature, was added NBS (304 mg, 1.71 mmol, 1.2 eq) in several portions and the reaction mixture was stirred for 1 h. The resulting mixture was purified by reverse flash chromatography [column, C18 silica gel; mobile phase, CH 3 CN in water, 10% to 50% gradient in 12 min; detector, UV 254 nm]: afforded methyl (3aR,4S,6R,6aS)-6-{5-bromo-4- chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxole-4- carboxylate 23a (460 mg, 75%) as an off-white solid. 1 H NMR (400 MHz, DMSO-c/5) 5 8.69 (s, 1H), 8.25 (s, 1H), 5.27-5.14 (m, 1H), 5.00-4.92 (m, 2H), 3.66 (s, 3H), 3.18-3.06 (m, 1H), 2.60-2.52 (m, 2H), 1.50 (s, 3H), 1.24 (s, 3H).

(3aR ; 4S,6R,6aS)-6-(5-Bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimi din-7-yl)-2,2-dimethyltetrahydro- 4H-cyclopenta[d][1,3]dioxole-4-carboxylic acid (24a).

Methyl (3aR,4S,6R,6aS)-6-{5-bromo-4-chloropyrrolo[2,3-d]pyrimidin-7 -yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxole-4-carboxylate 23a (400 mg, 0.93 mmol, 1.0 equiv) was dissolved in THF (4.0 mL) and H 2 O (2.0 mL) and then NaOH (74 mg, 1.86 mmol, 2.0 equiv) was added and the reaction mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum and purified by reverse flash chromatography with the following conditions [column, C18 silica gel; mobile phase, CH 3 CN in water, 10% to 30% gradient in 10 min; detector, UV 254 nm]: to afford (3aR,4S,6R,6aS)-6-{5-bromo-4-chloropyrrolo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxole-4-carboxylic acid 24a (180 mg, 47%) as a white solid. 1 H NMR (300 MHz, DMSO-r4) 5 8.68 (s, 1H), 8.42 (s, 1H), 5.11 (td, J = 8.0, 4.3 Hz, 1H), 4.95 (dd, 7= 6.5, 3.0 Hz, 1H), 4.83-4.63 (m, 1H), 2.67-2.59 (m, 1H), 2.46-2.41 (m, 1H), 2.38-2.21 (m, 1H), 1.46 (s, 3H), 1.22 (s, 3H). Chiral SFC [Volume: Column: Amylose C Neo 100x4.6mm 3.0um; Co Solvent: B: MeOH; Start Cone, of Pump B: 30.0%; Method Filename: 30- 50%; Total Flow: 3.00 mL/min; BPR Pressure: 15.00 MPa; BPR Temperature: 50 °C]: T R = 1.18 min; single peak.

7e/t-Butyl-(3-((3aR,4S,6R / 6aS)-6-(5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7- yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carboxamid o)propyl)(phenethyl)carbamate (25a).

(3aR,4S,6R,6aS)-6-{5-bromo-4-chloropyrrolo[2,3-d]pyrimidi n-7-yl]-2,2-dimethyl-tetrahydro-3aH- cyclopenta[d][1,3]dioxole-4-carboxylic acid 24a (180 mg, 0.43 mmol, 1.0 eq) and HATU (197 mg, 0.52 mmol, 1.2 eq) were dissolved in DMF (3.0 mL) and DIEA (168 mg, 1.29 mmol, 3.0 eq) was added. The resulting mixture was stirred for 10 min at room temperature and then te/f -butyl- A/- (3-aminopropyl)-A/-(2-phenylethyl)carbamate (144 mg, 0.52 mmol, 1.2 eq) was added and the reaction mixture was stirred for 2 h at room temperature. The resulting mixture was purified by reverse flash chromatography [C18-column, mobile phase, MeCN in water, 20% to 70% gradient in 12 min; detector, UV 220 nm]: to afford te/f-butyl-A/-(3-{[(3aR,4S,6R,6aS)-6-{5-bromo-4- chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4- yl]formamido}propyl)-/V-(2-phenylethyl)carbamate 25a (100 mg, 34%) as a light yellow solid. 1 H NMR (300 MHz, Chloroform-o) 5 8.65 (s, 1H), 7.50 (s, 1H), 7.37-7.29 (m, 2H), 7.28-7.03 (m, 4H), 5.23-5.19 (m, 1H), 5.01 (s, 1H), 4.88 (dd, 7 = 7.0, 5.0 Hz, 1H), 3.56-3.06 (m, 6H), 3.00-2.74 (m, 3H), 2.72-2.46 (m, 2H), 1.83 (s, 3H), 1.47 (s, 9H), 1.39 (s, 3H), 1.38-1.21 (m, 2H). fe/'AButyl-(3-((3aR,4S,6R,6aS)-6-(4-amino-5-bromo-7H-pyrrolo [2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carboxamid o)propyl)(phenethyl)carbamate (26a).

To te/f-butyl-/V-(3-{[(3aR,4S,6R,6aS)-6-{5-bromo-4-chloropyrrol o[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]formam ido]propyl)-A/-(2- phenylethyl)carbamate 25a (100 mg, 0.15 mmol, 1.0 eq) was added in NH 3 (3.0 mL, 7M in MeOH) in a sealed tube and the reaction mixture was stirred at 75 °C for 8 h. The resulting mixture was concentrated under vacuum to afford te/f-butyl-(3-((3aR,4S,6R,6aS)-6-(4-amino-5-bromo-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxole-4- carboxamido)propyl)(phenethyl)carbamate 26a (60 mg, crude) as a light yellow solid. The crude product was used in the next step directly without further purification. LCMS [conditions: Kinetex XB-C18, 3.0*30mm, Mobile Phase A: Water/0.1%FA, Mobile Phase B: Acetonitrile/0.05%FA, 5%- 95%B-2min(+), 1.20 mL/min, ES, m/z]: T R = 1.19 min; [M + H] + : 657, 659.

(1S,2R,3S,4R)-4-(4-Amino-5-bromo-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-2,3-dihydroxy-/V-(3- (phenethylamino)propyl)cyclopentane-1-carboxamide (452)

To te/'Abutyl-(3-((3aR,4S,6R,6aS)-6-(4-amino-5-bromo-7H-pyrrolo [2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carboxamid o)propyl)(phenethyl)carbamate 26a (60 mg, crude) was added TFA (1.0 mL) and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under vacuum and basified to pH >8 with NH 3 *H 2 O. The crude sample was purified by prep-HPLC [Xbridge Prep C18 OBD column, 5um, 19*150mm; mobile phase, Water (0.03% NH 4 OH) and CH 3 CN (10% up to 34% in 10 min); Detector, UV 220&254 nm]: to afford (1S,2R,3S,4R)-4-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-2,3- dihydroxy-/V-(3-(phenethylamino)propyl)cyclopentane-1-carbox amide 452 (23.2 mg, 49% over 2 steps) as a white solid. 1 H NMR (400 MHz, DMSO-t/ 6 ) 6 8.09 (s, 1H), 8.00 (t, 7 = 5.6 Hz, 1H), 7.63 (s, 1H), 7.31-7.23 (m, 2H), 7.23-7.12 (m, 3H), 6.85-6.45 (m, 2H), 5.02-4.89 (m, 3H), 4.16 (dt, 7= 7.6, 5.5 Hz, 1H), 4.06-3.98 (m, 1H), 3.12 (q, 7 = 6.6 Hz, 2H), 2.77-2.66 (m, 5H), 2.58-2.52 (m, 2H), 2.56-2.51 (m, 1H), 1.88-1.80 (m, 1H), 1.57-1.33 (m, 2H). LCMS [conditions: Cortecs C18+, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min.lcm, 1.50 mL/min, ES, m/z]: T R = 0.65 min; [M + H] + : 517, 519. Chiral SEC [Column: SC 100x4.6mm 3.0um; Co Solvent: B: MeOH (20mM NH 3 ); Start Cone, of Pump B: 30.0%; Total Flow: 3.00 mL/min; BPR Pressure: 15.00 MPa; BPR Temperature: 50 °C]: T R = 2.55 min; dr > 99:1.

Synthesis of (1S,2R,3S,4R)-4-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-2,3-dihydroxy- N-(((S)-piperidin-3-yl)methyl)cyclopentane-1-carboxamide (453)

7e/t-Butyl-(R)-3-(((3aR / 4S,6R,6aS)-6-(5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimi din-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carboxamid o)methyl)piperidine-1-carboxylate (28a)

Methyl (3aR,4S,6R,6aS)-6-{5-bromo-4-chloropyrrolo[2,3-d]pyrimidin-7 -yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxole-4-carboxylate 23a (200 mg, 0.46 mmol, 1.0 eq) and te/'Abutyl-(3R)-3-(aminomethyl)piperidine-1-carboxylate (149 mg, 0.70 mmol, 1.5 eq) were dissolved in toluene (3.0 mL) and the mixture was to cooled to 0 °C and then AIMe 3 (1 M in toluene, 0.93 mL, 0.93 mmol, 2.0 eq) was added and the reaction mixture was heated to 80 °C and stirred for 4 h. The resulting mixture was concentrated under vacuum. The crude residue was purified by silica gel column chromatography (12/1 DCM/MeOH) to afford te/f-butyl- (3R)-3-({[(3aR,4S,6R,6aS)-6-{5-bromo-4-chloropyrrolo[2,3-d]p yrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]formamido}methy l)piperidine-1-carboxylate 28a (120 mg, 42%) as an off-white solid. LCMS [conditions: Kinetex XB-C18, 3.0*30mm, 1.7um, Mobile Phase A: Water/0.1%FA, Mobile Phase B: Acetonitrile/0.05%FA, 5%-100%B-2.5min-P.lcm, 1.50 mL/min, ES, m/z]: T R = 1.34 min; [M + H] + : 614, 616.

7e/t-Butyl-(R)-3-(((3aR,4S,6R,6aS)-6-(4-amino-5-bromo-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carboxamid o)methyl)piperidine-1-carboxylate (29a)

To te/'f-butyl-(3R)-3-({[(3aR,4S,6R,6aS)-6-{5-bromo-4-chloropyr rolo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]formam ido]methyl)piperidine-1- carboxylate 28a (120 mg, 0.20 mmol, 1.0 eq) was added NH 3 (7M in MeOH, 3.0 mL) and the reaction mixture was stirred at 75 °C for 8 h . The resulting mixture was concentrated under vacuum to afford te/f-butyl (3R)-3-({[(3aR,4S,6R,6aS)-6-{4-amino-5-bromopyrrolo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4- yl]formamido}methyl)piperidine-1-carboxylate 29a (100 mg, crude) as a light yellow solid. The crude product was used in the next step without further purification.

(1S,2R,3S,4R)-4-(4-Amino-5-bromo-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-2,3-dihydroxy-/V-(((S)- piperidin-3-yl)methyl)cyclopentane-1-carboxamide (453) te/f-Butyl-(3R)-3-({[(3aR,4S,6R,6aS)-6-{4-amino-5-bromopyrro lo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]formam ido}methyl)piperidine-1- carboxylate 29a (100 mg, 0.17 mmol, 1.0 eq) was dissolved in TFA (3.0 mL) at room temperature and the reaction mixture was stirred for 2 h. The resulting mixture was concentrated under reduced pressure and the residue was basified to pH >10 with NH 3 *H 2 O. The resulting mixture was purified by Prep-HPLC [condition: column, Xbridge Prep C18 OBD column, 5um, 19*150mm; mobile phase, Water (0.03% NH 4 OH) and CH 3 CN (10% up to 34% in 10 min); Detector, UV 220&254 nm]: to afford (1S,2R,3S,4R)-4-{4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl }-2,3- dihyd roxy-/V- [(3S)-piperidin-3-ylmethyl] cyclopentane-1-carboxamide 453 (32.4 mg, 42%) as an off-white solid. 1 H NMR (400 MHz, DMSO-d6) 5 8.06 (s, 1H), 7.58 (s, 1H), 4.97-4.81 (m, 1H), 4.15- 4.10 (m, 1H), 4.03-3.98 (m, 1H), 3.05-2.84 (m, 4H), 2.77-2.69 (m, 1H), 2.48-2.41 (m, 1H), 2.40-2.18 (m, 2H), 1.90-1.77 (m, 1H), 1.75-1.32 (m, 4H), 1.09-0.95 (m, 1H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 5%-95%B- 3min-1.5.lcm, 1.50 mL/min, ES, m/z]: T R = 0.92 min; [M + H] + : 453, 455. Chiral SFC [conditions: Column: SC 100x4.6mm 3.0um; Co Solvent: B: MeOH (20mM NH 3 ); Start Cone, of Pump B: 45.0%; Total Flow: 3.00 mL/min; BPR Pressure: 15.00 MPa; BPR Temperature: 50 °C]: T R = 1.46 min (major peak); dr = 92:8.

Synthesis of (1S ; 2R,3S,4R)-4-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidi n-7-yl)-2,3-dihydroxy- N-(((R)-piperidin-3-yl)methyl)cyclopentane-1-carboxamide (454) fe/7'-Butyl-(S)-3-(((3aR,4S,6R,6aS)-6-(5-bromo-4-chloro-7H-p yrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carboxamid o)methyl)piperidine-1-carboxylate (30a)

To a mixture of methyl (3aR,4S,6R,6aS)-6-(5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimid in-7-yl)- 2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carbox ylate 23a (200 mg, 0.464 mmol, 1.0 eq) and te/'f-butyl-(3S)-3-(aminomethyl)piperidine-1-carboxylate (149 mg, 0.70 mmol, 1.5 eq) in toluene (3.0 mL) at 0 °C was added AIMe 3 (1M in toluene, 0.93 mL, 0.93 mmol, 2.0 eq) and the reaction mixture was heated at 80 °C for 4 h. The resulting mixture was concentrated under vacuum and the crude residue was purified by silica gel column chromatography (12/1 DCM/MeOH) to afford te/'Abutyl-(S)-3-(((3aR,4S,6R,6aS)-6-(5-bromo-4-chloro-7H-py rrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxole-4- carboxamido)methyl)piperidine-1-carboxylate 30a (100 mg, 35%) as an off-white solid. LCMS [conditions: Kinetex XB-C18, 3.0*30mm, 1.7um, Mobile Phase A: Water/0.1%FA, Mobile Phase B: Acetonitrile/0.05% FA, 5%-100%B-2.5min-P.lcm, 1.50 mL/min, ES, m/z]: T R = 1.35 min; [M + H] + : 614, 616.

7eW-Butyl-(S)-3-(((3aR,4S,6R,6aS)-6-(4-amino-5-bromo-7H-p yrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carboxamid o)methyl)piperidine-1-carboxylate (31a)

To te/'f-butyl-(S)-3-(((3aR,4S,6R,6aS)-6-(5-bromo-4-chloro-7H-p yrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carboxamid o)methyl)piperidine-1-carboxylate 30a (110 mg, 0.18 mmol, 1.0 eq) was added in NH 3 (7M in MeOH, 3.0 mL) and the reaction mixture was stirred at 75 °C for 8 h. The resulting mixture was concentrated under vacuum to afford terAbutyl (S)-3-(((3aR,4S,6R,6aS)-6-(4-amino-5-bromo-7H-pyrrolo[2,3-d] pyrimidin-7-yl)- 2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carbox amido)methyl)piperidine-1- carboxylate 31a (74 mg, crude) as an off-white solid. The crude product was used in the next step directly without further purification. LCMS [conditions: L-column3 ODS, 50*3.0 mm, 3.0 urn, Mobile Phase A: Water (0.05% ammonia water), Mobile Phase B: Acetonitrile, 5%-100%B-2.5min,

1.20 mL/min, ES, m/z]: T R = 1.35 min; [M + H] + : 593, 595.

(1S,2R,3S,4R)-4-(4-Amino-5-bromo-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-2,3-dihydroxy-/V-(((R)- piperidin-3-yl)methyl)cyclopentane-1-carboxamide (454)

To te/'f-butyl-(S)-3-(((3aR,4S,6R,6aS)-6-(4-amino-5-bromo-7H-py rrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-4-carboxamid o)methyl)piperidine-1-carboxylate 31a (74 mg, crude) was added TFA (1.0 mL) and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under vacuum and basified to pH >8 with NH 3 *H 2 O. The crude residue was purified by prep-HPLC [column, Xbridge Prep C18 OBD column, 5um, 19*150mm; mobile phase, water (0.03% NH 4 OH) and CH 3 CN (10% up to 34% in 10 min); Detector, UV 220&254 nm]: to afford (1S,2R,3S,4R)-4-{4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl }-2,3- dihydroxy-A/-[(3R)-piperidin-3-ylmethyl]cyclopentane-1-carbo xamide 454 (36.4 mg, 64%) as a white solid. 1 H NMR (300 MHz, DMSO-t/ 6 ) 5 8.07 (s, 1H), 7.59 (s, 1H), 4.92 (q, 7 = 8.6 Hz, 1H), 4.13 (dd, 7 = 7.6, 5.2 Hz, 1H), 4.01 (t, 7 = 4.7 Hz, 1H), 3.00-2.87 (m, 4H), 2.79-2.66 (m, 1H), 2.47-2.18 (m, 3H), 1.91-1.75 (m, 1H), 1.75-1.51 (m, 3H), 1.44-1.33 (m, 1H), 1.12-0.95 (m, 1H). LCMS [conditions: Acetonitrile, 5%-95%B-3min-1.5.lcm, 1.50 mL/min, ES, m/z]: T R = 0.93 min; [M+H] + : 453,455. Chiral SFC [condition: Column: SC 100x4.6mm 3.0um; Co Solvent: B: MeOH (20mM NH 3 ); Start Conc. of Pump B: 40.0%; Total Flow: 3.00 mL/min; BPR Pressure: 15.00 MPa; BPR Temperature: 50 °C]: TR = 1.85 min (major peak); dr = 92.8:7.2. Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((((S)- piperidin-3-yl)methyl)amino)methyl)cyclopentane-1,2-diol (455) tert-Butyl-(S)-3-(((tert-butoxycarbonyl)(((3aR,4R,6R,6aS)-6- (4-chloro-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-y l)methyl)amino)methyl)piperidine-1- carboxylate (145a) To tert-butyl-(3R)-3-(aminomethyl)piper te (0.13 g, 0.61 mmol, 1.3 equiv) in DCM (3.0 mL) and AcOH (0.28 g, 4.7 mmol, 10.0 eq) was added NaBH(OAc) 3 (0.19 g, 0.90 mmol, 2.0 eq), at room temperature and the resulting mixture was stirred for 30 min at room temperature. To this mixture was added (3aR,4S,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2 - dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxole-4-carbalde hyde 77a (0.15 g, 0.50 mmol, 1.0 eq) in DCM (1.0 mL) and the reaction mixture was stirred for 1 h at room temperature. After this time, Boc 2 O (0.15 g, 0.70 mmol, 1.5 eq) and TEA (0.70 g, 7.0 mmol, 15 eq) were added and the reaction mixture was stirred for 30 min at room temperature. The resulting mixture was concentrated under reduced pressure and the crude product was purified by Prep-HPLC [Column: Xtimate C1850x250mm, 10um; Mobile Phase A: Water(0.05%NH 3 •H 2 O), Mobile Phase B: ACN; Flow rate: 90 mL/min; Gradient: 90% B in 15 min; Wave Length: 220 nm]: to afford tert- butyl-(3S)-3-[({[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d]py rimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(tert- butoxycarbonyl)amino)methyl]piperidine-1-carboxylate 145a (0.13 g, 45%) as a yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 μm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-5min(+-), 1.50 mL/min, ES, m/z]: T R = 4.13 min; [ M+H] + : 620. tert-Butyl-(S)-3-(((((3aR,4R,6R,6aS)-6-(5-bromo-4-chloro-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)methyl)piperidine-1-carboxylate (146a) To tert-butyl-(3S)-3-[({[(3aR,4R,6R,6aS)- o[2,3-d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(tert- butoxycarbonyl)amino)methyl]piperidine-1-carboxylate 145a (0.13 mg, 0.20 mmol, 1.0 eq) in DMF (3.0 mL) was added NBS (45 mg, 0. 5 o, . eq) at oom temperature and the reaction mixture was stirred for 2 h at room temperature. The reaction was quenched by the addition of water (5.0 mL) at room temperature and the resulting mixture was extracted with AcOEt (3x10 mL). The combined organic phases were concentrated under reduced pressure and the crude residue was purified by Prep-TLC (95:5 DCM:MeOH) to afford tert-butyl-(3S)-3- [({[(3aR,4R,6R,6aS)-6-{5-bromo-4-chloropyrrolo[2,3-d]pyrimid in-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(tert-butoxycarbony l)amino)methyl]piperidine-1- carboxylate 146a (0.11 g, 75%) as a yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 μm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-5min(+), 1.50 mL/min, ES, m/z]: T R = 4.41 min; [M+H] + : 698, 700. tert-Butyl-(R)-3-(((((3aR,4R,6R,6aS)-6-(4-amino-5-bromo-7H-p yrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)methyl)piperidine-1-carboxylate (147a) To tert-butyl-(3S)-3-[({[(3aR,4R,6R,6aS)- oropyrrolo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert- butoxycarbonyl)amino)methyl]piperidine-1-carboxylate 146a (0.11 g, 0.15 mmol, 1.0 eq) was added NH3 (7M in MeOH, 3.0 mL) at room temperature and the reaction mixture was stirred overnight at 75 °C. The resulting mixture was concentrated under reduced pressure to afford tert-butyl- (3S)-3-[({[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrrolo[2,3-d]p yrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(tert- butoxycarbonyl)amino)methyl]piperidine-1-carboxylate 147a (80 mg, crude) as a yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 μm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-5min(+-), 1.50 mL/min, ES, m/z]: TR = 3.98 min; [M+H] + : 679, 681. (1R,2S,3R,5R)-3-(4-Amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((((S)-piperidin-3- yl)methyl)amino)methyl)cyclopentane-1,2-diol (455) To tert-butyl-(3S)-3-[({[(3aR,4R,6R,6aS)- omopyrrolo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert- butoxycarbonyl)amino)methyl]piperidine-1-carboxylate 147a (80 mg, 0.10 mmol, 1.0 eq) was added TFA (3.0 mL) at room temperature and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and basified to pH 10 with NH 3 •H 2 O. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5μm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 •H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 50% B in 7 min, 50% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-{4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl }-5-({[(3S)-piperidin-3- ylmethyl]amino}methyl)cyclopentane-1,2-diol 327 (20.5 mg, 39%) as an off-white solid. 1 H NMR (400 MHz, DMSO-d 6 +D 2 O) δ 8.08 (s, 1H), 7.57 (s, 1H), 4.93–4.77 (m, 1H), 4.29–4.08 (m, 1H), 3.77– 3.72 (m, 1H), 3.46–2.48 (m, 5H), 2. 3 . 5 ( , ), . 3 .56 (m, 5H), 1.52–1.36 (m, 2H), 1.23–0.96 (m, 1H). LCMS [conditions Atlantis T3, 100*4.6 mm, 3 μm, Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 0%-30%-95%B-7min, 1.20 mL/min, ES, m/z]: T R = 3.33 min; [M+H] + : 439, 441. Chiral-SFC [Column: IG 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. Gradient 50% solvent B for 4 mins]: TR = 1.95 min, single peak. Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((((R)- piperidin-3-yl)methyl)amino)methyl)cyclopentane-1,2-diol (456) tert-Butyl-(R)-3-(((tert-butoxycarbonyl)(((3aR,4R,6R,6aS)-6- (4-chloro-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-y l)methyl)amino)methyl)piperidine-1- carboxylate (148a) To tert-butyl-(3S)-3-(aminomethyl)piperi te (0.13 mg, 0.60 mmol, 1.3 eq), NaBH(OAc) 3 (0.19 g, 0.90 mmol, 2.0 eq) in DCM (3.0 mL) was added AcOH (0.27 g, 4.60 mmol, 10 eq) at room temperature and the resulting mixture was stirred for 30 min at room temperature. After this time, (3aR,4S,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2 -dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxole-4-carbaldehyde 77a (0.15 g, 0.50 mmol, 1.0 eq) in DCM (1.0 mL) was added and the reaction mixture was stirred for 1 h at room temperature. To the resulting mixture was then added Boc 2 O (0.15 g, 0.70 mmol, 1.5 eq) and TEA (0.70 g, 7.0 mmol, 15 eq) and the reaction mixture was stirred for 30 min at room temperature. The resulting mixture was concentrated under reduced pressure and the crude product was purified by Prep-HPLC [Column: Xtimate C1850x250mm, 10um; Mobile Phase A: Water (0.05%NH 3 •H 2 O), Mobile Phase B: ACN; Flow rate: 90 mL/min; Gradient: 90% B in 15 min; Wave Length: 220 nm]: to afford tert- butyl-(3R)-3-[({[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d]py rimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(tert- butoxycarbonyl)amino)methyl]piperidine-1-carboxylate 148a (0.14 g, 50%) as a yellow solid. LCMS [Xbridge Shield RP18, 50*3.0 mm; Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-95%B-5min(+-), 1.20 mL/min, ES, m/z]: T R = 3.70 min; [M+H] + : 620. tert-Butyl-(R)-3-(((((3aR,4R,6R,6aS)-6-(5-bromo-4-chloro-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)methyl)piperidine-1-carboxylate (149a) To tert-butyl-(3R)-3-[({[(3aR,4R,6R,6aS)-6 lo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(tert- butoxycarbonyl)amino)methyl]piperidine-1-carboxylate 148a (0.14 g, 0.20 mmol, 1.0 eq) in DMF (3.0 mL) was added NBS (50 mg, 0.30 o, . eq) at oom temperature and the reaction mixture was stirred for 2 h at room temperature. The reaction was quenched by the addition of water (5.0 mL) at room temperature and the resulting mixture was extracted with AcOEt (3x10 mL). The combined organic extracts were concentrated under reduced pressure and purified by Prep-TLC (95:5 DCM/MeOH) to afford tert-butyl-(3R)-3-[({[(3aR,4R,6R,6aS)-6-{5-bromo-4- chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4- yl]methyl}(tert-butoxycarbonyl)amino)methyl]piperidine-1-car boxylate 149a (0.14 g, 86%) as a yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 μm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-5min(+), 1.00 mL/min, ES, m/z]: T R = 4.32 min; [M+H] + : 698, 700. tert-Butyl-(R)-3-(((((3aR,4R,6R,6aS)-6-(4-amino-5-bromo-7H-p yrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)methyl)piperidine-1-carboxylate (150a) To tert-butyl-(3R)-3-[({[(3aR,4R,6R,6aS)- oropyrrolo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert- butoxycarbonyl)amino)methyl]piperidine-1-carboxylate 149a (0.14 g, 0.20 mmol, 1.0 eq) was added NH3 (7M in MeOH, 3.0 mL) at room temperature and the reaction mixture was stirred at 75 °C overnight and the resulting mixture was concentrated under reduced pressure to afford crude tert-butyl-(3R)-3-[({[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrr olo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert- butoxycarbonyl)amino)methyl]piperidine-1-carboxylate 150a (0.12 g, crude) as a yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 μm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-5min(+-), 1.00 mL/min, ES, m/z]: T R = 3.98 min; [M+H] + : 679, 681. (1R,2S,3R,5R)-3-(4-Amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((((R)-piperidin-3- yl)methyl)amino)methyl)cyclopentane-1,2-diol (456) To tert-butyl-(3R)-3-[({[(3aR,4R,6R,6aS)- mopyrrolo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert- butoxycarbonyl)amino)methyl]piperidine-1-carboxylate 150a (0.12 g, 0.20 mmol, 1.0 eq) was added TFA (3.0 mL) at room temperature and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and the crude residue was basified to pH=10 with NH 3 •H 2 O and purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5μm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1% NH 3 •H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 50% B in 7 min, 50% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-{4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl }-5-({[(3R)-piperidin-3- ylmethyl]amino}methyl)cyclopentane-1,2-diol 456 (34.8 mg, 45%) as an off-white solid. 1 H NMR (400 MHz, DMSO-d 6 +D 2 O) δ 8.07 (s, ), 7.6 7. 6 ( , ), 4.97–4.77 (m, 1H), 4.29–4.06 (m, 1H), 3.89–3.56 (m, 2H), 3.51–3.38 (m, 1H), 3.36–2.82 (m, 2H), 2.73–2.59 (m, 1H), 2.57–2.48 (m, 1H), 2.46–2.32 (m, 2H), 2.26–2.11 (m, 1H), 2.07–1.98 (m, 1H), 1.81–1.70 (m, 1H), 1.67–1.56 (m, 2H), 1.51– 1.40 (m, 2H), 1.18–0.93 (m, 1H). LCMS [conditions Atlantis T3, 100*4.6 mm, 3 μm, Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 0%-30%-95%B-7min, 1.20 mL/min, ES, m/z]: TR = 3.39 min; [M+H] + : 439, 441. Chiral-SFC [Column: IG 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. Gradient 50% solvent B for 4 mins]: T R = 1.21 min, single peak. Synthesis of ((1R,2S,3R,5R)-3-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin -7-yl)-5-(((3-((3- phenoxyphenethy l)amino)propyl)amino)methyl)cyclopentane-1,2-diol (457) tert-Butyl-(3-(1,3-dioxoisoindolin-2-yl)propyl)(3-phenoxyphe nethyl)carbamate (50a). To a stirred mixture of tert-butyl-(3-hydrox phenoxyphenethyl)carbamate 47a (1.4 g, 3.77 mmol, 1.0 eq), phthalimide (1.11 g, 7.54 mmol, 2.0 eq) and PPh 3 (1.98 g, 7.54 mmol, 2.0 eq) in THF (40 mL) were added DIAD (1.52 g, 7.54 mmol, 2.0 eq) dropwise at 0 o C under nitrogen and the reaction mixture was stirred for 2 hours at 0 o C. The reaction was quenched by the addition of water (20 mL) at room temperature and the resulting mixture was extracted with EtOAc (150 mL). The organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (5:1 Petroleum ether/AcOEt) to afford tert-butyl-(3-(1,3-dioxoisoindolin-2-yl)propyl)(3-phenoxyphe nethyl)carbamate 50a (1.8 g, 95%) as a white solid. LCMS [conditions: Xbridge Shield RP18, 50*3.0 mm, 3.5 μm, Mobile Phase A: Water/0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-100%B-2.0min(+), 1.20 mL/min, ES, m/z]: T R = 1.52 min; [M+H] + : 501. tert-Butyl (3-aminopropyl)(3-phenoxyphenethyl)carbamate (51a). To a solution of tert-butyl-(3-(1,3-dioxoisoi propyl)(3-phenoxyphenethyl)carbamate 50a (1.80 g, 3.60 mmol, 1.0 eq) in EtOH (20 mL) was added NH 2 NH 2 .H 2 O (1.06 g, 18.0 mmol, 5.0 eq, 85%), dropwise, at room temperature under nitrogen and the reaction mixture was stirred for at 80 o C 3 h . The resulting mixture was allowed to cool to room temperature and concentrated in vacuum. The resulting residue was partitioned between water (20 mL) and DCM (50 mL) and the organic layer was washed with brine (20 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to afford te/'Abutyl-(3-aminopropyl)(3-phenoxyphenethyl)carbamate 51a (1.3 g, 98%) as a light yellow oil, which was used to next step without further purification. LCMS [conditions: Kinetex XB-C18, 3.0*30mm, 1.7um, Mobile Phase A: Water/0.1%FA, Mobile Phase B:

Acetonitrile/0.05%FA, 5%-100%B-1.2 min(+), 1.50 mL/min, ES, m/z]: T R = 0.58 min; [M + H] + : 371. 7e/t-Butyl-(3-((7e/t-butoxycarbonyl)(((3aR,4R,6R ; 6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7- yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl) methyl)amino)propyl)(3- phenoxyphenethyl)carbamate

To (3aR,4S,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl) -2,2-dimethyltetrahydro-4H- cyclopenta[d][1,3]dioxole-4-carbaldehyde 77 (140 mg, 0.44 mmol, 1.0 eq) and te/f-butyl-(3- aminopropyl)(3-phenoxyphenethyl)carbamate 51a (177 mg, 0.48 mmol, 1.1 eq) in DCM (5.0 mL) was added NaBH(AcO) 3 (30.0 mg, 1.31 mmol, 3.0 eq) at room temperature under nitrogen and the reaction mixture was stirred for 1 h at room temperature. To this mixture was added TEA (220 mg, 2.18 mmol, 5.0 eq) and Boc 2 O (142 mg, 0.65 mmol, 1.5 eq), at room temperature. The reaction mixture was stirred at room temperature for 3 hours and was then quenched by the addition of sat. NH 4 CI (aq.) (5 mL) and then diluted with

DCM (20 mL). The organic layer was washed with brine (10 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (5:1 Petroleum ether/AcOEt) to afford te/'f-butyl-(3-((te/'A butoxycarbonyl)(((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)a mino)propyl)(3- phenoxyphenethyl)carbamate 52a (140 mg, 41%) as a light yellow oil. 1 H NMR (400 MHz, Chloroform-d) 5 8.65 (s, 1H), 7.39-7.30 (m, 3H), 7.25 (d, 7 = 7.9 Hz, 1H), 7.12 (t, 7 = 7.4 Hz, 1H), 7.02 (d, 7 = 8.0 Hz, 2H), 6.94 (s, 1H), 6.87 (d, 7 = 7.5 Hz, 2H), 6.66 (d, 7 = 3.6 Hz, 1H), 5.07-4.89 (m,

2H), 4.64-4.55 (m, 1H), 3.52-3.33 (m, 4H), 3.26-3.17 (m, 5H), 2.89-2.76 (m, 2H), 2.49-2.33 (m, 2H), 1.85-1.72 (m, 2H), 1.56 (s, 3H), 1.45 (s, 18H), 1.29 (s, 3H). LCMS [conditions: HPH-C18, 50*3.0 mm, 2.7 urn, Mobile Phase A: Water/0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-100%B-

2.0min(+), 1.20 mL/min, ES, m/z]: T R = 1.61 min; [M + H] + : 776, 778.

7e/t-Butyl(3-((((3aR,4R ; 6R,6aS)-6-(5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidin -7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( 7e/t- butoxycarbonyl)amino)propyl)(3-phenoxyphenethyl)carbamate (53a). To a solution of tert-butyl-(3-((tert-bu 6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4- yl)methyl)amino)propyl)(3-phenoxyphenethyl)carbamate 52a (50 mg, 0.064 mmol, 1.0 eq) in DMF (2.0 mL) was added NBS (11.4 mg, 0.064 mmol, 1.0 eq) at room temperature under nitrogen and the reaction mixture was stirred for 1 h at room temperature. The reaction was quenched by the addition of sat. NaHCO 3 (aq.) (10 mL) at room temperature and extracted with EtOAc (20 mL). The organic layer was washed with brine (10 mL), dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (5:1 Petroleum ether/AcOEt) to afford tert-butyl(3- ((((3aR,4R,6R,6aS)-6-(5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyri midin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)propyl)(3-phenoxyphenethyl)carbamate 53a (50 mg, 91%) as a light yellow solid. 1 H NMR (400 MHz, Chloroform-d) δ 8.64 (s, 1H), 7.41-7.32 (m, 3H), 7.26 (d, J = 8.1 Hz, 1H), 7.12 (t, J = 7.4 Hz, 1H), 7.05–6.99 (m, 2H), 6.94 (d, J = 7.3 Hz, 1H), 6.87 (d, J = 6.9 Hz, 2H), 5.08-4.87 (m, 2H), 4.61-4.52 (m, 1H), 3.51-3.32 (m, 4H), 3.16-3.22 (m, 5H), 2.86-2.78 (m, 2H), 2.51- 2.38 (m, 2H), 1.83-1.74 (m, 2H), 1.56 (s, 3H), 1.46 (s, 18H), 1.32-1.25 (m, 3H). LCMS [conditions: Xbridge Shield RP18, 50*3.0 mm, 3.5 μm, Mobile Phase A: Water/0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-100%B-2.0min(+), 1.20 mL/min, ES, m/z]: T R = 1.72 min; [M+H] + : 854, 856. tert-Butyl(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-bromo-7H-pyrrol o[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)propyl)(3-phenoxyphenethyl)carbamate (54a). To tert-butyl(3-((((3aR,4R,6R,6aS)-6- o[2,3-d]pyrimidin-7-yl)-2,2- dimethy ltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)(tert- butoxycarbonyl)amino)propyl)(3-phenoxyphenethyl)carbamate 53a (40 mg, 0.047 mmol, 1.0 eq) was added NH 3 (7M in MeOH, 5.0 mL) at room temperature and the reaction mixture was stirred at 90 o C overnight. The resulting mixture was allowed to cool to room temperature and was concentrated under vacuum to afford tert-butyl(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-bromo- 7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-c yclopenta[d][1,3]dioxol-4- yl)methyl)(tert-butoxycarbonyl)amino)propyl)(3-phenoxyphenet hyl)carbamate 54a (40 mg, crude) as light yellow solid, which was used in the next step without further purification. 1 H NMR (300 MHz, Chloroform-d) 5 8.25 (s, 1H), 7.42-7.32 (m, 2H), 7.29 (s, 1H), 7.25 (d, 7 = 8.0 Hz, 1H), 7.12 (t, 7 = 7.4 Hz, 1H), 7.07-6.80 (m, 5H), 5.99-5.78 (m, 2H), 5.03-4.81 (m, 2H), 4.59-4.49 (m, 1H), 3.56-3.33 (m, 4H), 3.25-3.18 (m, 5H), 2.88-2.75 (m, 2H), 2.55-2.34 (m, 2H), 1.83-1.72 (m, 2H), 1.55 (s, 3H), 1.45 (s, 18H), 1.28 (s, 3H). LCMS [conditions: Xbridge Shield RP18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-100%B-

2.0min(+), 1.20 mL/min, ES, m/z]: T R = 1.59 min; [M + H] + : 835, 837.

((1R,2S,3R,5R)-3-(4-Amino-5-bromo-7H-pyrrolo[2,3-d]pyrimi din-7-yl)-5-(((3-((3- phenoxyphenethyl)amino)propyl)amino)methyl)cyclopentane-1,2- diol (457)

To te/'Abutyl(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-bromo-7H-pyrrol o[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( te/'A butoxycarbonyl)amino)propyl)(3-phenoxyphenethyl)carbamate 54a (25 mg, 0.03 mmol, 1.0 eq) was added TEA (1.0 mL) and the reaction mixture was stirred at room temperature for 1 h under nitrogen. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by Prep-HPLC [Column: Sunfire C18 OBD; Mobile phase: A: water (0.01% HCI); B: ACN; Gradient: 32-53%B in 7 min; detector: 220 nm; flow rate: 20 ml/min]: to afford ((1R,2S,3R,5R)-3-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin -7-yl)-5-(((3-((3- phenoxyphenethyl)amino)propyl)amino)methyl)cyclopentane-1,2- diol 457 (5.4 mg, 30%) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) 5 8.08 (s, 1H), 7.56 (s, 1H), 7.38 (t, 7 = 7.9 Hz, 2H), 7.27 (t, 7 = 7.9 Hz, 1H), 7.13 (t, 7 = 7.4 Hz, 1H), 6.98 (t, 7 = 8.3 Hz, 3H), 6.87 (d, 7 = 2.7 Hz, 1H), 6.80 (d, 7 = 8.0 Hz, 1H), 6.67 (s, 2H), 4.87 (q, 7 = 9.0 Hz, 1H), 4.76 (d, 7 = 6.4 Hz, 1H), 4.64-4.53 (m, 1H), 4.20- 4.13 (m, 1H), 3.77-3.72 (m, 1H), 2.80-2.59 (m, 7H), 2.35-2.31 (m, 1H), 2.23-2.12 (m, 1H), 2.04-1.94 (m, 1H), 1.61-1.41 (m, 3H). LCMS [Halo C18, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-50%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 1.27 min; [M + H] + : 595, 597.

Synthesis of (1R ; 2S,3R,5R)-3-(5-bromo-4-(methylamino)-7H-pyrrolo[2,3-d] pyrimidin-7-yl)-5-(((3- ((3-phenoxyphenethyl)amino)propyl)amino)methyl)cyclopentane- 1,2-diol (458) tert-Butyl-(3-((((3aR,4R,6R,6aS)-6-(5-bromo-4-(methylamino)- 7H-pyrrolo[2,3-d]pyrimidin-7-yl)-

2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)m ethyl)(7e/t- butoxycarbonyl)amino)propyl) (3-phenoxyphenethyl)carbamate (55a). To tert-butyl(3-((((3aR,4R,6R,6aS)-6-(5- -pyrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)propyl)(3-phenoxyphenethyl)carbamate 53a (140 mg, 0.16 mmol, 1.0 eq) was added CH 3 NH 2 (30% in MeOH, 5.0 mL) at room temperature and the reaction mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum to afford tert-butyl-(3-((((3aR,4R,6R,6aS)-6-(5-bromo-4-(methylamino)- 7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)(tert- butoxycarbonyl)amino)propyl)(3-phenoxyphenethyl)carbamate 55a (110 mg, 79%) as a light yellow solid. LCMS [HPH-C18, 50*3.0 mm, 2.7 um, Mobile Phase A: Water/0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-100%B-2.5min, 1.50 mL/min, ES, m/z]: T R = 1.92 min; [M+H] + : 849, 851. (1R,2S,3R,5R)-3-(5-Bromo-4-(methylamino)-7H-pyrrolo[2,3-d]py rimidin-7-yl)-5-(((3-((3- phenoxyphenethyl)amino)propyl)amino)methyl)cyclopentane-1,2- diol (458). To tert-butyl-(3-((((3aR,4R,6R,6aS)-6-(5-b romo- -(met yamino)-7H-pyrrolo[2,3-d]pyrimidin-7- yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl) methyl)(tert- butoxycarbonyl)amino)propyl)(3-phenoxyphenethyl)carbamate 55a (50 mg, 0.059 mmol, 1.0 eq) was added TFA (1.0 mL) and the reaction mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated under vacuum and the crude residue was purified by prep-HPLC [Column:Sunfire C18 OBD; Mobile phase:A: water (0.05%NH 3 .H 2 O); B: ACN; Gradient:32-53% B in 7 min; detector:220 nm; flow rate; 20 mL/min]: to afford (1R,2S,3R,5R)-3-(5- bromo-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((( 3-((3- phenoxyphenethyl)amino)propyl)amino)methyl)cyclopentane-1,2- diol 458 (14.3 mg, 40%) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.17 (s, 1H), 7.54 (s, 1H), 7.45-7.32 (m, 2H), 7.27 (s, 1H), 7.18-7.08 (m, 1H), 7.05-6.93 (m, 3H), 6.90-6.75 (m, 2H), 6.55 (s, 1H), 4.98-4.66 (m, 2H), 4.17 (s, 1H), 3.75 (s, 1H), 3.05-2.91 (m, 3H), 2.79-2.63 (m, 4H), 2.25-1.93 (m, 2H), 1.62-1.41 (m, 3H). LCMS [ZORBAX SB-Aq, 50*4.6 mm, 1.8 μm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-60%-95%B-5min, 1.50 mL/min, ES, m/z]: T R = 2.06 min; [M+H] + : 609, 611. Chiral-SFC [Column Name: SB 100x4.6mm 3.0um, Solvent: B: MeOH (20mM NH 3 ), Start Conc. of Pump B: 30.0%; Oven Temperature: 35 o C; Total Flow: 3.00 mL/min; BPR Pressure: 15.00 MPa; BPR Temperature: 50 o C]: Two diastereomers; T R = 1.44 min (major peak), 1.95 min (minor peak); dr > 99:1. Synthesis of (1R,2S,3R,5R)-3-(4-Amino-5-ethyl-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3-((3- phenoxyphenethyl)amino)propyl)amino)methyl)cyclopentane-1,2- diol (459) tert-Butyl(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-vinyl-7H-pyrrol o[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)propyl)(3-phenoxyphenethyl)carbamate (102a) To a solution of tert-butyl-N-[3-({[(3aR,4 R,6R,6aS)-6-{4-amino-5-bromopyrrolo[2,3-d]pyrimidin- 7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4 -yl]methyl}(tert- butoxycarbonyl)amino)propyl]-N-[2-(3-phenoxyphenyl)ethyl]car bamate 101a (0.13 g, 0.20 mmol, 1.0 eq) and 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (36 mg, 0.20 mmol, 1.5 eq) in dioxane (2.0 mL) and H 2 O (0.2 mL) were added Na 2 CO 3 (49 mg, 0.50 mmol, 3.0 eq) and Pd(dppf)Cl 2 (11 mg, 0.02 mmol, 0.1 eq) and the reaction mixture was stirred at 100 °C for 2 h, under nitrogen. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (95:5 DCM:MeOH) to afford tert-butyl- N-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-ethenylpyrrolo[2,3-d]py rimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(tert-bu toxycarbonyl)amino)propyl]-N-[2-(3- phenoxyphenyl)ethyl]carbamate 102a (91 mg, 74%) as a yellow solid. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 μm, Mobile Phase A: Water/5mM NH4HCO3, Mobile Phase B: Methanol, 10%-95%B-2.0min(+), 1.20 mL/min, ES, m/z]: T R = 1.72 min; [M+H] + : 783. tert-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-ethyl-7H-pyrro lo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)propyl)(3-phenoxyphenethyl)carbamate (103a) To a solution of tert-butyl-N-[3-({[(3aR,4R ,6R,6aS)-6-{4-amino-5-ethenylpyrrolo[2,3-d]pyrimidin- 7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4 -yl]methyl}(tert- butoxycarbonyl)amino)propyl]-N-[2-(3-phenoxyphenyl)ethyl]car bamate 102a (52 mg, 0.07 mmol, 1.0 eq) in 1.0 mL MeOH was added Pd/C (10%, 4 mg) in a pressure tank and the reaction mixture was hydrogenated at room temperature under 5 psi of hydrogen pressure for 1 h. The resulting mixture was filtered through a Celite pad and concentrated under reduced pressure to afford tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-ethylpyrrolo [2,3-d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(tert-bu toxycarbonyl)amino)propyl]-N-[2-(3- phenoxyphenyl)ethyl]carbamate 103a (35 mg, 67%) as a yellow solid. LCMS [conditions: Xbridge Shield RP18, 50*3.0 mm, 3.5 μm,Mob e ase : Wate /0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-100%B-2.0min(+), 1.20 mL/min, ES, m/z]: T R = 1.52 min; [M+H] + : 785. (1R,2S,3R,5R)-3-(4-Amino-5-ethyl-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3-((3- phenoxyphenethyl)amino)propyl)amino)methyl)cyclopentane-1,2- diol (459) To tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{4 ylpyrrolo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert- butoxycarbonyl)amino)propyl]-N-[2-(3-phenoxyphenyl)ethyl]car bamate 103a (35 mg, 0.05 mmol, 1.0 eq) was added TFA (2.0 mL) at room temperature and the reaction mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under reduced pressure and the residue was basified to pH 10 with NH 3 •H 2 O. The crude product was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5μm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 23% B to 55% B in 7 min, 55% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-{4-amino-5-ethylpyrrolo[2,3- d]pyrimidin-7-yl}-5-{[(3-{[2-(3-phenoxyphenyl)ethyl]amino}pr opyl)amino]methyl}cyclopentane- 1,2-diol 459 (12 mg, 49%) as an off-white solid. 1 H NMR (400 MHz, Chloroform-d) δ 8.23 (s, 1H), 7.39–7.32 (m, 2H), 7.31–7.26 (m, 1H), 7.16–7.07 (m, 1H), 7.05–6.95 (m, 3H), 6.93–6.84 (m, 2H), 6.73 (s, 1H), 5.18–5.13 (m, 2H), 4.73–4.62 (m, 1H), 4.24–4.16 (m, 1H), 4.06–3.98 (m, 1H), 2.99–2.90 (m, 2H), 2.88–2.79 (m, 10H), 2.53–2.42 (m, 1H), 2.29 (s, 2H), 1.83–1.72 (m, 3H), 1.34 (t, J = 7.4 Hz, 3H). LCMS [conditions ZORBAX SB-Aq, 50*4.6 mm, 1.8 μm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 1.29 min; [M+H] + : 545. Chiral- SFC [Column: Lux-4100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. Gradient 50% solvent B for 4 mins]: T R = 2.50 min, single peak. Synthesis of (1R,2S,3R,5R)-3-(4-Amino-5-cyclopropyl-7H-pyrrolo[2,3-d]pyri midin -7-yl)-5-(((3-((3- phenoxyphenethyl)amino)propyl)amino)methyl)cyclopentane-1,2- diol (460) tert-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-cyclopropyl-7H -pyrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)propyl)(3-phenoxyphenethyl)carbamate (104a) To a solution of tert-butyl-N-[3-({[(3aR,4 mino-5-bromopyrrolo[2,3-d]pyrimidin- 7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4 -yl]methyl}(tert- butoxycarbonyl)amino)propyl]-N-[2-(3-phenoxyphenyl)ethyl]car bamate 101a (80 mg, 0.10 mmol, 1.0 eq) and cyclopropylboronic acid (16 mg, 0.20 mmol, 2.0 eq) in toluene (2.0 mL) and H 2 O (0.10 mL) were added K 3 PO 4 (61 mg, 0.30 o, 3 eq), d( cO) 2 (2.0 mg, 0.01 mmol, 0.1 eq) and PCy 3 (5.0 mg, 0.02 mmol, 0.2 eq) and the reaction mixture was stirred at 100 °C for 2 h, under nitrogen. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (90:10 DCM:MeOH) to afford tert-butyl-N-[3- ({[(3aR,4R,6R,6aS)-6-{4-amino-5-cyclopropylpyrrolo[2,3-d]pyr imidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(tert-bu toxycarbonyl)amino)propyl]-N-[2-(3- phenoxyphenyl)ethyl]carbamate 104a (36 mg, 47%) as a yellow solid. LCMS [conditions: Xbridge Shield RP18, 50*3.0 mm, 3.5 μm,Mobile Phase A: Water/0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-100%B-2.0min(+), 1.20 mL/min, ES, m/z]: T R = 1.57 min; [M+H] + : 797. (1R,2S,3R,5R)-3-(4-Amino-5-cyclopropyl-7H-pyrrolo[2,3-d]pyri midin-7-yl)-5-(((3-((3- phenoxyphenethyl)amino)propyl)amino)methyl)cyclopentane-1,2- diol (460) To tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{4 opropylpyrrolo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert- butoxycarbonyl)amino)propyl]-N-[2-(3-phenoxyphenyl)ethyl] carbamate 104a (36 mg, 0.05 mmol, 1.0 eq) was added TFA (2.0 mL) at room temperature and the reaction mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under reduced pressure and basified to pH 10 with NH 3 •H 2 O. The crude product was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5μm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 25% B to 60% B in 7 min, 60% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-{4-amino-5- cyclopropylpyrrolo[2,3-d]pyrimidin-7-yl}-5-{[(3-{[2-(3- phenoxyphenyl)ethyl]amino}propyl)amino]methyl}cyclopentane-1 ,2-diol 460 (8.1 mg, 32%) as an off-white solid. 1 H NMR (400 MHz, Chloroform-d) δ 8.20 (s, 1H), 7.39–7.30 (m, 2H), 7.28–7.22 (m, 1H), 7.15–7.07 (m, 1H), 7.05–6.99 (m, 2H), 6.98–6.93 (m, 1H), 6.92–6.83 (m, 2H), 6.69 (s, 1H), 5.54 (s, 2H), 4.72–4.61 (m, 1H), 4.22–4.14 (m, 1H), 4.05–3.98 (m, 1H), 2.93–2.85 (m, 2H), 2.84–2.69 (m, 8H), 2.50–2.39 (m, 1H), 2.34–2.26 (m, 1H), 1.97–1.86 (m, 1H), 1.79–1.64 (m, 3H), 0.95–0.88 (m, 2H), 0.72– 0.64 (m, 2H). LCMS [conditions ZORBAX SB-Aq, 50*4.6 mm, 1.8 μm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-50%-95%B-5min, 1.50 mL/min, ES, m/z]: T R = 2.43 min; [M+H] + : 557. Chiral-SFC [Column: Lux-4100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. Gradient 50% solvent B for 4 mins] T R = 2.11 min, single peak. Synthesis of (1R,2S,3R,5R)-3-(4-Amino-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin -7-yl)-5-(((3-((3- phenoxyphenethyl)amino)propyl)amino)methyl)cyclopentane-1,2- diol (461) tert-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-bromo-7H-pyrro lo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)propyl)(3-phenoxyphenethyl)carbamate (105a) To a solution of tert-butyl-N-[3-({[(3aR,4 mino-5-bromopyrrolo[2,3-d]pyrimidin- 7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4 -yl]methyl}(tert- butoxycarbonyl)amino)propyl]-N-[2-(3-phenoxyphenyl)ethyl]car bamate 101a (0.10 g, 0.12 mmol, 1.0 eq) and phenyl boronic acid (17 mg, 0.14 mmol, 1.2 eq) in dioxane (2.0 mL) and H 2 O (0.2 mL) were added Na 2 CO 3 (38 mg, 0.36 mmol, 3.0 eq) and Pd(dppf)Cl 2 (9 mg, 0.01 mmol, 0.1 eq) and the reaction mixture was stirred at 100 °C for 2 h under nitrogen. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (90:10 DCM:MeOH) to afford tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5- phenylpyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4- yl]methyl}(tert-butoxycarbonyl)amino)propyl]-N-[2-(3-phenoxy phenyl)ethyl]carbamate 105a (45 mg, 45%) as a yellow solid. LCMS [conditions: Xbridge Shield RP18, 50*3.0 mm, 3.5 μm,Mobile Phase A: Water/5 mM NH4HCO3, Mobile Phase B: Methanol, 10%-95%B-2.0min(+), 1.20 mL/min, ES, m/z]: T R = 1.72 min; [M+H] + : 833. (1R,2S,3R,5R)-3-(4-Amino-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin -7-yl)-5-(((3-((3- phenoxyphenethyl)amino)propyl)amino)methyl)cyclopentane-1,2- diol (461) To tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{4 nylpyrrolo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert- butoxycarbonyl)amino)propyl]-N-[2-(3-phenoxyphenyl)ethyl]car bamate 105a (35 mg, 0.04 mmol, 1.0 eq) was added TFA (2.0 mL) and the reaction mixture was stirred for 2 h at room temperature. The reslting mixture was concentrated under reduced pressure and basified to pH 10 with NH 3 •H 2 O. The crude product was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5μm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 23% B to 55% B in 7 min, 55% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-{4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-y l}-5-{[(3-{[2-(3- phenoxyphenyl)ethyl]amino}propyl)amino]methyl}cyclopentane-1 ,2-diol 461 (7.7 mg, 31%) as an off-white solid. 1 H NMR (400 MHz, Chloroform-d) δ 1 H NMR (300 MHz, DMSO-d 6 ) δ 8.31 (s, 1H), 7.52–7.43 (m, 4H), 7.42–7.29 (m, 3H), 7.28–7.22 (m, 1H), 7.15–7.07 (m, 1H), 7.06–6.98 (m, 3H), 6.97–6.93 (m, 1H), 6.92–6.89 (m, 1H), 6.88–6.83 (m, 1H), 5.16 (s, 2H), 4.86–4.75 (m, 1H), 4.32–4.24 (m, 1H), 4.11–4.03 (m, 1H), 2.94–2.86 (m, 2H), 2.85–2.77 (m, 4H), 2.76–2.70 (m, 4H), 2.57–2.46 (m, 1H), 2.33 (s, 1H), 1.89–1.76 (m, 1H), 1.75–1.67 (m, 2H). LCMS [conditions ZORBAX SB-Aq, 50*4.6 mm, 1.8 μm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-50%-95%B- 5min, 1.50 mL/min, ES, m/z]: T R = 2.18 min; [M+H] + : 593. Chiral-SFC [Column: Lux-4100x4.6mm 3.0um, Solvent B: MeOH (20mM N 3 ), Ove e pe atu e: 35 °C, Total Flow: 3.00 mL/min. Gradient 50% solvent B for 4 mins]: T R = 3.04 min, single peak. Synthesis of (1R,2S,3R,5R)-3-{4-Amino-5-ethenylpyrrolo[2,3-d]pyrimidin-7- yl}-5-{[(3-{[2-(3- phenoxyphenyl)ethyl]amino}propyl)amino]methyl}cyclopentane-1 ,2-diol (462) (1R,2S,3R,5R)-3-{4-Amino-5-ethenylpyrrolo[2,3-d]pyrimidin-7- yl}-5-{[(3-{[2-(3- phenoxyphenyl)ethyl]amino}propyl)amino]methyl}cyclopentane-1 ,2-diol (462). To (1R,2S,3R,5R)-3-{4-amino-5-bromopyr midin-7-yl}-5-{[(3-{[2-(3- phenoxyphenyl)ethyl]amino}propyl)amino]methyl}cyclopentane-1 ,2-diol (0.08 g, 0.10 mmol, 1.0 eq), 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.03 g, 0.20 mmol, 1.5 eq), and Na 2 CO 3 (0.04 g, 0.40 mmol, 3.0 eq) in dioxane (1.5 mL) and H 2 O (0.2 mL) was added Pd(dppf)Cl 2 (0.01g, 0.01 mmol, 0.1 eq) at room temperature and the reaction mixture was stirred at 100 °C for 3 h, under N 2 . The reaction mixture was filtered and the filtrate was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5μm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 •H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 24% B to 49% B in 7 min, 49% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-{4-amino-5-ethenylpyrrolo[2,3- d]pyrimidin-7-yl}-5-{[(3-{[2-(3-phenoxyphenyl)ethyl]amino}pr opyl)amino]methyl}cyclopentane- 1,2-diol 462 (15 mg, 20%) as an off-white solid. 1 H NMR (300 MHz, DMSO-d 6 ) δ 8.03 (s, 1H), 7.62- 7.57 (m, 1H), 7.43-7.35 (m, 2H), 7.34-7.23 (m, 1H), 7.19-7.04 (m, 2H), 7.02-6.94 (m, 3H), 6.91-6.86 (m, 1H), 6.85-6.79 (m, 1H), 6.64-6.58 (m, 2H), 5.55 (d, J = 17.5 Hz, 1H), 5.08 (d, J = 11.0 Hz, 1H), 4.93-4.79 (m, 1H), 4.24-4.15 (m, 1H), 3.85-3.73 (m, 1H), 2.88-2.59 (m, 10H), 2.31-2.00 (m, 2H), 1.73- 1.39 (m, 3H). LCMS [conditions Halo C18, 50*3.0 mm, 2.7 μm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 L/min, ES, m/z), 2 min, ES, m/z]: T R = 1.30 min; [M+H] + : 543 . Chiral-SFC [Column: IG 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. Gradient 50% solvent B for 4 mins]: T R =1.97 min, single peak. Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (463) Synthesis of tert-Butyl-N-(3-aminopropyl)-N-(2-phenylethyl)carbamate (110a) 3-(Phenethylamino)propan-1-ol (56a) A mixture of 2-bromoethyl benzene (5.0 1.0 eq) and propanolamine (12.2 g, 162 mmol, 6.0 eq) in ethanol (30 mL) was heated at 80 °C for 3 h. The reaction mixture was then concentrated under vacuum, diluted with DCM and washed with water. The aqueous layer was extracted with DCM and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated to a o d 3 (p e et ya ino)propan-1-ol 56a (4.50 g, 85%) as a light yellow oil. 1 H NMR (300 MHz, DMSO-d 6 ) δ 7.35-7.24 (m, 2H), 7.23-7.12 (m, 3H), 3.46 (t, J = 6.3 Hz, 2H), 2.70 (q, J = 5.0, 4.0 Hz, 4H), 2.60 (t, J = 6.8 Hz, 2H), 1.55 (p, J = 6.6 Hz, 2H). tert-Butyl (3-hydroxypropyl)(phenethyl)carbamate (57a) To a stirred mixture of 3-(phenethylamin 6 (4.50 g, 25.1 mmol, 1.0 eq) and Et 3 N (5.10 g, 50.3 mmol, 2.0 eq) in DCM (80 mL) was added di-tert-butyl dicarbonate (6.60 g, 30.2 mmol, 1.2 eq) in several portions at 0 °C and the reaction mixture was stirred for 3 h at room temperature. The reaction was quenched with water (100 mL) and then extracted with DCM (60 mL). The organic layer were dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (6:1 Petroleum ether/AcOEt) to afford tert-butyl (3- hydroxypropyl)(phenethyl)carbamate 57a (5.00 g, 71%) as a colorless oil. 1 H NMR (300 MHz, DMSO-d6) δ 7.35-7.25 (m, 2H), 7.24-7.15 (m, 3H), 4.41 (t, J = 5.1 Hz, 1H), 3.44-3.28 (m, 4H), 3.16 (t, J = 7.2 Hz, 2H), 2.76 (dd, J = 8.6, 6.4 Hz, 2H), 1.68-1.53 (m, 2H), 1.36 (s, 9H). tert-Butyl (3-(1,3-dioxoisoindolin-2-yl)propyl)(phenethyl)carbamate (140a) To a stirred mixture of tert-butyl (3-h y o yp opy p e e yl)carbamate 57a (5.00 g, 17.9 mmol, 1.0 eq), phthalimide (5.30 g, 35.8 mmol, 2.0 eq) and PPh 3 (9.40 g, 35.8 mmol, 2.0 eq) in THF (50 mL) was added DIAD (7.20 g, 35.8 mmol, 2.0 eq), dropwise, at 0 °C and the reaction mixture was stirred for 2 h, at 0 °C, under nitrogen. The resulting mixture was quenched by the addition of water (20 mL) at room temperature and extracted with EtOAc (3x150 mL). The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (80:20 Petroleum ether: AcOEt) to afford tert-butyl (3-(1,3-dioxoisoindolin-2- yl)propyl)(phenethyl)carbamate 140a (5.50 g, 75%) as a white solid. tert-Butyl (3-aminopropyl)(phenethyl)carbamate (110a) To a solution of tert-butyl (3-(1,3-dioxoisoindolin-2-yl)propyl)(phenethyl)carbamate 140a (5.50 g, 13.5 mmol, 1.0 eq) in EtOH (50 mL) was added NH 2 NH 2 •H 2 O (3.30 g, 67.4 mmol, 5.0 eq), dropwise, at room temperature, under nitrogen and the reaction mixture was stirred at 80 o C for 3 h . The resulting mixture was allowed to cool to room temperature and concentrated in vacuo and the residue was partitioned between water (20 mL) and DCM (80 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuum to afford tert-butyl (3-aminopropyl)(phenethyl)carbamate 110a (3.20 g, 85%) as a brown oil, which was used in the next step without further purification. tert-Butyl (3-((tert-butoxycarbonyl)(((3aR,4R,6R,6aS)-6-(4-chloro-7H-py rrolo[2,3-d]pyrimidin-7- yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4- yl)methyl)amino)propyl)(phenethyl)carbamate (107a) To tert-butyl-N-(3-aminopropyl)-N-(2- ate 110a (1.82 g, 6.50 mmol, 1.2 eq), and NaBH(OAc) 3 (2.31 g, 10.9 mmol, 2.0 eq) in DCM (25.0 mL) was added AcOH (3.27 g, 54.4 mmol, 10.0 eq) at room temperature and the resulting mixture was stirred for 30 min at room temperature. Then (3aR,4S,6R,6aS)-6-{4-chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2 -dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxole-4-carbaldehyde 77a (2.50 g, 5.40 mmol, 1.0 eq) in DCM (10.0 mL) was added and the reaction mixture was stirred for 1 h at room temperature. After this time, Boc 2 O (1.78 g, 8.20 mmol, 1.5 eq) and TEA (8.26 g, 81.6 mmol, 15.0 eq) were added and the reaction mixture was stirred for 30 min at room temperature. The resulting mixture was concentrated under reduced pressure and the crude product was purified by prep-HPLC [Column:Xtimate C18 50x250mm, 10um; Mobile Phase A: Water(0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 90 mL/min; Gradient: 45% B to 75% B in 12 min; Wave Length: 220 nm]: to afford tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d] pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(tert-bu toxycarbonyl)amino)propyl]-N-(2- phenylethyl)carbamate 107a (1.43 g, 38%) as a yellow solid. 1 H NMR (400 MHz, Chloroform-d) δ 8.65 (s, 1H), 7.38–7.29 (m, 3H), 7.27–7.14 (m, 3H), 6.67 (d, J = 3.6 Hz, 1H), 5.11–4.83 (m, 2H), 4.69– 4.51 (m, 1H), 3.55–3.31 (m, 4H), 3.29–3.04 (m, 4H), 2.93–2.78 (m, 2H), 2.55–2.36 (m, 2H), 2.27–1.95 (m, 1H), 1.86–1.70 (m, 2H), 1.57 (s, 3H), 1.49–1.42 (m, 18H), 1.29 (s, 3H). LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 μm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-2min(+), 1.50 mL/min]: T R = 2.09 min; [M+H] + : 684. tert-Butyl-(3-((((3aR,4R,6R,6aS)-6-(5-bromo-4-chloro-7H-pyrr olo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (108a) To tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{ -c oropyrroo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(tert-bu toxycarbonyl)amino)propyl]-N-(2- phenylethyl)carbamate 107a (1.20 g, 1.80 mmol, 1.0 eq) was added NBS (0.37 g, 2.10 mmol, 1.2 eq) in DMF (15 mL) at room temperature and the reaction mixture was stirred for 2 h at room temperature. The reaction was quenched by the addition of water (30 mL) at room temperature and the reaction mixture was extracted with AcOEt (3x10 mL). The combined organic extracts were concentrated under reduced pressure and the crude residue was purified by Prep-TLC (95:5 DCM/MeOH) to afford tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{5-bromo-4-chloropyrrol o[2,3- d]pyrimidin 7 yl} 2,2 dimethyl tet a yd o 3a cycope ta[d][1,3]dioxol 4 yl]methyl}(tert butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 108a (1.21 g, 90%) as a yellow solid. 1 H NMR (400 MHz, Chloroform-d) δ 8.63 (s, 1H), 7.39–7.30 (m, 2H), 7.26–7.15 (m, 4H), 5.08–4.81 (m, 2H), 4.63–4.49 (m, 1H), 3.55–3.31 (m, 3H), 3.28–3.09 (m, 5H), 2.88–2.79 (m, 2H), 2.53–2.37 (m, 2H), 2.00–1.89 (m, 1H), 1.84–1.71 (m, 2H), 1.55 (s, 3H), 1.50–1.41 (m, 18H), 1.28 (s, 3H). LCMS [conditions: Kinetex XB-C18, 3.0*30mm, 1.7um, Mobile Phase A: Water/0.1%FA, Mobile Phase B: Acetonitrile/0.05%FA, 5%-95%B-2min (+).lcm, 1.2 mL/min]: T R = 1.75: [M+H] + : 762, 764. tert-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-bromo-7H-pyrro lo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (109a) To tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6 pyrrolo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert- butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 108a (1.00 g, 1.30 mmol, 1.0 eq) was added NH 3 (7M in MeOH, 10 mL) at room temperature and the reaction mixture was stirred at 75 °C for 12 h. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (1:1 Petroleum ether/AcOEt) to afford tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrrolo [2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert-butoxycarbonyl)amino) propyl]-N-(2-phenylethyl)carbamate 109 (0.70 g, 72%) as an off-white solid. LCMS [conditions: Kinetex XB-C18, 3.0*30mm, 1.7um, Mobile Phase A: Water/0.1%FA, Mobile Phase B: Acetonitrile/0.05%FA, 5%-95%B-2min (+).lcm, 1.2 mL/min]: T R = 1.42 min; [M+H]+: 743, 745. 1H NMR (400 MHz, Chloroform-d) δ 8.25 (s, 1H), 7.35–7.30 (m, 2H), 7.26–7.21 (m, 3H), 7.08 (s, 1H), 6.13 (s, 2H), 5.05–4.79 (m, 2H), 4.60–4.48 (m, 1H), 3.49–3.29 (m, 4H), 3.28–3.06 (m, 4H), 2.92–2.79 (m, 2H), 2.53–2.33 (m, 2H), 2.30–2.00 (m, 1H), 1.87–1.70 (m, 2H), 1.55 (s, 3H), 1.47–1.41 (m, 18H), 1.28 (s, 3H). (1R,2S,3R,5R)-3-(4-Amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (463) To tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrrolo [2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate 109a (35 mg, 0.05 mmol, 1.0 eq) was added TFA (1.0 mL, 13.5 mmol, 286 eq) and the reaction mixture was stirred for 0.5 h at 50 °C. The resulting mixture was concentrated under reduced pressure and basified to pH >8 with NH 3 *H 2 O. The crude residue was dissolved in DMF (3.0 mL) and purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 24% B to 49% B in 7 min, 49% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-{4-amino-5-bromopyrrolo[2,3- d]pyrimidin-7-yl}-5-[({3-[(2-phenylethyl)amino]propyl}amino) methyl]cyclopentane-1,2-diol 463 (10.8 mg, 45%) as an off-white solid. 1 H NMR (400 MHz, DMSO-5 6 ) 58.08 (s, 1H), 7.58 (s, 1H), 7.30-7.22 (m, 2H), 7.21-7.12 (m, 3H), 6.68 (s, 2H), 4.93-4.83 (m, 1H), 4.82-4.77 (m, 1H), 4.21-4.13 (m, 1H), 3.76-3.74 (m, 1H), 2.73-2.56 (m, 10H), 2.22-2.10 (m, 1H), 2.05-2.01 (m, 1H), 1.60-1.41 (m, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min]: T R = 0.99 min; [M + H] + : 503, 505. Chiral-SFC [Column: SC 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 50 °C, Total Flow: 3.00 mL/min. Gradient 30% solvent B for 5 mins]: T R = 2.93 min, single peak.

Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-vinyl-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (464)

(1R,2S,3R,5R)-3-(4-Amino-5-vinyl-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (464)

To a stirred mixture of (1R,2S,3R,5R)-3-{4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl }-5-[({3-[(2- phenylethyl)amino]propyl]amino)methyl]cyclopentane-1,2-diol 325 (50 mg, 0.10 mmol, 1.0 eq) and 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (21 mg, 0.13 mmol, 1.5 eq) in 1,4-dioxane (1.0 mL) and H 2 O (0.1 mL) were added Pd(dtbpf)CI 2 (2.91 mg, 0.004 mmol, 0.05 eq) and < 3 PO 4 (57 mg, 0.30 mmol, 3.0 eq) and the resulting mixture was stirred at 80 °C, for 0.5 h, under nitrogen. The resulting mixture was concentrated under reduced pressure and partitioned between AcOEt and water. The aqueous layer was extracted with AcOEt (x2) and the combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure and the resulting crude residue was dissolved in methanol (3.0 mL) and purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 55% B in 7 min, 55% B; Wave Length: 220 nm]: to afford (1 R,2S,3 R, 5R)-3-{4- amino-5-ethenylpyrrolo[2,3-d]pyrimidin-7-yl}-5-[({3-[(2- phenylethyl)amino]propyl]amino)methyl]cyclopentane-1,2-diol 464 (16.3 mg, 40%) as a white solid. 1 H NMR (400 MHz, DMSO-5 6 +D 2 O) 58.03 (s, 1H), 7.61 (s, 1H), 7.30-7.23 (m, 2H), 7.22-7.04 (m, 4H), 5.62 (d, 7 = 17.2 Hz, 1H), 5.09 (dd, 7 = 10.8, 1.2 Hz, 1H), 4.87 (q, 7 = 8.4 Hz, 1H), 4.26-4.13 (m, 1H), 3.84-3.72 (m, 1H), 3.25-2.53 (m, 10H), 2.23-2.00 (m, 2H), 1.66-1.41 (m, 3H). LCMS (conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min), T R = 0.58 min; [M + H] + : 451. Chiral-SFC [Column: IG 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. Gradient 40% solvent B for 4 mins]: T R = 1.76 min, single peak.

Synthesis of (1S,2R ; 3S,5S)-3-(4-Amino-5-ethyl-7H-pyrrolo[2,3-d]pyrimidin-7 -yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (465) fe/7-Butyl-(3-((((3aR ; 4R / 6R,6aS)-6-(4-amino-5-vinyl-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( fe/7-butoxycarbonyl)amino) propyl)(phenethyl)carbamate (111a)

To a stirred solution of te/f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrrol o[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'f- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate 108a (70 mg, 0.10 mmol, 1.0 eq) and 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (29 mg, 0.20 mmol, 2.0 eq) in 1,4-dioxane (1.0 mL) and H 2 O (0.1 mL) were added Pd(dtbpf)CI 2 (3 mg, 0.005 mmol, 0.05 eq) and K 3 PO 4 (60 mg, 0.3 mmol, 3.0 eq) and the reaction mixture was stirred at 80 °C for 0.5 h, under nitrogen. The resulting mixture was concentrated under reduced pressure and partitioned between AcOEt and water. The aqueous layer was extracted with AcOEt (2x) and the combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (50:50 AcOEtpetroleum ether) to afford te/f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5- ethenylpyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro -3aH-cyclopenta[d][1,3]dioxol-4- yl]methyl}(te/f-butoxycarbonyl)amino)propyl]-/V-(2-phenyleth yl)carbamate 111a (60 mg, 88%) as a white solid. LCMS [conditions: Kinetex XB-C18, 50*3.0 mm, 2.6pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 2%-95%B-3min(+).lcm, 1.50 mL/min]: T R = 1.71 min; MS [M + H] + : 691. fe/7-Butyl-(3-((((3aR ; 4R / 6R,6aS)-6-(4-amino-5-ethyl-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( fe/7- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (112a)

To a solution of te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-ethenylpyr rolo[2,3-d]pyrimidin-

7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxo l-4-yl]methyl}(te/'f- butoxycarbonyl)amino)propyl]-N-( p e yet y)ca ba ate 111a (60 mg, 0.10 mmol, 1.0 eq) in 2.0 mL MeOH was added Pd/C (10%, 2.0 mg) in a pressure tank and the reaction mixture was hydrogenated at room temperature under 5 psi of hydrogen pressure for 0.5 h. The resultant mixture was filtered through a Celite pad and concentrated under reduced pressure to afford the crude product tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-ethylpyrrolo [2,3-d]pyrimidin-7- yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-y l]methyl}(tert- butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 112a (55 mg, 96%) which was used in the next step without further purification. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 μm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-2min(+).lcm, 1.00 mL/min]: T R = 1.60 min; [M+H] + : 693. (1R,2S,3R,5R)-3-(4-Amino-5-ethyl-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (465) To tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-ethylpyrrolo [2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert- butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 112a (55 mg, 0.1 mmol, 1.0 eq) was added TFA (1.0 mL) and the resulting mixture was stirred at 50 °C for 0.5 h. The resulting mixture was allowed to cool and was concentrated under reduced pressure and basified to pH >8 with NH 3 •H 2 O. The crude residue was dissolved in DMF (3.0 mL) and purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5μm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1% NH 3 •H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 25% B to 50% B in 7 min, 50% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-{4-amino-5-ethylpyrrolo[2,3-d]pyrimidin-7- yl}-5-[({3-[(2-phenylethyl)amino]propyl}amino)methyl]cyclope ntane-1,2-diol 465 (18 mg, 48%) as an off-white solid. 1 H NMR (300 MHz, DMSO-d 6 +D 2 O) δ 7.98 (s, 1H), 7.35-7.12 (m, 5H), 7.01 (s, 1H), 4.89-4.74 (m, 1H), 4.19-4.07 (m, 1H), 3.86-3.68 (m, 1H), 3.30-2.82 (m, 6H), 2.79-2.67 (m, 5H), 2.61-2.59 (m, 1H), 2.19-2.04 (m, 2H), 1.68-1.54 (m, 2H), 1.52-1.37 (m, 1H), 1.20 (t, J = 7.4 Hz, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 μm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min]: T R = 0.98 min; [M+H] + : 453. Chiral-SFC [Column: IG 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min]: T R =2.04 min; single peak Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin -7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (466) tert-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-phenyl-7H-pyrr olo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (113a)

To a stirred mixture of te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrrol o[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'f- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate 108a (70 mg, 0.1 mmol, 1.0 eq) and phenyl boronic acid (18 mg, 0.15 mmol, 1.5 eq) in 1,4-dioxane (1.0 mL) and H 2 O (0.1 mL) were added Pd(dtbpf)CI 2 (3 mg, 0.005 mmol, 0.05 eq) and K 3 PO 4 (60 mg, 0.3 mmol, 3.0 eq) and the reaction mixture was stirred at 80 °C for 1 h under nitrogen. The resulting mixture was concentrated under reduced pressure and partitioned between AcOEt and water. The aqueous layer was extracted with AcOEt (2x) and the combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated and the crude residue was purified by silica gel column chromatography (50:50 THF:petroleum ether) to afford tert- butyl-A/-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-phenylpyrrolo[2, 3-d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(te/'f-b utoxycarbonyl)amino)propyl]-/V-(2- phenylethyl)carbamate 113a (60 mg, 86%) as a yellow solid. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-

95%B-2min(+).lcm, 1.00 mL/min]: T R = 1.66 min; [M + H] + : 741.

(1R,2S,3R,5R)-3-(4-Amino-5-phenyl-7H-pyrrolo[2,3-d]pyrimi din-7-yl)-5-(((3-

(phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (466)

HO

To te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-phenylpyrr olo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl ](te/'A butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate 113a (60 mg, 0.05 mmol, 1.0 eq) was aded TEA (1.0 mL) and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under vacuum and was basified to pH >8 with ammonium hydroxide. The crude residue was dissolved in DMF (3.0 mL) and purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 «H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 24% B to 49% B in 7 min, 49% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-{4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-y l}-5-[({3-[(2- phenylethyl)amino]propyl}amino)methyl]cyclopentane-1,2-diol 466 (12.3 mg, 50%) as a white solid. 1 H NMR (400 MHz, Chloroform-o) 58.27 (s, 1H), 7.52-7.44 (m, 4H), 7.37 (br s, 1H), 7.32-7.26 (m, 2H), 7.22-7.17 (m, 3H), 6.98 (s, 1H), 5.17 (br s, 2H), 4.86-4.73 (m, 1H), 4.30-4.22 (m,

1H), 4.03 (br s, 1H), 2.93-2.88 (m, 2H), 2.85-2.70 (m, 8H), 2.50-2.42 (m, 1H), 2.34-2.22 (m, 1H), 1.82-

1.68 (m, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min]: T R = 1.08 min; [M+H] + : 501. Chiral-SFC [Column: SC 00 .6 3.0u , Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. Gradient 30% solvent B for 4 mins]: T R = 2.90 min, single peak. Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-methyl-7H-pyrrolo[2,3-d]pyrimidin -7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (467) tert-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-methyl-7H-pyrr olo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (122a) To a solution of tert-butyl-N-[3-({[(3aR,4 mino-5-bromopyrrolo[2,3-d]pyrimidin- 7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4 -yl]methyl}(tert- butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 108a (80 mg, 0.10 mmol, 1.0 eq) and 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (27 mg, 0.20 mmol, 2.0 eq) in dioxane (2.0 mL) and H2O (0.2 mL) was added Na2CO3 (34 mg, 0.30 mmol, 3.0 eq) and Pd(dppf)Cl2 (16 mg, 0.02 mmol, 0.2 eq) and the reaction mixture was stirred at 100 °C, for 3 h, under nitrogen. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (90:10 CH 2 Cl 2 : MeOH) to afford tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6- {4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]methyl}(tert-butoxycarbonyl)am ino)propyl]-N-(2- phenylethyl)carbamate 122a (27 mg, 37%) as a yellow solid. LCMS [conditions: Xbridge Shield RP18, 50*3.0 mm, 3.5 μm; Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2min(+), 1.50 mL/min, ES, m/z]: T R = 1.27 min; [M+H] + : 679. (1R,2S,3R,5R)-3-(4-Amino-5-methyl-7H-pyrrolo[2,3-d]pyrimidin -7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (467) To tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{ ylpyrrolo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert- butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 122a (27 mg, 0.04 mmol, 1.0 eq) was added TFA (1.0 mL) and the reaction mixture was stirred at 50 °C for 2 h. The resulting mixture was concentrated under reduced pressure and basified to pH = 10 with NH 3 •H 2 O. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5μm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1% NH 3 •H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 23% B to 54% 7 , 5 % ; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-{4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-y l}-5-[({3-[(2- phenylethyl)amino]propyl}amino)methyl]cyclopentane-1,2-diol 467 (6.8 mg, 39%) as an off-white solid. 1 H NMR (400 MHz, Chloroform-d) δ 8.22 (s, 1H), 7.36–7.30 (m, 2H), 7.27–7.20 (m, 3H), 6.73 (s, 1H), 5.16 (br s, 2H), 4.72–4.63 (m, 1H), 4.24–4.11 (m, 1H), 4.04–3.90 (m, 1H), 3.00–2.92 (m, 2H), 2.91–2.84 (m, 2H), 2.83–2.69 (m, 6H), 2.49–2.36 (m, 4H), 2.32–2.23 (m, 1H), 1.85–1.65 (m, 3H). LCMS [conditions ZORBAX SB-Aq, 50*4.6 mm, 1.8 μm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 0.95 min; [M+H] + : 439. Chiral- SFC [Column: Lux-4100x4.6mm 3.0um, Solvent B: MeOH (20 mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min]: T R = 1.48 min; single peak. Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-cyclopropyl-7H-pyrrolo[2,3-d]pyri midin-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (468) tert-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-cyclopropyl-7H -pyrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3] dioxol-4-yl)methyl)(tert- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (123a) To a solution of tert-butyl-N-[3-({[(3aR, , , mino-5-bromopyrrolo[2,3-d]pyrimidin- 7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4 -yl]methyl}(tert- butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 108a (70 mg, 0.10 mmol, 1.0 eq) and cyclopropylboronic acid (16 mg, 0.20 mmol, 2 eq) in toluene (2.0 mL) and H 2 O (0.2 mL) was added K 3 PO 4 (60 mg, 0.30 mmol, 3.0 eq), Pd(AcO) 2 (4.0 mg, 0.02 mmol, 0.2 eq) and PCy 3 (10 mg, 0.04 mmol, 0.4 eq) and the reaction mixture was stirred at 100 °C, for 2 h, under nitrogen. The resulting mixture was concentrated under reduced pressure and the crude residue purified by silica gel column chromatography (90:10 DCM:MeOH) to afford tert-butyl-N-[3- ({[(3aR,4R,6R,6aS)-6-{4-amino-5-cyclopropylpyrrolo[2,3-d]pyr imidin-7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(tert-bu toxycarbonyl)amino)propyl]-N-(2- phenylethyl)carbamate 123a (60 mg, 90%) as a yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 μm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-2min(+), 1.00 mL/min, ES, m/z]: T R = 1.62 min; [M+H] + : 705. (1R,2S,3R,5R)-3-(4-Amino-5-cyclopropyl-7H-pyrrolo[2,3-d]pyri midin-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (468) To tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{ propylpyrrolo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]-dioxol-4-yl]methy l}(tert- butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 123a (60 mg, 0.10 mmol, 1.0 eq) was added TFA (2.0 mL) at room temperature and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and basified to pH=10 with NH3•H2O. The crude product was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5μm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1% NH 3 •H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 25% B to 55% B in 7 min, 55% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-{4-amino-5-cyclopropylpyrrolo[2,3-d]pyrimidi n-7-yl}-5-[({3-[(2- phenylethyl)amino]propyl}amino)methyl]cyclopentane-1,2-diol 468 (14.9 mg, 38%) as an off- white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.00 (s, 1H), 7.33–7.12 (m, 5H), 6.96 (s, 1H), 6.51 (s, 2H), 4.90–4.68 (m, 1H), 4.24–4.04 (m, 1H), 3.78–3.69 (m, 1H), 2.87–2.49 (m, 10H), 2.19–1.94 (m, 3H), 1.62–1.53 (m, 2H), 1.49–1.33 (m, 1H), 0.94–0.78 (m, 2H), 0.64–0.49 (m, 2H). LCMS [conditions Cortecs C18+, 50*3.0 mm, 2.7 μm, Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 0.99 min; [M+H] + : 465. Chiral-SFC [Column: Amylose C Neo 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. Gradient 30% solvent B for 4 mins]: T R = 1.30 min (major peak), T R = 1.77 min (minor peak), dr = 97.5:2.5. Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-(sec-butyl)-7H-pyrrolo[2,3-d]pyri midin-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (469) tert-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-((E)-but-2-en- 2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7- yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3] dioxol-4-yl)methyl)(tert- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (124a) To a solution of tert-butyl-N-[3-({[(3aR, , , a - - -amino-5-bromopyrrolo[2,3-d]pyrimidin- 7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4 -yl]methyl}(tert- butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 108a (90 mg, 0.12 mmol, 1.0 eq) and potassium (2-Z)-but-2-en-2-yltrifluoroboranuide (39 mg, 0.24 mmol, 2.0 eq) in toluene (2.5 mL) and H 2 O (0.3 mL) were added K 3 PO 4 (77 mg, 0.36 mmol, 3.0 eq), Pd(OAc) 2 (5 mg, 0.02 mmol, 0.2 eq) and PCy 3 (13 mg, 0.04 mmol, 0.4 eq) and the reaction mixture was stiired at 100 °C for 2 h, under nitrogen. The resulting mi tu e was co ce t ated under reduced pressure and the crude residue was purified by silica gel column chromatography (90:10 DCM:MeOH) to afford tert- butyl-N-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-[(2E)-but-2-en-2- yl]pyrrolo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3] dioxol-4-yl]methyl}(tert- butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 124a (40 mg, 46%) as a yellow solid. LCMS [Xbridge Shield RP18, 50*3.0 mm, 3.5 μm; Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2min(+), 1.50 mL/min, ES, m/z]: T R = 1.46 min; [M+H] + : 719. tert-Butyl (3-((((3aR,4R,6R,6aS)-6-(4-amino-5-(sec-butyl)-7H-pyrrolo[2, 3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (125a) To a solution of tert-butyl-N-[3-({[(3aR,4 R,6R,6aS)-6-{4-amino-5-[(2-E)-but-2-en-2- yl]pyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH -cyclopenta[d][1,3]dioxol-4- yl]methyl}(tert-butoxycarbonyl)amino)propyl]-N-(2-phenylethy l)carbamate 124a (40 mg, 0.05 mmol, 1.0 eq) in 3.0 mL MeOH was added Pd/C (10%, 2 mg) and the reaction mixture was hydrogenated at room temperature for 1 h, under a hydrogen balloon. The resultant mixture was filtered through a Celite pad and concentrated under reduced pressure to afford tert-butyl- N-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(sec-butyl)pyrrolo[2,3- d]pyrimidin-7-yl]-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(tert-bu toxycarbonyl)amino)propyl]-N-(2- phenylethyl)carbamate 125a (30 mg, 75%) as a yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 μm; Mobile Phase A: Water/5 mM NH4HCO3, Mobile Phase B: MeOH, 10%-95%B-3min(+), 1.50 mL/min, ES, m/z]: T R = 2.49 min; [M+H] + : 721. (1R,2S,3R,5R)-3-(4-Amino-5-(sec-butyl)-7H-pyrrolo[2,3-d]pyri midin-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (469) To tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-[ butyl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert- butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 125a (30 mg, 0.04 mmol, 1.0 eq) was added TFA (2.0 mL), at room temperature and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and basified to pH=10 with NH 3 •H 2 O. The crude product was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5μm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1% NH 3 •H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 22% B to 53% B in 7 min, 53% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-amino-5 (sec buty)py oo[ ,3 d]pyrimidin-7-yl]-5-[({3-[(2- phenylethyl)amino]propyl}amino) methyl]cyclopentane-1,2-diol 469 (9.9 mg, 50%) as an off-white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.00 (s, 1H), 7.33–7.23 (m, 2H), 7.21–7.13 (m, 3H), 7.01 (s, 1H), 6.36 (s, 2H), 4.88–4.78 (m, 1H), 4.71 (s, 1H), 4.18–4.10 (m, 1H), 3.81–3.71 (m, 1H), 3.15–3.06 (m, 1H), 2.82–2.65 (m, 6H), 2.63–2.54 (m, 4H), 2.20–2.09 (m, 1H), 2.07–1.94 (m, 1H), 1.79–1.67 (m, 1H), 1.58–1.40 (m, 4H), 1.25–1.16 (m, 3H), 0.94–0.82 (m, 3H). LCMS [conditions ZORBAX SB-Aq, 50*4.6 mm, 1.8 μm, Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 1.07 min; [M+H] + : 481. Chiral-SFC [Column: Lux-4100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min]: T R = 1.82 min, single peak. Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]p yrimidin-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (470) tert-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-(pyridin-4-yl) -7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( tert- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (126a) To a solution of tert-butyl-N-[3-({[(3aR, ino-5-bromopyrrolo[2,3-d]pyrimidin- 7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4 -yl]methyl}(tert- butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 108a (70 mg, 0.10 mmol, 1.0 eq) and pyridin-4-ylboronic acid (17 mg, 0.15 mmol, 1.5 eq) in dioxane (2.0 mL) and H 2 O (0.2 mL) were added K 3 PO 4 (60 mg, 0.30 mmol, 3.0 eq) and Pd(dtbpf)Cl 2 (12 mg, 0.02 mmol, 0.2 eq) and the reaction mixture was stirred at 80 °C for 1 h, under nitrogen. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (90:10 DCM:MeOH) to afford tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5- (pyridin-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tet rahydro-3aH-cyclopenta[d][1,3]dioxol- 4-yl]methyl}(tert-butoxycarbonyl)amino)propyl]-N-(2-phenylet hyl)carbamate 126a (55 mg, 79%) as a yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 μm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-3min(+), 1.50 mL/min, ES, m/z]: T R = 2.41 min; [M+H] + : 742. (1R,2S,3R,5R)-3-(4-Amino-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]p yrimidin-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (470) To tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-[ in-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]- 2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]me thyl}(tert- butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 126a (55 mg, 0.08 mmol, 1.0 eq) was added TFA (2.0 mL) at room temperature and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and basified to pH=10 with NH3•H2O. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5μm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 28% B to 59% B in 7 min, 59% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-amino-5-(pyridin-4-yl)pyrrolo[2,3-d]pyrim idin-7-yl]-5-[({3-[(2- phenylethyl)amino]propyl} amino)methyl]cyclopentane-1,2-diol 470 (13.7 mg, 37%) as an off- white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.66–8.48 (m, 2H), 8.17 (s, 1H), 7.75 (s, 1H), 7.51–7.43 (m, 2H), 7.29–7.22 (m, 2H), 7.21–7.13 (m, 3H), 6.29 (s, 2H), 5.11–4.88 (m, 1H), 4.38–4.17 (m, 1H), 3.97–3.72 (m, 1H), 2.86–2.53 (m, 10H), 2.31–2.17 (m, 1H), 2.15–1.99 (m, 1H), 1.69–1.44 (m, 3H). LCMS [conditions ZORBAX SB-Aq, 50*4.6 mm, 1.8 μm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 0.90 min; [M+H] + : 502. Chiral- SFC [Column: SB 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min]: T R = 2.16 min, single peak. Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-(pyrimidin-4-yl)-7H-pyrrolo[2,3-d ]pyrimidin-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (471) tert-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-(pyrimidin-4-y l)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)- 2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)meth yl)(tert- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (127a) To tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6- opyrrolo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(tert- butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 108a (140 mg, 0.20 mmol, 1.0 eq), in dioxane (2.0 mL) at room temperature were added 4-(tributylstannyl)pyrimidine (45 mg, 0.60 mmol, 3.0 eq), Pd(PPh 3 ) 4 (11 mg, 0.009 mmol, 0.05 eq), LiCl (21 mg, 0.50 mmol, 2.5 eq) and CuI (2.0 mg, 0.009 mmol, 0.05 eq) and the reaction mixture was stirred at 120 °C for 12 h, under N 2 . The resulting mixture was concentrated under vacuum and the crude residue was dissolved in AcOEt, filtered and the filter cake was ed wt cO t (3 10 mL). The combined washings were concentrated under reduced pressure and the crude residue was purified by Prep-TLC (80:20 AcOEt:petroleum ether) to afford tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(pyrimidin-4 - yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH -cyclopenta[d][1,3]dioxol-4- yl]methyl}(tert-butoxycarbonyl)amino)propyl]-N-(2-phenylethy l)carbamate 127a (67 mg, 48%) as a white solid. LCMS [conditions: L-column3 ODS, 50*3.0 mm, 3.0 um, Mobile Phase A: Water (0.05% ammonia water), Mobile Phase B: Acetonitrile, 5%-95%B-3min(+).lcm, 1.50 mL/min]: T R = 2.22 min; [M+H] + : 743. (1R,2S,3R,5R)-3-(4-Amino-5-(pyrimidin-4-yl)-7H-pyrrolo[2,3-d ]pyrimidin-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (471) To tert-butyl-N-[3-({[(3aR,4R,6R,6aS)-6-[ 4-amino-5-(pyrimidin-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]- 2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]me thyl}(tert- butoxycarbonyl)amino)propyl]-N-(2-phenylethyl)carbamate 127a (67 mg, 0.09 mmol, 1.0 eq) was added TFA (2.0 mL) and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and was basified to pH >8 with NH 3 •H 2 O. The crude residue was dissolved in DMF and purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5μm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 55% B in 7 min, 55% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-amino-5-(pyrimidin-4-yl)pyrrolo[2,3-d]pyr imidin-7-yl]-5-[({3-[(2- phenylethyl)amino]propyl}amino)methyl]cyclopentane-1,2-diol 471 (23.2 mg, 51%) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.09 (d, J = 1.3 Hz, 1H), 8.67 (d, J = 5.7 Hz, 1H), 8.54 (s, 1H), 8.10 (s, 1H), 8.07-8.00 (m, 1H), 7.29-7.22 (m, 2H), 7.21-7.11 (m, 3H), 5.02-4.90 (m, 1H), 4.33-4.25 (m, 1H), 3.84-3.77 (m, 1H), 2.72-2.63 (m, 5H), 2.62-2.54 (m, 5H), 2.29-2.18 (m, 1H), 2.09-2.04 (m, 1H), 1.60-1.47 (m, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 μm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min]: T R = 0.10 min; [M+H] + : 503. Chiral HPLC [CHIRALPAK IJ-3, 100*4.6mm, 3um, Mobile Phase A: Water/0.05% TFA, Mobile Phase B: CAN, Total Flow: 1.00 mL/min]: T R = 2.55 min, single peak. Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-(1H-pyrazol-5-yl)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-5- (((3-(phenethylamino)propyl)amino)methyl)cyclopentane-1,2-di ol (472) tert-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-(1-(tetrahydro -2H-pyran-2-yl)-1H-pyrazol-5-yl)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4- yl)methyl)(tert-butoxycarbonyl)amino)propyl)(phenethyl)carba mate (128a) To a stirred mixture amino-5-bromopyrrolo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'f- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate (60 mg, 0.08 mmol, 1.0 eq) and 1- (oxan-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)p yrazole 108a (34 mg, 0.12 mmol, 1.5 eq) in 1,4-dioxane (1.0 mL) and H 2 O (0.1 mL) were added Pd(dtbpf)CI 2 (2.6 mg, 0.004 mmol, 0.05 eq) and K 3 PO 4 (52 mg, 0.24 mmol, 3.0 eq) and the reaction mixture was stirred at 80 °C for 1 h, under N 2 . The resulting mixture was concentrated under reduced pressure and extracted with AcOEt (3x20mL). The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (50:50 tetrahydrofuran:petroleum ether) to afford te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-[2-(oxan-2- yl)pyrazol-3-yl]pyrrolo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'A butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate 128a (58 mg, 88%) as a light yellow solid. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2min(+).lcm, 1.50 mL/min]: T R = 1.32 min; [M + H] + : 815.

(1R,2S,3R,5R)-3-(4-Amino-5-(1H-pyrazol-5-yl)-7H-pyrrolo[2 ,3-d]pyrimidin-7-yl)-5-(((3-

(phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (472)

HO

To te/f-butyl-A/-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-[2-(oxan-2- yl)pyrazol-3-yl]pyrrolo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'f- butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate 128a (58 mg, 0.07 mmol, 1.0 eq) was added TEA (1.0 mL) and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and was basified to pH >8 with NH 3 *H 2 O. The crude residue was dissolved in DMF and purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1% NH 3 *H 2 O), Mobile Phase B:

ACN; Flow rate: 30 mL/min; Gradient: 25% B to 65% B in 7 min, 65% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-amino-5-(2H-pyrazol-3-yl)pyrrolo[2,3-d]py rimidin-7-yl]-5-[({3-[(2- phenylethyl)amino]propyl}amino)methyl]cyclopentane-1,2-diol 472 (15.3 mg, 44%) as an off- white solid. 1 H NMR (400 MHz, DMSO-t/ 6 ) <512.81 (br s, 1H), 9.17 (br s, 1H), 8.03 (s, 1H), 7.84-7.71

(m, 2H), 7.36-7.02 (m, 6H), 6.73-6.61 (m, 1H), 4.99-4.72 (m, 2H), 4.27-4.17 (m, 1H), 3.86-3.77 (m, 1H), 3.01-2.57 (m, 10H), 2.26-2.15 (m, 1H), 2.12-2.02 (m, 1H), 1.64-1.46 (m, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95% B-3min, 1.50 mL/min]: T R = 1.01 min; [M + H] + : 491. Chiral-SFC [Column: Lux-4 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. Gradient 50% solvent B for 4 mins]: T R = 1.46 min, single peak.

Synthesis of (1R ; 2S,3R,5R)-3-(4-amino-5-(1H-imidazol-2-yl)-7H-pyrrolo[2 ,3-d]pyrimidin-7-yl)-5- (((3-(phenethylamino)propyl)amino)methyl)cyclopentane-1,2-di ol (473) fe/7-Butyl-(3-((fe/7-butoxycarbonyl)(phenethyl)amino)propyl) (((3aR,4R ; 6R ; 6aS)-6-(4-chloro-5- iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro -4H-cyclopenta[d][1,3]dioxol-4- yl)methyl)carbamate

To a stirred solution -chloropyrrolo[2,3-d]pyrimidin-7-yl}- 2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]me thyl}(te/'f- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate 106a (0.50 g, 0.70 mmol, 1.0 eq) and Na 2 CO 3 (0.19 g, 1.80 mmol, 2.5 eq) in DCM (5.0 mL) was added, dropwise, ICI (1.8 mL, 1.80 mmol, 2.5 eq), at room temperature and the reaction mixture was stirred at room temperature for 4 h. The reaction was quenched with saturated sodium thiosulfate solution and was extracted with AcOEt (3x20mL). The combined organic layers were washed with saturated sodium thiosulfate solution, saturated sodium bicarbonate solution and brine, then dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (70:30 tetrahydrofurampetroleum ether) to afford te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-{4-chloro- 5-iodopyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4- yl]methyl}(te/'Abutoxycarbonyl)amino)propyl]-A/-(2-phenyleth yl)carbamate 129a (0.42 g, 71%) as a brown yellow solid. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95% B-3min(+).lcm, 1.50 mL/min]: T R = 2.62 min; [M + H] + : 810. fe/t- Butyl (((3aR,4R,6R,6aS)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)( 3-((fe/t- butoxycarbonyl)(phenethyl)amino)propyl)carbamate (130a) To te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-{4-chloro-5-iodopyrrol o[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(te/'f- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate 129a (0.42 g, 0.50 mmol, 1.0 eq) was added and NH 3 (7M in MeOH, 5.0 mL) at room temperature and the reaction mixture was stirred at 70 °C for 12 h, under N 2 . The resulting mixture was concentrated under reduced pressure to afford crude te/f-butyl-A/-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-iodopyrrolo [2,3-d]pyrimidin-7-yl}-

2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl ]methyl}(te/'f- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate 130a (0.33 g, 81%) which was used in the next step without further purification. 1 H NMR (400 MHz, Chloroform-^ 5 8.24 (s, 1H), 7.36- 7.29 (m, 2H), 7.26-7.13 (m, 4H), 4.62-4.45 (m, 1H), 3.45-3.10 (m, 8H), 2.97-2.74 (m, 3H), 2.56-2.32 (m, 3H), 1.95-1.66 (m, 3H), 1.55 (s, 3H), 1.46 (s, 18H), 1.28 (s, 3H). fcW-Butyl-(((3aR,4R,6R,6aS)-6-(4-amino-5-(1-((2-(trimethylsi lyl)ethoxy)methyl)-1H-imidazol-2-yl)- 7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-c yclopenta[d][1,3]dioxol-4- yl)methyl)(3-((fcW-butoxycarbonyl)(phenethyl)amino)propyl)ca rbamate (131a)

To a stirred solution of chloro(1-{[2-(trimethylsilyl)ethoxy]methyl}imidazol-2-yl)zin c 133a (2.0 mL, 0.18 mol/L, 1.8 eq) was added, dropwise, a solution of te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-{4- amino-5-iodopyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetra hydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]methyl}(te/f-butoxycarbonyl)am ino)propyl]-A/-(2- phenylethyl)carbamate 130a (0.10 g, 0.10 mmol, 1.0 eq), Pd 2( dba) 3 *CHCI 3 (13 mg, 0.013 mmol, 0.1 eq), tris(furan-2-yl)phosphane (6.0 mg, 0.03 mmol, 0.2 eq) and < 3 PO 4 (81 mg, 0.40 mmol, 3.0 eq) in THF (2.0 mL) at room temperature under N 2 and the reaction mixture was stirred at 60 °C for 12 h. The reaction was quenched with saturated ammonium chloride solution and extracted with AcOEt (3x20mL). The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 30% B to 85% B in 7 min, 85% B; Wave Length: 220 nm]: to afford te/'Abutyl-/V-[3- ({[(3aR,4R,6R,6aS)-6-[4-amino-5-(1-{[2-(trimethylsilyl)ethox y]methyl}imidazol-2-yl)pyrrolo[2,3- d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'f- butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate 131a (15 mg, 14%) as a white solid. LCMS [conditions: Cortecs C18+, 50*3.0 mm, 2.7 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 2%-80%B-5min(+).lcm, 1.50 mL/min]: T R = 3.83 min; [M + H] + : 861.

(1R,2S,3R,5R)-3-(4-Amino-5-(1H-imidazol-2-yl)-7H-pyrrolo[ 2,3-d]pyrimidin-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (473)

To te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(1-{[2-(tri methylsilyl)ethoxy]methyl]imidazol- 2-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3 aH-cyclopenta[d][1,3]dioxol-4- yl]methyl](te/'Abutoxycarbonyl)amino)propyl]-A/-(2-phenyleth yl)carbamate 131a (15 mg, 0.017 mmol, 1.0 eq) was added TFA (0.5 mL) and the reaction mixture was stirred at 50 °C for 0.5 h. The resulting mixture was concentrated under reduced pressure and basified to pH >8 with NH 3 *H 2 O and the crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 24% B to 49% B in 7 min, 49% B; Wave Length: 220 nm]: to afford (1R,2S,3R, 5R)-3-[4-amino-5-(1H-imidazol-2-yl)pyrrolo[2,3-d]pyrimidin-7 -yl]-5-[({3-[(2- phenylethyl)amino]propyl}amino)methyl]cyclopentane-1,2-diol 473 (4.5 mg, 53%) as an off-white solid. 1 H NMR (300 MHz, DMSO-5 6 +D 2 O) 58.03 (s, 1H), 7.94-7.78 (m, 1H), 7.36-7.07 (m, 6H),

7.05-6.89 (m, 1H), 5.04-4.75 (m, 1H), 4.24-4.02 (m, 1H), 3.91-3.75 (m, 1H), 3.40-2.57 (m, 10H), 2.35-2.19 (m, 1H), 2.17-1.97 (m, 1H), 1.73-1.33 (m, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.02%TFA, Mobile Phase B: MeOH, 5%-95%B-5min, 1.50 mL/min]: T R = 1.86 min; [M + H] + : 491. Chiral SFC [CHIRALPACK IF-3 50*3.0mm,3.0um, Solvent A: CO2, Solvent B: MeOH (0.2%MSA), Total Flow: 1.00 mL/min. Gradient: 10% to 50% in 2.0 min, hold 1.0 min at 50%]: T R = 1.69 min; single peak.

Synthesis of (1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)zinc( ll) chloride (41a)

2-Bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole (132a) u.

SEhJl

To a stirred suspension of 2-bromo-1H-imidazole (0.50 g, 3.40 mmol, 1.0 eq) and < 2 CO 3 (0.94 g, 6.80 mmol, 2.0 eq) in acetone (5.0 mL) was added SEMCI (0.68 g, 4.10 mmol, 1.2 eq) in acetone (3.0 mL) dropwise at room temperature and the reaction mixture was stirred at 28 °C for 12 h. The resulting mixture was concentrated under vacuum and the resultant residue was dissolved in AcOEt (60 mL) and then washed with brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography, (40:60 AcOEt: petroleum ether) to afford 2-bromo-1-{[2- (trimethylsilyl)ethoxy]methyl]imidazole 133a (0.50 g, 53%) as a colorless oil.

(1-((2-(Trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)zi nc(ll) chloride (133a)

To a stirred solution of 2-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl]imidazole 132a (0.30 g, 1.10 mmol, 1.0 eq) in THF (3.0 mL) was added /7-BuLi (0.48 mL, 1.20 mmol, 1.1 eq), dropwise, at -78 °C under N 2 and the reaction mixture was stirred at -78 °C for 0.5 h (the reaction progress was monitored by deuterium methanol quenching an alequote of the reaction mixture). To the resulting mixture was added ZnCI 2 (1.86 mL, 1.30 mmol, 1.2 eq) dropwise at -40 °C and the resulting mixture was stirred for additional 1 h at -20 °C (monitored by Deuterium methanol quenching) and the crude mixture of (1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)zinc( ll) chloride 133a was used in the next step without further purification.

Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-(thiazol-2-yl)-7H-pyrrolo[2,3-d]p yrimidin-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (474) fe/7-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-(thiazol-2-yl) -7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetra hydro-4H -cyclopenta [d][1, 3]dioxol-4-yl)methyl)(fe/7- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (134a)

To te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrro lo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(te/'A butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate 108a (80 mg, 0.11 mmol, 1.0 eq) in toluene (1.0 mL) at room temperature was added 2-(tributylstannyl)-1,3-thiazole (0.12 g, 0.33 mmol, 3.0 eq) and Pd(PPh 3 ) 2 CI 2 (4.0 mg, 0.005 mmol, 0.05 eq) and the reaction mixture was stirred at 120 °C for 12 h, under N 2 . The resulting mixture was concentrated under vacuum and AcOEt (20 mL) was added. The resulting suspension was filtered through diatomite and the filter cake was washed with AcOEt (3x10 mL). The combined filtrate was concentrated under reduced pressure and the crude residue was purified by Prep-TLC (80:20 AcOEtpetroleum ether) to afford te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(1,3-thiazo l-2-yl)pyrrolo[2,3-d]pyrimidin- 7-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4 -yl]methyl}(te/'A butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate 134a (63 mg, 78%) as a light yellow solid. LCMS [conditions: L-column3 ODS, 50*3.0 mm, 3.0 urn, Mobile Phase A: Water/0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-100%B-2min(+).lcm, 1.50 mL/min]: T R = 1.57 min; [M + H] + : 748.

(1R,2S,3R,5R)-3-(4-Amino-5-(thiazol-2-yl)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (474)

HO

To te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(1,3-thiazo l-2-yl)pyrrolo[2,3-d]pyrimidin-7- yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-y l]methyl}(te/'f- butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate 134a (63 mg, 0.08 mmol, 1.0 eq) was added TFA (2.0 mL) and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and the residue was basified to pH >8 with NH 3 *H 2 O and dissolved in DMF (3.0 mL). The crude product was purified by Prep-HPLC [Column: YMC- Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1% NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 55% B in 7 min, 55% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-amino-5-(1,3-thiazol-2-yl)pyrrolo[2,3- d]pyrimidin-7-yl]-5-[({3-[(2-phenylethyl)amino]propyl]amino) methyl]cyclopentane-1,2-diol 474 (25.5 mg, 60%) as an off-white solid. 1 H NMR (400 MHz, DMSO-r/ 6 +D 2 O) <58.15 (s, 1H), 8.09 (s, 1H), 7.81 (d, 7 = 3.4 Hz, 1H), 7.59 (d, 7 = 3.4 Hz, 1H), 7.29-7.22 (m, 2H), 7.19-7.11 (m, 3H), 4.97-4.86 (m, 1H), 4.33-4.25 (m, 1H), 3.83-3.76 (m, 1H), 2.87-2.49 (m, 10H), 2.26-2.14 (m, 1H), 2.13-1.97 (m, 1H), 1.63-1.50 (m, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min]: T R = 1.04 min;

[M + H] + : 508. Chiral HPLC [CHIRALPAK IC-3, 50*4.6mm, Sum, Mobile Phase A: Water/0.05% TFA, Mobile Phase B: CAN, Total Flow: 1.00 mL/min]: T R = 1.17 min; single peak.

Synthesis of (1R ; 2S,3R,5R)-3-(4-amino-5-(1H-1,2 ; 4-triazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)- 5-(((3-(phenethylamino)propyl)amino)methyl)cyclopentane-1,2- diol (475) fe/'AButyl-(((3aR,4R,6R,6aS)-6-(4-amino-5-(1-(tetrahydro-2H- pyran-2-yl)-1H-1,2,4-triazol-5-yl)-

7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4 H-cyclopenta[d][1,3]dioxol-4- yl)methyl)(3-((fe/'Abutoxycarbonyl)(phenethyl)amino)propyl)c arbamate (135a)

A crude sample of (1-(tetrahydro-2H-pyran-2-yl)-1H-1,2,4-triazol-5-yl)zinc(ll) chloride 136a (1.5 mL, 0.35mol/L in THF) was added dropwise, at room temperature under N 2 , to a solution of tert- butyl-A/-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-iodopyrrolo[2,3- d]pyrimidin-7-yl]-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl](te/'Abu toxycarbonyl)amino)propyl]-A/-(2- phenylethyl)carbamate 130a (50 mg, 0.06 mmol, 1.0 eq), Pd 2 (dba) 3 *CHCI 3 (7.0 mg, 0.006 mmol, 0.1 eq), tris(furan-2-yl)phosphane (3 mg, 0.013 mmol, 0.2 eq) and < 3 PO 4 (41 mg, 0.20 mmol, 3.0 eq) in THF (1.0 mL) and the reaction mixture was stirred at 60 °C for 12 h. The reaction was quenched with saturated ammonium chloride solution and the resulting mixture was extracted with AcOEt (3x20 mL). The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 30% B to 80% B in 7 min, 80% B; Wave Length: 220 nm]: to afford teW-butyl- A/-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-[2-(oxan-2-yl)-1,2,4-t riazol-3-yl]pyrrolo[2,3-d]pyrimidin-7- yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-y l]methyl}(te/'f- butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate 135a (25 mg, 49%) as a white solid. LCMS [conditions: Cortecs C18+, 50*3.0 mm, 2.7 urn, Mobile Phase A: Water/0.05% TFA, Mobile Phase B: Acetonitrile, 2%-95%B-3min(+), 1.20 mL/min]: T R = 2.15 min; [M + H] + : 816.

(1R,2S,3R,5R)-3-(4-Amino-5-(1H-imidazol-2-yl)-7H-pyrrolo[ 2,3-d]pyrimidin-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (475)

HO

To te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-[2-(oxan-2 -yl)-1,2,4-triazol-3-yl]pyrrolo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'f- butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate 135a (25 mg, 0.025 mmol, 1.0 eq) was added TFA (0.5 mL) and the reaction mixture was stirred at 50 °C for 0.5 h. The resulting mixrure was concentrated under reduced pressure, basified to pH >8 with NH 3 *H 2 O and the crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H2O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 50% B in 7 min, 50% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-amino-5-(2H-1,2,4-triazol-3-yl)pyrrolo[2, 3-d]pyrimidin-7-yl]-5-[({3-[(2- phenylethyl)amino]propyl]amino)methyl]cyclopentane-1,2-diol 475 (5.0 mg, 42%) as an off-white solid. 1 H NMR (300 MHz, DMSO-5 6 +D 2 O) 58.39-8.24 (m, 1H), 8.08 (s, 1H), 8.05-7.89 (m, 1H), 7.33-7.09 (m, 5H), 4.94 (br s, 1H), 4.19 (br s, 1H), 3.80 (br s, 1H), 3.35-2.79 (m, 2H), 2.75-2.51 (m, 8H), 2.31-2.17 (m, 1H), 2.13-1.97 (m, 1H), 1.73-1.42 (m, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/ 0.05% ammonia water, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min]: T R = 1.03 min; [M + H] + : 492. Chiral HPLC [Cellulose SC, 100*4.6mm, Sum, Mobile Phase A: Water/0.05% MSA, Mobile Phase B: CAN, Total Flow: 1.00 mL/min. gradient 10% B in 10 min]: T R = 1.75 min (major isomer), T R = 2.18 min (minor isomer); dr = 98.7:1.3.

Synthesis of (1-(tetrahydro-2H-pyran-2-yl)-1H-1,2,4-triazol-5-yl)zinc(ll) chloride (136a) 1-(Tetrahydro-2H-pyran-2-yl)-1H-1,2,4-triazole (137a)

/I

W

To a stirred mixture of 1,2,4-triazole (0.50 g, 7.20 mmol, 1.0 eq) and dihydropyran (0.91 g, 10.9 mmol, 1.5 eq) in THF (5.0 mL) was added imidazole (0.74 g, 10.9 mmol, 1.5 eq) at room temperature and the reaction mixture was stirred at 70 °C for 2 h . The crude mixture was purified by silica gel column chromatography (35:65 AcOEt: petroleum ether) to afford 1-(oxan- 2-yl)-1,2,4-triazole 137a (0.60 g, 54%) as a colourless oil.

(1-(Tetrahydro-2H-pyran-2-yl)-1H-1,2,4-triazol-5-yl)zinc( ll) chloride (136a)

'N'^ZnCI THF^

To a stirred solution of 1-(oxan-2-yl)-1,2,4-triazole 137a (0.20 g, 1.30 mmol, 1.0 eq) in THF (2.0 mL) was added /7-BuLi (0.57 mL, 1.40 mmol, 1.1 eq) dropwise at -78 °C under N 2 and the resulting mixture was stirred at -78 °C for 0.5 h (the reaction progression was monitored by deuterium- methanol quenching). To the above mixture was added ZnCI 2 (2.24 mL, 1.60 mmol, 1.2 eq), dropwise, at -40 °C. The reaction mixture was stirred for additional 1 h at -20 °C (reaction progress was monitored by deuterium-methanol quenching) and the crude sample of (1- (tetrahydro-2H-pyran-2-yl)-1H-1,2,4-triazol-5-yl)zinc(ll) chloride 136a was used in the next step directly without isolation or purification.

Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-(1-methyl-1H-pyrazol-3-yl)-7H-pyr rolo[2,3-d]pyrimidin- 7-yl)-5-(((3-(phenethylamino)propyl)amino)methyl)cyclopentan e-1,2-diol (476) fe/7-Butyl-(((3aR ; 4R / 6R,6aS)-6-(4-amino-5-(1-methyl-1H-pyrazol-3-yl)-7H-pyr rolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)(3-((fe/7- butoxycarbonyl)(phenethyl)amino)propyl)carbamate (170a)

To a stirred mixture of te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrro lo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'f- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate 108a (35 mg, 0.05 mmol, 1.0 eq) and 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyra zole (20 mg, 0.10 mmol, 2.0 eq) in 1,4-dioxane (1.0 mL) and H 2 O (0.1 mL) was added Pd(dtbpf)CI 2 (1.5 mg, 0.002 mmol, 0.05 eq) and K 3 PO 4 (30 mg, 0.10 mmol, 3.0 eq) and the reaction mixture was stirred at 90 °C for 0.5 h, under N 2 . The resulting mixture was concentrated under reduced pressure and partitioned between AcOEt and brine. The organic layer was dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by Prep-TLC (60:40 THE: petroleum ether) to afford te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(1- methylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethy l-tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]methyl}(te/7-butoxycarbonyl)am ino)propyl]-/V-(2- phenylethyl)carbamate 170a (30 mg, 86%) as a light yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-3min, 1.00 mL/min, ES, m/z]: T R = 2.44 min; [M + H] + : 745.

(1R,2S,3R,5R)-3-(4-Amino-5-(1-methyl-1H-pyrazol-3-yl)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-5-(((3-

(phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (476)

To te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(1-methylp yrazol-3-yl)pyrrolo[2,3- d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'A butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate (30 mg, 0.04 mmol, 1.0 eq) was added TFA (1.0 mL) and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and was basified to pH >8 with NH 3 *H 2 O. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H2O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 55% B in 9 min, 55% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-amino-5-(1-methylpyrazol-3-yl)pyrrolo[2,3 -d]pyrimidin-7-yl]-5-[({3-[(2- phenylethyl)amino]propyl}amino)methyl]cyclopentane-1,2-diol 476 (12.3 mg, 61%) as a white solid. 1 H NMR (400 MHz, DMSO-5 6 +D 2 O) 58.02 (s, 1H), 7.77 (s, 1H), 7.70 (d, 7 = 2.3 Hz, 1H), 7.30- 7.21 (m, 2H), 7.20-7.11 (m, 3H), 6.63 (d, 7 = 2.3 Hz, 1H), 4.94-4.82 (m, 1H), 4.26-4.16 (m, 1H), 3.87 (s, 3H), 3.81-3.75 (m, 1H), 2.82-2.51 (m, 10H), 2.25-2.14 (m, 1H), 2.10-2.00 (m, 1H), 1.63-1.41 (m, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min]: T R = 1.01 min; [M + H] + : 505. Chiral SFC [condition: Column Name: CHIRALPACK IF-3 50*3.0mm,3.0um, Co-Solvent: MeOH:DCM=7:3 (20 mM NH 3 ), Gradient (B%): 10% to 50% in 2.0 min, hold 1.0 min at 50%, Flow (mL/min): 2.00 mL/min]: T R = 2.23 min, single peak.

Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-(1-benzyl-1H-pyrazol-3-yl)-7H-pyr rolo[2,3-d]pyrimidin- 7-yl)-5-(((3-(phenethylamino)propyl)amino)methyl)cyclopentan e-1,2-diol (477) fe/t-Butyl-(((3aR,4R,6R,6aS)-6-(4-amino-5-(1-benzyl-1H-pyraz ol-3-yl)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)(3-((fe/7- butoxycarbonyl)(phenethyl)amino)propyl)carbamate (171a)

To a stirred mixture of te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrro lo[2,3- d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'A butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate 108a (40 mg, 0.05 mmol, 1.0 eq) and 1-benzyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyra zole (31 mq, 0.10 mmol, 2.0 eq) in 1,4-dioxane (1.0 mL) and H 2 O (0.1 mL) were added Pd(dtbpf)CI 2 (2.0 mq, 0.003 mmol, 0.05 eq) and < 3 PO 4 (34 mq, 0.20 mmol, 3.0 eq) and the reaction mixture was stirred at 90 °C for 0.5 h, under N 2 . The resultinq mixture was concentrated under reduced pressure and partitioned between AcOEt and brine. The orqanic layer was dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by Prep-TLC (60:40 THF:petroleum ether) to afford te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(1- benzylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethy l-tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]methyl}(te/'f-butoxycarbonyl)a mino)propyl]-/V-(2- phenylethyl)carbamate 171a (33 mg, 75%) as a light yellow solid. LCMS [L-column3 ODS, 50*3.0 mm, 3.0 urn; Mobile Phase A: Water/5mM NH 4 HC0 3 +0.05% Ammonia, Mobile Phase B: Acetonitrile/5%water, 5%-100%B-2min(+), 1.20 mL/min, ES, m/z]: T R = 1.71 min; [M + H] + : 821.

(1R,2S,3R,5R)-3-(4-Amino-5-(1-benzyl-1H-pyrazol-3-yl)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (477)

HO

To te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(1-benzylp yrazol-3-yl)pyrrolo[2,3- d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'A butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate 171a (33 mg, 0.04 mmol, 1.0 eq) was added TEA (1.0 mL) and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and was basified to pH >8 with NH 3 *H 2 O. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 25% B to 55% B in 7 min, 55% B; Wave Length: 220 nm]: to afford (1R,2S,3R, 5R)-3-[4-amino-5-(1-benzylpyrazol-3-yl)pyrrolo[2,3-d]pyrimid in-7-yl]-5-[({3-[(2- phenylethyl)amino]propyl}amino)methyl]cyclopentane-1,2-diol 477 (16 mg, 69%) as a white solid. 1 H NMR (400 MHz, DMSO-t/ 6 ) 5 8.09 (s, 1H), 7.97 (s, 1H), 7.60 (s, 1H), 7.38-7.34 (m, 3H), 7.32-7.28 (m, 3H), 7Z1-722 (m, 2H), 7.19-7.12 (m, 3H), 5.37 (s, 2H), 4.94-4.84 (m, 1H), 4.21-4.13 (m, 1H), 3.79-3.72 (m, 1H), 2.72-2.62 (m, 5H), 2.57-2.49 (m, 5H), 2.22-2.14 (m, 1H), 2.09-1.98 (m, 1H), 1.60-1.43 (m, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min]: T R = 1.40 min; [M + H] + : 581. CHIRAL_HPLC [Column: CHIRALPAK ID-3, 50*4.6mm, Sum, 25 dergree, Solvent B: MeOH (0.2%MSA), Solvent A: MTBE, keep Gradient 30% solvent B for 4 mins]: T R = 1.92 min, single peak.

Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-(1-methyl-1H-pyrazol-4-yl)-7H-pyr rolo[2,3-d]pyrimidin- 7-yl)-5-(((3-(phenethylamino)propyl)amino)methyl)cyclopentan e-1,2-diol (478)

7e/t-Butyl-(3-((((3aR ; 4R,6R,6aS)-6-(4-amino-5-(1-methyl-1H-pyrazol-4-yl)-7H- pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)(7e/t- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (172a) To a solution of te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrrol o[2,3-d]pyrimidin- 7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4 -yl]methyl}(te/'f- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate 108a (50 mg, 0.07 mmol, 1.0 eq) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyra zole (21 mg, 0.10 mmol, 1.5 eq) in dioxane (1.0 mL) and H 2 O (0.1 mL) were added K 3 PO 4 (41 mg, 0.20 mmol, 3.0 eq) and Pd(dtbpf)CI 2 (9.0 mg, 0.01 mmol, 0.2 eq) and the reaction mixture was stirred at 90 °C for 0.5 h, under nitrogen. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (95:5 DCM:MeOH) to afford te/f-butyl- A/-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(1-methylpyrazol-4-yl) pyrrolo[2,3-d]pyrimidin-7-yl]-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(te/'f- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate 172a (50 mg, 99%) as a yellow oil. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-3min(+), 1.50 mL/min, ES, m/z]: T R = 2.41 min; [M + H] + : 745.

(1R,2S,3R,5R)-3-(4-Amino-5-(1-methyl-1H-pyrazol-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-5-(((3- (phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (478)

To te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(1-methylpy razol-4-yl)pyrrolo[2,3- d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl](te/'A butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate 172a (50 mg, 0.07 mmol, 1.0 eq) was added TEA (1.0 mL) at room temperature and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and residue was basified to pH 10 with NH 3 *H 2 O. The crude product was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1% NH 3 «H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 22% B to 53% B in 7 min, 53% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-amino-5-(1-methylpyrazol-4-yl)pyrrolo[2,3 -d]pyrimidin-7- yl]-5-[({3-[(2-phenylethyl)amino]propyl}amino)methyl]cyclope ntane-1,2-diol 478 (12 mg, 35%) as an off-white solid. 1 H NMR (400 MHz, DMSO-d6) 58.09 (s, 1H), 7.81 (s, 1H), 7.54 (s, 1H), 7.31 (s, 1H), 7.29-7.11 (m, 5H), 6.12 (br s, 2H), 4.99-4.81 (m, 1H), 4.80-4.61 (m, 1H), 4.33-4.14 (m, 1H), 3.89 (s, 3H), 3.84-3.76 (m, 1H), 2.81-2.54 (m, 10H), 2.26-2.14 (m, 1H), 2.11-1.99 (m, 1H), 1.68-1.45 (m, 3H). LCMS [conditions ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 1.07 min; [M + H] + : 505. CHIRAL SFC [Column: CHIRALPACK ID-3 50*3.0mm, 3.0um. 50 degree, Solvent B: MeOH (0.2%MSA), Solvent A: CO2, 10% to 50% in 2.0 min, hold 1.0 min at 50%]: T R = 2.19 min, single peak.

Synthesis of (1R ; 2S,3R,5R)-3-(4-amino-5-(tetrahydro-2H-pyran-4-yl)-7H-p yrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3-(phenethylamino)propyl)amino)methyl)cyclopentan e-1,2-diol (479) fe/7-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-(3 ; 6-dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)(fe/7- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (138a)

To a stirred mixture of te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrro lo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'f- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate 108a (90 mg, 0.12 mmol, 1.0 eq) and 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-diox aborolane (38 mg, 0.18 mmol, 1.5 eq) in 1,4-dioxane (1.0 mL) and H 2 O (0.1 mL) was added Pd(dtbpf)CI 2 (4.0 mg, 0.006 mmol, 0.05 eq) and K 3 PO 4 (77 mg, 0.36 mmol, 3.0 eq) and the reaction mixture was stirred at 80

°C for 1 h, under N 2 . The resulting mixture was concentrated under reduced pressure and was disolved in AcOEt (60 mL), washed with saturated brine, dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by

Prep-TLC (50:50 tetrahydrofurampetroleum ether) to afford te/'Abutyl-/V-[3-({[(3aR,4R,6R,6aS)-6- [4-amino-5-(3,6-dihydro-2H-pyran-4-yl)pyrrolo[2,3-d]pyrimidi n-7-yl]-2,2-dimethyl-tetrahydro-

3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(te/'f-butoxycar bonyl)amino)propyl]-/V-(2- phenylethyl)carbamate 138a (80 mg, 89%) as an off-white solid. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-

95%B-2min(+).lcm, 1.50 mL/min]: T R = 1.61 min; [M + H] + : 747. fe/7-Butyl-(3-((((3aR ; 4R,6R,6aS)-6-(4-amino-5-(tetrahydro-2H-pyran-4-yl)-7H- pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)(fe/t- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (139a)

Boc-

2

Boc-

To a solution of te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(3,6-dihyd ro-2H-pyran-4- yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH -cyclopenta[d][1,3]dioxol-4- yl]methyl}(te/'Abutoxycarbonyl)amino)propyl]-A/-(2-phenyleth yl)carbamate 138a (70 mg, 0.09 mmol, 1.0 eq) in THE (1.0 mL) was added 10% Pd/C (2.0 mg) in a pressure tank and the reaction mixture was hydrogenated at room temperature under 20 psi of hydrogen pressure for 12 h. The resulting mixture filtered through a Celite pad and concentrated under reduced pressure to afford the crude product te/f-butyl-A/-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(oxan-4-yl) pyrrolo[2,3- d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'A butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate 139a (65 mg, 93%) was used in the next step without further purification. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-95%B-5min(+).lcm, 1.20 mL/min]: T R = 3.47 min; [M + H] + : 749.

(1R,2S,3R,5R)-3-(4-Amino-5-(tetrahydro-2H-pyran-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-5-(((3-

(phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (479)

HO

To te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(oxan-4-yl )pyrrolo[2,3-d]pyrimidin-7-yl]-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(te/'f- butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate 139a (65 mg, 0.09 mmol, 1.0 eq) was added TFA (1.0 mL) and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and was basified to pH >8 with NH 3 *H 2 O. The crude residue was dissolved in DMF and was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1% NH 3 «H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 55% B in 7 min, 55% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-amino-5-(oxan-4-yl)pyrrolo[2,3-d]pyrimidi n-7-yl]-5-[({3-[(2- phenylethyl)amino]propyl}amino)methyl]cyclopentane-1,2-diol 479 (32.5 mg, 74%) as an off- white solid. 1 H NMR (400 MHz, DMSO-5 6 +D 2 O) 58.00 (s, 1H), 7.29-7.23 (m, 2H), 7.22-7.12 (m, 3H), 7.07 (s, 1H), 4.88-4.77 (m, 1H), 4.19-4.11 (m, 1H), 3.92-3.83 (m, 2H), 3.80-3.75 (m, 1H), 3.54- 3.45 (m, 2H), 3.23-3.13 (m, 1H), 2.98-2.54 (m, 10H), 2.17-1.95 (m, 2H), 1.87-1.79 (m, 2H), 1.66-1.41 (m, 5H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05% TFA, Mobile Phase B: Acetonitrile, 5%-95% B-3min, 1.50 mL/min]: T R = 0.98 min; [M + H] + : 509. Chiral-SFC [Column: IG 100x4.6mm 3.0um, Solvent B: MeOH (20 mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min]: T R = 1.70 min; single peak.

Synthesis of (1R ; 2S,3R,5R)-3-(4-amino-5-(1-methylpiperidin-4-yl)-7H-pyr rolo[2,3-d]pyrimidin-7- yl)-5-(((3-(phenethylamino)propyl)amino)methyl)cyclopentane- 1,2-diol (480)

7e/t-Butyl-(3-((((3aR,4R,6R,6aS)-6-(4-amino-5-(1-methyl-1 ,2,3 ; 6-tetrahydropyridin-4-yl)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4- yl)methyl)(7e/t-butoxycarbonyl)amino)propyl)(phenethyl)carba mate (141a) To a stirred mixture of te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrrol o[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'f- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate 108a (110 mg, 0.15 mmol, 1.0 eq) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6 -dihydro-2H-pyridine (50 mg, 0.22 mmol, 1.5 eq) in 1,4-dioxane (1.5 mL) and H 2 O (0.15 mL) were added Pd(dtbpf)CI 2 (5 mg, 0.007 mmol, 0.05 eq) and K 3 PO 4 (95 mg, 0.45 mmol, 3.0 eq) and the reaction mixture was stirred at 80 °C for 1 h, under N 2 . The resulting mixture was concentrated under reduced pressure and partitioned between AcOEt and brine. The organic layer was dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The crude residue was purified by Prep-TLC (50:50 tetrahydrofurampetroleum ether) to afford te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-[4-amino- 5-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)pyrrolo[2,3-d]pyrimi din-7-yl]-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(te/'Abutoxycarbony l)amino)propyl]-/V-(2- phenylethyl)carbamate 141a (83 mg, 74%) as an off-white solid. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%- 95%B-2.5min(+).lcm, 1.50 mL/min]: T R = 2.03 min; [M + H] + : 760

7e/t-Butyl-(3-((((3aR ; 4R,6R,6aS)-6-(4-amino-5-(1-methylpiperidin-4-yl)-7H-py rrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)(7e/t- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (142a)

Bo

Bo

To a solution of terf-butyl-A/-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(1-methyl-3 ,6-dihydro-2H- pyridin-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tetr ahydro-3aH-cyclopenta[d][1,3]dioxol- 4-yl]methyl}(te/'Abutoxycarbonyl)amino)propyl]-A/-(2-phenyle thyl)carbamate 141a (43 mg, 0.06 mmol, 1.0 eq) in THE (1.0 mL, 0.014 mmol, 0.15 eq) was added 10% Pd/C (1.2 mg,) in a pressure tank and thereaction mixture was hydrogenated at room temperature under 20 atm of hydrogen pressure for 12 h. The resulting mixture was filtered through a Celite pad and concentrated under reduced pressure to afford the crude product terf-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-[4- amino-5-(1-methylpiperidin-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl ]-2,2-dimethyl-tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]methyl](te/'Abutoxycarbonyl)am ino)propyl]-A/-(2- phenylethyl)carbamate 142a (40 mg, 93%) as a yellow solid which was used in the next step without further purification. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-3min(+).lcm, 1.20 mL/min]: T R =

2.17 min; [M + H] + : 762.

(1R,2S,3R,5R)-3-(4-Amino-5-(1-methylpiperidin-4-yl)-7H-py rrolo[2,3-d]pyrimidin-7-yl)-5-(((3-

(phenethylamino)propyl)amino)methyl)cyclopentane-1,2-diol (480)

To te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(1-methylpi peridin-4-yl)pyrrolo[2,3- d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'f- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate (40 mg, 0.04 mmol, 1.0 eq) was added TFA (1.0 mL) and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and was basified to pH >8 with NH 3 *H 2 O. The crude residue was dissolved in DMF and was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 «H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 15% B to 60% B in 7 min, 60% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-amino-5-(1-methylpiperidin-4-yl)pyrrolo[2 ,3-d]pyrimidin-7- yl]-5-[({3-[(2-phenylethyl)amino]propyl}amino)methyl]cyclope ntane-1,2-diol 480 (4.5 mg, 21%) as a white solid. 1 H NMR (400 MHz, DMSO-r/ 6 +D 2 O) <58.01 (s, 1H), 7.30-7.22 (m, 2H), 7.21-7.13 (m, 3H), 7.05 (s, 1H), 6.36 (br s, 2H), 4.89-4.78 (m, 1H), 4.20-4.12 (m, 1H), 3.81-3.74 (m, 1H), 2.99-2.84 (m, 3H), 2.83-2.59 (m, 9H), 2.22-2.16 (m, 3H), 2.14-1.97 (m, 5H), 1.92-1.83 (m, 2H), 1.66-1.43 (m, 5H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min]: T R = 0.85 min; [M + H] + : 522. Chiral- SFC [Column: IG 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. Gradient 50% solvent B for 4 mins]: T R = 2.09 min; single peak.

Synthesis of 1-(4-(4-amino-7-((1R,2S,3R,4R)-2,3-dihydroxy-4-(((3- (phenethylamino)propyl)amino)methyl)cyclopentyl)-7H-pyrrolo[ 2,3-d]pyrimidin-5-yl)piperidin-1- yl)ethan-1-one (481)

7e/Y-Butyl-(3-((((3aR,4R,6R,6aS)-6-(5-(1-acetyl-1,2,3 ; 6-tetrahydropyridin-4-yl)-4-amino-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cycl openta[d][1,3]dioxol-4- yl)methyl)(7e/t-butoxycarbonyl)amino)propyl)(phenethyl)carba mate (143a)

To a stirred mixture of te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrrol o[2,3- d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl](te/'A butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate 108a (80 mg, 0.11 mmol, 1.0 eq) and 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihyd ro-2H-pyridin-1-yl]ethanone (41 mg, 0.16 mmol, 1.5 eq) in dioxane (1.0 mL) and H 2 O (0.1 mL) was added Pd(dtbpf)CI 2 (3.5 mg, 0.005 mmol, 0.05 eq) and < 3 PO 4 (90 mg, 0.33 mmol, 3.0 eq) and the reaction mixture was stirred at 80 °C for 1 h, under N 2 . The resulting mixture was concentrated under reduced pressure and was partitioned between AcOEt and brine. The orgaic layer was dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by Prep-TLC (50:50 THF:petroleum ether) to afford terf-butyl- A/-[3-({[(3aR,4R,6R,6aS)-6-[5-(1- acetyl-3,6-dihydro-2H-pyridin-4-yl)-4-aminopyrrolo[2,3-d]pyr imidin-7-yl]-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(te/'f-b utoxycarbonyl)amino)propyl]-/V-(2- phenylethyl)carbamate 143a (53 mg, 63%) as an off-white solid. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5pm, Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%- 95%B-2min(+).lcm, 1.00 mL/min]: T R = 1.57 min; [M + H] + : 788.

7e/Y-Butyl-(3-((((3aR,4R,6R,6aS)-6-(5-(1-acetylpiperidin- 4-yl)-4-amino-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)methyl)(7e/t- butoxycarbonyl)amino)propyl)(phenethyl)carbamate (144a)

To a solution of te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-[5-(1-acetyl-3,6-dihyd ro-2H-pyridin-4-yl)-4- aminopyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3 aH-cyclopenta[d][1,3]dioxol-4- yl]methyl}(te/'Abutoxycarbonyl)amino)propyl]-A/-(2-phenyleth yl)carbamate 143a (53 mg, 0.07 mmol, 1.0 eq) in THE (1.0 mL) was added Pd/C (1.4 mg, 0.013 mmol, 0.2 eq) in a pressure tank and the reaction mixture was hydrogenated at room temperature under 20 atm of hydrogen pressure for 12 h The resulting mixture was filtered through a Celite pad and concentrated under reduced pressure to afford crude terf-butyl- A/-[3-({[(3aR,4R,6R,6aS)-6-[5-(1-acetylpiperidin-4-yl)-4- aminopyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3 aH-cyclopenta[d][1,3]dioxol-4- yl]methyl}(te/'Abutoxycarbonyl)amino)propyl]-A/-(2-phenyleth yl)carbamate 144a (50 mL, 94%) which was used in the next step without further purification. LCMS [conditions: XBridge C18, 50*3.0 mm, 3.5pm, Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%- 100%B-3min(+).lcm, 1.20 mL/min),]: T R = 1.90 min; [M + H] + : 790.

1-(4-(4-Amino-7-((1R,2S,3R,4R)-2,3-dihydroxy-4-(((3- (phenethylamino)propyl)amino)methyl)cyclopentyl)-7H-pyrrolo[ 2,3-d]pyrimidin-5-yl)piperidin-1- yl)ethan-1-one (481)

To te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-[5-(1-acetylpiperidin- 4-yl)-4-aminopyrrolo[2,3- d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'A butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate (50 mg, 0.06 mmol, 1.0 eq) was added TEA (1.0 mL) and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and was basified to pH >8 with NH 3 *H 2 O. The crude residue was dissolved in DMF and purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1% NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 24% B to 49% B in 7 min, 49% B; Wave Length: 220 nm]: to afford 1-(4-{4-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[({3-[(2- phenylethyl)amino]propyl}amino)methyl]cyclopentyl]pyrrolo[2, 3-d]pyrimidin-5-yl}piperidin-1- yl)ethanone 481 (20.9 mg, 60%) as a white solid. 1 H NMR (400 MHz, DMSO-c/ 6 +D 2 O) <58.01 (s, 1H), 7.29-7.21 (m, 2H), 7.20-7.11 (m, 3H), 7.06 (s, 1H), 4.88-4.77 (m, 1H), 4.46 (d, 7 = 12.8 Hz, 1H), 4.16-4.08 (m, 1H), 3.89-3.81 (m, 1H), 3.78-3.71 (m, 1H), 3.27-3.17 (m, 2H), 2.79-2.51 (m, 11H), 2.17- 2.06 (m, 1H), 2.04-1.95 (m, 1H), 2.01 (s, 3H), 1.95-1.86 (m, 2H), 1.58-1.53 (m, 2H), 1.50-1.24 (m, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min]: T R = 0.98 min; [M + H] + : 550. Chiral-SFC [Column: IG 100x4.6mm 3.0um, Solvent B: MeOH (20 mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. Gradient 50% solvent B for 4 mins]: T R = 1.31 min, single peak.

Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-(1-methyl-1,2,3,6-tetrahydropyrid in-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-5-(((3-(phenethylamino)propyl)amino)methyl )cyclopentane-1,2-diol (482)

(1R,2S,3R,5R)-3-(4-Amino-5-(1-methyl-1,2,3 ; 6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-(((3-(phenethylamino)propyl)amino)methyl)cyclopentan e-1,2-diol (482) p HO

To te/'Abutyl-A/-[3-({[(3aR,4R,6R,6aS)-6-[4-amino-5-(1-methyl-3 ,6-dihydro-2H-pyridin-4- yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH -cyclopenta[d][1,3]dioxol-4- yl]methyl](te/'Abutoxycarbonyl)amino)propyl]-A/-(2-phenyleth yl)carbamate 141a (40 mg, 0.05 mmol, 1.0 eq) was added TFA (1.0 mL) and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and was basified to pH >8 with NH 3 *H 2 O. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1%NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 60% B in 7 min, 60% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-[4-amino-5-(1-methyl-3,6-dihydro-2H-pyridin- 4-yl)pyrrolo[2,3- d]pyrimidin-7-yl]-5-[({3-[(2-phenylethyl)amino]propyl]amino) methyl]cyclopentane-1,2-diol 482 (6.6 mg, 24%) as an off-white solid. 1 H NMR (400 MHz, DMSO-t/ 6 +D 2 O) <58.07 (s, 1H), 7.36 (s, 1H), 7.31-7.21 (m, 2H), 7.20-7.12 (m, 3H), 5.67 (s, 1H), 4.93-4.82 (m, 1H), 4.21-4.13 (m, 1H), 3.80-3.73 (m, 1H), 3.05-2.99 (m, 2H), 2.74-2.54 (m, 12H), 2.49-2.45 (m, 2H), 2.31-2.26 (m, 3H), 2.21-2.10 (m, 1H), 2.08-2.03 (m, 1H), 1.61-1.54 (m, 2H), 1.53-1.42 (m, 1H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B- 3min, 1.50 mL/min]: T R = 0.85 min; [M + H] + : 520. Chiral-SFC [Column: IG 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. Gradient 50% solvent B for 4 mins]: T R = 1.65 min, single peak. Synthesis of 4-amino-7-((1R,2S,3R,4R)-2,3-dihydroxy-4-(((3- (phenethylamino)propyl)amino)methyl)cyclopentyl)-7H-pyrrolo[ 2,3-d]pyrimidine-5-carbonitrile (483)

Synthesis of fe/t-butyl-/V-[3-({[(3aR ; 4R / 6R,6aS)-6-{4-amino-5-cyanopyrrolo[2 / 3-d]pyrimidin-7-yl}- 2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]me thyl}(fe/7- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate (152a)

? / ,N

Boc"N III

< A? 2 i 'O

To a stirred mixture of te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrro lo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}(te/'f- butoxycarbonyl)amino)propyl]-/V-(2-phenylethyl)carbamate 108a (100 mg, 0.13 mmol, 1.0 eq), Zn(CN) 2 (47 mg, 0.40 mmol, 3.0 eq), dppf (0.03 mmol, 0.20 eq) in NMP (2.0 mL) was added Pd 2 (dba) 3 (12 mg, 0.013 mmol, 0.1 eq) at room temperature under nitrogen and the reaction mixture was irradiated under microwave radiation for 0.5 h at 140 °C. The resulting mixture was allowed to cool to room temperature and was concentrated under vacuum. The crude residue was purified by silica gel column chromatography (90:10 CH 2 CI 2 :MeOH) to afford te/f-butyl-/V-[3- ({[(3aR,4R,6R,6aS)-6-{4-amino-5-cyanopyrrolo[2,3-d]pyrimidin -7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}(te/'f-butoxycarbon yl)amino)propyl]-/V-(2- phenylethyl)carbamate 152a (80 mg, 86%) as a yellow solid. LCMS [Xbridge Shield RP18, 50*3.0 mm; Mobile Phase A: Water/0.05% Ammonia, Mobile Phase B: Acetonitrile, 5%-100%B-2min(+), 1.20 mL/min, ES, m/z]: T R = 1.36 min; [M + H] + : 690.

4-Amino-7-((1R,2S,3R,4R)-2,3-dihydroxy-4-(((3- (phenethylamino)propyl)amino)methyl)cyclopentyl)-7H-pyrrolo[ 2,3-d]pyrimidine-5-carbonitrile (483)

To te/'f-butyl-/V-[3-({[(3aR,4R,6R,6aS)-6-{4-amino-5-cyanopyrro lo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl }(te/'f- butoxycarbonyl)amino)propyl]-A/-(2-phenylethyl)carbamate 152a (80 mg, 0.12 mmol, 1.0 eq) was added TEA (2.0 mL) and the reaction mixture was stirred for 1 h at room temperature. The resulting mixture was concentrated under reduced pressure and was basified to pH >8 with NH 3 *H 2 O and the crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1% NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 60% B in 7 min, 60% B; Wave Length: 220 nm]: to afford 4-amino-7-((1R,2S,3R,4R)-2,3-dihydroxy-4-(((3- (phenethylamino)propyl)amino)methyl)cyclopentyl)-7H-pyrrolo[ 2,3-d]pyrimidine-5-carbonitrile 483 (10.2 mg, 20%) as a white solid. 1 H NMR (300 MHz, DMSO-ofe) 6 8.38 (s, 1H), 8.21 (s, 1H), 7.31-7.23 (m, 2H), 7.22-7.10 (m, 3H), 6.79 (br s, 2H), 4.90-4.85 (m, 2H), 4.25-4.22 (m, 1H), 3.77-3.73 (m, 1H), 2.81-2.50 (m, 9H), 2.31-2.19 (m, 1H), 2.08-1.97 (m, 1H), 1.55-1.49 (m, 3H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min]: T R = 1.03 min; [M + H] + : 450. Chiral-SFC [Column: Lux- 4 100x4.6mm 3.0um, Solvent B: MeOH (20 mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min. Gradient 30% solvent B for 4 mins]: T R = 2.66 min, single peak.

Synthesis of (1R,2S,3R,5R)-3-(4-Amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-((3- ((phenethylamino)methyl)azetidin-1-yl)methyl)cyclopentane-1, 2-diol (484)

Synthesis of tert-butyl-(azetidin-3-ylmethyl)(phenethyl)carbamate (114a)

Benzyl 3-(((7e/t-butoxycarbonyl)amino)methyl)azetidine-1-carboxylat e (118a)

To a stirred solution of terAbutyl-A/-(azetidin-3-ylmethyl)carbamate (1.00 g, 5.40 mmol, 1.0 eq) and TEA (1.09 g, 10.7 mmol, 2.0 eq) in DCM (10.0 mL) was added, dropwise, Cbz-CI (1.01 g, 5.90 mmol, 1.1 eq) in DCM (5.0 mL), and the reaction mixture was stirred at room temperature for 1 h. The resulting mixture was extracted with DCM (3 x 20 mL) and the combined organic layers were washed with saturated ammonium chloride solution, brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (60:40 AcOEtpetroleum ether) to afford benzyl 3-{[(te/'f-butoxycarbonyl)amino]methyl}azetidine-1-carboxyla te 118a (1.50 g, 87%) as a colorless oil.

Benzyl 3-(aminomethyl)azetidine-1-carboxylate (119a)

To benzyl 3-{[(te/'f-butoxycarbonyl)amino] carboxylate 118a (1.50 g, 4.70 mmol, 1.0 eq) in DCM (20 mL) was aded TFA (1.07 g, 9.40 mmol, 2.0 eq), at room temperature, and the reaction mixture was stirred for 1 h. The resulting mixture was concentrated under reduced pressure to afford benzyl 3-(aminomethyl)azetidine-1-carboxylate 119a (1.10 g, 96 %) which was used in the next step directly without further purification.

Benzyl 3-((phenethylamino)methyl)azetidine-1-carboxylate (120a)

To a stirred solution of benzyl 3-(aminomethyl)azetidine-1-carboxylate 119a (1.10 g, 2.50 mmol, 1.0 eq) and NaBH(OAc) 3 (0.79 g, 3.70 mmol, 1.5 eq) in DCM (10 mL) was added phenylacetaldehyde (0.30 g, 2.50 mmol, 1.0 eq), dropwise, at 0 °C and the reaction mixture was stirred for 0.5 h at room temperature. The resulting mixture was diluted with dichloromethane (60 mL) and washed with brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by reverse flash chromatography [column, C18 silica gel; mobile phase, CH 3 CN in water, 20% to 45% gradient in 12 min; detector, UV 220 nm]: to afford benzyl 3-{[(2- phenylethyl)amino]methyl}azetidine-1-carboxylate 120a (420 mg, 52%) as a colorless oil.

Benzyl 3-(((7e/t-butoxycarbonyl)(phenethyl)amino)methyl)azetidine-1 -carboxylate (121a)

To benzyl 3-{[(2-phenylethyl)amino]methyl}azetidine-1-carboxylate 120a (0.32 g, 0.70 mmol, 1.0 eq) in MeOH (3.0 mL) was added Boc 2 O (0.19 g, 0.90 mmol, 1.2 eq) and the reaction mixture was stirred for 1 h at room temperature. The resulting mixture was evaporated and the crude residue was purified by reverse flash chromatography [column, C18 silica gel; mobile phase, MeOH in water, 30% to 80% gradient in 10 min; detector, UV 220 nm]: to afford benzyl 3-{[(terf- butoxycarbonyl)(2-phenylethyl)amino]methyl}azetidine-1-carbo xylate 121a (230 mg, 73%) as a colorless oil. fe/'A Butyl (azetidin-3-ylmethyl)(phenethyl)carbamate (114a)

To a solution of benzyl 3-{[(te/'f-butoxycarbonyl)(2-phenylethyl)amino]methyl}azetid ine-1- carboxylate 121a (0.23 g, 0.50 mmol, 1.0 eq) in MeOH (3.0 mL) was added Pd/C (10%, 6 mg) in a pressure tank. The reaction mixture was hydrogenated at room temperature under 30 psi of hydrogen pressure for 1 h. The resulting mixture was filtered through a Celite pad and the filtrate was concentrated under reduced pressure to afford crude te/'f-butyl-/V-(azetidin-3-ylmethyl)-/V- (2-phenylethyl)carbamate 114a (140 mg, 89%) which was used in the next step directly without further purification. LCMS [conditions: Xbridge Shield RP18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Phase B: Acetonitrile, 5%-100%B-2min, 1.50 mL/min]: T R = 1.18 min; [M + H] + : 291. fe/'AButyl-((1-(((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)a zetidin-3- yl)methyl)(phenethyl)carbamate (115a)

To terAbutyl-A/-(azetidin-3-ylmethyl)-A/-(2-phenylethyl)carbama te 114a (98 mg, 0.34 mmol, 1.0 eq), in DCM (2.0 mL) was added AcOH (0.21 g, 3.40 mmol, 10.0 eq) at room temperature and the resulting mixture was stirred for 30 min at room temperature and then (3aR,4S,6R,6aS)-6-{4- chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxole-4- carbaldehyde 77 (W02020033288) (0.15 g, 0.40 mmol, 1.2 eq) in DCM (2.0 mL) was added dropwise at room temperature. The reaction mixture was stirred for 1 h at room temperature and concentrated under reduced pressure. The crude residue was dissolved in methanol and purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1% NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 25% B to 50% B in 7 min, 50% B; Wave Length: 220 nm]: to afford te/'Abutyl-/V-[(1-{[(3aR,4R,6R,6aS)-6- {4-chloropyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tetrahyd ro-3aH-cyclopenta[d][1,3]dioxol-4- yl]methyl}azetidin-3-yl)methyl]-A/-(2-phenylethyl)carbamate 115a (130 mg, 65%) as a white solid. LCMS [conditions: Xbridge Shield RP18, 50*3.0 mm, 3.5 pm, Mobile Phase A: Water/0.05% Ammonia, Phase B: Acetonitrile, 5%-95%B-5min, 1.50 mL/min]: T R = 3.57 min; [M + H] + : 596. fe/7'-Butyl-((1-(((3aR,4R,6R,6aS)-6-(5-bromo-4-chloro-7H-pyr rolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)a zetidin-3- yl)methyl)(phenethyl)carbamate (

To te/'Abutyl-A/-[(1-{[(3aR,4R,6R,6aS)-6-{4-chloropyrrolo[2,3-d ]pyrimidin-7-yl]-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl]azetidin -3-yl)methyl]-A/-(2- phenylethyl)carbamate 115a (0.11g, 0.20 mmol, 1.0 eq) in DMF (2.0 mL) was added Br 2 (33 mg, 0.20 mmol, 1.1 eq) in DMF (1.0 mL), dropwise, at 0°C and the reaction mixture was stirred for 4 h at room temperature. The resulting mixture was quenched by the addition of saturated sodium thiosulfate solution and was extracted with AcOEt (3x10 mL). The combined organic layers were washed with saturated sodium bicarbonate solution, brine and dried over anhydrous sodium sulfate. The solute was filtered, concentrated under reduced pressure and the crude residue was purified by Prep-TLC (95:5 DCM: MeOH) to afford te/'Abutyl-A/-[(1-{[(3aR,4R,6R,6aS)-6-{5-bromo- 4-chloropyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydr o-3aH-cyclopenta[d][1,3]dioxol-4- yl]methyl}azetidin-3-yl)methyl]-A/-(2-phenylethyl)carbamate 116a (94 mg, 76%) as a white solid. LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min]: T R = 1.12 min; [M + H] + : 674, 676. fe/7'-Butyl-((1-(((3aR,4R,6R,6aS)-6-(4-amino-5-bromo-7H-pyrr olo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)a zetidin-3- yl)methyl)(phenethyl)carbamate. (

To te/'Abutyl-A/-[(1-{[(3aR,4R,6R,6aS)-6-{5-bromo-4-chloropyrro lo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl ]azetidin-3-yl)methyl]-A/-(2- phenylethyl)carbamate 116a (94 mg, 0.13 mmol, 1.0 eq) was added NH 3 (7M in MeOH, 2.0 mL) at room temperature and the reaction mixture was stirred at 75° C for 12 h. The resulting mixture was concentrated under reduced pressure to afford the crude product te/f-butyl- A/-[(1- {[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrrolo[2,3-d]pyrimidin- 7-yl]-2,2-dimethyl-tetrahydro-

3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}azetidin-3-yl)me thyl]-/V-(2-phenylethyl)carbamate 117a (80 mg) which was used in the next step without further purification. LCMS [Cortecs C18+, 50*3.0 mm, 2.7 urn; Mobile Phase A: Water/0.05%TFA, Phase B: Acetonitrile, 2%-100%B-2min(+), 1.50 mL/min, ES, m/z]: T R = 0.88 min; [M + H] + : 655, 657.

(1R,2S,3R,5R)-3-(4-Amino-5-bromo-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-((3- ((phenethylamino)methyl)azetidin-1-yl)methyl)cyclopentane-1, 2-diol (484)

HO

To te/'Abutyl-A/-[(1-{[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrrol o[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl ]azetidin-3-yl)methyl]-A/-(2- phenylethyl)carbamate 117a (80 mg, 0.10 mmol, 1.0 eq) was added TEA (2.0 mL) and the reaction mixture was stirred at 40 °C for 0.5 h. The resulting mixture was concentrated under reduced pressure and was basified to pH >8 with NH 3 *H 2 O. The crude residue was dissolved in DMF and purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1% NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 55% B in 7 min, 55% B; Wave Length: 220 nm]: to afford (1 R,2S,3 R, 5R)-3-{4- amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl}-5-[(3-{[(2-phenyl ethyl)amino]methyl}azetidin-1- yl)methyl]cyclopentane-1,2-diol 484 (29.9 mg, 53%) as a white solid. 1 H NMR (300 MHz, DMSO- t/ 6 ) <58.08 (s, 1H), 7.57 (s, 1H), 7.31-7.24 (m, 2H), 7.23-7.12 (m, 3H), 6.67 (br s, 2H), 4.92-4.82 (m, 3H), 4.18-4.10 (m, 1H), 3.73-3.66 (m, 1H), 3.27-3.20 (m, 2H), 2.82-2.60 (m, 8H), 2.52-2.51 (m, 1H), 2.47-2.28 (m, 2H), 2.19-2.07 (m, 1H), 1.87-1.78 (m, 1H), 1.47-1.35 (m, 1H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min]: T R = 0.98 min; [M + H] + : 515, 517. Chiral-SFC [Column: Lux-4 100x4.6mm 3.0um, Solvent B: MeOH (20mM NH 3 ), Oven Temperature: 35 °C, Total Flow: 3.00 mL/min]: T R = 1.39 min (major isomer), T R = 2.48 min (minor isomer), dr = 97.8:2.2.

Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-vinyl-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-5-((3-(((4- fluorophenethyl)amino)methyl)azetidin-1-yl)methyl)cyclopenta ne-1,2-diol (485)

((3aR ; 4R,6R,6aS)-6-(5-bromo-4-chloro-7H-pyrrolo[2 / 3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro- 4H-cyclopenta[d][1,3]dioxol-4-yl)methanol (163a)

Br

To a solution of methyl-(3aR,4S,6R,6aS)-6-{5-bromo-4-chloropyrrolo[2,3-d]pyri midin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxole-4-carboxyl ate 23a (0.50 g, 1.20 mmol, 1.0 eq) in MeOH (5.0 mL) was added NaBH 4 (88 mg, 2.30 mmol, 2.0 eq), at room temperature and the reaction mixture was stirred for 3 h at room temperature. The resulting mixture was quenched with saturated ammonium chloride solution and extracted with AcOEt (3x20 mL). The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (40:60 AcOEtpetroleum ether) to afford [(3aR,4R,6R,6aS)-6-{5-bromo- 4-chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydr o-3aH-cyclopenta[d][1,3]dioxol-4- yl]methanol 163a (0.30 g, 64%) as a yellow solid. LCMS [Xbridge Shield C18, 50*3.0 mm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 5%-100%B-2.5min(+)-P, 1.50 mL/min, ES, m/z]: T R = 1.35 min; [M + H] + : 402, 404.

(3aR,4S,6R,6aS)-6-(5-Bromo-4-chloro-7H-pyrrolo[2,3-d]pyri midin-7-yl)-2,2-dimethyltetrahydro- 4H-cyclopenta[d][1,3]dioxole-4-carbaldehyde (164a) Br

To [(3aR,4R,6R,6aS)-6-{5-bromo-4-chloropyrrolo[2,3-d]pyrimidin- 7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl] methanol 163a (0.18 g, 0.50 mmol, 1.0 eq) in DCM (3.0 mL) was added DMP (0.27 g, 0.60 mmol, 1.4 eq) at room temperature and the reaction mixture was stirred for 1 h at room temperature. The crude mixture was purified by silica gel column chromatography (40:60 AcOEtpetroleum ether) to afford (3aR,4S,6R,6aS)-6-{5-bromo-4- chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxole-4- carbaldehyde 164a (0.14 g, 78%) as a yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-2min(+), 1.00 mL/min, ES, m/z]: T R = 0.77 min; [M + H] + : 400, 402. fe/7'-Butyl-((1-(((3aR,4R,6R,6aS)-6-(5-bromo-4-chloro-7H-pyr rolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)a zetidin-3-yl)methyl)(4- fluorophenethyl)carbamate (166a)

To te/'Abutyl-A/-(azetidin-3-ylmethyl)-A/-[2-(4-fluorophenyl)et hyl]carbamate 165a (0.12 g, 0.40 mmol, 1.1 eq) in DCM (2.0 mL) was added NaBH(OAc) 3 (0.15 g, 0.70 mmol, 2.0 eq) and AcOH (0.21 mg, 3.50 mmol, 10 eq) at room temperature and the reaction mixture was stirred for 30 min at room temperature. To the resulting mixture was added (3aR,4S,6R,6aS)-6-{5-bromo-4- chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxole-4- carbaldehyde 164a (0.14 g, 0.35 mmol, 1.0 eq) in DCM (1.0 mL) and the reaction mixture was stirred for 1 h at room temperature. The resulting mixture was concentrated under reduced pressure and the crude product was purified by Prep-HPLC [Column: Xtimate C18 50x250mm, 10um; Mobile Phase A: Water (0.05% NH3*H2O), Mobile Phase B: ACN; Flow rate: 90 mL/min;

Gradient: 90% B in 16 min; Wave Length: 220 nm]: to afford te/'f-butyl-/V-[(1-{[(3aR,4R,6R,6aS)-6- {5-bromo-4-chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl- tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]methyl]azetidin-3-yl)methyl]-A /-[2-(4-fluorophenyl)ethyl] carbamate 166a (160 mg, 66%) as a white solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A:

Water/5 mM NH 4 HCO 3 , Mobile Phase B: MeOH, 10%-95%B-5min(+), 1.50 mL/min, ES, m/z]: T R = 4.29 min; [M + H] + : 692, 694. fe/7'-Butyl-((1-(((3aR,4R,6R,6aS)-6-(4-amino-5-bromo-7H-pyrr olo[2,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)a zetidin-3-yl)methyl)(4- fluorophenethyl)carbamate (167a)

To te/'f-butyl-/V-[(1-{[(3aR,4R,6R,6aS)-6-{5-bromo-4-chloropyrr olo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl ]azetidin-3-yl)methyl]-A/-[2-(4- fluorophenyl)ethyl]carbamate 166a (0.16 g, 0.20 mmol, 1.0 eq) was added NH 3 (7M in MeOH, 3.0 mL) at room temperature and the reaction mixture was stirred at 75 °C for 12 h. The resulting mixture was concentrated under reduced pressure and the crude sample was purified by silica gel column chromatography (50:50 AcOEtpetroleum ether) to afford te/'f-butyl-/V-[(1- {[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrrolo[2,3-d]pyrimidin- 7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl]azetidin-3-yl)methy l]-A/-[2-(4- fluorophenyl)ethyl]carbamate 167a (0.14 g, 87%) as an off-white solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5mM NH 4 HC0 3 +0.05% Ammonia, Mobile Phase B: Acetonitrile/5%water, 5%-100%B-2min(+).lcm, 1.20 mL/min, ES, m/z]: T R = 1.56 min; [M + H] + : 673, 675.

(1R,2S,3R,5R)-3-(4-Amino-5-bromo-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-((3-(((4- fluorophenethyl)amino)methyl)azetidin-1-yl)methyl)cyclopenta ne-1,2-diol (168a)

To te/'f-butyl-/V-[(1-{[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrro lo[2,3-d]pyrimidin-7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl ]azetidin-3-yl)methyl]-A/-[2-(4- fluorophenyl)ethyl]carbamate 167a (0.14 g, 0.20 mmol, 1.0 eq) was added TEA (1.0 mL) and the reaction mixture was stirred at 50 °C for 0.5 h. The resulting mixture was concentrated under reduced pressure and basified to pH >8 with NH 3 *H 2 O. The crude residue was purified by Prep- HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 «H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 55% B in 8 min, 55% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-{4-amino-5-bromopyrrolo[2,3- d]pyrimidin-7-yl]-5-{[3-({[2-(4-fluorophenyl)ethyl]amino]met hyl)azetidin-1- yl]methyl}cyclopentane-1,2-diol 168a (73 mg, 68%) as an off-white solid. LCMS [L-column3 ODS, 50*3.0 mm, 3.0 urn; Mobile Phase A: Water/5mM NH4HC03+0.05% Ammonia, Mobile Phase B: Acetonitrile/5%water, 5%-100%B-2.5min-1.2mL-P.lcm, 1.50 mL/min, ES, m/z]: T R = 1.21 min;

[M + H] + : 533, 535.

(1R,2S,3R,5R)-3-(4-Amino-5-vinyl-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-5-((3-(((4- fluorophenethyl)amino)methyl)azetidin-1-yl)methyl)cyclopenta ne-1,2-diol (485)

To a stirred mixture of (1R,2S,3R,5R)-3-{4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl }-5-{[3-({[2- (4-fluorophenyl)ethyl]amino}methyl)azetidin-1-yl]methyl}cycl opentane-1,2-diol 168a (73 mg, 0.14 mmol, 1.0 eq) and 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (32 mg, 0.21 mmol, 1.5 eq) in 1,4-dioxane (1.0 mL) and H 2 O (0.1 mL) were added Pd(dtbpf)CI 2 (5.0 mg, 0.007 mmol, 0.05 eq) and K 3 PO 4 (87 mg, 0.41 mmol, 3.0 eq) and the reaction mixture was stirred at 80 °C for 0.5 h, under N 2 . The resulting mixture was concentrated under reduced pressure and partitioned between AcOEt and brine. The organic layer was dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The crude residue was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water(10 mmol/L NH 4 HCO 3 +0.1% NH 3 «H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 22% B to 50% B in 9 min, 50% B; Wave Length: 220 nm]: to afford (1R,2S,3R,5R)-3-{4-amino-5- ethenylpyrrolo[2,3-d]pyrimidin-7-yl]-5-{[3-({[2-(4-fluorophe nyl)ethyl]amino]methyl)azetidin-1- yl]methyl}cyclopentane-1,2-diol 485 (28.7 mg, 44%) as a white soild. 1 H NMR (300 MHz, DMSO- t/ 6 ) <58.03 (s, 1H), 7.60 (s, 1H), 7.30-7.19 (m, 2H), 7.17-7.01 (m, 3H), 6.61 (br s, 2H), 5.55 (d, 7 = 17.1 Hz, 1H), 5.07 (d, 7 = 12.6 Hz, 1H), 4.96-4.70 (m, 2H), 4.67-4.29 (m, 1H), 4.23-4.08 (m, 1H), 3.77- 3.64 (m, 1H), 3.33-3.18 (m, 2H), 2.82-2.72 (m, 2H), 2.71-2.60 (m, 6H), 2.47-2.24 (m, 2H), 2.20-2.07 (m, 1H), 1.91-1.76 (m, 1H), 1.51-1.34 (m, 1H). LCMS [conditions: ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm, Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-95% B-5min, 1.50 mL/min]: T R = 1.65 min; [M + H] + : 481. Chiral SFC [condition: Column Name: CHIRALPACK IF-3 50*3.0mm,3.0um, Co-Solvent: MeOH (0.2%MSA), Gradient (B%): 10% to 50% in 2.0 min, hold 1.0 min at 50%, Flow (mL/min): 2.00 mL/min]: T R = 1.76 min (major peak), T R = 1.90 min (minor peak); dr = 95.5:4.5.

Synthesis of tert-butyl(azetidin-3-ylmethyl)(4-fluorophenethyl)carbamate (165a) Benzyl 3-(((7e/t-butoxycarbonyl)(4-fluorophenethyl)amino)methyl)aze tidine-1-carboxylate (169a)

A mixture of benzyl 3-(aminomethyl)azetidine-1-carboxylate (0.55 g, 2.50 mmol, 1.0 eq) and 2-(4- fluorophenyl)acetaldehyde (0.35 g, 2.50 mmol, 1.0 eq) were dissolved in DCM (5.0 mL) at room temperature. The resulting mixture was stirred for 10 min at room temperature then NaBH 4 (0.10 g, 2.70 mmol, 1.1 eq) was added. The mixture was stirred for 30 min at this temperature and then TEA (0.51 g, 5.00 mmol, 2.0 eq) and (Boc) 2 O (1.09 g, 5.00 mmol, 2.0 eq) in MeOH (5.0 mL) was added. The reaction mixture was stirred for 0.5 h at room temperature, the resulting mixture was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (40:60 AcOEtpetroleum ether) to afford benzyl-3-{[(te/'Abutoxycarbonyl)[2-(4- fluorophenyl)ethyl]amino]methyl}azetidine-1-carboxylate 169a (0.53 g, 48%) as a colorless oil. LCMS [Xbridge Shield C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/ Ammonia , Mobile Phase B: CH 3 CN, 5%-100%B-2.5min, 1.50 mL/min, ES, m/z]: T R = 1.00 min; [M + H] + : 443. tert- Butyl (azetidin-3-ylmethyl)(4-fluorophenethyl)carbamate (165a)

To a solution of benzyl 3-{[(te/'f-butoxycarbonyl)[2-(4-fluorophenyl)ethyl]amino]met hyl}azetidine- 1-carboxylate 169a (0.53 g, 1.10 mmol, 1.0 eq) in MeOH (5.0 mL) was added 10% Pd/C (0.11 g) in a pressure tank. The reaction mixture was hydrogenated at room temperature under 30 psi of hydrogen pressure for 1 h. The resulting mixture was filtered through a Celite pad and concentrated under reduced pressure to afford the crude product te/f -butyl- A/-(azetidin-3- ylmethyl)-A/-[2-(4-fluorophenyl)ethyl]carbamate 165a (0.33 g, 99%) was used in the next step directly without further purification. LCMS [Cortecs C18+, 50*3.0 mm, 2.7 pm; Mobile Phase A: Water/0.5% TEA, Mobile Phase B: CH 3 CN, 2%-100%B-2min (+), 1.50 mL/min, ES, m/z]: T R = 0.84 min; [M + H] + : 309.

Synthesis of (1R,2S,3R,5S)-3-(4-amino-5-(thiazol-2-yl)-7H-pyrrolo[2,3-d]p yrimidin-7-yl)-5- (azetidin-3-ylmethyl)cyclopentane-1,2-diol (486) tert- Butyl 3-(((3aR,4R,6aR)-2,2-dimethyl-6-oxotetrahydro-4H-cyclopenta[ d][1,3]dioxol-4- yl)methylene)azetidine-1-carboxylate (13b)

Into a 20 mL sealed tube were added (3aR,6aR)-2,2-dimethyl-3aH,6aH-cyclopenta[d][1,3]dioxol- 4-one (800 mg, 5.18 mmol, 1.0 eq), tert-butyl 3-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)methylidene]azetidine-1-carboxylate (2.29 g, 7.78 mmol, 1.5 eq) [Eur J. Org. Chem., 2019, 2019(33), 5624-5635\, [Rh(COD)CI] 2 (511 mg, 1.04 mmol, 0.2 eq), KOH (87 mg, 1.56 mmol, 0.3 eq), H 2 O (1.0 mL) and CH 3 OH (10.0 mL) at room temperature. The reaction mixture was irradiated with microwave radiation for 2h at 40 °C. The reaction was quenched with water (30 mL) and then extracted with EtOAc (3x30 mL). The organic layer was dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (95:5 AcOEtPetroleum ether) to afford tert-butyl 3-{[(3aR,4R,6aR)-2,2- dimethyl-6-oxo-tetrahydrocyclopenta[d][1,3]dioxol-4-yl]methy lidene}azetidine-1-carboxylate 13 b (860 mg, 51%) as an off-white solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5mM NH4HCO3, Mobile Phase B: Methanol, 10%-95%B-3min, 1.00 mL/min, ES, m/z]: T R = 1.98 min, ES m/z [M + H] + : 324. fe/t- Butyl 3-(((3aR,4S,6aR)-2,2-dimethyl-6-oxotetrahydro-4H-cyclopenta[ d][1,3]dioxol-4- yl)methyl)azetid i ne-1 -carboxylate (14b)

To a solution of tert-butyl 3-{[(3aR,4R,6aR)-2,2-dimethyl-6-oxo- tetrahydrocyclopenta[d][1,3]dioxol-4-yl]methylidene}azetidin e-1-carboxylate 13b (860 mg, 2.66 mmol, 1.0 eq) in MeOH (10 mL) was added 10% Pd/C (56 mg) in a 40 mL vial. The mixture was hydrogenated at room temperature for 1h under a hydrogen balloon, filtered through a Celite pad and concentrated under reduced pressure to afford tert-butyl 3-{[(3aR,4S,6aR)-2,2-dimethyl- 6-oxo-tetrahydrocyclopenta[d][1,3]dioxol-4-yl]methyl}azetidi ne-1-carboxylate 14b (740 mg, 85%) as an off-white crude solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5mM NH4HCO3, Mobile Phase B: Methanol, 10%-95%B-3min, 1.00 mL/min, ES, m/z]: T R = 2.00 min, ES m/z [M + H] + : 326. fe/t- Butyl 3-(((3aR,4S,6aS)-6-hydroxy-2,2-dimethyltetrahydro-4H-cyclope nta[d][1,3]dioxol-4- yl)methyl)azetid i ne-1 -carboxylate (15 b)

To a stirred solution of tert-butyl 3-{[(3aR,4S,6aR)-2,2-dimethyl-6-oxo- tetrahydrocyclopenta[d][1,3]dioxol-4-yl]methyl}azetidine-1-c arboxylate 14b (740 mg, 2.Z1 mmol, 1.0 eq) in MeOH (10.0 mL) were added NaBH 4 (129 mg, 3.41 mmol, 1.5 eq) in portions at 0 °C. The resulting mixture was stirred for 1 h at room temperature. The reaction was quenched with water (30 mL) and then extracted with EtOAc (3x30 mL). The organic layer was dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The crude product was purified by Prep-HPLC [Column: Xtimate C18 50x250mm, 10um; Mobile Phase A: 0.5% NH3.H2O, Mobile Phase B: ACN; Flow rate: 90 mL/min; Gradient: 90% 15min; Detector, UV 220 nm] to afford tert-butyl 3-{[(3aR,4S,6aS)-6-hydroxy-2,2-dimethyl-tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]methyl}azetidine-1-carboxylate 15b (550 mg, 73%) as an off-white solid. LCMS [L-column3 ODS, 50*3.0 mm, 3.0 urn; Mobile Phase A: Water/5mM NH 4 HC0 3 +0.05% Ammonia, Mobile Phase B: Acetonitrile/5%water, 5%-100%B-3min, 1.00 mL/min, ES, m/z]: T R = 1.62 min, ES m/z [M + H] + : 328. fe/'A Butyl 3-(((3aR,4S,6aR)-2,2-dimethyl-6-(((trifluoromethyl)sulfonyl) oxy)tetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)methyl)azetidine-1-carboxylate (16b)

Into a 40 mL vial were added tert-butyl -hydroxy-2,2-dimethyl-tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]methyl}azetidine-1-carboxylate 15b (550 mg, 1.68 mmol, 1.0 eq), DCM (10.0 mL) and pyridine (332 mg, 4.20 mmol, 2.5 eq) at room temperature. Tf 2 O (947 mg, 3.36 mmol, 2.0 eq) was added dropwise at 0 °C. The resulting mixture was stirred for 1h at room temperature, then concentrated under reduced pressure to afford tert-butyl 3-{[(3aR,4S,6aR)-2,2- dimethyl-6-(trifluoromethanesulfonyloxy)-tetrahydro-3aH-cycl openta[d][1,3]dioxol-4- yl]methyl}azetidine-1-carboxylate 16b (500 mg, crude) as a yellow oil. The crude product was used in the next step directly without further purification. LCMS [L-column3 ODS, 50*3.0 mm, 3.0 urn; Mobile Phase A: Water/5mM NH 4 HC0 3 +0.05% Ammonia, Mobile Phase B:

Acetonitrile/5%water, 5%-100%B-3min, 1.00 mL/min, ES, m/z]: T R = 2.21 min, ES m/z [M + H] + : 460. fe/t- Butyl 3-(((3aR,4S,6R,6aS)-6-(5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyr imidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)a zetidine-1-carboxylate (17b)

To a stirred solution of tert-butyl 3-{[(3aR,4S,6aR)-2,2-dimethyl-6-(trifluoromethanesulfonyloxy )- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl}azetidin e-1-carboxylate 16b (500 mg, 1.08 mmol, 1.0 eq) and 5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine (303 mg, 1.30 mmol, 1.2 eq) in DMF (5.0 mL) was added 60% NaH (104 mg, 4.35 mmol, 4.0 eq) in portions at 0 °C. The resulting mixture was stirred for 1h at room temperature. The reaction was quenched with water (30 mL) and then extracted with EtOAc (3x30 mL). The organic layer was dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 AcOEtPetroleum ether) to afford tert-butyl 3- {[(3aR,4S,6R,6aS)-6-{5-bromo-4-chloropyrrolo[2,3-d]pyrimidin -7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl]azetidine-1-carboxy late 17b (350 mg, 59%) as a yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-3min, 1.00 mL/min, ES, m/z]: T R = 2.39 min, ES m/z [M + H] + : 541, 543. fe/t- Butyl 3-(((3aR / 4S,6R,6aS)-6-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimid in-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)a zetidine-1-carboxylate (18b)

Into a 40 mL vial were added tert-butyl 3-{[(3aR,4S,6R,6aS)-6-{5-bromo-4-chloropyrrolo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]methyl}azetidine-1- carboxylate 17b (350 mg, 0.64 mmol, 1.0 eq) and 7M NH 3 in MeOH (5.0 mL) at room temperature. The resulting mixture was stirred for 16h at 70 °C. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 AcOEt : petroleum ether) to afford tert-butyl 3-{[(3aR,4S,6R,6aS)-6-{4- amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tetr ahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]methyl}azetidine-1-carboxylate 18b (240 mg, 71%) as a yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-3min, 1.00 mL/min, ES, m/z]: T R = 2.20 min, ES m/z [M + H] + : 522, 524. fe/t-Butyl 3-(((3aR,4S,6R,6aS)-6-(4-amino-5-(thiazol-2-yl)-7H-pyrrolo[2 ,3-d]pyrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)methyl)a zetidine-1-carboxylate (19b)

To a solution of tert-butyl 3-{[(3aR,4S,6R,6aS)-6-{4-amino-5-bromopyrrolo[2,3-d]pyrimidi n-7-yl}- 2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]me thyl}azetidine-1-carboxylate 18b (100 mg, 0.19 mmol, 1.0 eq) and 2-(tributylstannyl)-1,3-thiazole (107 mg, 0.28 mmol, 1.5 eq) in toluene (2.0 mL) were added Pd(PPh 3 )2Cl2 (26 mg, 0.04 mmol, 0.2 eq). After stirring for 2 h at 120 °C under a nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure, then extracted with EtOAc (3x10 mL). The organic layer was dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 AcOEt : petroleum ether) to afford tert-butyl 3- {[(3aR,4S,6R,6aS)-6-[4-amino-5-(1,3-thiazol-2-yl)pyrrolo[2,3 -d]pyrimidin-7-yl]-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl]azetidin e-1-carboxylate 19b (65 mg, 64%) as a yellow solid. LCMS [L-column3 ODS, 50*3.0 mm, 3.0 urn; Mobile Phase A: Water/5mM NH 4 HC0 3 +0.05% Ammonia, Mobile Phase B: Acetonitrile/5%water, 5%-100%B-3min, 1.50 mL/min, ES, m/z]: T R = 2.01 min, ES m/z [M + H] + : 527.

(1R ; 2S,3R,5S)-3-(4-amino-5-(thiazol-2-yl)-7H-pyrrolo[2,3-d ]pyrimidin-7-yl)-5-(azetidin-3- ylmethyl)cyclopentane-1,2-diol (486)

Into a 8 mL vial were added tert-butyl -amino-5-(1,3-thiazol-2- yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH -cyclopenta[d][1,3]dioxol-4- yl]methyl}azetidine-1-carboxylate 19b (65 mg, 0.12 mmol, 1.0 eq) and TEA (2.0 mL) at room temperature. The resulting mixture was stirred for 1h at 50 °C, then concentrated under reduced pressure and basified to pH >8 with NH 3 -H 2 O. The mixture was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 55% B in 9 min; Detector, UV 220&254 nm] to afford (1R,2S,3R,5S)-3-[4-amino-5-(1,3-thiazol-2- yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(azetidin-3-ylmethyl)cycl opentane-1,2-diol 486 (13.7 mg, 28%) as an off-white solid. 1 H NMR (300 MHz, DMSO-t4+ D 2 O) 5 8.14 (s, 1H), 8.09 (s, 1H), 7.81 (d, 7 = 3.3 Hz, 1H), 7.60 (d, 7 = 3.3 Hz, 1H), 4.90-4.76 (m, 1H), 4.25 (dd, 7 = 8.0, 6.2 Hz, 1H), 3.82-3.76 (m, 2H), 3.73-3.63 (m, 1H), 3.44-3.38 (m, 2H), 2.93-2.46 (m, 1H), 2.19-2.05 (m, 1H), 1.83-1.77 (m, 2H), 1.70-1.58 (m, 1H), 1.57-1.41 (m, 1H). LCMS [ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm; Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 0.96 min, ES m/z [M + H] + : 387. Chiral-SFC [Cellulose SB 50*3.0mm,3.0um, Solvent B: MeOH (0.2% MSA), Oven Temperature: 35 °C, Total Flow: 2.00 mL/min. Gradient 30% to 50% in 2.0 min, hold 1.0 min at 50%]: T R = 1.73 min (3 min run), single peak. Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-(thiazol-2-yl)-7H-pyrrolo[2,3-d]p yrimidin-7-yl)-5- (piperidin-4-yl)cyclopentane-1,2-diol (487) fe/t- Butyl 4-((3aR,4R,6aR)-2,2-dimethyl-6-oxotetrahydro-4H-cyclopenta[d ][1,3]dioxol-4-yl)-3,6- d ihyd ropyrid i ne-1 (2H)-carboxylate (

To (3aR,6aR)-2,2-dimethyl-3aH,6aH-cyclopenta[d][1,3]dioxol-4-on e (0.80 g, 5.19 mmol, 1.0 eq) in a sealed tube was added te/f-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro- 2H-pyridine-1-carboxylate (2.40 g, 7.78 mmol, 1.5 eq), [Rh(COD)CI] 2 (0.26g, 0.52 mmol, 0.1 eq), KOH (58 mg, 1.04 mmol, 0.2 eq), H 2 O (0.34 mL) and MeOH (36.0 mL) at room temperature and the reaction mixture was stirred under microwave radiation at 40 °C for 2 h. The resulting mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (5:95 AcOEt: petroleum ether) to afford te/7-butyl 4-((3aR,4R,6aR)-2,2-dimethyl- 6-oxotetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)-3,6-dihydr opyridine-1(2H)-carboxylate 166a (0.80 g, 46%) as a yellow oil. 1 H NMR (400 MHz, Chloroform-d) 55.34 (s, 1H), 4.67-4.63 (m, 1H), 4.28-4.21 (m, 1H), 3.89-3.84 (m, 2H), 3.54-3.47 (m, 2H), 2.97-2.80 (m, 2H), 2.36-2.28 (m, 1H), 2.25-2.16 (m, 1H), 2.12-2.05 (m, 1H), 1.47 (s, 9H), 1.46 (s, 3H), 1.36 (s, 3H). LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%- 95%B-3min(+), 1.00 mL/min, ES, m/z]: T R = 2.06 min; [M + H] + : 338. fe/t- Butyl 4-((3aR,4R,6aR)-2,2-dimethyl-6-oxotetrahydro-4H-cyclopenta[d ][1,3]dioxol-4- yl)piperidine-1-carboxylate (167a)

To a solution of te/7-butyl 4-[(3aR,4R,6aR)-2,2-dimethyl-6-oxo- tetrahydrocyclopenta[d][1,3]dioxol-4-yl]-3,6-dihydro-2H-pyri dine-1-carboxylate 167a (0.80 g, 2.37 mmol, 1.0 eq) in 10.0 mL MeOH was added 10% Pd/C (75 mg, 0.71 mmol, 0.3 eq) in a pressure tank. The mixture was hydrogenated at room temperature under 10 psi of hydrogen pressure for 1 h, filtered through a Celite pad and concentrated under reduced pressure to afford te/7-butyl 4- ((3aR,4R,6aR)-2,2-dimethyl-6-oxotetrahydro-4H-cyclopenta[d][ 1,3]dioxol-4-yl)piperidine-1- carboxylate 192a (0.70 g, crude) as a yellow oil. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-3min(+), 1.00 mL/min, ES, m/z]: T R = 2.04 min; [M + H] + : 340. fe/t- Butyl 4-((3aR,4R / 6S,6aS)-6-hydroxy-2,2-dimethyltetrahydro-4H-cyclopenta [d][1,3]dioxol-4- yl)piperidine-1-carboxylate (168a) To a solution of te/f-butyl 4-[(3aR,4R,6aR)-2,2-dimethyl-6-oxo- tetrahydrocyclopenta[d][1,3]dioxol-4-yl]piperidine-1-carboxy late 167a (0.70 g, 2.06 mmol, 1.0 eq) in MeOH (10.0 mL) was added NaBH 4 (117 mg, 3.09 mmol, 1.5 eq) at 0 °C and the reaction mixture was stirred at 0 °C for 1 h. The resulting mixture was quenched by the addition of water (1.0 mL) at 0 °C, filtered and the filter cake was washed with MeOH (3x2.0 mL). The combined filtrate was concentrated under reduced pressure and the crude product was purified by Prep- HPLC [Column: Xtimate C18 50x250mm, 10um; Mobile Phase A: 0.5% NH 3 *H 2 O, Mobile Phase B: ACN; Flow rate: 90 mL/min; Gradient: 90% 15 min; Detector, UV 220 nm]: to afford terf-butyl 4- ((3aR,4R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydro-4H-cyclope nta[d][1,3]dioxol-4-yl)piperidine- 1-carboxylate 168a (0.50 g, 71%) as a yellow oil. 1 H NMR (400 MHz, Chloroform-d) <54.51-4.46 (m, 1H), 4.39-4.35 (m, 1H), 4.16-4.08 (m, 2H), 4.07-4.02 (m, 1H), 2.75-2.61 (m, 2H), 2.52 (s, 1H), 2.09- 1.95 (m, 2H), 1.85-1.77 (m, 1H), 1.67-1.58 (m, 1H), 1.58-1.53 (m, 1H), 1.53 (s, 3H), 1.46 (s, 9H), 1.37 (s, 3H), 1.32-1.08 (m, 3H). LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5mM NH4HCO3, Mobile Phase B: Methanol, 10%-95%B-3min(+), 1.00 mL/min, ES, m/z]: T R = 2.03 min; [M + H] + : 342. fe/t-Butyl 4-((3aR,4R ; 6S,6aR)-2,2-dimethyl-6-(((trifluoromethyl)sulfonyl)oxy )tetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)piperidine-1-carboxylate (169a)

To a solution of te/7-butyl 4-[(3aR,4R,6S,6aS)-6-hydroxy-2,2-dimethyl-tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]piperidine-1-carboxylate 168a (500 mg, 1.46 mmol, 1.0 eq) in DCM (5.0 mL) was added pyridine (347 mg, 4.40 mmol, 3.0 eq) and Tf 2 O (826 mg, 2.93 mmol, 2.0 eq) at room temperature and the reaction mixture was stirred for 1 h at room temperature. The resulting mixture was concentrated under reduced pressure to afford terf-butyl 4- [(3aR,4R,6S,6aR)-2,2-dimethyl-6-(trifluoromethanesulfonyloxy )-tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]piperidine-1-carboxylate 169a (600 mg, crude) as a yellow oil. The crude product was used in the next step without purification. LCMS [L-column3 ODS, 50*3.0 mm, 3.0 urn; Mobile Phase A: Water/5mM NH 4 HC0 3 +0.05% Ammonia, Mobile Phase B: Acetonitrile/5%water, 5%-100%B-3min(+), 1.00 mL/min, ES, m/z]: T R = 2.24 min; [M + H] + : 474. fe/t- Butyl 4-((3aR,4R ; 6R,6aS)-6-(5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidin -7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)piperidi ne-1-carboxylate (170a)

To a solution of terf-butyl 4-[(3aR,4R,6S,6aR)-2,2-dimethyl-6-(trifluoromethanesulfonylo xy)- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]piperidine-1-ca rboxylate 169a (600 mg, 1.27 mmol, 1.0 eq) and 5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine (353 mg, 1.52 mmol, 1.2 eq) in DMF (15 mL), at 0 °C, was added NaH (62 mg, 2.53 mmol, 2.0 eq), in several portions over 5 min, and the reaction mixture was stirred for 1 h at room temperature. The reaction was quenched with H 2 O (10 mL) at 0 °C and the aqueous layer was extracted with AcOEt (3x10mL). The combined organic layers were dried over anhydrous Na 2 SO 4 , filtered and then the filtrate was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (AcOEt: petroleum ether 20:80) to afford terf-butyl 4-[(3aR,4R,6R,6aS)-6-{5-bromo-4- chloropyrrolo[2,3-d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro- 3aH-cyclopenta[d][1,3]dioxol-4- yl]piperidine-1-carboxylate 170a (220 mg, 31%) as a yellow solid. 1 H NMR (400 MHz, Chloroform- d) <58.63 (s, 1H), 7.36 (s, 1H), 4.98-4.87 (m, 2H), 4.58-4.51 (m, 1H), 4.23-4.07 (m, 2H), 2.74-2.65 (m, 2H), 2.51-2.39 (m, 1H), 2.29-2.09 (m, 2H), 2.02-1.88 (m, 2H), 1.70-1.60 (m, 2H), 1.56 (s, 3H), 1.47 (s, 9H), 1.30 (s, 3H), 1.25-1.15 (m, 1H). LCMS [L-column3 ODS, 50*3.0 mm, 3.0 urn; Mobile Phase A: Water/5mM NH 4 HC0 3 +0.05% Ammonia, Mobile Phase B: Acetonitrile/5%water, 5%- 100%B-3min(+), 1.00 mL/min, ES, m/z]: T R = 2.40 min; [M + H] + : 555, 557. fe/t- Butyl 4-((3aR,4R ; 6R,6aS)-6-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)piperidi ne-1-carboxylate (171a)

To terf-butyl 4-[(3aR,4R,6R,6aS)-6-{5-bromo-4-chloropyrrolo[2,3-d]pyrimidi n-7-yl]-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]piperidine-1-ca rboxylate 170a (105 mg, 0.19 mmol, 1.0 eq) was added NH 3 (7M in MeOH, 3.0 mL) at room temperature and the reaction mixture was stirred at 75 °C for 16 h. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by silica gel column chromatography (AcOEt: petroleum ether 20:80) to afford te/f-butyl 4-[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrrolo[2,3-d]pyrimidin -7-yl}-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]piperi dine-1-carboxylate 171a (80 mg, 79%) as a yellow solid. 1 H NMR (400 MHz, Chloroform-d) <58.26 (s, 1H), 7.03 (s, 1H), 5.76 (br s, 2H), 4.99-4.78 (m, 2H), 4.59-4.49 (m, 1H), 4.23-4.03 (m, 2H), 2.81-2.65 (m, 2H), 2.48-2.37 (m, 1H), 2.19-1.83 (m, 5H), 1.70-1.60 (m, 1H), 1.56 (s, 3H), 1.48 (s, 9H), 1.31 (s, 3H), 1.27-1.16 (m, 1H). LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-3min(+), 1.00 mL/min, ES, m/z]: T R = 2.24 min; [M + H] + : 536, 538. fe/t- Butyl 4-((3aR,4R ; 6R,6aS)-6-(4-amino-5-(thiazol-2-yl)-7H-pyrrolo[2,3-d]p yrimidin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)piperidi ne-1-carboxylate (172a)

To a solution of te/f-butyl 4-[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrrolo[2,3-d]pyrimidin -7-yl}- 2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]pi peridine-1-carboxylate 171a (80 mg, 0.15 mmol, 1.0 eq) in toluene (1.0 mL) was added Pd(PPh 3 ) 2 CI 2 (31 mg, 0.05 mmol, 0.3 eq), and 2- (tributylstannyl)-1,3-thiazole (167 mg, 0.45 mmol, 3.0 eq), in a sealed tube, at room temperature and the reaction mixture was stirred at 120 °C for 16 h, under nitrogen. The resulting mixture was concentrated under reduced pressure and the crude residue was purified by Prep-TLC (50:50

THF: petroleum ether) to afford te/f-butyl 4-[(3aR,4R,6R,6aS)-6-[4-amino-5-(1,3-thiazol-2- yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH -cyclopenta[d][1,3]dioxol-4- yl]piperidine-1-carboxylate 172a (50 mg, 62%) as a yellow solid. 1 H NMR (400 MHz, Chloroform-d) <59.61 (br, s, 1H), 8.26 (s, 1H), 7.70 (d, 7 = 3.4 Hz, 1H), 7.49 (s, 1H), 7.18 (d, 7 = 3.4 Hz, 1H), 5.77 (br, s, 1H), 5.11-5.01 (m, 1H), 4.94-4.80 (m, 1H), 4.58 (dd, 7 = 7.6, 6.2 Hz, 1H), 4.25-4.04 (m, 2H), 2.82- 2.62 (m, 2H), 2.50-2.38 (m, 1H), 2.30-2.13 (m, 1H), 1.98-1.87 (m, 2H), 1.71-1.62 (m, 1H), 1.57 (s, 3H), 1.51 (s, 1H), 1.47 (s, 9H), 1.32 (s, 3H), 1.30-1.10 (m, 2H). LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-5min(+), 1.00 mL/min, ES, m/z]: T R = 3.70 min; [M + H] + : 541.

(1R,2S,3R,5R)-3-(4-Amino-5-(thiazol-2-yl)-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-5-(piperidin-4- yl)cyclopentane-1,2-diol (487)

To te/f-butyl 4-[(3aR,4R,6R,6aS)-6-[4-amino-5-(1,3-thiazol-2-yl)pyrrolo[2, 3-d]pyrimidin-7-yl]-2,2- dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]piperi dine-1-carboxylate 172a (50 mg, 0.09 mmol, 1.0 eq) was added TEA (1.0 mL) at room temperature and the reaction mixture was stirred at 50 °C for 1 h. The resulting mixture was concentrated under reduced pressure and residue was dissolved in DMF (2.0 mL) and basified to pH =10 with NH 3 *H 2 O. The crude mixture was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 *H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 55% B in 8 min, 55% B; Detector, UV 220&254 nm]: to afford (1R,2S,3R,5R)-3-[4-amino-5-(1,3- thiazol-2-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(piperidin-4-yl )cyclopentane-1,2-diol 487 (18.9 mg, 51%) as an off-white solid. 1 H NMR (400 MHz, DMSO-t/+D 2 O) <58.15 (s, 1H), 8.09 (s, 1H), 7.80 (d, 7 = 3.4 Hz, 1H), 7.59 (d, 7 = 3.4 Hz, 1H), 4.90-4.76 (m, 1H), 4.28-4.17 (m, 1H), 3.85-3.71 (m, 1H), 3.03-2.86 (m, 2H), 2.48-2.36 (m, 2H), 2.11-1.97 (m, 1H), 1.85-1.76 (m, 1H), 1.70-1.48 (m, 3H), 1.46- 1.31 (m, 1H), 1.21-1.00 (m, 2H). LCMS [Cortecs C18+, 50*3.0 mm, 2.7 pm; Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 0.53 min; [M + H] + : 401. Chiral-SFC [Cellulose SB 50*3.0mm,3.0um, Solvent B: MeOH (0.2% MSA), Oven Temperature: 35 °C, Total Flow: 2.00 mL/min. Gradient 10% to 50% in 2.0 min, hold 1.0 min at 50%]: T R = 1.72 min, single peak.

Synthesis of (1R ; 2S,3R,5R)-3-(4-amino-5-(4-benzylthiazol-2-yl)-7H-pyrro lo[2,3-d]pyrimidin-7-yl)- 5-(piperidin-4-yl)cyclopentane-1,2-diol (488). tert- Butyl 4-((3aR,4R,6R,6aS)-6-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrim idin-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)piperidi ne-1-carboxylate (27b)

To a stirred solution of tert-butyl 4-[(3aR,4R,6S,6aR)-2,2-dimethyl-6-

(trifluoromethanesulfonyloxy)-tetrahydro-3aH-cyclopenta[d ][1,3]dioxol-4-yl]piperidine-1- carboxylate (200 mg, 0.42 mmol, 1.0 eq) and 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (141 mg, 0.50 mmol, 1.2 eq) in DMF (4.0 mL) was added NaH (40 mg, 1.69 mmol, 4.0 eq) in portions at 0 °C. The resulting mixture was stirred for 1h at room temperature. The reaction was quenched with water (10 mL) and then extracted with EtOAc (3x10 mL). The organic layer was dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 AcOEt : petroleum ether) to afford tert-butyl 4-[(3aR,4R,6R,6aS)-6-{4-chloro-5-iodopyrrolo[2,3-d]pyrimidin -7-yl}-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]piperidine-1-ca rboxylate 27 (78 mg, 30%) as a yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-3min, 1.00 mL/min, ES, m/z]: T R = 2.40 min, ES m/z [M + H] + : 603, 605. fe/t- Butyl 4-((3aR,4R,6R,6aS)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimi din-7-yl)-2,2- dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)piperidi ne-1-carboxylate (28b)

Into a 40 mL vial were added tert-butyl 4-[(3aR,4R,6R,6aS)-6-{4-chloro-5-iodopyrrolo[2,3- d]pyrimidin-7-yl}-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][ 1,3]dioxol-4-yl]piperidine-1- carboxylate 27b (75 mg, 0.12 mmol, 1.0 eq) and 7M NH 3 in MeOH (3.0 mL) at room temperature. The resulting mixture was stirred for 16h at 70 °C then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 AcOEt : petroleum ether) to afford tert-butyl 4-[(3aR,4R,6R,6aS)-6-{4-amino-5-iodopyrrolo[2,3-d]pyrimidin- 7-yl]-2,2-dimethyl- tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]piperidine-1-ca rboxylate 28b (52 mg, 71%) as a yellow solid. LCMS [L-column3 ODS, 50*3.0 mm, 3.0 urn; Mobile Phase A: Water/5mM NH 4 HC0 3 +0.05% Ammonia, Mobile Phase B: Acetonitrile/5%water, 5%-100%B-3min, 1.20 mL/min, ES, m/z]: T R = 2.11 min, ES m/z [M + H] + : 584. fe/t- Butyl 4-((3aR,4R,6R,6aS)-6-(4-amino-5-(4-benzylthiazol-2-yl)-7H-py rrolo[2,3-d]pyrimidin-7- yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl) piperidine-1-carboxylate (29b)

To a solution of tert-butyl 4-[(3aR,4R,6R,6aS)-6-{4-amino-5-iodopyrrolo[2,3-d]pyrimidin- 7-yl}- 2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]pi peridine-1-carboxylate 28b (52 mg, 0.09 mmol, 1.0 eq) and 4-benzyl-2-(tributylstannyl)-1,3-thiazole (62 mg, 0.13 mmol, 1.5 eq) [ W02011105590\ in toluene (2.0 mL) were added Pd(PPh 3 ) 2 CI 2 (12 mg, 0.02 mmol, 0.2 eq). After stirring for 2 h at 120 °C under a nitrogen atmosphere, the resulting mixture was concentrated under reduced pressure, then extracted with EtOAc (3x10 mL). The organic layer was dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 AcOEt : petroleum ether) to afford tert-butyl 4-[(3aR,4R,6R,6aS)-6-[4-amino-5-(4-benzyl-1,3-thiazol-2-yl)p yrrolo[2,3-d]pyrimidin-7- yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-y l]piperidine-1-carboxylate 29b (20 mg, 35%) as a yellow solid. LCMS [Halo C18, 30*3.0 mm, 2.0 pm; Mobile Phase A: Water/0.05%TFA, Mobile Phase B: Acetonitrile, 5%-100% B - 2 min, 1.50 mL/min, ES, m/z]: T R = 1.22 min, ES m/z [M + H] + : 631.

(1R,2S,3R,5R)-3-(4-amino-5-(4-benzylthiazol-2-yl)-7H-pyrr olo[2,3-d]pyrimidin-7-yl)-5-(piperidin- 4-yl)cyclopentane-1,2-diol (488)

Into a 8 mL vial were added tert-butyl -amino-5-(4-benzyl-1,3-thiazol-2- yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH -cyclopenta[d][1,3]dioxol-4- yl]piperidine-1-carboxylate 29b (20 mg, 0.03 mmol, 1.0 eq) and TEA (1.0 mL) at room temperature. The resulting mixture was stirred for 1h at 50 °C, then concentrated under reduced pressure. The mixture was basified to Ph>8 with NH 3 -H 2 O. The crude product was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 50% B in 8 min; Detector, UV 220&254 nm] to afford (1R,2S,3R,5R)-3-[4-amino-5-(4-benzyl- 1,3-thiazol-2-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(piperidin- 4-yl)cyclopentane-1,2-diol 488 (1.0 mg, 6%) as an off-white solid. 1 H NMR (300 MHz, Acetonitrile-^) 5 8.08 (s, 1H), 7.80 (s, 1H), 7.40-7.18 (m, 5H), 7.04 (s, 1H), 4.87-4.77 (m, 1H), 4.25-4.20 (m, 1H), 4.19 (s, 2H), 3.98-3.88 (m, 1H), 3.44-3.20 (m, 2H), 2.92-2.75 (m, 2H), 2.31-2.14 (m, 1H), 2.14-2.04 (m, 1H), 1.88-1.78 (m, 2H), 1.71-1.53 (m, 2H), 1.45-1.39 (m, 2H), 1.30-1.24 (m, 1H).LCMS [ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm; Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 5%-95%B-3min, 1.50 mL/min, ES, m/z]: T R = 1.22 min, ES m/z [M + H] + : 491.

Synthesis of (1R,2S,3R,5R)-3-(4-amino-5-(1-benzyl-1H-pyrazol-3-yl)-7H-pyr rolo[2,3-d]pyrimidin- 7-yl)-5-(piperidin-4-yl)cyclopentane-1,2-diol (489). tert- Butyl 4-((3aR,4R,6R,6aS)-6-(4-amino-5-(1-benzyl-1H-pyrazol-3-yl)-7 H-pyrrolo[2,3- d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)piperidine-1- carboxylate (30b)

To a solution of tert-butyl 4-[(3aR,4R,6R,6aS)-6-{4-amino-5-bromopyrrolo[2,3-d]pyrimidin -7-yl}- 2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]pi peridine-1-carboxylate 6 (50 mg, 0.09 mmol, 1.0 eq) and 1-benzyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyra zole (31 mg, 0.11 mmol, 1.2 eq) [ W0201704045C\ in dioxane (2.0 mL) and H 2 O (0.2 mL) were added K 3 PO 4 (59 mg, 0.28 mmol, 3.0 eq) and Pd(dppf)CI 2 (13 mg, 0.02 mmol, 0.2 eq). After stirring for 2 h at 80 °C under a nitrogen atmosphere, the reaction was quenched with water (10 mL) and then extracted with EtOAc (3x10 mL). The organic layer was dried over anhydrous Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:1 AcOEt : petroleum ether) to afford tert-butyl 4-[(3aR,4R,6R,6aS)-6-[4- amino-5-(1-benzylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]- 2,2-dimethyl-tetrahydro-3aH- cyclopenta[d][1,3]dioxol-4-yl]piperidine-1-carboxylate 30b (31 mg, 54%) as a yellow solid. LCMS [XBridge C18, 50*3.0 mm, 3.5 pm; Mobile Phase A: Water/5mM NH 4 HCO 3 , Mobile Phase B: Methanol, 10%-95%B-3min, 1.00 mL/min, ES, m/z]: T R = 2.34 min, ES m/z [M + H] + : 614.

(1R,2S,3R,5R)-3-(4-amino-5-(1-benzyl-1H-pyrazol-3-yl)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-5- (piperidin-4-yl)cyclopentane-1,2-diol (489)

Into a 8 mL vial were added tert-butyl 4-[(3aR,4R,6R,6aS)-6-[4-amino-5-(1-benzylpyrazol-3- yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-tetrahydro-3aH -cyclopenta[d][1,3]dioxol-4- yl]piperidine-1-carboxylate 30b (31 mg, 0.05 mmol, 1.0 eq) and TEA (2.0 mL) at room temperature. The resulting mixture was stirred for 1h at 50 °C then concentrated under reduced pressure. The mixture was basified to pH >8 with NH 3 -H 2 O. The crude product was purified by Prep-HPLC [Column: YMC-Actus Triart C18 ExRS, 30*150 mm, 5pm; Mobile Phase A: Water (10 mmol/L NH 4 HCO 3 +0.1%NH 3 .H 2 O), Mobile Phase B: ACN; Flow rate: 30 mL/min; Gradient: 20% B to 50% B in 8 min; Detector, UV 220&254 nm] to afford (1R,2S,3R,5R)-3-[4-amino-5-(1- benzylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(piperidi n-4-yl)cyclopentane-1,2-diol 489 (9 mg, 37%) as an off-white solid. 1 H NMR (400 MHz, DMSO-t4+D 2 O) 5 7.99 (s, 1H), 7.87 (d, 7 = 2.3 Hz, 1H), 7.77 (s, 1H), 7.40-7.32 (m, 2H), 7.32-7.24 (m, 3H), 6.66 (d, 7 = 2.3 Hz, 1H), 5.33 (s, 2H), 4.85-4.74 (m, 1H), 4.12 (dd, 7 = 9.1, 6.4 Hz, 1H), 3.77 (t, 7 = 5.2 Hz, 1H), 2.94-2.86 (m, 2H), 2.44- 2.34 (m, 2H), 2.07-1.96 (m, 1H), 1.81-1.74 (m, 1H), 1.68-1.62 (m, 1H), 1.54-1.50 (m, 2H), 1.40-1.31 (m, 1H), 1.10-1.05 (m, 2H). LCMS [ZORBAX SB-Aq, 50*4.6 mm, 1.8 pm; Mobile Phase A: Water/0.02%TFA, Mobile Phase B: Acetonitrile, 5%-40%-95%B-5min, 1.50 mL/min, ES, m/z]: T R = 2.31 min, ES m/z [M + H] + : 474. Chiral-SFC [Cellulose SB 50*3.0mm,3.0um, Solvent B: MeOH (0.2% MSA), Oven Temperature: 35 °C, Total Flow: 2.00 mL/min. Gradient 30% to 50% in 2.0 min, hold 1.0 min at 50%]: T R = 1.91 min, single peak.

Synthesis of (1S,2R,3R,5R)-3-(piperidin-4-yl)-5-(6,7,8,9-tetrahydro-2H-2, 3,5,6- tetraazabenzo[cd]azulen-2-yl)cyclopentane-1,2-diol (490) tert-butyl 4-((3aR,4R,6R,6aS)-2,2-dimethyl-6-(6,7,8,9-tetrahydro-2H-2,3 ,5,6- tetraazabenzo[cd]azulen-2-yl)tetrahydro-4H-cyclopenta[d][1,3 ]dioxol-4-yl)piperidine-1- carboxylate (31b)

Tert-butyl 4-((3aR,4R,6S,6aR)-2,2-dimethyl-6-(((trifluoromethyl)sulfony l)oxy)tetrahydro-4H- cyclopenta[d][1,3]dioxol-4-yl)piperidine-1-carboxylate (60 mg, 0.13 mmol, 1.0 eq) and 6, 7,8,9- tetrahydro-2H-2,3,5,6-tetraazabenzo[cd]azulene (27 mg, 0.16 mmol, 1.2 eq) [ W02020050406\ in DMF (4.0 mL) was added 60% NaH (21 mg, 0.52 mmol, 4.0 eq) in portions at 0 °C. The resulting mixture was stirred for 1h at r